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Yüksel Filik, Christoph Kornauth, Heidi A. Neubauer, Leonhard M ̈ullauer, Gary Tin, 
Jisung Park, Elvin D. de Araujo, Patrick T. Gunning, Gregor Hoermann, Fabrice Gouilleux, 
Robert Kralovics, Richard Moriggl and Peter Valent
STAT5 is Expressed in CD34+/CD38− Stem Cells and Serves as a Potential Molecular Target in 
Ph-Negative Myeloproliferative Neoplasms
Reprinted from: Cancers 2020, 12, 1021, doi:10.3390/cancers12041021 . . . . . . . . . . . . . . . . 141
Linus Wahnschaffe, Till Braun, Sanna Timonen, Anil K. Giri, Alexandra Schrader, 
Prerana Wagle, Henrikki Almusa, Patricia Johansson, Dorine Bellanger, Cristina López, 
Claudia Haferlach, Marc-Henri Stern, Jan D ̈urig, Reiner Siebert, Satu Mustjoki, 
Tero Aittokallio and Marco Herling
JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL
Reprinted from: Cancers 2019, 11, 1833, doi:10.3390/cancers11121833 . . . . . . . . . . . . . . . . 165
Emma I. Andersson, Oscar Brück, Till Braun, Susanna Mannisto, Leena Saikko, Sonja
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Preface to ”Targeting STAT3 and STAT5 in Cancer”
Cancer is often driven by hyperactivation of the JAK–STAT core cancer pathway, which is
associated with inappropriate functions of normal signaling pathways involving cytokine, growth
factor and hormone action. The successful implementation of clinically approved JAK kinase
inhibitors (baracitinib, ruxolitinib and tofacitinib) validates that JAK–STAT targeting is beneficial.
Consequently, targeting oncogenic transcription factors of the STAT family, namely STAT3, STAT5A,
and STAT5B, as major funnels for gene regulatory processes including chromatin remodeling has
clear therapeutic power. STAT3/5 proteins are attractive targets for drug discovery since they
steer cell proliferation, survival and metabolism. Targeting protein-protein interactions, however,
is challenging since the interacting surfaces are typically large and flat, having non-contiguous
binding hot spots and a lack of deep tractable pockets. Furthermore, transcription factors were long
considered “undruggable”. Emerging drug design strategies and medicinal chemistry approaches,
including methods to impair function, to destabilize or degrade transcription factors or to interfere
with interaction partners and cofactors, initiated new concepts and changed this paradigm. Here,
we summarize approaches for targeting STAT3/5, where the field moves into clinical application.
We cover the design paradigms and medicinal chemistry approaches to illuminate limitations
in specificity, potency, and in vivo bioavailability, necessitating new approaches and further
developments.






Targeting STAT3 and STAT5 in Cancer
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1. Introduction
Insights into the mutational landscape of the human cancer genome coding regions defined about
140 distinct cancer driver genes in 2013, which approximately doubled to 300 in 2018 following advances
in systems cancer biology studies [1,2]. The rapid growth and understanding led to taxonomical
organization of known oncogenes into 12 core cancer pathways that regulate cellular differentiation,
survival, and genome maintenance [1,3]. Despite significant advances in functional cancer genomics,
only a subset of these onco-targets has been successfully tackled in clinical settings, with a predominant
emphasis on small molecule kinase inhibitors. Contrastingly, targeting transcription factors has been
challenging due to shallow binding sites and non-contiguous surfaces. However, several signaling
networks converge upon the Janus Kinase-Signal Transducer and Activator of Transcription (JAK-STAT)
pathway and are explored in this special issue (Figure 1). Herein, we describe current concepts and
paradigms of oncogenic STAT3/5 targeting.
The JAK-STAT pathway controls cell survival, differentiation, and metabolism, with critical roles
in shaping the chromatin landscape, immune response, and mitochondrial function (Figure 1) [3].
To add another layer of complexity, current STAT studies are focused on in vitro model systems,
which may not fully represent the intricate complexities of stimulatory or inhibitory cancer cell-stroma
interactions as well as paracrine and endocrine cellular signaling. Additionally, the pleiotropic action
of the JAK-STAT pathway in different cell types is complex. It is well known that JAK-STAT3/5
hyperactivation promotes tumorigenesis, both in solid tumors as well as blood cancers. As such,
we have focused the themes of this special issue on targeting STAT3 and STAT5, while also highlighting
the effects of changes to the collective expression and activity profiles. This is critical as the entire
signaling cascade is interconnected with iterative response profiles, best illustrated by the tumor
suppressive action of STAT family members, STAT1/2.
The first chapter explores targeting concepts of STAT3/5, with an emphasis on hematopoietic
cancers and disease-associated mutations, providing both overview articles as well as original work.
Chapter 2 discusses the role of STAT3 and STAT5 across a wide range of solid cancers. Chapter 3
highlights emerging concepts influencing upstream or downstream regulatory mechanisms for targeting
oncogenic STAT3/5 action. Each chapter is prefaced with an overview article to appropriately outline
and introduce the disease topics for targeting concepts.
Cancers 2020, 12, 2002; doi:10.3390/cancers12082002 www.mdpi.com/journal/cancers1
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Figure 1. STAT activation pathway with opportunities for inhibition.
An oversimplification of the definition of core cancer pathways is helpful for pharmacologic
targeting concepts, since one can aim to target single or multiple core cancer pathways with pathway
blocker(s). The JAK-STAT signaling pathway plays a dominant role interconnecting and driving several
core cancer networks. Hyperactivated JAK-STAT activity is associated with aberrant functioning
of cytokine, growth factor, chemokine, and hormone signaling pathways, ultimately transforming
chromatin landscapes and gene reprogramming [3]. Stimulating ligands normally trigger JAK-STAT
action in a transient or gradient-like manner. This is well documented for Wnt signaling in crypt villi
or upon expansion of the immune system during infection, where a cytokine storm is followed by
down-regulation to homeostatic conditions and memory response [4–6]. However, the situation in the
cancer phenotype is very different and where age dominant clones can originate. For example, 10–15%
of individuals over the age of 70 develop Clonal Hematopoiesis of Indeterminate Potential (CHIP),
whereby small imbalances of external signals are known to promote acute leukemia and lymphoma
outbreak [7,8].
Loss of control over cytokine signaling, as observed with gain-of-function mutations in oncogenic
JAK-STAT components, directly promotes neoplastic outgrowth [9–11]. Moreover, in recent years,
advancements in understanding processes, such as unphosphorylated uSTAT action [12] as well as STAT
involvement in mitochondrial metabolism [13], have transitioned the consensus away from the idea of
2
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a linear signaling JAK-STAT cascade. Several negatively acting controls are also implemented
on JAK-STAT signaling to suppress transformation [10,11]. However, cancer is a multi-genetic
disease, and lost or lowered tumor suppressor protein function associated with global methylation
changes [14] decreased proteolysis of receptor-kinase components (e.g., lost or methylated SOCS family
members) [15] and/or inhibited phosphatase action [16] can all provoke hyperactivated JAK-STAT
action, culminating into cancer initiation and progression. Within the scope of this special issue,
several articles also focused on STAT3/5 hyperactivity in the microenvironment for complex immune
cell function or interplay with cancer cells or other stromal components. Overall, aberrant STAT3/5
functioning extends beyond cancer phenotypes into additional malignances, including autoimmunity,
chronic inflammation, and infectious disease.
The successful implementation of clinically approved JAK kinase inhibitors (ruxolitinib, tofacitinib,
baracitinib, and ifacitinib) validates the therapeutic utility of JAK-STAT targeting in a wide variety of
cancers and chronic inflammatory and autoimmune diseases. Current JAK kinase inhibitors are ATP
competitive analogues, with limited subtype selectivity. Some selectivity was achieved by covalently
targeting a Cys residue in close proximity to the orthosteric pocket of JAK3 [17]. JAK kinase inhibitors
have recently been employed for autoimmune-driven diseases including rheumatoid arthritis and
exploration for basket trials in cancer, such as those performed for BRAF or HER2 kinase inhibitors,
and could further propel clinical use [18]. However, there are significant challenges to overcome
in cancer targeting, and several of the proposed inhibitors in literature could be enhanced through
deeper understanding of the direct biophysical and target engagement profiles, in conjunction with
phenotypic screening.
Here, we summarize targeting approaches on STAT3/5, where we combine review articles from
experts in the field as well as original articles from multiple groups employing different targeting
strategies to advance clinical development. Inhibitor designs and medicinal chemistry approaches are
covered, highlighting limitations in the current modalities, such as selectivity, potency, and in vivo
efficacy for targeting hematopoietic and solid cancers. We have structured this special issue into three
main chapters.
Chapter 1: Targeting STAT3/5 in Hematopoietic Cancers
This chapter examines the drug targeting concept of STAT3/5 in hematopoietic cancers as well
as exploring less-studied STAT-driven indications. The chapter is prefaced by a review outlining
a brief history and identification of the involvement of STAT3 and STAT5 gene products and their
current mutational landscape. The major gain-of-function driver mutations in hematologic cancers are
highlighted, as well as detailed reports of indirect and direct inhibitors of STAT3 and STAT5 and their
current stage of clinical development [19]. These themes are further developed by Orlova et al., where the
current paradigms in direct small molecule targeting of STAT3 and STAT5 are explored in the context
of unphosphorylated STATs, as well as chromatin remodeling [20]. Furthermore, the involvement
of STAT signaling in the immune system and T-cell development have also led to proposed studies
for hijacking and re-wiring the immune suppressive tumor-associated macrophages in the context
of STAT3/5 [21]. The central ideas are expanded upon by Rébé et al., where they examine the critical
role of STAT3 in the immune system and T-cell differentiation as well as checkpoint inhibitors [22].
As seen above, several STAT3/5 targeting options were explored for hematopoietic cancers. However,
the role of STAT3 and STAT5 in specific indications is still being established and is often revealed
through somatic mutations identified from patient tumors. The molecular-level functional effects
of specific disease-associated SH2 domain mutations are highlighted in the context of the current
protein crystal structures [23]. Additional studies have explored the role of STATs in hematological
malignancies. Phospho-STAT5 was shown to play a key role in CD34+/CD38− myeloproliferative
neoplasms with downregulation by pharmacologic inhibition of JAK and STAT [24]. JAK/STAT
mutations were also identified in patients with the rare and aggressive T-cell prolymphocytic leukemia
(T-PLL), pointing towards a possible mode of transformation [25]. Additionally, STAT3 (and not
3
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STAT5B) mutations were identified in multiple peripheral T-cell lymphomas (PTCL), as well as high
pY-STAT3 expression, particularly in angioimmunoblastic T-cell lymphoma (AITL) and anaplastic
large cell lymphoma (ALCL) patient samples, two different PTCL cancer types [26]. From an
inhibition perspective, a derivatized indole was shown to be effective in both chronic myeloid
leukemia (CML) and acute myeloid leukemia (AML), as well as aggressive STAT5-N642H tumors [27].
Collectively, these studies shed light on the importance of STAT3/5 in several hematopoietic cancers,
potentially offering disease biomarkers and hallmarks across several different indications.
Chapter 2: Targeting STAT3/5 in Solid Cancers
This chapter highlights the role of STAT3/5 across a range of solid cancer models and is prefaced by
a thorough review highlighting the importance of STAT3 in inflammation, stemness, and mitochondrial
functions. It also depicts the mutational landscape with recurrent hotspot mutations in the three
different STAT3/5 gene products throughout these solid cancers [28]. The detailed mutational maps,
related to the oncogenic STAT3/5 proteins, indicate key functional amino acid residues, and their
appearance highlights where they might play critical cell-type specific roles [28]. Successively, Polak et al.
highlight the importance of leveraging selective STAT-targeting, arising from the STAT3-driven
cancer-stem cell properties and STAT3/5-enhanced immunosuppression, in contrast to the tumor
suppression activity of STAT1/2 [29]. These concepts form the foundation for the discussion of STAT3/5
across multiple solid cancers and indications. Notably, aberrant STAT3/5 function alters tumorigenic
properties across multiple organs, further highlighting their critical role as cancer drivers. Herein,
we briefly outline the different indications explored within the chapter.
Melanoma and causatively linked autoimmune diseases are directly tied to hyperactivation of
STAT3/5 cascades, and dual/simultaneous targeting could reduce the overall disease burden [30].
For colon cancer-based therapies, upstream targeting of IL-6 trans-signalling was explored in the context
of the ligand-releasing protease, ADAM17 [31]. Aggressive epithelial ovarian cancer was discussed
relative to the STAT3/5 activating tumor microenvironment and their correlation to the persistence
of recurrent neoplasms [32]. In prolactin-driven prostate cancer mouse models, STAT5A/B deletions
were found to significantly delay the onset of tumorigenesis, further highlighting a potential targeting
opportunity [33]. For breast cancer-based models, STAT3 was identified to promote PDL-1 expression,
leading to reduced immune responses, which was validated through gene silencing and pharmacologic
inhibition [34]. Direct targeting nanomedicine-based approaches were also applied in syngeneic
glioblastoma mouse models, where lipid-formulated siRNA was capable of suppressing STAT3 activity
and tumor growth [35]. STAT3 activation was also explored in hepatocellular carcinoma (HCC)
arising from hepatitis C infections. Aydin et al. identified that HCC progression was mediated through
NRF2, leading to STAT3 activation and suppression of miR-122 [36]. Finally, nano-formulated STAT3
inhibitors were also shown to be effective in myeloma xenograft models, enhancing the therapeutic
properties of the inhibitor alone [37].
Collectively, the range of indications examined in this chapter underscore the importance
of STAT3/5 signalling in transformation, but also the potential for cross-indication utility for
prospective therapies.
Chapter 3: General Targeting Aspects to Block the JAK1/2/3/TYK2-STAT3/5 Core Cancer Pathway
This chapter broadens the scope of current STAT targeting strategies. This has led to studies
of STAT within companion animals, particularly canine species, that offer advantages over current
pre-clinical models which are also a major hurdle in drug development safety/toxicity studies.
Moreover, companion animals share the same environment as their owners and similarities in cancers,
e.g., driver mutation conservation for key STAT domains could be important for understanding the
mechanistic detail within comparative pathology studies. Different animal species can also provide
additional mechanistic insights into STAT evolution and the signaling cascades [38]. For instance,
4
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understanding STAT activation in the context of heat shock proteins (HSPs) is critical for their
involvement in cellular stress and the immune response which was explored by Jego et al [39].
Alternative strategies for STAT targeting were also discussed within this chapter.
Nucleotide therapeutics, which were directed towards the STAT3 DNA-binding domain, were also
employed in clinical trials and represent a promising avenue in STAT inhibition that was distinct from
small molecules [40]. Alternatively, targeting the specific nucleocytoplasmic STAT transport shuttles
offers a creative mechanism for gaining STAT-inhibition selectivity [41]. The role and importance
of targeting TYK2, in addition to the JAK1-3, in the context of inducing STAT activation, was also
thoroughly discussed [42]. Similarly, the mTOR-STAT3 axis was investigated in Shwachman-Diamond
syndrome as a potential kinase target in blockading persistent STAT3 activation [43]. Collectively,
these strategies offer non-conventional approaches to the JAK-STAT targeting regimens.
2. Conclusions
In summary, this special issue offers an overview of different STAT3/5 targeting approaches
in the context of multiple disease indications. Emerging drug design strategies and medicinal
chemistry approaches, including methods to impair function [44] destabilize or degrade transcription
factors [45–47], interfere with interaction partners and cofactors [48], block DNA binding [49],
nuclear shuttling [41], or target specific subsets of cell types/microenvironment [50], initiated new
concepts for broad views on targeting. Consequently, targeting oncogenic transcription factors of the
STAT family, namely STAT3, STAT5A, and STAT5B as three distinct gene products are major funnels
for gene regulatory processes, including chromatin remodeling. Targeting these STAT gene products
has therapeutic power, as demonstrated with proof-of-concept studies, although advanced clinical
trials are not available. Thus, greater efforts need to be undertaken to identify new targets and develop
selective and less toxic clinical-grade inhibitors.
From a contemporary standpoint, the COVID-19 pandemic has highlighted the vulnerability of
cancer patients to infection [51]. We want to conclude that research on STAT3/5 targeting molecules and
concepts are broadly underexplored, as the 2020 SARS-CoV-2 pandemic revealed. SARS-CoV-2 infection
accounts for ≈28% mortality in New York cancer patients, from a cohort of 218 infected individuals.
Even therapeutic success will leave potential comorbidities that can flip the coin between life and
death [52]. SARS-CoV-2 infection rates were also associated with a 37% higher mortality in hematologic
malignancies predominantly associated with CHIP, pointing to the importance of regulation of
the blood and immune system, which is under the control of external stimuli, i.e., the JAK-STAT
pathway. Currently, mortality of SARS-CoV-2 infections can be reduced by blocking the cytokine storm
paradoxically with either tocilizumab or dexamethasone [53,54]. These drugs display well known
immunosuppressive action aside from other more systemic impacts on metabolism. STAT3/5 are
well known to interact with the glucocorticoid receptor. They can promote cytokine and growth
factor feed forward loops, and are critically involved in cytokine or growth factor, as well as hormone
signalling. Whether or not STAT3/5 inhibition is beneficial to treatment of COVID-19 infections is
unclear, illustrating the gaps in the research ahead of us, as well as the many opportunities, options,
and value in targeting STAT3/5.
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Abstract: Signal Transducer and Activator of Transcription (STAT) 3 and 5 are important effectors
of cellular transformation, and aberrant STAT3 and STAT5 signaling have been demonstrated in
hematopoietic cancers. STAT3 and STAT5 are common targets for different tyrosine kinase oncogenes
(TKOs). In addition, STAT3 and STAT5 proteins were shown to contain activating mutations in
some rare but aggressive leukemias/lymphomas. Both proteins also contribute to drug resistance
in hematopoietic malignancies and are now well recognized as major targets in cancer treatment.
The development of inhibitors targeting STAT3 and STAT5 has been the subject of intense investigations
during the last decade. This review summarizes the current knowledge of oncogenic STAT3 and
STAT5 functions in hematopoietic cancers as well as advances in preclinical and clinical development
of pharmacological inhibitors.
Keywords: STAT3; STAT5; hematopoietic cancers; therapeutic targeting; pharmacological inhibitors
1. Introduction
Signal Transducer and Activator of Transcription (STAT) proteins are a seven-member family
of cytoplasmic transcription factors that relay signals emanating from cell-surface cytokine and
growth factor receptors to the nucleus [1,2]. STAT proteins control fundamental cellular processes,
including survival, proliferation, differentiation, and immune responses [3]. It is now well-established
that three of these members, STAT3 and the closely related STAT5A and STAT5B proteins (Figure 1) are
also important effectors of cellular transformation. Aberrant STAT3, STAT5A, and STAT5B signaling
have been described in different solid tumors such as prostate, breast, colon, gliomas, head and neck
cancer, melanoma, and in hematopoietic malignancies [4–7] (see also [8] in this issue). Historically,
persistent activation of these transcription factors was frequently found in many tumor cells as a
consequence of deregulated tyrosine kinase activity. STAT5A/5B and/or STAT3 are downstream
effectors of various tyrosine kinase oncogenes (TKOs) such as TEL-JAK2, JAK2V617F, SRC, TEL-ABL,
BCR-ABL, TEL-SYK, NPM-ALK, TEL-PDGFR, and mutated forms of FLT3 and KIT receptors [9–19].
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Figure 1. Structure of Signal Transducer and Activator of Transcription (STAT)5A, STAT5B, STAT3,
and the spliced isoform STAT3β proteins. Functional domains: ND, NH2-terminal domain; CCD,
coiled-coil domain; DBD, DNA binding domain; LD, linker domain; SH2, Src homology 2 domain; TAD,
transactivation domain. Post-translational modifications: Ac, acetylation; Me, methylation; O-Glc-Nac,
O-GlcNacylation; P, phosphorylation; Sumo, sumoylation.
Inhibition of STAT3/STAT5 signaling has a negative impact on the transforming potential of
these tyrosine kinases in vitro and in vivo. Evidence for a direct role of STAT3 or STAT5A/5B in cell
transformation was provided by the use of constitutively active variants. These proteins, designated
STAT3C, STAT51*6 or cS5F, are able to induce cell transformation in vitro and solid tumors or leukemias
in vivo [20–23]. More recently, gain-of-function (GOF) mutations in STAT5B and STAT3 have been
found in patients with leukemias and lymphomas (Figure 2) [24–27]. Occurring primarily within the
SH2 domain, these mutations confer persistent and prolonged signaling and have been linked to poorer
prognosis and relapse in patients [28–30]. Collectively, these data would undoubtedly define STAT3
and STAT5A/5B as important therapeutic targets in hematologic cancers. Nevertheless, STAT3 and
STAT5 also behave as tumor suppressors in other tissues and regulate the antitumoral response of
immune cells [31–37]. Thus, the respective and specific functions of STAT3 and STAT5, as well as their
interactions in hematopoietic cancers, still need to be refined to develop therapeutic strategies that
selectively block STAT3 and/or STAT5 activity in these diseases. In this review, we will first summarize
the respective contribution of STAT3 and STAT5 in hematologic cancers as well as the canonical and
non-canonical oncogenic properties of STAT3/STAT5. Finally, we will describe the different strategies
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used to target STAT3 or STAT5 and will discuss the potential future development of single or combined
therapies to block STAT3 and/or STAT5A/5B activity/expression in hematologic cancers.
Figure 2. Map of somatic mutations detected in human STAT5A, STAT5B, and STAT3 in patients with
hematologic cancers. Individual missense mutations found in at least two patients, as well as all reported
nonsense (*) and frameshift (fs) mutations (bold), are depicted. The numbers in each box represent
the number of cases reported for each mutation. Data were mined from the Catalogue of Somatic
Mutations in Cancer (COSMIC) database. ND, NH2-terminal domain; CCD, coiled-coil domain; DBD,
DNA binding domain; LD, linker domain; SH2, Src homology 2 domain; TAD, transactivation domain.
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2. STAT3 and STAT5A/5B in Hematopoietic Cancers
2.1. STAT3/STAT5 in Hematopoietic Cancers: An Amazing 23-Year-Old Story
In 1996, pioneering works demonstrated that STAT3 and/or STAT5 are constitutively activated in
leukemic cells from patients with acute myeloid leukemia (AML) or acute lymphoblastic leukemia
(ALL) [38]. Surprising was the high constitutive STAT5 DNA binding activity detected in leukemic
cells from Philadelphia chromosome-positive ALL (Ph+ ALL) patients. These original findings already
pointed to STAT5 as a potential effector of the BCR-ABL tyrosine kinase fusion protein, the transforming
agent in Ph+ALL and chronic myeloid leukemia (CML), and were confirmed a few months later by other
groups [15,16]. 23 years later with more than 4000 publications in the field, it is now clearly established
that STAT3/STAT5A/STAT5B are essential and/or contribute to the development of hematopoietic
malignancies, affecting both myeloid and lymphoid compartments (Table 1). Data also showed that
deregulated STAT3 and STAT5 activity promotes drug resistance in leukemias/lymphomas/myelomas,
highlighting the crucial interest to develop pharmacological molecules that selectively target STAT3
and/or STAT5 in hematologic cancers.
Table 1. STAT3 and STAT5 in hematologic cancers.
Hematopoietic Lineage Hematologic Malignancies Contribution of STAT3 and/or STAT5A/5B
Myeloid compartment


















T-ALL STAT3 STAT5A STAT5B











Changes in font size and bold text refer to the level of contribution of each STAT protein in the disease. ALCL
(anaplastic large cell lymphoma), AML (acute myeloid leukemia), APL (acute promyelocytic leukemia), B- or
T-ALL (B- or T- acute lymphoblastic leukemia), CBF-AML (core binding factor-acute myeloid leukemia), CLL
(chronic lymphocytic leukemia), CML (chronic myeloid leukemia), DLBCL (diffuse large B cell lymphoma), ET
(essential thrombocythemia), Flt3-ITD (FMS-like tyrosine kinase 3-internal tandem duplication), HL (Hodgkin
lymphoma), Ph+MPN and Ph−MPN (Philadelphia chromosome-positive and Philadelphia chromosome-negative
myeloproliferative neoplasm), NK (natural killer cell), PMF (primary myelofibrosis), PV (polycythemia vera), SM
(systemic mastocytosis), and T-LGL (T cell large granular lymphocytic) leukemia.
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2.2. STAT3/5 in Myeloproliferative Neoplasms (MPNs)
Myeloproliferative neoplasms (MPNs) are hematologic diseases characterized by abnormal
proliferation and accumulation of mature myeloid cells in the bone marrow and peripheral blood [39].
An increased risk of developing acute myeloid leukemia is also associated with MPNs. MPNs are
classified as BCR-ABL-positive (or Ph+) and BCR-ABL-negative (Ph−) MPNs [40]. Both Ph+ and
Ph− MPNs are clonal disorders that result from the transformation of hematopoietic stem cells
(HSCs). While the BCR-ABL fusion protein is the transforming agent in CML, driver mutations in
JAK2, CALR, and MPL genes are variably present and are mostly mutually exclusive in Ph−MPNs,
which include essential thrombocythemia (ET), polycythemia vera (PV), and primary myelofibrosis
(MF) [41]. The JAK2 GOF mutation (JAK2V617F) has been identified in 95% to 97% of PV patients [42,43].
This mutation, located in the pseudokinase domain of the JAK2 protein, constitutively activates
the kinase. JAK2, MPL, and CALR mutants have been functionally validated and are sufficient to
induce MPNs in mice [41]. Systemic mastocytosis (SM), a subcategory of MPNs, is a heterogeneous
clonal disorder characterized by an accumulation of mast cells in various organs [44]. The GOF
mutation in KIT (KITD816V) causing activation of the KIT receptor tyrosine kinase was found in
80–95% of patients with SM. Studies with transgenic mice suggested that this mutation alone is
sufficient to cause SM [45]. The KITD816V mutant has also been detected in leukemic cells from AML
patients [46]. The presence of KITD816V in AML is highly associated with co-existing SM [47]. Activation
of STAT3 and/or STAT5 by BCR-ABL, JAK2V617F, and KITD816V has been abundantly documented in
the literature. However, conflicting results (cell lines vs. primary cells and/or human vs. murine
leukemic cells) have emerged from these studies. For instance, tyrosine phosphorylation of STAT3
(Y705) was observed in murine BCR-ABL+ cells but barely detected in human BCR-ABL+ cells [16,48].
Using stat3- or stat5a/5b-deficient mice, previous studies demonstrated that while STAT3 and STAT5 are
required for the initial step of BCR-ABL-dependent cell transformation, only STAT5 is necessary for the
maintenance of BCR-ABL-induced leukemia [49]. The effective role of STAT3 and STAT5 in maintenance,
self-renewal, or transformation of normal HSCs might explain why both proteins are required in the
BCR-ABL-dependent leukemia-initiating stem cell population [50–53]. More recently, dissection of
the respective contributions of STAT5A and STAT5B in BCR-ABL-dependent transformation revealed
that STAT5B, but not STAT5A, is a critical effector of BCR-ABL-driven leukemia development [54].
Besides survival- and growth-promoting effects, STAT5B facilitates leukemogenesis by suppressing
IFN-α and IFN-γ signaling in these animal models. The development of tyrosine kinase inhibitors
(TKIs) targeting BCR-ABL, such as imatinib mesylate (IM), has revolutionized the treatment of CML.
However, imatinib mesylate (IM) is not totally curative and approximately 50% of patients remain
therapy-free after IM discontinuation. The inability of IM to completely eradicate quiescent leukemic
stem cells (LSCs) is probably responsible for the relapse of CML patients [55]. Moreover, the occurrence
of BCR-ABL mutations in progressive or relapsed diseases promotes IM resistance of CML cells [56].
Studies indicated that high levels of phosphorylated STAT5 enhance the resistance of CML cells to
TKIs but also triggers BCR-ABL mutations by inducing the production of reactive oxygen species
(ROS) responsible for DNA damage [57–59]. Moreover, STAT5 was shown to play a key role in the
maintenance of IM-resistant LSCs from CML patients [60,61].
The contribution of STAT3 in IM resistance was also demonstrated using an in vitro model of
cocultures mimicking the bone marrow microenvironment of CML cells. In this model, bone marrow
stromal cells stimulated the phosphorylation of STAT3 in CML cells in a BCR-ABL-independent manner
and promoted the resistance of these leukemic cells to IM [62]. Interestingly, combined targeting of
STAT3 and STAT5 has been proposed to overcome drug resistance in CML cells [63].
While STAT5 plays a critical role in JAK2V617F-driven mouse models of MPN, studies have shown
that STAT3 is not required for myeloid expansion induced by this TKO [64–67]. Moreover, activation
of STAT3 negatively regulates JAK2V617F-driven MPN in mice by enhancing thrombocytosis and
shortening overall survival [67]. Further studies are therefore required to determine if STAT3 plays a
pathogenic role in human MPNs.
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STAT3, STAT5, and also STAT1 are activated by the KITD816V mutant in transformed mast cells, but
only STAT5 seems to be transcriptionally active in these cells [68]. Phosphorylation of STAT5 has been
detected in mast cells from SM patients. shRNA-mediated knockdown, dominant-negative mutant
and pharmacological molecules targeting STAT5 all abrogate the growth of human neoplastic mast
cells in vitro, indicating that STAT5 is a critical effector of KITD816V in human neoplastic mast cells [12].
Collectively, all data indicate that STAT5A/5B proteins are particularly relevant therapeutic targets
in Ph+ MPN and Ph− MPN and in the resistance to TKIs. Although the pathogenic role of STAT3 in
human MPN still remains questionable, the contribution of STAT3 to TKI resistance elicited by the
leukemic microenvironment would suggest that combination therapy or dual molecules targeting
STAT3 and STAT5 might help to eradicate resistant leukemic cells in their “niche.”
2.3. STAT3/5 in Acute Myeloid Leukemia (AML)
AML is a heterogeneous clonal disorder characterized by immature myeloid cell proliferation
and bone marrow failure. A two-hit model has been suggested as the probable mechanism in the
pathogenesis of AML [69]. In this model, gene mutations that give a growth advantage and block
normal hematopoietic differentiation are responsible for AML development. For instance, activating
mutations in FLT3 (FMS-related tyrosine kinase 3) and KIT receptors promote proliferation and survival,
while mutations affecting the transcription factor CEBPα inhibit myeloid differentiation. However,
there are several other gene classes such as those involved in epigenetic regulation or metabolism that
are mutated in AML [70].
Analyses of primary peripheral blood and bone marrow specimens have demonstrated constitutive
activation of STAT3 and/or STAT5 in AML [6,37]. Importantly, constitutive activation of STAT3 and
STAT5 has been linked with disease outcomes in AML. Bone marrow evaluation of AML patients
revealed that the activation of STAT3 was significantly associated with poor overall survival and
reduced progression-free survival [71]. In sharp contrast, the spliced STAT3β isoform was shown
to have a suppressor function in AML [33]. A higher STAT3β/α mRNA ratio was found in AML
cells and correlated with a favorable prognosis and increased overall survival. Stat3β expression
in mouse models of AML resulted in decelerated disease progression and extended survival. It is,
however, unclear whether tyrosine phosphorylation and dimerization are required for the tumor
suppressor activity of STAT3β in these animal models. The contribution of STAT3 in AML may not
only depend on the STAT3β/α ratio but also on the subtype of AML cells or acquired mutations in this
disease. For instance, KITD816V, which is frequently found in core-binding factor (CBF)-AML leukemias,
stimulates autophagy through activation of STAT3 [72]. Inhibition of STAT3 blocked autophagy and
reduced tumor growth in mouse xenograft models. Importantly, inhibition of STAT3 also stimulates
the antitumoral immune response in animal models of AML, indicating that targeting STAT3 would
not only block the growth and survival of AML but also AML-induced immune evasion [73,74].
Mutations in FLT3, either involving internal tandem duplications (FLT3-ITD) or point mutations
in the activating loop of the tyrosine kinase domain (FLT3-KD), were observed in approximately 30% of
AML patients and are associated with poor prognosis [75]. Although FLT3 mutants activate both STAT3
and STAT5 in cell lines, results showed that tyrosine-phosphorylated STAT5 is selectively associated
with expression of FLT3-ITD in primary blasts from AML patients. Activation of STAT5 by FLT3-ITD
is required to induce primary cell survival in vitro and leukemia in vivo [76–80]. Pharmacological
inhibition of STAT5 also blocks FLT3-ITD-driven leukemias in mouse xenograft models [81]. FLT3-ITD
promotes genomic instability by increasing ROS production via activation and association of STAT5
with the GTPase Rac1, which is an essential component of certain NADPH oxidases such as Nox2 [82].
Conversely, ROS production and p22phox, a membrane subunit of NADPH oxidase, are required
for FLT3-ITD-induced STAT5 phosphorylation in the endoplasmic reticulum (ER) [83]. Importantly,
recent works demonstrated that FLT3-ITD-independent activation of STAT5 induced by the leukemic
microenvironment promotes resistance of FLT3-ITD+ AML cells to quizartinib, an FLT3 inhibitor that
is now in phase 3 clinical trial [84].
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Lastly, we should also mention the identification of a fusion between STAT5B and Retinoic Acid
Receptor (RAR)α resulting from an interstitial deletion on chromosome 17 in acute promyelocytic
leukemia (APL) [85]. The corresponding fusion protein enhances STAT3 signaling and blocks myeloid
maturation by inhibiting RARα/retinoid X receptor (RXR)α transcriptional activity [86].
2.4. STAT3/5 in Acute Lymphoblastic Leukemia (ALL)
ALL is the most common form of cancer in children and predominantly arises from the
transformation of B cell progenitors (80–85% of cases) [87]. Mouse studies suggest that STAT5
is functionally important in certain types of B-ALL [88]. Transgenic overexpression of a constitutively
active STAT5A mutant (cS5F) cooperates with p53 deficiency to promote B-ALL in mice [89]. Genetic
or pharmacological targeting of STAT5 suppresses human Ph+ ALL cell growth and leukemia
development in mouse xenograft models [90]. Deregulation of precursor B cell antigen receptor
(pre-BCR) signaling has been shown to be important in the development of B-ALL, and constitutive
activation of STAT5B cooperates with defects in pre-BCR signaling components to initiate B-ALL [91].
Similarly, haploinsufficiency of B cell-specific transcription factors such as EBF1 or PAX5 synergizes
with activated STAT5 in ALL [92]. Despite strong evidence for the oncogenic activity of STAT5 in
TKO-driven B-ALL, the role of STAT5 appears to be context-dependent. For example, the deletion
of STAT5 accelerates the development of B-ALL induced by c-myc in mouse models [93]. Activating
mutations in STAT5B have been found in T-ALL [24,28]. The amino acid substitution N642H in the
phosphotyrosine binding pocket of the SH2 domain promotes the constitutive activation of STAT5B
and the capacity to induce T cell neoplasia in transgenic mice [29,30]. The role of STAT3 in ALL is
poorly documented. However, data indicated that blockade of STAT3 signaling compromises the
growth of B-ALL cells overexpressing the high mobility group A1 (HMGA1)-STAT3 pathway [94].
Unlike STAT5B, there are no recurrent STAT3 mutations detected in T-ALL and, in fact, only single
frameshift mutations are reported (Figure 2).
2.5. STAT3/5 in T Cell Large Granular Lymphocytic (T-LGL) Leukemia
Activating mutations in the SH2 domain of STAT3 (Y640F, D661Y/V) and STAT5B (N642H) were
also described in T-LGL leukemia which is a chronic lymphoproliferative disorder characterized by the
expansion of some cytotoxic T cell or NK cell populations (Figure 2) [95–97]. STAT3 mutations have
been described in 30–40% of T-LGL leukemia patients while STAT5B mutations were found in rare but
typical CD4+ T-LGL leukemia cases. However, STAT5B mutations were more frequently detected in
patients with a severe clinical course. In all cases, mutations were shown to increase the transcriptional
activity of both STAT3 and STAT5B proteins, but only the STAT5BN642H mutation was demonstrated to
drive T-LGL leukemias in mouse models [98,99].
2.6. STAT3/5 in Chronic Lymphocytic Leukemias (CLL)
CLL is characterized by the accumulation of mature clonal B cells in peripheral blood, bone marrow,
and lymphoid tissues. These cells are characterized by an extended lifespan due to intrinsic defects in
apoptosis [100]. Increasing STAT3 phosphorylation on S727 but not on Y705 is believed to be a hallmark
of CLL progression [101]. Phosphorylation of S727 regulates the transcriptional activity of the STAT3
protein but it is also involved in the mitochondrial localization of STAT3 in primary cells from CLL
patients [102]. Cytokines such as interleukin (IL)-15 secreted by the microenvironment contribute to
the survival of CLL cells through JAK-mediated tyrosine phosphorylation of STAT5 [103].
2.7. STAT3/5 in Lymphomas
Lymphomas are cancers of the lymphatic system. They are divided into two categories: Hodgkin
lymphoma (HL) and non-Hodgkin lymphoma (NHL). Data from the literature underscored the
important contribution of STAT3 and STAT5 in the proliferation and/or survival of HL cells [104–106].
Most NHLs are B cell lymphomas. Diffuse large B cell lymphoma (DLBCL) is the most common subtype
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of NHL and consists of at least two phenotypic subtypes: the germinal center B cell-like (GCB-DLBCL)
and the activated B cell-like (ABC-DLBCL) groups. High-level STAT3 expression and activation are
preferentially detected in ABC-DLBCL, which is associated with poor outcomes [107,108]. Inhibition of
STAT3 expression/activity in ABC-DLBCL cells abrogates lymphoma cell growth and triggers apoptosis.
Moreover, STAT3 coordinates migration to facilitate the dissemination of DLBCL [109]. Among
NHL subtypes, peripheral T cell lymphoma (PTCL) and natural killer (NK)/T cell lymphoma (NKTL)
represent a heterogeneous group of diseases with varied clinical features, prognosis and response to
treatment. PTCL has been categorized into several subtypes including PTCL-not otherwise specified
(PTCL-NOS), angioimmunoblastic TCL (AITL), anaplastic large cell lymphoma (ALCL), and the
predominant subsets of cutaneous TCL (CTCL) [110]. Deregulation of STAT3/STAT5 activity was
shown to be important for CTCL pathogenesis and cancer progression [111]. ALCL can be divided
into anaplastic lymphoma kinase (ALK) positive and ALK negative subgroups, based on ALK gene
rearrangements. The nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) fusion protein is the
major oncogenic driver in ALK+ ALCL and it activates STAT3 and STAT5 [17,18]. While STAT3 is
required for NPM-ALK-induced cell transformation and B cell lymphomagenesis, the contribution
of STAT5 is still unclear [112]. Studies indicated that STAT5A, but not STAT5B, is epigenetically
silenced in NPM-ALK tumors and behaves as a tumor suppressor when reactivated to suppress
NPM-ALK expression [34]. Activating mutations of STAT3 and STAT5B have been found in NKTLs
and γδ-T cell lymphomas [25,27]. Recurrent hot spot mutations Y640F and D661Y/V/H/N in the SH2
domain of STAT3 have been identified most commonly in T-LGL leukemia, NK, NK/T, and adult
T cell leukemia/lymphoma (ATLL) patients, while the aggressive STAT5BN642H mutation has been
predominantly found in T-ALL and γδ-T cell lymphomas, such as hepatosplenic TCL, monomorphic
epitheliotropic intestinal TCL, and primary CTCL (Figure 2) [113]. These mutations were shown to be
associated with increased phosphorylated STAT3 and STAT5B proteins and to confer a growth advantage
to transduced cell lines or normal NK cells [27]. Activating STAT3 mutations E616G and E616K in the
SH2 domain found in NK/T cell lymphoma patients were shown to increase the phosphorylation and
transcriptional activity of STAT3 [114]. Interestingly, programmed cell death-ligand 1 (PD-L1) was
overexpressed in NK/T cells harboring hotspot STAT3 mutations, and overexpression of a STAT3E616K
or STAT3E616G mutant was sufficient to enhance PD-L1 expression. These data are consistent with the
role of STAT3 as an important regulator of tumor immune evasion [115]. In summary, STAT3 and
STAT5B, but not STAT5A, are relevant therapeutic targets in the treatment of lymphomas. All recurrent
STAT3 and STAT5B mutations in hematopoietic cancers are summarized in Figure 2.
2.8. STAT3/5 in Myelomas
Multiple myeloma (MM) is a B cell malignancy characterized by the proliferation of clonal plasma
cells in the bone marrow accompanied by secretion of monoclonal immunoglobulin [116]. Constitutive
tyrosine phosphorylation of STAT3 has been evidenced in MM cell lines and primary CD138+ cells
from MM patients [117,118]. Patients with STAT3 activation were found to have significantly shorter
progression-free and overall survival [119]. STAT3 activation has been reported to contribute to MM
progression both directly, by upregulating survival and anti-apoptotic target genes, as well as indirectly
by activating myeloid-derived suppressor-cells (MDSCs) in the bone marrow microenvironment,
which facilitates tumor progression [120,121]. Myeloma cells rely on the pleiotropic cytokine IL-6,
which activates the JAK/STAT3 pathway. IL-6 signaling is tightly regulated by tyrosine phosphatases
SHP-1 and SHP-2, and suppressor of cytokine signaling 1 (SOCS1). The disruption of this negative
feedback loop results in the constitutive activation of STAT3 [122]. Accordingly, SHP-1 and SOCS1 genes
were found to be silenced by hypermethylation in MM patients [123]. In addition to the induction of
anti-apoptotic gene expression in MM cells, STAT3 also regulates the expression of microRNA-21 with
strong anti-apoptotic potential, suggesting that noncoding RNAs have an impact on the pathogenesis
of human MM [124]. Moreover, the expression of five long noncoding RNAs (lncRNAs) was found to
be regulated by STAT3 in MM cells [125]. However, the role of these lncRNAs in the progression of MM
16
Cancers 2020, 12, 240
remains to be elucidated. The role of STAT5 seems to be marginal and restricted to immunoglobulin
production in MM [126].
3. Canonical and Non-Canonical Roles of STAT3/STAT5 in Hematopoietic Cancers
It was presumed that most, if not all, of the oncogenic activities of STAT3/STAT5 are due to
canonical functions. However, STAT3/5 proteins are also active through alternate non-canonical
pathways impacting cell transformation. Post-translational modifications affecting canonical and
non-canonical roles of STAT3 and/or STAT5 have been extensively reviewed in the literature. To be in
line with this review, we will focus on canonical and non-canonical activities of STAT3/5 that have
been described in cell transformation (Figure 3).
3.1. Canonical Function of STAT3/STAT5
In the canonical model, STAT3, STAT5A, and STAT5B are primarily activated by phosphorylation
on tyrosine residues Y705, Y694, and Y699, respectively (Figure 1). In a physiological situation,
STAT3 and STAT5 are transiently phosphorylated by JAK in response to cytokine receptor signaling,
and contribute to hematopoietic cell proliferation and differentiation. In contrast, persistent tyrosine
phosphorylation of STAT3/5 induced by TKOs promotes hematopoietic cell transformation [6,7].
Phosphorylation of additional tyrosine residues in STAT5A and STAT5B proteins in TKO-transformed
cells has also been described in the literature, but the functional and physiological meaning of
such phosphorylations remains unclear [127,128]. P-Y705-STAT3 (herein referred to in this review
as P-Y-STAT3), P-Y694-STAT5A (P-Y-STAT5A), and P-Y699-STAT5B (P-Y-STAT5B) proteins dimerize
through reciprocal interactions between the SH2 domain of one monomer and the phospho-tyrosine
residue of the other. P-Y-STAT3, P-Y-STAT5A, and P-Y-STAT5B form homodimers but P-Y-STAT5A can
also dimerize with P-Y-STAT5B. The formation of STAT5A/5B heterodimers is not only dependent on the
relative abundance of each protein but can also be differentially affected by upstream signaling events.
For instance, BCR-ABL is less efficient in inducing STAT5A/5B heterodimerization than IL-3 [128].
Heterodimers between P-Y-STAT3 and P-Y-STAT5A or P-Y-STAT5B have never been reported despite
the capacity of some TKOs to simultaneously activate these proteins. After dimerization, STAT3,
STAT5A, and STAT5B are translocated into the nucleus. Nuclear import is dependent on a nuclear
localization signal present in the coiled-coil domain [129]. The nuclear import of STAT3/STAT5 occurs
independently of their tyrosine phosphorylation and is mediated by the importin-α3/β1 system coupled
to Ras-related nuclear (Ran) proteins bound to GDP or GTP [129]. Molecules other than importins and
Ran also participate in the regulation of the nuclear translocation of STAT3/5. The small GTPase Rac1
and the GTPase-activating protein MgcRacGAP form a ternary complex with P-Y-STAT3 or P-Y-STAT5
to induce their translocation via the importin α/β pathway [130]. The MgcRacGAP/Rac1 complex
also regulates the tyrosine phosphorylation of STAT3/5 induced by cytokines [131,132]. Interestingly,
p21-activated kinases (PAK1 and PAK2), which are important effectors of Rac1, were shown to induce
phosphorylation of the S779 residue and nuclear translocation of STAT5A in BCR-ABL-expressing
cells [133]. In a similar vein, activation of focal adhesion kinase (FAK) by FLT3-ITD or KITD816V
in AML cells was demonstrated to induce the nuclear translocation of STAT5 via the Rac1/PAK1
pathway [134]. In sharp contrast, several reports indicated that P-Y-STAT5 is abundantly detected
in the cytoplasm of BCR-ABL+ cells and that Src kinases might be responsible for the cytoplasmic
retention of P-Y-STAT5A [135,136]. The reasons for these apparent controversial data remain unclear
but might be related to the cellular context.
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Figure 3. STAT3 and STAT5 signaling in hematologic malignancies. (A) Canonical function. In the
canonical model, TKOs, or GOF mutations induce persistent activation (e.g., tyrosine phosphorylation)
and nuclear translocation of STAT3 and STAT5, which then bind as dimers or tetramers to specific
promoter sequences to regulate transcription of genes involved in cell growth, apoptosis, angiogenesis
and immune response. Other post-translational modifications, as indicated, regulate the oncogenic
activity of STAT3/STAT5. OGT (O-GlcNAc transferase). (B) Non-canonical function. uSTAT3 and
uSTAT5 (non-tyrosine phosphorylated STAT3/5) proteins also have an active role in the nucleus,
mitochondrion, ER (endoplasmic reticulum), GA (golgi apparatus), ETC (electron transport chain).
Besides their transcriptional activity, P-Y-STAT3 and P-Y-STAT5 interact with different signaling
pathways in the cytoplasm and ER.
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Tyrosine phosphorylated STAT3/STAT5 dimers bind to specific DNA elements found in
promoters, enhancers, and the first intron of target genes. These binding sites are characterized
by clusters of conserved motifs with an interferon gamma-activated site (GAS)-like core sequence
(TTCT/CNA/GGAA). STAT5 was shown to bind as a tetramer on adjacent GAS sequences with
high or weak affinity in target gene promoters [137,138]. The tetramerization domain located in
the NH2-terminal region of STAT5 was found to promote constitutively active, STAT5A mutant
(cS5F)-induced leukemia in mice [23]. The NH2-terminal domain of STAT3 is also required for
oligomerization and IL-6-dependent transcriptional regulation [139]. This domain is involved
in STAT3-mediated survival of solid tumor cells but its role in hematologic cancers is currently
unknown [140].
TKO-mediated activation of STAT3 and/or STAT5 regulates expression of common as well
as specific genes involved in hematopoietic cell survival, proliferation, metabolism, hypoxia,
autophagy, migration and tumor immune evasion. BCL2-family members, cell cycle-regulated
genes, proto-oncogenes such as PIM1, c-MYC, BCL6, and genes involved in cytokine receptor signaling
or immune response are often targets of STAT3/STAT5-mediated transcription in hematopoietic
cancers [141]. Transcription of these genes is also dependent on P-Y-STAT3/5 levels in the nucleus.
For instance, previous works demonstrated that nuclear P-Y-STAT5 proteins at low, intermediate,
and high levels differentially affect self-renewal, proliferation, and differentiation of leukemic stem cells
by regulating the expression of distinct sets of genes [142]. Accordingly, P-Y-STAT5 regulates D-type
cyclins and c-MYC expression at intermediate levels to promote proliferation but upregulates expression
of the cyclin-dependent kinase (CDK) inhibitor p21waf1 at high levels to induce growth arrest and
differentiation. Similarly, while constitutively active STAT3 was shown to protect CLL cells from
apoptosis, at high levels it induced apoptosis and caspase-3 expression [143]. These data emphasize that
increasing nuclear levels of P-Y-STAT3/5 might confer a growth disadvantage to leukemic cells [143,144].
Protein–protein interactions also drive the regulation of STAT3/STAT5-dependent gene expression.
STAT3 and STAT5 interact with many transcription factors, co-factors, and/or chromatin remodeling
proteins such as enhancer of zeste homolog 2 (EZH2), CREB-binding protein (CBP)/p300, ten-eleven
translocation 2 (TET2), and DNA methyltransferase 1 (DNMT1), which largely impact hematopoiesis
or leukemogenesis. Blocking these proteins also interferes with STAT3/STAT5-mediated transcription
and cancer cell growth. Most of these interacting partners were exhaustively described in a recent
review and will not be discussed here [141]. In addition, serine phosphorylation plays an important
role in STAT3/5-dependent cell transformation. Constitutive phosphorylation of S727, which is
located in the COOH-terminal transactivation domain of STAT3 (Figure 1), was shown to increase
the transcriptional activity of this protein in CLL cells [101]. The oncogenic activity of STAT5A is
highly dependent on S725 and S779 phosphorylation, and both residues (S726 and S780 in humans)
were found to be constitutively phosphorylated in AML, ALL, and CML cells [145]. Importantly,
PAK-dependent S779 phosphorylation of STAT5A is required for BCR-ABL-induced leukemogenesis
but is not affected by BCR-ABL tyrosine kinase inhibitor treatment, indicating that oncogenic activation
of STAT5A is mediated by independent pathways in BCR-ABL-expressing cells [133]. Phosphorylation
of S779/780 on STAT5A also promotes the expansion and transformation of human hematopoietic
stem/progenitor cells (HSCs/HPCs) [53]. Constitutive phosphorylation of S193 on STAT5B has been
detected in various lymphoid tumor cell lines as well as in primary cells from leukemia or lymphoma
patients [146]. Phosphorylation of S193 was found to be sensitive to inhibitors of mammalian targets
of rapamycin (mTOR) and to play an important role in the DNA binding and transcriptional activity of
STAT5B. Other post-translational modifications such as glycosylation affect the oncogenic functions
of STAT5. O-GlcNAcylation at threonine 92 in STAT5A and STAT5B was shown to regulate tyrosine
phosphorylation and transcriptional activity of oncogenic STAT5 in leukemic cells [147].
STAT3 and STAT5 also undergo acetylation on multiple lysine residues by the CBP/p300 histone
acetyltransferase [148]. Acetylation of K685 located in the SH2 domain of STAT3 can enhance
transcriptional activity by increasing dimer stability. Mutation of K685 affects dimerization but not
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tyrosine or serine phosphorylation of STAT3, and acetylation of STAT3 can occur in the absence of
tyrosine phosphorylation [149,150]. AcK685-STAT3 also recruits DNMT1 to induce the epigenetic
silencing of tumor suppressor genes [151]. Acetylation of STAT5A and STAT5B at K696 and K694/K701
residues, respectively, is also required for STAT5 dimerization [152]. The contribution of acetylation
in the canonical functions of oncogenic STAT3/5 on one hand, and in hematopoietic cancers, on the
other hand, remains very unclear. Previous work indicated that acetylation of K685 does not play an
essential role in the expression of the great majority of P-Y-STAT3-dependent genes, suggesting that
acetylation might be more important for the non-canonical functions of STAT3/5 [153].
Methylation of nuclear STAT3 on K140 or K49/K180 by the histone-modifying enzymes SET
domain-containing lysine methyltransferase 9 (SET9) or EZH2, respectively, have been reported to
mediate opposing effects on STAT3-dependent transcriptional activity [154–156]. STAT5 also interacts
with EZH2 in B cells to repress the Igκ locus [157]. The methylation status of STAT3 and STAT5 in
hematopoietic cancers has yet to be investigated. Similarly, other post-translational modifications such
as oxidation, glutathionylation, or sumoylation were shown to negatively regulate STAT3/5 activity,
but their impact on STAT3/5-driven hematologic malignancies are still unknown [158–162].
The concomitant activation of STAT3/5 by TKOs is probably the most intriguing event in
leukemogenesis as both proteins in cancer cells have compensatory and/or opposing effects on gene
expression and cell fate [163]. For instance, the competitive binding of STAT3 and STAT5 to the regulatory
loci of BCL6 and IL-17 has been shown to modify gene expression and cell phenotype [164,165].
The differential recruitment of co-activators and/or co-repressors might explain these opposing effects
on gene expression. Activation status of both STAT5 and STAT3 might, therefore, provide important
diagnostic and prognostic information in hematologic cancers. Notably, JAK2V617F activates both STAT3
and STAT5, but only STAT3 negatively regulates JAK2V617F-dependent MPN development [66,67].
3.2. Non-Canonical Functions of STAT3/STAT5
Subcellular localization of P-Y-STAT3/5 is not restricted to the nucleus and previously published
data highlighted important functions of P-Y-STAT3/5 in the cytoplasm and/or other subcellular
organelles of cancer cells. Cytoplasmic localization of P-Y-STAT5 was abundantly found in leukemic
cells expressing BCR-ABL, JAK2V617F, or KITD816V. Here, it was shown to interact with the scaffolding
adapter Gab2 to favor the activation of the phosphatidylinositol-3-kinase (PI3K)/AKT pathway and
leukemic cell survival [12,135,166]. The deletion of Gab2 attenuated the transforming potential of an
oncogenic STAT5 mutant in mouse models [167]. Interaction of P-Y-STAT5 with Rac1, which is
also an important component of certain membrane-bound NADPH-oxidase (NOX) enzymatic
complexes, promotes ROS production in FLT3-ITD-expressing AML cells thereby increasing cell
growth concomitantly with DNA damage [82]. BCR-ABL- and JAK2V617F-induced ROS generation
is mediated by P-Y-STAT5, and binding of P-Y-STAT5 to the NOX2 complex in BCR-ABL+ cells also
requires active Rac1 (unpublished data) [58,59,168]. P-Y-STAT3 has been detected in focal adhesions
of cancer cells where it interacts with phosphorylated paxillin and FAK, thereby regulating cell
migration [169]. Constitutively active STAT3 also controls Ca2+ release in the ER by interacting
with inositol 1,4,5-triphosphate receptors (IP3R3), facilitating its proteasomal degradation [170].
Accordingly, the binding of STAT3 to IP3R3 protects cells from oxidative/ER stress and apoptosis.
Finally, the mitochondrial localization and the potential role of P-Y-STAT3 and P-Y-STAT5 in regulating
the mitochondrial genome have also been reported [171–173]. Collectively, these data suggest that
P-Y-STAT3/5 distribution in subcellular organelles or cytoplasmic structures may directly impact cancer
cell growth and survival independently of their transcriptional activity in the nucleus. It would then
be relevant to explore in further detail the subcellular localization and function of P-Y-STAT3/5 in
hematologic malignancies.
Constitutive phosphorylation of STAT3 on residue S727, but not on Y705, plays a role in the
pathogenesis of CLL by regulating STAT3-dependent expression of genes associated with cell growth
and survival [101]. DNA binding and transcriptional activity of P-S727-STAT3 probably require
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acetylation of K685 because (1) persistent acetylation of K685 on STAT3 has been observed in CLL
cells, (2) acetylation of K685 promotes dimer formation, DNA binding and activation of transcription,
and (3) K685 acetylation provides CLL cells with survival advantages [174]. In addition to its nuclear
localization, P-S727-STAT3 was also found in mitochondria where it contributes to the viability of
CLL cells and protects against oxidative stress [102]. The oncogenic activity of mitochondrial STAT3
was first demonstrated in H-RasV12-transformed cells where it promotes anchorage-independent cell
growth and tumor induction in mice [175]. Phosphorylation of S727 is carried out by the MAPK/ERK
kinase (MEK)/Extracellular signal-regulated kinases (ERK) pathway and is necessary for Ras-mediated
cell transformation [176]. Mitochondrial P-S727-STAT3 also supports K-RasG12D-driven hematologic
neoplasms [177]. Retinoid interferon-induced cell mortality (GRIM)19, a component of the electron
transport chain (ETC) complex 1 and binding partner of STAT3, was shown to mediate STAT3
uptake into mitochondria [178]. However, other proteins such as the chaperone TOM20 have also
been suggested as mitochondrial carriers of STAT3 [179]. Phosphorylation of S727 is important for
mitochondrial STAT3 to upregulate ETC activity and ATP production, and mutation of S727 decreases
the mitochondrial translocation of STAT3 [178]. In addition, CBP-dependent acetylation of K87 was
also found to promote the mitochondrial localization of STAT3 [180]. Hematopoietic cell-targeted
deletion of the stat3 gene demonstrated the critical role of mitochondrial STAT3 in HSC/HPC function.
stat3−/− mice have a blood phenotype with similarities to human diseases of myelodysplastic syndrome
(MDS) and MPN, supporting, as mentioned above, a negative regulatory role of STAT3 in MPN
development [181]. These data also suggest that targeting mitochondrial STAT3 in K-Ras-induced
hematopoietic malignancies might have adverse effects on normal HSCs. In addition to mitochondrial
functions, non-tyrosine phosphorylated STAT3 and STAT5 proteins (uSTAT3/5) also have important
roles in the nucleus, ER, and Golgi apparatus (GA). The knockdown of STAT5A/5B in human pulmonary
arterial endothelial and smooth muscle cells resulted in a loss of uSTAT5A and uSTAT5B associated
with the GA, leading to a dramatic destabilization of the ER and GA. This was accompanied by the
activation of ER stress pathways, indicating a potential role of uSTAT5 in maintaining the structure and
function of these organelles [182]. Inhibition of uSTAT5 activity/expression induced ROS production
and apoptosis in pre-B leukemic cells, indicating that uSTAT5 may also provide protection against
oxidative stress [183] (unpublished data).
uSTAT3/5 are also involved in the regulation of transcription and chromatin remodeling as
preformed anti-parallel dimers [129,141]. The NH2-terminal domain mediates the dimerization
of uSTAT3 and is essential for its nuclear accumulation, DNA binding, chromatin remodeling,
and regulation of gene expression [184,185]. Acetylation of K685 was shown to be crucial for uSTAT3 to
form stable dimers and regulate gene transcription [149]. Accordingly, the majority of uSTAT3-mediated
gene expression depends on the ability of K685 to become acetylated [153]. Interestingly, nuclear
uSTAT3 regulates the expression of well-known genes in cancer, suggesting that uSTAT3 might
contribute to oncogenesis [186]. The role of uSTAT5 is less documented but data from the literature
indicates that nuclear uSTAT5 behaves as a partial antagonist of P-Y-STAT5 and acts as a repressor to
maintain self-renewal of hematopoietic cells and to block differentiation [187]. The role of uSTAT3/5
in the initiation, emergence and/or progression of hematologic cancers has yet to be determined.
However, previous studies suggested that uSTAT5 provides preferential and critical cell survival
signals in lymphoid tumor cells, indicating that uSTAT3/5 should also be considered as therapeutic
targets in certain hematologic malignancies [188]. Our understanding of the molecular mechanisms
involved in non-canonical functions of STAT3/5 is still incomplete. Most of these activities contribute
to the known roles of STAT3/5 in hematopoiesis and hematopoietic neoplasms, and this knowledge
complicates the already difficult task of targeting STAT3/5 for therapeutic purposes.
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4. Pharmacological Inhibitors of STAT3 and STAT5
4.1. Introduction
Modalities for targeting STAT3 and STAT5 in hematologic cancers can be classified into direct
and indirect approaches. Compounds directly targeting STAT3 or STAT5 canonical functions may
either inhibit dimerization, DNA binding, or transcriptional activity. Indirect approaches include
preventing ligands binding to growth factor or cytokine receptors, inhibiting upstream tyrosine
kinases such as TKOs, targeting the nucleocytoplasmic shuttling of STAT3/5, or activating negative
regulators of STAT3/5 such as the tyrosine phosphatases SOCS or PIAS [189–191]. Both direct or
indirect approaches might also be applied to non-canonical functions. Molecules targeting STAT3/5
protein expression/stability or disrupting interactions with partners that play critical roles in oncogenic
STAT3/5 activity should also be considered.
Historically, abnormal activation of STAT3 in solid tumors was first appreciated before STAT5 was
implicated, and as such, various therapeutics to target STAT3 were first developed based on one or
more of these strategies described above. Pioneering works using phospho-Y-peptides to compete with
P-Y705 for binding to the SH2 domain of STAT3 and peptidomimetic derivatives provided the proof
of concept that disrupting the P-Y705/SH2 domain interaction could be an efficient strategy to block
oncogenic STAT3 signaling [192,193]. However, peptides and peptidomimetics have certain limitations
in line with their in vivo instability and poor membrane permeability [194]. Nevertheless, these
limitations provided the necessary impetus in many programs to design small molecules with greater
and more specific inhibitory effects. Blocking DNA binding using decoy oligonucleotides (Duplex
ODN), G-quartet oligonucleotides (GQ-ODN), or DBD peptide aptamers was another strategy to
suppress canonical functions of STAT3 and STAT5. Treatment with STAT3 or STAT5 ODNs inhibits cell
growth and/or induces apoptosis by preventing nuclear translocation of STAT3/5 in cancer cells [195].
RNA interference (RNAi) or antisense oligonucleotides (ASO) were also employed to target STAT3/5
mRNA in leukemia or lymphoma cells [195]. Some of these tools have been promising in modulating
STAT3/5 signaling and inhibiting tumor cell growth. However, the therapeutic success of these different
approaches relies on the effective entry and stability of the oligonucleotides in the cells and therefore
requires chemical modifications for this purpose. Finally, cell-based screening with chemical compound
libraries has allowed the identification of natural, synthetic, or clinically used molecules that inhibit
STAT3/5 transcriptional activity [196,197]. However, hits derived from these assays have indirect effects
that are challenging to determine. Due to an ever-growing list of STAT3/5 inhibitors and reviews in
the field, we will focus on those that have been tested in hematopoietic cancers. We will discuss the
limitations of STAT3/5 inhibitors in the treatment of these diseases but also promising outcomes when
combined with other pharmacological compounds.
4.2. Indirect Inhibitors of STAT3 and STAT5 Signaling in Hematopoietic Cancers
4.2.1. Targeting Upstream Tyrosine Kinases
Most agents that are described as indirect STAT3/5 inhibitors actually target upstream kinases
such as JAK, Src, BCR-ABL, FLT3, or KIT receptors. Activation of STAT3 and/or STAT5 is dependent
on the leukemic cell type in which the kinase is active. The development of IM and related BCR-ABL
kinase inhibitors such as nilotinib, dasatinib, bosutinib, and ponatinib has made a major breakthrough
in targeted cancer therapy, CML and Ph+ALL treatment [198–204]. IM leads to complete inhibition
of BCR-ABL-dependent STAT5 activation and this is likely an important part of the effectiveness
of this molecule [49,90]. However, some patients cannot tolerate the side effects of IM and related
TKIs. In addition, the development of resistance to TKIs is a significant clinical problem, and is
due, in part, to acquired point mutations in BCR-ABL such as T315I [205]. Although second- and
third-generation TKIs were found to be effective against some BCR-ABL mutants, TKIs alone do not
eradicate LSCs and de novo resistance of CML cells [55,56,62]. Targeting the kinase activity of FLT3
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mutants has also been adopted to inhibit aberrant signaling in AML [206]. Among the agents that
have been or are being evaluated in preclinical studies and/or clinical trials are multi-kinase inhibitors
midostaurin (PKC412), sorafenib (BAY 43-9006), lestaurtinib (CEP701), KW-2449 (which also targets
T315I-mutated BCR-ABL), sunitinib (SU11248), tandutinib (MLN518), and quizartinib (AC220), as
well as compounds more specific for FLT3 mutants, including crenolanib (CP-868596) and gilteritinib
(ASP2215) (Table 2) [207–219]. Few of them were approved for the treatment of FLT3-mutated AML as
a single-agent or in combination with other therapeutic drugs. Although the effectiveness of these
inhibitors was shown in preclinical studies, mixed results have been observed in clinical trials. Clinical
activity of some of these molecules was evidenced in patients with FLT3-mutated AML but was
often transient and relapse eventually occurred [206]. Secondary mutations in FLT3 and/or mutations
associated with epigenetic regulators or transcription factors are responsible for the loss of therapeutic
response to FLT3 inhibitors [206,220]. In addition, the bone marrow microenvironment provides
protection against FLT3-TKIs [221]. Midostaurin, crenolanib, and tandutinib were also employed
to inhibit KITD816V activity in mast cells from SM patients, while lestaurtinib was tested in two
phase 2 trials for MPN treatment (Table 2) [222–226]. Other potent and selective KITD816V inhibitors
including avapritinib (BLU-285) and DCC-2618 have entered clinical trials with promising results for
the treatment of SM [222].
A breakthrough in understanding myeloproliferative diseases occurred after the discovery of GOF
mutations in JAK2, leading to the development of small-molecule inhibitors of JAK2 for the treatment
of MPNs [227]. In clinical trials, responses obtained with JAK inhibitors are independent of the driver
mutations. However, treatment with JAK inhibitors was shown to have some limitations, partly
because the targeted pathway is required for normal hematopoiesis and because specific inhibitors
targeting the JAK2V617F mutant are yet to be developed. Consequently, JAK2 inhibitors have been
disappointing in their ability to induce molecular remissions in MPN patients, indicating that JAK2
inhibitors do not preferentially target MPN cells over normal cells [228]. In addition, some of the
JAK inhibitors that entered clinical trials were discontinued due to their adverse effects. A crystal
structure and biochemical properties of the pseudokinase domain of JAK2 will certainly assist in
developing JAK2V617F-specific inhibitors in the future. Selective JAK and pan-JAK inhibitors that
variably affect P-Y-STAT3/5 levels in hematologic neoplasms are presented in Table 2. Ruxolitinib is the
first clinically-approved JAK1/2 inhibitor for PV and MF treatment and is also in clinical trials either
alone or in combination with other pharmacological agents or TKIs for HL, MM, or CML treatment
(Table 2) [227–232]. Ruxolitinib and most of the JAK inhibitors that are in clinical trials are type I
inhibitors, which means that they block the ATP-binding site of JAKs under the active conformation
of the kinase domain [227,233–237]. Type II inhibitors bind to the ATP-binding pocket of the JAK2
kinase domain in the inactive conformation, while allosteric inhibitors interact with other sites in the
JAK2 protein [227]. Importantly, JAK2 target inhibition in MPN can be improved with the type II
inhibitor NVP-CHZ868 offering increased therapeutic efficacy [238]. NVP-CHZ868 was also shown
to act synergistically with dexamethasone in suppressing the growth and survival of human B-ALL
cells in PDX models [239]. JAK2-specific inhibitors such as pacritinib are in the final stages of clinical
trials for primary and secondary MF, and display increased potency compared to currently available
JAK inhibitors [233]. Gandotinib, which is in a phase 2 study for JAK2V617F-mutated MPN treatment,
showed an increased potency for the JAK2V617F mutant [240]. Another example of a JAK2 inhibitor,
fedratinib, which was previously burdened with a clinical hold in 2013, was recently FDA-approved for
the treatment of MPN patients who have failed therapy with ruxolitinib [241]. Fedratinib also blocks the
growth of HL and Mediastinal Large B-cell Lymphoma (MLBCL) in vitro and in vivo as demonstrated
in preclinical studies [242]. Many JAK inhibitors with different selectivity and/or mechanisms of action
have been tested in leukemias, lymphomas and MM (Table 2) [243–268]. For instance, AZD1480,
INCB20, INCB16562, NS-018 and momelotinib (CYT-387) showed promising in vitro and/or in vivo
efficacy against MM cells (Table 2) [246–248,251,261]. In all cases, P-Y-STAT3 was markedly reduced in
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MM cells treated with these inhibitors. Collectively, these data strongly support that JAK inhibition
has significant potential as a therapeutic strategy in MM.
4.2.2. Natural and Synthetic Molecules
Historically, natural compounds have been successfully used in the management of various human
diseases. Natural products may also serve as a basis for the synthesis of derivatives aiming to increase
their efficacy. There are several compounds that are known to exert anti-tumor effects through their
indirect or direct action on STAT3 and/or STAT5 signaling. These natural molecules have a low toxicity
profile and can act synergistically with other pharmacological agents to reverse chemoresistance.
A number of plant-derived molecules such as avicin D, curcubitacin I, butein, honokiol, capsaicin,
celestrol, and piperlongumine have been reported to inhibit growth or survival of leukemia, lymphoma,
or myeloma cells in preclinical studies (Table 2) [269–277]. However, the mechanistic basis of their
effects on STAT3/STAT5 signaling is still unknown. Inhibition of upstream kinases JAK1/2 and Src,
and upregulation and/or activation of SHP1 or other protein tyrosine phosphatases appear to be a
common feature of these compounds. Curcumin, a naturally derived phytochemical from plants such
as turmeric (Curcuma longa), has been extensively investigated for its anti-tumor effects [278]. Curcumin
was shown to block STAT3 and/or STAT5 phosphorylation in leukemia, lymphoma, and myeloma
cells (Table 2) [279–283]. Although the administration of curcumin has been shown to be safe in
humans, its clinical utility is somewhat limited due to the poor bioavailability and target selectivity.
Therefore, efforts were made to design and synthesize novel curcumin analogs. FLLL32, one of these
analogs, was shown to inhibit P-Y-STAT3 and growth of MM cells with greater efficacy but, again,
target selectivity and mechanisms of action remained poorly defined [284]. The synthetic triterpenoid,
CDDO-Imidazolide, which acts as an anti-inflammatory and anti-cancer drug, was demonstrated to
suppress STAT3 and STAT5 phosphorylation and to induce apoptosis in MM cells [285]. EC804, a
synthetic derivative of indirubin, an active component in a traditional Chinese medicine formulation,
was reported to inhibit STAT3 and/or STAT5 phosphorylation as well as the growth of sensitive or
TKI-resistant CML and AML cells [286,287]. This compound also blocks STAT3 activity in solid
tumors [288]. Natural and synthetic compounds such as sulforaphane and the BET inhibitor JQ1
were found to inhibit STAT5-mediated transcription in CML and T-ALL cells, probably via epigenetic
mechanisms [289,290]. Naphthoquinone (NPQ)-based derivatives could be also mentioned as indirect
inhibitors of STAT5 probably through their multikinase modulatory effects in leukemias [291]. Research
in our laboratory is focused on the synthesis and development of small-molecule inhibitors of STAT5.
We recently identified 17f as a compound that selectively inhibits STAT5 phosphorylation and expression
in AML and CML cells [292]. Moreover, we found that 17f overcomes the resistance of CML and AML
cells to IM and Ara-C, a conventional therapeutic agent used in AML treatment [293]. We also found
that 17f, when associated with IM or Ara-C, inhibits expression of STAT5B but not STAT5A in resistant
CML and AML cells via translational or post-translational mechanisms. The mechanistic basis of this
inhibitory effect is currently under investigation.
4.2.3. Drug Repositioning
Cell-based assays for high-throughput screening were employed to identify compounds that
specifically block the transcriptional activity of STAT3/5 [196,197]. This type of strategy utilizes cells
that are stably transfected with a construct containing the luciferase reporter gene under the control of
a specific and high-affinity STAT3 or STAT5 responsive promoter. Chemical libraries of compounds
biased toward bioactives and drugs known to be safe in humans were used in the screening. Using this
approach, nifuroxazide, niclosamide, and pyrimethamine were identified as specific inhibitors of STAT3,
while pimozide was found to inhibit STAT5 activity (Table 2). Nifuroxazide, an antidiarrheic agent, was
shown to decrease STAT3 tyrosine phosphorylation, most probably via inhibition of JAK kinase activity,
and to reduce the viability of MM cells [294]. Niclosamide, an antiparasitic drug, blocks P-Y-STAT3 and
myeloma cell growth via unknown mechanisms. Niclosamide lacks selectivity because it also inhibits
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NFkB activity in MM cells [295]. The antiparasitic and antifolate drug pyrimethamine also displays
significant activity in vitro against MM cell lines harboring P-Y-STAT3 [196]. Pyrimethamine inhibited
P-Y-STAT3 and transcriptional activity without affecting its upstream kinase JAK2. Three-dimensional
modeling studies indicated that pyrimethamine binds to the SH2 domain, suggesting that it might be a
direct inhibitor of STAT3, but this interaction needs to be biophysically demonstrated. Pyrimethamine
was also found to be a potent inducer of apoptosis in AML cells [296]. However, it is still unclear
whether the antitumor activity of pyrimethamine is due to its inhibitory effect on STAT3 and/or on
folic acid metabolism [297]. Pyrimethamine is currently in a phase 1 clinical trial for the treatment of
high-risk MDS and in phase 12 trials for CLL and small lymphocytic lymphoma (SLL) treatment.
Pimozide was identified by high-throughput drug screening as a potent inhibitor of STAT5.
Pimozide was shown to inhibit P-Y-STAT5 and survival of CML and MPN cells without affecting the
kinase activity of BCR-ABL, JAK2 or Src [298,299]. Pimozide shows synergistic effects with IM/nilotinib
in killing CML cells and overcomes TKI resistance in BCR-ABLT315I mutant cells [298]. The effects of
pimozide are not limited to CML and MPN cells, and the efficacy of this drug was also demonstrated
in AML. Pimozide can also inhibit P-Y-STAT5 and STAT5-dependent gene expression in AML cells
expressing FLT3-ITD, and it acts synergistically with FLT3 inhibitors to induce apoptosis in these
leukemic cells [79]. The mechanisms involved in pimozide-mediated inhibition of P-Y-STAT5 is
currently not known. Pimozide also inhibits P-Y-STAT3 in myeloma cells indicating that it is not a
selective STAT5 inhibitor [196]. Antidiabetic drugs such as pioglitazone and rosiglitazone were shown
to have antileukemic activity [300]. Both synthetic compounds belong to the thiazolidinedione (TZD)
class of ligands that bind to the nuclear receptor PPARγ. Activation of PPARγ by pioglitazone not only
inhibits the growth of CML cells but also reduces the expression of STAT5 genes [60]. Quiescent CML
stem cells, which are known to be resistant to TKI treatment, are highly sensitive to pioglitazone when
combined with IM. This suggests that besides phosphorylation, targeting STAT5 expression might be
important for eradicating resistant CML stem cells. Whether PPARγ directly regulates STAT5A and
STAT5B gene promoter activity remains to be investigated. Pioglitazone combined with IM are now
in a phase 2 trial to evaluate the impact of this combination therapy on CML residual disease [301].
Activation of PPARγ was also shown to induce apoptosis in Ph+ ALL cells [302]. Finally, PPARγ
agonists were found to inhibit the transcriptional activity of STAT3 in MM cells. In that case, it has
been proposed that PPARγ and STAT3 may compete for binding to nuclear co-factors [303].
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4.3. Direct Inhibitors of STAT3 and STAT5 in Hematopoietic Cancers (Table 3)
The mechanisms of direct STAT3/5 inhibition include disruption of tyrosine phosphorylation,
dimerization, nuclear translocation and/or DNA binding. Targeting the SH2 domain was, therefore,
the main focus for the design and identification of selective inhibitors.
4.3.1. Inhibitors Targeting the SH2 Domain
Dimerization is an essential step in the canonical functions of STAT3 and STAT5. Blocking this
process seems to be an optimal solution to directly inhibit aberrant STAT3/5 signaling in hematopoietic
cancers. The SH2 domain is not only required for dimer formation but also in the recruitment of
STAT3/5 to tyrosine-phosphorylated receptor complexes. Therefore, initial strategies aiming to identify
phosphopeptide (P-Y-peptide) inhibitors able to block SH2/P-Y interactions were pursued by several
teams. This approach was first attempted by Turkson et al. who demonstrated that the peptide
PY*LKTK (where Y* represents P-Y705) inhibits STAT3 dimerization and tumor cell growth [192].
P-Y-peptides derived from STAT3 docking sites of gp130 and other cytokine or growth factors receptors
were also used to identify the P-Y-peptide YLPQTV as a potent blocker of STAT3 dimerization and
DNA binding [304,305]. Although highly specific, peptides usually have poor membrane permeability,
low stability, and consequently low biological activities. This prompted investigators to develop
peptidomimetics using the tripeptide PY*L, the minimum P-Y-peptide sequence required for STAT3
inhibition. One of these peptidomimetics, ISS610 was shown to be more potent in disrupting STAT3
dimerization and DNA binding but still had poor membrane permeability [193]. Structural and
computational analysis of the interaction between ISS610 and the STAT3 SH2 domain led to the
development of the peptidomimetic molecule, S3I-M2001, having increased membrane permeability
but similar capacity in inhibiting STAT3 DNA binding [306]. Despite hard work in developing peptides
or peptidomimetics with potent STAT3-inhibitory activity, poor permeability and metabolic stability
have precluded their clinical testing. For the same reason, no peptide/peptidomimetic inhibitors of
STAT5 have been developed. Based on the proof of concept that the STAT3-SH2/pY-peptide interaction
was amenable to targeting, small nonpeptidic compounds that could specifically bind to the SH2
domains of STAT3 or STAT5 have become attractive candidates. Here, we will discuss the SH2
domain inhibitors that have been used in preclinical studies and clinical trials for the treatment of
hematologic malignancies.
Most of the small molecules targeting the SH2 domain of STAT3 were identified by structure-based
high-throughput virtual screening. The available X-ray crystallographic data of both the monomer
and dimerized STAT3 bound to DNA were essential for these in silico studies [307]. Among these
molecules, S3I-201, STA-21, C188, and STX-0119 were shown to block the phosphorylation, dimerization,
DNA binding, and transcriptional activity of STAT3 as well as growth and survival of cancer
cells [308–311]. In modeling studies, S3I-201 was shown to bind to the STAT3-SH2 domain through its
salicylic acid moiety, which is known as a P-Y mimetic [308]. However, Genetic Optimization for Ligand
Docking (GOLD) studies indicated that binding of S3I-201 was suboptimal, and structure–activity
relationship (SAR) analyses based on this “hit” compound were conducted to derive analogs with
improved STAT3 inhibitory activity. One of these analogs, S3I-1757, bound to the SH2 domain of STAT3
but still had a modest potency for decreasing STAT3 DNA binding [312]. However, S3I-1757 embedded
in nanoparticles that had been conjugated with monoclonal antibodies against CD38 (denoted as
CD38-S3I-NP) was demonstrated to have some increased efficacy in suppressing P-Y-STAT3 and tumor
growth in xenograft models of MM. Data describing this compound are presented in this Cancers
issue [313]. Among various S3I-201 derivatives, SF-1-066 was found to be the most potent. SF-1-066
was shown to directly bind STAT3 and to inhibit P-Y-STAT3 and growth of AML and MM cell lines
with greater potency than S3I-201 [314,315]. A family of sixteen sulfonamide analogs of SF-1-066 was
synthetized and BP-1-102 (17o) was proved to be the most active compound in this series. BP-1-102
exhibited improved inhibition of P-Y-STAT3 in MM cell lines [316]. In addition, BP-1-102 blocked
P-Y-STAT3 in B-ALL cells overexpressing HMGA1 chromatin remodeling proteins and suppressed
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their growth [94]. Growth inhibition induced by this salicylic acid-based inhibitor was also reported
for T-ALL cell lines [94]. N-alkylated derivatives of both SF-1-066 and BP-1-102, such as 16i and
21h molecules, were demonstrated to inhibit STAT3 function and to induce MM cell apoptosis, but
these molecules also lost selectivity toward STAT3 [317]. BP-5-087, another analog of SF-1-066, was
identified by SAR-based drug design and compound library screening. BP-5-087 was shown to be a
more potent salicylic acid-based STAT3 inhibitor than SF-1-066 and to overcome IM resistance in CML
stem cells [318].
A library of phosphopeptide mimicking salicylic acid-based molecules targeting the STAT3-SH2
domain was also employed to identify potent and STAT5-selective inhibitors. Among compounds
that were selected in the screening via fluorescence polarization (FP) assays, BP-1-108 was found to
be the more potent STAT5 inhibitor [319]. BP-1-108 significantly reduced P-Y-STAT5 and exhibited
growth inhibitory properties in CML and AML cell lines. In silico-based studies using BP-1-108
as a scaffold identified compound 13a (or AC-4-130) as a selective and first nanomolar inhibitor of
the STAT5B-SH2 domain [320]. AC-4-130 did not exhibit off-target kinase activity and suppressed
P-Y-STAT5 at low micromolar concentrations in CML and AML cell lines, as well as in primary AML
cells [81]. AC-4-130 inhibited the growth of AML cells in vitro and tumor formation in xenograft
models of AML. Furthermore, AC-4-130 was also shown to synergistically increase the cytotoxic
effect of the JAK1/2 inhibitor ruxolitinib and the p300/pCAF inhibitor garcinol in FLT3-ITD+ AML
cells [81]. IST5-002, another STAT5 inhibitor, was identified using in silico structure-based screening
and medicinal chemistry. IST5-002 was demonstrated to bind to the SH2 domain of STAT5B, to inhibit
P-Y-STAT5 and to reduce the growth and viability of sensitive and IM-resistant CML and Ph+ALL cell
lines [321]. Patient-derived CML or newly diagnosed and relapsed/TKI-resistant Ph+ALL cells were
also sensitive to IST5-002 treatment. Moreover, IST5-002 was found to reduce leukemia development
in PDX models of Ph+ALL [90]. A chromone-derived acyl hydrazine compound, identified through
a high-throughput FP screen, was the first inhibitor to directly target the SH2 domain of STAT5B.
However, high concentrations of this compound was required to disrupt STAT5 DNA binding and
P-Y-STAT5 in CML and Burkitt’s lymphoma (BL) cell lines, respectively [322]. The same group
next identified catechol-biphosphate as a selective inhibitor of the STAT5B SH2 domain. One of the
catechol-biphosphate derivatives, stafib-1, was shown to be a nanomolar inhibitor of the STAT5B SH2
domain with more than 50-fold selectivity over the STAT5A-SH2 domain [323]. SAR studies based on
the Stafib-1 compound and rational design led to the development of Stafib-2 with improved and high
selective activity against STAT5B in CML cells [324].
Structure-based high-throughput virtual screening of four different chemical libraries followed by
cell-based reporter assays identified STA-21 (or deoxytetrangomycin) as a new SH2 domain-targeting
inhibitor of STAT3 [309]. STA-21 induced apoptosis of primary cells from chronic lymphoproliferative
disorders of natural killer cells (CLPD-NK) and T-LGL patients and DLBCL cells when associated with
YM155, a survivin suppressant [325,326]. A structural analog of STA-21, LLL-3, was developed to
improve the cellular permeability of STA-21. LLL-3 was shown to promote apoptosis of CML cell lines
and to synergistically act with IM to suppress CML cell growth and survival [327]. LLL-3 was further
optimized by replacing its acetyl group with a sulfonamide to produce LLL-12, which prevented the
phosphorylation of STAT3 and induced apoptosis in MM cell lines and primary MM cells in vitro,
even in samples from patients with relapsed/refractory MM. LLL-12 also suppressed tumor formation
in xenograft models of MM [328]. However, LLL-12 was required in high concentrations for in vivo
studies due to low bioavailability. C188 compound was identified by virtual ligand screening of eight
chemical libraries [310]. C188 was shown to inhibit P-Y-peptide binding to the SH2 domain of STAT3
by surface plasmon resonance (SPR) assays. Using C188 as the scaffold, C188-9 was identified in a
hit-to-lead program and was shown to bind to the STAT3-SH2 domain with greater potency than the
C188 compound. C188-9 effectively suppressed G-CSF-induced P-Y-STAT3 in AML cell lines and
patient samples without affecting JAK or Src kinases. C188-9 also induced apoptosis and blocked
the clonogenic growth of AML cells [329]. In silico screening studies followed by STAT3-dependent
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luciferase reporter gene assays led to the identification of STX-0119, another STAT3 inhibitor impacting
the growth of lymphoma cell lines. Oral administration of STX-0119 was shown to reduce STAT3 target
gene expression and to induce apoptosis in a xenograft model of lymphoma [311]. The STAT3-SH2
domain inhibitor STATTIC was identified by screening chemical libraries in an FP-based binding assay.
This compound was demonstrated to selectively inhibit the dimerization and transcriptional activity
of STAT3, although a report indicated that it also blocks STAT1 phosphorylation [330]. STATTIC
reduced P-Y-STAT3 and viability of MM cells in three-dimensional (3D) culture and sensitized them
to bortezomib, a proteasome inhibitor that is clinically used in MM treatment (this issue) [331].
Moreover, STATTIC suppressed growth and survival of NK/T cell lymphoma cell lines expressing
the STAT3Y640F mutant [332]. Among the STAT3-SH2 domain targeting inhibitors, OPB-31121 and
OPB-51602 were the only compounds to have reached early phase clinical trials for treatment of
hematopoietic malignancies [333]. OPB-31121 was shown to inhibit P-Y-STAT3 and P-Y-STAT5
without affecting upstream kinase activity in various myeloid leukemia cell lines expressing BCR-ABL,
FLT3-ITD, or JAK2V617F, as well as in BL and MM cell lines [334]. Treatment with OPB-31121 also
induced growth inhibition of these hematopoietic malignant cells and reduced tumor formation in PDX
models of ALL, CML, and AML. Computational docking and molecular dynamics simulations (MDS)
demonstrated that OPB-31121 bound with high affinity to the SH2 domain of STAT3 [335]. In the
same way, OPB-51602 was also shown to interact with high affinity with the STAT3 SH2 domain to
inhibit P-Y-STAT3 and to be effective against MM, BL, and AML cells in preclinical in vitro and in vivo
studies [336]. Although promising data were obtained from these preclinical studies, clinical trials
were terminated for both of these inhibitors due to poor pharmacokinetic properties, significant toxicity
and lack of antitumor activity. Very recently, SD-36, a proteolysis targeting chimera (PROTAC) that
selectively degrades STAT3 protein has been developed. This molecule consists of the cell-permeable
STAT3-SH2 domain-targeting inhibitor, SI-109, conjugated to a ligand of Cereblon, an important
component of the E3 ubiquitin ligase complex that is involved in ubiquitination and degradation
of multiple cellular proteins. The resulting PROTAC binds to and recruits both STAT3 and the E3
ligase to form a productive ternary complex for ubiquitination and degradation. SD-36 was shown to
induce STAT3 degradation, cell growth arrest, and apoptosis in lymphoma and leukemia cells lines
as well as tumor regression in multiple xenograft mouse models of leukemias and lymphomas [337].
Lastly, several plant-derived molecules were also demonstrated to be direct inhibitors of STAT3.
Using computational modeling and docking simulations, Withaferin A, a natural product isolated
from the medicinal plant Withania somnifera, was found to interact with the SH2 domain of STAT3.
Consequently, Withaferin A prevented IL-6–mediated or persistently activated P-Y-STAT3 and induced
apoptosis in MM cells [338]. In a similar vein, YL064, a derivative of Sinomenine, a plant component
that has been used to treat rheumatic diseases, was shown to target the SH2 domain of STAT3 and to
induce MM cell death [339].
4.3.2. Inhibitors Targeting the DNA Binding Domain (DBD)
STAT3/5 bind to specific DNA response elements within promoters to mediate transcriptional
activation of target genes. Concerted efforts were therefore made to identify specific inhibitors targeting
the DBD of STAT proteins. Most of the DBD inhibitors presented in this section were historically used
against STAT3 and proved to be effective in some hematopoietic cancers.
Platinum (IV) compounds such as CPA-1, CPA-7, and platinum (IV) tetrachloride, were shown to
inhibit STAT3 DNA binding activity [340]. IS3 295, a member of this class of molecules, was identified
by screening of the NCI 2000 diversity set using electrophoretic mobility shift assays (EMSA). IS3 295
was demonstrated to irreversibly bind to the DBD of STAT3 in its active and inactive form and to
prevent its interaction with specific response elements. This compound inhibited the constitutive DNA
binding of STAT3 and induced apoptosis in MM cells [341]. Peptide aptamers as inhibitors of STAT3
represent one of the effective approaches to disrupt STAT3 DNA binding. The DBD-directed peptide
aptamer DBD-1 was identified in yeast two-hybrid screenings, and its cell-penetrating form DBD-1-9R
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was shown to inhibit STAT3 DNA binding in EMSAs and to induce growth inhibition and apoptosis in
MM cells [342].
Another class of STAT DBD inhibitors being used are duplex ODN (decoy oligonucleotides or
dODN) and GQ-ODN. dODNs targeting STAT proteins are double-stranded DNA molecules mimicking
the consensus STAT DNA binding sequence. These duplex ODNs act by competitively inhibiting
the DNA binding of STAT proteins to their endogenous promoter elements thereby preventing
their nuclear function [195]. For instance, a STAT5 dODN was shown to block DNA binding and
transcriptional activity of STAT5 and to induce growth arrest and apoptosis in CML cell lines [343].
STAT3 dODN, and the second-generation cyclic STAT3 decoy (CS3D) with a longer half-life, were only
tested in solid tumors and will not be discussed here. However, a dual-function molecule CpG-STAT3
dODN, which consists of a STAT3 dODN fused to the TLR9 agonist cytosine guanine dinucleotide
(CpG), was reported to induce growth-inhibitory and immune-mediated effects against AML and
DLBCL [74,344]. These compounds are rapidly internalized by TLR9+ immune and malignant cells
to block the oncogenic activity of STAT3 and to promote an antitumor immune response. Both
TLR9 stimulation and concurrent STAT3 inhibition were critical for immune-mediated therapeutic
effects. GQ-ODN are G-rich oligodeoxynucleotides that form intra- and inter-molecular four-stranded
structures [195]. For example, the GQ-ODN T40214 was shown to inhibit IL-6–induced P-Y-STAT3 and
STAT3-mediated transcription [345]. Computer-simulated docking studies indicated that GQ-ODNs
interact mainly with the SH2 domain of STAT3 and are able to disrupt STAT3 dimers bound to DNA.
Blocking STAT3 with the GQ-ODN T40214 loaded into nanoparticles was shown to be effective in a
mouse model of T-ALL [346]. However, the use of GQ-ODN remains problematic due to the large size
and potassium-dependence of this molecular probe.
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AML (acute myeloid leukemia), ALCL (anaplastic large cell lymphoma), B-ALL/T-ALL (B- or T- acute lymphoblastic
leukemia), Ph+ ALL (Philadelphia chromosome-positive acute lymphoblastic leukemia), BL (Burkitt’s lymphoma),
CLPD-NKs (chronic lymphoproliferative disorders–natural killer cells), CML (chronic myeloid leukemia), DLBCL
(diffuse large B cell lymphoma), HL (Hodgkin’s lymphoma), MDS (myelodysplastic syndrome), MM (multiple
myeloma), NHL (non-Hodgkin’s lymphoma), T-LGL (T cell large granular lymphocytic) leukemia.
4.3.3. Inhibitors Targeting STAT3/5 mRNAs
Oligonucleotide-based inhibition of STAT3 and STAT5 has also been achieved by using antisense
oligonucleotides (ASO) or mRNA knockdown (siRNA) [195]. Although siRNAs and ASOs were widely
used to illuminate the oncogenic activity of STAT3 and STAT5 in hematopoietic malignant cells, few of
these molecules were developed as anticancer therapeutic agents. We will discuss here two examples
of ASOs and siRNAs that gave promising results in preclinical studies and clinical trials. The first
example is the chemically modified ASO, AZD9150, which specifically targets STAT3 mRNA and is
now in phase 1/2 clinical trials. AZD9150, without any delivery agent, was shown to inhibit STAT3
expression in primary AML/MDS leukemia stem cells and to inhibit leukemic cell growth in vitro and
in vivo using PDX models of AML/MDS [347]. Inhibitory effects of AZD9150 on STAT3 expression
and cell growth were also demonstrated in preclinical models of lymphomas [348]. Furthermore,
AZD9150 was well tolerated and demonstrated efficacy in patients with highly treatment-refractory
lymphoma [349]. The second example is a STAT3 siRNA conjugated to the TLR9 ligand CpG described
above. STAT3 silencing mediated by this CpG-siRNA inhibited tumor growth in xenograft models
of AML or MM [350]. In an elegant study, Hossain et al. demonstrated that the CpG-STAT3 siRNA
conjugate stimulates systemic antitumor immunity and antigen-specific activation of CD8+ T cells
in a mouse model of AML [73]. Intravenous administration of CpG-STAT3 siRNA showed a direct
immunogenic effect on leukemic cells indicating that targeted STAT3 inhibition and TLR9 triggering
blocks leukemia cell growth by promoting antitumor immunity rather than direct tumor cell killing.
To date, no inhibitors targeting STAT5A/STAT5B mRNAs were developed for therapeutic purposes.
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5. STAT3/5 Inhibitors in Hematopoietic Cancers: Inherent Limitations and Future Challenges
Despite intensive efforts made during the last 15 years, clinically applicable STAT3/5 inhibitors still
remain elusive. Toxicity, poor tumor targeting, lack of cell penetrance and rapid degradation are some
examples of the problems to be considered and addressed. There are also several other reasons that
could hinder the development of such inhibitors. First, STAT3 and STAT5 display multifaceted activity
due to their canonical and non-canonical functions in cancer cells. The definition of constitutively active
STAT3/5 only based on P-Y-STAT3 and/or P-Y-STAT5 levels as described in chapter 3 may not be broadly
representative. For example, the use of decoy ODNs or SH2 domain-targeting inhibitors would not be
effective in CLL cells, in which a predominant mitochondrial localization and function of P-S727-STAT3
has been evidenced [102]. Furthermore, it has been shown that nuclear translocation and DNA binding
of STAT3 or STAT5 can occur independently of their P-Y status. These observations indicate that
SH2 domain-targeting inhibitors may not be sufficient to fully abrogate STAT3/5 oncogenic functions,
which may contribute to the limited success of these compounds. Second, extensive crosstalk and
alternative signaling pathways present in TKO-driven hematopoietic malignancies probably render
single-agent STAT3/5 inhibition less effective. Third, adverse effects of STAT3/5 inhibitors may be
associated with the physiological function of these proteins in normal tissues including hematopoietic
and lymphoid tissues, resulting in STAT3- or STAT5-specific toxicity. Previous studies indicated
that STAT5-deficient NK cells induce angiogenesis and promote tumor progression, highlighting the
potentially detrimental effects of STAT5 inhibitors on NK cell-mediated tumor immune surveillance [37].
Moreover, STAT3 and STAT5 were also shown to activate tumor suppressor pathways, strengthening
the possible adverse effects of STAT3/5 inhibitors. Most of these tumor suppressor functions were
described in different reviews including one published as part of this special issue [8,32]. One of
the tumor suppressor activities of STAT3 is linked to the level of STAT3β expression, which could
explain why different AML patient subsets, based on the STAT3β/STAT3α mRNA ratio, are more or
less sensitive to STAT3 inhibitors [34]. In such a case, STAT3 direct inhibitors would also target STAT3β
which is unwanted for AML treatment. Despite these limitations, optimization of currently available
STAT3/5 inhibitors and discovery of new compounds that specifically target other functional domains
such as the NH2-terminal domain, domains involved in the subcellular localization of STAT3/5 or
STAT3/5/Rac1 interacting domains, as well as drugs activating negative regulators of STAT3/5 such
as SOCS and PIAS proteins, still have to be considered in the future. Although most of the direct
inhibitors have shown a moderate efficacy in treating hematologic cancers as single agents, they act
synergistically with clinically used chemotherapeutic drugs or TKIs. Importantly, targeting STAT3
and/or STAT5 signaling was demonstrated to overcome drug resistance in hematopoietic malignant
cells, suggesting that combination therapy using STAT3/5 inhibitors is the most attractive approach
to fight against relapsed hematopoietic malignancies. For example, STAT3 and STAT5 were both
recognized as important effectors of de novo and acquired IM-resistance in CML cells [57,60,62]. In fact,
activation of STAT3 was demonstrated to be an important positive autocrine-paracrine feedback loop
in the therapeutic treatment of oncogene-addicted cancer cells [351]. Activation of STAT3/5 elicited
by bone marrow microenvironment-derived signals was found to mediate resistance of CML cells
to IM treatment, and inhibition of STAT3/5 suppressed IM-resistant CML cells in the niche. In both
cases, extrinsic activation of STAT3 or STAT5 was induced by JAK kinases, and the JAK1/2 inhibitor
ruxolitinib was shown to act synergistically with IM in killing resistant CML cells [62,229]. In a similar
vein, the STAT5-SH2 domain inhibitor AC-4-130 increased the cytotoxicity of ruxolitinib in AML
cells [81]. Combined targeting of STAT3 and STAT5 is another approach to overcome TKI resistance
in CML cells. For example, the triterpenoid CDDO-Me (bardoxolone methyl) was shown to act
synergistically with IM to kill resistant BCR-ABL-expressing cells [63]. In addition, blocking STAT3
and/or STAT5 with natural compounds or drugs that have been proven to be safe in humans might help
to reduce the side effects of combination therapies. For example, piperlongumine (Table 2) enhanced
the anti-MM effect of the proteasome inhibitor bortezomib, while pimozide increased the cytotoxic
effects of TKIs in myeloid leukemias [277,298]. Besides its oncogenic activity, STAT3 is a central immune
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checkpoint regulator in cancer cells and tumor-associated immune cells. Oncogenic STAT3 drives
PD-L1 expression in lymphoma and AML cells and may promote tumor immune evasion by inducing
an immunosuppressive microenvironment [73,114]. In this context, the combination of STAT3 inhibitors
with anti-checkpoint antibodies blocking PD-L1/programmed cell death 1 (PD-1) interactions might be
a promising therapeutic approach for lymphomas and leukemias. Collectively, these data indicate that
combination therapies using inhibitors that indirectly or directly target STAT3 and/or STAT5 might
provide new therapeutic opportunities for relapsed or refractory hematopoietic malignancies.
6. Conclusions
The design and development of STAT3/5 inhibitors evolved rapidly during the last 10 years.
Computer simulations and other in silico studies such as high-throughput virtual screening, cell-based
assays, biophysical and biochemical approaches led to the identification of selective STAT3/5 inhibitors
with potent anticancer effects. STAT3/5 inhibitors are likely to become a valuable addition to the
expanding arsenal of drugs against hematopoietic cancers and solid tumors. However, there are some
limitations to this relative success story that must be taken into account. Optimization of STAT3/STAT5
inhibitors by chemical modifications and drug delivery systems are both required for resolving
issues linked to stability, cell permeability, and targeted delivery to tumor cells. The development of
antibodies conjugated to STAT3/5 inhibitors or antibody-conjugated nanoparticles harboring STAT3/5
inhibitors might be promising but remains challenging. Identification of new inhibitors targeting the
non-canonical functions of STAT3/5 is also desirable in treating some hematologic malignancies. Last but
not least, the optimization of combination therapies using STAT3/5 inhibitors with molecules targeting
tyrosine kinases or other key players in cancer will be required for finding the right combination that
safely unlocks drug resistance in hematologic cancers.
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Abstract: Signal transducer and activator of transcription (STAT)3 and STAT5 are important
transcription factors that are able to mediate or even drive cancer progression through hyperactivation
or gain-of-function mutations. Mutated STAT3 is mainly associated with large granular lymphocytic
T-cell leukemia, whereas mutated STAT5B is associated with T-cell prolymphocytic leukemia, T-cell
acute lymphoblastic leukemia and γδ T-cell-derived lymphomas. Hyperactive STAT3 and STAT5
are also implicated in various hematopoietic and solid malignancies, such as chronic and acute
myeloid leukemia, melanoma or prostate cancer. Classical understanding of STAT functions is
linked to their phosphorylated parallel dimer conformation, in which they induce gene transcription.
However, the functions of STAT proteins are not limited to their phosphorylated dimerization form.
In this review, we discuss the functions and the roles of unphosphorylated STAT3/5 in the context of
chromatin remodeling, as well as the impact of STAT5 oligomerization on differential gene expression
in hematopoietic neoplasms. The central involvement of STAT3/5 in cancer has made these molecules
attractive targets for small-molecule drug development, but currently there are no direct STAT3/5
inhibitors of clinical grade available. We summarize the development of inhibitors against the SH2
domains of STAT3/5 and discuss their applicability as cancer therapeutics.
Keywords: STAT3; STAT5; cancer; small-molecule inhibitors
1. Introduction
The Janus kinase/Signal transducer and activator of transcription (JAK-STAT) pathway is one
of the core cancer pathways that integrates signals from cytokines, hormones and growth factors to
induce or repress gene expression in cells [1]. The pathway consists of four JAK kinases (JAK1, JAK2,
JAK3 and TYK2) and seven STAT transcription factors (STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B
and STAT6). Despite conserved structure and a common mechanism of action, STAT family members
show distinct and even opposite functions in tumor biology.
STAT1 is generally not associated with promoting tumor growth and mostly mediates
tumor-suppressive and pro-apoptotic functions [2,3]. Consistently, STAT1−/− mice are more prone
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to tumor development and STAT1 deletion in leukemic cells decreases MHC class I expression [4,5].
Surprisingly, in a v-abl-driven model of STAT1−/− leukemic cells initially harboring low MHC class I,
enhanced MHC class I expression was gained during the disease progression, thereby reducing tumor
recognition by NK cells [6]. As an exception, STAT1 was shown to be an oncogenic driver in T-cell
acute lymphoblastic leukemia (T-ALL) and ALK+ anaplastic large cell lymphoma (ALCL), and STAT1
is associated with the JAK2 exon 12 mutation in the progression of myeloproliferative neoplasms
(MPNs) [7–9]. Reports on direct involvements of STAT2, STAT4 and STAT6 in cancerous processes
are scarce and are not discussed here further [10]. Associations of STAT3 and STAT5 with cancer
progression are well established and heavily studied, and hence, are the main focus of this review.
2. Role of STAT3 and STAT5 in Cancer
STAT3 and STAT5 proteins are of particular interest in cancer research, as their hyperactivation
was reported in processes ranging from inflammation and autoimmunity to infection and cancer.
Within the latter, these proteins have been implicated in tumor initiation, as well as in metastasis
or in conferring drug resistance mechanisms [10–12]. Constitutive hyperactivation of STAT3 and
STAT5, as a result of their gain-of-function mutations or via enhanced signaling from upstream drivers,
promotes tumor cell growth and survival [3].
STAT3 is the best-studied family member of the JAK-STAT pathway in cancer, and is a
known oncogene in various types of solid malignancies, like melanoma or lung cancer [13–15].
Furthermore, both STAT3 and STAT5 are reported to play a major role in the progression and
pathogenesis of prostate cancer [16–18]. Hyperactivation of STAT3 and STAT5 is commonly associated
with an upstream oncogenic driver, such as hyperactive mutated tyrosine kinases, for example,
JAK2V617F or FLT3-ITD, or fusion proteins such as BCR-ABL, TEL-JAK2 or TEL-ABL1 [3,19–21].
The role of STAT5 in the transformation process induced by BCR-ABL p210 fusion protein has been
particularly well-studied. It was shown that the absence of STAT5 diminishes the ability of cells to
transform even upon harboring potent oncogenes such as BCR-ABL. Inducible deletion of STAT5
arrests and kills chronic myeloid leukemia (CML) cell lines, defining STAT5 as a therapeutic cancer
target [22]. Hyperactivation of STAT3 and STAT5 can also occur via direct mutation in these genes,
which is also associated with cancer progression in patients [1]. Interestingly, mutated STAT3 is mainly
associated with large granular lymphocytic T-cell leukemia (T-LGLL), whereas mutated STAT5B is
found in patients with T-cell prolymphocytic leukemia (T-PLL), T-ALL, γδ T-cell-derived lymphoma
and monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) [23–25].
Inhibitors of kinases upstream of STAT3/5 are available, but patients often relapse by
developing drug resistance through persistent signaling or enhanced upregulation of STAT3 or
STAT5 expression [21,26]. Targeting STAT3 and STAT5 directly or in combination with tyrosine kinase
inhibitors might be an attractive way to overcome these resistance mechanisms [27].
3. Non-Canonical Functions of STAT3 and STAT5
STAT proteins share similar structural architecture including five domains: an N-terminal domain,
a coiled-coil domain, a DNA-binding domain, an SH2 domain and a C-terminal transactivation
domain [11] (Figure 1a). Upon phosphorylation, STAT5 undergoes a conformational change and
forms parallel dimers via the SH2 domain (Figure 1b). This conformation allows the dimers to be
recognized by importins and facilitates transport into the nucleus, where they bind GAS consensus
sequences to induce target gene transcription. Such dramatic conformational rearrangements are
possible due to the flexible linkers that are connecting the core fragment of STAT5 with its N- and
C-terminus [28–30]. The complex approach of molecular dynamic simulations and bioinformatic
analyses identified three distinct interaction surfaces within the dimer unique to STAT5, which include
intramolecular interactions between the SH2 domain and the phosphotyrosine motif [28,31].
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Figure 1. Functions of STAT5. (a) Domain structure of STAT5. Position of the critical
activating tyrosine phosphorylation site is depicted with Y. ND—N-domain; CCD—coiled-coil
domain; DBD—DNA-binding domain; L—linker; SH2—SH2 domain; TAD—transactivation domain.
(b) Conformational changes of STAT5 from an unphosphorylated antiparallel dimer (uSTAT5) to a
phosphorylated parallel dimer (pYSTAT5). (c) Dimer and oligomer conformations of STAT5 result
in binding to GAS sites on DNA with different affinities, resulting in expression of different genes.
Examples of dimer versus tetramer target genes are incorporated from [32,33].
Interestingly, the SH2 domain of the hyperactivated gain-of-function variant STAT5BN642H
was also crystallized and compared to wild type human STAT5B. The crystal structure revealed two
conformations of the mutant SH2 domain: one conformation is more closed, potentially allowing longer
tyrosine phosphorylation lifetimes by blocking phosphatase attack. The other conformation, preserved
in the crystal structure, revealed a more open conformation, which could facilitate phospho-peptide or
protein interactions leading to hyperactivation [34].
Interestingly, the functions of STAT proteins are not limited to their state as phosphorylated dimers.
Unphosphorylated STAT dimers (uSTAT), as well as tetramer/oligomer conformations, are involved
in the functionality of some STATs [32,35]. Two phosphorylated dimers can form tetramers via their
N-terminal oligomerization domains. This interaction stabilizes DNA binding and allows attraction
of the tetramers to low-affinity sites, thereby providing altered binding selectivity and fine-tuning of
transcriptional responses [36] (Figure 1c).
STAT5 is particularly known for forming oligomers, a function shared with STAT1 and STAT4.
In contrast, STAT3 shows weaker tetramer formation upon activation. STAT2 and STAT6 were not
reported to form oligomers in cellulo [32,37–39]. However, yeast hybridization assays showed that
recombinant N-domains of all STATs are able to self-dimerize [40]. Interestingly, this interaction
is clearly homotypic, which might facilitate individual functions of different STATs. In addition,
recombinant STAT2 and STAT6 N-domains can form oligomers with the same affinity as other STAT
members, but this was not observed in cellulo [40].
The N-terminus also plays an important role in the function of STAT3: it mediates dimerization
of uSTAT3, whereas for phosphorylated STAT3 (pYSTAT3) it can enable tetramerization [41,42].
Interestingly, oligomerization of STAT3 is not commonly observed in cellulo. Still, expression of certain
genes like A2M (α2-macroglobulin) was shown to depend on an N-domain interaction of STAT3 [42].
Hu et al. showed that in STAT3−/− MEFs, exogenous expression of an N-terminally truncated
STAT3 protein leads to a decrease in expression of a small subset of genes, compared to expression of
wild type STAT3 [43]. Not surprisingly, mutated STAT3Y705F, which is unable to become phosphorylated
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and to form parallel dimers, significantly affected global gene expression. However, certain genes
(e.g., MRAS, MET) were still activated even by uSTAT3 [44]. Interestingly, STAT3Y705F was able to
weakly bind to selected promoters and to induce gene expression, thereby promoting an anti-viral,
anti-proliferative effect in response to interferon stimulation. It would be interesting to determine if this
activity is connected to the heterodimerization of STAT3 with STAT1 or if it is fully mediated
through uSTAT3 [45]. uSTAT3 was also reported to be involved in interactions and complex
formation with unphosphorylated nuclear factor kappa-light-chain-enhancer of activated B cells
(NF-κB), which resulted in activation of a subset of NF-κB-dependent genes. Of note, the authors
showed an additional subset of uSTAT3-dependent, but NF-κB-independent genes [46].
Timofeeva et al. showed that uSTAT3 plays a repressive role in the apoptosis of cancer cells and
that inhibition of STAT3 N-domain functions can abolish this repressive effect. Treatment with the
STAT3 N-domain peptidomimetic, ST3-H2A2, hindered STAT3 binding to the regulatory domains of
various genes, including the gene for the proapoptotic C/EBP-homologous protein (CHOP). This, in
turn, led to a decrease in the heterochromatin mark H3K9me3 in the promoter region of this gene [47].
uSTAT5 is mostly localized in the cytoplasm in the form of anti-parallel dimers. In mammalian
cells, cytoplasmic uSTAT5 was shown to associate with and stabilize the Golgi apparatus [48]. On the
other hand, a smaller proportion of uSTAT5 was also found in the nucleus where it colocalizes with the
transcriptional repressor CTCF, thereby diminishing megakaryocyte differentiation via competition
for DNA binding with the transcription factor ERG [35]. Additionally, there is evidence that uSTAT5
can migrate into the nucleus and bind heterochromatin protein 1α (HP1α) to promote the formation
of heterochromatin. This leads to repression of various genes, among which many are found to be
involved in cancer development [49].
One function of the STAT5 N-terminal domain involves docking of STAT5 to receptors. For
example, it was shown that STAT5 interacts via the N-terminal domain with the glucocorticoid
receptor [50]. The N-domain of STAT5 has an O-GlcNAc modification site on threonine 92. For
STAT5A, it was shown that the presence of this glucose-derived modification within the N-domain is
essential for full activation, suggesting cross-talk between the N- and C-domains and involvement of
the N-domain in the regulation of metabolic functions in cells [51].
Another function of the STAT5 N-domain is mediating STAT5 tetramerization. Tetramerization was
shown to be essential for proper T-cell development and was also found to be associated with enhanced
activity of STAT5 as an oncogene [32]. STAT5 tetramers can bind to different motifs compared with
STAT5 dimers, to induce or repress gene expression (Figure 1c) [52]. It was shown that deletion of the
N-domain of STAT5 results in an absence of c-MYC, BCL-2 and cyclin D2 expression upon stimulation,
indicating that oligomers can induce a different subset of genes than dimers [32]. Extensive studies
by Lin et al., using a mutated STAT5 N-domain that is unable to form oligomers in vivo, defined
the oligomer-dependent subset of genes as well as the importance of oligomerization in NK cell
maturation [33,52].
The STAT5 N-domain was shown to be essential for leukemogenic transformation. Deletion of
the N-domain or mutation of the O-GlcNAc-modified residue (T92A) abolished the initiation of the
leukemic disease driven by gain-of-function STAT5A [32,51,53]. This suggests an important function
of the STAT5 N-domain in oncogenic transformation and it proposes that the N-domain can serve as a
novel targeting interface of STAT5.
4. Role of STAT3/5 in Chromatin Landscape
Over the last years, it was shown that STAT3 and STAT5 transcription factors can influence
gene expression not only directly by binding to gene promoters but also through recruiting various
chromatin remodelers and influencing gene expression and chromatin states on the global level.
STAT3/5 can change the chromatin landscape in a cell by recruiting various chromatin-remodeling or
DNA-modifying enzymes to the DNA, such as histone acetyltransferases (HATs), histone deacetylases
(HDACs), as well as ten-eleven translocation methylcytosine dioxygenase 1/2 (TET1/2) or DNA
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(cytosine-5)-methyltransferase 1 (DNMT1) [54–57] (Figure 2a,b). These interactions influence eu-
or hetero-chromatin formation or DNA methylation, thereby activating or repressing transcription.
The STATs themselves can also be post-translationally modified by these enzymes: for example,
methylation of STAT3 by the enhancer of zeste homolog 2/polycomb repressive complex 2 (EZH2/PRC2),
or acetylation of STAT3 and STAT5 by CREB-binding protein (CBP)/p300 [1].
Figure 2. Role of STAT3/5 in regulating the chromatin landscape. (a) pYSTAT3 interacts with and
recruits chromatin remodelers, and thereby promotes changes in chromatin compaction. (b) uSTAT5
and pYSTAT5 interact with different chromatin remodelers, thereby promoting chromatin changes
associated with euchromatin (green arrows) or heterochromatin (red arrows) formation.
In the case of STAT3, acetylation or methylation at different residues leads to different activity
and functionality of the protein (Figure 2a) [12]. For example, acetylation of STAT3 by CBP/p300
on lysine 685 in the C-terminal domain increases the DNA binding ability of STAT3 [58]. On the
other hand, methylation of phosphorylated, promoter-bound STAT3 on lysine 140 by SET9 reduces
its transcriptional activity on a subset of target genes [59], whereas dimethylation on lysine 49 by
EZH2 is required for the expression of IL-6-dependent genes [60]. It was also shown that STAT3 binds
to the promoter of the tyrosine phosphatase SHP-1 and recruits DNMT1 and HDAC1 to silence its
transcription in cutaneous T-cell lymphoma (CTCL) and in ALK+ ALCL cell lines [57]. In regulatory
T-cells, STAT3 was found to cooperate with FoxP3 and HAT1 to induce expression of IL-10 [61].
STAT5 is also known to recruit chromatin remodelers (Figure 2b). One example of such an
interaction is co-activation of STAT5 by HAT nuclear receptor coactivator 1 (NCoA-1). NCoA-1 and
STAT5A transiently co-transfected in HEK293T cells were shown to interact with each other by
co-immunoprecipitation. This interaction required amino acids 751 to 753 in the STAT5 transactivation
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domain, which is conserved in both STAT5A and STAT5B [54]. Furthermore, in Ba/F3 cells, STAT5A
was shown to interact with HDAC3 and lysine-specific demethylase 1 (LSD1), thereby activating or
repressing gene expression [55]. The interaction between STAT5A and LSD1/HDAC3 is mediated by
the STAT5A DNA-binding domain, linker and its SH2 domain and HDAC3 can additionally interact
with the coiled-coil domain of STAT5A [55]. STAT5 influences not only the acetylation but also the
methylation status of its surroundings, for example by recruiting TET1/2 to the Foxp3 locus. This causes
demethylation of the locus and plays an important role in regulatory T-cell differentiation [56].
Mandal et al. showed that during B-cell maturation and B-cell receptor rearrangement, gene
regions required for immunoglobulin κ light chain expression are silenced by histone methyltransferase
EZH2-STAT5 tetramer interactions (Figure 2b) [62]. This underlines the importance of the STAT5
N-terminal domain and tetramerization during B-cell development or as a mechanism for acute B-cell
leukemia initiation or progression.
5. Direct STAT Targeting of the SH2 Domain
Treating cancers with hyperactivated or mutated STAT3 and STAT5 is currently achieved by
targeting upstream kinases. However, despite tyrosine kinase inhibitors being significantly superior
to classical chemotherapy, their application often causes severe side-effects and development of
resistance [63]. Therefore, development of more specific and effective inhibitors that also target
downstream components of hyperactivated pathways is desirable to overcome limitations of current
strategies. In the following section, we focus specifically on small-molecule inhibitors of the STAT3/5
SH2 domains.
5.1. STAT3 Inhibitors
The first two small-molecule STAT3 inhibitors were fragment-sized compounds discovered by
random biochemical and virtual screening. One compound, Stattic, was identified in a high-throughput
screen of a diverse chemical library (Figure 3a) [64]. Another anthraquinone-based compound, STA-21
(Figure 3b), was discovered by structure-based virtual screening against the published X-ray structure
of STAT3β [65,66]. Later, multiple analogs of STA-21 were reported, such as LLL-3 and LLL-12
(Figure 3c,d) [67,68]. Recently, several different chemotypes have emerged, often consisting of ring
systems connected by amide-containing linkers. An important step forward was the identification of
the salicylic acid moiety that is an efficient bioisostere of the phosphate group required for STAT-STAT
dimer formation. Salicylic acid analogs were described as potent STAT3 inhibitors as exemplified by
the inhibitor S31-201 (Figure 3e), as well as its optimized successors, SF-1-066, SF-1-121 and S31-1757
(Figure 3f,g) [69–71].
Virtual screening was useful to find new chemotypes of STAT3 inhibitors. Matsuno et al. and
Xu et al. described further double-digit micromolar STAT3 inhibitors, STX-0119 and Cpd30-12
(in cellular assays; Figure 3h,i) [72,73]. Furthermore, a number of natural products (or analogs thereof)
and antioxidants have been proposed and identified as potential inhibitors of STATs, most particularly
STAT3, displaying even single-digit micromolar inhibitory activities [74–78].
Another noteworthy study reported an in silico fragment-based drug discovery approach, resulting
in a single-digit micromolar STAT3 inhibitor, LY5 (in both cell-free and cell-based assays; Figure 3j),
targeted towards the SH2 domain [79]. Recently, Zhang et al. identified benzothiazole as a novel
scaffold among STAT3 inhibitors, resulting from a virtual screening of more than 200,000 compounds
by a multistep protocol. In this study, four compounds were confirmed experimentally, with the
benzothiazole-based compound 9 (Figure 3k) displaying a single-digit micromolar IC50 value against
the IL-6/STAT3 signaling pathway [80]. Two further analogs were discovered by a similarity-based
hit expansion. When the number of known STAT3 inhibitors reached a sufficient level to compile
a training set for a three-dimensional (3D) pharmacophore-based virtual screening study, Leung et al.
screened a small in-house dataset and tested five compounds, out of which one (Cpd1, Figure 3l) was
experimentally confirmed in multiple STAT3-related endpoints [81].
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Figure 3. Chemical structures of STAT3 and STAT5 inhibitors (in their order of citation in the main text).
Compounds with identical names (Cpd1) are further specified by citations.
The compounds OPB-31121, OPB-51602 and OPB-111077, which are substances from Otsuka
Pharmaceuticals, were designed to inhibit STAT3 phosphorylation in cancer cell lines and xenograft
models by targeting the STAT3 SH2 domain. Available studies with OPB-51602 indicate induction
of STAT3 aggregation in autophagosomes. Additionally, there has been controversy on the activity
of OPB-51602 against mitochondrial STAT3. Two of these STAT3 SH2 inhibitors, OPB-31121 and
OPB-51602, were already tested in phase I/II clinical trials for solid tumors, non-Hodgkin lymphoma,
myeloma and other hematopoietic malignancies [81]. In these studies, the compounds were promising
based on a relatively long half-life, suggesting the possibility of a reduced dosing regimen to limit toxic
side effects. However, the clinical trials for both lead structure drugs were terminated due to minimal
antitumor activity, toxicity issues and poor pharmacokinetics. Another STAT3 inhibitor, OPB-111077,
has completed a phase I trial for solid cancers (NCT02250170), and phase I/II trials are recruiting for
acute myeloid leukemia (AML) (NCT03197714) and other refractory tumors (NCT03158324) [82,83].
Efficacies of the above-mentioned STAT3 SH2 inhibitors in vitro and in vivo are summarized in Table 1.
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Table 1. Small-molecule compounds targeting the STAT3 SH2 domain.
Cpd










Stattic pY binding 5.1
HepG2,
MDA-MB-231 viability 3.8 [64,84,85]
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S31-1757 pY binding 13.5
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STX-0119



































Cpd1 FP ~10 HeLa reporter assay,DNA binding ~10 [81]
a s (20): significant effect at 20 μM (or other concentration, as indicated); cpd—compound;
FP—fluorescence polarization.
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5.2. STAT5 Inhibitors
The first landmark papers on STAT5 SH2 domain inhibitors were published in 2008 by the Berg
group. These were driven by the development of a robust high-throughput screening assay for STAT5B
inhibitors [90,91]. This facilitated the discovery of chromone-based STAT5B inhibitors as well as a
nicotinoyl hydrazine derivative, Cpd1 (Figure 3m), as a selective STAT5B inhibitor (in comparison to
STAT1 and STAT3) [91].
Later, four salicylic acid-based compounds (including the single-digit micromolar inhibitor
SF-1-088, Figure 3n) were identified by the Gunning group [92]. These hits were optimized to
generate the STAT5B inhibitor, 13a, through a structure-guided approach (Figure 3o). Studies with
13a have shown it can effectively reduce pYSTAT5B levels in cellulo, and follow up thermal stability
studies showed an inhibitor-induced reduction in STAT5 stability and the potential to block de novo
phosphorylation [28,93,94]. Additional studies extended this work to demonstrate AML cell viability
inhibition with AC-4-130, a further improved lead compound (Figure 3p) [95].
It is worth noting that in a 2011 study, Nelson et al. identified the neuroleptic drug pimozide as a
STAT5 inhibitor (Figure 3q). However, recent studies have linked pimozide with proteolysis upstream
of STAT5, rather than direct binding [96]. Nonetheless, the discovery later prompted Rondanin et al. to
synthesize and screen a series of pimozide derivatives, two of which have surpassed the cytotoxic
potency of pimozide as evaluated against imatinib-resistant BCR-ABL-expressing leukemia cells [97].
In 2016, the same group synthesized and tested 22 iodoacetamide-containing heterocycles for STAT5
inhibition, many of which (including TR120, Figure 3r) were confirmed experimentally in an in vitro
cytotoxicity assay, although direct binding to STAT5 was not examined [98].
In 2015, Liao et al. conducted a large scale structure-based virtual screening campaign for
STAT5A/B inhibitors [99]. Using a STAT3 based homology model of STAT5, the authors docked
~30 million compounds to the dimerization interface on the SH2 domain [65]. The top 30 hits were
evaluated in various cell lines, with IST5-002 (Figure 3s) identified as a lead compound that inhibited
STAT5A and STAT5B in the low micromolar range in cellulo. However, the first STAT5A/B gene
product-selective inhibitor was developed in the same year, by the Berg group. Stafib-1 (Figure 3t),
a catechol type bisphosphate-containing nanomolar STAT5B inhibitor (as evaluated in a fluorescence
polarization assay), was identified by structure-based virtual screening against the SH2 domain of a
STAT5B model derived from the structure of unphosphorylated STAT5A [30,100]. This compound was
recently optimized into the single-digit nanomolar inhibitor Stafib-2 (Figure 3u) using a structure-based
approach [101]. Stafib-2, similar to its predecessor, has shown high selectivity for STAT5B compared to
other STAT proteins, including STAT5A. The hydrophilicity of the phosphate motifs was reduced by
generating a pro-drug precursor, which employs pivaloyloxymethyl esters to conceal the negatively
charged phosphate groups and increase cell penetrance. Recently, Natarajan et al. reported Stafia-1,
a selective inhibitor for STAT5A, discovered by docking-based screening [102]. Tested applications for
STAT5 inhibitors in vivo and in vitro are summarized in Table 2.
Berg et al. also identified nucleotide scaffolds with potentially selective inhibition properties
against STAT5B. Although, the IC50 values in a fluorescence polarization assay are in the high
micro-molar range (STAT5B, IC50[ATP] = 97.4 ± 0.9 μM, IC50[GTP] = 95.5 ± 3.2 μM; STAT5A,
IC50[ATP] = 443 ± 34 μM, IC50[GTP] = 311 ± 46 μM), these concentrations are still well below
intracellular ATP concentrations (>2 mM). It would be of high interest to validate these findings in
cellulo. These results suggest STAT5B may also play a role in directly coupling gene expression to cellular
metabolism, and also highlight a potential new targeting strategy using nucleotide-based inhibitor
scaffolds [104]. Recently, a novel mechanism of selectively blocking STAT5B activity was proposed
through protein-mediated Mannich reactions. The ligand-efficient 4-amino-furazan-3-carboxylic
acid molecule (Kd = 420 μM, STAT5B fluorescent polarization assay) was identified from a library
of 17,000 compounds. This phosphate-mimetic reacts with 1H-tetrazoles in the presence of
formaldehyde, and this reaction only proceeds in acidic conditions (pH 5.0). However, the addition
of MBP-tagged STAT5B-SH2 domain peptide catalyzed the reaction even at physiological conditions.
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Although tetrazoles were not active against STAT5B (>10 mM), the ligation products showed substantial
activity, which the authors attribute to super-additive binding interactions. Intracellular physiological
concentrations of formaldehyde also emphasize the viability of this molecule as a STAT inhibitor and
the utility of bio-catalytic Mannich reactions [105].
Table 2. Small-molecule compounds targeting the STAT5 SH2 domain.
Cpd









Cpd1 FP 47 K562,Daudi
DNA binding,
pYSTAT5 s (100) [91]
SF-1-088 FP 8.3 K562,MV4-11 viability,pYSTAT5 80–77 [92]
13a


































s (5) Prostate cancer
xenograft
(25, 50, 100 mg/kg)
[99]
viability 3.5
Stafib-1 FP 0.044 K562 pYSTAT5 s (3) [100]








a s (100): significant effect at 100 μM (or other concentration, as indicated); cpd—compound;
FP—fluorescence polarization.
A study by Juen et al. reported the optimization of the STAT5 inhibitor, Cpd17f (Figure 3v) [103].
Interestingly, the initial hit was originally intended for PPARα/γ inhibition, while the inhibition of
STAT5 phosphorylation was an off-target effect [106]. Since the compound did not inhibit PPARs,
but showed a considerable inhibition of STAT5 phosphorylation, 18 analogs were synthesized and
tested in a cell-based assay. As shown by Brachet-Bottineau et al., in this special issue, Cpd17f inhibits
STAT5B protein expression through non-transcriptional mechanisms. However, as with the majority of
the aforementioned inhibitors, further confirmatory assays demonstrating the mechanism of action
are required. Although multiple studies using molecular modeling or computational dynamics have
been insightful in STAT5 inhibitor design, protein-inhibitor complexes characterized with atomic-level
resolution, such as through X-ray crystallization, would provide a clearer understanding of target
engagement in efficacy and selectivity studies.
Apart from these efforts targeting the SH2 domain of STAT3 or STAT5 molecules, studies have
also reported describing approaches to block STAT3/5 DNA binding or the use of antisense RNA
interference, discussed further in this special issue with separate overview articles.
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6. Conclusions
STAT3 and STAT5 are the key nodes in transcriptional activation downstream of cytokine or kinase
action in multiple cancers. This makes them attractive, but challenging targets for drug development.
Recent findings expand on a previously rather simplistic understanding of STAT3/5 function as
parallel phosphorylated dimers. It has become evident that higher-order conformations of pYSTATs,
as well as uSTAT, are involved in chromatin landscape shaping, thereby acting beyond classical
transcription factors. This knowledge provides a deeper understanding of their role in cancer biology,
which together with various targeting efforts, will open novel therapeutic options.
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Abstract: Oncogene-induced STAT3-activation is central to tumor progression by promoting cancer
cell expression of pro-angiogenic and immunosuppressive factors. STAT3 is also activated in
infiltrating immune cells including tumor-associated macrophages (TAM) amplifying immune
suppression. Consequently, STAT3 is considered as a target for cancer therapy. However, its interplay
with other STAT-family members or transcription factors such as NF-κB has to be considered in
light of their concerted regulation of immune-related genes. Here, we discuss new attempts at
re-educating immune suppressive tumor-associated macrophages towards a CD8 T cell supporting
profile, with an emphasis on the role of STAT transcription factors on TAM functional programs.
Recent clinical trials using JAK/STAT inhibitors highlighted the negative effects of these molecules
on the maintenance and function of effector/memory T cells. Concerted regulation of STAT3 and
STAT5 activation in CD8 T effector and memory cells has been shown to impact their tumor-specific
responses including intra-tumor accumulation, long-term survival, cytotoxic activity and resistance
toward tumor-derived immune suppression. Interestingly, as an escape mechanism, melanoma cells
were reported to impede STAT5 nuclear translocation in both CD8 T cells and NK cells. Ours and
others results will be discussed in the perspective of new developments in engineered T cell-based
adoptive therapies to treat cancer patients.
Keywords: inflammation; tumor-associated macrophages; adoptive T cell therapy; immune
suppression; STAT transcription factors
1. Introduction
Inflammation is now considered as a hallmark of cancer [1] and the inflammatory context in
many cancers is strongly linked to poor prognosis and resistance to therapy. Activating mutations
in oncogenic RAS/BRAF/MEK pathways trigger a tumor-intrinsic inflammatory network with the
concerted regulation of master transcription factors (TFs) including STAT3 [2], NF-κB and AP-1 [3,4]
which in turn trigger the expression of cytokines, including IL-6, IL-1, IL-10, TNF and VEGF [5].
The presence of cytokines is a major regulator of immune cell differentiation/function and is a crucial
factor to consider for immunotherapy protocols. Many of these cytokines signal through the stimulation
of STAT TFs. In this review, we will comment on the role of STAT TFs (i) for the recruitment and
function of tumor-associated macrophages (TAM) and (ii) for the regulation of T cell functions. As STAT
Cancers 2019, 11, 1832; doi:10.3390/cancers11121832 www.mdpi.com/journal/cancers73
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TFs are key players in the regulation of functions of these immune cells, their manipulation can have a
beneficial or detrimental effect on the anti-tumor response depending on the targeted cell type.
2. Tumor-Induced Inflammation Drives Accumulation of Tumor-Infiltrating Myeloid Cells
Cytokine receptor-induced signaling sustains and amplifies the activation of STAT3, NF-κB
and AP-1 in a positive amplification loop, fueling tumor-associated inflammation. As such, a core
inflammation-related gene set regulated by STAT3, NF-κB and AP-1 has recently been proposed as an
“inflammatory index” in breast cancer cell lines and patient samples [4]. Importantly, in correlation
with this inflammatory index, this study reported a concerted regulation of (i) non-inflammatory
genes related to angiogenesis, metastasis, and cell proliferation; (ii) tumor genome instability; and
(iii) heterogeneity of the tumor microenvironment (TME), including the recruited immune cells.
Remarkably, these co-regulated characteristics were found across several cancer types driven by
distinct oncogenes [4].
Tumor-derived cytokines have been linked to the accumulation of immune-suppressive myeloid
cells including both myeloid-derived suppressor cells (MDSCs; IMCs) and tumor-associated
macrophages (TAM). In both human and mouse melanomas, IMCs have an important role in
malignant progression and evasion from anti-tumor immunity that is linked to the suppression of T
cell responses [6–9]. While increased TAM accumulation has been ascribed to a poor prognosis in
established tumors [10], this notion should be refined given the extreme phenotypic and functional
heterogeneity of these cells during tumor growth.
Cancer-related inflammation (i) promotes the recruitment of monocyte-derived cells into the tumor
bed and (ii) acts systemically as shown by the dysregulated transcriptomic signature of circulating
monocytes in breast cancer patients as compared to healthy controls [11]. Numerous therapeutic
attempts (reviewed in [12]) to block cytokine-induced monocyte recruitment are under clinical trials
using either blocking mAbs (anti-CCR2; anti-CSF1R) or small inhibitors for downstream cytokine
receptor signaling (receptor tyrosine kinase inhibitor, Pexidartinib; CSF1R inhibitor, PLX3397).
Once recruited to the tumor, monocyte progenitors (CD11b+ SiglecF− Ly-6G−Ly6C+ F4/80−
CD169− MHC-II−) undergo a multistep differentiation program [13,14], passing through an immature
stage (Ly6C+ F4/80− CD169int MHC-IIhi) before reaching a mature state (Ly6C− F4/80+ CD169hi
MHC-IIhi or low). Recently, the heterogeneity of TAM in several cancer types has been emphasized by
single-cell RNA-sequencing paired with mass cytometry, including lung [15], kidney [16], breast and
endometrial cancers [11], as well as in mouse sarcoma [17]. In the case of renal cell carcinoma, 17 TAM
subsets have been characterized [16], most of them expressing CD169 while being discriminated by
expression of CD163, CD204 and CD206. Of note, when compared to steady-state tissue-resident
macrophages or monocytes, TAM exhibited peculiar gene expression profiles [11,16], highlighting a
tumor-induced dysregulation.
There is compelling evidence for high levels of phenotypic plasticity in macrophages, exhibiting
differential functional programs depending on their surrounding microenvironment. In response
to microbial stimuli pro-inflammatory macrophages—often referred to as of “M1-type” - express
cytokines supporting T cell activation. However, in malignancies, alternatively activated macrophages
- referred as of “M2-type”-secrete cytokines that sustain tumor growth and exert immune suppressive
functions. Therefore, differential signal transduction pathways downstream of cell surface sensors
define gene expression programs underlying anti- or pro- tumor functions of macrophages [18,19].
As such, IFNγ stimulates STAT1/STAT2 and IRF1/8, which can further promote pro-inflammatory
macrophages. While GM-CSF/STAT5 activates a pro-inflammatory signature in monocytes [20], it rather
induces a unique reparative program in macrophages after sterile renal injury [21]. Tumor-induced
inflammation involving the IL-6/gp130/STAT3 [22] and ERK5/STAT3 [23] axes was shown to drive
a pro-tumor transcriptomic program. Additionally, we recently showed that ovarian cancer cells
reprogram macrophages towards an IL-4/AKT/STAT6-mediated tumor-promoting phenotype through
increased cholesterol efflux from the TAM membrane [24]. Moreover, IL-6 synergizes with IL-4 in
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the programming of human monocyte-derived macrophages through the concerted activation of
STAT6 and STAT3 DNA-binding activities [25]. Given the spectrum of STAT3-regulated genes in TAM
encoding pro-tumor and immune suppressive mediators (Table 1), STAT3-modulators are currently
being developed to dampen the cancer supportive functions of TAM, as reported in this issue by Rébé
and Ghiringhelli [26]. As such, the specific targeting of a highly immune suppressive TAM (CD11b+
CD163+) subset by liposome-encapsulated STAT3-inhibitors showed some success in reprogramming
TAM towards a pro-inflammatory profile [27].
Table 1. STAT3–regulated genes in tumor-associated macrophages (TAM).




m-PDAC CD68+, IL-10Ra+ [29]
Il23a * positive m-melanoma CD11b+ CD11c− [30]
Il10ra, Il4ra positive m-PDAC CD68+, IL-10Ra+ [29]
Tgfb1 * positive m-melanoma CD11b+ CD11c− [30]
Il12a negative m-melanoma CD11b+ [28]; CD11b+ CD11c− [30]
Ifng negative m-melanoma CD11b+ [28]
Chemokines/Chemokine Receptors
Ccl5, Cxcl9-10-11 Negative m-melanoma CD11b+ [28]
Cxcl2, Cxcl12 positive m-melanoma
BMDM+Tumor conditioned media [31]
MDSC: CD11b+ GR1+ CD11c− [22]
Scavenger receptors/Endocytosis
Mrc1 (CD206) positive m-breast CD11b+ Ly-6Clo F4/80hi CD24lo MHC-IIlo [32]
CD163 positive
h-gastric CD163+ CD209a+ [33]
h-SCC ERK5+ CD163+ [23]
m-PDAC CD68+, IL-10Ra+ [29]
Cd209a positive m-PDAC CD68+, IL-10Ra+ [29]
Immune suppression
Arg1 positive m-PDAC; h-PDAC CD68+, IL-10Ra+ [29]; blood CD14+ [34]
Cox2 positive m-melanoma BMDM + Tumor conditioned media [31]
Ido1 positive m-liver metastasis liver-MDSC: CD11b+ Ly-6Cint/hi Ly-6G+ [35]
Pdl1 (CD274) positive
h- & m-glioma h-CD68+; m-CD11b+ CD115+ [36]
h-breast CD163+ [37]
m-liver metastasis liver-MDSC: CD11b+ Ly-6Cint/hi Ly-6G+ [35]
Extra-cellular Matrix/Angiogenesis
Mmp2 positive m-melanoma BMDM + Tumor conditioned media [31]
Vegf positive m-melanoma CD11b+ [28]; MDSC: CD11b+ GR1+ CD11c- [22]
Cathepsin (B, L) positive m-PDAC CD68+, IL-10Ra+ [29]
Cell cycle/TFs
Ccnd1 positive m-melanoma BMDM + Tumor conditioned media [31]
ATF6, sXBP1 positive m-PDAC CD68+, IL-10Ra+ [29]
* Immune suppressive cytokines.
3. Re-Educating TAM to Restore Anti-Tumor T Cell Functions.
Extensive studies are being conducted to reprogram pro-tumoral TAM towards an inflammatory T
cell supporting profile (recently reviewed in [38]). Mature TAM exert both trophic functions—through
the promotion of angiogenesis and tissue remodeling—and immune regulatory functions. Here we
will focus on the immune aspects of TAM functions, even though these two activities might be closely
inter-connected. Indeed, prolonged interactions between stromal TAM (mainly CD163+ CD206+) and
CD8 tumor-infiltrating lymphocytes (TILs) observed by dynamic imaging microscopy, are limiting
CD8 T cell motility and their consecutive access to both human lung squamous cell carcinomas and
mouse MMTV-PyMT tumors [39].
Recent parallel analyses of TAM and TILs from cancer patients have greatly expanded our
knowledge on the reciprocal regulation of these cell lineages. Paired CyTOF-based analyses of CD8
TILs and TAM in human renal cell carcinomas [16] showed some correlation between exhausted CD8
TILs, CD4 regulatory T cells and a few peculiar TAM subpopulations (either CD169- CD163- CD68hi
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CD38hi CD204+; or CD169+ CD163+ CD68hi CD38hi CD204+ CD206+). These molecular data had been
further correlated with clinical features, with the result that patients with the former TIL/TAM subsets
showed increased cancer progression.
We recently reported [13] that a subset of mature CD163+ TAM present in mouse melanomas,
exhibit transcripts related to T cell immune suppression. Interestingly, a high proportion of
CD163+ macrophages expressing phospho-STAT3 have been observed in human skin tumors [23].
Targeted-depletion of this minor CD163+ TAM subset enhanced melanoma-infiltration by CD8 T cells
and promoted CD8 T cell-mediated tumor regression in mice [13]; this was also accompanied by the
recruitment of fresh monocytes and immature macrophages with an immune stimulatory phenotype
(Figure 1).
 
Figure 1. (A). Concerted regulation of tumor-induced inflammation promotes accumulation of
immune-suppressive TAM. Oncogene activation in tumors induced secretion of inflammatory cytokines
that activate STAT3 and promote the accumulation of immune-suppressive TAM; IL-4-derived signals
through STAT6 sustain the pro-tumor TAM function that further sustains tumor growth in a positive
feedback loop. (B). Targeted depletion of specific TAM subsets displaying strong T cell suppressive
activity favors the recruitment of monocyte-derived immature TAM that secrete CXCL9/10 and display
T cell activating capacities. Reinvigorated CD8 TILs with activated pSTAT5 secrete IFNγ that further
maintains TAM anti-tumor functions and sensitizes tumors to T cell killing.
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Cancer treatments have recently benefited from immune checkpoint therapies (ICT) targeting
inhibitory signaling pathways in T lymphocytes (PD-1/PD-L1 and CTLA-4). Despite remarkable success
in a subset of patients (objective responses ~20–30% for monotherapy and ~30–40% for combined
therapy), primary resistance is observed in more than 50% of the patients and a subset of initial
responders can later develop acquired resistance [40]. Analysis of pre-treatment tumor biopsy samples
has revealed that patients with a pre-existing local CD8 T cell infiltrate (T cell inflamed) were more
likely to show a clinical response to anti- PD-1/PD-L1 [41]. Furthermore, PD-L1-expression on dendritic
cells and macrophages but not on cancer cells has been shown to shape the response to the PD-L1/PD-1
blockade [42,43].
Given the aforementioned reciprocal regulation of TAM and TILs, one should expect that ICT-based
therapies could conjointly unleash tumor-specific T cells and reprogram TAM functions. Several
groups exploring immune cells dynamics in vivo before and after ICT recently addressed this issue.
In carcinoma-bearing mice, immune-PET monitoring showed that ICT induced an important infiltration
of CD8 T cells within the tumor in responders as compared to non-responders; the responders displayed
CD11b+ TAM with a “M1-type” transcriptomic signature [44]. scRNA-seq and longitudinal CyTOF
analyses also revealed ICT-induced dynamic changes in both TAM and TILs present in induced mouse
sarcomas [17]. This study identified an ICT-induced decrease of both CD4 regulatory T cells and
exhausted CD8 T cells. Meanwhile, conventional CD4 T cells and tumor-specific CD8 T cells displayed
an activated profile as did recruited NK cells, with all these effector cells exhibiting an enhanced NF-κB
and IFNγ-driven gene signatures. ICT consequently conferred a remarkable dynamic remodeling on
intra-tumor monocytes and macrophages. Distinct TAM populations expressing IFNγ-induced iNOS,
while down-regulating IL-4-responsive CD206 proteins, were enriched upon ICT Pathway analyses,
which showed ICT-driven enrichment of IFNγ and NF-κB signaling as well as glucose metabolism.
Concurrently, alternative “M2-type” TAM clusters with a MerTKhi CD206+ CCL2+ CD274+ IL4Rα+
phenotype were reduced by approximately one-third. Kinetic CyTOF analyses further highlighted an
important crossroads between days 7 and 9—a time window where the TME drives the TAM behavior
towards a pro-inflammatory/T cell supporting or an anti-inflammatory/immune suppressive program.
The TME agent mediating monocyte/macrophage reprogramming was ascribed to be IFNγ secreted
by ICT-unleashed tumor-specific T cells. Importantly, T cell produced IFNγ not only engages its
receptor signaling on surrounding TAM but also on tumor cells themselves. As such, STAT1-activation
was reported to sensitize hepatocarcinomas to T cell mediated killing [45] (see Figure 1). Therefore,
the therapeutic use of STAT/JAK-modulators should be carefully evaluated for their specific targeting
of STAT3 activity while preserving IFNγ-induced STAT1/2 signaling, which appears to be beneficial for
anti-tumor immune responses.
In the large fraction of patients who are non-responsive to ICT other therapeutic approaches must
be proposed to reinvigorate anti-tumor responses. Providing an infusion of autologous tumor-specific
CD8 T cells manipulated to express an effector (IFNγ-proficient) program could be a way to fight
cancer and induce TAM reprogramming. This will be addressed in the next section.
4. STAT5 versus STAT3 in Adaptive CD8 T Cell Responses to Cancer
Cytokines are major regulators of T cell differentiation/function and are crucial factors to consider
for immunotherapy protocols. Many of these cytokines signal through the stimulation of STAT3 and/or
STAT5. This makes these two TFs key players in the regulation of functions of T cells. Both STAT3 and
STAT5 activation can have a beneficial or detrimental effect on the anti-tumor response depending on
the T cell type targeted. In this part, we will focus on the T cell-intrinsic role of these TFs and on the
possibility to manipulate them for improving CD8 T cell anti-tumor responses.
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4.1. STAT5 in the Adaptive T Cell Responses
The STAT5 pathway is predominantly activated in T cells by members of the γc cytokine family
(IL-2, -7, -9 and -15) (reviewed in [46]). These cytokines signal through receptors containing the
γc (CD132) subunit and lead to the activation of the JAK3 tyrosine kinase. In addition, activation
of JAK1 occurs through its interaction with the IL-2Rβ (CD122) (for IL-2 and IL-15), but also, with
the IL-4Rα, IL-7Rα and IL-9Rα units. For IL-2, high-affinity binding to its receptor requires the
association of an additional subunit (IL-2Rα or CD25) to the IL-2Rβ and the γc components. IL-15
signaling is further peculiar in that it requires the association “in-trans” of the IL-15Rα component
with the IL-2Rβ and the γc components [47]. The specificity of signaling by these cytokines is thus
partially explained by the recruited STAT proteins, but also by the differential expression of the relevant
receptors. STAT5-activating cytokines have a general role in the maintenance and expansion of T cell
subsets. IL-2 has a central role in the expansion phase of T cells following their primary antigenic
stimulation [47,48]. The roles of IL-7 or IL-15 are rather associated with the maintenance of naïve or
memory T cells [47,49,50].
In adaptive immunity, except for a population of CD4 T cells with a regulatory function (Treg),
IL-2Rα (CD25) is not expressed at a significant level at the surface of naïve CD4 and CD8 T cells.
Although the two other chains of the IL-2R are expressed at low basal levels on naïve T cells, IL-2 fails
to activate these T cells, consistent with the report that only Tregs respond promptly to in vivo IL-2
exposure [51]. Thus, antigen stimulation of the TCR/CD3 complex is a pre-requisite for the secondary
signaling by the IL-2R. TCR/CD3 initiated signals, which do not involve STAT activation, lead to
transient expression of genes, including il2ra. IL-2R mediated signaling through STAT5 activation
further increases CD25 expression at the cell surface and leads to the stabilization of a panel of
genes initially induced by the TCR [52,53]. We and others reported that TCR-initiated signaling is
influenced by the avidity of TCR-peptide/MHC interaction, which impacts strength and duration
of TCR engagement [54–56]. Strong TCR/CD3 stimulation causes production of IL-2, leading to an
autocrine effect on IL-2R signaling, which is not induced by low avidity Ags. In this latter case,
exogenous IL-2 or expression of a constitutive-active STAT5 protein [52,53] can serve as a substitute for
the lack of the IL-2/IL-2R amplification loop. Interestingly, a study evaluating the IL-2R/JAK-regulated
phospho-proteome in CD8 CTL revealed a dominance of proteins that control mRNA stability and
components of the protein translational machinery leading to an accumulation of cytokines and
effector molecules, as well as proteins that support metabolic processes essential for cell “fitness” and
important oxygen-sensing components [57]. Of note, active STAT5 does not substitute for all IL-2
induced signaling events that also involve MAP kinase- and phospho-inositol 3-kinase-dependent
pathways [58]. Altogether, for CD8 T cells, depending on their state of activation and on the dose
of cytokine provided, IL-2 may amplify effector function and proliferation and induce terminal
differentiation or activation-induced cell death [47,48].
The synergistic action of TCR-induced TFs and STAT5 in CD8 T cells mirrors the cooperation
between STAT5 and (i) TCR-induced GATA3 in CD4 Th-2 cells to control the accessibility of Il4
gene locus [59]; (ii) Tbet in Th-1/Tc-1 for the regulation of the Ifng locus [60,61]; and (iii) BCL6 in B
lymphocytes for the generation of memory B cells [62]. Additionally, STAT5 activation was shown to
promote GM-CSF [63] and IL-9 [64], producing T cells and to be a prerequisite for Foxp3-expressing
Tregs [65,66]. By contrast, STAT5 is a negative regulator of Th-17 [67] and T-Fh [68] by competing with
STAT3 and BCL6, respectively. Altogether, STAT5 appears to control secondary decisions in adaptive
immunity (see Table 2).
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Table 2. Concerted gene regulation by STAT3 and STAT5 in helper and cytotoxic lymphocytes.
STAT3 and STAT5-Regulated Genes in T and NK cells
Target Genes STAT3 Input Cell Subsets STAT5 Input Cell Subsets
Cytokines/Cytokine receptors
Il17 positive hCD4 Th-17 [69]
Il10 positive mCD4 Th-2 [70]
Il2ra (CD25) positive mCD4 Th-21 [71] positive mCD4 Th-1 [71], mCD8 [60], mNK [72]
Il7ra (CD127) negative mCD8 [60]
Il6st negative mCD8 [60]
Tgfb2r negative mCD8 [60]
Homing
CCR7 negative mCD8 [60]
Sell (CD62L) negative mCD8 [60]
TFs
Prdm1 (Blimp) positive mCD4 Th-2 [70]
Eomes positive mCD8 [60]
Tbx21 (Tbet) positive mCD8 [60]
Cytotoxicity
Gzmb positive mCD8 [60], mNK [73]
Prf1 positive mCD8 [60], mNK [73]
Ifng positive mCD8 [60], mNK [73]
Fasl positive mCD8 [60]
Cell cycle/Cell survival
Myc positive hT lymphoma [74] positive mCD8 [60]
Pim1 positive hT lymphoma [74] positive mCD8 [60,75]
Bcl2 positive hT lymphoma [74] positive mCD8 [49,60]; NK [73]
Competitive gene regulation by STAT3 and STAT5 in T cells *
Target Genes STAT3 Input STAT5 Input T Cell Subsets
Il17 positive competitor mCD4 Th-17 [67]
Il9 competitor positive mCD4 Th-9 [64,76]
Bcl6 positive competitor mCD4 Tfh; mCD4 Th-1 [68,77]
Socs3 positive positive mCD4 Th-17/Treg balance [78]
* Mechanisms underlying competitive gene regulation by STAT3 and STAT5 are reviewed in [79].
Role of STAT5 in the Generation of Memory CD8 T Cells and Maintenance of Effector Functions
Several STAT5A mutants have been shown to confer cytokine-independent growth to Ba/F3
cells [72]. While a STAT5A S710F single-mutant displayed a strong constitutive activity sufficient to
complement STAT5Anull bone marrow progenitors, a STAT5A double-mutant H298R/S710F was not
able to complement STAT5Anull cells [80]. Further studies highlighted that the H298R mutation in the
DNA-binding domain renders this protein inactive unless it can form heterodimers with endogenous
wild-type STAT5 (see Figure 2). Therefore, the constitutive activity of STAT5 H298R/S710F is modest
and limited by the bioavailability of wild-type STAT5 to pair with. By contrast, the single STAT5 S710F
mutant exerts a strong constitutive activity in both CD8 T cells [81] and Ba/F3 cells [82].
Retroviral expression of STAT5A H298R/S710F (hereafter referred to as STAT5ca) in in vitro
activated CD8 T cells led to the generation and maintenance of long-lived CD8 T effector cells upon
their adoptive transfer [83]. Transcriptomic analyses of STAT5ca-expressing CD8 T cells highlighted
a role for STAT5ca in the stabilization of a broad Tc-1 gene expression program initiated by TCR
stimulation [60] (see Table 2, Figure 2). This observation is in agreement with the reported chromatin
interactions of STAT5 in super-enhancers to activate IL-2 highly inducible genes [71].
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Figure 2. (A). Ag presented by APC (Ag-presenting cells) triggers a T cell activation cascade leading to
gene transcription including Il2 and IL2Rα genes. Binding of IL-2 to its receptor further amplifies the
TCR-initiated gene transcription program. (B). Ag expressed on tumor cells mediates chronic TCR
engagement on CD8 TILs leading to their “exhaustion”, which is characterized by expression of multiple
inhibitory receptors (as shown in Figure 1). For simplicity, we represent PD-1 only that recruits the
phosphatase SHP-2 mediating inhibition of ERK and PI3K/AKT pathways as well as dephosphorylation
of STAT5. (C). Expression of STAT5ca (H298R/S710F, here represented by dashed symbols as compared
to the wild type (WT) protein) in CD8 T cells not only recapitulates the IL-2-mediated TCR-initiated
gene transcription, but also stabilizes this functional program. This leads to a sustained Tc-1 program
reminiscent of effector memory cells. Of note, while being PD-1hi due to the chronic TCR engagement
by their cognate Ag, STAT5ca-expressing T cells remain functional, as the S710F substitution reduces
the SHP-2-mediated dephosphorylation. Additionally, STAT5ca represses the expression of il6st and
Tgfb2r genes, rendering these cells insensitive to IL-6/STAT3 and TGFβ1/Smad signaling.
Of note, the in vivo maintenance of STAT5ca-expressing CD8 T cells remains under the control of
γc-cytokines (IL-7, IL-15) and TCR tickling by self MHC class I [81]; these properties again point towards
a moderate and controlled activity of this double-mutant. Accordingly, Kaech’s group also reported that
STAT5ca promoted memory CD8 T cells [49] that did not display any sign of transformation. However,
Moriggl and colleagues recently demonstrated that high expression of S710F gain-of-function mutated
STAT5A induced PTLC-nos (Peripheral T cell leukemia and lymphoma—not otherwise specified) cells
when expressed during T cell development in transgenic mice [84].
Mice expressing a constitutively active STAT5Bca (H298R/S715F) transgene in the lymphoid
lineage have been shown to present a selective expansion of memory-like CD8 T cells. Their analysis
further suggested that moderate STAT5B activation underlies both IL-7/IL-15-dependent homeostatic
proliferation of naive and memory CD8 T cells and IL-2-dependent development of CD4 CD25+
Tregs [85]. When expressed in the B cell lineage in mouse models, STAT5Bca (H298R/S715F) induces
B cell acute lymphoblastic leukemia thanks to cooperative molecular events targeting JAK1 activity,
tumor-suppressor genes, and pre-BCR signaling [86]. Indeed, mutated STAT5Bca was shown to
antagonize preBCR-initiated TFs (NF-κB, IKAROS) for binding to B cell specific super enhancers [87].
Finally, mice which expressed a transgene, i.e., a human gain-of-function mutation of STAT5B (hSTAT5B
N642H) identified in leukemic patients, developed lymphomas from multiple T cell subsets [88].
The recent crystal structure of hSTAT5B N642H highlighted important conformational changes in
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correlation to its resistance to dephosphorylation [89]. Overall, strong STAT5B hyperactivity appeared
to trigger B or T lymphomas when express during lymphoid cell development and to directly influence
disease aggressiveness and therapeutic resistance [87,89].
4.2. Role of STAT3 in T Cells
Several cytokines/cytokine receptors trigger STAT3 signaling in T cells, including IL-6-type
cytokines (IL-6 and Oncostatin M), IL-10, IL-17, IL-21 and IL-27. Among the STAT3-activating
cytokines, IL-21 is peculiar: While its receptor contains the γc (CD132) subunit, signals downstream
of IL-21R converge on STAT3 and to a lesser extent on STAT1, rather than on STAT5 activation [46].
Intriguingly, IL-21 was shown to promote in vitro proliferation of CD8 T naïve and memory cells
in synergy with STAT5-inducing cytokines IL-7/IL-15 [90]. Indeed, Leonard’s group reported that
IL-2 vs. IL-21 cytokine stimulation of pre-activated T cells induces STAT5 and STAT3 binding,
respectively, to incompletely overlapping super enhancers [71]. Understanding the fine-tuning of
cytokine-modulated STAT3/5 activities will require further effort as reviewed in [46]: This tight
regulation relies on the T cell context, including cell lineage, differentiation state, and cytokine milieu,
triggering synergistic/antagonistic STAT-mediated transcriptional regulation. Thus, the amplitude of
STAT3 activation differs from one T cell subset to another in correlation with differential expression
of the corresponding T cytokine receptor [91]. Interestingly, chronic TCR engagement was recently
shown to enhance the sensitivity to IL-6/STAT3 signals [92], indicating again a cross-talk between
TCR-induced and STAT TFs.
The function of STAT3 in various T cell subtypes is summarized in Table 2, but further details are
described in this issue by both Rébé and Ghiringhelli [26] and Logotheti and Putzer [93].
The overall effect of STAT3 stimulation in T cells is generally correlated with a poor
cytotoxic/increased regulatory response and as such, is associated with a defective anti-tumor immune
response [94]. In the next part, we will focus on the role of STAT3 in the maintenance and formation of
memory CD8 T cells.
4.2.1. Role of STAT3 in the Maintenance and Memory Formation of CD8 T Cells
Several studies have highlighted the role of IL-21 and STAT3 activation in T cell memory regulation.
Using LCMV chronic infection in mice, Kaech’s group showed that IL-10 and/or IL-21-induced STAT3
was required for the differentiation of memory CD8 T cells with a preserved replicative potential [95].
Indeed, in the absence of STAT3, memory precursor cells were replaced by T effector-like cells that
failed to undergo homeostatic proliferation or to protect against secondary infection. Interestingly,
STAT3 appeared to act both by induction of “pro-memory” TFs, such as Eomes and BCL6, and by
dampening inflammation-driven TFs, including STAT4 and Tbet.
A similar role for STAT3 in human T cells [96] was reported in a cohort of patients suffering from
autosomal-dominant hyper-IgE syndrome, which is caused by dominant-negative STAT3 mutations.
These patients have increased numbers of naïve T cells but fewer central memory CD4+ and CD8
memory T cells, leading to an increased susceptibility to EBV infections. This was associated with a
defect of these naïve T cells to express the TFs important for memory formation.
Accordingly, IL-21 repressed the cytolytic effector program in tumor-specific CD8 T cells while
preserving their replicative potential [97].
4.2.2. Role of STAT3 in the CD8 T Cell-Mediated Anti-Tumor Responses
STAT3-activating cytokines such as IL-6 and IL-10 are found in abundance within the tumor
microenvironment. It was clearly shown that STAT3 inactivation in tumor-specific CD8 T cells increased
their potential for tumor elimination after adoptive transfer [98,99]. Altogether, these studies suggest
that a general inhibition of STAT3 in T cells would be a beneficial treatment for increasing tumor
control. However, contradicting data exist in the literature [100]. In mice bearing transplanted tumors,
a combination of anti-OX40 mAb and TGFβ/Smad inhibitors improved the CD8 T cell mediated
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tumor rejection. Use of OX40-Cre STAT3fl/fl mice further demonstrated that in absence of STAT3 in
OX40-expressing T cells, the response to the treatment was lost [100]. These authors did not prove
formally that the deletion of STAT3 in CD8 T effector cells only was mediating the same effect; but their
data suggest that depending on the T cell subset or the immunotherapy used, inhibiting STAT3 could
become detrimental and lead to poor survival of T cells and loss of the benefit of the treatment.
The reported discrepancies for the function of STAT3 in CD8 T cell mediated anti-tumor responses
may rely on distinct roles of this TF depending on the T cell differentiation state (effector versus
memory), the combined immunotherapy regimen and the STAT3-inducing cytokines in the TME.
All these parameters may contribute to differential STAT3-activation thresholds triggering distinct T
cell responses, a hypothesis that needs to be tested in refined analyses.
5. Adoptive CD8 T Cell Therapy and CAR-T Cell Generation for Cancer Immunotherapy
5.1. Increasing the Frequency of Tumor-Specific CD8 T Cells
As mentioned earlier in Section 3, beside tremendous achievements for patients with various types
of cancers, immunotherapies aimed at blocking inhibiting receptors still failed for more than 50% of
cancer patients. This could be the consequence of the paucity of tumor-specific CD8 T cells, an obstacle
that could be circumvented by infusions of in vitro amplified tumor-specific T cells. Indeed, Adoptive
Cell Transfer (ACT) of amplified TILs and Chimeric Antigenic Receptor (CAR) treatments are based
on the use of the patient’s T cells [101]. Historically, T cells used for ACT were obtained from tumor
pieces/biopsies, amplified in vitro and transferred back into the patient when a sufficient number was
reached (up to 1011 cells) [102]. The progress in gene engineering removed many hurdles to generate
cancer specific T cells. CAR-T cells are gene-engineered products obtained from the expression in T
cells of a construct encoding a domain of a single-chain variable antibody fragment recognizing a
tumor antigen, fused to intracellular signaling motifs inducing T cell activation upon recognition of
the target cells [103]. T cells from the blood are used for this therapy, allowing an increased potential
to generate these cells on a large scale. CD19-directed CAR-T cells have shown impressive results in
the treatment of patients with B-cell lymphoma [104]. However, evidence for the use of CAR-T cells
against solid tumors is still sparse. The main limitation for application being the identification of Ags
expressed exclusively on solid tumors and not on the non-transformed cell counterparts. Defining
tumor-specific Ags for solid cancers is still a challenge [105,106]. Such an attempt was reported using
mesothelin-specific CAR-T cells to treat patients bearing pancreatic ductal adenocarcinoma [107].
Of note, antibody-targeted chimeric T cells display receptors (i) of higher avidity for tumor-Ags than
regular TCRs; (ii) which are not MHC restricted and thereby, are not impacted by tumor editing in the
Ag processing/presentation pathway, (iii) interacting only with Ags expressed at the tumor cell surface.
Despite some clinical success using ACT or CAR-T cells, much effort is being made to improve T
cell survival and resistance to immunosuppression in the frame of these therapies. Given the ability of
IL-2 to expand CD8 T cells and to maintain their cytotoxic function, infusion of recombinant IL-2 in
cancer patients was the first reported effective immunotherapy for human cancer [108]. However, IL-2
concomitantly acts on Tregs that suppress anti-tumor responses, and systemic IL-2 injections had severe
adverse effects including vascular leak syndrome and pulmonary edema due to IL-2Rα expression
on endothelial cells [109]. This has led to the development of (IL-2/anti-IL-2 mAb) complexes [110]:
depending on the mAb the binding of the resulting complex is favored on IL-2Rβ/γc-expressing cells
such as the memory CD8 T and NK cells, but prevented on IL-2Rα+ Tregs and endothelial cells. Such
approaches enhance the cytokine half-life in vivo and were shown to induce a massive (>100-fold)
expansion of CD8 T cells in vivo [110,111] thereby boosting anti-tumor immune responses in mice and
humans [112].
IL-21 is also considered to expand less differentiated CD8 T memory stem cells with both
proliferative and multipotent potential [113] to be used in ACT.
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The manipulation of cytokine-induced STAT-signaling in tumor-specific CD8 T lymphocytes may
be another solution to potentiate adoptive T cell cancer therapies.
5.2. On CD8 T cell Intrinsic Modifications For adoptive T Cell Therapies
5.2.1. Promoting Effector Memory CD8 T Cells Through STAT5
Another hurdle for ACT is the persistence of the infused T cells, their capacity to home in
tumor-invaded peripheral organs and to resist the local immune suppression. As such, CD19-directed
CAR-T cells had limited capacities to control the growth of CD19+ murine melanomas in relation with
their scarcity in the tumor [114]. To infiltrate non hematologic solid tumors, T cells must acquire an
effector phenotype: this includes the simultaneous loss of CD62L (L-selectin) and CCR7 expression, and
acquisition of tissue-specific homing molecules such as adhesion molecules and chemokines/chemokine
receptors [115]. Given the multiplicity of the molecular partners involved in T cell egress and migration,
it is illusory to manipulate these targets, one by one or in combination. However, manipulating TFs
known to be activated during T effector cell differentiation may have broader effects. We brought this
proof of concept by expression of STAT5ca during the in vitro differentiation of CD8 T cells, which
modified their in vivo migration upon ACT with increased infiltration of both non-lymphoid tissues in
healthy mice and melanomas in tumor-bearing mice [60]. At the transcriptomic and protein levels,
coincident down-regulation of CD62L and up-regulation of CCR2, CCR5 and CXCR3 was induced by
STAT5ca as compared to standard CD8 T effector cells. Altogether, STAT5ca-CD8 T cells acquired a
long-lived effector memory phenotype in correlation with a concerted STAT5-mediated regulation of
Tbx21 and Eomes genes (Table 2 and [60]). Coupled to their enhanced effector functions—Ag-driven
cytotoxity and IFNγ production—these engineered STAT5ca-CD8 T cells mediated efficient melanoma
rejection as compared with conventional CD8 T effector cells [83]. Importantly, this STAT5ca-induced
reprogramming applies to both polyclonal and monoclonal (TCR transgenic) CD8 T cells, after primary
or secondary stimulation [83]: these characteristics are of particular importance for translation to cancer
patients’ CD8 T cells. Finally, STAT5ca-expression in tumor-specific T cells had better therapeutic
potential than the potentiation of standard CD8 T effector cells with combined infusions of IL-2
complexes, the effect of which disappeared at the end of treatment [83].
5.2.2. Promoting Central Memory CD8 T Cells Through STAT3
Recent studies have highlighted the importance of a memory-like CD8 T cell population to
unleash an anti-tumor response by anti-PD-1 treatment [116,117]. In these studies, a small subset of
CD8 TILs expressing PD-1 and the transcription factor TCF1 responded to anti-PD-1 immunotherapy
by differentiating into highly cytotoxic TILs that mediated long-term tumor control. These studies
highlight the importance of a long lasting, less differentiated population to mediate a more efficient
control of the cancer.
This point is also valid for ACT, as transfer of expanded T cells that are too differentiated could lead
to a failure of the treatment related to a lack of survival of the cells [118]. For that purpose, IL-21, a STAT3
stimulating cytokine, is efficient in driving the differentiation of central memory CAR or TCR engineered
CD8 T cells in vitro [119]. Additionally, a recent study showed that CD19-directed CAR-T cells initially
activated in vitro with optimal stimulation (anti-CD3/CD28) progressively acquired an “exhausted”
phenotype upon transfer in tumor bearing mice. Thus, when retrieved from the tumor 12 days after
their transfer, they presented a characteristic high surface expression of inhibitory receptors, diminished
production of IFNγ and TNFα, and low cytolytic activity as well as the expression of the high-mobility
group (HMG)-box TFs - TOX and TOX2. Expression of the latter TFs was recently described as resulting
in commitment of CD8 T cells to an exhausted transcriptional and epigenetic developmental program
distinct from that of functional CD8 T effector and T memory cells [120]. To understand further the
factors associated with an efficient CAR response, Fraietta et al. [121] performed a transcriptomic
profiling of CAR-T cells from complete-responding patients with chronic lymphocytic leukemia
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compared to non-responders. The gene signature was enriched in memory-related genes, including
IL-6/STAT3 signatures, whereas T cells from non-responders upregulated programs involved in effector
differentiation, glycolysis, exhaustion and apoptosis. Moreover, highly functional CAR-T cells from
patients produced the STAT3-activating cytokine IL-6 and its concentration in serum was correlated
with CAR-T cell expansion. These results showed STAT3 signaling is beneficial for an efficient CAR-T
cell response [121]. This finding is further validated by the use of a new-generation CD19-CAR that
encodes a truncated cytoplasmic domain from IL-2Rβ and a STAT3-binding tyrosine-X-X-glutamine
motif. These CAR-T cells showed antigen-dependent activation of the JAK kinase and of the STAT3
and STAT5 TFs signaling pathways, which promoted their proliferation and prevented their terminal
differentiation in vitro. The CAR-T cells demonstrated superior in vivo persistence and anti-tumor
effects in models of hematologic malignancies as compared with CAR-T cells expressing a CD28 or 4-1BB
co-stimulatory domain alone [114]. It should be noted that while a subtle increased STAT3 activation
by these newly engineered IL-2Rβ-CAR-T cells was therapeutically beneficial, STAT3 gain-of-function
mutants induced multi-organ autoimmunity and large granular lymphocytic leukemia [122].
In conclusion, these studies strengthen the interest of regulating STAT3/STAT5 activities in CD8 T
cells to improve adoptive cell therapy: given their tightly balanced contribution to T cell memory fates,
increased STAT3 or STAT5 activity is expected to improve the therapeutic success of hematological and
non-hematological cancers, respectively. This hypothesis has to be validated in relevant preclinical
mouse models.
5.2.3. On the STAT5 versus STAT3 Balance in T Cells
Several groups have provided data showing that the competitive binding of STAT3 and STAT5
dimers to DNA dictates the transcriptional regulation of certain target genes in T cells and thereby
either trigger autoimmune disorders or promote tumor rejection (some examples are reported in
Table 2). These data highlight the need for both in silico analyses [123] and appropriate cell/animal
models to evaluate the outcome of competition between STAT TFs on T cell fates.
6. STAT5 and Resistance to Immunosuppression in the Tumor Microenvironment
Chronic stimulation of tumor-specific T cells promotes an exhausted phenotype, sharing
strong [124] but not-completely overlapping similarities [125] with virus-induced exhausted CD8 T
cells. Both the diversity and the high expression of inhibitory receptors by CD8 TILs (reviewed in [126])
can contribute to ICT resistance. However, combining blocking antibodies towards several inhibitory
receptors to improve anti-tumor responses may further increase the adverse effects among which
autoimmune attacks [127]. Therefore, manipulating CD8 T cells to resist local tumor-derived immune
suppression may be of clinical benefit.
6.1. Immunosuppression by PD-1
PD-1 is related to the CD28 superfamily and is expressed on activated T cells, B cells, monocytes
and macrophages. Engagement of PD-1 by its ligands (PD-L1 or PD-L2) induces inhibitory signals in T
cells [128] through the induced phosphorylation of ITIM/ITSIM motives in its cytoplasmic domain,
which leads to recruitment of the SHP-2/SHP-1 phosphatases. This dampens both TCR and CD28
signaling leading to abrogation of the PI3K/AKT and ERK pathways, as shown notably in primary
CD4 T cells [129]. Interestingly, SHP-2 recruited by PD-1 was shown to counteract phospho-STAT5
signaling in human Tregs from HCV-infected patients’ livers [130]. It was also demonstrated that
PD-1 intrinsically regulates a subpopulation of high PD-1 expressing innate cells (ILC2) involved
in helminth immunity (γc dependent proliferation) by inhibiting STAT5 phosphorylation through
SHP-1/SHP-2 phosphatases [131]. Similarly, for T cells, the inhibitory effect of PD-1 is observed on
populations expressing high levels of surface PD-1 such as exhausted T cells in contrast to acutely
activated T cells [132]. However, in a melanoma model, in spite of upregulation of the PD-1/PD-L1
immunosuppressive pathway in the tumor microenvironment, STAT5ca-expressing CD8 T effector
84
Cancers 2019, 11, 1832
cells were found to be resistant to inhibition by PD-1/PD-L1 engagement as measured by their efficient
IFNγ production, in contrast to their control counterpart [132]. Thus, the previously reported increased
resistance to dephosphorylation of STAT5ca [72] may also contribute to its resistance to the phosphatases
recruited to checkpoint inhibitors (Figure 2) [133,134].
6.2. Other Immune Suppressive Pathways
The diversity of immune suppressive mechanisms associated with inflammatory melanoma have
previously been reported [133], with several involving tumor-derived proteins.
TGFβ1, an immunosuppressive cytokine produced by a number of cancer cells, was shown
to inhibit both Th-1/Tc-1 cytokine production and Tc-1/NK cytolytic effector functions through the
repression of Ifng, Gzmb, and FasL gene transcription [135,136]. Interestingly, STAT5ca-expressing
T cells maintained efficient induction of both IFNγ and Gzmb in the presence of TGFβ1 [132].
The insensitivity to TGFβ1 may be linked to the STAT5ca-mediated negative regulation of Tgfbr2
expression as well as its positive effects on Ifng and Gzmb gene transcription [60]; thus, STAT5ca-gene
regulation counterbalances the transcriptional repression exerted by TGFβ1-induced Smad2/3.
Indeed, two STAT5-activating cytokines, IL-2 [136] and IL-15 [137], have been shown to counteract
TGFβ1-mediated immune suppression.
Of note, while TGFβ1 and IL-6 contribute to Maf up-regulation in exhausted CD8 T cells [125],
STAT5ca-expressing T cells displayed reduced levels of Il6st, Tgfbr2, and Maf transcripts [60] and
maintained a functional antitumor program.
Another tumor-secreted protein, the Dickkopf-related protein 2 (DKK2), was shown to be
overexpressed in human colorectal cancers and melanomas, and to promote tumor progression by
suppressing the activation of both CD8 T and NK cells [138]. Mechanistically, tumor cells secrete
DKK2 that binds its receptor LRP5 inducing interactions between the intracellular domain of LRP5 and
STAT5; while STAT5-phosphorylation was not precluded, STAT5 nuclear localization was impeded in
cytotoxic cells. Conversely, DKK2 blockade enhanced cytotoxic immune cell activation.
Altogether, maintenance of active STAT5 signaling in cytotoxic cells appears to correlate with
efficient anti-tumor immunity [73,83].
7. Conclusions
The frequency of tumor-specific CD8 T cells can now be increased in cancer patients through
sophisticated personalized medical approaches including in vitro derived and expanded TILs or
engineered CAR-T cells. Nevertheless the ability of adoptively transferred T cells to survive in
cancer-invaded hosts and to efficiently penetrate into the tumor are dampened by the solid tumor
landscape including cancer cells, tumor stroma and immune suppressive myeloid cells. Therefore,
enhancing tumor T cell infiltration is one way to improve cancer immunotherapy. This could imply (i)
manipulation of the T cells themselves through their transduction with chemokine receptors promoting
non-hematopoietic tissue colonization [139,140] or manipulation of TFs that regulate expression of
these homing receptors [60]; (ii) depletion of specific TAM subsets that exert trophic and/or immune
suppressive functions either by ablation [13] or inactivation using STAT3 inhibitors [27]. The enhanced
killing of cancer cells together with the recruitment of fresh monocytes will favor the engagement of
the host immune system thanks to the presentation of tumor-derived Ags by professional APCs such
as dendritic cells and/or immature TAM. This would result in spreading of tumor-derived epitopes
ensuring a polyclonal anti-tumor response that could ultimately prevent antigen escape. Importantly,
this favorable loop was observed when using STAT5ca-expressing CD8 T cells in ACT as their efficient
capacity to infiltrate and kill inflammatory melanomas is accompanied by a concomitant infiltration of
host T cells [83]. Compared to systemic treatment, such as IL-2 infusions, the targeted manipulation of
STAT5 activity in tumor-specific CD8 T lymphocytes circumvents the negative stimulation of Tregs,
which are also recruited into tumor beds. We here propose to transiently express (i.e., through mRNA
transfection for example) the STAT5A H298R/S710F mutant in human CD8 T cells specific for Ags
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expressed on solid malignancies to be used in ACT: Both their efficient infiltration into tumors and IFNγ
production resistant to tumor-derived suppression should help to restore endogenous T cell responses
and to reprogram TAM. Although the IFNγ/STAT1 signature induced by T cells has recently been
reported as a good prognostic factor for ICT response [141], a close control of this cytokine-induced
signaling must be maintained since excess IFNγ can induce death of anti-tumor CD8 T cells at a certain
stage of their differentiation/activation [142–144].
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Abstract: Immune cells in the tumor microenvironment regulate cancer growth. Thus cancer
progression is dependent on the activation or repression of transcription programs involved in the
proliferation/activation of lymphoid and myeloid cells. One of the main transcription factors involved
in many of these pathways is the signal transducer and activator of transcription 3 (STAT3). In this
review we will focus on the role of STAT3 and its regulation, e.g., by phosphorylation or acetylation
in immune cells and how it might impact immune cell function and tumor progression. Moreover,
we will review the ability of STAT3 to regulate checkpoint inhibitors.
Keywords: STAT3; cancer; CD4+ T cells; CD8+ T cells; myeloid cells; immune check point
1. Introduction
STAT3 is part of the Signal Transducer and Activator of Transcription (STAT) family which includes
seven members encoded by distinct genes. STAT3 has evolutionary conserved amino acid sequences
between H. sapiens and S. harrisii (99.09%) [1]. In resting cells, STAT3 remains in an inactive form in the
cytoplasm. Once activated, mainly through phosphorylation, STAT3 translocates to the nucleus to
play its transcription activity for specific target genes [2]. STAT3 phosphorylation on tyrosine (Y705) is
mainly regulated by members of Janus-activated kinases (JAK), whereas its phosphorylation on serine
(S727) is commonly regulated by mitogen-activated protein kinases, CDK5 and protein kinase C [3].
Finally, histone acetyltransferase-mediated reversible acetylation of STAT3 on a single lysine residue
(K685) is a third mechanism of STAT3 activation through STAT3 dimer stabilization [4]. However, the
phosphorylation on S727 is responsible for a mitochondrial relocalization of STAT3 where it exerts
non-transcriptional roles. This mitochondrial localization enables STAT3 to increase cell respiration
(through electron transport chain complex activation) and Ras transformation [5]. Non-nuclear STAT3
can also regulate glycolysis, thus enhancing lactate production leading to the protection of cells from
apoptosis and senescence and can also regulate calcium homeostasis, energy production and apoptosis
at the endoplasmic reticulum level [6].
Regulation of STAT protein activation is controlled by negative regulators, e.g., PIAS (protein
inhibitor of activated STAT) and SOCS (suppressors of cytokine signaling) proteins as well as protein
tyrosine phosphatases. PIAS are nuclear factors that negatively regulate STAT transcriptional activity
through many mechanisms, especially by interacting and thus blocking the DNA binding activity [7].
SOCS proteins directly or indirectly interact with tyrosine kinase SH2 domains to prevent JAK
from activating STAT3 [8]. Protein tyrosine phosphatases (such as CD45, SHP-1 and SHP-2) remove
phosphates from activated STATs, which represent a third level of STAT modulation [9–11]. Lastly,
STAT3 has also been shown to go through ubiquitination-dependent proteosomal degradation [12].
Moreover, because of their homologies, STATs can form homodimer and heterodimers. Specificity
depends on the activator signal and leads to the transcription of different target genes. For example,
STAT3 can heterodimerized with STAT1, under IL-6 treatment [13].
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It is now well-established that STAT3 signaling is a major intrinsic pathway driving apoptosis,
inflammation, cellular transformation, survival, proliferation, invasion, angiogenesis and metastasis in
cancer [14–17]. Moreover, STAT3 in cancer cells affects stromal cells function, establishing crosstalk
between cancer cells and its microenvironment. For example STAT3 can dampen STAT1-mediated
upregulation of MHC class I, allowing immune escape [1]. The other way for STAT3 to drive tumor
immune escape is to regulate the function of stromal cells and more particularly immune cells.
In general, all seven STAT family members have prominent roles in T-cell function or T-cell
differentiation, survival or expansion. STAT4 is essential for Th1 and STAT6 is important for Th2
differentiation. Similarly, all STAT proteins have all seven prominent roles in myeloid cells and they
all influence each other’s expression and activity status on complex and not understood chromatin
regulation. All that makes the interpretation of complex immune cell scenarios triggered by multiple
action of cytokines, growth factors, hormones and chemokines a tricky business to correctly relate
functions to this or that STAT family member. Importantly, T-cell expansion by common γ-chain
cytokines and many T-cell effector functions such as CD8+ T-cell, γδ T-cell generations and cytokine
release function and mounting a killing or efficient cytokine signaling response against foreign or
mutated antigen is a STAT5-mediated affair together with proper recognition and signaling through
the T-cell receptor (TCR), where again interplays are not carefully understood or worked out [18,19].
Furthermore, STAT5 is also essential to generate Treg cells, where both Foxp3 and Cd25 are direct STAT5
target genes [20]. STAT5 has also essential functions in erythropoiesis or macrophage or dendritic
cell (DC) polarization, but due to space constrains and focus on fine-tuning and twisting immune
responses in health or disease we will here illuminate STAT3 function in immune cells. We illuminate
many important immune modulatory interplays of STAT3 signaling in distinct T-cell and myeloid
cell compartments. We describe current knowledge on the impact of STAT3 activation in immune
cells on the balance between immunosurveillance and immunoescape. We will describe how STAT3
affects both myeloid and lymphoid cells usually in a way to inhibit anti-tumor immune response and
to promote tumor growth.
2. STAT3 and T-Cells
T lymphocytes or T-cells play a central role in host adaptive immune response to cancer [21].
Tumor-infiltrating CD4+ and CD8+ T-cells are associated with varying clinical outcomes and survival in
many types of cancer such as colorectal, [22] breast [23] and lung cancers [24]. Cytokines can shape
T-cells immune response and tune CD4+ T-cells differentiation and CD8+ T-cells activation [25]. Among
T-cells, different subsets have been described (regulatory T-cells, cytotoxic T-cells, T helper cells) with
distinct functions that could be regulated by STAT3 (Table 1).
2.1. Th1/Th2
CD4+ T helper (Th) cells assist other hematopoietic cells in immune processes, including activation
of cytotoxic T lymphocytes (CTLs), natural killer (NK) cells and macrophages. Th cells are activated
when stimulated with a peptidic sequence of the antigen they specifically recognize. These peptides are
presented to Th cells by antigen presenting cells (APCs), such as DCs through MHC class II molecules.
Once activated, they rapidly proliferate and secrete cytokines that will inhibit or assist the active immune
response [26].
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Expression levels of Th1 cell genes coding for Interferon-γ (IFNG), TAP1, Granzym B (GZMB) are
significantly higher in colorectal tumors than in normal tissue. A high expression of Th1 cytotoxic genes
was associated with significantly improved disease-free survival whereas a low expression of those
genes lead to disease recurrence [63]. T-BET, the master transcriptional regulator for Th1 differentiation
is induced by TCRs and IL-12 stimulation [64]. In contrast, GATA-3 is the master assessor for Th2
differentiation, after stimulation with IL-4 [65]. IL-27, a member of the IL-6/IL-12 family produced by
macrophages and DCs, favors Th1 differentiation by up-regulating T-BET, down-regulating GATA-3
and suppressing proinflammatory cytokine production such as IL-2, IL-4, and IL-13 [27,66]. In this
context, only the IL-27-dependent Th1 proliferation was mediated by STAT3 [27]. In contrast, in a
different cytokine context, in patients harboring STAT3 dominant negative mutations or STAT1 or
IL-21R loss of function mutations, it was shown that IL-21/IL-21R, STAT3 and STAT1 signaling are
required for in vitro differentiation of IL-10-secreting cells, related to Th2 [28].
2.2. Th17
Th17 cells are CD4+ T-cells induced by TCR triggering together with IL-6, transforming growth
factor (TGF)-β, and IL-23, an IL-12 family member, stimulation [67]. Th17 cells have emerged as key
drivers of a wide range of autoimmune disorders, including inflammatory bowel disease, psoriasis,
and ankylosing spondylitis [68]. Th17 cell expansion was observed in human cancers such as ovarian,
melanoma, breast or colon cancers [69]. In colorectal cancer, patients with low expression of Th17
genes seem to have a prolonged disease-free survival [63]. However, a positive role of Th17 was
proposed in melanoma and ovarian cancer. Therefore, the role of Th17 cells in cancer immunity
remains controversial [70].
Th17 are characterized by the expression of the transcription factors RORγt and RORα and the
production of IL-17A [71]. In addition, STAT3 is also essential for Th17 cell differentiation, since STAT3
ablation in mice CD4+ T-cells, abrogates Th17 differentiation [29,30]. Moreover, in patients harboring
STAT3 dominant negative mutations, IL-21R loss of function mutations or STAT1 gain of function
mutations, it was shown that IL-21/IL-21R/STAT3 signaling is required for in vitro production of
IL-17A/F by Th17 cells whereas STAT1 overexpression inhibits it [28]. STAT3 can associate with Trim28
and RORγt to drive the transcription of target cytokines such as IL-17A/F [72]. Moreover, many in vitro
studies have shown that STAT3 can be activated by several pro-inflammatory cytokines including IL-6,
IL-21 and IL-23 leading to the regulation of RORγt and RORα expression, along with the development
and the stabilization of Th17 cells [31–35]. We found that the n-3 fatty acid docosahexaenoic acid (DHA)
was able to induce the expression of SOCS3 in a PPARγ-dependent manner. SOCS3 then inhibits
pSTAT3 and Th17 differentiation [36]. Another regulator of STAT3 activation in Th17 is the tyrosine
phosphatase SHP1, which dampens IL-6- and IL-21-driven Th17 development and limits colitis in
mice [37]. Similarly, the Platelet Factor 4 (PF4) can also up-regulate SOCS3 expression leading to the
inhibition of STAT3, Th17 differentiation and tumor growth [73].
The STAT3 acetylation profile is also involved in Th17 polarization. First, lysyl oxidase-like 3
(LOXL3) is able to deacetylate STAT3 and to inhibit its transcriptional activity. Loxl3 deficiency leads to
constitutive STAT3 K685 acetylation causing reduced Th17 differentiation associated with resistance
to DSS-induced colitis in mice [38]. Second, we showed that metformin and resveratrol, two SIRT1
activators, entail STAT3 acetylation leading to Th17 differentiation impairment and limit tumor growth
in mice. The capacity of metformin to promote acetylation of STAT3 and to decrease Th17 differentiation
was also shown in patients [39].
We have shown that in vitro Th17 cells differentiated with IL-6 and TGF-β and in vivo
tumor-infiltrating Th17 cells express CD39 and CD73 ectonucleotidases. This ectonucleotidase catalytic
machinery entails the degradation of extracellular ATP into adenosine, an immunosuppressive molecule
which suppresses effector T-cells. The expression of ectonucleotidases is dependent on IL-6-driven STAT3
activation and TGF-β-mediated downregulation of the zinc finger protein Growth Factor Independent-1
(Gfi-1), both required for the transcriptional regulation of ectonucleotidase expression during Th17 cell
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differentiation. CD39 expression at the surface of Th17 cells fosters tumor growth, suggesting that the
immunosuppressive functions of Th17 cells in cancer are dictated by ectonucleotidase expression [40].
It has been reported that naive T-cells can be differentiated into Th17 cells with IL-1β, IL-6, IL-23
and without TGF-β. Unlike Th17 cells generated with TGF-β and IL-6, these Th17 cells were highly
pathogenic in vivo [74] and didn’t express ectonucleotidases [40]. These observations propose STAT3
and Gfi-1 as key determinants in the immunoregulatory function of Th17 cells, at least in part through
the regulation of ectonucleotidase expression [40].
The mechanistic role of STAT3 in Th17 positive effects on anti-tumoral response is less documented.
TAM-derived exosomes can deliver miR-29a-3p and miR-21-5p to CD4+ T-cells leading to the inhibition
of STAT3 and consequently to Th17 polarization in favor to Treg, which is beneficial for epithelial
ovarian cancer progression [41].
2.3. Treg
Suppressor regulatory T-cells (Treg) maintain peripheral immune tolerance [75,76]. Co-stimulation
of naive CD4+ T-cells with TCR and TGF-β, triggers the generation of CD4+/CD25+ Treg cells. This
leads to the expression of FOXP3, Tregs master transcription factor [77]. These T-cells accumulate
in tumors and in cancer patients peripheral blood [78]. An increase in Treg frequency is generally
considered as a marker of poor prognosis in cancer, probably because Treg mediate suppression of
anti-tumor immunity [79–81].
The role of STAT3 in Foxp3 expression regulation in Tregs appears to be context-dependent. In vitro,
IL-2 induces the binding of STAT3 and STAT5 to a highly conserved STAT-binding site located within
the first intron of the Foxp3 gene, leading to FOXP3 expression up-regulation in purified CD4+CD25+
T-cells but not in CD4+CD25− cells [42].
In tumor-infiltrating Tregs, both STAT3 and STAT5 bind to a STAT consensus site in the Foxp3
promoter to enhance FOXP3 expression which seems to be important in maintaining Tregs inhibitory
functions [42–44]. S1PR1 (Sphingosine-1 Phosphate Receptor 1) signaling has been shown to restrain
Treg number and functions. An increase in S1PR1 in CD4+ T-cells promotes STAT3 activation
and JAK/STAT3-dependent Treg tumor migration, whereas STAT3 ablation in T-cells diminishes
tumor-associated Treg accumulation and tumor growth [45]. Treatment of metastatic cancer or chronic
myelogenous leukemia after allogeneic hematopoietic stem cell transplantation in patients with low-dose
IL-2, leads to an increase of peripheral blood CD4+CD25+ cells and to FOXP3 expression in CD3+
T-cells [42]. STAT3 and FOXP3 co-operatively control a subset of genes, responsible for Treg cell ability to
suppress Th17 cell-mediated inflammation [82]. In contrast, IL-21 which activates STAT3 but not STAT5
has no effect on Treg viability, activation or function, suggesting that in this context IL-21-mediated
STAT3 activation is not sufficient [83]. The regulation of Foxp3 expression by STAT3 was strengthened
by other studies. CDK5 increases Foxp3 gene expression through phosphorylation of STAT3 at serine
727 [47]. GATA-3 controls the expression of miR-125a-5p, which in turn inhibits the expression of IL-6R
and STAT3 and dampens Treg conversion [48]. In contrast, differentiation of naive T-cells into Tregs
in vitro, is impaired when STAT3 is activated (by IL-6 or IL-27) [34,46]. In a different context, STAT3
binds to a silencer element within the Foxp3 locus [84] and could also inhibit STAT5 interacting with the
Foxp3 promoter [85], to prevent FOXP3 expression.
One possible explanation for these ambivalent actions of STAT3 on Treg differentiation could be
the phosphorylation site. Indeed, wogonin, a natural flavonoid from Scutellaria baicalensis, inhibits
Treg induction by down-regulating ERK and STAT3-Y705 phosphorylation and promoting NF-κB
and STAT3-S727 activation [49]. The modulation of STAT3 activity by molecular compounds could
lead to inhibition of Tregs activity. Thus, WP1066 (an inhibitor of STAT3 signaling) enhances T-cell
cytotoxicity against melanoma through inhibition of FOXP3+ Tregs [50]. Compound9#, a fluorinated
β-amino-ketone molecule, also inhibits Treg induction both in vitro and in vivo, via blockage of JAK2
signaling [51]. Finally, STAT3 inhibition with anti-sense oligonucleotides in association with radiation
is a potent therapeutic target against Tregs [52]. All these studies suggest that STAT3 is required for
immunosuppressive functions of Tregs.
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2.4. T Follicular Helper Cells
Tfh differentiation is complex because it requires interaction with other cells such as B cells or DC.
In mice, IL-6, IL-21 and IL-27 are essential for Tfh formation while in humans, Tfh generation relies on
TGF-β, IL-12, IL-23. In both mammalian species of rodents or humans, Tfh cells express BCL6, ASCL2,
IL-21, PD-1, and ICOS and produce IL-21 and CXCL13 [86,87]. While the role of Tfh is ambiguous
in lymphoid tumors, many studies report that accumulation of Tfh in tertiary structures within the
tumor is of good prognosis for breast, colon and non-small cell lung cancer patients [88,89]. Even if the
protective effects of Tfh cells seem to be dependent on IL-21 and CXCL13-mediated recruitment of
leucocytes, little is known about the accurate mechanism of Tfh anti-tumoral effects.
Generation of Tfh cells in patients with impaired STAT3 DNA-binding function is compromised due
to the inability of IL-12 to induce IL-21 production without affecting its capacity to induce ICOS, BCL6 or
CXCR5 expression [54]. When siRNA specific for STAT3 was used, TGF-β, IL-12, IL-23 failed to induce
BCL6 expression in vitro [53]. However, the requirement of STAT3 seems to depend on the differentiation
status of Tfh cells: It is required for Tfh generation but once these cells are generated it is no longer
required [90]. In the same context, murine STAT3-deficient CD4+ T-cells, Tfh cells expressed less or more
BCL6 and IL-21 according to the immune environment [91,92]. Moreover, in conditions where STAT3 is
necessary for Tfh differentiation, two studies showed that it cooperates with the IkZF transcription
factors Aiolos and Ikaros. Moreover, the kinase activity of ROCK2 (Rho-associated coiled-coil kinase
2, an actin cytoskeleton assembly regulator) is required to induce STAT3 phosphorylation, nuclear
relocalization and DNA binding to regulate Bcl6 expression [93,94]. Finally, the importance of STAT3 in
Tfh differentiation was strengthened by its capacity to block the expression of the Th2-associated genes
Gata3 and Il4 [53,55].
A new protumorigenic IL-21+ Tfh-like cell subset with a CXCR5−PD-1− BTLA−CD69hi phenotype
was identified in hepatocellular carcinoma (HCC). STAT1 and STAT3 activation are critical for these
Tfh-like cell induction which operate via IL-21-IFN-γ pathways to induce plasma cells and create
conditions for M2b macrophage polarization and tumor growth [56].
The importance of STAT3 in Tfh differentiation and its pro- or anti-tumoral role is not clear and
could be dependent on differentiation stage, localization and environment.
2.5. Th9
Th9 cells have been characterized as a proinflammatory CD4 T-cell subset that can be generated
through TGF-β and IL-4 stimulation. These cells are characterized by IL-9 secretion. Th9 harbor potent
IL-9-dependent anti-cancer properties in most solid tumors and especially in melanoma while they can
promote the development of many hematological human tumors, including Hodgkin’s lymphoma
and other B cell lymphoma. Th9 cells activate both innate and adaptive immune responses, thereby
favoring anti-cancer immunity and tumor elimination [95].
In this CD4 T-cell subset, STAT3 was shown to dampen IL-9 production through STAT5 inhibition
in Th9 cells [57]. In vitro, Th9 long term ability to secrete IL-9 is inhibited by pSTAT3 through an IL-10
receptor signaling [58]. In contrast, in humans Th9, pSTAT3 (mainly driven by IL-21 self-induction)
inhibits pSTAT1-mediated T-BET induction, through SOCS3 induction. Since T-BET is an inhibitor of
IL-9 transcription, this sustains IL-9 production. Patient-derived Th9 cells with dysfunctional STAT3,
lose their capacity to produce IL-9, because of SOCS3 expression down-regulation, which leads to an
increase pSTAT1 and T-BET expression. In the same study, the loss of function mutations observed in
patients were recapitulated with deletion studies in mice, revealing that absence of STAT3 culminates
into increased IL-9 production [59].
2.6. CD8+
CD8+ T lymphocytes are central players in cancer immune response, through their capacity to kill
malignant cells. Upon recognition by the TCR of specific antigenic peptides presented on the surface
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of target cells by human leukocyte antigen class I (HLA-I)/beta-2-microglobulin (β2m) complexes, the
CTL effector functions are activated. These functions are mediated either directly, through exocytosis
of cytotoxic granules containing perforin and granzym into the target cells, resulting in cancer cell
destruction, or indirectly, through secretion of cytokines, including IFN-γ and TNF [96].
The stimulation of the human and murine CD8+ T-cells CD28, stabilizes the tyrosine kinase
Lck activity and pSTAT3-mediated transcription of NKG2D. NKG2D expressing CD8+ T-cells exert
cytolytic activity against target tumor cells in vitro and significantly improve the antitumor therapeutic
effects in vivo [62]. Even if IL-10 is considered as an immune suppressor it can also increase expansion
and cytotoxic activity of CD8+ cells. Tumor-resident CD8+ T-cells express high levels of IL-10R, leading
to high levels of activated pSTAT3 and pSTAT1 in response to IL-10 [97]. In contrast, circulating CD8+
T-cells from peripheral blood of HCC patients present high amounts of pSTAT3 which is correlated
with high amount of IL-4, IL-6 and IL-10 and low quantity of IFN-γ which may result in abnormal
immune surveillance against tumor cells [98]. In murine CD8+ T-cells, STAT3 has been shown to inhibit
both IFN-γ-mediated CXCL10 production by myeloid cells and CD8+ T-cells CXCR3 expression (the
receptor of CXCL10), blocking the migration of these cells to the tumor site [60].
In an adoptive transfer therapeutic strategy in mice, ablating STAT3 in CD8+ T-cells prior to
transfer, allows efficient tumor infiltration and robust CD8+ T-cell proliferation, resulting in increased
tumor antigen-specific T-cell activity and tumor growth inhibition [61].
Altogether STAT3 seems to inhibit CD8+ T-cell expansion and cytolytic activity except in some
particular conditions.
3. STAT3 and Myeloid Cells
APCs dictate immune system response, since these cells have been shown to capture antigens
in the periphery, migrate to the lymphoid organs, and present processed peptides to T-cells in a way
that may lead either to priming or tolerance induction [99]. Among myeloid cells, different subsets
have been described (Macrophages, DCs, Myeloid-Derived Suppressor Cells (MDSCs)) with distinct
functions that could be regulated by STAT3 (Table 2).
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3.1. Macrophages
Tumor-associated macrophages (TAMs) are subdivided into two subsets, M1 and M2 macrophages,
based on their capacity to express or produce Nitric Oxide Synthase/IL-12/TNF-α or arginase-1/IL-10/
TGF-β, respectively. M1 has potent microbicidal properties and promotes Th1 responses, whereas
M2 supports Th2-associated effector functions [143,144]. M2 macrophages includes M2a, M2b or M2c
subtypes. Tumor-derived signals, such as Macrophage-Colony Stimulating Factor (M-CSF/CSF-1),
Monocyte Chemoattractant Protein-1 (MCP-1), or Chemokine (C-C motif) Ligand-2 (CCL2) entails
the accumulation of M2 at the tumor site. M2 macrophages participate in tumor growth by releasing
proangiogenic cytokines and growth factors, e.g. Epidermal Growth Factor (EGF), Vascular Endothelial
Growth Factor (VEGF), Platelet-Derived Growth Factor (PDGF), Colony Stimulating Factor-1 (CSF-1),
and basic Fibroblast Growth Factor (βFGF). They also generate arginase-1, IL-10 and TGF-β. These
molecular messengers will inhibit the antitumor function of T-cells and NK cells. This will favor tumor
tolerance and impairment of antitumor immunotherapies efficacy [145–147].
IL-6 inhibition of M-CSF-induced colony formation observed in animals was abolished in mice
mutated for the gp130-STAT1/3 signaling, suggesting that the IL-6/STAT3 pathway could regulate
macrophage homeostasis [148]. Moreover, breast cancer-derived exosomes are capable of inducing
IL-6 secretion and a pro-tumoral phenotype (IL-6, IL-10, CCL2 production) in macrophages, partially
via gp130/STAT3 signaling [106]. More particularly, STAT3 directly induces the expression of the M2
marker CD163, both in macrophages and tumor cells [103]. Prostate-cancer cells induce a change in
macrophage phenotype from M1 into M2, through STAT3 activation [104]. This can be induced by
Plasminogen Activating Inhibitor (PAI)-1 secreted by cancer cells [105].
The inhibition of STAT3 signaling in either macrophages or bone marrow-derived DCs is of great
importance in cancer immunotherapy, because it allows these APCs to restore the responsiveness
of tolerant T-cells from tumor-bearing mice. STAT3 signaling is a negative regulator in peritoneal
elicited macrophages, as its targeted disruption gives a constitutively activated phenotype and an
increased ability to produce inflammatory mediators in response to LPS. This may be the consequence
of an increased STAT1 activity (leading to high production of inflammatory factors) or a lack of IL-10
production [100]. Moreover, macrophages derived from conditional STAT3 knockout mice are better
than wild-type macrophages to prime cognate CTL responses and to cross-present tumor-derived
antigen to CTLs in vitro. This leads to a more important proliferation of CTLs and an increased
production of IFN-γ and TNF-α. Similarly, removing STAT3 in hematopoietic cells, leads to rapid
activation of innate immunity by CpG (a TLR9 ligand), with enhanced activation of macrophages,
neutrophils and NK cells and production of IFN-γ, TNF-α, IL-12 to eradicate B16 melanoma tumors [102].
Targeting STAT3 signaling therefore represents an attractive strategy to increase CTL responses in
the tumor-bearing host [101]. Immunosuppressive activities of TAMs correlate with over-activated
STAT3 signaling, whereas disruption of TAMs STAT3 activity can enhance rat immune response
to breast cancer [149]. In glioblastoma patients, tumor-infiltrating macrophages were shown to be
predominantly STAT3-positive M2 macrophages, which are associated with a poor prognosis [150].
The same team proposed that corosolic acid and oleanic acid can prevent tumor formation through
their capacity to suppress macrophages M2 polarization and tumor cell proliferation by inhibiting
STAT3 activation [107,108]. CD163-targeted corosolic acid-containing liposomes were also shown to
reprogram M2 macrophages into M1 (increased expression of TNF-α, IFN-γ, IL-12, IL-2 and decreased
expression of IL-10) [109]. Since ERK5 mediates Y705 phosphorylation of STAT3 in myeloid cells,
blocking ERK5 might constitute a treatment strategy to reprogram macrophages toward an antitumor
state by inhibiting STAT3-induced gene expression [110]. In intrahepatic cholangiocarcinoma (ICC),
patients with high counts of CD163+ M2 macrophages showed poor disease-free survival. Tumor cell
supernatant from HuCCT1 ICC cell lines induces the production of IL-10 and VEGF-A by macrophages
through activation of STAT3 and polarization towards the M2 phenotype [113]. Similarly, renal cell
carcinoma-derived BMP (Bone Morphogenetic Protein)-6 mediates IL-10 expression in macrophages
through Smad5 and STAT3, and M2 polarization [114]. These observations were confirmed by the fact
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that macrophages isolated from mouse tumors displayed activated STAT3 and induced angiogenesis
in an in vitro tube formation assay via STAT3 induction of angiogenic factors, including VEGF and
βFGF [115]. STAT3 signaling within the tumor microenvironment induces the production of IL-23, a
procarcinogenic cytokine, via direct transcriptional activation of the IL-23/p19 gene in TAMs, while
inhibiting the production of IL-12, a central anticarcinogenic cytokine, thereby shifting the balance of
tumor immunity towards carcinogenesis [44]. The M-CSF-inducible DC-SIGN (Dendritic cell-specific
ICAM-3-grabbing nonintegrin or CD209) expression along monocyte-to-macrophage differentiation
is dependent on JNK and STAT3 activation. DC-SIGN contributes to the release of IL-10 that would
maintain STAT3 activation in tumor cells, thus implying that DC-SIGN favors the maintenance of an
activated STAT3 context in the tumor stroma. This will compromise the ability of TAMs and DCs to
generate an effective antitumor response and to maintain an immunosuppressive environment [111].
This effect is potentiated by STAT3-activating cytokines IL-6 and IL-10 produced by STAT3-activated
tumor cells. In the same way, IL-6-derived from gastric cancer cells induces normal macrophages
differentiation to M2 macrophages with higher IL-10 and TGF-β expression, and lower IL-12 expression,
via STAT3 phosphorylation. IL-6-induced M2 macrophages exert a pro-tumor function by promoting
GC cell proliferation and migration [151].
However, an anti-tumoral role of STAT3 in macrophages has also been proposed, based on
studies that investigated the importance of STAT3 in macrophages through an indirect manner,
using SOCS3 conditional knockout mice in macrophages. Hyperactivation of STAT3 in myeloid cells
simultaneously exerted anti-inflammatory as well as anti-tumor effects [112]. Thus, Lipoxin A4 induces
STAT3 phosphorylation and mediates differentiation of monocytic-like cells into M2 subtypes with
anti-tumorigenic activities [152]. The discrepancies between these studies could be explained by the
fact that SOCS3 and lipoxin signaling should regulate other pathways such as NF-κB.
3.2. Dendritic Cells (DCs)
DCs are another differentiated stage of monocytes and are the key APCs of the immune system.
DCs play a main role as immune sentinels in the initiation of T-cell response against microbial pathogens,
tumors and inflammation [153,154].
The first evidence that STAT3 is important for DCs fate was made in mice lacking STAT3
expression in hematopoietic progenitors. These animals present a profound deficiency in DCs which
are unresponsive to Flt3L stimulation [116]. However, the same mice bearing a tumor, present enhanced
DC, T-cell, NK cell and neutrophil functions and a decreased tumor progression [117]. DCs derived
from LysMcre/STAT3flox/flox mice display higher cytokine production in response to TLR stimulation
and activate more efficiently T-cells. Intratumoral administration of these DCs significantly inhibits
MC38 tumor growth [119]. Moreover, ablating STAT3 in myeloid cells increases CpG-induced DCs
maturation, T-cell activation, tumor antigen-specific T-cells generation and long-lasting antitumor
immunity in B16 melanoma tumor model [102]. Similarly, CpG was used to administer STAT3
siRNA specifically to myeloid and B cells. Ablation of STAT3 in these cells increases DC engagement
and adoptively transferred CD8+ T-cells effector functions in vivo, with an upregulation of effector
molecules such as perforin, granzym B, and IFN-γ [118]. Mice without STAT3 in myeloid compartment
of tumor stroma, including DCs and macrophages, present reduced numbers of tumor-infiltrating
CD4+CD25+/FOXP3+/LAG3+ Tregs, along with an increase in CD8+ effector T-cells [117]. Constitutive
STAT3 activation in tumor-residing DCs reduces expression of MHC class II and costimulatory
molecules, impairs the antigen-presenting function of DC and contributes to the expansion of
tumor-infiltrating FOXP3+ T-cells and attenuates CD4+ Th cell responses [117,122,123]. This can
be partly explained by the fact that STAT3 inhibits the ID2 (inhibitor of differentiation 2) expression
which promotes tumor immunity [124]. Finally, IL-6 is a suppressor of bone marrow-derived DC
activation/maturation and a regulator of DC differentiation in vivo, through STAT3 phosphorylation.
Then, DC differentiation/maturation is controlled by IL-6-gp130-STAT3, suggesting that this amplification
loop may represent a target for controlling T-cell-mediated immune responses [155]. Similarly, mammary
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tumor-derived exosomes inhibit the differentiation of murine myeloid precursor cells into DCs in vitro.
This was correlated with an increased IL-6 level and phosphorylated STAT3 and was blocked in bone
marrow cells derived from IL-6 knockout mice. This suggests that tumor cells can dampen DCs
differentiation through an autocrine activation of STAT3 by IL-6 [125].
In humans, tumor-derived factors suppress DC generation through STAT3-mediated PKCβII
reduced expression [156]. STAT3-depleted DCs with adenoviral STAT3 short hairpin RNA (shRNA)
or siRNA presented an altered cytokines production profile under TLR stimulation (such as more
IL-12 and TNF-α and less IL-10), and induced tumor Ag-specific T-cells and IFN-γ-producing γδ T
lymphocytes more efficiently than control DCs [119–121]. The impact on IL-12 can be explained by
a competition of STAT3 with CDK9 on a binding site on the IL-12p35 promoter [157]. The effects of
STAT3 on IL-10 expression can be explained by the fact that HDAC6 forms a complex with STAT3,
recruited to a specific DNA sequence element in the Il10 gene promoter [158].
3.3. Myeloid-Derived Suppressor Cells (MDSCs)
MDSCs have been identified in humans and mice as a population of immature myeloid cells with
the ability to suppress T-cell activation [159]. In tumor-bearing mice, these cells have been shown to
markedly expand in lymphoid organs and blood [160]. In addition, an increased MDSCs frequency
was detected in the blood of patients with different types of cancers [161,162]. In mice and humans,
MDSCs from tumor bearers induce antigen-specific MHC class I restricted tolerance of CD8+ T-cells
and are one of the major suppressors of antitumor immunity [163]. In humans the phenotype of
MDSCs is a matter of debate. However, two major subsets of MDSCs have been identified: monocytic
MDSCs (M-MDSCs), similar to monocytes and polymorphonuclear MDSCs (PMN-MDSCs) sharing
phenotypic and morphologic features with neutrophils [164].
STAT3 is probably one of the main transcription factors that regulate MDSCs functions. MDSCs
from tumor-bearing mice present high levels of phosphorylated STAT3, compared with immature
myeloid cells from naive mice [128]. Moreover, ablation of STAT3 expression through the use of
conditional knockout mice or selective STAT3 inhibitors (JSI-124) markedly reduce the expansion of
MDSCs, promote accumulation of DCs and increase T-cell responses in tumor-bearing mice [117,127,128].
In mice, when STAT3 was specifically deleted in myeloid cells, the ability of MDSCs to inhibit CD4+
and CD8+ T-cell-dependent apoptosis by cell-cell contact and to induce Treg polarization through
TGF-β, IL-10 and NOX2 secretion was decreased [131]. When STAT3 was specifically turned off in
myeloid cells expressing TLR9 from prostate cancer patients, using a CpG-STAT3 siRNA or CpG-STAT3
antisense oligonucleotides, it abrogated the immunosuppressive effects of patient-derived MDSCs on
effector CD8+ T-cells [129,130]. In contrast, deletion of SOCS3 in myeloid cells leads to an increased
activation of the STAT3 and to differentiation into Gr-1+CD11b+Ly6G+ MDSCs, enhancing tumor
growth [165]. STAT3 can also be regulated in MDSCs by the epigenetic-associated protein, p66a, which
may physically interact with STAT3 to suppress its activity through posttranslational modification [166].
We have shown that tumor-derived exosome (TDE)-associated HSP70 led to STAT3 activation in
MDSCs. This activation depends on TLR2/MyD88 and autocrine production of IL-6. TDEs from
human tumor cell lines activate human MDSCs suppressive functions but not their expansion in an
HSP70/TLR2-dependent manner, showing that the mechanism described in mice is also relevant in
cancer patients [133]. In tumor cell supernatants, tumor soluble factors induce activation of ERK,
which results in MDSCs expansion, while TDEs trigger STAT3 activation without promoting MDSCs
expansion [133]. How can these discrepancies be explained? It is well known that STAT3 signaling
in myeloid cells, entails the expression of Bcl-xL, c-myc, cyclin D1 or survivin, which favors cell
proliferation and inhibits cell apoptosis and differentiation to mature cell types [15,167].
STAT3 controls the G-CSF-and G-MCSF responsive induction of C/EPBβ (CCAAT-enhancer-
binding protein β) expression and the interferon regulatory factor 8 (IRF8) downregulation in myeloid
cells [126,134]. The transcription factor C/EBPβ was reported to play a crucial role in controlling the
differentiation of myeloid precursors to functional MDSCs [126] whereas IRF8 attenuated MDSC
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accumulation, phenotype and function [134]. These data suggest also a link between CSF and STAT3
pathway in the regulation of MDSC biology.
Finally, recent studies highlighted the importance of signaling pathways downstream STAT3 in
MDSCs differentiation. MDSCs isolated from mouse tumors present activated STAT3. STAT3 favors
the production of angiogenic factors, including VEGF and βFGF to induce angiogenesis in an in vitro
tube formation assay [115]. STAT3 as well as STAT5 control the cytokine-induced expression of the
cytoplasmic NADPH oxidase NOX2 [168], being e.g., crucial for DNA damage response in AML
cells, leading together with mitochondrial ROS production, which is a predominant STAT3 affair to
the production of ROS, responsible for MDSCs-induced immune suppression in murine colon, lung,
mammary carcinoma, thymoma, sarcoma models and in patients with head and neck cancers [132].
STAT3 also favors immunosuppressive functions of MDSCs by inducing the expression and the activity
of IDO (Indoleamine 2,3-dioxygenase 1) in breast [137] and liver [135] cancers or arginase-1 in head and
neck squamous cell carcinoma [136]. STAT3-inducible up-regulation of the myeloid-related protein
S100A9 enhances MDSCs production in cancer. Mice lacking this protein mount potent antitumor
immune responses and reject implanted tumors, an effect reversed by administration of wild-type
MDSCs [169].
However, STAT3 activity can be endogenously controlled in intra-tumoral MDSCs. Thus, tumor
hypoxia led to CD45 protein tyrosine phosphatases activation, resulting in STAT3 activity downregulation
and in M-MDSC differentiation into tumor-promoting TAMs [138].
Moreover, many inhibitors were proposed such as the XIAP inhibitor embelin [139], PM01183 a
novel synthetic agent derived from trabectedin [140], alisertib (MLN8237), a small-molecule inhibitor
of Auror-A kinase [141], STATTIC or BBI608 [142] to inhibit STAT3 in MDSCs with a potential clinical
application to favor anti-tumor response.
4. STAT3 and Check Points Inhibitors
The emergence of immune ‘checkpoint inhibitors’, blocking negative regulators of T-cell immunity
opened new clinical applications of cancer immunotherapies. The more widely studied are cytotoxic
T lymphocyte antigen 4 (CTLA-4) and programmed death receptor 1 (PD-1). CTLA-4 is mainly
expressed on T helper and Treg cells and binds to its ligands B7–1 (CD80) and B7–2 (CD86) on
APCs [170]. PD-1 expression is induced both on activated CD8+ T-cells, Tfh and Treg present in tumor
microenvironment, and on activated B cells and NK cells. PD-1 has two ligands: PD-L1 (B7-H1) and
PD-L2 (B7-DC). PD-1 signaling contributes to T-cell exhaustion [170]. Other checkpoints can also be
implicated in tumor immune escape such as Lymphocyte activation gene 3 protein (LAG-3) and T-cell
immunoglobulin and mucin domain-containing 3 (TIM-3), IDO1, B- and T-lymphocyte attenuator
(BTLA), V-domain immunoglobulin suppressor of T-cell activation (VISTA) and the A2A adenosine
receptor (A2A-R) [170,171].
STAT3 can bind the promoter of murine Pdcd1 gene coding for PD-1 in T-cells [172]. STAT3 has
been demonstrated to bind to the Pdcd1l1 promoter (coding for PD-L1) to regulate its transcriptional
expression in cancer cells. It requires either mutated oncogene chimeric nucleophosmin/anaplastic
lymphoma kinase (ALK) in T-cell lymphoma [173], Latent membrane protein-1 (LMP1) of Epstein–Barr
virus in nasopharyngeal carcinoma [174], HDAC6 in osteosarcoma [175], NF-κB in melanoma [176] or
HIF-1α in pulmonary adenocarcinoma [177]. In contrast, a study shows that STAT3 is necessary for
docetaxel-mediated inhibition of PD-1 expression [178].
In CRC patients, FGFR2 expression is correlated to PD-L1 expression. FGFR2 stimulation leads to
STAT3 activation, PD-L1 expression and colon cancer cell death [179]. The EGFR signaling pathway
can also regulate PD-L1 expression through the IL-6/JAK/STAT3 pathway in non-small cell lung cancer
(NSCLC) cells [180,181]. The expression of PD-L1 is associated with a poor prognosis and inhibition
of PD-L1 expression (e.g., through STAT3 or its partner inhibition) is associated to a decrease in cell
proliferation and/or an increase in tumor cell death in most of these studies. However, the effects on
T-cell anti-tumor response were not tested here.
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PD-L1/L2 can be expressed in non-tumoral cells. In liver MDSCs, GM-CSF is responsible for
STAT3 activation which in turn induces PD-L1 and IDO1 expression [135]. GBM cells secrete IL-6
which in turn activates STAT3 in infiltrated myeloid cells leading to STAT3 activation and PD-L1
expression. An anti-IL-6 therapy decreases PD-L1 expression and tumor size in a CD8+ T-cell-dependent
manner [182]. In HCC, a similar regulation was observed. In this setting, the HCC-associated fibroblasts
produce IL-6 which in turn increases PD-L1 expression in neutrophils [183]. Similarly, in prostate
carcinoma, DC generated in the presence of stromal myofibroblasts factors expressed significantly
elevated levels of PD-L1 in a STAT3 and IL-6-dependent manner [184]. In chronic lymphocytic leukemia
(CLL), STAT3 is required to PD-L1 expression and IL-10 production which in turn seems to be responsible
for PD-1 expression in CD4+ and CD8+ T-cells [185]. In adult T-cell lymphoma, IL-27B production by
Lymphoma cells and IL-27p28 production by macrophages lead to STAT3 activation and PD-L1/L2
expression in macrophages [186]. TGF-β is another cytokine secreted by inflammatory or tumor cells
that can increase PD-L1 expression in DC in a STAT3-dependent manner [187]. The use of IFN-α in
clinical oncology for many types of cancers is reconsidered, as IFN-α induces the expression of PD-L1
molecule, in the majority of the specific immune cell populations, particularly in DCs [188]. However, it
should be noted that interferons are highly liver toxic and they act on all cell types in the body, where
many unwanted side effects from neurotoxic problems to fever symptoms were reported in therapy,
making their window of opportunity in fragile patients delicate.
Little is known about the ability of STAT3 to regulate other checkpoints. One study shows that
STAT3/IRF1 are required for PD-L2 expression in melanoma cells [189]. In a non-cancerous context, it
has been shown that CTLA-4 as well as PD-1, LAG-3 and TIM-3 expression is induced in HIV-infected
DCs in a STAT3-dependent manner [190].
In contrast, the immunosuppressive effect of these checkpoints can be dependent on STAT3
activation in target-cells. For example, IDO1 may promote EMT (Epithelial-Mesenchymal Transition)
by activation of the IL-6/STAT3/PD-L1 signaling pathway [191]. TIM-3+ endothelial cells modulate
T-cell response to lymphoma surrogate antigens by suppressing activation of CD4+ T lymphocytes
through the activation of the IL-6-STAT3 pathway, inhibiting Th1 polarization and providing protective
immunity [192]. Finally, CTLA-4 critically shapes the characteristics of IL-17 producing CD8+ cells (Tc17
a pro-tumoral population) in a STAT3 activation-dependent manner and inhibition of CTLA-4-induced
STAT3 activity reverses Tc17 signature to Tc1-like cells with enhanced cytotoxic potential [193].
5. Conclusions
STAT3 regulates genes involved in biological functions of cancer and immune cells, rendering this
pathway an interesting therapeutic target. STAT3 could be inhibited directly by peptides or natural
compounds or indirectly by blocking upstream signaling pathways such as IL-6 and JAK2 pathways
(For review see [194,195]). However, the complexity of STAT3 biology and its broad effects may render
its clinical development complex. This review underlines the ambivalent effects of STAT3 on the
antitumoral immune response, with both positive or negative effects, depending on the context or cell
types involved. Additional translational studies on patients treated with STAT3 inhibitors are awaited
to understand their effects on the complexity of tumor biology.
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Abstract: Src Homology 2 (SH2) domains arose within metazoan signaling pathways and are
involved in protein regulation of multiple pleiotropic cascades. In signal transducer and activator
of transcription (STAT) proteins, SH2 domain interactions are critical for molecular activation and
nuclear accumulation of phosphorylated STAT dimers to drive transcription. Sequencing analysis
of patient samples has revealed the SH2 domain as a hotspot in the mutational landscape of
STAT proteins although the functional impact for the vast majority of these mutations remains
poorly characterized. Despite several well resolved structures for SH2 domain-containing proteins,
structural data regarding the distinctive STAT-type SH2 domain is limited. Here, we review the
unique features of STAT-type SH2 domains in the context of all currently reported STAT3 and STAT5
SH2 domain clinical mutations. The genetic volatility of specific regions in the SH2 domain can result
in either activating or deactivating mutations at the same site in the domain, underscoring the delicate
evolutionary balance of wild type STAT structural motifs in maintaining precise levels of cellular
activity. Understanding the molecular and biophysical impact of these disease-associated mutations
can uncover convergent mechanisms of action for mutations localized within the STAT SH2 domain
to facilitate the development of targeted therapeutic interventions.
Keywords: STAT3; STAT5; SH2 domain; mutations; cancer; autosomal-dominant hyper IgE
syndrome; inflammatory hepatocellular adenomas; T-cell large granular lymphocytic leukemia;
T-cell prolymphocytic leukemia; growth hormone insensitivity syndrome
1. Introduction
Several key cellular pathways converge on the multidomain signal transducer and activator
of transcription (STAT) proteins highlighting their importance in the development and progression
of oncogenic and malignant diseases. Conventional STAT activation is initiated by cytokine or
growth-factor interactions with extracellular receptors, stimulating SH2 domain-mediated recruitment
Cancers 2019, 11, 1757; doi:10.3390/cancers11111757 www.mdpi.com/journal/cancers119
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of tyrosine kinases and STAT isoforms to the receptor cytoplasmic domains [1,2]. Nuclear translocation
and accumulation of the resulting phosphorylated STAT dimers facilitates transcription of a wide array
of gene products involved in proliferation and cellular survival including C-MYC [3], BCL-XL [3],
MCL-1 [4], FOXP3 [5], BCL-2 [6], HIF [7], D-type cyclins [8], IGF-1 [9], and self-regulation of
STAT3/STAT5 [10]. Normal STAT function is dependent on the SH2 domain which arbitrates homo- or
hetero- STAT dimerization as well as multiple protein–protein interactions. As such, structurally altered
SH2 domains exhibit considerable effects on STAT activity, leading to either hyperactivated or refractory
STAT mutants. These critical roles in governing the transcriptional capacity, coupled with the relatively
shallow binding surfaces elsewhere on the protein, resulted in the STAT SH2 domain dominating
therapeutic interest for small molecule inhibitor development and intervention [11–15]. However,
currently there are no clinical drug candidates directly targeting the STAT protein family. This is
partially due to the limited structural data available on the STAT SH2 domains or their mutated
disease-associated counterparts, and further compounded by observations that STAT SH2 domains are
distinct from those found in other well characterized systems such as Src kinase. Here, we summarize
structural features of STAT-type SH2 domains in the context of STAT3/STAT5 disease-associated
mutations, and discuss their effects on protein activity, as well as potential new druggable pockets
within the STAT SH2 domain.
2. Structure of STAT SH2 Domains
SH2 domains are modular units that arose within multicellular life, approximately 600 million
years ago, and are therefore heavily tied to metazoan signal transduction [16]. There are 121 human
SH2 domains that are classified into different groups based on their structural or phylogenetic
characteristics [16]. Broadly, they have been classified into either STAT- or Src-type SH2 domains
based on the presence of either an α-helix (STAT-type) or β-sheet (Src-type) at the C-terminus [17].
Alternatively, phylogenetic analysis has categorized SH2 domain-containing proteins into 38 different
sub-families [16]. Functional activity-based screens have also been employed to stratify SH2
domain-containing proteins into four categories based on the identity of the fifth residue in the
βD strand, which has been shown to be a critical determinant in phospho-peptide selectivity [18,19].
Despite different methods for classification, all SH2 domains contain conserved structural motifs that
are canonical to the core function of phospho-Tyr (pY) peptide binding. These features represent an
evolutionary compromise to preserving critical structural motifs while maintaining highly specific
peptide recognition capacity.
The structure of an SH2 domain consists of a central anti-parallel β-sheet (with the three β-strands
conventionally labeled βB-βD) interposed between two α-helices (αA and αB), often referred to as
the αβββα motif [16]. The structure and nomenclature for the motifs of STAT SH2 domains is shown
in Figure 1a,b. The β-sheet partitions the SH2 domain into two subpockets, referred to as the pY
(phosphate-binding) and pY+3 (specificity) pocket [16]. The pY pocket is formed by the αA helix,
the BC loop (region connecting βB-βC strands) and one face of the central β-sheet. The pY+3 pocket is
created by the opposite face of the β-sheet as well as residues from the αB helix and CD and BC* loops
(regions connecting βC-βD strands and αB-αC helices, respectively). Both the pY and pY+3 pockets are
common targets for drug design due to well defined features and conserved residues. Within the pY+3
pocket, there are additional clefts that also have drug targeting potential. This includes the C-terminal
region of the pY+3 pocket, also known as the evolutionary active region (EAR) [17]. The EAR contains
an additional α-helix (αB’) in STAT-type SH2 domains, as opposed to the Src-type which harbors a
β-sheet (βE and βF although each strand is not always observed). Additionally, there is a cluster of
non-polar residues (referred to as the hydrophobic system [20]) at the base of the pY+3 pocket that
assists in stabilizing the conformation of the β-sheet and maintaining the integrity of the overall SH2
domain. The αB, αB’, and BC* loop also participate in SH2-mediated STAT dimerization forming
important cross-domain interactions. Therefore, residues in the pY+3 pocket can have a dual effect on
STAT dimerization capacity and phospho-peptide binding. Conventional phospho-peptide binding
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occurs perpendicular to the β-sheet with the peptide adopting a binding mode as illustrated with
STAT1 in Figure 1c. The phospho-Tyr interacts with conserved amino acids in the pY pocket, while the
C-terminal residues stretch across the SH2 domain into the pY+3 pocket.
 
Figure 1. (a) Secondary structural motifs in STAT3 (blue) and STAT5 (green) with mutations annotated;
(b) Structure of STAT3 SH2 domain; (c) Structure of pY-peptide-STAT1 SH2 domain. The pY residue is
depicted in red with the C-terminal residues in violet; (d) Structure of STAT3 SH2 domain with
Sheinerman residues (red), hydrophobic system residues (yellow) and the selectivity filter (cyan);
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(e) Structure of STAT5B SH2 domain with the same color scheme as above; (f) STAT3 SH2 domain
with all mutations highlighted in spheres. The volume of each sphere is proportional to frequency of
cases identified. Red spheres indicate an activating mutation, yellow spheres indicate a destabilizing
mutation and magenta spheres represent sites where both activating and refractory mutations are
observed; (g) STAT5B SH2 domain with all mutations highlighted in spheres. The color scheme is
the same as in (f). Protein structures were visualized using Chimera [21] with PDB codes: 4E68 [22]
(STAT3), 6MBW (STAT5B) [23], 1YVL (STAT1) [24].
These residues are critical for maintaining proper binding interactions to facilitate protein
dimerization, and specific mutations here can alter normal STAT function. An issue of particular
relevance for drug discovery is protein flexibility, and indeed, STAT SH2 domains exhibit a particularly
flexible behavior even in sub-microsecond timescales [23,25]. Notably, the accessible volume of the
pY pocket varies dramatically. Also, crystal structures do not necessarily preserve even the main,
targetable pockets in an accessible state. This further underlines the importance of accounting for
protein dynamics in STAT-directed drug discovery efforts.
3. Disease-Associated Mutations in STAT3 and STAT5B SH2 Domains
Sequencing analysis of patient samples has identified multiple point mutations within the SH2
domain of STAT3 (Table 1) and STAT5B (Table 2) leading to variable effects on physiological activity.
In mice, homozygous disruption of STAT3 is embryonically lethal [26], and correspondingly germline
homozygous loss-of-function (LOF) mutations have not been identified in humans. Heterozygous loss
of STAT3 can be tolerated to different extents and contributes to immunological deficiencies,
most commonly autosomal-dominant Hyper IgE syndrome (AD-HIES) as a result of a reduced
STAT3-mediated Th17 T-cell response [27–29]. Classical STAT3 function is implicated in Th17 T-cell
lineage commitment, through upregulation of RORγt, promoting the release of IL-17 and IL-22.
This stimulates transcription of genes associated with Th17 development. Loss of STAT3 function
strongly diminishes Th17 T-cell expansion, thereby reducing the immunologic response leading to
recurrent staphylococcal infections and exceedingly high levels of IgE that contribute to clinical
presentations of eczema and eosinophilia.






Cases Pathology Type Ref
K591E αA2 pY Sheinerman 1771A>G 1 AD-HIES Germline [30]
K591M αA2 pY Sheinerman 1772A>T 1 AD-HIES Germline [31]
R593P αA4 pY - 1778G>C 1 AD-HIES Germline [32]
R609G βB5 pY Sheinerman&Signature 1825A>G 1 AD-HIES Germline [33]
S611G βB7 pY Sheinerman 1831A>G 2 AD-HIES Germline [34,35]
S611N βB7 pY & SignatureSheinerman 1832G>A 2 AD-HIES Germline [36,37]
S611I βB7 pY Sheinerman &Signature 1832G>T 1 AD-HIES Germline [38]
S614G BC3 pY Sheinerman 18040A>G 1 AD-HIES Germline [34]













Cases Pathology Type Ref
E616G BC5 pY BC loop 1847A>G 1 DLBCL,NOS Somatic [44]
E616K BC5 pY BC loop 1846G>A 1 NKTL Somatic [45]
G617E BC6 pY BC loop 1850G>A 1 AD-HIES Germline [46]
G617V BC6 pY BC loop 1850G>T 1 AD-HIES Germline [34]
G617R BC6 pY BC loop 1849G>A 1 DLBCL,NOS Somatic [44]




G618D BC6 pY BC loop 1853G>A 2 AD-HIES Germline [35,37]
T620A βC2 pY - 1858A>G 2 AD-HIES Germline [34,49]
T620S βC2 pY - 1859C>G 1 AD-HIES Germline [33]
F621V βC3 pY+3 Hydro. Sys. 1861T>G 3 AD-HIES Germline [36,37,50]
F621L βC3 pY+3 Hydro. Sys. 1863C>G 2 AD-HIES Germline [51,52]
F621S βC3 pY+3 Hydro. Sys. 1862T>C 1 AD-HIES Germline [53]
T622I βC4 pY - 1865C>T 4 AD-HIES Germline [30,34,36]
D627E CD1 - 1881C>A 1 ATLL Somatic [54]
S636F βD4 pY Sheinerman 1907C>T, 1 AD-HIES Germline [49]
S636Y βD4 pY Sheinerman 1907C>A 1 AD-HIES Germline [30]
V637M βD5 pY+3 Sel. Filter 1909G>A 43 AD-HIES Germline [30,32–37,49,52,55,56]
V637L βD5 pY+3 Sel. Filter 1909G>T 1 AD-HIES Germline [36]
V637A βD5 pY+3 Sel. Filter 1910T>C 1 AD-HIES Germline [30]
E638G βD6 pY Sheinerman 1913A>G 4 AD-HIES Germline [49,51,57,58]
P639A βD7 pY+3 - 1915C>G 1 AD-HIES Germline [37]
P639S βD7 pY+3 - 1915C>T* 2 AD-HIES Germline [30,34]
P639T βD7 pY+3 - 1915C>A 1 AD-HIES Germline [35]











K642E αB’1 - Dimer Inter 1924A>G 1 AD-HIES Germline [34]
Q643K αB’2 - Dimer Inter 1927C>A 1 T-LGLL Somatic [68]
Q644P αB’3 - Dimer Inter 1929A>C 3 AD-HIES Germline [52,70]
Q644del αB’3 - Dimer Inter 1930del CAG 2 AD-HIES Germline [35,36]
N646K αB’5 pY+3 Dimer Inter 1938C>G 2 EOAD Germline [71]
N647D αB’6 pY+3 Dimer Inter 1939A>G 8 AD-HIES Germline [36,72]




E652K αB3 pY+3 Dimer Inter 1954G>A 1 AD-HIES Germline [36]
G656D αB7 pY+3 Dimer Inter 1967G>A 1 T-LGLL Somatic [73]
G656_Y657insF αB7 pY+3 Hydro. Sys. 1968C>T;1969_1970insTTT 1 IHCA Somatic [66]
Y657C BC1* pY+3 Hydro. Sys. 1970A>G 5 AD-HIES Germline [30,34,36,58]
Y657S BC1* pY+3 Hydro. Sys. 1970A>C 1 AD-HIES Germline [74]
Y657N BC1* pY+3 Hydro. Sys. 1969T>A 1 AD-HIES Germline [52]
Y657ins BC1* pY+3 Hydro. Sys. - 1 TCL Somatic [47]
Y657dup BC1* pY+3 Hydro. Sys. - 3 T-LGLL Somatic [48,65,72]
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Cases Pathology Type Ref
Y657_M660dup BC1* pY+3 Hydro. Sys. 1969T_1980Gdup 1 IHCA Somatic [66]
K658M BC2* pY+3 Dimer Inter 1973A>T 2 T-LGLL Somatic [67,72]
K658N BC2* pY+3 Dimer Inter 1974G>T 1 T-LGLLEOAD Somatic/Germline [65,71]
K658Y BC2* pY+3 Dimer Inter 1972A>T;1974G>T 1 IHCA Somatic [66]
K658E BC2* pY+3 Dimer Inter 1972A>G 1 AD-HIES Germline [75]
I659N BC3* pY+3 Hydro. Sys. 1976A>T 1 AD-HIES Germline [58]
I659L BC3* pY+3 Hydro. Sys. 1975A>C 2 T-LGLL Somatic [57,72]
M660R BC4* pY+3 Dimer Inter 1979T>G 1 AD-HIES Germline [55]
M660T BC4* pY+3 Dimer Inter 1978T>A 1 AD-HIES Germline [76]
D661I BC5* - Dimer Inter 1981G>A;1982A>T 1 CLPD-NK Somatic [67]





D661ins BC5* - Dimer Inter - 1 T-LGLL Somatic [47]
D661V BC5* - Dimer Inter 1981A>T 10 T-LGLL Somatic [65,67]
D661H BC5* - Dimer Inter 1981G>C 1 T-LGLL Somatic [65]
A662V BC6* - Dimer Inter 1985C>T 1 ALK-ALCL Somatic [78]
T663I BC7* - Dimer Inter 1988, 1989>TT 2 DLBCL/B1 Germline [44,75]
I665N BC9* - Dimer Inter 1998T>A 2 AD-HIES Germline [34]
V667L BC11* - Dimer Inter 1999C>G 1 NKTL Somatic [45]
S668F BC12* - Dimer Inter 2003C>T 3 AD-HIES Germline [30,34,37]
S668Y BC12* - Dimer Inter 2003C>A 1 AD-HIES Germline [34]
The final search date for mutations from medical case reports and literature was 30 August, 2019. Abbreviations:
AD-HIES, autosomal-dominant Hyper IgE syndrome; ALK-ALCL, anaplastic lymphoma kinase negative anaplastic
large cell lymphoma; ANKL, aggressive natural killer cell leukemia; ATLL, adult T-cell leukemia lymphoma; EOAD,
early onset autoimmune disease; CLPD-NKs, Chronic lymphoproliferative disorders of natural killer cells; DLBCL,
NOS, Diffuse large B-cell lymphoma, not-otherwise-specified; NKTL, extranodal NK/T-cell lymphoma; HSTL,
Hepatosplenic T-cell lymphoma; IHAC, inflammatory hepatocellular adenomas; IHT, inflammatory hepatocellular
tumors; NK-LGLL, Natural killer cell large granular lymphocytic leukemia; T-LGLL, T-cell large granular lymphocytic
leukemia; TCL, γδ-T-cell lymphoma.
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Cases Pathology Type Ref.
G596V βA2 - - 1787G>T 1 APL Somatic [79]





A630P βC4 pY - 1888G>C 1 GHI Germline * [82]
D634V βC8 pY - 1901A>T 1 T-PLL Somatic [83]
Q636P CD2 pY+3 - 1907A>C 1 MEITL Somatic [81]














F646S DB’1 pY+3 - 1937T>C 1 GHI Germline * [103]
T648S DB’3 pY+3 - 1942A>T 1 T-ALL Somatic [101]










Y665H BC3* DimerInter Hydro. Sys. 1993T>C 2 T-PLL Somatic [80]
* Patients were homozygous for the point mutation. The final search date for mutations from medical case reports
and literature was 30 August, 2019. Abbreviations: AAA, acquired aplastic anemia; AML, acute myeloid leukemia;
APL, acute promyelocytic leukemia; CNL, chronic neutrophilic leukemia; GHI, growth hormone insensitivity;
HSTL, hepatosplenic T-cell lymphoma; MEITL, monomorphic epitheliotropic intestinal T cell lymphoma;
PCTL, primary cutaneous γδ T-cell lymphoma; PTCL-NOS, peripheral T-cell lymphoma not-other-specified;
T-ALL, T-cell acute lymphoblastic leukemia; T-LGLL, T-cell large granular lymphocytic leukemia; T-PLL, T-cell
prolymphocytic leukemia.
Comparatively, homozygous loss of both STAT5 gene products in mice is lethal late in embryonic
development, due to the defective erythropoiesis and with loss of STAT5B manifesting with a myriad
of physiological effects including sexual dimorphic body growth [104–106]. Clinical cases of patients
with STAT5B LOF mutations on both alleles exhibit features similar to growth hormone insensitivity
syndrome (GHIS). However, heterozygous human carriers of STAT5B LOF mutations generally do
not present with any immunological deficiencies or growth complications, although there have been
three germline dominant-negative heterozygous STAT5B mutations recently reported that result in
postnatal growth impairment among other physiological symptoms [107]. Although these growth
deficiencies are likely multifactorial in etiology, the growth hormone (GH)-growth hormone receptor
(GHR) interactions that recruit JAK kinase and stimulate phosphorylation of STAT5B remain intact,
suggesting a breakdown in corresponding STAT5B activity. STAT5B LOF patients often carry additional
immunological burdens including reduced populations of several T-cell subtypes, suggesting multiple
roles for STAT5 in T-cell differentiation [108].
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Gain-of-function (GOF) germline mutations for STAT3 and STAT5 are rare and clinically diverse.
STAT3 GOF mutations present with autoimmune responses, likely due to Th17 clonal expansion which
also suppresses regulatory T-cell (Treg) formation. Clinical presentations of STAT3 GOF mutations also
show parallels with STAT5 LOF mutations [28]. This is partially an effect of compensatory upregulation
of SOCS3 (suppressor of cytokine signaling-3) which strongly inhibits hyperactivated STAT3, but by
extension also dampens STAT5 and STAT1 activity. This potently reduces basal levels of STAT5 leading
to growth immunodeficiencies.
Contrastingly, multiple de novo somatic GOF mutations arise in STAT3 and STAT5B leading
to cancer pathogenesis, and such mutations have been implicated in both solid and liquid tumors.
Hyperactivated STAT3 is identified in patients with diverse phenotypes and multiple somatic mutations
have been associated with T-LGLL (T-cell large granular lymphocytic leukemia, 40–70% of all cases)
and NK-LGLL (natural killer cell large granular lymphocytic leukemia, 30% of all cases), as well as
different hepatocellular adenomas [40]. STAT5 is upregulated, directly and indirectly, through multiple
mechanisms in several hematological malignancies leading to neoplastic transformation. For instance,
in ~30% of acute myeloid leukemia (AML) cases, STAT5B is activated by mutated FLT3 (Fms-Like
Tyrosine Kinase 3) [109]. Similarly, ~99% of all chronic myeloid leukemia (CML) cases, which result from
the appearance of the Philadelphia chromosome, result in STAT5B hyperactivation [110]. B-cell cancers,
such as B-ALL (B-cell acute lymphoid leukemia) and B-CLL (B-cell chronic lymphoid leukemia) are
driven by upregulation of IL-7 and IL-22 which also simulate STAT5B [111–113]. Acute and chronic
T-cell cancers have lower incidence, but a larger diversity, and are heavily implicated by STAT5B
GOF driver mutations [84,114,115]. STAT GOF mutations generally stabilize protein structure thereby
enhancing transcriptional output, leading to apoptosis-evading and survival phenotypes. LOF mutants
generally distort secondary structure and contribute to either loss of activity or increased STAT
degradation. Herein, we highlight the structural significance and mechanism of action of malignant
STAT3/5B point mutations in the SH2 domain. Notably, STAT5A mutations are less frequently
identified which is likely due to the differential roles of the protein isoforms. Although STAT5B
has been characterized as a driver in several malignancies, STAT5A has been associated with tumor
suppression [116,117]. STAT5A and STAT5B have similar SH2 domains (~93% amino acid similarity)
with significant changes in the βD strand which likely contributes to varying peptide selectivity.
3.1. Mutations in the pY Pocket
As previously described, the pY pocket is formed by the αA helix, BC loop, and one face of the
central β-sheet, and it harbors an overall positive electrostatic potential to stabilize binding with the
electronegative phospho-Tyr side-chain (Figure 1). This region of the SH2 domain is characterized by
strongly conserved residues that facilitate interactions with the phosphorylated peptide. It includes
the SH2 domain signature sequence as well as a group of 8 phospho-Tyr interacting amino acids
that have been collectively referred to as Sheinerman residues [20]. The SH2 domain signature
sequence, FLXRXS (where X is a hydrophobic amino acid), corresponds to FLLRFS in all STAT
proteins and is located on the βB strand. The eight Sheinerman residues correspond to the positions:
αA2, αA6, βB5, βB7, BC1, BC2, βD4 and βD6 [20]. Critically, the βB5 residue is located within the
SH2 domain signature sequence as an invariant Arg residue, which is conserved in 118 of 121 SH2
domain-containing proteins [16]. This indispensable Arg residue is the principal binding partner for
phospho-Tyr with the side-chain guanidinium group participating in a bidentate ionic interaction with
the phosphate. The side-chains of the αA2 (Arg/Lys in 118/121 SH2 domains), βB7 (Ser in 106/121
SH2 domains) and βD4 (His in 80/121 SH2 domains) residues also participate in direct interactions
with the phospho-Tyr [16]. Notably, the αA2, βB7, and βD4 residues correspond to Lys591, Glu638,
and Ser636 in STAT3 and Lys600, Ser620, and Asn642 in STAT5B. These interactions are highly important
for phospho-peptide binding and are reported to contribute to >50% of Gibbs free energy of the
protein–peptide interaction [16]. The high fidelity of these interactions ostensibly suggests that a
mutation at these sites will have a dramatic effect on the activity or binding capacity of STAT3/5.
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3.1.1. Mutations in Sheinerman Residues
Mutations identified at the αA2 site in STAT3 (Lys591Glu [30] and Lys591Met [31]) contribute to
AD-HIES, a STAT3-deficient malignancy, due to removal of the positively-polarized Lys side-chain that
directly coordinates the phospho-Tyr. Similarly, mutations at other critical residues in the pY pocket
present with analogous clinical outcomes. Mutation of the invariant βB5 position (Arg609Gly [33])
in STAT3 leads to AD-HIES, presenting with reduced expression profiles of Th17 T-cells and high
serum levels of IgE (11,300 IU/mL). Replacement of βD4 (Ser636Phe [49]) leads to strongly elevated
IgE levels (17,407 IU/mL) with presentation of eczema, abscesses, and pneumonia, also characteristic
of AD-HIES pathologies. Interestingly, a patient with a semi-conservative substitution (Ser636Tyr [30])
that retains H-bonding capacity at the βD4 position still presented with a reduced percentage of Th17
cells (0.31%) compared to healthy patients (>1%), highlighting the substantive role of changes in sterics
at the phosphate binding positions. Examining the prevalence of mutations within the remaining
Sheinerman residues shows infrequent mutations, such as STAT3 βB7 (in which Ser611Gly [34]/Asn [36]
have been reported), which also lead to ablation of activity and AD-HIES. In cellulo studies with
Ser611Asn indicate a reduced capacity for activation by phosphorylation consistent with altered
phospho-Tyr binding [118]. Similarly, substitution at the Sheinerman βD6 position is also capable of
triggering the AD-HIES phenotype. Notably, this βD6 (Glu638Gly [49,51]) mutation likely causes gross
conformational changes in the β-sheet due to removal of a complete side-chain. Although mutations
in the pY pocket of STAT3 tend to abolish peptide binding, specific mutations in the BC loop lead to
either hyperactivation and LGL leukemias or protein dysfunction and AD-HIES. Since the BC loop
is directly involved in multiple domain interactions including the pY and pY+3 pockets, mutations
identified in this region will be discussed in detail in Section 3.3.
In STAT5, mutations at the conserved Sheinerman residues have not been identified apart from
the βD4 position. In the majority of SH2 domain-containing proteins, the βD4 residue is a His, directly
coordinating the phosphate, and mutagenesis of this residue abolishes peptide binding capacity [16].
As seen with STAT3 (Ser636Tyr), modification in sterics at this position greatly modulates phospho-Tyr
peptide binding. In STAT5B, the βD4 residue is an Asn642, and the absence of a conserved His
residue may represent an evolutionary response to tune down the basal activity of STAT5. Notably,
this residue is most frequently mutated in STAT5B (Asn642His) and has been reported in multiple
cancer phenotypes (>150 cases [41,62,69,77,80,81,83–102]), most commonly T-cell-prolymphocytic
leukemia (T-PLL), monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), and T-cell acute
lymphoblastic leukemia (T-ALL). Asn642His is an extremely aggressive oncodriver of T-cell neoplasia
and previous studies have shown multiple T-cell subset organ infiltration and transformation in
transgenic mice [23,119]. Recently, the crystal structure for the STAT5B Asn642His mutation was
reported which suggested different SH2 domain conformations with either a neatly packed βD strand
forming a tight central β-sheet or a more dissociated βD strand that provides greater access to the SH2
domain [23]. Additionally, different biophysical studies [23,41] have confirmed the substantial increase
(~5–7 fold) in the affinity of pY containing peptides for mutated STAT5B (Asn642His) compared
to wild type. This provides a molecular basis for the lower threshold of mutant STAT5B towards
cytokine activation and the aggressive phenotype observed in patients. The Asn642His mutation
is also predicted to lead to a more stable dimer interface and reduced dephosphorylation kinetics,
prolonging the lifetime of the activation state [23].
3.1.2. Mutations Outside Sheinerman Residues
The mutational landscape of STAT3 and STAT5B within the pY pocket also extends to less
conserved residues, predominantly on the βC strand. Mutations at βC4 have been identified in both
STAT3 (Thr620Ser [33]/Ala [34,49]) and STAT5B (Thr628Ser). In STAT5B, this conservative mutation is
commonly observed in T-PLL and T-ALL [86]. In vitro studies with STAT5B Asn642 variants have
shown that bulkier substituents in the pY pocket reduce phospho-Tyr affinity [23]. Therefore, the loss of
a single methylene group from Thr628 can better accommodate the cognate peptide yielding increased
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transcriptional activity. However, contrary effects are observed with Thr620Ser in STAT3, where this
mutation, as well as Thr620Ala, both lead to reduced protein activity and AD-HIES. The contrasting
effects of the same mutation at identical positions in STAT3 and STAT5B underscores the unique aspects
of each structural motif, and more broadly, the potential for isoform specific drug targeting. Generally,
STAT3 is less robust to molecular modifications with slight changes capable of strongly diminishing
activity. This is unusual considering the melting temperature of isolated STAT3 (52.5 ± 0.7 ◦C) is higher
than STAT5B (44.5 ± 0.3 ◦C) [120]. The total protein stability is likely the result of both structural and
complex protein dynamics and requires further investigation. One destabilizing mutation has been
observed in the pY pocket of STAT5B at the βC4 position (Ala630Pro [121]) which disrupts the β-sheet,
reducing protein solubility and leading to misfolding and a clinical presentation of severe growth
deficiency. Thus, destabilizing mutations are observed in STAT5B, but with a reduced frequency.
3.2. Mutations in the pY+3 Pocket
Adjacent to the pY pocket of the SH2 domain is the pY+3, or specificity pocket which interacts
with C-terminal residues of the phospho-Tyr peptide. The βD strand is critical in facilitating these
interactions, particularly the βD5 residue which controls accessibility to this pocket. In Src-type SH2
domains, additional interactions with the cognate phospho-peptide occur between residues in the
evolutionary active region (EAR). This includes the βE and βF strands as well as the loops in between
these structural elements. In STAT3 and STAT5, the EAR motif is comprised of an α-helix (αB’), and the
corresponding interactions occur within the DB’ region (loop in between βD strand and αB’ helix),
αB’, and αB helices. There is also a clustering of predominantly aromatic, hydrophobic residues at the
base of the pY+3 pocket which has been referred to as the hydrophobic system (βC3, βC5, βD3, BC1*,
and BC3*). In STAT3, this includes residues Phe621 (βC3), Trp623 (βC5), Tyr657 (BC1*), and Ile659
(BC3*) and in STAT5B, Ile629 (βC3), Trp631 (βC5), Phe633 (βC7), Trp641 (βD3), Leu663 (BC1*) and
Tyr665 (BC3*). In STAT3, the hydrophobicity of this pocket is reduced by the presence of Gln635 and
Lys626 at the βD3 and βC7 positions, respectively. The increased polarity leads to a reduced STAT3
preference for phospho-peptides with non-polar residues in the C-terminal positions compared to
STAT5B. The SH2 dimerization interface is in close proximity to the pY+3 pocket and is formed by the
BC* loop, αB’ helix and one face of the αB helix. As such, alterations in the pY+3 pocket directly affect
the dimerization interface.
3.2.1. Mutations in the Hydrophobic System and βD Strand
The pY+3 pocket is a hotspot for STAT SH2 domain mutations. Generally, mutations that
increase the polarity of this pocket result in protein destabilization and LOF. This was demonstrated
in Epstein–Barr virus (EBV)-transformed B-cells expressing AD-HIES-associated STAT3 mutations.
In these assays, the half-life of wild type STAT3 (25 ± 2 h) was shown to be substantially reduced by
polar mutations at βD5 (Val637Met = 5.3 ± 4.5 h) and BC1* (Tyr657Cys = 5.5 ± 4.1 h) [122]. Conversely,
STAT3 mutant Tyr640Phe (DB’1), which is a commonly identified mutation in solid and liquid tumors,
leads to constitutive activation across several cell lines (hepatic epithelial cells, lung carcinomas,
fibroblasts, etc.) through enhanced stability of STAT3 dimerization, nuclear accumulation and
increased transcriptional activity following IFNγ stimulation [44,47,48,59–62,65–69]. In wild type
STAT3, Tyr640 points directly into the hydrophobic system. Increasing hydrophobicity, through removal
of the hydroxyl group tightens the packing of the pocket and enhances the activation potential.
The STAT3 Tyr640Phe mutation has been identified in over >110 cancer cases in the COSMIC database
and is most frequently observed in patients with T-LGLL. An analogous mutation is observed at
the BC3* site in STAT5B where the second most frequent mutation (Tyr665Phe) results in STAT5B
hyperactivation and has also been observed in patients with T-LGLL.
Within the hydrophobic system, the presence of aromaticity for π-π stacking interactions from
key residue side-chains is strongly favored over non-aromatic Van der Waals interactions. This is
especially seen at the βC3 position with patients harboring Phe621Val [36,37,50]/Leu [51,52]/Ser [53]
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mutations resulting in STAT3-deficient AD-HIES. In cellulo mutagenesis studies with the Phe621Val
mutation have elucidated impaired STAT3 phosphorylation, resulting in defective DNA binding
capacity. This strong requirement for aromaticity is also observed in STAT5B, where Tyr665His leads
to a hyperactive mutant, since it retains the aromaticity of the imidazole ring to interact with Trp631
(βC5), despite the increase in side-chain polarity.
In addition to the hydrophobic system, the βD strand is critical for controlling pocket accessibility.
This is primarily governed by the residue at the βD5 position in SH2 domains and corresponds to
Val637 in STAT3. This residue serves as a selectivity filter, interacting with C-terminal amino acids of
the phospho-Tyr peptide. In Src kinase, the βD5 residue corresponds to a Tyr and the aromatic ring
is sandwiched between the Glu (pY+1 residue) and Ile (pY+3 residue) of the phospho-peptide [18].
In other SH2 domain-containing kinases, the βD5 residue interacts with all three C-terminal amino
acids of the pY-peptide. Given the critical nature of this site, it is not unexpected that mutations
strongly impair STAT3 activity. STAT3 Val637Met has been identified in a number of patient samples
(>40 cases) and is associated with AD-HIES due to impaired response to cytokine activation and
transcriptional activity. The importance of Val637Met [30,33,34,36,49,56] is further underscored by
insensitivity to 100-fold increases in IL-6 to simulate phosphorylation. This inability to recognize
specific phospho-peptides contributes to the defective STAT pathway observed in AD-HIES. As a
crucial selectivity filter, even semi-conservative mutations Val637Leu [36] and Val637Ala [30] have also
been shown to be disruptive to STAT3 activity and result in AD-HIES. Although STAT3 Val637Met may
be a result of reduced protein stability [122], circular dichroism spectra for STAT3 Val637Ala suggest
that this substitution does not cause large structural perturbations. Alternatively, this substitution
likely reduces phospho-peptide binding in the pY+3 pocket [123]. The βD7 position also assists in the
orientation of the βD5 residue, and mutation of the rigid Pro639 to 639Ala [37]/Ser [30,34]/Thr [35] also
results in AD-HIES.
3.2.2. Mutations in the Dimerization Interface
In comparison to pY and pY+3 pockets of the SH2 domain, the dimerization interface represents
a delicate balance in carefully regulating STAT activity. This region is littered with disease-causing
mutations and slight changes to sterics or electronics at the αB, αB’, or BC* loop propagate their
effects exponentially and lead to highly contrasting effects. There are multiple examples of such
mutations throughout the dimerization interface. For instance, at the αB’6 site, patients with STAT3
Asn647Asp [36,72] exhibit symptoms of AD-HIES, but the Asn647Ile [57,65,67] mutation results in
STAT3 hyperactivation manifesting as chronic lymphoproliferative disorder of NK cells (CPLD-NK)
and T-LGLL. Comparable to trends observed at the central pY+3 pocket, hydrophobic or aromatic
substitutions at the interface stabilize STAT3 dimer formation and subsequent phosphorylation,
while changes in polarity, or in this case, an electrostatic reversal, effectively abolish STAT3
activity. Analogous effects are also observed at the BC1*–BC6* positions. At BC1* and BC2*,
Tyr657Ser [74]/Asn [52]/Cys [30,34,36,58] and Lys658Glu [75] lead to AD-HIES, whereas Tyr657ins [47],
Tyr657dup [48,72] and Lys658Met [67,72]/Asn [65]/Tyr [66] elicit several types of T-cell cancers [124].
At the BC3* position, Ile659Leu [57,72] has been characterized in T-LGLL, whereas the recently
identified Ile659Asn [58] mutation distorts STAT3 activity leading to AD-HIES. Only destabilizing
(AD-HIES causing) mutations have been identified at BC4* (Met660Arg [55] and Met660Thr [76])
in STAT3. The BC5* position was found to be genetically volatile with mutations occurring as
Asp661His [65]/Val [78]/Tyr [41,47,48,60,63,65,67,68,72,77]/Ile [67], with all mutations resulting in
STAT3 activation and enhanced response to cytokines. Finally, the BC6* (Ala662) and BC8* (Asn664)
positions are critical SH2 domain interface determinants, where mutagenesis experiments have created
artificial disulfide linked STAT3-Ala662Cys-Asn664Cys dimers that are constitutively active in cellulo
and induce malignant transformation [66]. This further reinforces the role of the BC* loop in maintaining
the dimer interface to control STAT activity. Individually, these Cys-mutations are likely destabilizing,
but their pairing allows for covalent tethering of the STAT3 monomers and active dimer formation.
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Within STAT3, the disordered BC* loop tends to be the only site amenable to insertion/deletion
mutations. Since different mutations in this BC* loop lead to either hyper- or refractory activity,
likely the substitutions have some degree of compensatory effect that allow them to persist compared
to other regions of the SH2 domain. Furthermore, the remaining motifs of the SH2 domain are highly
structured and less likely to tolerate insertions or deletions.
The volatility shown by each of the residues in the BC* loop to trigger such extreme changes in
STAT3 behavior underscores both the importance of this region to STAT activity, but also the necessity
to understand the underlying molecular dynamics that result in such variability. This is particularly
true for the BC5* residue which has no prescribed role in other SH2 domains. However, as seen
above, its malignant capacity is revealed in >100 identified cases featuring a mosaic of mutations,
according to the COSMIC database. Specifically, the STAT3 Asp661Tyr mutation represents one of the
most frequently occurring mutation in the SH2 domain of STAT3 along with Tyr640Phe (>100 cases).
Although the increases in hydrophobicity and aromaticity have been speculated as critical determinants
for the aggressive nature of this mutation, the site-specific mechanism of activation remains unclear.
Notably, both of these frequently cancer-associated mutation sites in STAT3 (Tyr640 and Asp661) are by
default Phe and Ile respectively in STAT5B. This substitution to the STAT3 cancer-associated genotype
in STAT5B suggests that the protein may be more optimized for protein dimerization. This is an
interesting observation and further suggests a delicate evolutionary balance in STAT5B by potentially
improving interactions at the dimerization interface while reducing activity through the lack of an
efficient phosphate-coordinating βD4 residue (Asn642). The functional significance of these changes
in STAT5B, compared to STAT3, has not been biophysically characterized and may also suggest that
additional mechanisms are relevant to the disease-associated phenotype including changes to protein
stability or transcriptional regulation.
3.3. Mutations in the Additional Regions of the SH2 Domain
Mutational hotspots in regions outside the pY and pY+3 pockets may highlight additional areas
that are important for protein regulation and exploitable for drug targeting and understanding disease
progression. There is a tight clustering of mutations in the BC loop of STAT3 on the periphery of the
pY pocket. Similar to the dimerization interface, mutations at these residues can either enhance or
reduce STAT activity. This region is in close proximity to the pY pocket, pY+3 pocket, dimerization
interface, and STAT linker domain and likely serves as an important allosteric communication bridge
for interdomain signaling. As such, interactions at this region of the BC loop require a complex balance
of flexibility and rigidity. For instance, at the STAT3 BC3 position, a mutation at Ser614Arg [39–42]
leads to hyperactivation and LGLL, whereas a Ser614Gly [34] results in LOF and AD-HIES. Increasing
the positive electrostatic potential at this region generally leads to STAT hyperactivation and draws
the BC loop closer into the pY pocket. Mutations found at neighboring sites BC5, BC6, and B7
delineate similar trends, where Glu616Lys [45], Glu616Gly [44], Gly617Arg [44], and Gly618Arg [47,48]
are found in diffuse large B-cell lymphoma and NK-malignancies. Corresponding electronegative
or bulky substitutions are associated with AD-HIES and dysfunctional STAT3 (Gly617Glu [46],
Gly618Asp [35,37], and Gly617Val [34]).
There are additional mutations that are located across STAT5 and identified in single patient cases.
Given the general robust nature of STAT5 to mutations, it is difficult to assess the oncogenic driving
capacity of a single mutation, or whether the disease is multifactorial in etiology. For instance, a mutation
in the short βA strand was identified within STAT5B as Gly596Val [79]. However, this mutation was
identified in a chimeric protein of STAT5B and retinoic acid receptor-α (STAT5B-RARα), which is
associated with acute promyelocytic leukemia (APL) and is also resistant to all-trans retinoic acid
therapy. All-trans retinoic acid (ATRA) is capable of inducing remission in almost all APL cases,
with several exceptions [125]. Since this is a rare subtype of APL, where the fusion protein was
identified in a small minority of cases (<10), it is difficult to judge the importance of the mutation to the
progression of the disease, although the residue is conserved across species. Notably, a STAT3-RARα
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fusion was also recently discovered in an APL patient with a similar ATRA-resistance profile [126].
Surprisingly, no STAT5A fusions have been discovered. It would be interesting to define if the
dimerization mechanism of these RARα fusions is mediated through a partially intact SH2 domain or
other dimerization domain of STAT. Other mutations in STAT5B are located in non-hotspots including
Asp634Val (βC8), Gln636Pro (CD2), and Arg659Cys (αB4) and were identified in patients with T-PLL
and MEITL. Similar to STAT3, these mutations are in close proximity to the dimerization interface and
increase the hydrophobicity of the region, which can facilitate hyperactivation. It is interesting to note
that T-PLL represents the disease with most hyperactive STAT3/5B and JAK3 mutations among all
subgroups of largely untargeted orphan T-cell neoplasias, and future targeting efforts in this pathway
will likely benefit these patients.
4. Conclusions
Disease associated mutations are more frequently identified in STAT3 compared to STAT5B,
suggesting that STAT5B is more robust to the alterations in structural motifs, or that STAT3 has a more
pronounced role in normal physiological functioning. However, it is clear that even slight alterations
to electronics or sterics in the SH2 domain can dramatically alter STAT3 activity. In STAT3, the majority
of mutations identified in the pY pocket impair protein function, with the most substantial effects
observed upon mutation of conserved Sheinerman residues (Figure 1f). In STAT5B, pY mutations
are generally activating with the Asn642His substitution occurring most frequently in aggressive
T-cell cancers (Figure 1g). The pY+3 specificity pockets are characterized by multiple mutations with
variable effects. Broadly, mutations that improve hydrophobicity or introduce aromaticity lead to
hyperactivation, while increases in pY+3 pocket polarity or removal of aromatic substituents diminish
STAT function. This trend is also observed at the SH2 domain dimerization interface which is a hot-spot
for mutations, and different substitutions at a single position can result in severe loss- or gain-of-function.
Finally, the BC loop may be a critical region for allosteric communication pathways throughout the
protein and has been evolutionarily tuned for the precise interactions. As such, marginally reducing
electronegativity or increasing electropositivity leads to hyper- and hypo-activation, respectively.
Currently, additional structural studies and molecular dynamics simulations are required for a
better understanding of the molecular mechanisms of STAT3/5B mutations at different sites within the
SH2 domain. Considering the conformational flexibility of the main binding sites with state-of-the-art
computational methods, for example thermodynamic integration, should be more thoroughly exploited
in further work. These can be used to propose alternative treatments or highlight therapeutic
approaches. For instance, the relative instability of the wild type STAT3 protein is shown to be
amplified by AD-HIES-causing mutations. The use of small molecules that can trigger stimulation
of protein chaperones to rescue dysfunctional STAT3 mutants has been shown to be effective in
cellulo [122]. Alternatively, hyperactivated STAT3 is only marginally more stable than the wild-type
protein which may be exploited by degradation enhancing therapeutic strategies such as the use of
PROTACs and hydrophobic tagging. These efforts can be extended to STAT5 as well as examining
the Asn642His site, as this hot-spot mutation mimics SH2 domain superbinders and is excessively
aggressive due to its prime role in the pY pocket. Collectively, these structural studies offer a predictive
approach for understanding the molecular foundations of additional mutations identified in the SH2
domain, based on their location and alterations to pocket electronics and sterics.
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Abstract: Janus kinase 2 (JAK2) and signal transducer and activator of transcription-5 (STAT5) play a
key role in the pathogenesis of myeloproliferative neoplasms (MPN). In most patients, JAK2 V617F
or CALR mutations are found and lead to activation of various downstream signaling cascades and
molecules, including STAT5. We examined the presence and distribution of phosphorylated (p)
STAT5 in neoplastic cells in patients with MPN, including polycythemia vera (PV, n = 10), essential
thrombocythemia (ET, n = 15) and primary myelofibrosis (PMF, n = 9), and in the JAK2 V617F-positive
cell lines HEL and SET-2. As assessed by immunohistochemistry, MPN cells displayed pSTAT5 in all
patients examined. Phosphorylated STAT5 was also detected in putative CD34+/CD38− MPN stem
cells (MPN-SC) by flow cytometry. Immunostaining experiments and Western blotting demonstrated
pSTAT5 expression in both the cytoplasmic and nuclear compartment of MPN cells. Confirming
previous studies, we also found that JAK2-targeting drugs counteract the expression of pSTAT5
and growth in HEL and SET-2 cells. Growth-inhibition of MPN cells was also induced by the
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STAT5-targeting drugs piceatannol, pimozide, AC-3-019 and AC-4-130. Together, we show that
CD34+/CD38− MPN-SC express pSTAT5 and that pSTAT5 is expressed in the nuclear and cytoplasmic
compartment of MPN cells. Whether direct targeting of pSTAT5 in MPN-SC is efficacious in MPN
patients remains unknown.
Keywords: MPN; STAT5; JAK2 V617F; neoplastic stem cells
1. Introduction
Classical myeloproliferative neoplasms (MPN) are incurable stem cell disorders characterized
by the abnormal expansion of myeloid cells in the bone marrow (BM), elevated blood counts,
extramedullary myelopoiesis, and a genetic instability with enhanced risk to transform to secondary
acute myeloid leukemia (sAML) [1–6]. In most patients, a mutation in the calreticulin (CALR) gene or
the Janus kinase 2 (JAK2) point mutation V617F is found [3–6]. MPN-related morbidity and mortality
are emerging health problems in the Western world. Notably, improved diagnostics and therapy,
together with an enhanced life expectancy, have led to an increasing prevalence of MPN. For patients
with advanced MPN or sAML, the only curative approach is allogeneic hematopoietic stem cell
transplantation [7–9]. However, this therapy can only be offered to a subset of patients. In all other
cases, disease management is based on symptom control and the use of growth-inhibitory drugs,
including interferon-alpha, anagrelide, hydroxyurea or ruxolitinib [10–15]. However, these drugs have
little if any curative potential and in many cases resistance develops during therapy [10–15]. Therefore,
current research is seeking new molecular targets and is attempting to develop new targeted drugs for
patients with MPN.
Based on the classification of the World Health Organization (WHO), three types of classical
MPN have been defined: polycythemia vera (PV), essential thrombocythemia (ET) and primary
myelofibrosis (PMF) [3]. Each of these neoplasms exhibits unique clinical, histopathological and
molecular features [1–4,6]. However, the three MPN entities share molecular and pathologic
characteristics, and in many cases an overlap or transition from one into another type of MPN
is seen. In most patients, mutations in the JAK2, CALR or thrombopoietin receptor (MPL) gene are
found [16–20]. Independent of the disease variant, JAK2 activation leads to a cascade of downstream
signaling molecules and pathways in neoplastic cells [21–25]. One of the key downstream signaling
molecules is the ’signal transducer and activator of transcription-5’ (STAT5) protein [21–27].
Although STAT5 was initially characterized as a key transcription factor in various physiologic
and pathologic processes, more recent data suggest that STAT5 also serves as a cytoplasmic signaling
molecule that binds to and interacts with other signaling molecules in neoplastic cells to promote
oncogenesis. Both the cytoplasmic and the nuclear fractions of STAT5 are considered to critically
contribute to leukemogenesis in patients with myeloid neoplasms [28–30].
Similar to other myeloid neoplasms, MPN are considered to develop from transformed myeloid
stem cells [31–35]. As only the neoplastic stem cells of an MPN (MPN-SC) can propagate the malignancy
for unlimited time periods, they represent an important cellular target of therapy. However, little is
known about the phenotype and target expression profiles of neoplastic stem cells in MPN. As in other
myeloid neoplasms, MPN-SC are considered to reside within the CD34+/CD38− population of the
clone [32,33,35]. It has also been described that the immature CD34+ cells in MPN patients express
JAK2 V617F [35].
The aims of the present study were to examine MPN cells for expression of phosphorylated (p)
STAT5, to study the cellular distribution of pSTAT5 and to analyze the effects of pSTAT5-targeting
drugs on MPN cells. Our data show that pSTAT5 is expressed in CD34+/CD38− MPN stem cells and
serves as a potential therapeutic target in MPN.
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2. Results
2.1. Primary MPN Cells Express Nuclear and Cytoplasmic pSTAT5
As assessed by immunohistochemistry (IHC), primary MPN cells in the BM of patients with
PV, ET and PMF expressed pSTAT5 in their nuclear and cytoplasmic compartment (Figure 1A and
Table 1). The expression of pSTAT5 in normal BM cells (controls) was similar to that found in MPN BM
sections examined by IHC. In all samples tested, megakaryocytes stained clearly positive for pSTAT5
(positive control), whereas erythroid cells stained negative for pSTAT5 (negative control). We were
also able to confirm expression of cytoplasmic pSTAT5 in BM cells in patients with various MPN by
multi-color flow cytometry (Figure 1B). In these experiments, all myeloid cells tested, including CD15+
granulomonocytic cells, CD14+ monocytes and CD34+ stem and progenitor cells, were found to stain
positive for pSTAT5 (Figure 1C). pSTAT5 was identified in BM cells in all three categories of MPN,
regardless of expression of JAK2 V617F and without major differences in staining intensities (Figure 1B,
Table 1).
Figure 1. (A) Sections prepared from paraffin-embedded bone marrow (iliac crest) of patients
with polycythemia vera (PV; patient #06), essential thrombocythemia (ET; patient #34) or primary
myelofibrosis (PMF; patient #29) were stained with an anti-phosphorylated signal transducer and
activator of transcription-5 (pSTAT5) antibody using immunohistochemistry. Examples of nuclear-
and cytoplasmic staining are shown in Figure A1. Scale bar: 30 μm. Patient characteristics are
shown in Table A1. (B,C) Bone marrow (BM) mononuclear cells (MNC) of patients with PV (patient
#30), ET (patient #08) or PMF (patient #29) were stained with an anti-pSTAT5 Alexa-647 antibody.
Intracellular expression levels of pSTAT5 were analyzed by flow cytometry in total MNC (B), or in cell
subsets gated for CD34, CD14 or CD15 (C). The isotype-matched control antibody is also shown (open
black histogram). Numbers in the small boxes represent the staining index defined as the ratio of the
median fluorescence intensity (MFI) obtained with the anti-pSTAT5 antibody and MFI obtained with
the isotype-matched control antibody (mIgG1).
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Table 1. Immunohistochemical detection of pSTAT5 in bone marrow cells of MPN patients and controls.
Diagnosis PV PV PV PMF PMF PMF ET ET ET nBM nBM nBM nBM
Patient # 18 06 30 20 29 16 34 02 23 46 48 50 51
Megakaryocytes ++ ++ ++ + ++ ++ ++ ++ + ++ ++ ++ ++
Myeloid prog. + + + + + + + +/− +/− + +(+) + +
Neutrophil gran. + + +/− + + + + − +/− +/− + − +/−
Eosinophil gran. − − − − − − − − n.a. − − n.a. n.a.
Erythroid prog. − − − − − − − − − − − − −
Score: ++, strong expression in most cells; +, clear expression in the majority of cases; +/-, expressed in subsets of
cells or only weakly expressed; −, no expression (below detection limit). Abbreviations: CM, cutaneous mastocytosis;
ET, essential thrombocythemia; gran., granulocytes; MPN, myeloproliferative neoplasm; n.a., not analyzed (no cells
found by microscopy); nBM, normal bone marrow; NHL, Non-Hodgkin lymphoma; PMF, primary myelofibrosis;
prog., progenitors; PV, polycythemia vera.
2.2. Primary CD34+/CD38− MPN-SC Express pSTAT5
Expression of pSTAT5 in CD34+/CD38− cells was examined in normal/reactive BM cells and in
BM samples obtained from patients with MPN by multi-color flow cytometry. As visible in Figure 2,
pSTAT5 was found to be expressed in normal CD34+/CD38− stem cells as well as in CD34+/CD38−
MPN-SC. We also found that pSTAT5 levels were higher in JAK2 V617F+ CD34+/CD38− MPN-SC
compared to normal stem cells (p = 0.015) (Figure 2A). In addition, we found that pSTAT5 is expressed
at slightly higher levels in CD34+/CD38− MPN-SC in JAK2 V617F+ patients compared to JAK2 V617F-
patients, although the difference was not statistically significant (p = 0.073) (Figure 2B). However, no
substantial differences in pSTAT5 expression in CD34+/CD38− MPN cells were found when comparing
various subsets of MPN (PV vs. ET vs. PMF) (Figure 2C).
Figure 2. Bone marrow cells from patients with PV, ET or PMF were analyzed for intracellular expression
of pSTAT5 in CD34+/CD38−/CD45dim cells using an anti-pSTAT5 Alexa-647 antibody. (A) Expression
of pSTAT5 in normal/reactive bone marrow (Control, n = 6) and bone marrow of MPN patients (MPN,
n = 24). (B) Expression of pSTAT5 in CD34+/CD38−/CD45dim bone marrow cells in JAK2 V617F+
patients (V617F+, n = 24) and patients with wild type JAK2, a CALR mutation or an MPL mutation
(V617F−, n = 10). (C) Expression of pSTAT5 in CD34+/CD38−/CD45dim bone marrow cells in the three
different MPN subgroups (PV, n = 10; ET, n = 15, PMF, n = 9). Boxes indicate the upper and lower
quartiles, the median is defined by a horizontal line inside the boxes, and the whiskers show the highest
and lowest values.
2.3. Detection of pSTAT5 in HEL and SET-2 Cells
We next examined the JAK2 V617F+ cell lines HEL and SET-2 by immunocytochemistry (ICC).
Confirming previous studies [36,37], we found that both cell lines express pSTAT5. Interestingly,
both cell lines expressed pSTAT5 in their nuclear and cytoplasmic compartments (Figure 3A).
Intracellular expression of pSTAT5 in these cell lines was also confirmed by flow cytometry (Figure 3B).
Preincubation of HEL and SET-2 cells with JAK2-targeting drugs (ruxolitinib [38,39], R763 [40],
TG101348 [41,42], AZD1480 [43,44]) or STAT5-targeting drugs (piceatannol [45], pimozide [46,47],
AC-3-019 [48], AC-4-130 [48,49]) resulted in reduced pSTAT5 staining (Figure A2). The characteristics
of the STAT5- and JAK2-targeting drugs used in these experiments together with their main targets are
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depicted in Table A2. We also compared pSTAT5 levels in purified nuclear and cytoplasmic fractions
of HEL and SET-2 cells by Western blotting. Total STAT5 (STAT5A and STAT5B) was expressed more
abundantly in the cytoplasmic extracts of HEL and SET-2 cells than in nuclear extracts (Figure 3C).
Moreover, pSTAT5 was found at higher levels in the cytoplasm of HEL cells compared to nuclear
fractions. By contrast, in SET-2 cells, pSTAT5 was found to be expressed more abundantly in the
nuclear fractions compared to cytoplasmic fractions (Figure 3C).
Figure 3. (A) Cytospin preparations of HEL cells and SET-2 cells were stained overnight with an
anti-pSTAT5 antibody using immunocytochemistry. Scale bar: 20 μM. (B) HEL cells and SET-2 cells
were stained with an anti-pSTAT5 Alexa-647 antibody for 30 min at room temperature and intracellular
expression levels were analyzed by flow cytometry. (C) Nuclear (NE) and cytoplasmic (CE) fractions of
HEL or SET-2 cells were analyzed for expression of phosphorylated STAT5 (pSTAT5), total STAT5a and
total STAT5b by Western blotting. Antibodies against RAF-1 (cytoplasm) and TOPO-1 (nucleus) were
used as fraction controls. The columns show the densitometry for pSTAT5. Uncropped blots are shown
in Figure S1.
2.4. Effects of JAK2 V617F and CALR Mutants on Expression of Total STAT5 and pSTAT5 in Ba/F3 Cells
To explore the mechanism of expression and activation of STAT5 in MPN cells, we expressed
JAK2 V617F and mutated CALR in Ba/F3 cells containing human MPL (Ba/F3-MPL). As expected,
expression of JAK2 V617F was followed by an increase in pSTAT5 levels in these cells (Figure A3).
Moreover, we were able to show that drugs targeting STAT5 (piceatannol, pimozide) or JAK2 (AZD1480,
TG101348, R763, ruxolitinib) counteract mutant-induced overexpression of pSTAT5 in our Ba/F3-MPL
cells (Figure 4).
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Figure 4. Ba/F3 cells modified to express JAK2 V617F or CALRdel52 were incubated with various
JAK2 or STAT5 inhibitors (as indicated) for four hours at 37 ◦C. Thereafter, the expression of activated
STAT5 (pSTAT5), total STAT5 (STAT5) and heat shock cognate 70 (HSC70), which was used as loading
control, was analyzed using Western blotting. The results were quantified using densitometry and are
expressed as the ratio of activated and total STAT5 normalized to the results obtained with control cells
(Ctrl). Uncropped blots are shown in Figure S2.
2.5. Effects of Targeted Drugs on the Growth and Survival of HEL and SET-2 Cells
To confirm that pSTAT5 serves as a molecular target in MPN cells, we applied various
JAK2-targeting drugs and STAT5-targeting drugs on HEL cells and SET-2 cells. As shown in Figure 5,
the JAK2 blockers (ruxolitinib, R763, TG101348, AZD1480) and the STAT5 blockers (piceatannol,
pimozide, AC-3-019, AC-4-130) were found to inhibit 3[H]-thymidine uptake and thus proliferation
with varying potency. For several drugs, these data confirmed previous studies [50–53]. In our study,
the rank order of potency for HEL cells was AZD1480 > TG101348 > ruxolitinib > R763 > AC-4-130 >
AC-3-019 > pimozide > piceatannol. The rank order of potency for SET-2 cells was R763 > ruxolitinib
> AZD1480 > TG101348 > pimozide > AC-4-130 > AC-3-019 > piceatannol. Next, we examined the
effects of various targeted drugs on the survival of MPN cells. In these experiments, we found that the
JAK2 and STAT5 blockers examined induce apoptosis in HEL cells and SET-2 cells (Figure A4). In a
separate set of experiments, we applied ruxolitinib and AC-4-130 in combination in HEL and SET-2
cells. However, no clear additive or synergistic effects of this drug combination was observed (Data
not shown [54]). We also examined the effects of the JAK2 and STAT5 inhibitors on proliferation of two
pSTAT5-low/negative solid cancer cell lines, A2780 and A375. As shown in Table A3, these cells were
in general less sensitive to these drugs compared to HEL cells or SET2 cells.
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Figure 5. HEL and SET-2 cells were incubated with different concentrations of JAK2 or STAT5 targeting
drugs for 48 h at 37 ◦C. Thereafter, 3[H]-thymidine was added for 16 h and its incorporation was
analyzed using a beta counter. The diagrams show the mean ± standard deviation (SD) of at least three
independent experiments performed in triplicate.
2.6. Effects of Targeted Drugs on Primary Human MPN Cells
In a final step, we examined the effects of various JAK-2-targeting drugs and STAT5-targeting
drugs on the growth and survival of primary mononuclear cells (MNC) obtained from the BM of
patients with MPN. In these experiments, we found that the JAK-2 blockers and the STAT5 blockers
used in this study are capable of inhibiting the proliferation of primary MPN cells (Figure 6A). Moreover,
we found that these drugs decrease the relative numbers of primary CD34+/CD38− MPN-SC in vitro
(Figure 6B,C). Interestingly, ruxolitinib was found to decrease MPN-SC numbers after 48 h but not
after 24 h. All drugs also decreased pSTAT5 levels in MPN-SC, although the downregulating effects of
these drugs were rather weak (Figure 6D).
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Figure 6. (A) Mononuclear cells isolated from the bone marrow of MPN patients were incubated
with different concentrations of JAK2 or STAT5 targeting drugs for 48 h. Thereafter, 3[H]-thymidine
was added for 16 h and its incorporation was analyzed using a beta counter. The diagrams show
the mean ± SD of three independent experiments for JAK2-targeting drugs (patients #07, #20 and
#23) or five independent experiments for STAT5-targeting drugs (patients #20, #23, #37, #35 and #39).
(B,C) Mononuclear cells isolated from the bone marrow of MPN patients were incubated with different
concentrations of JAK2 or STAT5 targeting drugs for 24 h (B) or 48 h (C). Then, the numbers of putative
MPN stem cells (MPN-SC), defined as CD34+/CD38−/CD45dim, were assessed using counting beads.
The graphs show MPN-SC as percent of control in four patients (#14, #29, #30 and #31) in (B) and in
three patients (#31, #42 and #43) in (C). Horizontal lines indicate mean values. (D) pSTAT5 levels in
CD34+/CD38− MPN-SC determined by flow cytometry (same patients as in (C)) after an incubation
with targeted drugs (as indicated) for 4 h. Values represent pSTAT5 levels relative to the control.
The mean staining index is also shown (horizontal bars). Patient characteristics are shown in Table A1.
3. Discussion
Recent data suggest that STAT5 activation is a critical event triggering oncogenesis and growth
of neoplastic cells in various hematologic malignancies [55,56]. It has also been described that
leukemia-specific oncoproteins, such as BCR-ABL1, induce activation of STAT5 and thereby contribute
to clonal expansion of neoplastic cells [57]. Several studies have shown that phosphorylated STAT5
(pSTAT5) is expressed in the cytoplasm and nuclei of neoplastic cells in patients with chronic myeloid
leukemia (CML) and systemic mastocytosis (SM) [28,58]. Our study shows that neoplastic cells in PV
and PMF also express nuclear and cytoplasmic pSTAT5 in a constitutive manner. In addition, we found
that putative CD34+/CD38− MPN-SC display pSTAT5. Finally, our data show that pharmacologic
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targeting of STAT5 reduces the growth of MPN cells and the numbers of MPN-SC. Together, these data
suggest that the STAT5 pathway may contribute to oncogene-dependent growth of neoplastic cells in
MPN. Whether inhibitors of pSTAT5, alone or in combination with other drugs, can exert clinically
meaningful effects in MPN patients, remains unknown at present.
Recent data suggest that pSTAT5 is detectable in the cytoplasm of neoplastic cells in patients
with AML, CML and SM, and that STAT5 acts as a pro-oncogenic driver in these myeloid
neoplasms [28–30,58–60]. An interesting observation has been that the levels of cytoplasmic pSTAT5
often exceed the amounts of pSTAT5 found in the nuclear compartments in these cells [28,58]. In the
current study, we found that pSTAT5 is located in both the cytoplasmic and nuclear fractions of primary
MPN cells and in the MPN-related cell lines HEL and SET-2. In both cell lines, cytoplasmic and nuclear
pSTAT5 were detected by ICC, flow cytometry and Western blotting (Figure 3). As assessed by Western
blotting, the cytoplasmic and nuclear fractions of these cells displayed detectable levels of pSTAT5,
and total STAT5 was found to be expressed more abundantly in the cytoplasmic fraction. Currently,
it remains unknown whether nuclear pSTAT5 or cytoplasmic pSTAT5 plays a more important role in
oncogenesis in MPN. Whereas nuclear pSTAT5 is considered to act as a pro-oncogenic transcription
factors, cytoplasmic pSTAT5 may be involved in pro-oncogenic signaling involving the PI3 kinase
pathway, similar to the situation in AML and SM [29,61].
MPN cells are considered to be organized in a ‘stem cell hierarchy’ similar to normal
hematopoiesis [34]. In addition, MPN cells can undergo differentiation and terminal maturation
in the same way as normal myeloid cells. As in normal hematopoiesis, only the most immature
neoplastic stem cells (MPN-SC) have the capacity of self-renewal in MPN, a hypothesis that has major
implications regarding drug therapy [62,63]. Notably, this model predicts that these cells can propagate
the malignancy for unlimited time periods and that anti-neoplastic drugs have curative potential only
when eliminating most or all of these neoplastic stem cells in a given neoplasm. So far, only little
is known about the phenotype and function of MPN-SC [35,64]. Like in other myeloid neoplasms,
these cells are considered to reside in a CD34+ fraction of the clone [31]. In the present study, we were
able to show that pSTAT5 is not only expressed in more mature clonal MPN cells, but also in immature
CD34+/CD38− (putative) MPN-SC (Figures 1 and 2). To the best of our knowledge, our study is the
first to demonstrate that CD34+/CD38− MPN-SC express pSTAT5. Regarding more mature clonal
cells, monocytes, known to play a major role in MPN [65–67], were found to express high levels of
pSTAT5, making these cells an additional potential target of STAT5 inhibition. As assessed by flow
cytometry, we also found that the levels of pSTAT5 are higher in putative MPN-SC in patients with
JAK2 V617F+ MPN compared to patients with JAK2 V617F− MPN or normal CD34+/CD38− stem cells.
In contrast, no statistically significant difference was observed when comparing patients with JAK2
V617F− MPN or normal CD34+/CD38− stem cells, although some patients with JAK2 V617F− MPN
showed higher pSTAT5 levels than normal controls. Interestingly, when testing for pSTAT5 levels by
IHC, no differences were found between the BM of MPN patients and normal controls, which seems to
be in contrast to our flow cytometry results. However, our flow cytometry staining experiments were
performed on stem cells, whereas IHC was performed on the bulk of MPN cells. Moreover, the IHC
stain may be less capable of precisely quantifying differences in staining intensities compared to flow
cytometry. This hypothesis is supported by the work of Teofili et al. [68], who did not detect differences
in pSTAT5 levels between different subsets of MPN when using IHC in bulk cells. By contrast, using
a flow cytometry approach, Abba et al. [69], were able to show differences in pSTAT5 levels when
comparing CD34+ MPN cells with normal CD34+ cells.
In our study, no differences were seen when comparing pSTAT5 expression levels in CD34+/CD38−
MPN-SC among the three groups of MPN patients, and in each case, pSTAT5 was homogenously
expressed in all MPN-SC in all patients. Collectively, these data suggest that neoplastic stem and
progenitor cells in MPN patients express pSTAT5. As mentioned above, our results are also in line
with the data published by Abba et al. [69], who showed that pSTAT5 levels are higher in CD34+ MPN
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cells compared to normal CD34+ cells. However, Abba et al. did not look into the more immature
fraction of CD34+/CD38− stem cells [69].
A number of previous and more recent studies have shown that STAT5 activation is a critical event
triggering oncogenesis in MPN (stem) cells and that mutated forms of JAK2 and CALR can induce
STAT5 activation [22–25]. In our study, we were able to show that putative SC in MPN express pSTAT5,
but these cells only expressed pSTAT5 in excess over normal stem cells in patients with JAK2-mutated
MPN. These data suggest that STAT5 may play a particular role in MPN-SC downstream of JAK2.
However, more studies are required to define the exact role that STAT5 activation plays in the immature
stem cell compartment in MPN.
Inhibitors of JAK2 and STAT5 were found to suppress expression of pSTAT5 in HEL and SET-2 cells
(Figure A1). For several of these drugs, our data confirm the available literature [50–53]. An interesting
observation was that whereas the JAK2-targeting drugs blocked STAT5 activation and MPN cell growth
at relatively low concentrations, much higher concentrations of the STAT5 blockers were required to
counteract proliferation in MPN cells (Figure 5). These observations suggest that targeting of STAT5
may be an interesting approach to block oncogenic signaling in MPN cells directly, but more potent
and specific STAT5 inhibitors need to be developed to better inhibit MPN cell growth. Indeed, multiple
attempts have been made recently to develop selective and potent STAT5 inhibitors. In the present
study, we examined the effects of two such novel STAT5 inhibitors, AC-3-019 and AC-4-130 [49].
Similar to piceatannol and pimozide, these selective STAT5-SH2-domain-targeting drugs produced
growth inhibition and apoptosis, albeit at relatively high concentrations (Figures 5 and A4). We also
observed the effects of these inhibitors and of the other STAT5 or JAK2 blockers on MPN-SC. However,
the effects on MPN-SC were weak, so these drugs are not expected to be able to eradicate the disease.
One explanation for this result may be that other downstream signaling molecules and pathways are
also involved in triggering oncogenesis and neoplastic stem cell growth in MPN. Therefore, we believe
that more specific and more potent STAT5 blockers may be a reasonable approach to target MPN cells,
and additional drugs or drug combinations, as proposed by Bar-Natan et al. [53] and others, may be
required to elicit optimal anti-neoplastic or even curative effects.
4. Materials and Methods
4.1. Patients
Thirty-four patients with MPN, including 10 with PV, 15 with ET and 9 with PMF were examined
for levels of pSTAT5 in MPN-SC. MPN variants were diagnosed according to WHO criteria [3].
Patient characteristics are shown in Table A1. Routine staging included physical examination, blood
counts, morphologic examination of cells on BM smears, BM histology and immunohistochemistry,
and analysis of BM and peripheral blood cells for expression of JAK2 V617F, CALR and MPL
mutations. Expression of JAK2 V617F was determined by two PCR assays: the qualitative Ipsogena
MutaScreen assay and the quantitative MutaQuant assay. Both assays were applied according to
the recommendations of the manufacturer (Qiagen, Venlo, Netherlands). In JAK2 V617F-negative
patients, MPN cells were screened for CALR mutations using fluorescence- based PCR, followed by
Sanger sequencing of codons 351–404 of CALR as described [16]. When no JAK2 or CALR mutations
were detected, the patients were analyzed for MPL mutations using an allelic discrimination assay as
described [20]. In 15 patients (PV, n = 4; ET, n = 5; PMF, n = 6), BM mononuclear cells (MNC) were
enriched using Ficoll. These MNC were used to assess drug effects on proliferation and/or survival.
In addition, BM cells obtained from eight donors without MPN (control BM samples) were analyzed
(Table A4). All investigations were approved by the local ethics committee of the Medical University of
Vienna (ethic code: 224/2006; 1184/2014; 1063/2018). Informed consent was obtained from all patients.
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4.2. Antibodies (Ab) and Other Reagents
The anti-pSTAT5 alpha (Tyr694) polyclonal Ab was purchased from Invitrogen (order number
71-6900; Carlsbad, CA, USA), anti-pSTAT5 (Y694) Alexa Fluor® 647 monoclonal Ab (mAb) 47 (order
number: 612599) and an isotype-matched control antibody (mIgG1-Alexa Fluor® 647, order number:
557783) from BD Biosciences Pharmingen (San Jose, CA, USA), piceatannol (order number: P0453)
and pimozide (order number: P1793) from Merck (Darmstadt, Germany), and the JAK2 blockers
AZD1480 (order number: CT-A1480), TG101348 (order number: CT-TG101) and ruxolitinib (order
number: CT-INCB) from ChemieTek (Indianapolis, IN, USA). The specificity of pSTAT5 (Y694) Alexa
Fluor® 647 was confirmed by flow cytometry experiments performed with human cell lines with
detectable pSTAT5 (KOPT-K1 and MYLA) or no detectable pSTAT5 (HUT78 and HH). In addition, we
employed Ba/F3 cells with IL-3-inducible expression of pSTAT5. In these experiments, the specificity of
the antibody was confirmed (Figure A5a,b). pSTAT5 expression in the cell lines tested was confirmed
by Western Blotting (Figure A5c,d). Roswell Park Memorial Institute (RPMI) 1640 medium (order
number: 10-041-CVR) was purchased from Corning (Manassas, VA, USA) and fetal calf serum (FCS;
order number: 10270-106) from Gibco (Karlsbad, CA, USA). The JAK2 and Aurora kinase-targeting
drug R763 was kindly provided by Yasumichi Hitoshi (Rigel Pharmaceuticals, San Francisco, CA,
USA). The STAT5 inhibitors AC-3-019 and AC-4-130 were produced as described [48]. Stock solutions
of drugs were prepared by dissolving in dimethyl sulfoxide (DMSO) (order number: D2650; Merck).
4.3. Cell Lines
A375 were purchased from LGC Standards (Wesel Germany); HEL and SET-2 cell lines
were purchased from Deutsche Sammlung von Mikroorganismen und Zellkulturen (Braunschweig,
Germany); KOPT-K1 cells were kindly provided by Takaomi Sanda (Cancer Science Institute of
Singapore, Singapore); HH, HUT78 and MYLA were kindly provided by Marco Herling (University
Hospital Cologne, Cologne, Germany). A2780 cells were purchased from Sigma (St. Louis, MO, USA).
All cell lines were cultured in RPMI 1640 medium supplemented with 10% FCS.
4.4. Immunohistochemistry and Immunocytochemistry
Immunohistochemistry was performed on paraffin-embedded, formalin-fixed BM biopsy
specimens using the indirect immunoperoxidase staining technique following established protocols [28].
Endogenous peroxidase was blocked by methanol/H2O2 and heat-induced epitope retrieval was
performed (96 ◦C, 20 min, pH 9). A polyclonal anti-pSTAT5 antibody was applied at 1:100 for 20 h
at 4 ◦C. Biotinylated goat anti-rabbit IgG (Vector Laboratories, Burlingham, CA, USA, order number:
BA-1000) was applied as secondary antibody for 30 min at room temperature. Then, slides were
exposed to an avidin/biotinylated peroxidase complex (Vectastain ABC Kit from Vector, order number:
PK-6100) for 30 min. The chromogen 3-amino-9-ethylcarabzole (AEC) was then used. Finally, slides
were counterstained in Mayer’s hematoxylin (Morphisto, Frankfurt am Main, Germany, order number:
10231.01000). In each sample, the specificity of the anti-pSTAT5 stain was controlled by analyzing
the internal negative control and positive control. In fact, erythroid cells always stained negative
and megakaryocytes always stained positive as reported previously [28]. Immunocytochemistry was
performed using HEL and SET-2 cells as described [28]. Cells were spun on cytospin slides and fixed
with acetone for 8 min. Slides were pretreated in citrate buffer (pH 6.0) at 95 ◦C for 20 min and
incubated with a polyclonal anti-pSTAT5 antibody (Invitrogen, Carlsbad, CA, USA order number:
71-6900) diluted 1:100, overnight at 4 ◦C. Slides were incubated with biotinylated goat anti-rabbit
IgG (Biocare Medical, Walnut Creek, CA, USA) for 30 min at room temperature (RT) and then with
streptavidin AP label (Biocare Medical, Walnut Creek, CA, USA) for 30 min. Neofuchsin (Nichirei,
Tokyo, Japan) was used as the chromogen. All slides were counterstained in Mayer´s hematoxylin.
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4.5. Flow Cytometry
Expression of cell surface antigens on primary neoplastic stem cells was analyzed by multicolor
flow cytometry using antibodies against CD34, CD38 and CD45 as described [70]. Putative stem cells
were defined as CD34+/CD38−/CD45dim. The gating strategy is shown in Figure A6. For assessing
the absolute numbers of stem cells by flow cytometry, Absolute Counting Beads (Thermo Fisher
Scientific, Waltham, MA, USA, order number: C36950) were used according to the instructions by the
manufacturer. For the flow cytometric detection of cytoplasmic pSTAT5, cells were first stained for
cell surface antigens and then fixed in formaldehyde (2%). Cells were subsequently permeabilized by
exposure to 50% methanol (−20 ◦C, 10 min), washed in phosphate-buffered saline containing 0.1%
bovine serum albumin (order number: A4503; Merck) and stained with the Alexa 647-conjugated
anti-pSTAT5 mAb 47 pY694 or an isotype-matched control antibody for 30 min at RT. Cells were then
washed and analyzed on a FACSCanto (BD Biosciences). Staining reactions were expressed as median
fluorescence intensity (MFI). pSTAT5 expression levels are shown as staining index (SI) defined as MFI
produced by anti-pSTAT5 antibody:MFI of the isotype-matched control antibody.
4.6. Western Blot Analysis of Expression of pSTAT5 in Ba/F3 Cells
To confirm the selective effects of JAK2 or STAT5 targeting drugs, Western blot experiments were
performed using the pSTAT5 antibody Tyr694 on Ba/F3 and Ba/F3-MPL cells engineered to express
JAK2 V617F and CALRdel52, respectively. Ba/F3 cells were generated as described [71,72]. Cells were
incubated with drugs targeting JAK2 (AZD1480, TG101348, ruxolitinib, R763; 1–5 μM) or STAT5
(piceatannol, pimozide; 10–45 μM) for 4 h. Then, pSTAT5 expression was analyzed by Western blotting
essentially as described [49]. Nitrocellulose membranes (0.45 μm Amersham Protran; order number:
10600002; GE Healthcare, Buckinghamshire, UK) were incubated with the following antibodies at the
dilution indicated: polyclonal rabbit anti-phospho-STAT5 (Y694) antibody (order number: 71-6900;
1:1000; Invitrogen, Camarillo, CA, USA), monoclonal mouse anti-STAT5 antibody 89/Stat5 (order
number: 610191; 1:1000; BD Biosciences), mouse anti-HSC70 monoclonal antibody B-6 (order number:
SC-7298; 1:10,000; Santa Cruz, St. Louis, MO, USA), IRDye® 680RD goat anti-rabbit IgG (order number:
925-68071; 1:10000; LI-COR, Lincoln, NE, USA), and IRDye® 800CW goat anti-mouse IgG (order
number: 925-32210; 1:10000; LI-COR). pSTAT5 levels were quantified by densitometry and expressed
as the pSTAT5/loading control ratio normalized to control (untreated) cells.
4.7. Isolation of the Cytoplasmic and Nuclear Fractions of HEL and SET-2 Cells
HEL and SET-2 cells were lysed in hypotonic buffer (20 mM HEPES, 10 mM KCl, 1 mM
ethylenediaminetetraacetic acid, 0.2% NP40, 10% glycerol, 5 μg/mL aprotinin, 5 μg/mL leupeptin,
1 mM phenylmethylsulfonide fluoril, and 1 mM Na2VO4). Cell lysates were centrifuged (5 min, 800× g)
to separate cytoplasmic and nuclear fractions [61]. Supernatants (cytoplasmic fraction) were frozen
at −70 ◦C. Pelleted nuclei were resuspended in hypertonic buffer (hypotonic buffer plus 350 mM
NaCl) and protein extracts were prepared by agitation (30 min, 4 ◦C). After debris was removed
by centrifugation, nuclear extracts were frozen at −70 ◦C. Expression of pSTAT5 was determined
by Western blotting and quantified by densitometry as reported [61]. Fractionation of subcellular
compartments was controlled by applying anti-RAF-1 (cytoplasmic) and anti-topoisomerase-1 (nuclear)
antibodies in parallel. All antibodies were from Santa Cruz.
4.8. Evaluation of Drug Effects on the Growth and Survival of MPN Cells
To further determine the functional role of STAT5 in MPN cells, we applied several targeting drugs:
piceatannol, pimozide, AZD1480, TG101348, R763, ruxolitinib, AC-3-019 and AC-4-130 (Table A2).
Primary human MPN cells (ET, n = 2; PMF, n = 3; PV, n = 2), HEL cells and SET-2 cells were incubated
with increasing drug concentrations at 37 ◦C for 48 h. Thereafter, 3[H]-thymidine was added, and its
uptake was analyzed after 16 h using a beta-counter. For evaluation of apoptosis, HEL and SET-2
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cells were incubated in control medium or in various drug concentrations for 24 h and 48 h at 37 ◦C.
The percentage of apoptotic cells was quantified using Annexin V/Propidium Iodide staining as
described [73]. In a subset of patients, we examined drug effects on putative CD34+/CD38− MPN-SC.
5. Conclusions
STAT5 is a critical molecule in MPN cells that acts downstream of oncogenic JAK2 V617F and
mutant CALR. We found that pSTAT5 is expressed abundantly in the nuclear and cytoplasmic
compartment of MPN cells and that pSTAT5 is not only present in more mature clonal cells, but also in
putative CD34+/CD38− MPN-SC. Moreover, we show that STAT5 expression correlates with survival of
MPN cells and that drugs targeting STAT5 can block growth and survival of these cells. Since MPN-SC
display STAT5, and STAT5 is downstream of both JAK2 V617F and mutant CALR, targeting of STAT5
may be a promising approach to treat MPN.
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Appendix A
Figure A1. The picture shows an enlarged part of the picture of patient #06 (PV) from Figure 1A.
The arrows point at examples of cytoplasmic ‘C’, nuclear ‘N’ and cytoplasmic/nuclear ‘C+N’ staining.
‘Ery’ marks examples of erythroid cells that were used as internal negative controls. Scale bar: 30 μm.
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Figure A2. HEL and SET-2 cells were incubated with various concentrations of JAK2-targeting drugs
(ruxolitinib, R763, TG101348, AZD1480) or STAT5-targeting drugs (piceatannol, pimozide, AC-3-019,
AC-4-130) for 4 h. Thereafter, expression of pSTAT5 was analyzed by multicolor flow cytometry.
The levels of pSTAT5 are depicted as median fluorescence index (MFI) values relative to the untreated
control (Co).
Figure A3. Wild type (wt) Ba/F3 cells or Ba/F3 cells transfected with either JAK2 V617F or CALRdel52
were incubated overnight in medium without IL-3. After, cell lysates were subjected to Western blotting
using antibodies against pSTAT5, STAT5 and HSC70. The columns show the levels of pSTAT5 in percent
of HSC70 as analyzed by densitometry. Uncropped blots are shown in Figure S3.
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Figure A4. HEL and SET-2 cells (as indicated) were incubated with different concentrations of JAK2 or
STAT5 targeting drugs for 24 h or 48 h at 37 ◦C. Thereafter, apoptosis induction was assessed using
Annexin V/propidium iodide (PI) staining. The columns show the sum of cells positive for Annexin
V-only, PI-only or Annexin V/PI for each condition and are depicted as mean ± SD of at least three
independent experiments.
Figure A5. Ba/F3 cells were kept in medium without IL-3 overnight and split in the morning. One half
was incubated with 10 ng/mL IL-3 for 40 min (Ba/F3 + IL-3), while the other half was kept in medium
without IL-3 (Ba/F3 − IL-3). Thereafter, cells were analyzed for expression of pSTAT5 either by flow
cytometry (A) or Western blotting (C). In (A), an Alexa-647-labeled anti-pSTAT5 antibody was used
(with IL-3: blue histogram; without IL-3: open blue histogram). mIgG1 Alexa-647 was used as an
isotype control (open black histogram) in Ba/F3 + IL-3 cells (A). Human lymphoma cell lines with
detectable pSTAT5 levels (KOPT-K1 and MYLA) or no detectable pSTAT5 (HUT78 and HH) were also
analyzed for pSTAT5 expression using flow cytometry (B) and Western blotting (D). In Western blot
experiments, HSC70 served as a loading control. The columns show the levels of pSTAT5 in percent of
HSC70 as analyzed by densitometry. Uncropped blots are shown in Figure S4.
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Figure A6. To identify immature CD34+/CD38− stem cells (SC), we performed a sequential gating
algorithm, indicated by pink arrows using FlowJo software. After excluding CD45-negative cells,
immature cells were identified by their expression of CD34 (upper left panel) and were then gated
as CD45 dim-positive blast cells (lower left panel). Thereafter, viable cells were selected by their
light-scatter properties (lower right panel) and were then gated according to the lack (pink gate) of
CD38 (upper right panel). The example shows bone marrow cells from patient #23.
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Table A3. IC50 concentrations of JAK2- and STAT5 targeting drugs in pSTAT5 high and low cell lines.
IC50 Obtained with Drugs in Various Cell Lines (SI pSTAT5)
Inhibitor HEL (13.4) SET-2 (8.6) A375 (1.93) A2780 (1.97)
Piceatannol 10–17.5 10–17.5 >75 17.5–25
Pimozide 5–7.5 5–7.5 12.5–15 12.5–15
AC-3-019 3.5–4 9–10 10–12.5 12.5–15
AC-4-130 3.5–4 7–8 >15 >15
AZD1480 0.5–1 0.05–0.1 >2 0.5–1
TG1010348 1–2 0.1–0.25 >2 1–2
Ruxolitinib 1–2 0.0025–0.05 >2 >2
IC50 concentration: half maximal inhibitory concentration; SI: Staining Index (MFI produced by the anti-pSTAT5
antibody:MFI of the isotype-matched control antibody).
Table A4. Characteristics of control bone marrow donors.
# Sex Age at Sampling Diagnosis pSTAT5 FACS pSTAT5 IHC
44 f 33 NHL yes -
45 m 37 nBM yes -
46 m 40 NHL yes yes
47 m 24 B-ALL (CR) yes -
48 f 47 CM yes yes
49 m 26 NHL yes -
50 f 33 NHL - yes
51 m 61 NHL - yes
B-ALL (CR), b-cell acute lymphoblastic leukemia in complete remission; CM, cutaneous mastocytosis; nBM, normal
bone marrow; NHL, non-Hodgkin lymphoma; PMF, primary myelofibrosis; pSTAT5 FACS, sample analyzed for
expression of pSTAT5 in CD34+/CD38− putative stem cells; pSTAT5 IHC, sample analyzed by immunohistochemistry
for expression of pSTAT5 in different bone marrow cells; PV, polycythemia vera.
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Abstract: T-cell prolymphocytic leukemia (T-PLL) is a rare and poor-prognostic mature T-cell
leukemia. Recent studies detected genomic aberrations affecting JAK and STAT genes in T-PLL.
Due to the limited number of primary patient samples available, genomic analyses of the JAK/STAT
pathway have been performed in rather small cohorts. Therefore, we conducted—via a primary-data
based pipeline—a meta-analysis that re-evaluated the genomic landscape of T-PLL. It included all
available data sets with sequence information on JAK or STAT gene loci in 275 T-PLL. We eliminated
overlapping cases and determined a cumulative rate of 62.1% of cases with mutated JAK or STAT genes.
Most frequently, JAK1 (6.3%), JAK3 (36.4%), and STAT5B (18.8%) carried somatic single-nucleotide
variants (SNVs), with missense mutations in the SH2 or pseudokinase domains as most prevalent.
Importantly, these lesions were predominantly subclonal. We did not detect any strong association
between mutations of a JAK or STAT gene with clinical characteristics. Irrespective of the presence
of gain-of-function (GOF) SNVs, basal phosphorylation of STAT5B was elevated in all analyzed
T-PLL. Fittingly, a significant proportion of genes encoding for potential negative regulators of
STAT5B showed genomic losses (in 71.4% of T-PLL in total, in 68.4% of T-PLL without any JAK
or STAT mutations). They included DUSP4, CD45, TCPTP, SHP1, SOCS1, SOCS3, and HDAC9.
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Overall, considering such losses of negative regulators and the GOF mutations in JAK and STAT genes,
a total of 89.8% of T-PLL revealed a genomic aberration potentially explaining enhanced STAT5B
activity. In essence, we present a comprehensive meta-analysis on the highly prevalent genomic
lesions that affect genes encoding JAK/STAT signaling components. This provides an overview of
possible modes of activation of this pathway in a large cohort of T-PLL. In light of new advances
in JAK/STAT inhibitor development, we also outline translational contexts for harnessing active
JAK/STAT signaling, which has emerged as a ‘secondary’ hallmark of T-PLL.
Keywords: JAK; STAT; T-PLL; T-cell leukemia; meta-analysis; STAT5B signaling
1. Introduction
T-cell prolymphocytic leukemia (T-PLL) is an aggressive malignancy characterized by an expansion
of mature T-lymphocytes [1]. Although with an incidence of <2.0/million/year in Western countries
infrequently encountered, T-PLL is the most common mature T-cell leukemia [2]. Patients suffering from
T-PLL typically present with exponentially rising white blood cell (WBC) counts accompanied by bone
marrow (BM) infiltration and splenomegaly, and at lower frequencies by various other manifestations
such as effusions or in skin [3]. Due to its chemotherapy-refractory behavior, T-PLL patients have a
dismal prognosis with a median overall survival (OS) of <3 years [4–6]. Clinicians treating T-PLL
face limited therapeutic options, mainly caused by a still incomplete mechanistic disease concept
and, therefore, a rudimentary understanding of targetable vulnerabilities in T-PLL. The most potent
single substance, the CD52-antibody alemtuzumab, leads to complete remissions in more than 80% of
patients, however, nearly all eventually relapse (at median already within 12 months) [3,4,7].
Due to the limited number of primary patient samples available, genomic analyses studying
the underlying disease mechanisms have been performed in rather small cohorts of T-PLL patients.
In these studies, the most common molecular features revealed were rearrangements that involve
chromosome 14 or X, resulting in juxtaposition of the T-cell leukemia/lymphoma 1A (TCL1A) or Mature
T-cell leukemia 1 (MTCP1) proto-oncogenes to TCRAD gene enhancer elements [8]. The second most
common lesions are genomic alterations of the tumor suppressor ataxia telangiectasia mutated (ATM),
found in >85% of cases [9]. In addition to these lesions, activating mutations targeting the Janus kinase
(JAK)/signal transducer and activator of transcription (STAT) pathway components were identified in
these series of genomic analyses [9–18].
The JAK/STAT pathway is a ubiquitous cytokine-mediated signaling cascade that regulates cell
proliferation, differentiation, migration, and apoptosis [19]. After recruitment of JAKs (JAK1, JAK2,
JAK3, TYK2) to cytokine receptors, they phosphorylate STAT proteins (STAT1, STAT2, STAT3,
STAT4, STAT5A, STAT5B, STAT6), which then bind DNA and regulate target gene transcription [20].
Dysregulation of the JAK/STAT axis has been described as a key event in the pathogenesis of various
hematologic malignancies [21]. Constitutively active JAK/STAT signaling induces T-cell tumors in
mice [22,23]. Using different sequencing approaches, activating mutations of JAK1, JAK3, and STAT5B
were identified as the most recurrent genomic aberrations affecting JAK/STAT genes in T-PLL [9–18].
However, prevalence of gene mutations, information on their allele frequencies, assessment of negative
regulators of JAK/STAT signaling, and the phosphorylation status of the most recurrently affected
JAK/STAT proteins vary considerably or are not reported in these studies [9–18].
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Therapeutic approaches blocking JAK/STAT signaling have so far improved patient outcomes
predominantly in autoimmune conditions and in graft-versus-host disease [24,25]. JAK inhibitors
are currently tested for a number of new indications [26]. T-PLL cells have shown a notable in vitro
sensitivity towards JAK inhibition, which was not directly linked to the JAK/STAT mutation status [15,16].
First reports present individual clinical activity of tofacitinib (pan JAK inhibitor) and ruxolitinib (JAK 1/2
inhibitor) in relapsed T-PLL [27,28].
Although many studies identified JAK and STAT genes to be commonly mutated in T-PLL,
these analyses have been performed in rather small cohorts not providing a sufficient dataset to
determine reliable mutation and variant allele frequencies (VAFs). In addition, the publication overlap
of these studies was unresolved and a systematic assessment for other potential genomic causes
(e.g., copy number alterations (CNAs)) has not been performed.
Here, we conducted a meta-analysis that was supplemented by new primary data, hence providing
the largest cohort to date that evaluated the genomic aberrations affecting JAK/STAT signaling in
T-PLL. In addition to summarizing information on the functional impact of the most recurrent lesions,
we propose a model of potential mechanisms leading to constitutive JAK/STAT signaling in T-PLL cells.
2. Results
2.1. Characteristics and Overlaps of Included Studies
The meta-analysis considered all available publications that have analyzed variants of any JAK or
STAT gene in cases of T-PLL, regardless of the sequencing approach used (Table S1). Redundantly
sequenced cases were identified to eliminate overlaps between these 10 studies (Figure 1A). The most
common sequencing approach was Sanger sequencing (Sanger seq., 7 studies), followed by targeted
amplicon sequencing (TAS, 5 studies), whole exome sequencing (WES, 4 studies), and whole genome
sequencing (WGS, 2 studies). JAK3 (n = 272 T-PLL patients), JAK1 (n = 246), and STAT5B (n = 209)
were predominantly sequenced due to the bias by the targeted approaches. Germline controls were
sequenced in 53 cases (19.3%). The number of analyzed patients varied from 3 to 71 patients across the
10 studies [9–18]. After subtracting all cases reported in more than one study, we identified 275 unique
T-PLL cases as the core cohort.
Notably, data that were acquired by WGS, WES, and SNP array analysis were re-analyzed as
primary data in cases, in which raw data were available (WES: 62.2%, n = 46/74 T-PLL patients; WGS:
50.0%, n = 4/8; SNP arrays: 100.0%, n = 71/71), while data gained through Sanger seq. or TAS were not
re-evaluated. By re-analyzing the WES and SNP array data through a uniform pipeline, homogeneity
of the resulting dataset was obtained. JAK1, JAK2, JAK3, TYK2, STAT1, STAT2, STAT3, STAT4, STAT5A,
STAT5B, and STAT6 are further referred to as ‘any JAK or STAT gene’.
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Figure 1. Meta-analyses of genomic profiling series in T-PLL underscore the high prevalence of
mutations affecting JAK and STAT genes. (A) T-PLL patients (n = 275) sequenced for any JAK or STAT
locus. Horizontal bar chart displays the total number of patients sequenced in each publication. Vertical
bar chart indicates the size of intersections between sets of patients analyzed in one or more publications.
Color-code of vertical bars indicates the number of studies reporting results of the same individual
case (black: 1; dark-orange: 2; medium-orange: 3; light-orange: 4; light grey: 5). Dot connecting
lines show the overlapping publications of each intersection. (B) Distribution of JAK/STAT mutations
(n = 87 T-PLL analyzed by whole genome sequencing (WGS)/whole exome sequencing (WES)): in
62.1% of these cases (n = 54) at least one mutation in a gene of the JAK/STAT family was found to be
mutated. (C) Relative frequencies of hotspot mutations of JAK1, JAK3, and STAT5B (as defined by
the genomic region containing more than 90% of the respective mutations; n = 275 cases analyzed
by WGS/WES/targeted amplicon sequencing (TAS)/Sanger sequencing). Every T-PLL case that was
sequenced for the respective hotspot region of JAK1 (Ex. 14–20), JAK3 (Ex. 11–19), and/or STAT5B
(Ex. 15–17), was included. (D) Box-whisker charted allele frequencies of missense mutations of JAK1,
JAK3, and STAT5B (n = 153 T-PLL analyzed by WGS/WES and/or TAS) illustrate a high heterogeneity
in variant allele fractions, with most lesions detected at lower frequencies (<50%).
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2.2. Mutations in JAK and STAT Genes are Predominantly Found at Subclonal Levels
We included T-PLL cases with available data from WGS or WES in order to calculate the frequency
of genomic variants in JAK and STAT genes. We identified a cumulative rate of 62.1% (n = 54/87,
Figure 1B) cases with variants in any JAK or STAT gene. The vast majority of them were somatic
single-nucleotide variants (SNVs) of missense type (96.0%, n = 72/75 of variants detected by WGS/WES).
The remaining three lesions (4.0%, n = 3/75) were small in-frame deletions in JAK1 or JAK3. In the
following these SNVs and small in-frame deletions are referred to as ‘mutations’. Somatic variants were
called and known single nucleotide polymorphisms were filtered out in those tumor samples for which
a matched germline sample was available. For T-PLL patients with a missing germline control (n = 38),
we included only those variants which were detected in the WES with matched germline samples. JAK3
(34.5%, n = 30/87), STAT5B (25.3%, n = 22/87), and JAK1 (9.2%; n = 8/87) were the most recurrently
mutated genes, while TYK2 (2.3%, n = 2/87), STAT4 (2.3%, n = 2/87), and STAT5A (1.1%, n = 1/87) were
mutated at lower frequencies. Nine of 87 cases (10.3%) presented with mutations affecting two genes
that encode for JAK or STAT proteins. Co-occuring (‘double’) JAK1 and JAK3 mutations were found in
1.1% of cases (n = 1/87), JAK3 and STAT4 in 1.1% (n = 1/87), and JAK1 and STAT4 mutations in 1.1%
(n = 1/87); JAK1 and STAT5B in 1.1% (n = 1/87), and JAK3 and STAT5B in 5.8% (n = 5/87). Co-occuring
JAK1, STAT5A, and STAT5B mutations (‘triple’) were detected in one case (1.1%).
Next, we calculated frequencies of missense mutations considering the hotspots of JAK1 (Ex. 14–20),
JAK3 (Ex. 11–19), and STAT5B (Ex. 15–17). Hotspot regions were defined as genomic regions containing
>90% of the respective mutations. By also including cases analyzed by TAS or Sanger seq. for the
respective hotspot region, we arrived at a larger cohort for these analyses. Based on this, the hotspot
of JAK1 showed a relative mutation frequency of 6.3% (n = 11/175). For the hotspot of JAK3 this was
36.4% (n = 75/206) and for the hotspot of STAT5B it was 18.8% (n = 38/202, Figure 1C).
As already described in smaller cohorts [9,16,18], most of these lesions presented as subclonal
events with low VAFs (medians: JAK1 6.0%, JAK3 28.5%, STAT5B 19.0%, Figure 1D); however,
we observed a high heterogeneity in VAFs. Notably, the N642H mutation of STAT5B was observed at a
VAF of >50% in four cases and the M511I mutation of JAK3 at VAFs >50% in five cases. Note that given
the data provided in the reports, the percentage of treatment-naïve samples was 72.7%; sequential
samples of individual T-PLL patients were not analyzed here.
2.3. Missense Mutations in JAK1, JAK3, and STAT5B Cluster Within the Conserved Pseudokinase and SH2 Domains
We further assessed the localization of the missense mutations of JAK1, JAK3, and STAT5B (Figure 2,
upper protein schemes) as well as the frequencies of hotspot SNVs in these genes (lower inset). To assess
the localization of the somatic SNVs of JAK1, JAK3, and STAT5B, we included all T-PLL cases which
have been sequenced for the whole coding genome by WES or WGS. All T-PLL cases which have
been sequenced for the respective lesion regardless of the sequencing approach were considered to
determine the frequencies of hotspot mutations. The pseudokinase domain (JH2 domain) of JAK1 was
predominantly affected (62.5% of all JAK1 mutations, n = 5/8) with V658F (3.7% of all analyzed cases, n
= 9/246, regardless of the sequencing approach) as the most prominent lesion (Figure 2A). In JAK3,
most somatic SNVs were found in the JH2-SH2-linker (69.7% of all JAK3 missense mutations, n = 23/33
detected missense mutations), followed by the JH2 domain (27.3%, n = 9/33, Figure 2B). The M511I
lesion was the most prevalent lesion in JAK3 (27.2% of all analyzed cases, n = 74/272, regardless of
the sequencing approach). Almost all missense mutations of STAT5B were found in the SH2 domain
(96.2% of all STAT5B missense mutations, n = 25/26 detected missense mutations; Figure 2C). N642H
(9.6% of all analyzed cases, n = 20/209, regardless of the sequencing approach), T628S (5.9%, n = 12/202),
and Y665F (3.3%, n = 7/209) were the most recurrent mutations affecting STAT5B. Remarkably, we did
not detect significant differences in the mutation frequencies with regard to the sequencing approach
(see bars of the lower inset of Figure 2).
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Figure 2. Missense mutations in JAK1/JAK3/STAT5B genes cluster within the conserved JH2
(pseudokinase) and SH2 domains. Upper protein scheme: gene-wide distribution of missense
mutations of JAK1 (A), JAK3 (B), and STAT5B (C); n = 87 T-PLL analyzed by WES/WGS, representing
the same cases as in Figure 1B. Lower inset for each sub-panel A–C: frequencies of hotspot mutations,
stratified for applied sequencing methods (n = 275 cases analyzed with WES/WGS/TAS/Sanger seq).
While JAK1 and JAK3 were predominately affected by lesions within the pseudokinase domains (JH2)
and the SH2-JH2 linker regions, STAT5B missense mutations were presented mostly in the SH2 domain.
170
Cancers 2019, 11, 1833
2.4. T-PLL Harboring any JAK or STAT Mutation Show Elevated TCL1A mRNA Level, but Present
Comparable Clinical Outcomes
When analyzing associations of JAK and STAT mutations with immunophenotypic and cytogenetic
data as well with the 18 most prevalent mutations found in T-PLL (as described by Schrader et al. [9]), we
detected a decreased proportion of T-PLL cells with CD40L expression (p = 0.05, Fisher’s exact test, Figure
S1A) and an increased proportion of T-PLL cells harboring NOTCH2 mutations (p = 0.03, Fisher’s exact
test, Figure S1B) in the JAK3 mutated cohort (overview of tested associations is provided in Table S2).
Notably, T-PLL with any JAK or STAT mutation showed elevated TCL1A mRNA levels as compared to
patients without any JAK or STAT mutation (fold change (Fc) = 4.1, p = 0.01, Student’s t-test, Figure 3A),
further underlined by an increased proportion of cases harboring an inversion 14 (q11q32) in the STAT5B
mutated cohort (p = 0.03, Fisher’s exact test, Figure S1C). TCL1A mRNA levels were also elevated by just
considering JAK3 mutated cases (Fc = 6.5, p = 0.002, Student’s t-test, Figure S1D) or STAT5B mutated cases
(Fc = 3.6, p = 0.02, Student’s t-test, Figure S1E) compared to T-PLL without either mutation, respectively.
To assess the functional role of variants in JAK or STAT genes in T-PLL patients, we screened for significant
associations between somatic JAK/STAT SNVs and clinical data, including outcome. For these analyses,
we merged clinical information from nine studies [9–16,18]. As not all considered publications reported
the same set of parameters, cohort sizes varied between the different analyses. When investigating an
association of the JAK/STAT mutation status with overall survival, we did not observe differences in
OS of T-PLL patients harboring any JAK or STAT mutation compared to patients without JAK or STAT
mutation (p = 0.42, log rank test, Figure 3B). In contrast to studies of smaller cohorts [12,16], we could not
observe a significantly shorter OS of JAK3 mutated T-PLL patients (p = 0.26, log rank test, Figure S2A).
Similarly, the JAK3 M511 mutation was not associated with a shorter OS (p = 0.39, log rank test, Figure
S2B). The OS of patients without any JAK or STAT mutations was comparable to those harboring a STAT5B
(p = 0.55, log rank test, Figure S2C), STAT5B N642H (p = 0.60, log rank test, Figure S2D), or JAK1 (p = 0.54,
log rank test, Figure S2E) mutation. Interestingly, the JAK1 L653F mutation status was associated with a
significantly shorter OS (p = 0.003, log rank test, Figure S2F). In addition, cases with a STAT5B Y665F
mutation also showed a shorter OS (p = 0.06, log rank test, Figure S2G). However, only two patients with
a JAK1 L653F mutation or five patients with a STAT5B Y665F mutation were included in the ‘mutated’
cohorts, so these results should be interpreted with caution. We did not detect any other association of
clinical characteristics of T-PLL patients with the presence of JAK or STAT mutations (Table S3).
Figure 3. JAK/STAT mutation status shows association with elevated TCL1A mRNA expression, but
not with patient outcomes. (A) TCL1A mRNA expression measured by array-based gene expression
profiling (GEP) of JAK/STAT mutated cases compared to cases without any JAK or STAT mutation
(fold change: 4.1; p = 0.01, Student’s t-test). (B) Overall survival (OS) of JAK/STAT mutated cases
(median OS: 21.0 months) compared to cases without any JAK or STAT mutation (median OS: 25.5
months, p = 0.42, log rank test). Significant associations between mutations affecting JAK3 or STAT5B
with immunophenotypic, mutational, and expression data are displayed in Figure S1. Associations of
mutations affecting JAK1, JAK3, or STAT5B with OS are presented in Figure S2.
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2.5. T-PLL Cells Show Basal STAT5B Phosphorylation, Regardless of Their JAK/STAT Mutation Status
Even though STAT5B was shown to be predominantly affected in T-PLL in previous series,
its phosphorylation, and therefore activation state, was often not aligned with the genomic profiling
data [9–11]. By analyzing primary samples of eight T-PLL cases, we observed noticeable basal STAT5B
phosphorylation in every case (Figure 4A, no exposure to any culturing). We discovered no obvious
association between STAT5B phosphorylation and the presence of any JAK or STAT mutation.
Samples without JAK or STAT mutation showed similar levels of high basal phospho-STAT5B to
those that harbored such lesions, as already previously shown in a series of 6 T-PLL cases [9].
We further correlated the immunoblot data with alterations involving key regulators of STAT5B
activity (either mutations or CNAs). For this, we pre-selected a set of 105 genes encoding for
proteins known to regulate JAK/STAT signaling based on available literature (Table S4). We next
identified of these 105 genes 7 which showed recurrent genomic lesions in the overall T-PLL cohort
and which were reported to have a regulatory effect on STAT5B signaling in vitro or in vivo (Table S5).
Overall, we identified recurrent mutations or genomic losses of seven negative regulators potentially
leading to constitutive STAT5B activity (DUSP4, CD45, TCPTP, SHP1, SOCS1, SOCS3, and HDAC9) in
71.4% of analyzed T-PLL cases (n = 35/49 cases analyzed with WES/WGS and SNP array, Figure 4B).
About 68.4% of T-PLL cases that did not reveal a mutation in any JAK or STAT gene showed such a
CNA of a STAT5B signaling regulator. This resulted in a total of 89.8% of T-PLL cases that harbor a
genomic lesion potentially explaining constitutive STAT5B signaling (either genomic losses of negative
regulators, and/or mutations of JAK or STAT genes). Gene expression signatures (array-based) of cases
that harbor a genomic loss or a mutation of a negative regulator of JAK/STAT signaling (and that
lack a JAK or STAT mutation) were comparable to those of cases with a mutation in any JAK or STAT
gene (principal component analysis in Figure S4A). Both cohorts showed similar activation (as per
upregulated gene expression) of STAT5B target genes. All T-PLL with a mutation in a JAK or STAT
gene and 90% of patients with a mutation or loss in a negative JAK/STAT regulator (and without any
mutation in a JAK or STAT gene) showed overexpression of at least one STAT5 target gene. In contrast,
the frequency of overexpressed STAT5 target genes was significantly lower in T-PLL without a genomic
lesion potentially activating JAK/STAT signaling (60%, Figure S4B). In detail, DUSP4, CD45, SOCS3,
SHP1, and HDAC9 showed the highest prevalences of genomic losses with a higher frequency in T-PLL
cases without any JAK or STAT mutation (Figure 4C). In addition, we identified genomic gains of
STAT2 (n = 1/49 T-PLL), STAT3, (n = 5/49 T-PLL), STAT5A (n = 5/49 T-PLL), and STAT5B (n = 5/49
T-PLL). These lesions were detected only in combination with mutations of a JAK or STAT gene or with
genomic losses of a negative regulator of STAT5B signaling (Figure 4D).
Overall, we propose a model of constitutive JAK/STAT signaling induced by mutations of a
predicted gain of function (GOF) in JAK1, JAK3, and STAT5B genes and by copy-number losses of
negative regulators of STAT5B activity.
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Figure 4. T-PLL cells show basal STAT5B phosphorylation, regardless of their JAK/STAT mutation status.
(A) Elevated basal STAT5B phosphorylation levels of T-PLL cells. Controls: CD3+ pan T-cells isolated
from healthy individuals. ‘Loss of neg. reg.’: key regulators which negatively affect STAT5B activation
(namely DUSP4, CD45, TCPTP, SHP1, SOCS1, SOCS3, and HDAC; see (D) for case-wise depiction) were
considered based on available literature and based on data of their copy number alterations (CNA) in
T-PLL. (B) Distribution of genomic lesions affecting any JAK or STAT gene and their regulators (n = 49
cases analyzed with WES/WGS and with SNP arrays). Inner pie chart: distribution of JAK/STAT mutations.
Outer pie chart: Prevalence of genomic lesions of regulators activating JAK/STAT (either genomic losses of
negative regulators or genomic gains of positive regulators). An overall proportion of 89.8% of T-PLL
cases carried a genomic lesion potentially explaining constitutive STAT5B activation (mutation or CNA
of JAK/STAT regulator). (C) Prevalence of the five most common genomic lesions affecting negative
regulators of the JAK/STAT pathway (n = 49 cases analyzed with WES/WGS and SNP array): T-PLL cases
without any mutation in a JAK or STAT gene showed a higher prevalence of genomic losses of DUSP4,
CD45, and HDAC9 as compared to JAK/STAT mutated cases. (D) Mapped genomic events involving JAK
and STAT genes and their regulators (n = 49 cases analyzed with WES/WGS and SNP array). An overview
of genomic lesions resulting in a suggested activation of the JAK/STAT pathway across all considered
T-PLL cases is given in Figure S3.
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3. Discussion
Here, we present a comprehensive meta-analysis of primary data from 275 T-PLL cases from 10
published studies that evaluated genomic lesions involving elements of JAK/STAT signaling. In this
large cohort, we identified genomic aberrations potentially leading to constitutive JAK/STAT signaling
in approximately 90% of cases, thus establishing this as a molecular hallmark of T-PLL. Our analysis
provides an overview on the genomic causes of JAK/STAT signaling activation including JAK/STAT
GOF mutations as well as CNAs of JAK/STAT genes or negative regulators of JAK/STAT signaling.
About 62% of T-PLL cases showed GOF mutations affecting any JAK or STAT gene, while previous
publications reported a mutation frequency varying between 36% and 76% [10,18]. In accordance with
these studies, we predominantly detected missense mutations in the SH2 or pseudokinase domains
of JAK1, JAK3, and STAT5B, mostly occurring at a subclonal level. Mutations of genes encoding
for components of the JAK/STAT pathway are frequently found in T-cell neoplasms (predominantly
mutations of JAK3, STAT3, and STAT5B). Their reported incidences range from 10% (e.g., for Sézary
syndrome [29]) to 70% (e.g., for intestinal T-cell lymphoma [30]). Compared to those, the cumulative
mutation frequency of JAK and STAT genes in T-PLL documented in this meta-analysis is high [31].
Another important finding was the high basal phosphorylation of STAT5B in all analyzed T-PLL
samples. In addition to a high proportion of T-PLL cases mutated in any JAK or STAT gene, we identified
seven negative regulators to be commonly lost in T-PLL, potentially explaining cytokine-independent
STAT5B activation. This affected 71.4% of all cases and 68.4% of those cases without a detectable
JAK/STAT SNV. Of these negative regulators, DUSP4, SOCS3, and CD45 were most frequently affected.
While genomic losses of DUSP4 and SOCS3 were already reported in primary T-PLL [9,17,18], losses of
CD45 have not been described previously. Compared to CD4+ T-cells isolated from healthy individuals,
DUSP4 and CD45 mRNA was observed to be strongly downregulated in T-PLL cells [16]. Furthermore,
the downregulation of CD45 transcripts was associated with an increased phosphorylation of STAT5,
implicating a functional relevance of this negative regulator [17].
T-PLL cells usually show a complex karyotype and a high frequency of somatic CNAs [9,32].
In detail, the loci of the negative regulators DUSP4 (chr.8p12) and of SOCS3 (chr.17q25.3) are known to
be highly affected by structural aberrations in T-PLL. Therefore, a secondary origin of the detected
CNAs due to background imbalances has to be considered. T-PLL cases already harboring an activating
mutation of a JAK or STAT gene or a genomic loss of a negative regulator showed in few cases (12.2%)
also genomic gains of JAK or STAT genes, however, the functional impact of these genomic gains
remains unclear.
Certainly, there is the possibility of other, yet-unknown regulators, which we did not include in
our analysis. Furthermore, our analysis did not assess for epigenetic regulations or post-translational
modifications of JAK and STAT genes or their regulators, as further causes of active JAK/STAT signaling.
Moreover, constitutive T-cell-receptor or cytokine input of the malignant T-cell may represent other
modes of (milieu-derived) JAK/STAT activation in T-PLL.
Another important result of the provided meta-analyses is the first description of elevated TCL1A
in JAK and STAT mutated T-PLL. TCL1A overexpression is known to be associated with elevated
levels of reactive oxygen species (ROS) [33]. In addition, an 8-oxoguanine DNA damage signature
is characteristic for T-PLL, likely resulting from ROS-mediated DNA insults [9]. In this context,
the initiating oncogene TCL1A is likely to contribute to the occurrence of new mutations, especially
when the guardian of genome-integrity ATM is deleted or mutated, potentially explaining a higher
prevalence of arising subclonal JAK and STAT mutations in T-PLL. Furthermore, a possible explanation
for the association of reduced CD40L expression with the presence of JAK3 mutations is a state of
less T-cell receptor and cytokine dependent activation of T-PLL cells in the context of an acquired
hyperactivating mutation of a signaling intermediate such as JAK3.
In line with our finding, that nearly every T-PLL case presents with a genomic aberration that
potentially causes activated JAK/STAT signaling, we could not observe any differential association
of the JAK/STAT mutation status with clinical characteristics, i.e., those indicating a more aggressive
174
Cancers 2019, 11, 1833
phenotype of T-PLL cells. Previous studies on small cohorts have shown a negative influence of the
presence of JAK3 mutations on OS [12,16]. However, as these studies used JAK3 wild type T-PLL as a
control group, they potentially included patients with mutations of other JAK or STAT genes, therefore
not representing a proper control.
Although functional validations of the herein described genomic aberrations is outside the scope
of this work, mechanistic analyses of many of the detected genomic aberrations and of their impact on
tumorigenesis have been performed in various other entities. Such functional findings of mutations of JAK1,
JAK3, and STAT5B are summarized in the following (an overview of literature is provided in Table S5).
JAK1, the third most frequently mutated JAK or STAT gene in this meta-analysis, showed a
cumulative hotspot mutation rate of 6.3% in our analysis, in line with the mutation rates calculated in
previous studies. V658F, the most prevalent lesion affecting JAK1 in T-PLL, was initially described in
the development of T-ALL [34]. The V658F lesion is homologous to the JAK2 V617F mutation and
was shown to lead to constitutive active JAK1 signaling in a cell line model [35]. Cells harboring
the respective lesion presented enhanced basal JAK1, STAT5, and ERK phosphorylation and showed
cytokine-independent growth [36]. S7031 and L653F, less frequently detected JAK1 mutations, were also
proven to act as GOF mutations [37,38]. While the S703I mutation was shown to mediate proliferative
effects in vitro and in vivo, the L653F mutation is predicted to soften the negative regulation of
JAK1 in a biophysical model. The JAK1 V617F, S703I, and L653F mutations potentially mediate
cytokine-independent phosphorylation of STAT5B in T-PLL.
JAK3 mutations were the most recurrent genomic aberration affecting JAK/STAT genes in this
meta-analysis with a hotspot mutation rate of 36.4% (literature: 21% [12]–71% [17]). The oncogenic
potential of the most frequent JAK3 mutation M511I as well as the less frequently occurring mutations
A573V and V674A was shown in various systems: M511I, A573V, as well as V674A mutant cell
lines demonstrated high phosphorylation of STAT5 and ERK, leading to cytokine independent
growth [39,40]. When transplanting mice with bone marrow progenitor cells harboring the M511I
or A573V mutation in JAK3, they develop a T-ALL-like disease, characterized by an expansion of
immature CD8+ T-cells. In contrast, mice transplanted with V674A mutant bone marrow progenitor
cells presented severe lymphadenopathy and splenomegaly without a significant increase of the WBC
count [41]. The mentioned JAK3 mutations were also described in T-ALL [42]. The Q507P mutation, the
third most frequent genomic aberration affecting JAK3 in T-PLL, was not discovered in other entities
and has so far not been investigated for its functional relevance.
In this analysis, 18.8% of T-PLL cases were mutated within the hotspot region of STAT5B,
while the mutation rate in the literature varied from 7% [16] to 36% [10]. The most frequently found
N642H mutation is a well described GOF mutation: STAT5B N642H transduced cell lines showed
prolonged phosphorylation and dimerization of STAT5B, resulting in an enhanced transcriptional
activity [43,44]. The N642H mutation leads to a sustained stability to the anti-parallel dimer as shown by
crystallization [45]. Transgenic mice harboring the STAT5B N642H lesion rapidly developed aggressive
CD8+ T-cell neoplasms [46]. The STAT5B Y665F mutation, which had a notable influence on OS of T-PLL
patients in our analysis, revealed highly phosphorylated STAT5B, an enhanced transcriptional activity
and increased proliferation in a cell culture model, comparable to the STAT5B N642H mutation. The
above-mentioned genomic aberrations, which have also been described in the mutational landscape of
T-LGL [47], may play an important role in the activation of JAK/STAT signaling in T-PLL. The functional
role of the second most detected STAT5B aberration, the T628S mutation, is much less established. This
genetic aberration is previously described in hepatosplenic T-cell lymphoma and associated with an
increased phosphorylation of STAT5 in a cell line model [48]. Notably, the three commonly affected
JAK/STAT genes (JAK1, JAK3, STAT5B) are crucial for IL-2 signaling, the cytokine secreted at highest
levels in T-PLL [49]. Targeted approaches in appropriate models have to address the chronological role
of such lesions as most of them were detected at subclonal levels.
Given that nearly every T-PLL case harbors a genomic aberration potentially activating JAK/STAT
signaling, JAK and STAT proteins are clinically relevant targets for T-PLL therapy [50]. Interestingly,
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in a large panel of blood cancers, primary T-PLL patient cells showed high sensitivity towards
JAK-targeting compounds. Moreover, JAK inhibitors were among the top 25 most effective drugs in an
ex vivo drug screen of 39 T-PLL patient samples exposed to 301 different substances [15,16]. Previous
case reports also showed the initial promising results of a combination therapy of the JAK inhibitors
ruxolitinib (JAK 1/2 inhibitor) and tofacitinib (pan JAK inhibitor) [27,28]. However, previous studies
have also argued that the JAK/STAT mutation status alone does not predict ex-vivo sensitivity towards
JAK inhibitors [16]. This is in line with the observation of multiple, potentially distinct mechanisms,
apart from missense mutations of JAK/STAT genes, that are required for activating this pathway.
In general, predicting sensitivity of kinase inhibitors often requires larger panels of biomarkers, some
of which may be outside of the target pathways or direct drivers of the disease. Therefore, therapeutic
targeting of JAK/STAT signaling has to be expanded on various levels, including the development
of novel STAT3/5 inhibitors and the extension of pre-clinical and clinical studies to large cohorts
of T-PLL and other T-cell lymphomas, all with well-characterized tumor material (e.g., JAK/STAT
activation state). Selective STAT5 inhibitors which bind to the SH2 domain of STAT5 are currently
under development [51].
4. Materials and Methods
4.1. Data Acquisition
Available literature was systematically screened for all genomic profiling studies that have
information on the mutational status of any JAK or STAT gene in T-PLL, regardless of the sequencing
technique. We identified a total of 10 publications meeting these criteria (Table S6). Raw data of these
publications was obtained from different sources, either publicly available or kindly provided by the
corresponding authors. Full descriptions of the composed data set and detailed information on the
sources of data are provided in Table S6. Considered T-PLL patients had provided written informed
consent and all the studies were originally approved by their institutional review boards.
4.2. Data Merging
Considering the rarity of T-PLL and the strong collaboration network in T-PLL research,
we assumed a pronounced exchange of patient samples between different centers and studies.
To determine all redundantly analyzed patients in our cohort, we requested basic patient information
to allow us to precisely identify potential overlaps while still ensuring anonymity of all the patients
(Figure 1A). In cases where genomic regions were sequenced by different methods, we included the
information provided by the widest type of analysis, ranking WGS >WES > TAS > Sanger sequencing.
In total, 275 distinct T-PLL patients were included in our analyses.
4.3. Raw Data Analysis
Data acquired through whole-exome sequencing and SNP-array analysis was re-analyzed for
those cases in which raw data was available, while data obtained through Sanger sequencing or
targeted amplicon sequencing was not re-analyzed. Studies where raw data was not available were
included by applying the already analyzed data. Detailed information on the data sources are listed
in Table S6 and on the applied tools with references in Table S7. The below subsections describe the
various genomic analyses performed for the meta-analysis.
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4.3.1. Whole-Exome Sequencing (WES)
The sequenced raw exome reads were trimmed of B blocks from the end using Trimmomatic
(RWTH Aachen, Aachen, Germany). The trimmed data were aligned to the human reference
genome (GRCh build 37) using Burrows Wheeler Aligner (bwa-0.7.12, Wellcome Trust Sanger
Institute, Cambridge, UK). After alignment the potential PCR duplicates were removed using Picard
(Broad Institute of Harvard and MIT, Cambridge, MA, USA), and BAM files were generated, sorted,
and indexed using SAMtools (Wellcome Trust Sanger Institute, Cambridge, UK). Exomic regions were
re-aligned and the base quality scores were re-calibrated according to the Genome Analysis Toolkit Best
Practices recommendations (GATK 4.1.3.0). VarScan2.2.3 (The Genome Institute, St. Louis, MO, USA)
was used to call somatic mutations with the following parameters: strand-filter 1, min-coverage-normal
8, min-coverage-tumor 6, somatic-p-value 0.01, min-var-freq 0.05. The putative somatic mutations
were annotated for functional consequences using SnpEff 4.03 (Institute of Environmental Health
Sciences, Detroit, MI, USA). Variants present in 1000 genome or dbSNP 2.0 Build were filtered out from
the analysis.
In order to call somatic single-nucleotide variants in 38 patients without matched germline
samples, MuTect v2 (Broad Institute of Harvard and MIT) was employed with default parameters.
Because we were mostly interested in identifying sequence variants that were likely to contribute to
T-PLL pathogenesis, we focused on those variations that were identified in our analysis of 22 patients
with matched healthy control samples. Only these filtered mutations have been reported for the
patients without matched germline samples.
4.3.2. Somatic Copy-Number Alterations (sCNAs)
Genotyping of Affymetrix GenomeWide SNP6 array (Thermo Fisher Scientific, Waltham, MA,
USA) was performed using Genotype Console Software 4 (GTC4, Thermo Fisher Scientific) with the
default parameters using Birdseed v2 algorithms (Broad Institute of Harvard and MIT). In order
to infer copy number variations in the T-PLL genome, we used the pooled controls as a reference
(non-tumor hematopoietic cell DNA as ‘germline’ from T-PLL patients, n = 13) created using the
GTC pipeline. The Canary algorithm was used to call CN state using the default settings in GTC.
We performed segmentation analysis on the basis of identified SNPs/CNVs using inbuilt algorithm.
Copy number values and segmentation were visually assessed in the Integrative Genomics Viewer
(Broad Institute, Cambridge, MA, USA). Since the segmentation algorithm only reports significantly
altered segments/regions, we mapped identified genomic regions to genes based on version 75 of the
Ensembl annotation using BiomaRt (version 2.38 and the GenomicRanges R package, version 1.34.0).
4.3.3. Gene Expression Profiling (GEP)
The processed normalized expression profiles generated with GenomeStudio were downloaded
from GEO. Data were merged and adjusted for batch effects using linear regression. A differential
expression analysis was performed using Student’s t-test on expression values of patients and healthy
controls (CD3+ pan T-cells from 10 healthy donors). The differentially expressed probes were mapped
to the respective genes by Illumina provided annotation files. Principal component analysis of the
whole gene expression set was performed with R.
177
Cancers 2019, 11, 1833
4.4. Clinical Data and Statistical Analyses
All publications were screened for accompanying clinical data and authors were contacted for
further information. In total, we obtained and merged clinical data from nine publications [9–16,18].
For patients who were reported in multiple studies, we included the most detailed clinical data set.
To assess possible correlations between mutational status and clinical phenotypes, we performed
a screening approach testing for a broad range of parameters (Table S3), where the patients were
stratified by overall mutational status, mutational status of specific genes, and by specific mutations.
As a control, we used clinical data from T-PLL patients, who were unmutated in all JAK/STAT genes
analyzed with WES/WGS.
All statistical analyses were performed using R software and R packages (Table S7). Analysis of
overall survival, as measured from day of diagnosis until day of event or censoring, was performed
and graphed with R survival and R survminer packages. Log rank statistics were calculated to
test for differences in survival distributions. Continuous clinical parameters were tested for normal
distribution with Shapiro–Wilk test and further assessed for their associations to JAK/STAT mutational
status with either Student’s t-test or Wilcoxon rank sum test, depending on the normality test. Fisher’s
exact test was used for testing differences in categorical data in patients with JAK/STAT mutations
compared to unmutated patients. A p < 0.05 was considered to be statistically significant.
4.5. Immunoblots
We performed Western blots of whole-cell lysates of primary T-PLL cells and CD3+ pan T-cell
isolated from age matched healthy controls by magnetic-bead based cell enrichment. Positive selection
of CD3+ pan T-cells of healthy controls was performed according to the manufactures instruction
(Biolegend). Following antibodies from Cell Signaling Technology were used in a 1:1000 dilution
according to the manufacturer’s instruction: phospho-STAT5TYR694 (clone C11C5, catalogue #9359),
STAT5 (polyclonal, #9363), and GAPDH (clone 14C10, #2118). As a secondary antibody we made use
of HRP-coupled anti-rabbit (Dianova) in a 1:5000 dilution. Immunoblots were done using Western
Bright ECL (Advansta, Menlo Park, CA, USA) and luminescence intensities were evaluated by
densitometry (ImageJ software, National Institute of Health, Bethesda, MD, USA). Uncropped images
of the immunoblots are displayed in Figure S5.
4.6. Data Accessibility
All genomic data analyzed in this study was gathered from published series. For detailed sources
of raw data and/or information on JAK/STAT mutations, see Table S6.
5. Conclusions
Overall, this meta-analysis provides an overview of the lesional landscape of JAK/STAT associated
genes in the largest cohort of T-PLL cases to date and summarizes the potential functional impact of the
most common genomic aberrations. Nearly every T-PLL case in our cohort had a genetic aberration,
which can be intuitively implicated in constitutively active JAK/STAT signaling. Besides GOF missense
mutations in JAK/STAT genes, genomic losses of negative regulators of the JAK-STAT signaling axis
are frequently found in T-PLL, linking the high basal phosphorylation of STAT5B to genomic causes.
We propose a model for these distinct mechanisms implicated in constitutive STAT5B signaling in
T-PLL (Figure 5). Our data provide a rational framework for strategies to inhibit JAK/STAT signaling in
T-PLL, even in patients whose leukemia does not carry mutations in a JAK or STAT gene. Development
of novel STAT inhibitors and their application, including with synergistic partners, in model systems
and in T-PLL patients, represent future tasks.
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Figure 5. Proposed model of recurrent genomic lesions leading to an enhanced activation of STAT5B in
T-PLL. Regulatory network summarizing detected genomic lesions (sCNAs, mutations) in JAK/STAT
genes and their direct regulators. Mutations of JAK and STAT genes and genomic losses of negative
STAT5B regulators being affected in more than 5% of T-PLL patients were included. Frequent missense
mutations occur in the JH2 and SH2-JH2 linker of JAK1 and JAK3, potentially leading to elevated
phosphorylation and dimerization of STAT5B. Activation of JAK1 and JAK3 is potentially enhanced
through genomic losses (DUSP4, SOCS1, SOCS3, CD45, SHP1, HDAC9, and TCPTP) and mutations
(HDAC9) of negative regulators. STAT5B activation might be further increased through GOF mutations
in its SH2 domain. Cytoplasmatic (SHP1, TCPTP) as well as nuclear (DUSP4, HDAC9) regulators are
commonly affected by genomic losses in T-PLL, leading to intensified STAT5B signaling. Constitutive
active STAT5B translocates into the nucleus and regulates transcription of many target genes relevant
for T-cell development, differentiation, proliferation, migration, and apoptosis [52].
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Abstract: Peripheral T-cell lymphomas (PTCL) are a heterogeneous, and often aggressive group of
non-Hodgkin lymphomas. Recent advances in the molecular and genetic characterization of PTCLs
have helped to delineate differences and similarities between the various subtypes, and the JAK/STAT
pathway has been found to play an important oncogenic role. Here, we aimed to characterize the
JAK/STAT pathway in PTCL subtypes and investigate whether the activation of the pathway correlates
with the frequency of STAT gene mutations. Patient samples from AITL (n = 30), ALCL (n = 21) and
PTCL-NOS (n = 12) cases were sequenced for STAT3, STAT5B, JAK1, JAK3, and RHOA mutations
using amplicon sequencing and stained immunohistochemically for pSTAT3, pMAPK, and pAKT. We
discovered STAT3 mutations in 13% of AITL, 13% of ALK+ ALCL, 38% of ALK− ALCL and 17% of
PTCL-NOS cases. However, no STAT5B mutations were found and JAK mutations were only present
in ALK- ALCL (15%). Concurrent mutations were found in all subgroups except ALK+ ALCL where
STAT3 mutations were always seen alone. High pY-STAT3 expression was observed especially in
AITL and ALCL samples. When studying JAK-STAT pathway mutations, pY-STAT3 expression was
highest in PTCLs harboring either JAK1 or STAT3 mutations and CD30+ phenotype representing
primarily ALK− ALCLs. Further investigation is needed to elucidate the molecular mechanisms of
JAK-STAT pathway activation in PTCL.
Keywords: lymphoma; T-cells; STAT3; RHOA; NGS
1. Introduction
Peripheral T-cell lymphomas (PTCLs) form a heterogeneous, uncommon, and often aggressive
group of non-Hodgkin’s lymphomas (NHL) representing approximately 10–15% of all new NHL
diagnoses [1]. The most prevalent PTLCs are PTCL not otherwise specified (NOS), angioimmunoblastic
Cancers 2020, 12, 702; doi:10.3390/cancers12030702 www.mdpi.com/journal/cancers183
Cancers 2020, 12, 702
T-cell lymphoma (AITL), anaplastic lymphoma kinase–negative (ALK− ALCL), and anaplastic
lymphoma kinase-positive anaplastic large cell lymphoma (ALK+ ALCL) [2,3].
Despite generally favorable response rates to chemotherapy, remissions are often not durable,
and as such the natural history of PTCL is characterized by relapses and refractory disease. For this
reason, upfront hematopoietic stem cell transplantation (HSCT) is often recommended in first remission
for patients who are fit and have chemo-sensitive disease [4]. For patients who are not suitable for
transplantation, chances of long-term disease control are very limited, with an average progression-free
survival (PFS) of 5.5 months [5]. In this setting, optimal therapeutic approaches remain undefined
representing an unmet clinical need.
Recent advances in the molecular and genetic characterization of PTCL have helped to delineate
differences and similarities between the various subtypes [6]. Several recurrent mutations have been
identified in small subsets of patients potentially enabling more accurate disease classification and
guide treatment decisions. In AITL, the three most commonly identified genetic lesions occur in the
Tet methylcytosine dioxygenase 2 gene (TET2), the Ras homolog gene family, member A (RHOA),
and the isocitrate dehydrogenase 2 gene (IDH2). Besides AITL, TET2 mutations can be seen with
a high frequency also in PTCL-NOS with a T follicular helper cell phenotype [7]. RHOA, a small
GTPase participating in T-cell activation and polarization, has recently been found to have a specific
G17V mutation in 68% of AITL cases [8], predominantly in the background of TET2 mutations.
The overwhelming majority of IDH2 mutations in PTCL affect the R172 residue [9]. However, STAT3
mutations are relatively uncommon (5%) in AITL [10].
In ALK+ ALCL, the ALK chimeras activate STAT3, thus maintaining the neoplastic phenotype in
ALK+ ALCL. In concordance with this, gene expression profiling has revealed a transcriptional gene
signature including ALK, TNFRSF8 (CD30), MUC1, Th17-associated genes (IL-17A, IL-17F, and ROR-γ),
a small group of immunoregulatory cytokines and receptors regulating STAT3 pathway [11].
A systematic characterization of the genetic alterations driving ALCL was recently undertaken
using sequencing strategies. Activating mutations of JAK1 and STAT3 genes were found in 20%
of ALK− ALCLs, 38% of which displayed double lesions [12]. As the JAK/STAT pathway has a
critical role in hematopoietic development, it is not surprising that it plays, when deregulated, an
important oncogenic role in lymphoproliferative malignancies [13]. Many cancers and hematologic
malignancies have been associated with the constitutive activation of the STAT family of proteins, which
depends on JAK-mediated tyrosine phosphorylation for transcriptional activation [14]. In particular,
activated JAK1/STAT3 and JAK2/STAT5 have been shown to facilitate T-cell transformation [15,16].
Activating mutations of JAK1-3 and STAT3-5 have also been found in a subset of NK/T-cell lymphomas,
non-hepatosplenic gamma-delta T-cell lymphoma, large granular lymphocytic leukemia and T-cell
prolymphocytic leukemia [10,17–22].
Here, we aimed to further characterize the JAK/STAT pathway in PTCL by investigating whether
the activation of the pathway quantified with immunohistochemistry correlates with the frequency
of JAK, STAT, and RHOA mutations. In addition, we associated JAK-STAT pathway activation with
prognosis and essential clinical and pathological parameters. Finally, we identified novel therapeutic
approaches for patients with high STAT3 phosphorylation using Reverse Phase Protein Array and
drug sensitivity data from the Broad Institute Cancer Cell Line Encyclopedia (CCLE).
2. Results
2.1. STAT3 Mutations Are Frequent in PTCLs
As STAT3 is constitutively expressed in both AITLs and ALCLs, we sequenced for STAT3 and
STAT5B mutations. The entire STAT3 gene and the hotspot SH2-domain of STAT5B were screened by
targeted amplicon sequencing in 63 patients with T-cell lymphoma. We discovered that 13% of AITL
and ALK+ ALCL cases harbored STAT3 mutations, while 17% of PTCL-NOS cases were found to harbor
STAT3 mutations (Table 1). The highest frequency of STAT3 mutations was found in the ALK− ALCL
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subgroup (38%). The frequency of STAT3 mutations in the entire patient cohort was 19%. While most
mutations were found in the SH2-domain of STAT3, we observed one K290T mutation in the coiled
coil domain and three patients harbored a P715L mutation in the transactivation domain (Figure 1
and Table S1). The most prevalent mutation type was the P715L mutation and the E616 deletion,
which were identified in three patients each. No STAT5B SH2-domain mutations were identified in this
cohort. JAK1 mutations were found in two ALK− ALCL patients (15%). Both mutations (G902R and
G1097C) were seen in the protein tyrosine kinase domain of JAK1. No JAK3 mutations were detected
in any subgroup.











AITL 30 13% 0% 70% 10%
NOS 12 17% 0% 17% 8%
ALK+ ALCL 8 13% 0% 0% None
ALK− ALCL 13 38% 15% 0% 8%
All 63 19% 3% 37% 8%
 
Figure 1. STAT3 structure and mutation sites in ALCL, AITL, and PTCL-NOS patients of the study cohort.
As RHOA mutations are highly prevalent in AITL and have been found to cause activation of
the MAPK/PI3K/AKT pathway and T cell receptor signaling, the hotspot mutation G17V was also
screened [23,24]. The results showed that these mutations were frequent in AITL (70%) and PTCL-NOS
(17%) but remained absent in ALCLs (Table 1). Some cases harbored both STAT3 and RHOA mutations
(10%). DNA samples from nodular lymphocyte predominant Hodgkin lymphoma with abundant
follicular T helper cells (n = 13), were also available for STAT3/STAT5B and RHOA screening but no
mutations were detected in these samples.
2.2. STAT3 Phosphorylation Levels Are Highest in ALK+ and ALK− ALCL Cases
To characterize JAK-STAT pathway activation, we stained for pY-STAT3, pMAPK, and pAKT
in AITL (n = 29), ALCL (n = 20) and PTCL-NOS (n = 12) patients and control lymph nodes (n = 4)
using immunohistochemistry (Supplementary Figure S1). The differences between disease groups
were significant notably for phosphorylation of pY-STAT3 and recapitulated well previous reports [25].
Further post-hoc analysis showed that pY-STAT3 was shown to be more frequently phosphorylated in
AITL (mean = 43.7%) and ALCL (ALK−: mean = 62.3%, ALK+: mean = 79.7%) patients compared to
control lymph nodes (mean 12.6%; Figure 2).
MAPK phosphorylation was significantly elevated in AITL patients (mean 10.5%) followed by
ALK− ALCL (mean 6.8%) and PTCL NOS (5.2%) when compared to control lymph node (Figure 2).
No significant difference in pAKT levels between PTCL patients and control lymph nodes was observed.
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Figure 2. Phosphorylation percentage of pY-STAT3, MAPK, and AKT in PTCL subgroups and healthy
controls (n = 2–3) analyzed by immunohistochemistry. Individual dots represent the proportion of
positive cells for pSTAT3, pMAPK, and pAKT. Boxplots represent the median and interquartile range
of protein phosphorylation levels. The antibodies used were specific for Tyr705 (pStat3), Thr202/Tyr204
(pMAPK), and Thr450 (pAKT). Comparison was analyzed with ANOVA and post-hoc tests between
disease groups and healthy controls. *: p < 0.05; **: p < 0.01, ****: p < 0.0001; ns: not significant.
To confirm the findings and study STAT3 activation in other T cell malignancies, we measured
STAT3 and pY-STAT3 levels by Western blotting in ALCL, acute T-lymphoblastic leukemia (T-ALL),
NK/T-cell lymphoma (NKT), T-cell large granular lymphocyte leukemia (T-LGL), and PTCL cell lines
(Figure 3). We confirmed high phosphorylation of pY-STAT3 (Tyr705) in ALCL but not in other T cell
malignancies. Total STAT3 was most prominent in PTCL, ALCL and T-ALL cell lines. High JAK3
phosphorylation was observed in SupM2, Karpas299 and TLRB1 (ALCL) as well as NKL (NKT) cell
lines and was not associated with pY-STAT3 phosphorylation.
To further investigate the association of protein expression to transcriptome data, we compared the
JAK1, JAK3, AKT, and MAPK RNA level expression with STAT3 RNA level expression and pSTAT3Tyr705
phosphorylation defined with reverse phase protein arrays (RPPA) from the CCLE database (Figure S2).
Both STAT3 expression (535 vs. 198 CPM p = 0.003, t-test) and phosphorylation (3.6 vs. −0.10 RPPA unit,
p < 0.001) were observed to be superior in ALCL than non-ALCL malignant T-cells as shown in Figure 2.
Higher JAK3 expression was noted in ALCL over non-ALCL lines (364 vs. 53 CPM, p < 0.001), and
correlated with STAT3 expression (r = 0.60, p = 0.01). Moreover, higher MAPK expression was detected
in ALCL over non-ALCL cell lines (127 vs. 68, p = 0.05), which correlated with STAT3 expression (r =
0.65, p = 0.006). No correlation between STAT3 and JAK1 or AKT expression was observed.
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Figure 3. Western blot of p-STAT3 (Tyr705), STAT3, p-JAK3 (Tyr980/981), and JAK3 was characterized
in T cell malignancy cell lines. Beta-ACTIN is used as a reference protein.
2.3. STAT3 Phosphorylation Is Associated with JAK1/STAT3 Mutation Status in CD30+ ALK− ALCLs
Next, we studied whether STAT3 mutations would be associated with STAT3, MAPK, and AKT
phosphorylation. No association between STAT3 mutation status and pY-STAT3, pMAPK, or pAKT (%)
expression was noted when studying all PTCL subtypes (Figure 4A). No association with pY-STAT3
phosphorylation was noted even after adjusting with tumor proportion (mean pSTAT3 77% vs. 66%
in STAT3 mutated vs. non-mutated PTCLs). Most of the mutations were noted in relatively low
variant allele frequencies (VAF 5–9%), which might in part explain the lack of correlation. Further
evidence for this observation was found from cell line data, as the four ALCL cell lines in Figure 2
exhibit high pY-STAT3 phosphorylation but only one of the cell lines harbored a JAK/STAT mutation
(Table S1). The TLBR1 cell line represents ALK− ALCL and harbors a known activating STAT3 missense
mutation S614R in the SH2 domain [26]. The other ALCL cell lines expressed ALK, which explains the
constitutive STAT3 activation. Both T-ALL cell lines MOLT4 and Jurkat also harbor missense STAT3/5B
mutations but conversely, the cell lines did not exhibit any pY-STAT3 phosphorylation. This could be
explained by the mutations being localized elsewhere than in the activating SH2-domain.
Some PTCL cases harbored both STAT3 and RHOA mutations (8%). Our results showed that the
MAPK phosphorylation degree was higher in patients with RHOA mutations than patients without
RHOA mutations (RHOA-positive mean = 12.4% vs. RHOA-negative mean 5.7%, p = 0.005, t-test;
Figure 4B). Yet, RHOA mutation was not observed to be associated with STAT3 or AKT phosphorylation.
Phosphorylated STAT3 has been shown to induce CD30 expression in PTCL [27]. In addition,
STAT3 mutations are more frequent in CD30+ than CD30− T-cell lymphomas [28]. Therefore, we
sought to investigate the interaction between mutations in the JAK-STAT pathway, CD30 phenotype
and pY-STAT3 phosphorylation. Positive CD30 tumor phenotype was associated with higher STAT3
and AKT phosphorylation, but not with pMAPK (Figure S3A). Interestingly, pSTAT3 expression was
highest in samples with CD30+ tumors and simultaneous mutation in STAT3 or JAK1 (Figure 4C). This
phenotype was represented primarily by the ALK− ALCL subtype (p < 0.001, chi2 test, Figure 4D),
and their pSTAT3 expression (mean 68.7%) to stand above the mean of ALK− (62.3%) but below ALK+
ALCL (79.7%). We observed that 50% (6/12) of CD30+ ALK− ALCLs harbored a mutation in JAK1
or STAT3. Higher JAK1/STAT3 VAF trended for higher pY-STAT3 phosphorylation but the result
remained non-significant possibly due to sample size (81.3% vs. 61.1% mean pSTAT3 expression in
tumors with high (n = 4) vs. low (n = 4) JAK1/STAT3 VAF p = 0.22, t-test). Unexpectedly, lowest STAT3
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phosphorylation was observed in CD30− patients with a STAT3 gene mutation. Interestingly, all three
in-frame E616 deletions were found in CD30− AITL cases.
 
Figure 4. Comparison of the phosphorylation level of (A) STAT3, MAPK, and AKT by STAT3 mutation
status and by (B) RHOA mutation status (t-test). The phosphorylation level of pStat3 (Tyr705), pMAPK
(Thr202/Tyr204) and pAKT (Thr450) was measured by immunohistochemistry. (C) Combinatory effect
of CD30 phenotype and JAK1 or STAT3 mutation status on pSTAT3 expression was studied with
one-way ANOVA and post-hoc correction. Green dots correspond to patients with STAT3 mutations,
the red dot correspond to a patient with JAK1 mutation and blue dots correspond to samples without
mutations in JAK1 or STAT3. (D) Frequency table of patients by CD30 phenotype and JAK1 or STAT3
mutation status (rows) and different PTCL histologies (columns). *: p < 0.05; ns: not significant.
EBV status has been shown to be associated with STAT3 activation in B cell lymphomas [29].
No associations between STAT3, MAPK, and AKT phosphorylation and EBV+ tumors could be
observed in our PTCL cohort (Figure S3B).
As fixation rate differs in samples of various origin and size, we investigated their association
with STAT3, MAPK, and AKT phosphorylation. The sample cohort included 9 biopsy samples and 52
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excised tumors. Biopsy samples were associated with higher pY-STAT3 but not with MAPK or AKT
phosphorylation (Figure S4A). Moreover, correlation between pY-STAT3 and sample size remained
non-significant (Figure S4B). Therefore, we hypothesize the difference to be due primarily to biological
rather than technical reasons. Except for four samples, the sample cohort consisted of lymph node
tissue samples. AKT phosphorylation was higher in lymph node samples, while no difference was
observed between pY-STAT3 and MAPK phosphorylation levels (Figure S4B).
To further elucidate the spatial localization of STAT3 phosphorylation, 6 T-cell lymphoma samples
(5 AITL, and 1 ALCL) and 2 NLPHL samples were stained for pY-STAT3, PD1, CD4, and CD8 using
multiplex immunohistochemistry. Of the 5 AITL samples, two harbored STAT3 mutations at 5% and
7% VAF, respectively. We found that the staining pattern or level of pY-STAT3 phosphorylation was
not associated with STAT3 mutation status (Figure 5).
 
Figure 5. IHC stainings of four angioimmunoblastic T-cell lymphoma (AITL) lymph node samples.
(A). Samples containing low amount of pSTAT3. (B). Samples containing high amounts of pSTAT3.
Each slide has been digitalized with a 20× lens and similar exposure time per channel. Images have
been further magnified 30× for visualization purposes. The first four rows of images represent single
stainings of dapi counterstain, CD4, PD1, and pSTAT3 (Tyr705), respectively, and the last figure their
composite image. Staining: red = CD4, blue = PD1, green = pSTAT3.
2.4. High pY-STAT3 Expression Is Associated with CD3− CD5− CD7− CD30+ Immunophenotype Common
to ALCL
To understand the association of JAK-STAT signaling pathway activity with clinical determinants,
we combined pY-STAT3, pMAPK, and pAKT proportion defined by IHC with information on PTCL
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disease histology, stage, peripheral blood lactate dehydrogenase (LD) level at diagnosis, survival status,
STAT3 and RHOA mutation status (Figure 6). We noted that pY-STAT3, pMAPK, and pAKT expression
did not correlate with each other. High pY-STAT3 expression was noted to be associated with ALCL
histology as presented before (Figure 2). No association with survival status (p = 0.17, t-test), disease
stage (p = 0.40, one-way ANOVA), LD level (r = -0.13, p = 0.31, Pearson correlation), STAT3 (p = 0.56,
t-test) or RHOA mutation status (p = 0.11, t-test) was noted.
 
Figure 6. Heatmap visualizing the quantity of pY-STAT3, pMAPK, and pAKT and their association with
clinicopathological parameters. The amount of phosphorylated STAT3, MAPK, and AKT have been
median-centered and max-scaled, and organized columnwise by pY-STAT3 quantity and rowwise by
hierarchical clustering using Spearman correlation distance and Ward linkage (ward.D2) method. Red
color denotes higher and blue color lower proportion. Clinical parameters denoting disease histology,
disease stage, log10-transformed lactate dehydrogenase (LD) level, survival status, and STAT3 and
RHOA mutation status are added as annotations over the heatmap. CD3, CD4, CD5, CD7, CD8, and
CD30 immunophenotype status classified as positive or negative, EBV seropositivity and the MIB
proliferation index (%) are presented below the heatmap.
To correlate the expression of the JAK-STAT signaling pathway with immunohistochemical
and serological factors of disease pathology, we investigated EBV seropositivity, and expression
of immunophenotype markers as defined with IHC (Figure 6). Lower pY-STAT3 expression was
associated with negative CD3 (37.7% and 75.4% mean pSTAT3 expression, p < 0.001, t-test), CD5 (42.8%
and 68.4%, p = 0.03, t-test), CD7 (45.2% and 64.6%, p = 0.01) and positive CD30 phenotype (Figure
S4A) designating ALCL immunophenotype as reported in Figure 2 [30]. No association with EBV
seropositivity (Figure S4B), CD4 (p = 0.86, t-test) or CD8 (p = 0.35, t-test) immunophenotype nor MIB
proliferation index (r = 0.20, p = 0.19, Pearson correlation) was noted.
2.5. Novel Potential Inhibitors of STAT3 Activation
In myeloproliferative neoplasms the JAK-STAT signaling pathway can be inhibited with the
JAK1/JAK2 inhibitor ruxolitinib and in rheumatoid arthritis with less selective JAK inhibitors such
as tofacitinib and baricitinib [31]. Several other pharmacological compounds affecting the JAK-STAT
pathway are currently investigated in clinical trials [31]. We hypothesized that drugs investigated for
other indications might induce differential sensitivity in cancer cell lines with active JAK-STAT signaling.
By comparing cytotoxicity measured by the area under the curve (AUC) of 265 investigational and
accepted compounds in pSTAT3 high (n = 27) and low (n = 583) cancer cell lines reported in the Sanger
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GDSC and CCLE databases respectively, we identified the JAK-STAT inhibitor ruxolitinib to be more
potent in pSTAT3 high cell lines (Figure 7). Interestingly, we discovered also the cell cycle checkpoint
kinase Chk1/2 inhibitor AZD7762, the poly ADP ribose polymerase (PARP) inhibitor talazoparib and
the nucleoside analog gemcitabine to exhibit most sensitivity in pSTAT3 cell lines.
 
Figure 7. Differential drug sensitivity in pSTAT3 high (n = 27) and low (n = 583) cancer cell lines. The
pSTAT3 phosphorylation level has been quantified with reverse phase protein array (RPPA, cut-off
pSTAT3Tyr705 = 1). The drug sensitivity data represent the area under the curve (AUC) response of
265 different phamacological compounds, and has been retrieved from the Sanger GDSC dataset. The
RPPA data are derived from the Broad Institute the Cancer Cell Line Encyclopedia (CCLE) database.
Differential drug sensitivity has been computed with multiple T-tests, and the fold change defined
as the mean AUC ratio in pSTAT3 high-to-low cell lines. Drugs with a fold change (FC) less than 1.0
are more sensitive in pSTAT3 high cell lines. The target pathway of the top pharmacological hits have
been color-labeled.
3. Discussion
PTCL patients face unfavorable prognosis as chemotherapy results in poor 5-year overall survival
rates [32]. Targeted treatment options only exist for ALK+ ALCL, but are urgently needed for other
PTCL entities. Using targeted sequencing, we demonstrated that STAT3 alterations are prevalent in all
PTCL subgroups. We discovered that 13% of AITL and ALK+ ALCL cases and 17% of PTCL-NOS cases
harbored STAT3 mutations. The highest prevalence of STAT3 mutations was seen in ALK− ALCL (38%).
The mutations were found mostly in the SH2-domain of STAT3 but also in the coiled coil (K290T) and
transactivation domains (P715L). While we observed no association between overall STAT3 mutation
and pY-STAT3 phosphorylation, pY-STAT3 phosphorylation was most elevated in PTCL patients with
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combined CD30+ tumor phenotype and mutations in either STAT3 or JAK1 representing primarily
ALK− ALCLs and suggesting heterogenous mechanisms of STAT3 activation. Unexpectedly, PTCLs
with CD30- phenotype and STAT3 mutation were associated with lowest pY-STAT3 phosphorylation.
As CD30 transcription is regulated by pSTAT3, the result might be explained by non-activating
mutations or interference in the JAK-STAT pathway [27].
JAK/STAT mutations have been previously reported in PTCL-NOS, ALCL, and AITL [12,33,34],
supporting the results of our study. The frequency of JAK/STAT mutations in different cohorts of PTCL
has been reported to be around 20% which compares well to the mutation frequency seen in this study.
In the whole cohort one of the most prevalent STAT3 mutation was an in-frame deletion of E616, which
was identified in three AITL patients. The E616 deletion has been shown to induce myeloid malignancy
in a mouse bone marrow transplantation model [19]. The mutation has been observed previously in
AITL, but also in adult T-cell lymphoma [10,35]. The STAT3 mutation P715L observed in two ALK−
ALCLs and one PTCL-NOS case has been observed in NKTL previously [36].
Some AITL and PTCL-NOS cases harbored concurrent STAT3 and RHOA mutations (3/30 AITL
and 1/12 PTCL-NOS). The incidence of RHOA mutations in our AITL cohort was 70%, which is
somewhat higher than the incidence seen in previous AITL cohorts (68% and 53%) [8,23]. In PTCL-NOS
the mutation incidence was 17% (2/12). Our results also showed that the MAPK phosphorylation
degree correlated with RHOA mutations in our PTCL cohort.
Although this study included limited number of patients representing various PTCLs subtypes, our
results suggest that pY-STAT3 is frequently constitutively phosphorylated in PTCL, especially in ALCLs
and AITLs, but this was associated with STAT3 mutations in only a fraction of PTCL samples. Previous
studies have reported mechanisms underlying the constitutive activation of STAT3 independent of
STAT3 mutations. Gain-of–function mutations involving JAK genes have been implicated in activating
STAT3 and contributing to the pathogenesis of hematologic malignancies and solid tumors [37,38].
Various cytokines (e.g., IL-6, IL-10, and IL-11) that are released into the microenvironment by tumor
cells have also been shown to activate STAT3 [39]. Another mechanism of STAT3 activation is possible
through the deregulation of suppressors of the JAK/STAT pathway such as SOCS3 [40] leading to
constitutive STAT activation and oncogenesis. In addition, further studies are needed to combine any
association with JAK-STAT pathway activation and expression of essential transcription factors such
as GATA3 and Tbet, which define new subclasses of PTCL-NOS with prognostic consequences, where
GATA3 signatures are associated with worse prognosis [41,42].
In our cohort high pSTAT3 expression correlated with the CD3− CD5− CD7− CD30+
immunophenotype typical for ALCL. No association with neither immunophenotype markers nor
essential clinical variables such as survival status, disease stage, MIB proliferation index or LD level
was seen.
By comparing cytotoxicity measured by the area under the curve (AUC) of 265 investigational and
accepted compounds in pSTAT3 high and low cancer cell lines, we identified novel potential inhibitors
of STAT3 activation. The JAK-inhibitor ruxolitinib was among the top candidates. Ruxolitinib, a
selective JAK1/2 inhibitor approved by the FDA for myeloproliferative neoplasms, is being studied in
relapsed B-cell lymphoma and PTCL (NCT01431209).
Among compounds exhibiting most sensitivity in pSTAT3 high cell lines were the cell cycle
checkpoint kinase Chk1/2 inhibitor AZD7762, the poly ADP ribose polymerase (PARP) inhibitor
talazoparib, and the nucleoside analog gemcitabine. In phase II studies, gemcitabine monotherapy has
shown activity against T-cell lymphomas. Zinzani et al. reported a 70% response rate in a phase II study
of 44 pretreated patients with mycosis fungoides or cutaneous PTCL-unspecified [43]. In another phase
II study, gemcitabine was given in combination with romidepsin to relapsed/refractory PTCL patients
but the synergy observed in preclinical phase did not improve clinical outcomes [44]. Moreover,
gemcitabine has been tested in combination with cisplatin and methylprednisolone as both upfront
treatment and in relapsed/refractory PTCL, but did not significantly improve OS [45,46].
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4. Materials and Methods
4.1. Patients and Cell Lines
Samples from 63 patients with PTCL were collected. Of these samples 30 were AITL, 12 PTCL-NOS
and 21 ALCL (13 ALK− and 8 ALK+). Four control samples from normal lymph nodes were also
collected. The study was undertaken in compliance with the principles of the Helsinki Declaration and
was approved by the ethics committee in the Helsinki University Hospital (Finland). As the samples
studied were older diagnostic samples, the ethics committee required no written informed consent
(TEO 5326/04/046/06, Valvira 9115/05.01.00.06/2011, HUS 302/E0/2006, HUS/1230/2017). The clinical and
pathological characteristics of our study objects are summarized in Table S2.
4.2. Cell Lines and Cell Culture Conditions
The T-cell lines were cultured in RMPI-1640 medium including L-glutamine (Gibco, Grand Island,
NY, USA) supplemented with 10% (L82, Karpas299, TLRB1, Molt4, Jurkat, and NKL cell line) or 20%
(SupM2, MTA, MOTN1, and SMZ1 cell line) fetal bovine serum (FBS, Gibco) and Penicillin/Streptomycin
(100 U/l, Gibco). IL2 (10ng/mL, MedChemExpress, Monmouth Junction, NJ, USA) was added for
culturing of TLRB1 and NKL cells. Suspension cells were maintained at a density of 2.0–8.0 × 105.
Culturing was done in an incubator at 37 ◦C and 5% CO2 with 90% humidity.
4.3. Sample Preparation
According to standard clinical procedure, fresh tissue samples consisting mostly of lymph nodes
(LN) were fixated in formalin and embedded in paraffin (FFPE) in the central pathology laboratory of
Helsinki University Hospital (HUCH), Finland. Consequently, we cut 3.5 μm whole-tissue sections on
Superfrost objective slides (Kindler O Gmbh, Freiburg, Germany).
4.4. DNA Extraction
DNA was extracted from FFPE tissue blocks. Ten 10μm sections were cut with standard microtome
(Leica SM2000 R Sliding Microtome, Wetzlar, Germany) using disposable blades. Excess paraffin was
trimmed off and the sections were collected into sterile 1.5 mL microcentrifuge tubes. The sections
were then deparaffinized with three pre-warmed (55 C) xylene washes followed by 95%, 75%, and 50%
ethanol rinses. The tissue pellets were dried briefly at 37 ◦C to remove traces of ethanol. The pellets
were then digested with 20 μL proteinase K (20 mg/mL proteinase K, Roche Diagnostics GmbH,
(Mannheim, Germany) and 180 μL digestion buffer (10 mM Tris-HCl, pH 8.0 100 mM EDTA, pH
8.0 50 mM NaCl, and 0.5% SDS). Samples were incubated at 55 ◦C with mild agitation for 3 to 72 h.
Fresh Proteinase K was added every 24 h followed by heat inactivation at 90 ◦C for 1 h after the
tissue had been fully dissolved. For phenol-chloroform extraction, equal volume of phenol (Amresco,
Solon, OH, USA) was added and vortexed. After spinning for 3 min at 14,000 rpm, the aqueous
layer was transferred to a new tube. Then, an equal volume of phenol-chloroform-isoamyl alcohol
(25:25:1) (Invitrogen, Carlsbad, CA, USA) was added, and the solution was vortexed and spun for
5 min at 14,000 rpm in a microcentrifuge. The aqueous layer was again transferred to a new tube
and treated with RNase A at 100 μg/mL for 1 h at 37 ◦C. To remove any remaining RNase A phenol
and phenol-chloroform-isoamyl alcohol steps were repeated. The aqueous layer was transferred to
a new tube and the DNA was precipitated with 1/10 volume of 3 M sodium acetate and 1 volume
of isopropanol. After thorough mixing, the solution was placed in a freezer for 30 min then spun at
14,000 rpm at 4 ◦C in a microcentrifuge for 10 min. The supernatant was discarded, and the pellet was
washed with 1 mL 70% cold ethanol and spun at 14,000 rpm for 10 min at 4 ◦C. The supernatant was
carefully discarded, and the pellet dried and finally suspended with 50 μL dH2O.
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4.5. Targeted Deep Amplicon Sequencing
Locus-specific primers were designed for STAT3, STAT5B, JAK1, JAK3, and RHOA mutation
hotspots using Primer3 with user-defined parameters (http://primer3.wi.mit.edu/). After designing
the locus-specific primer sequences (Table S3), sequence tails corresponding to the Illumina adapter
sequences, were added to the 5′ end of the forward and reverse locus-specific primers, respectively.
All oligonucleotides were ordered from Sigma-Aldrich (St. Louis, MO, USA). Deep targeted amplicon
sequencing of known recurrent somatic mutations in the genes STAT3, STAT5B, JAK1, JAK3, and RHOA
was performed with the Illumina MiSeq platform (San Diego, CA, USA)as previously described [47].
The data were analyzed with a bioinformatics pipeline, which is based on calling of variants with
certain count/frequency of reads and filtering out false positives using the estimated error rate and
quality data of amplicon reads.
4.6. Immunohistochemistry
4.6.1. Single Color Immunohistochemistry
Tissue sections were deparaffinized, rehydrated in graded ethanol series and then subjected
to heat-induced epitope retrieval in Tris-HCl (10 mM Tris, pH 8.5, 25 min; for Phospho-MAPK
and Phospho-AKT) or in EDTA buffer (10 mM EDTA, pH 8.0, 20 min; for Phospho-Stat3 and
-5) in a Pre-Treatment module (DAKO/Agilent Technologies, Waltham, MA, USA). Samples were
stained using LabVision autostainer (Thermo Fisher Scientific, Fremont, CA, USA). The endogenous
peroxidase activity was blocked with Peroxidase-Blocking Solution (Dako/Agilent Tehnologies).
The samples were treated with primary antibody for 1 h at RT. The antibodies used were rabbit
monoclonal antibodies from Cell Signaling (Leiden, the Netherlands): clone Tyr705 for pY-STAT3
(1:300), clone Thr202/Tyr204 for Phospho-p44/42MAPK (1:300) and Thr450 for Phospho-AKT (1:100).
BrightVision polymerisation technology was utilized to prepare polymeric HRP-linker antibody
conjugates (ImmunoLogic, Duiven, the Netherlands) and 3,3-diaminobenzidine (DAB) was used as
chromogen. Sections were counterstained with Mayer’s hematoxylin (Dako/Agilent Tehnologies) and
mounted with Eukitt (Honeywell Fluka, Frankfurt, Germany).
Protein expression was defined by visual examination. Five representative 400×-magnified
high-power field-of-view (FOV) were selected, and protein expression (%) was estimated as the
proportion of positive cells of 100 cells analyzed by FOV. Finally, the mean proportion of positive cells
was calculated and used for statistical analyses.
4.6.2. Multiplex Immunohistochemistry
All phases were performed in room temperature (if not otherwise specified) and protein blocking
as well as antibody incubations were performed in a humid chamber. The slides were washed with
0.1% Tween-20 (Thermo Fisher Scientific) diluted in 10 mM Tris-HCL buffered saline pH 7.4 (TBS)
three times after peroxide block, each antibody staining, and fluorochrome reaction. Antibodies were
tested with normal lymph node and pY-STAT3 was validated with tissue samples from a patient with
large granular lymphocyte leukemia (Figure S5).
The slides were deparaffinized in xylene and rehydrated with graded series of ethanol and H2O.
HIER was performed in 10 mM Tris-HCl - 1 mM EDTA buffer (pH 9) in +99 ◦C for 20 min (PT Module,
Thermo Fisher Scientific). The peroxide activity was then blocked in 0.9% H2O2 solution for 15 min,
and 10% normal goat serum was subsequently applied (TBS-NGS) for 15 min. We applied the primary
antibody anti-PD1 (1:5000; clone PDCD1; LsBio, Seattle, WA, USA) diluted in TBS-NGS for 1 h 45 min,
and then anti-mouse horseradish peroxidase (HRP) conjugated secondary antibodies (Immunologic)
diluted 1:2 in washing buffer for 45 min. Then, we applied tyramide signal amplification (TSA) Alexa
Fluor 488 (PerkinElmer, Boston, MA, USA) diluted 1:50 in TBS on the slides for 10 min. In order to
multiplex antibodies, we denatured the primary antibody and quenched the enzymatic activity of HRP
by repeating HIER as well as performing peroxide and protein block similarly as above. We applied
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the primary antibody against pY-STAT3 (Tyr705; 1:2500; clone D3A7; CellSignaling) overnight in +4 ◦C,
anti-mouse HRP-conjugated secondary antibody diluted 1:5 in washing buffer for 45 min, and TSA
Alexa Fluor 555 (PerkinElmer) for 10 min. We repeated HIER, peroxide block and protein block as
above. Next, we applied anti-CD4 (1:150; clone EPR6855; Abcam, Cambridge, UK) diluted in TBS-NGS
for 3 h and later AlexaFluor647-conjugated secondary antibody (1:300; Thermo Fisher Scientific) and
Hoechst 33,342 (1 μg/mL; Sigma-Aldrich) counterstain diluted in washing buffer for 45 min. Finally,
we applied ProLong Gold (Thermo Fisher Scientific) to mount the slides.
The tissue slides were scanned with 20x magnification with the Panoramic P250 Flash II whole
slide scanner (3DHistech, Budapest, Hungary). We used DAPI, FITC, Cy3, and Cy5 filters and
visually-optimized exposure times.
4.7. Western Blot
Immunoblots were performed on whole-cell protein lysates according to standard techniques. All
primary antibodies (pJAK3Tyr980/981, clone D44E3; JAK3, clone D7B12; pY-STAT3Tyr705, clone D3A7;
STAT3, clone 124H6; beta-ACTIN, clone 13E5) were ordered from Cell Signaling Technology and
used at 1:1000 dilutions. Anti-mouse and anti-rabbit, both from Dianova, were used as secondary
HRP-coupled antibodies in a 1:5000 dilution. Development of the immunoblots was performed by
using Western Bright ECL (Advansta, Menlo Park, CA, USA). The original blots and densitometry
readings of each band is available in the Supplementary Materials (Figure S6 and Table S4).
4.8. CCLE and DepMap Data
All CCLE pre-processed data were downloaded from the CCLE data portal (https://portals.
broadinstitute.org/ccle/data). RPPA data dated 3 October2018, RNA-seq gene count data dated 29
September 2018, cell line annotation dated 26 December 2018, and mutation data dated 18 July 2018
were used. Gene counts were converted to CPM values using the edgeR and the TMM normalization
method without log transformation. The cut-off for high vs. low STAT3 phosphorylation was set to
pSTAT3Tyr705 = 1 (RPPA unit) based on the shape of the pSTAT3Tyr705 frequency histogram.
Area under the curve (AUC) drug sensitivity data annotated as “Sanger GDSC v17.3” and dated
March 2018 were downloaded from the Cancer Dependency Map portal (https://depmap.org/portal/
download/). Drugs not characterized in both pSTAT3 high and low cell line groups were removed
from the analysis. Cell lines with no pSTAT3 RPPA data were removed from the analysis.
4.9. Statistical Analysis
Comparison of continuous variables between two groups was computed with unpaired t-test and
between multiple groups with one-way ANOVA and post-hoc correction between disease groups and
healthy controls.
Overall survival was defined as the time from diagnosis to death or last follow-up. Patients alive at
the last follow-up date were censored. The log-rank test was used to compute Cox proportional-hazards.
Differential drug sensitivity was computed using t-test between pSTAT3 high (n = 27) and low
(n = 583) cancer cell lines. The fold change in drug sensitivity was defined as the mean AUC ratio
in pSTAT3 high-to-low cell lines. Drugs with a fold change (FC) less than 1.0 are more sensitive in
pSTAT3 high cell lines.
R 3.5.1. [48] and Prism 6.0 was used for statistical analyses. R packages edgeR 3.24.0, forestplot
1.7.2, survminer 0.4.3, ggplot2 3.2.1, and ComplexHeatmap 2.3.2 were used.
5. Conclusions
In summary, this study discovered that pY-STAT3 phosphorylation was associated with both ALK+
ALCLs and JAK1/STAT3 mutated CD30+ ALK− ALCLs suggesting a subgroup potentially benefitting
of JAK/STAT targeted therapy.
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staining of pSTAT3Tyr705 in CD8+ LGL-leukemia as a positive control stain for pSTAT3 antibody, Figure S6: Full
western blot of p-STAT3 (Tyr705), STAT3, p-JAK3 (Tyr980/981), and JAK3 in T cell malignancy cell lines, Table S1:
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Abstract: Signal transducers and activators of transcription 5A and 5B (STAT5A and STAT5B) are
crucial downstream effectors of tyrosine kinase oncogenes (TKO) such as BCR-ABL in chronic myeloid
leukemia (CML) and FLT3-ITD in acute myeloid leukemia (AML). Both proteins have been shown to
promote the resistance of CML cells to tyrosine kinase inhibitors (TKI) such as imatinib mesylate (IM).
We recently synthesized and discovered a new inhibitor (17f) with promising antileukemic activity.
17f selectively inhibits STAT5 signaling in CML and AML cells by interfering with the phosphorylation
and transcriptional activity of these proteins. In this study, the effects of 17f were evaluated on CML
and AML cell lines that respectively acquired resistance to IM and cytarabine (Ara-C), a conventional
therapeutic agent used in AML treatment. We showed that 17f strongly inhibits the growth and
survival of resistant CML and AML cells when associated with IM or Ara-C. We also obtained
evidence that 17f inhibits STAT5B but not STAT5A protein expression in resistant CML and AML cells.
Furthermore, we demonstrated that 17f also targets oncogenic STAT5B N642H mutant in transformed
hematopoietic cells.
Keywords: pharmacological inhibitor; STAT5 signaling; chemotherapy resistance; myeloid leukemia
1. Introduction
STAT5A and STAT5B are two closely related signal transducers and activators of transcription
family members. Both proteins are crucial downstream effectors of tyrosine kinase oncogenes (TKO)
such as Fms-like receptor tyrosine kinase 3 with internal tandem duplications (Flt3-ITD), BCR-ABL
and JAK2V617F which cause AML, CML and other myeloproliferative diseases (MPD), respectively [1].
STAT5 proteins are recognized as major drivers in the development and/or maintenance of CML as
well as in the proliferation and survival of AML cells [2–4]. The development of tyrosine kinase
inhibitors (TKI) targeting BCR-ABL such as imatinib mesylate (IM) has revolutionized the treatment
of CML. Despite this success story, IM is not totally curative and approximately 50% of patients remain
therapy-free after IM discontinuation. The inability of IM to completely eradicate leukemic stem
cells (LSC) is probably responsible for the relapse of CML patients [5]. Moreover, the occurrence
of BCR-ABL mutations in progressive or relapsed disease promotes IM resistance of CML cells [6].
Therefore, there is a need for complementary therapeutic strategies to cure CML. STAT5 fulfils all
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the criteria of a major drug target in CML [7]. High STAT5 expression levels have been shown not
only to enhance IM resistance in CML cells but also to trigger BCR-ABL mutations by inducing the
production of reactive oxygen species (ROS) responsible for DNA damage [8,9]. Moreover, STAT5 was
shown to play a key role in the maintenance of chemoresistant CML stem cells [10]. Thus, targeting
STAT5 would also benefit relapsed CML patients who became resistant to TKI. Several approaches
have been used to target STAT5 in leukemia. Among them, cell-based screening with small molecule
libraries of already approved drugs allowed the identification of the psychotropic drug pimozide as
a potential STAT5 inhibitor in CML cells [11]. Pimozide decreased the tyrosine phosphorylation of
STAT5 and induced growth arrest and apoptosis in CML cells. In addition, pimozide was shown
to target the deubiquitinating (DUB) enzyme, USP1, in leukemic cells indicating that the effects of
pimozide on STAT5 activity might be indirect [12]. Indirubin derivatives were also reported to inhibit
STAT5 phosphorylation in CML cells but the mechanism of inhibition is most likely suppression
of upstream tyrosine kinases [13]. More recently, a number of small inhibitors that bind to the Src
homology domain 2 (SH2) required for STAT5 activation and dimer formation, have been described [14].
These compounds exhibit potent and selective binding activity for STAT5 by effectively disrupting
phosphopeptide interactions. Some of these inhibitors bind STAT5 proteins in a nanomolar range
and inhibit the tyrosine phosphorylation of STAT5 and CML/AML cell growth in a micromolar
range [15–17]. A final approach is to target STAT5 activity through the activation of peroxisome
proliferator-activated receptor gamma (PPARγ) [18]. Indeed, the existence of cross-talk between PPARγ
and STAT5 has been discussed. For instance, antidiabetic drugs such as glitazones, which are PPARγ
agonists, were shown to have antileukemic activity [19,20]. Activation of PPARγ by pioglitazone not
only decreases the phosphorylation of STAT5 in CML cells but also reduces expression of STAT5 genes
in quiescent and resistant CML stem cells [10]. Importantly, the combined use of pioglitazone and IM
triggers apoptosis of these leukemic cells suggesting that besides phosphorylation, inhibition of STAT5
expression is of prime importance for resistant CML stem cell eradication. Based on these different
data, we sought to identify new STAT5 inhibitors in a library of PPARα/γ ligands that were synthetized
in our laboratory [21,22]. The synthesis of derivatives of a “hit” compound identified in the library
screening allowed the discovery of a new inhibitor of STAT5 signaling in CML and AML cells [23].
This molecule (17f) selectively inhibits the phosphorylation and transcriptional activity of STAT5 and
induces apoptosis of CML and AML cells. Herein, we showed that 17f associated with IM or Ara-C
resensitizes CML and AML cells, respectively, that acquired resistance to these drugs. We demonstrated
that 17f treatment reduces STAT5B protein levels in resistant CML and AML cells, suggesting that 17f
overcomes chemotherapy resistance though the downregulation of this protein. We also found that 17f
suppresses expression of oncogenic STAT5N642H mutant in transformed Ba/F3 cells.
2. Results
2.1. Effects of 17f Compound on Growth and Viability of IM-Sensitive and IM-Resistant BCR-ABL+ Cells
Initial experiments were carried out to determine the effects of 17f alone (see structure in Figure S1)
on K562 cells that are sensitive (K562S) or resistant (K562R) to IM treatment. These in vitro models are
depicted in Figure 1A. Sensitive and resistant cells were treated with various concentrations of 17f
(ranging from 1 to 10 μM). Growth and viability were determined by trypan blue exclusion (Figure 1B)
and MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) (Figure 1C) assays. Addition
of 17f clearly blocked the growth of K562S cells while K562R cells remain insensitive to 17f treatment at
the same concentration. The EC50 value was found to be two times higher in K562R cells than in K562S
cells (14.5 ± 4.8 μM vs. 6.9 ± 1.7 μM). We also observed that treatment with 5 μM 17f did not affect the
growth and viability of K562R cells and used this suboptimal concentration in most experiments to
evaluate the combined effects of 17f and IM.
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Figure 1. Effects of 17f molecule on K562S and K562R cell growth (A) Imatinib mesylate (IM)-sensitive
K562 (K562S) and IM-resistant K562 cells (K562R) were treated with 1 μM IM or DMSO as control
(Co) for 48 h. Cell viability was determined by MTT assays (data are presented as mean ± SD of
three independent experiments (n = 3) in triplicates, *** p < 0.001; one sample t-test). (B) K562S and
K562R cells were treated with 17f or DMSO as control (Co) for the indicated times. Growth kinetics
were determined by trypan blue dye exclusion assays (n = 3 in triplicates, data are mean ± SD).
(C) Cell viability was measured by MTT assays after treatment of K562S or K562R cells with increasing
concentrations of 17f or DMSO as control (Co) during 48 h (n = 3 in triplicates, data are mean ± SD,
** p < 0.01, *** p < 0.001; one sample t-test).
2.2. 17f Induces Apoptosis and Cell Cycle Arrest in K562R Cells and Relieves the Resistance to IM
We then addressed whether 17f in combination with IM might directly abrogate the resistance of
K562R cells to IM. K562S and K562R cells were treated with 17f in the presence of IM and cell growth and
viability were determined by MTT assays (Figure 2A). As expected, IM strongly inhibited the growth
of K562S cells. This inhibition was further enhanced by 17f in a dose-dependent fashion. Interestingly,
we found that the addition of 1 μM 17f in the presence of IM was already enough to significantly reduce
the growth and viability of K562R cells. Treatment with 5 μM and 10 μM of 17f further increased this
inhibitory effect. To analyze the growth-suppressive properties of 17f in K562R cells, we determined
the impact of this small molecule on apoptosis and the cell cycle. 17f induced apoptosis and changes
in cell cycle phase distribution in a concentration-dependent manner (Figure 2B,C). 17f significantly
increased the number of cells in the G0 phase indicating that treatment with this compound induced
quiescence of K562R cells.
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Figure 2. 17f overcomes the resistance of K562R cells to IM treatment. (A) K562S and K562R cells were
treated with IM or not (Co) with or without 17f for 48 h. Cell viability was determined by MTT assays.
(B) K562R cells cultured for 48 h with IM and 17f or IM vs. DMSO as control. Cells were stained
with anti-annexin V coupled with FITC (fluorescein isothiocyanate) and with 7-amino-actinomycin
D (7-AAD) to determine the percentages of apoptotic cells. One representative experiment is shown
(left panel). (C) K562R cells treated for 48 h with IM and 17f or IM and DMSO as control were stained
with 7-AAD and an Alexa Fluor 488-conjugated anti-Ki-67 antibody. Cell cycle phase distributions
were then estimated by flow cytometry. The histogram presents the percentage of cells in the G0 phase.
One representative experiment is shown (left panel) (n = 3 in triplicates, data are mean ± SD, * p < 0.05,
** p < 0.01, *** p < 0.001, **** p < 0.0001).
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2.3. 17f Inhibits STAT5-Dependent Transcriptional Activity in K562R Cells
We previously showed that 17f inhibits the transcriptional activity of STAT5 in CML cells. We then
asked whether this small molecule also affects the activity of these proteins in IM-resistant K562R
cells. We first determined the impact of this compound on the transcriptional activation of a reporter
gene driven by a STAT5-specific promoter. K562S and K562R cells were transfected with a construct
containing six tandem copies of the STAT5 response element in front of the minimal TK promoter
fused to the luciferase reporter gene (6×(STAT5)-TK-luc). As control, cells were also transfected with a
TK-luciferase vector without STAT5 response elements (TK-luc). Luciferase activity was determined
48 h post-transfection in K562S and K562R cells treated with DMSO as control, 17f (5 μM) and/or IM
(1 μM). As expected, constitutive STAT5 activity induced by BCR-ABL increased luciferase activity in
K562S cells transfected with the STAT5-dependent promoter construct compared to cells transfected
with the control TK-luc vector (Figure 3A). This enhanced luciferase activity was strongly reduced after
17f or IM treatment. In sharp contrast, the luciferase activity remained elevated after treatment with
IM in K562R cells transfected with the STAT5-dependent reporter construct, although this enzymatic
activity was strongly decreased after the addition of 17f and IM. qRT-PCR experiments were then
conducted to determine the effects of 17f on STAT5-dependent expression of target genes such as PIM1
and CISH (Figure 3B). As expected, 17f or IM reduced expression of both genes in sensitive K562S
cells while this effect was observed in resistant K562R cells after treatment with both compounds.
Collectively, these data strongly suggest that 17f inhibits the transcriptional activity of STAT5 to bypass
IM resistance in K562R cells.
2.4. 17f Inhibits STAT5B Protein Expression in IM-Resistant K562 Cells
We then determined the impact of 17f on BCR-ABL-induced tyrosine phosphorylation of STAT5
(P-Y694/699-STAT5) by western blot and flow cytometry analysis (Figure 4A, Figures S2–S4). K562S and
K562R cells were treated for 24 h instead of 48 h to analyze the early effects on STAT5 phosphorylation.
IM strongly reduced P-Y-STAT5 levels in K562S, and the addition of 17f further enhanced this effect.
P-Y-STAT5 levels were maintained in IM-treated K562R cells but were decreased after the addition of
17f. Interestingly, the level of STAT5 phosphorylation was strikingly enhanced in K562R cells after
removal of IM and was weakly affected by the addition of 17f (Figure S5). To determine whether
changes in P-Y-STAT5 levels reflect differences in protein abundance, immunoblots were performed
with an anti-STAT5 antibody that recognizes STAT5A and STAT5B proteins (Figure 4B and Figure S2).
As expected, IM inhibited the phosphorylation of STAT5 in sensitive and resistant cells. Interestingly,
we observed that the association of 17f with IM reduces STAT5 expression in K562R cells but not
in K562S cells (see Figure S3A,B for quantification). qRT-PCR experiments were then conducted to
evaluate the impact of combination treatments on STAT5A and STAT5B gene expression in K562R cells.
Results showed that STAT5A/5B mRNA levels were not affected by 17f when associated with IM
(Figure 4B). In contrast, western blot analysis clearly evidenced that STAT5B protein expression was
decreased after combination treatments suggesting that 17f sensitizes K562R cells to IM treatment by
targeting STAT5B protein (Figure 4C).
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Figure 3. 17f associated with IM inhibit STAT5 activity in resistant K562R cells. (A) K562S or K562R cells
transfected with a 6×(STAT5)-TK-luciferase reporter construct or a control TK-luciferase vector were
treated or not (Co) with 17f (5 μM), IM (1 μM) or with the combination of 17f and IM for 48 h. Luciferase
activities were then determined as described in Methods. Luciferase activity (arbitrary units) in the
histogram represents the relative luminescence unit (rlu) values/mg of proteins (n = 3 in triplicates,
data are mean ± SD, * p < 0.05, ** p < 0.001). (B) qRT-PCR analysis of PIM1 and CISH expression in
K562S and K562R treated or not (Co) with IM (1 μM),17f (5 μM) or with combined 17f and IM for 24 h.
Results are presented as the fold change in PIM1 and CISH gene expression in treated cells normalized
to internal control genes (GAPDH, ACTB and RPL13a) and relative to control condition (normalized to 1)
(n = 3 in triplicates, data are mean ± SD, * p < 0.05; one-sample t-test).
206
Cancers 2019, 11, 2043
Figure 4. 17f associated with IM inhibits STAT5B protein expression in K562R cells (A) Protein extracts
from K562S and K562R cells treated with 17f 5 μM or DMSO with or without IM for 24 h were analyzed
by western blotting to detect P-Y694/699-STAT5 and STAT5 protein expression (n = 2). Actin served
as the loading control. (B) qRT-PCR analysis of STAT5A and STAT5B expression in K562R cultured
with IM (1 μM) as control or treated with 17f (5μM) and IM for 24 h. Results are presented as the fold
change in STAT5A and STAT5B gene expression in treated cells normalized to internal control genes
(GAPDH, ACTB and RPL13a) and relative to control condition (normalized to 1) (n = 3 in triplicates,
data are mean ± SD, * p < 0.05; one sample t-test). (C) Expression of STAT5A and STAT5B proteins in
K562R cells treated or not with 17f (5 μM) was analyzed by western blot (n = 2). Actin served as the
loading control.
2.5. Effects of 17f on Growth and Viability of Ara-C-Sensitive and Ara-C-Resistant FLT3-ITD Expressing
Leukemic Cells
STAT5 is also phosphorylated by FLT3-ITD, a major TKO in AML cells. To exclude the possibility
that 17f-mediated inhibition of STAT5 and cell growth is a peculiarity of IM-resistant BCR-ABL+
cells, we used MV4-11 cells expressing FLT3-ITD that acquired resistance to Ara-C, a conventional
therapeutic agent that affects DNA replication. Sensitive and resistant MV4-11 cell models are depicted
in Figure 5A. We first evaluated the impact of 17f alone on MV4-11S and MV4-11R cell growth and
showed that MV4-11R cells were more resistant to 17f treatment than MV4-11S cells (Figure 5B).
Based on these data, IC50 values were found to be three-fold higher in MV4-11R than in MV11-4S cells
(10.79 ± 3.2 vs. 3.55 ± 0.47).
2.6. 17f Sensitizes MV4-11R Cells to Ara-C Treatment
We then analyzed the effects of 17f on MV4-11S and MV4-11R cell growth in the presence of Ara-C
using trypan blue dye exclusion (Figure 6A) and MTT assays (Figure 6B). Addition of 17f significantly
enhanced the growth inhibition and cytotoxic effect of Ara-C in MV4-11S cells. Importantly, 17f greatly
reduced the growth of resistant MV4-11R cells cultured with Ara-C in a concentration-dependent fashion.
This growth inhibition was already observed with 1 μM, a concentration that did not affect the growth
of MV4-11R cells cultured in the absence of Ara-C. These data indicated that the addition of 17f
overcomes the resistance of MV4-11R cells to Ara-C.
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Figure 5. Effects of 17f on MV4-11S and MV4-11R cell growth (A) Ara-C-sensitive MV4-11 (MV4-11S)
and Ara-C-resistant MV4-11 (MV4-11R) cells were treated with 1 μM Ara-C or DMSO as control (Co)
for 48 h. Cell viability was then determined by MTT assays (n = 3 in triplicates, data are mean ± SD,
**** p < 0.0001; one-sample t-test). (B) MV4-11S and MV4-11R cells were treated or not (Co) with
increasing concentrations of 17f during 48 h. Cell viability was determined by MTT assays (n = 3 in
triplicates, data are mean ± SD, ** p < 0.01, *** p < 0.001, **** p < 0.0001; one-sample t-test).
Figure 6. 17f relieves the resistance of MV4-11R cells to ARA-C treatment. (A) MV4-11S or MV4-11R cells
were treated with Ara-C or not (Co) with or without 17f. Growth kinetics were determined by Trypan blue
dye exclusion assays (n = 3 in triplicates, data are mean ± SD). (B) MV4-11S or MV4-11R cells were treated
with Ara-C or not (Co) with or without 17f for 48 h. Cell viability was determined by MTT assays (n = 3 in
triplicates, data are mean ± SD, * p < 0.05, ** p < 0.01, **** p < 0.0001; one-sample t-test).
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2.7. 17f Triggers Apoptosis, Cell Cycle Arrest and Inhibition of STAT5B Expression in MV4-11R Cells
We then evaluated the effects of 17f on apoptosis and the cell cycle in MV4-11R cells. A significant
increase in apoptotic cells was observed (Figure 7A) only after treatment with 5 μM 17f, while the
addition of 1 μM was enough to enhance the number of cells in the G0 phase of the cell cycle (Figure 7B).
These results indicated that the growth-suppressive properties of 17f primarily affect the cell cycle
in MV4-11R cells and apoptosis at higher concentrations. We then asked whether 17f interferes with
STAT5 signaling in Ara-C-resistant AML cells and analyzed the impact of 17f on phosphorylation and
expression of STAT5 in MV4-11R cells. In the absence of Ara-C, the level of STAT5 phosphorylation
was slightly enhanced in MV4-11R cells (Figure S5C,D). The addition of 17f with or without Ara-C
inhibited STAT5 expression in MV4-11R cells (Figure 7C and Figures S2B and S3C). Likewise, STAT5B
expression was reduced after treatment with 17f alone or with Ara-C in resistant cells (Figure 7D).
Figure 7. 17f promotes apoptosis, cell cycle arrest and inhibition of STAT5B protein expression in
MV4-11R cells. (A) Flow cytometry histogram of MV4-11R cells cultured for 48 h with Ara-C and
17f or Ara-C and DMSO as control. Cells were stained with anti-annexin V coupled with FITC and
with 7-AAD to determine the percentages of apoptotic cells (n = 3 in triplicates, data are mean ± SD,
** p < 0.01). (B) MV4-11R cells treated for 48 h with Ara-C and 17f or Ara-C and DMSO as control
were stained with 7-AAD and an Alexa Fluor 488-conjugated anti-Ki67 antibody. Cell cycle phase
distributions were then estimated by flow cytometry. The histogram presents the percentage of cells in
the G0 phase (n = 3 in triplicates, data are mean ± SD, * p < 0.05, *** p < 0.001). (C) Protein extracts
from MV4-11R cells treated with Ara-C and 17f or Ara-C and DMSO for 24 h were analyzed by
immunoblotting to detect P-Y694/699-STAT5 and STAT5 protein expression (n = 2). Actin served as the
loading control. (D) Expression of STAT5A and STAT5B proteins in MV4-11R cells treated or not with
17f (5 μM) was also analyzed by western blot (n = 2).
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2.8. 17f Inhibits Expression of Oncogenic STAT5BN642H Mutant
Gain of function mutations of STAT5B have been described in hematopoietic malignancies.
The recurrent hotspot mutation N642H has been identified in T cell leukemia and lymphomas and
the STAT5BN642H mutant was shown to induce T cell neoplasia in transgenic mice [24–27]. We therefore
tested the ability of 17f to inhibit STAT5BN642H expression and growth of hematopoietic cells transformed
by this mutant. For this purpose, we used Ba/F3 cells expressing flag-tagged STAT5BN642H or flag-tagged
wild-type STAT5B (wtSTAT5B) as control [27]. We found that Ba/F3-STAT5BN642H cells were more sensitive
to 17f treatment than control Ba/F3-wtSTAT5B cells (Figure 8A). We then addressed whether STAT5N642H
expression was impacted by 17f and showed that 17f reduces expression of this mutant in Ba/F3 cells but
does not affect wtSTAT5B or endogenous STAT5A expression after 24 h treatment (Figure 8B).
Figure 8. 17f inhibits STAT5BN642H activity and expression in Ba/F3 cells. (A) Cells were treated or not
with 17f (10 μM). Growth were then determined by Trypan blue dye exclusion assays at the indicated
times (n = 5 in triplicates, data are mean ± SD). (B) Protein extracts from MV4-11R cells treated with
17f for 24 h were analyzed by immunoblotting to detect flag-tagged wtSTAT5B, STAT5BN642H and
endogenous STAT5A/STAT5B protein expression (n = 2). Actin served as the loading control.
3. Discussion
The development of pharmacological inhibitors targeting the JAK/STAT pathway has been the
subject of intense investigation during the last decade. Among the STAT family members, STAT5
proteins are now recognized as important therapeutic targets in hematologic malignancies and also
in certain solid tumors [28]. Distinct pharmacological compounds that directly or indirectly affect
STAT5 activity and leukemia cell growth have been used or developed during these last years.
We recently synthesized and discovered a new compound (17f) that inhibits STAT5 phosphorylation
and transcriptional activity in various CML and AML cells, without detectable effects on other signal
210
Cancers 2019, 11, 2043
transduction molecules, such‚ as STAT3 and the protein kinases ERK1/2 and AKT [23]. We also
demonstrated that 17f strongly reduces the growth of CML and AML cells with EC50 values below
10 μM close to EC50 values obtained with the STAT5 inhibitor pimozide (unpublished data) indicating
that 17f as pimozide targets myeloid leukemia cells addicted to STAT5 signaling (see also Figure S1 for
17f and pimozide structures). In this study, we bring evidences that 17f also relieves the resistance of
CML and AML cells to IM and Ara-C, respectively. Interestingly, we found that the concentrations
of 17f required to restore the response to IM and Ara-C in resistant leukemic cells were much lower
than EC50 values obtained for each resistant cell type. Indeed, inhibition of cell growth was already
observed with 1 μM when combined with IM or Ara-C while EC50 values obtained for 17f compound
alone were greater than 10 μM in these resistant cells. Depletion of IM or Ara-C in resistant cells
might explain changes in the growth inhibitory effects of 17f. Indeed, we observed that the removal of
IM strongly increases the phosphorylation of STAT5 in K562R cells. In these conditions, P-Y-STAT5
protein levels remain much higher in K562R cells after 17f treatment than in treated K562S cells, which
are sensitive to lower concentrations of 17f. These data are in close agreement with a previously
published study showing that high STAT5 levels mediate IM resistance in CML cells [8]. Although the
removal of Ara-C results in a slight increase in STAT5 phosphorylation, the resistance of MV4-11R
cells to this drug is not directly linked to overactivated STAT5. ERK1/2 and AKT kinases that also
play a crucial role in cell survival, are involved in the resistance of MV4-11 cells to Ara-C [29]. It is
then likely that Ara-C depletion may overexpress or overactivate these survival pathways in resistant
MV4-11 cells. Whatever the resistance mechanism associated or not with STAT5 signaling, our data
suggest that combination treatments with a STAT5 inhibitor might efficiently eliminate resistant CML
and AML cells.
While 17f alone inhibited STAT5 phosphorylation in IM-depleted K562R cells, it decreased STAT5
expression in Ara-C-depleted MV4-11R cells. Importantly, combination treatments reduced expression
of STAT5 in both resistant leukemic cells. The mechanisms involved in this downregulation remain
unknown but are not associated with changes in STAT5A and STAT5B gene expression and specifically
affect STAT5B protein. Importantly, we also demonstrated that 17f inhibits expression of STAT5BN642H
protein expression in transformed Ba/F3 cells. STAT5BN642H is a driver mutation for T cell neoplasia
and has been associated with aggressiveness, poor prognosis and an increased risk of relapse in T cell
leukemia-lymphoma patients [24–27]. In addition to myeloid leukemia, 17f might be then employed to
target lymphoproliferative disorders and lymphomas addicted to STAT5BN642H signaling.
It is likely that 17f inhibits STAT5B expression via the ubiquitin/proteasome-dependent
degradation of this protein. Indeed, STAT5 proteins were previously shown to be ubiquitinated
and several ubiquitination sites have been identified in STAT5A and STAT5B protein sequences [30,31].
Cbl, a well-known E3 ubiquitin ligase was found to interact with STAT5 and to induce its
ubiquitination [30]. Moreover, cytokine-mediated STAT5 phosphorylation was enhanced in
hematopoietic stem cells from c-cbl knockout mice [32]. 17f alone or associated with IM or Ara-C might
then promote ubiquitination and proteasomal degradation of STAT5B protein in resistant leukemic
cells as well as in STAT5BN642H-expressing cells. In a similar vein, pimozide was shown to target USP1,
a ubiquitin specific protease involved in the deubiquitination of transcription factors such as ID-1.
Pimozide-mediated inhibition of USP-1 promotes ID1 degradation and inhibition of leukemic cell
growth [12]. It is therefore conceivable that 17f activity is connected to a proteasome regulatory network
that controls STAT5B protein degradation. Alternatively, the combination of 17f and IM or Ara-C
might also target chaperone molecules such as the heat shock proteins HSP90 or HSP70 proteins which
were previously shown to regulate expression and/or stability of STAT5 [33,34]. The dual inhibition of
BCR-ABL and HSP90 was shown to abrogate the growth of IM-resistant CML cells [35]. Furthermore,
a key role of STAT5 has been demonstrated in the synergistic effects of FLT3 and HSP90 inhibitors in
FLT3-ITD-expressing leukemic cells [36]. Importantly, HSP90 inhibitors not only target STAT5 but also
overcome the resistance of AML cells to FLT3 inhibitors [37]. HSP70 was also found to induce STAT5
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expression and drug resistance in AML and CML cells and inhibition of STAT5 activity was sufficient
to resensitize resistant leukemic cells to chemotherapy [34,38].
If the downregulation of STAT5A and STAT5B expression can occur via
ubiquitin/proteasome-dependent protein degradation, the selective effect of 17f on STAT5B
still remains unclear. Nevertheless, using a bacterial two-hybrid screening approach, we previously
identified the tumor suppressor hTid1 as a specific binding partner of STAT5B [39]. hTid1 belongs to
the DnaJ chaperone protein family, which contains the J domain, a highly conserved domain that
binds to Hsp70. The DnaJ-Hsp70 complexes are involved in protein folding and protein degradation
and hTid1 was shown to promote the ubiquitination and degradation of various cellular proteins
including transcription factors [40]. We demonstrated that overexpression of hTid1 specifically
suppresses STAT5B protein expression and the transforming potential of a constitutively active STAT5B
variant (STAT5B1*6) in hematopoietic cells. 17f might then target specific effectors of STAT5B protein
stability/degradation, a hypothesis that has yet to be experimentally tested.
Besides these potential mechanisms, the capacity of 17f to restore the sensitivity of resistant
CML or AML cells to IM or Ara-C suggests that inhibitors targeting STAT5 expression would
also benefit AML or CML patients who have developed resistance to chemotherapy. Accordingly,
PPARγ agonists were shown to inhibit STAT5A and STAT5B gene expression and to synergize
with IM to eradicate resistant CML stem cells [10]. Our findings suggest that targeting STAT5B
protein is a promising therapeutic strategy to eradicate leukemic cells that acquired resistance to
chemotherapeutic agents. This is also supported by previous works showing that STAT5B but not
STAT5A plays a key role in BCR-ABL-induced leukemogenesis and in the sensitivity of CML cells
to TKI treatment [41,42]. Recent studies indicated that STAT5 proteins also exert important non
canonical functions in normal and cancer cells. For instance, unphosphorylated STAT5 (uSTAT5: non
phosphorylated on Y694/699 residues) were shown to be transcriptionally active in self-renewing
hematopoietic stem cells and to promote leukemia/lymphoma cell survival [43,44]. Selective inhibitors
that only block tyrosine phosphorylation and dimer formation might then be insufficient to fully
abrogate STAT5 activity and resistance to chemotherapy. Herein, we showed that that inhibition of
STAT5B expression elicited by 17f might unlock drug resistance in CML and AML cells. Using these
promising data as a lead, we carried out a rational search for new derivatives of 17f with enhanced
antileukemic activity. Modeling work was initiated to identify a pharmacophore that could help to
optimize the development of 17f derivatives working in the nanomolar range. These new compounds
could represent promising drugs to overcome chemotherapy resistance in leukemia or lymphomas.
4. Materials and Methods
4.1. Cell Cultures and Reagents
IM-sensitive (K562S) and IM-resistant (K562R) BCR-ABL+ cells and MV4-11 cells were obtained
from American Type Culture Collection (ATCC) and Deutsche Sammlung von Mikroorganismens
und Zellkulturen (DSMZ), respectively, and maintained according to the supplier’s recommendations.
K562R and Ara-C-resistant MV4-11 (MV4-11R) cells were obtained after cultures of K562S and
sensitive MV4-11 (MV4-11S) cells with increasing concentrations of IM and Ara-C (until 1 μM).
Ba/F3-STAT5BN642H and Ba/F3-wtSTAT5B cells were previously described in [27]. All cell lines
were cultured in RPMI 1640, with 10% fetal bovine serum, 2 mM glutamine, 100 U/mL penicillin
and 100 μg/mL streptomycin at 37 ◦C, 5% CO2. Resistant cells were cultured with 1 μM IM or
Ara-C. IM was purchased from Selleckchem (Houston, TX, USA) and Ara-C from Sandoz France
(Levallois-Perret, France). Ba/F3-wtSTAT5B were cultured with IL-3. The synthesis of the 17f compound
was previously described in [23].
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4.2. Cell Proliferation Assays
Cell viability and proliferation were studied using a MTT cell proliferation assay (Sigma-Aldrich,
St Louis, MO, USA). Briefly, 2 × 104 leukemic cells were cultured in 100 μL of RPMI medium in
96-well plates and treated with drugs for 48 h. Cells were then incubated with 10 μL of MTT working
solution (5 g/L of methylthiazolyldiphenyl-tetrazolium bromide) for 4 h. Cells were lysed overnight
at 37 ◦C with 100 μL of SDS 10%, HCl 0.003%. Optical density (OD) at 570 nm was then measured
using a spectrophotometer CLARIOstar® (BMG Labtech, Offenburg, Germany). Living cells were also
enumerated using the trypan blue dye exclusion method.
4.3. Apoptosis and Cell Cycle Analysis
Cells were washed with PBS, then stained (106 cells) in buffer containing FITC-annexin V and
7-amino-actinomycin D (7-AAD) (Beckmann Coulter, Fullerton, CA, USA) for 15 min at 4 ◦C and
analyzed by flow cytometry (Becton Dickinson Accuri™ C6 flow cytometer). For cell cycle analysis [45],
cells were first incubated with fixing solution (PFA 2%, Hepes 1%, saponin 0.03%) for 15 min and
then in PFS permeabilization solution (PBS 1×, SVF 10%, saponin 0.03%, Hepes 1%). Cells were next
stained for 30 min at room temperature with anti-Ki67-Alexa Fluor 488 monoclonal antibody or the
corresponding isotype as control (Becton-Dickinson, Franklin Lakes, NJ, USA) before analysis by
flow cytometry (Becton Dickinson Accuri™ C6 flow cytometer). The FlowJo® software (V10.1, BD
Biosciences, Franklin Lakes, NJ, USA) was used to analyze data.
4.4. Plasmids, Transfection and Luciferase Reporter Assays
The 6×(STAT5)-TK-luc containing six tandem copies of the STAT5 binding site linked to the
minimal TK-luciferase reporter gene and control TK-luc plasmids have been described elsewhere [46].
For transient transfection assays, cells were electroporated (270 V, 950 μF) with the different constructs
(50 μg). Transfected cells were expanded for 24 h in medium and then treated for 48 h. Cell extracts were
then prepared in luciferase buffer according to the manufacturer’s protocol (One Glo luciferase assay
kit, Promega, Madison, WI, USA). Luciferase activities were measured in a luminometer CLARIOstar®
(BMG Labtech, Offenburg, Germany).
4.5. Western Blot
Cells were suspended in Laemmli’s 2× buffer (Bio-Rad, Hercules, CA, USA), separated on
SDS/PAGE and blotted onto nitrocellulose membrane. Blots were incubated with the following
antibodies (Abs): P-Y694/699-STAT5, Actin (Cell Signaling Technology, Danvers, MA, USA), STAT5
(BD Transduction Laboratories, Franklin Lakes, NJ, USA), STAT5A and STAT5B (Zymed/ThermoFisher
Scientific, Waltham, MA, USA). Membranes were developed with the ECL chemiluminescence
detection system (GE Healthcare, Little Chalfont Buckinghamshire, UK) using specific peroxidase
(HRP) conjugated to rabbit or mouse IgG antibodies (Cell Signaling Technology).
4.6. P-Y694/699-STAT5 Flow Cytometry Analysis
Cells were washed in PBS and incubated with a fixing solution PFA 4% for 15 min at room
temperature. The first permeabilization solution PBS/Triton X-100 0.2% was then added and incubated
for 30 min at 37 ◦C. After being washed with PBS/BSA 0.5%, cells were suspended with the second
permeabilization solution PBS/MeOH 50% and incubated for 10 min on ice. Cells were then stained
with anti P-Y694/699-STAT5 antibodies or the corresponding isotype as control (BD Biosciences, NJ, USA)
for 30 min at room temperature before analysis by flow cytometry (FACS Canto II, BD Biosciences).
4.7. qRT-PCR Analysis
RNA samples were reverse-transcribed using the SuperScript®VILO cDNA synthesis kit
(Invitrogen, Carlsbad, CA, USA) as recommended by the supplier. The resulting cDNAs were used for
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quantitative real-time PCR (qRT-PCR). PCR primers (PIM1: for 5′-TTTCGAGCATGACGAAGAGA-3′,
rev 5′-GGGCCAAGCACCATCTAAT-3′; CISH: 5′- AGCCAAGACCTTCTCCTACCTT-3′, rev
5′-TGGCATCTTCTGCAGGTGT-3′; STAT5A: for 5′-TCCCTATAACATGTACCCACA-3′, rev
5′-ATGGTCTCATCCAGGTCGAA-3′; STAT5B: for 5′-TGAAGGCCACCATCATCAG-3′, rev
5′-TGTTCAAGATCTCGCCACTG-3′) were designed with the ProbeFinder software (Roche Applied
Sciences, Basel, Switzerland) and used to amplify the RT-generated cDNAs. qRT-PCR analyses were
performed on the Light Cycler 480 thermocycler II (Roche). GAPDH (glyceraldehyde-3-phosphate
dehydrogenase), ACTB (actin beta) and RPL13A were used as reference genes for normalization of
qRT-PCR experiments. Each reaction condition was performed in triplicate. Relative gene expression was
analyzed using the 2−ΔΔCt method [47].
5. Conclusions
In summary, this work shows for the first time that inhibition of STAT5B expression might
be a promising targeting strategy to bypass the resistance of CML and AML cells to TKI or
conventional chemotherapeutic agents. Investigations to elucidate the mechanisms involved in
STAT5B downregulation induced by these combination therapies might help to design new inhibitors
that specifically target cancer cells addicted to oncogenic STAT5B signaling.
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Abstract: The Signal Transducer and Activator of Transcription (STAT)3 and 5 proteins are activated by
many cytokine receptors to regulate specific gene expression and mitochondrial functions. Their role
in cancer is largely context-dependent as they can both act as oncogenes and tumor suppressors.
We review here the role of STAT3/5 activation in solid cancers and summarize their association with
survival in cancer patients. The molecular mechanisms that underpin the oncogenic activity of
STAT3/5 signaling include the regulation of genes that control cell cycle and cell death. However,
recent advances also highlight the critical role of STAT3/5 target genes mediating inflammation and
stemness. In addition, STAT3 mitochondrial functions are required for transformation. On the other
hand, several tumor suppressor pathways act on or are activated by STAT3/5 signaling, including
tyrosine phosphatases, the sumo ligase Protein Inhibitor of Activated STAT3 (PIAS3), the E3 ubiquitin
ligase TATA Element Modulatory Factor/Androgen Receptor-Coactivator of 160 kDa (TMF/ARA160),
the miRNAs miR-124 and miR-1181, the Protein of alternative reading frame 19 (p19ARF)/p53
pathway and the Suppressor of Cytokine Signaling 1 and 3 (SOCS1/3) proteins. Cancer mutations
and epigenetic alterations may alter the balance between pro-oncogenic and tumor suppressor
activities associated with STAT3/5 signaling, explaining their context-dependent association with
tumor progression both in human cancers and animal models.
Keywords: solid cancers; cell cycle; apoptosis; inflammation; mitochondria; stemness; tumor
suppression
1. Introduction
Activation of Signal Transducer and Activator of Transcription (STAT) proteins has been linked to
many human cancers. STATs were initially discovered as latent cytosolic transcription factors that are
phosphorylated by the Janus Kinase (JAK) family upon stimulation of membrane-associated cytokine
and growth factor receptors. Phosphorylation triggers STAT dimerization and translocation to the
nucleus to bind specific promoters and regulate transcription [1]. Here, we review the role of STAT
family members STAT3 and STAT5 in solid human malignancies, as well as the mechanisms that may
explain their association with either worse or better prognosis.
2. STAT3 and STAT5 in Solid Cancers
The discovery of cancer genes has been propelled by genetic analyses and more recently by next
generation DNA sequencing technologies. Combined, these studies have identified 127 significantly
mutated cancer genes that cover diverse signaling pathways [2]. Mutations acting as drivers in
cancer are positively selected during tumor growth and constitute solid proof of the involvement of
a particular gene as a driver in the disease. Mutations in STAT3 and STAT5 have been reported in
Cancers 2019, 11, 1428; doi:10.3390/cancers11101428 www.mdpi.com/journal/cancers219
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patients with solid cancers, but unlike hyperactivation of the JAK/STAT pathway, STAT3/5 mutations
in cancer are relatively infrequent and occur mostly in hematological malignancies.
An overview of reported STAT3/5 mutations in solid cancers is illustrated in Figure 1, based on data
collected from the Catalogue of Somatic Mutations in Cancer (COSMIC) database. Mutations in STAT3
are more prevalent than mutations in STAT5A or STAT5B genes. Noticeably, gastrointestinal cancers
have the highest rates of STAT3/5 mutations compared with other solid cancers (Figure 1). Missense
mutations tend to cluster within the SH2 domain, where gain-of-function mutations were previously
characterized [3,4], as well as within the DNA binding domain and to an extent the N-terminal domain
(Figure 1A). Interestingly, the STAT3 Tyrosine 640 into Phenylalanine (Y640F) hotspot gain-of-function
mutation reported in various lymphoid malignancies has also been detected in patients with liver
cancer (Figure 1A). Nonsense and frameshift mutations are less frequent and more disperse, likely
representing loss-of-function events (Figure 1B). Notably, a hotspot frameshift mutation at position
Q368 within the DNA binding domain of STAT5B has been reported in 24 patients with various types
of carcinoma; this frameshift generates a stop codon shortly after the mutation and is therefore likely
to be loss-of-function, although characterization of this mutation has not been performed.
As opposed to mutation rates, STAT3/5 activation is very frequent in human cancers, perhaps
reflecting increased cytokine signaling or mutations in cytokine receptors or negative regulators.
STAT3/5 activation can be detected using antibodies that measure total levels or activation marks in
STAT3/5 proteins (e.g. tyrosine phosphorylation). A better assessment of STAT3/5 activation can be
obtained by measuring downstream signaling targets (i.e., mRNA levels of STAT3 [5] and STAT5 [6]
target genes). A recent metanalysis of 63 different studies concluded that STAT3 protein overexpression
was significantly associated with a worse 3-year overall survival (OS) (OR = 2.06, 95% CI = 1.57 to
2.71, p < 0.00001) and 5-year OS (OR = 2.00, 95% CI = 1.53 to 2.63, p < 0.00001) in patients with solid
tumors [7]. Elevated STAT3 expression was associated with poor prognosis in gastric cancer, lung
cancer, gliomas, hepatic cancer, osteosarcoma, prostate cancer and pancreatic cancer. However, high
STAT3 protein expression levels predicted a better prognosis for breast cancer [7]. This study mixed
data of both STAT3 and phospho-STAT3 (p-STAT3) expression limiting its ability to associate pathway
activation to prognosis. Here, we summarize the data linking activation of STAT3/5 to overall survival
in several major human solid cancers identifying the biomarkers used in each study (Table 1). Taken
together, the results clearly show that STAT3 and STAT5 are important cancer genes despite their
relatively low mutation frequency.
STAT3 activation is clearly a factor linked to bad prognosis in patients with lung cancer, liver
cancer, renal cell carcinoma (RCC) and gliomas. In other tumors, the association is not significant. In
solid tumors, STAT3 activation is more frequent than STAT5 activation although no explanation for
this difference was proposed. In prostate cancer, both STAT3 and STAT5 have been associated with
castration-resistant disease and proposed as therapeutic targets [8,9]. In colon cancer, the association
between p-STAT3 and survival varies according to the study, but a high p-STAT3/p-STAT5 ratio
indicates bad prognosis [10]. Also in breast cancer, p-STAT5 levels are clearly associated with better
prognosis [11]. In liver cancer, STAT5 has ambivalent functions that were recently reviewed by Moriggl
and colleagues [12]. Understanding mechanistically how STAT3/5 promote transformation and tumor
suppression is important for the eventual design of new treatments. Also, survival data is highly
influenced by the response of patients to their treatment and may not always reflect all mechanistic
links between STAT3/5 activity and tumor biology. Of note, the effect of any gene is conditioned
by the genetic context of gene action. Some genes can clearly exert a tumor suppressor effect in the
initial stages of carcinogenesis that is lost when cancer mutations or epigenetic changes inactivate key
effectors of these tumor suppressor pathways [13]. Human studies are usually limited to late stage
tumors because it is easier to collect samples at that point. Studies in model systems, including primary
cells, organoids and mouse models are thus required for a full understanding of how cancer genes
work specifically at early stages in tumorigenesis.
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Table 1. STAT3/5 activity and overall survival in major human solid tumors.
Tumor Type Biomarker/Type of Study Overall Survival Ref
NSCLC High p-STAT3/Meta-analysis of 9 studies Log HR 0.67, 95% CI: 0.57–0.77, p < 0.0001 [14]
NSCLC High p-STAT3/Cox regressionmultivariate analysis HR 2.45, 95% CI: 1.084–5.556, p = 0.031 [15]
Lung cancer High p-STAT3/Meta-analysis of 13 studies HR 1.23, 95% CI: 1.04–1.46, p = 0.02 [16]
Pancreatic cancer High p-STAT3/Log-rank test No association p > 0.05 [17]
Liver cancer (HCC) High p-STAT3/Meta-analysis of 8 studies HR 1.69, 95% CI: 1.07–2.31, p < 0.0001 3yrHR 1.67, 95% CI: 1.18–2.15, p < 0.0001 5yr [18]
Breast cancer High p-STAT3/Meta-analysis of 12 studies No association p > 0.05 [19]
Breast cancer (ER+) High p-STAT3/Log-rank test No association p > 0.05 [20]
GBM High p-S727-STAT3/Cox regressionmultivariate analysis HR 1.797, 95% CI: 1.028–3.142, p = 0.040 [21]
RCC High p-S727-STAT3/Cox regressionmultivariate analysis HR 3.32, 95% CI: 1.26–8.71, p = 0.014 10yr [22]
Colon cancer High p-STAT3/p-STAT5 ratio/Coxregression multivariate analysis HR 4.468, p = 0.043 5yr [10]
Colon cancer High p-STAT3/Log-rank test Worse overall survival, p < 0.001 [23]
Colon cancer High p-STAT3/Cox regressionmultivariate analysis HR 1.61, 95% CI: 1.11–2.34, p = 0.015 [24]
Breast cancer Low p-STAT5/Cox regressionmultivariate analysis HR 2.49, 95% CI: 1.23–5.05, p = 0.012 5yr [11]
Prostate cancer High nuclear STAT5A/B/Cox regressionmultivariate analysis HR 1.59, 95% CI: 1.04–2.44, p = 0.034 [9]
ER+, estrogen receptor-positive; HCC, hepatocellular carcinoma; GBM, glioblastoma multiforme; NSCLC,
non-small-cell lung carcinoma; HR, hazard ratio; RCC, renal cell carcinoma.
3. Mechanisms of Transformation by STAT3/5 Proteins in Solid Cancers
STAT3 and STAT5 promote tumor progression by regulating the expression of cell cycle, survival
and pro-inflammatory genes. In addition, they control mitochondrial functions, metabolism and
stemness, as discussed below (Figure 2).
 
Figure 2. Mechanisms of tumorigenic activity of STAT3 and STAT5 signaling in solid tumors.
3.1. Cell Cycle and Apoptosis
As transcription factors, STAT3 and STAT5 regulate many genes required for cell cycle progression
and cell survival. A major target of the transcriptional control of the mammalian cell cycle is cyclin
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D. STAT3 regulates cyclin D expression in a complex with CD44 and the acetyltransferase p300.
The latter acetylates STAT3 promoting its dimerization, nuclear translocation and binding to the
cyclin D promoter [25]. Other cell cycle and survival genes regulated by STAT3 include c-MYC (myc
proto-oncogene), B-cell lymphoma 2 (BCL2), BCL2L1/BCL-XL (B-cell lymphoma-extra large), MCL1
(Myeloid Cell Leukemia Sequence 1) and BIRC5/survivin [26]. Recent studies combined ChIPSeq with
whole transcriptome profiling in ABC DLBCL (activated B cell-like diffuse large B cell lymphoma) cell
lines and revealed that STAT3 activates genes in the Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian
Target of Rapamycin (mTOR) pathway, the Nuclear Factor Kappa-Light-Chain Enhancer of Activated
B-Cells (NF-κB) pathway and the cell cycle regulation pathway, while repressing type I interferon
signaling genes [27]. STAT5 also regulates the expression of cell cycle and cell survival genes [13]
including AKT1 [28], which encodes a pro-survival kinase.
3.2. Inflammation and Innate Immunity
Although the induction of cell proliferation and cell survival genes by STAT3/5 proteins contribute
to their pro-cancer activity, in basal-like breast cancers the major genes associated with STAT3
activation control inflammation and the immune response [29]. Of note, inflammation is initially an
adaptive response to pathological insults such as oncogenic stimuli, and it therefore exerts a tumor
suppressive function. However, dysregulated inflammation in the long term provides a substrate
for tumorigenesis [30]. STAT3 alone or in cooperation with NF-κB regulates the expression of many
pro-inflammatory genes [31–33]. Starved tumor cells activate NF-κB and STAT3 via endoplasmic
reticulum (ER) stress and secrete cytokines that stimulate tumor survival and clonogenic capacity [34].
The coactivation of these two transcription factors amplifies pro-inflammatory gene expression driving
cancer-associated inflammation [35]. Of interest, the STAT3-NF-κB complex can repress the expression
of DNA Damage Inducible Transcript 3 (DDIT3), an inhibitor of CCAAT Enhancer Binding Protein
Beta (CEBPβ), another pro-inflammatory transcription factor [36].
Pharmacological agents that limit inflammation have been proposed for cancer prevention [37].
The use of metformin, a drug widely used to control diabetes, has been associated with a dramatic
reduction in cancer incidence in many tissues [38]. Although the primary site of action of this drug
is in mitochondria, a consequence of its effects is a potent reduction in the activation of NF-κB and
STAT3, suggesting that the promising anticancer actions of metformin are related to its ability to curtail
pro-inflammatory gene expression [39,40]. In contrast to STAT3, STAT5B inhibits NF-κB activity in the
kidney fibroblast cell line COS by competing with coactivators of transcription [41], while it stimulates
NF-κB in leukemia cells [42]. These results suggest the involvement of different regulatory mechanisms
of STAT5 in hematopoietic cancers compared with solid cancers.
3.3. Mitochondria
In addition to their canonical roles in inflammation and immunity, STAT3 and STAT5 have been
shown to localize to mitochondria. The mitochondrial localization of STAT3 is required for its ability
to support malignant transformation in murine embryonic fibroblasts and breast cancer cells [43–46],
and mito-STAT3 regulates mitochondrial metabolism and mitochondrial gene expression [45,47–51].
Several reports have suggested that STAT3 can be imported to mitochondria after phosphorylation
on S727 [44,45] or upon acetylation [52,53]. Other studies have revealed that STAT3 mitochondrial
translocation is mediated by interactions with Heat Shock Protein 22 (HSP22), Gene Associated
with Retinoic and Interferon-Induced Mortality 19 (GRIM-19) or Translocase of Outer Mitochondrial
Membrane 20 (TOM20) [54–56]. The mRNAs coding for some mitochondrial proteins are translated
close to or in physical interaction with the import complex TOM [57,58]. The structural motifs mediating
those interactions are located in the 3′ and 5′ UTRs of the mRNAs [59,60] and it will be interesting to
investigate whether the mRNA of STAT3 also possesses RNA localization signals (zip codes) to localize
in close proximity to mitochondria.
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Whereas the role of mitochondrial STAT3 has been extensively studied, the role of STAT5 in
mitochondria is less clear. The import of STAT5 to mitochondria is regulated by cytokines [43]. Once
imported into the mitochondria, STAT5 binds the D-loop of mitochondrial DNA, although no increase
in transcription of mitochondrial genes was observed [61]. Mito-STAT5 is also able to interact with the
Pyruvate Dehydrogenase Complex (PDC) and was shown to regulate metabolism towards glycolysis,
as observed in cells treated with cytokines [43,61]. In the same line, STAT3 was also shown to interact
with the PDC in mitochondria [53].
3.4. Reprogramming and Stemness
The role of STAT3 in stem cell biology was initially recognized due to the requirement for the
cytokine LIF to maintain pluripotency in cultures of mouse embryonic stem (ES) cells. STAT3 activation
mediates the induction or repression of several genes in mouse ES cells including the pluripotency
factors Oct4, Klf4, Tfcp2l1 and polycomb proteins [62–64]. Many pluripotency factors, such as
Homeobox Protein NANOG, are short-lived proteins. STAT3 controls protein stability by inducing
the expression of the deubiquitinase Ubiquitin Specific Peptidase 21 (USP21), stabilizing NANOG
in mouse ES cells. Induction of ES cell differentiation promotes the Extracellular Signal-Regulated
Kinase (ERK)-dependent phosphorylation of USP21 and its dissociation from NANOG, leading to
NANOG degradation [65]. STAT3 also plays a role in the reprogramming of somatic cells into induced
pluripotent stem (IPS) cells [66] and it has been suggested that its effects depend on the demethylation of
pluripotency factor promoters [67]. STAT3 also activates mitochondrial DNA transcription, promoting
oxidative phosphorylation during maintenance and induction of pluripotency [68]. It is thus likely
that the ability of STAT3 to stimulate stemness also plays a role in its oncogenic activity.
In many tumors, a subpopulation of cells possess a higher malignant capacity. These so-called
tumor-initiating cells are suspected to regenerate the tumor after cancer chemotherapy and express
many genes commonly expressed in ES cells [69]. It has been shown that STAT3 is required for
the formation of tumor spheres and the viability of the cancer stem cell pool in many different
tumors [39,40,70–83]. At least in breast cancer, a critical mechanism stimulated by STAT3 to regulate
stemness involves genes in fatty acid oxidation [78,79] and the ability of STAT3 to adjust the levels of
reactive oxygen species (ROS) produced in mitochondria [79]. In colorectal cancer cells, STAT3 forms a
complex with the stem cell marker CD44 and the p300 acetyltransferase. Acetylation of STAT3 by this
complex allows dimerization, nuclear translocation and binding to the promoters of genes required for
stemness such as c-MYC and TWIST1 [84].
The role of STAT5 in promoting cancer stemness does not affect many cell types and is mostly
confined to hematopoietic cancers [85]. However, Nevalainen and colleagues reported that STAT5B
induces stem cell properties in prostate cancer cells [86] in line with the increase in nuclear STAT5A/B
observed in these tumors in correlation with bad prognosis [9]. Furthermore, transgenic mice with
increased expression of prolactin in prostate epithelial cells displayed increases in the basal/stem cell
compartment in association with activation of STAT5. This enrichment of stem cells was partially
reversed by depletion of Stat5a/b [87]. The pro-stem cell oncogenic effect of STAT5 in the prostate
contrasts with its effects in the mammary gland where STAT5 induces cell differentiation [88]. The ETS
transcription factor Elf5 (E74-like factor 5) is a target of the prolactin-STAT5 axis and promotes mammary
cell differentiation [89–91], supporting the tumor suppressive role of STAT5 in the mammary gland.
4. Tumor Suppressor Functions and Negative Regulation of STAT3/5 Signaling
The oncogenic activity of JAK/STAT signaling is controlled by several molecular barriers that limit
the activation of this pathway. They include tyrosine phosphatases, E3 SUMO ligases of the Protein
Inhibitor of Activated STAT3 (PIAS) family, E3 ubiquitin ligases and miRNAs. In addition, oncogenic
STAT3/5 signaling can activate fail-safe tumor suppressors such as protein of alternative reading frame
19 (p19ARF), Suppressor of Cytokine Signaling 1 (SOCS1) and p53 that trigger apoptosis, ferroptosis
and/or senescence in potentially malignant cells (Figure 3). Understanding these different responses to
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STAT signaling in cancer is important to further distinguish tumors that would benefit from STAT3 or
STAT5 inhibitors and those that would not.
 
Figure 3. Tumor suppressor pathways acting on STAT3/5 activity (Protein Inhibitor of Activated
STAT3 PIAS, miRNAs, E3 ligases, phosphatases) or activated by STAT3/5 transcriptional activity
(Protein of alternative reading frame 19 (p19ARF) Suppressor of Cytokine Signaling 1 and 3 (SOCS1/3),
p53). Abbreviations: (PTPN2 (Tyrosine-protein phosphatase non-receptor type 2), PTPN9/MEG2
(Tyrosine-protein phosphatase non-receptor type 9), PTPN11/SHP2 (Tyrosine-protein phosphatase
non-receptor type 11), PTPN6/SHP1 (Tyrosine-protein phosphatase non-receptor type 6) and TNF
receptor associated factor 6 (TRAF6)).
4.1. Tyrosine Phosphatases
Activation of STAT3 and STAT5 in tumors is often associated with tyrosine phosphorylation,
a modification that can be reverted by several protein tyrosine phosphatases such as PTPN2
(Tyrosine-protein phosphatase non-receptor type 2), PTPN9/MEG2 (Tyrosine-protein phosphatase
non-receptor type 9), PTPN11/SHP2 (Tyrosine-protein phosphatase non-receptor type 11) [92,93],
CD45 [94] and PTPN6/SHP1 (Tyrosine-protein phosphatase non-receptor type 6) [95]. However, little
is known about a possible role of these phosphatases in STAT3 activation in solid tumors. In liver
cancers, SHP1 is downregulated in cells with mesenchymal features, and restoring its levels both
reduced STAT3 phosphorylation and reversed the mesenchymal phenotype of liver cancer cells [95].
SHP1 and SHP2 also target STAT5 [96,97] but the significance of this regulation in solid tumors remains
to be investigated.
4.2. PIAS
The Protein Inhibitor of Activated STAT3 (PIAS3) inhibits STAT3 transcriptional activity. In
gliomas, PIAS3 expression is reduced [98]. Mechanistically, SMAD6 promotes PIAS3 degradation,
promoting glioma cell growth and stem cell properties [76]. The PIAS proteins have SUMO E3
ligase activity acting on multiple proteins, and so their effects cannot be solely attributed to STAT3
inhibition [99]. Of interest, PIAS3 can bind NF-κB promoting its SUMOylation and inhibiting its
activity [100,101], potentially targeting the expression of many pro-inflammatory genes required for
tumor progression. Also, PIAS3 binds the N-terminus of p53 and prevents the interaction with its
negative regulator MDM2, leading to p53 stabilization [102].
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4.3. E3 Ligases
The Golgi resident and BC-box protein TATA Element Modulatory Factor/Androgen
Receptor-Coactivator of 160 kDa (TMF/ARA160) was reported as an E3 ligase that catalyzes STAT3
ubiquitination leading to its proteasome-dependent degradation in myogenic C2C12 cells. The level
of TMF/ARA160 was found to be significantly decreased in glioblastoma multiforme tumors, in
benign meningioma and in malignant anaplastic meningioma, where STAT3 is known to play an
oncogenic role [103]. TMF/ARA160 can also bind and ubiquitinate RELA/NF-κB leading to its
proteasome-dependent degradation and a decrease in the expression of inflammatory genes [104].
Furthermore, the ubiquitin ligase TNF receptor associated factor 6 (TRAF6) binds and ubiquitinates
STAT3 inhibiting the expression of STAT3 target genes [105]. During oncogene-induced senescence,
STAT3 is degraded by the proteasome but the E3 ligase responsible has not been identified [106].
Recent results revealed that the long non-coding RNA (lncRNA) PVT1 (long non-coding RNA encoded
by the human PVT1 gene) binds STAT3 and protects it from ubiquitin-dependent degradation in
gastric cancer [107]. PVT1 is upregulated in multiple cancers predicting poor prognosis for overall
survival [108–110].
4.4. MiRNAs
The miRNA miR-124 regulates STAT3 signaling by targeting the mRNAs of interleukin-6 receptor
(IL6R) [111] and STAT3 [112,113]. Suppression of this miRNA increases STAT3 phosphorylation
and induces transformation in immortalized mouse hepatocytes. Of interest, systemic delivery of
miR-124 prevented tumor growth in diethylnitrosamine (DEN)-treated mice, and miR-124 levels
were found to be reduced in human hepatocellular carcinomas (HCC) [111]. In gliomas, miR-124 is
poorly expressed but upregulation of its expression in glioma cancer stem cells inhibited the STAT3
pathway. In this model, STAT3 mediates immunosuppression, which was relieved upon systemic
miR-124 delivery [114]. The circular RNA (circRNA) 100782 is upregulated in pancreatic cancer and its
knockdown downregulates all miR-124 targets including IL6R and STAT3. This circRNA binds miR-124
suggesting that it may act as a miRNA sponge [115]. Furthermore, the miRNA miR-1181 also targets
STAT3 and is downregulated in pancreatic cancer, predicting poorer overall survival. Overexpression
of miR-1181 inhibited tumor formation and stem cell properties of pancreatic cancer cells [116].
4.5. The Suppressor of Cytokine Signaling SOCS
The members of the Suppressor of Cytokine Signaling (SOCS) family are major negative feedback
regulators of JAK/STAT signaling and their expression is dysregulated in many human cancers [117–119].
These genes provide a barrier for cells with aberrant cytokine activation by inhibiting cytokine
signaling [120]. In STAT3 driven cancers, SOCS3 seems to be the most important negative feedback
regulator and mouse models of SOCS3 ablation show strong STAT3 activation [119,121–124]. On the
other hand, in solid cancers where STAT5 plays a causal role such as liver and prostate cancer, in
addition to SOCS3, SOCS1 is frequently inactivated and mouse models of SOCS1 ablation increase both
liver and prostate tumorigenesis [125–132]. In addition to their role as JAK/STAT signaling barriers,
SOCS1 and SOCS3 can bind p53 and activate tumor suppressor responses such as senescence and
ferroptosis when their expression is induced by aberrant STAT5 signaling in primary cells [133–138].
In this way, SOCS1 and SOCS3 also act as fail-safe tumor suppressors in response to aberrant JAK/STAT
signaling. So far, the SOCS1-p53-senescence axis has been demonstrated in primary fibroblasts and
mammary epithelial cells [133,139–141]. This mechanism may explain the better prognosis of some solid
cancers with high p-STAT5 [142–144] and the high frequency of SOCS1 inactivation in STAT5-driven
cancers [125–132]. However, it is difficult to obtain evidence of a senescence tumor-suppression
response by studying established tumors that have already circumvented this pathway. Senescence
is particularly noticeable in premalignant lesions and benign tumors [40,106,145–150], and can be
reactivated by cancer chemotherapy [151,152]. For this reason, evidence of STAT5-induced senescence
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in human cancers is not yet available and should be studied in samples from premalignant tumors or
after chemotherapy.
The mechanisms that disable SOCS1 and SOCS3 in human cancers are often epigenetic, mediated
either by miRNAs, promoter methylation or protein phosphorylation [127,128,130,131,137,153–162].
The SRC family of kinases (SFK) phosphorylate SOCS1 at Y80, interfering with p53-SOCS1 interactions.
SFK inhibitors can reverse this effect and could be used to restore the SOCS1-p53 axis in tumors where
these two proteins remain intact [162]. It is also possible to consider treatments that re-express SOCS1/3
in tumors. Indeed, in liver cancer SOCS3 gene expression can be re-established by drugs that activate
the Farnesoid X receptor (FXR) [163,164]. Gene therapy strategies are also under development to
re-express SOCS1 or SOCS3 in tumors [165–167].
4.6. P19ARF-p53 Pathway
One of the first reports demonstrating that STAT3 can act as a tumor suppressor was shown in
glioblastoma multiforme (GBM) [168] where a combination of low Phosphatase and tensin homolog
(PTEN) expression and loss of STAT3 in astrocytes increased their tumorigenicity. This observation
is in contrast to papers cited above on the requirement for STAT3 to maintain tumor stem cells in
GBM [73,75,169]. This could be explained if STAT3 acts early in tumorigenesis as a tumor suppressor
but gains oncogenic functions in the context of the cancer genome and epigenome. An interesting
mechanism for the tumor suppressor role of STAT3 was recently described in the prostate where
STAT3 induces the expression of p19ARF [170]. The latter is a tumor suppressor that activates p53
and inhibits ribosome biogenesis inducing cellular senescence and apoptosis [171–174]. Loss of STAT3
disrupts this STAT3-ARF-p53 axis and permits tumor progression [175]. STAT3 and other STATs can
also induce p21 leading to cell cycle arrest or cellular senescence [176,177]. Further evidence for STAT3
as a tumor suppressor has been reported in lung [178], colon [179,180], thyroid [181], liver [182,183],
skin [184], neck [185], nasopharynx, rectum [186], salivary gland [187] and breast cancers [188] but the
mechanisms remain to be investigated.
5. Concluding Remarks
Context-dependent activities of STAT3 and STAT5 in solid human cancers justify detailed molecular
studies that will clarify the specific molecular mechanisms of action of these two cancer genes. The
cancer genome and transcriptome are shaped and selected to favor cancer cell survival and proliferation.
Although restoring mutated genes is technologically difficult, reprograming the transcriptome to
restore tumor suppression may be feasible. Drugs acting on STAT3/5 and their regulators may restore
the control of cell proliferation in cancer cells.
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Abstract: Driven by dysregulated IL-6 family member cytokine signaling in the tumor microenvironment
(TME), aberrant signal transducer and activator of transcription (STAT3) and (STAT5) activation have
been identified as key contributors to tumorigenesis. Following transformation, persistent STAT3
activation drives the emergence of mesenchymal/cancer-stem cell (CSC) properties, important
determinants of metastatic potential and therapy failure. Moreover, STAT3 signaling within
tumor-associated macrophages and neutrophils drives secretion of factors that facilitate metastasis and
suppress immune cell function. Persistent STAT5 activation is responsible for cancer cell maintenance
through suppression of apoptosis and tumor suppressor signaling. Furthermore, STAT5-mediated
CD4+/CD25+ regulatory T cells (Tregs) have been implicated in suppression of immunosurveillance.
We discuss these roles for STAT3 and STAT5, and weigh the attractiveness of different modes of
targeting each cancer therapy. Moreover, we discuss how anti-tumorigenic STATs, including STAT1
and STAT2, may be leveraged to suppress the pro-tumorigenic functions of STAT3/STAT5 signaling.
Keywords: STAT3; STAT5; cancer progression; cancer-stem cell; cytokine; therapy resistance;
metastasis; immunosuppression; tumor microenvironment; proliferation
1. Introduction
A complex milieu of both cellular and non-cellular components creates a heterogeneous tumor
and microenvironment [1–8]. As a tumor becomes more heterogeneous, the risk of metastasis and
therapy failure increases [9–12]. Cancer cells, pericytes, immune cells, fibroblasts, and endothelial
cells are just some of the cellular components of the tumor [13,14]. A highly dysregulated network of
cytokines and growth factors, emanating from cancer and stromal tumor microenvironment (TME)
cells, contributes to the evolution of cancer cells, and often, suppression of immune cell function.
Many of these cytokines and growth factors result in the phosphorylation and activation of signal
transducers and activators of transcription (STAT) proteins, which can drive cell-specific changes in
gene expression. STAT3 and STAT5 activity is often elevated in aggressive subtypes of cancer and
serve as prognostic indicators [15–24]. Here, we discuss the impact of microenvironmental signals
on STAT3/STAT5 activation during cancer development and progression. Elevated STAT3 activity
promotes epithelial-mesenchymal transition (EMT) and a stem cell program in cancer cells, while
also suppressing the function of immune cells within the tumor, all of which are important steps
that underlie metastasis and therapy failure [25–30]. Likewise, persistent STAT5 activity induces
(i) transformation, (ii) proliferation, and (iii) anti-apoptotic signals that contribute to hematological
malignancies, while also suppressing anti-tumor immunity by expanding CD4+/CD25+ regulatory
T cells (Tregs) [28,31–36]. We will discuss options for targeting STAT3/5 in cancer, either directly or
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indirectly through the inhibition of upstream kinases, receptors and/or ligands. In addition, we
will discuss how STAT1/2 activity can counter the more aggressive phenotypes induced by STAT3/5.
We propose that balancing STAT-activated cytokine signaling in the TME may serve as an effective
therapeutic strategy.
2. Activating STAT3 and STAT5
The STAT family of transcription factors is comprised of seven different members, STAT1, -2, -3,
-4, -5a, -5b, and -6. Hereafter, when discussing the overlapping functions of STAT5A and STAT5B, we
will refer to them as “STAT5”. STAT proteins transduce signals from the cell membrane to the nucleus,
bypassing the need for second messengers [37–39]. STATs are phosphorylated by Janus Kinases
(JAK1, 2, 3) or Tyrosine Kinase 2 (Tyk2), which are recruited to ligand-activated receptors, including
cytokine, growth factor, or g-protein associated receptors. Most important of the STAT3/5 activators
are the IL-6 family members, which include IL-6, IL-11, ciliary neurotrophic factor (CNTF), leukemia
inhibitory factor (LIF), oncostatin-m (OSM), cardiotrophin 1 (CT-1), cardiotrophin-like cytokine (CLC),
and IL-27. IL-6 family cytokines form a heterodimeric complex consisting of gp130 and a cytokine
specific subunit (IL-6Rα, IL-11Rα, CNTFRα, gp130, LIFR, and OSMR), recruiting and activating the
JAKs or Tyk2. Once phosphorylated, STATs dimerize and translocate to the nucleus, where they bind
to short stretches of DNA and act as transcription factors to induce the expression of genes implicated
in cell proliferation, survival, differentiation, motility, apoptosis, and metabolism (Figure 1) [37,40–43].
The crucial role STATs play in these normal physiological processes was first demonstrated
in STAT-deficient mouse models. The generation of tissue-specific STAT3 knockout models have
identified STAT3 as a key component in a wide variety of processes, including, but not limited
to: T-cell proliferation, suppression of apoptosis, epidermal regeneration during wound healing,
macrophage and neutrophil anti-inflammatory responses, and mammary gland involution [44–46].
Deletion of STAT5 in mice demonstrated high incidence of perinatal lethality, prevented the appropriate
development of B-cells and T-cells, and inhibited the function of hematopoietic stem cells [47]. Under
normal conditions, JAK/STAT activation is tightly regulated by protein inhibitors of activated STATs
(PIAS), tyrosine phosphatases, and suppressors of cytokine signaling (SOCS) proteins that inhibit
JAK catalytic activity [48,49]. In cancer however, STAT3 and STAT5 activity becomes dysregulated,
resulting in elevated STAT3/5-driven responses in tumor, stromal, and immune cells.
Advances in sequencing technologies have allowed scientists to investigate the frequency of
mutations in the JAK/STAT signaling pathway, resulting in the identification of mutations that
constitutively activate STAT3, STAT5, and JAK2. The majority of STAT mutations occur in the SH2
and C-terminal domains of STAT3 and STAT5B and associate with leukemias and lymphomas [50,51].
STAT3 is the most frequently mutated member of the STAT family, with high incidence of mutation in
T-cell large granular lymphocytic leukemias and NK lymphoproliferative disorders [52,53]. STAT5B
mutations were similarly identified in these diseases, but with lower frequency. In addition, sequencing
of STAT3 exons in diffuse large B-cell lymphoma patients identified a missense point mutation (M206K)
in the coiled-coil domain that affected SH2 domain function and drove robust proliferation [54,55].
Furthermore, JAK2 V617F, a constitutively active JAK2 mutant, phosphorylates both STAT3 and
STAT5 proteins and has high frequency in patients with hematopoietic stem cell diseases, such as
myeloproliferative diseases, essential thrombocythemia, polycythemia vera (PV), and idiopathic
myelofibrosis (IMF) [56]. In addition, JAK2 V617F mutations have transformation potential in in vivo
bone marrow transplantation assays and induce persistent activation of STAT5 and a PV phenotype [57].
While persistent activation of both STAT3 and STAT5 has been implicated in the transformation process,
the greater impact of dysregulated STAT3/5 appears to be their influence on the induction of aggressive
cancer cell properties and immunosuppression. The impacts of both cell-intrinsic reprogramming and
immune dysfunction are discussed below.
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Figure 1. STAT3/5 Signaling Cascades and Therapy Targets. Schematic representation of canonical
activation of signal transducer and activator of transcription-3 (STAT3) and STAT5 by IL-6 family
member cytokines. IL-6 family cytokines drive receptor heterodimerization and subsequent Janus
Kinase (JAK activation). JAKs phosphorylate tyrosine residues along the cytoplasmic domain of
the receptor dimer, which recruits STAT proteins and facilitates their binding to interferon-gamma
activation site-like (GAS-like) elements and regulation of large sets of genes. Asterisks (*) denote that
additional info can be found in Table 1.
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Therapies included in the far right column are listed by their respective name followed by their biological target in
parentheses. Italicized font denotes therapies that are not currently approved by the FDA as cancer therapies.
3. IL-6 Family Cytokine Dysregulation in the TME
A number of IL-6 family members have long been recognized for their involvement in the
pathogenesis of aggressive cancers [19,77–81]. For example, IL-6 levels serve as a prognostic biomarker
and predictor of therapeutic response in pancreatic ductal adenocarcinoma (PDAC), bladder, gastric,
lung adenocarcinoma, colorectal, cervical, liver, and breast cancers: all of which have a high incidence
of metastasis and resistance [77,82–86]. This is due to the pro-tumor effects of IL-6 in tumor cells
and stromal components. In tumor cells, IL-6 can drive EMT, therapy resistance, and invasive
characteristics [87–89]. Concurrently, IL-6 can shift the anti-tumor immune responses towards
immunosuppression via recruitment of myeloid-derived suppressor cells (MDSCs) and expansion of
FoxP3+ Tregs [90–92]. Furthermore, IL-6 secretion by certain stromal components (cancer-associated
fibroblasts, macrophages, and neutrophils) drives EMT in associated tumor populations, which is
supported by immunohistochemical staining at the invasive edge of patient breast tumors, where
levels of phosphorylated STAT3 and IL-6 is elevated [93,94].
Interestingly, IL-6 activation of STAT3 functions in a positive feed-forward loop to drive the
secretion of new IL-6 into the TME, which then interacts with IL-6R/gp130 to further activate JAK/STAT
signaling [93,95]. OSM also potently activates a feed-forward loop, resulting in the de novo production
of additional OSM and OSMR by tumor and immune cells [96]. Interestingly, OSM was first identified
to play a tumor suppressive role and inhibited the proliferation of melanoma cell models [97]. However,
later studies correlated OSM-OSMR signaling with robust STAT3 and STAT5 activation and more
aggressive tumor phenotypes [98–106]. Like IL-6, OSM feed-forward signaling is observed in aggressive
cancers with limited-therapeutic options, including glioblastoma (GBM), non-small cell lung carcinoma
(NSCLC), PDAC, and triple negative breast cancer (TNBC) [107–111]. Elevated signaling through the
OSM/OSMR axis induces high levels of an ‘inflammatory module’, which includes IL-6, CCL2, IL-1,
CXCL1, CXCL9, CXCL10, and CXCL11—all of which have been implicated in migration, invasion,
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therapy failure, and dedifferentiation to a cancer stem cell (CSC) program. Importantly, neutralization
of OSM by treatment with an Fc-tagged soluble OSMR suppresses this inflammatory module suggesting
that the OSM/OSMR feed-forward loop may be critical for the long-term maintenance of inflammatory
signaling [112,113].
IL-11 similarly engages in an autocrine feed-forward mechanism to drive persistent JAK2/STAT3
activation, which can promote resistance to platinum-based therapies [114]. Furthermore, IL-11 and LIF
both contribute to tumorigenesis by enhancing tumor cell survival through STAT3-mediated activation
of anti-apoptotic proteins, Bcl-2 and Survivin, and the inhibition of tumor suppressor p53 [114–116].
IL-11 and LIF also contribute to cancer progression by driving EMT through STAT3 and Akt/mTOR
signaling, thereby conferring an enhanced migratory capacity [81,117,118]. The impact of CT-1, CLC,
CNTF, and IL-27 on cancer progression is currently understudied. While IL-6 family cytokines are
important mediators of STAT3 activation, other cancer-associated receptors can also activate STAT3.
STAT3-driven tumor progression can also be achieved by epidermal growth factor receptors (both
wild-type EGFR and EGFRvIII), fibroblast growth factor receptors (FGFR), insulin-like growth factor
receptor (IGFR), hepatocyte growth factor (HGFR, also known as MET), platelet-derived growth factor
receptor (PDGFR), vascular endothelial growth factor receptor (VEGFR), v-src, and Bcr-Abl [119–127].
Interestingly, acetylation of STAT3 also induces tumor progression through enhanced pro-tumorigenic
IL-17A secretion [128,129]. These examples demonstrate the abundance of mechanisms through which
STAT3 can become activated.
4. STAT3 Activation of a Mesenchymal/CSC Program in Cancer Cells
The majority of cancers have constitutive activation of STAT3 [130–132]. STAT3 was first termed
oncogenic when its persistent activation was discovered in v-src transformed mouse embryonic
fibroblasts [133]. Subsequent studies demonstrated that expression of a constitutively active STAT3
isoform (STAT3-C) can drive transformation of pre-malignant human mammary epithelial cells (HMEC)
and MCF-10A cells to malignant breast cancer [134]. In addition, Ras-induced transformation in
bladder and breast carcinoma models exhibit mitochondrial accumulation of STAT3 and more robust
cellular glycolysis, a characteristic of cancer cells [135]. In PDAC, STAT3 is required for both the
development of pre-malignant pancreatic interepithelial neoplasias (PanINs), as well as the progression
of PanINs to PDAC [136]. While STAT3 has been strongly implicated as a driver of oncogenesis,
evidence suggests that persistent cytokine activation of STAT3 in pre-malignant lesions, engages a
tumor suppressive senescence response. In non-transformed HMEC models, OSM engages senescence
through a direct STAT3 interaction with mothers against decapentaplegic-3 (SMAD3). However,
downstream constitutive expression of c-Myc could overcome OSM-induced senescence and drive
EMT and invasion [137]. Beyond the genetic events that occur as a normal cell becomes transformed,
cancer progression relies heavily on an evolving microenvironment, which impacts both the cancer
cells and the immune system, ultimately influencing patient outcomes. In cancer cells, increased
STAT3 activity induces EMT-driving transcription factors, such as ZEB1, SNAIL, and Twist, which
initiate the repression of epithelial markers and expression of mesenchymal markers (N-cadherin,
Vimentin) [138–141]. In addition, STAT3 induces the expression of matrix metalloproteinases (MMP),
which can also contribute to the loss of cell-cell contacts [142–144].
While EMT is important in normal physiology to allow cells to migrate during development
and wound healing, inappropriate EMT and the loss of cell-cell interactions contributes to aggressive
cancer cell behaviors, including metastasis and resistance to therapy. In TNBC, the loss of E-cadherin
or gain of Vimentin, N-Cadherin, or Snail expression, typically at the tumor’s edge, correlates with
poor clinical outcome [145–149]. Likewise, the presence and abundance of circulating tumor cells
(CTC) that express mesenchymal markers have been referred to as the “silent predictors of metastasis”
because they correlate with tumor cell dissemination [150]. Moreover, mesenchymal CTC can be used
to track a patient’s response to therapy, with increasing numbers correlating with increased risk of
relapse [151–155].
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Likewise, the emergence of CSC properties, which are often defined experimentally as using
tumorsphere- or tumor-initiating assays, frequently occur concomitantly with a mesenchymal
phenotype [156–163]. STAT3 has been identified as an essential driver of the de novo reprogramming
to a CSC state through activation of Sox2, Nanog, and Oct4 [164–170]. Further evidence linking EMT
and a CSC phenotype is provided by the observation that a subset of CTC, responsible for initiating
metastasis termed the metastasis-initiating cells, express high levels of the STAT3-driven CSC marker
CD44 [151–153,171–174]
The importance of mesenchymal/CSC reprogramming in metastasis and therapy failure continues
to emerge. For example, single-cell analysis identified a predominantly mesenchymal/CSC program
in early-stage TNBC micro-metastases, in contrast to late-stage metastases [154]. The findings are
consistent with the idea that mesenchymal/CSC initiate metastatic outgrowth at a secondary site,
followed by differentiation. Single cell RNA sequencing (scRNA-seq) confirmed that EMT in primary
tumors proceeds through distinct, hybrid states, ranging from completely epithelial to completely
mesenchymal [155]. The epithelial-mesenchymal hybrids, which harbor the greatest level of phenotypic
plasticity, are more efficient at intravasating, surviving in circulation, extravasating to the lungs, and
forming metastases [175]. Acute exposure to Adriamycin or Taxanes drives the adaptive emergence
of therapy-resistant, CD44HIGH CSC in both breast tumor explants and breast cancer cell lines [176].
scRNA-seq determined that chemo-resistant cells activate an EMT program, which was not evident
before treatment [177]. In mouse models, the ability to undergo EMT is important for therapeutic
resistance [178,179]. These findings suggest that potent mesenchymal/CSC programming has significant
consequences that allow cancer cells to adapt to chemotherapy and survive, ultimately contributing to
therapy failure.
Indeed, STAT3 has also been implicated in acquired therapy resistance in many cancers
including NSCLC, GBM, PDAC, melanoma, and breast cancer [107,180–185]. Elevated STAT3
phosphorylation in ovarian cancer is associated with paclitaxel resistance and increased tumor
cell invasion post-therapy, consistent with the elevated expression of mesenchymal/CSC genes
and increased tumor initiating potential [176,186,187]. In Trastuzumab-resistant HER2+ breast
cancer, STAT3 feed-forward loops generate a TME rich with STAT3-activating cytokines that promote
and maintain the mesenchymal/CSC phenotypes. Inhibition of the STAT3 feed-forward activation
diminished tumor growth and metastasis and resensitized cells to therapy [188]. In cancer cells driven
by diverse receptor tyrosine kinases (RTKs) (EGFR, HER2, ALK, and MET), MEK inhibitors drive
feedback activation of STAT3 through FGFR and JAKs, resulting in therapy failure [189]. Likewise, in
NSCLC cells resistant to molecularly-targeted therapies (EGFR-TKI, ALK inhibitor Crizotinib, and
MEK inhibitor Selumetinib), OSM/JAK1/STAT3–signaling protects cells from targeted drug-induced
apoptosis [190]. JAK/STAT3 signaling also interacts with numerous other growth, proliferative, and
survival pathways, such as PI3K/Akt, MAPK, NF-kB, Notch, Wnt/β-Catenin, and TGF-β, among
others [191–196]. Tamoxifen-resistant breast cancers have elevated STAT3 and Notch4 expression
associated with metastasis and tumorigenicity. Interestingly, inhibition of Notch4 was able to reduce
the phosphorylation of STAT3 and suppress metastasis, suggesting STAT3 and Notch4 cooperate to
promote therapy resistance [197]. In addition, a STAT3/NF-kB complex promotes cisplatin resistance
in malignant mesothelioma, and targeted inhibition of this complex inhibits the growth of refractory
tumors [198]. Such evidence suggests STAT3 may not be solely responsible for therapy failure. Instead,
STAT3-mediated cross-talk with additional signaling effectors may coordinate resistance [140,199–201].
Nonetheless, the common theme appears to be a STAT3-activated, mesenchymal/CSC program.
5. A STAT3-Generated Pro-Metastatic Immune Microenvironment
An important and rapidly emerging area of research is the impact of the immune microenvironment
on metastasis and therapy failure. Beyond its impact on tumor cells, STAT3 has an important role in
restricting immune cell functions and producing immunosuppressive factors. STAT3-induced cytokines
are important mediators of the crosstalk between tumor cells, tumor-associated macrophages (TAMs),
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and tumor-associated neutrophils (TANs), which are responsible for generating a pro-metastatic
and pro-angiogenic TME [202]. In the TME, macrophages and neutrophils are exposed to a host
of STAT3-induced cytokines, such as IL-4, IL-6, IL-10, IL-13, VEGFA, and TGF-β that drive their
polarization to a pro-tumorigenic M2 (macrophages) or N2 (neutrophils) state [203,204]. Conversely,
robust STAT3 signaling activity in M2-TAMs and N2-TANs correlates with the production of factors
able to drive cancer cell EMT (OSM, IL-6, TGF-β) and angiogenesis (VEGF, TGF-β, PDGF, and
FGF) [205–208].
Importantly, because of their localization at the invasive edge of tumors, the contribution of
M2-TAMs and N2-TANs to metastasis is increasingly being recognized. For example, TAMs have been
demonstrated to form simultaneous physical contacts with tumor cells and endothelial cells that result
in the formation of invadopodia, which assist cancer cells in transendothelial migration and escape into
the circulatory system. These sites of cancer cell intravasation are called “tumor microenvironment of
metastasis (TMEM)” and have been validated as prognostic markers of metastasis. Chemotherapy
increases TMEM in breast cancer patients, thereby potentially facilitating metastasis [209,210]. STAT3
inhibition in TAM populations re-sensitizes breast cancer cells to paclitaxel, further suggesting tumor
and TAM crosstalk is an essential component in STAT3-driven therapy resistance [205,211]. TANs, on
the other hand, were found to function as circulatory escorts of CTC and promote their proliferation,
survival, and seeding of secondary sites [212–214]. Importantly, OSM and IL-6 were two of the 4 most
frequent cytokines secreted by neutrophils found clustered with CTC. These cytokines interact with
OSMR and IL-6R, which are expressed on cancer cells [212]. The neutrophil/CTC cross-talk promotes
the cell cycle progression in CTC, thereby expanding their metastatic potential.
Following the classical events of the metastatic cascade, after a tumor cell intravasates into
circulation, it extravasates to establish secondary sites. An emerging concept in the metastatic
cascade is the role of myeloid cells- such as basophils, neutrophils, eosinophils, monocytes, and
macrophages- in the establishment of a pre-metastatic niche [215]. Although the exact TME components
required for colonization of secondary sites remain a mystery, the activation of a STAT3-sphingosine
1-phosphate receptor-1 (S1PR1) axis in tumor cells, and secretion of IL-6 and IL-10, was observed to
persistently activate STAT3 at distant, pre-metastatic sites. At these pre-metastatic sites, persistent
STAT3 phosphorylation was associated with myeloid cell migration from the primary tumor to
the secondary site. Subsequent targeting of STAT3 in myeloid cells disrupted metastatic tumor
outgrowth, suggesting STAT3 plays an integral role in priming distant metastatic sites for tumor cell
outgrowth [216].
6. STAT5 in Cancer Cells
As previously mentioned, cells produce two different STAT5 proteins, STAT5A and STAT5B,
which share greater than 90% sequence homology [217]. However, evidence suggests STAT5A
and STAT5B play different functional roles in normal and cancer cell systems. Genetic deletion
of STAT5 in pure mouse backgrounds are embryonic lethal, due to the essential roles of STAT5 in
erythropoiesis and iron metabolism [218–220]. While the distinct roles of STAT5A and STAT5B remain
understudied, data from mammary gland-specific knockouts suggest that STAT5A is required for
lactogenesis in the mammary gland, while STAT5B is imperative for mammary gland differentiation
and development [221]. The function of STAT5A and STAT5B appear to be cell-specific. They can have
either synergistic or opposing effects, such as in memory B-cell differentiation, which may be due to
(i) the formation of STAT5A/STAT5B homo- or hetero-dimers, and/or (ii) differences in nuclear shuttling
mechanisms [222–224]. Furthermore, genetic tuning models depleting STAT5A and/or STAT5B have
demonstrated a critical role for STAT5 in the accumulation and development of innate lymphoid cells,
such as NK cells [225–227].
Given its role in lymphoid cell development and differentiation, it is not surprising that STAT5
activity contributes to hematologic malignancies. Deletion of STAT5 prevents transformation by
the Abl oncogene, thereby preventing leukemia development [228]. Genetic and pharmacologic
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inhibition of STAT5 activity decreases expression of apoptosis inhibitors MCL1 and BCL2 and inhibits
leukemogenesis of BCR-ABL1+ acute lymphoblastic leukemia (ALL), both in cell lines and newly
diagnosed and relapsed/TKI-resistant ALL patients [229]. Likewise, a new, STAT5 inhibitor suppressed
the proliferation of human acute myeloid leukemia (AML) cell lines and primary FLT3-ITD+ AML
patient cells [74]. Combined inhibition of STAT3 and STAT5 by shRNAs also suppressed growth in
chronic myeloid leukemia, suggesting that combinatorial suppression of STAT3 and STAT5 may be
efficacious in treating hematological malignancies [230].
STAT5 activation has also been implicated in the progression of solid tumor malignancies. Deletion
of STAT5 in the mammary gland, hepatocytes, and prostate cells delays the development of mammary,
liver, and prostate cancer [32,231,232]. Like STAT3, experimental evidence implicates STAT5B as a
driver of tumorigenesis, as it can drive EMT and increased invasiveness in hepatocellular carcinoma
(HCC) [233]. Moreover, in mammary epithelial cells, thymocytes, and epithelial prostate cancer cells,
persistent activation of STAT5 is sufficient to drive transformation [234–236]. Furthermore, the function
of STAT5 in solid tumors extends beyond oncogenesis as evidence has emerged that STAT5 signaling
can induce a metastatic cascade. For example, STAT5 inhibition in colorectal cancer induces G1 cell
cycle arrest and reduces cancer cell migration, demonstrating the role of STAT5 in proliferation and
metastasis [237]. Additional studies demonstrate that STAT5A/B signaling in prostate cancer and
squamous cell carcinoma of the head and neck drive EMT programming, which results in enhanced
cell migration, invasion, and formation of metastases [238,239].
An increasing number of reports demonstrate that STAT5 drives tumorigenesis and cancer
progression through cooperation with other intracellular signaling cascades and activation of
additional feed-forward loops. STAT5 activates transcription of AKT1 and PI3K, and, in turn,
Akt1 phosphorylates STAT5 to induce cell survival [240,241]. Furthermore, STAT5-dependent Akt
restores cyclin D expression, which promotes proliferation [241]. Once cells aberrantly proliferate,
apoptosis suppressors Bcl-xL and Bcl-2 are activated via persistent STAT5 signaling, driving tumor cell
survival [16,234,242–244]. BCL-XL expression is also enhanced via formation of a transcription factor
complex comprised of phosphorylated STAT5 and nuclear EGFRvIII. This transcription factor complex
binds to the BCL-XL promoter to induce its transcription and promote anti-apoptotic signaling [245].
Similar to STAT3, STAT5 translocates to tumor cell mitochondria, suggesting an interaction with the
mitochondrial genome to promote aerobic glycolysis (the Warburg Effect), a defining characteristic of
cancer cells [246]. Collectively, this data demonstrates that STAT5 mediates crosstalk between cancer
cell survival, and proliferation, and metabolism signaling pathways.
Surprisingly, STAT5 in certain model systems has been demonstrated to function in a tumor
suppressive manner. Human breast cancers infrequently (~7%) show signs of STAT5 activation
(compared to 40% of STAT3 activation). This elevated STAT5 activity trends with more differentiated
and lower grade tumors, suggesting that STAT5 does not induce the aggressive cancer cell program
initiated by STAT3, at least in breast cancer [247]. STAT5 expression in these models stabilizes
E-cadherin surface marker expression and reverses the undifferentiated mesenchymal phenotype [248].
In normal human fibroblasts, aberrant activation of STAT5A induces a senescence response concurrent
with accumulation of p53 and DNA damaged foci. Furthermore, knockdown DNA-repair kinase,
ATM, and tumor suppressor, retinoblastoma protein did not eliminate damaged foci, providing
evidence for the persistence of DNA damage in pre-malignant lesions [249]. Interestingly in HCC
models, liver specific STAT5 knockout results in tumor formation through the enhanced activation
of TGFβ/STAT3 signaling [20]. Physiologically, STAT proteins have been identified as drivers of
erythropoiesis. STAT5A/B double knockout mice in a mixed genetic background (Sv129 x C57Bl/6)
results in mild hematopoietic phenotypes, due to compensatory activation and enhanced DNA-binding
of STAT1/3 [218].
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7. STAT5 in Treg-Associated Immunosuppression
In addition to its impact on cancer cells, activated STAT5 dampens anti-tumor immune function.
This immunosuppressive function is largely driven by CD4+/CD25+Tregs, a subset of T cells that contribute
to tumor progression and metastasis [250] and correlates with poor patient prognosis [251,252]. Sustained
STAT5 phosphorylation in progenitor T cells induces the differentiation to a Treg population that, in
turn, significantly diminishes the function of cytotoxic and helper T cells [253–255]. Experimental
depletion of Tregs from the TME results in enhanced infiltration of mature CD4+ and CD8+ T cells into
the tumor, leading to tumor rejection [256,257]. Furthermore, STAT5-mediated Treg expansion increases
IL-10, IL-4, and IL-13, which skew TAMs to an M2 immunosuppressive phenotype. M2 macrophages
are immunosuppressive because they release elevated levels of IL-10 and transforming growth
factor-β (TGF-β) and restrict secretion of immune stimulatory cytokines via NF-kB repression [258,259].
STAT5-induced Tregs and M2 macrophage populations secrete VEGF-A, which, along with TGF-β,
promotes angiogenesis [255,260,261].
Tumor clearance mechanisms are also suppressed by Treg expansion through impediment of B cell
development and maturation [262]. STAT5-activated Tregs result in a decrease in follicular helper T (Tfh)
cell populations via Blimp-1, which severely hampers germinal center formation in lymph nodes [263].
This reduction in germinal centers diminishes the number of B cells that can be recruited and primed
to aid in an anti-tumor immune response. Interestingly, the differentiation and self-renewal of memory
B cells are respectively influenced by STAT5A-mediated repression and STAT5B-mediated induction of
BCL-6. Immunosuppression driven by the expansion of Tregs, relies on STAT5-mediated alteration
in T-cell metabolism. Mature effector T cells preferentially undergo glycolysis and require a de novo
fatty acid synthesis reliant on acetyl-coA carboxylase 1 whereas Tregs undergo lipid-oxidation and
readily synthesize fatty acids because of a structural reconfiguration of mitochondrial cristae [264–266].
Accumulation of intracellular lipids impairs autophagy, providing a mechanism for Treg-mediated
immunosuppression [267,268]. Just as STAT5 function in the mitochondria impacts tumor cell functions,
as described earlier, mitochondrial STAT5 activation drives metabolic shifts in the immune compartment,
inducing an expansion of Tregs.
However, while the suppression of Tregs increases tumor immunity, provided STAT5 remains
functional, the overall impact of suppressing STAT5 signaling in the remaining immune cells of the
TME remains open to debate. Mouse models deficient in STAT5 have depleted CD8+ T cell, NK cell,
and Treg populations, suggesting STAT5 plays an integral role in the proper development of multiple
immune cell types [269]. STAT5 signaling contributes to the differentiation of naive CD4+ T cells into
CD8+ T cells, Th1, Th2, Th9, ThGM, and Tregs, while inhibition of STAT5 is required for the generation
of Th17 and Tfh cells [270,271]. Importantly, STAT5 is heavily involved in the development, survival,
and lytic function of NK cells. Knock-out or suppression of STAT5 in NK populations sparked the
secretion of VEGF-A, a growth factor that supports tumor-associated angiogenesis in melanoma and
leukemia models [269,272]. Taken together, these findings suggest that targeting STAT5 may threaten
the integrity of anti-tumor immune functions and drive worse outcome in patients [269,272].
8. Targeting STAT Activity
Given the roles of STAT3 and STAT5 in tumor progression and immunosuppression discussed
above (Figure 2), multiple methods of inhibiting their activity are being pursued. Successful inhibition
of STAT3 would prevent the acquisition of, and potentially revert, a mesenchymal/CSC program,
making cancer cells less invasive and more sensitive to therapy. Moreover, STAT3 inhibition would help
activate anti-tumor immunity by reducing immunosuppressive factors and increasing the infiltration
of immune cells into the TME. Likewise, suppressing STAT5 in cancer cells, particularly leukemia, halts
proliferation and induces apoptosis, suggesting that STAT5 may be a valuable therapeutic target [74].
However, due to STAT5′s controversial roles in tumor progression and immune cell maturation
and differentiation, further studies are required to elucidate the effects of targeting STAT5 in cancer
patients. [273]. Generally speaking, the majority of small molecule inhibitors are designed to have
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high affinity for the catalytic domain of an enzyme; the ATP binding site for example, which STAT
proteins lack. Therefore, direct inhibition of STAT3 relies on disruption of binding motifs necessary for
downstream signal transduction. A series of STAT3 phospho-ester SH-2 domain inhibitors have been
developed, with the intent to inhibit dimerization of activated STAT3 (PY*L, S3I-2001, OPB-31121, etc.).
While these approaches are promising, the compounds continue to be refined [274–277]. An alternative
approach would involve targeting the upstream activator of STAT3, which could include neutralizing
antibodies for specific IL-6 family cytokines, competitive antibodies hindering cytokine-receptor
interactions, and JAK inhibitors.
 
Figure 2. Biological Impact of STAT3 and STAT5 Activation. Pre-malignant cell populations, in which
apoptotic signaling and immunosurveillance are functional, exhibit low levels of phosphorylated STAT3
(pSTAT3) and STAT5 (pSTAT5). Elevated activity of pSTAT3 and/or pSTAT5 accompanies tumorigenesis,
leading to the inhibition of apoptotic pathways and repression of immune cell recognition of a
burgeoning tumor. pSTAT3 is utilized by malignant cell populations to drive epithelial-mesenchymal
transition (EMT) and by tumor-associated macrophages (TAMs) and tumor-associated neutrophils
(TANs) to drive metastasis. pSTAT5 activity in progenitor T-cells drives expansion of a Treg population
that then secretes factors that inhibit the function of CD4+ and CD8+ T-cells as well as B-cells.
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One of the first IL-6 monoclonal antibodies generated was Tocilizumab, which inhibits IL-6
signaling by preventing IL-6 binding to both the soluble and transmembrane forms of IL-6R [278,279].
Pre-clinical studies demonstrated strong anti-tumor cell activity in multiple myeloma and therapeutic
efficacy in Castelman’s disease, rheumatoid arthritis, and cytokine release syndrome, however,
Tocilizumab is not currently FDA-approved for cancer treatments [280–283]. Clinical trials using
Tocilizumab in combination with other monoclonal antibodies, chemotherapies, and immunotherapies
to treat cancers such as HER2+ breast cancer, B-cell Non-Hodgkin Lymphoma, metastatic NSCLC,
and recurrent metastatic colorectal adenocarcinoma are ongoing [284]. In addition to Tocilizumab,
Siltuximab is an IL-6 specific neutralizing antibody that has emerged as another promising therapy.
Pre-clinical studies support Siltuximab use in KRAS-mutant lung cancer, particularly in tumors with
elevated stromal production of IL-6 [285]. Similar to Tocilizumab, Siltuximab is undergoing clinical
trials for patients with malignant solid tumors in cancers with elevated stromal presence, such as
ovarian, pancreatic, colorectal, head and neck, and lung neoplasms [286]. Furthermore, phase II studies
of combination therapy with Siltuximab have demonstrated anti-tumor effects for patients diagnosed
with metastatic prostate cancer, suggesting clinical efficacy of targeting the IL-6-STAT signaling axis
with combination therapies [287].
Our lab has focused on OSM, given its potent activity at inducing numerous inflammatory
cytokines that promote mesenchymal/CSC reprogramming in cancer cells and generate a pro-tumor
immune microenvironment [106,288–290]. Neither OSM nor OSMR protein are abundantly expressed
in normal tissues in the absence of inflammation, in contrast to JAK1, JAK2, and STAT3 (key OSM
effectors) [109]. This finding is supported by the observation that knocking out OSM or OSMR from
mice results in only mild phenotypes [291]. Moreover, OSMR has characteristics unique from other
IL-6 family co-receptors, resulting in distinct signaling and biological effects [43,292,293]. For example,
OSMR strongly recruits SHC, resulting in the hyper-activation of the MAPK signaling cascade [293].
Other gp130 co-receptors fail to do this, and rely solely on the gp130-mediated SHP-2 recruitment for
MAPK activation, which is less robust than the gp130/OSMR heterodimer [43]. Therefore, suppressing
the OSM signaling axis may have benefits in aggressive subtypes of cancer. Anti-OSM antibody
(GSK315234) and OSMR-fusion protein (OR-FC) were first examined in pre-clinical studies in chronic
inflammatory disease models, such as rheumatoid arthritis and inflammatory heart disease [294,295].
Antibodies suppressing OSM signaling ameliorate these pathological conditions, suggesting that OSM
is a driver of these chronic hyper-inflamed states. More recently, OSM signaling was identified as a
driver of inflammatory bowel disease (IBD), especially in patients who fail to respond to anti-tumor
necrosis factor-α (TNF-α) antibodies. Neutralization of OSM in IBD models suppresses a cadre of
inflammatory cytokines and reduces colitis severity, further supporting the OSM feed-forward loop as
a critical mediator in the long-term maintenance of inflammatory signaling, a state common in the
TME [112].
Another recent study investigating the effects of an anti-OSM antibody in a murine model of
lupus nephritis demonstrated that OSM-driven EMT and extracellular matrix secretion, leading to
renal fibrosis, could be suppressed, concomitant with the suppression of JAK/STAT3 activation [296].
More recently, a clinical grade OSM neutralizing antibody was used to treat pre-clinical models of
squamous cell carcinoma. Again, OSM neutralizing antibodies suppressed the STAT3 feed forward
signaling, resulting in reduced invasion and metastasis [96,297]. Disrupting cell surface receptor
activation of STAT3 by inhibiting OSMR signaling was recently described in a study of an OSMR/gp130
antagonist (SN79), which prevents STAT3 phosphorylation in astrogliosis [298]. While these studies
demonstrate the potential of OSM and OSMR inhibition as a therapeutic strategy, a number of
ligand/receptors activate STAT3 and STAT5, as described above. Therefore, additional studies will be
needed to define whether single ligand-receptor inhibitors can sufficiently impact STAT3 activation,
thus suppressing tumor growth.
Currently, JAK inhibitors are the most promising inhibitors of STAT-driven phenotypes. Commonly
used JAK 1/2 inhibitor, Ruxolitinib, has been shown to robustly block both STAT3 and STAT5 activation.
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Yet, while JAK inhibitors can reduce STAT3 activation, there is conflicting data on the impact of JAK
inhibitors. Some studies find that JAK inhibition suppresses tumor growth [93], while other studies
find that they ultimately enhance metastasis, likely because they also suppress the positive influence
of JAK activity on other STAT proteins (including STAT5 and STAT1/2, as discussed below) [299].
In addition, side effects of JAK inhibitors may be more pronounced, as JAKs activate other pathways,
such as MAPK and PI3K in normal cells as well as cancer [43].
9. Balancing Opposing STAT-Activated Cytokine Signaling as a Therapeutic Strategy
Though STAT proteins are grouped together based on their structural similarities and common
functions as transcription factors, individual STAT proteins can have diverse functions. We have focused
extensively on STAT3 and STAT5 and their described roles in cancer progression, however this is not the
universal effect among all STATs. For example, Interferon-β (IFNβ) induces the phosphorylation and
activation of STAT1/2, which form a complex with IRF9 to create the transcription factor complex ISGF3.
IFNβ/P-ISGF3 signaling induces interferon-stimulated genes (ISG), mesenchymal-epithelial transition
(MET), and the differentiation of CSC into a less aggressive epithelial, non-CSC state with reduced
migratory potential and reduced tumorsphere forming capabilities [111,300,301]. Importantly, the
IFNβ and OSM/STAT3 signaling pathways strongly oppose one another. OSM represses transcription
of IFNβ, thereby eliminating autocrine and paracrine IFNβ-mediated activation of P-ISGF3 and
repressing ISG expression in both cancer cells and immune cells [301].
In addition to the impact of IFNβ on cancer cells, increasing rationale supports developing
methods for the delivery of P-ISGF3 activators (or Type I IFN-agonists more generally) directly to
the TME. First, favorable responses to frontline chemotherapy correlate with robust IFN signaling
in both mouse and human studies [111,302–304]. Elevated IFN signaling in the tumor correlates
with immunologically “hot” tumors harboring elevated numbers of tumor infiltrating lymphocytes
(TILs), activated immune surveillance, increased tumor antigen cross presentation, and diminished
numbers of immunosuppressive cells including MDSCs and Tregs [111,302,305–307]. Second, loss
of Type I IFN signaling correlates with metastasis and decreased survival. Restoration of Type I
IFN signaling significantly decreases metastasis and improves survival outcome [303,304]. Third,
in contrast to STAT3 activators (which promote a pro-tumorigenic M2 state), addition of type I IFN
inhibits macrophage polarization to an M2 state [308,309]. Type I IFNs also induce the differentiation
of neutrophils into anti-tumor N1s [310]. Fourth, administration of IFNβ prior to surgical resection
significantly improves response rates to immunotherapies such as anti-PD1/anti-PDL-1 [311]. Therefore,
we propose balancing pro-tumor STAT3 activation with anti-tumor STAT1/STAT2 activation as a novel
therapeutic approach. This STAT3/STAT1 balancing would (i) reprogram mesenchymal/CSC to a
non-CSC state, making them more susceptible to chemotherapy and (ii) enhance anti-tumor immunity,
thereby facilitating immune cell-mediated tumor cell killing. Yet, while IFN treatment is currently
approved to treat hematological malignancies and some solid tumors (melanoma), the high doses of
IFNs needed to inhibit cancer cell proliferation or induce cell death result in side-effects that limit
its effectiveness [311–313]. We suggest tumor targeting antibodies (or nanobodies) linked to IFNβ.
Generation of an oncogenic cytokine or receptor antibody conjugated to an IFNβ first demonstrated
success in limiting resistance to EGFR inhibitors in breast cancer [314]. The designed therapy sought to
re-activate innate and adaptive immune components, while simultaneously targeting the oncogenic
receptor EGFR [303]. IFNβ-conjugated antibodies show immense promise. They would limit toxicity
by using tumor-associated receptors to target IFNs to the TME and suppress STAT3 activation, while
simultaneously, activating STAT1/2 in both tumor cells and immune cells [315].
10. Conclusions
As discussed throughout this review, STAT3 and STAT5 have emerged as essential components
involved in regulating tumor progression. Cytokines and cytokine receptors of the IL-6 family are
some of the most widely recognized STAT activators and are abundantly expressed on cancer cells
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as well as tumor-infiltrating immune cells. The role of STAT3 in promoting molecular programs in
cancer cells that induce tumor metastasis and therapy resistance mechanisms continue to emerge, as
does the impact of STAT3 as a suppressor of immune cell function in the TME. These findings suggest
that specifically suppressing STAT3 activation would be beneficial to patients. Targeting STAT5 in
hematological malignancies is gaining traction, and the clinical successes of JAK and tyrosine kinase
inhibitors in disrupting STAT3 and STAT5 activation, provide strong support for the development
of direct STAT3 and STAT5 inhibitors, summarized in Table 1. Specific suppression of STAT5 in
immune-suppressive Tregs could also prove beneficial, but STAT5 is essential for many other immune
cells as well. Thus, systemic suppression of STAT5 activity could undermine tumor immunity and
promote tumor progression, as recently reported for STAT5 knock-out from NK cells [272]. However,
reducing the aberrant activation of STAT5 without complete ablation may have therapeutic efficacy
upon combination with other vulnerabilities. We conclude that targeting STAT3, either directly by
disrupting STAT3-homodimer formation or indirectly by suppressing the activation of receptors
responsible for persistent STAT3 phosphorylation, would reverse the cellular programs driving
metastasis and therapy failure. Furthermore, by activating STAT1/2 within TME cells, the programs
that prevent metastasis and enhance therapeutic efficacy could be re-engaged. This STAT balancing
would improve outcomes for patients, particularly those with aggressive cancers that may currently
have limited therapeutic options.
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Abstract: Melanoma is a skin cancer which can become metastatic, drug-refractory, and lethal if
managed late or inappropriately. An increasing number of melanoma patients exhibits autoimmune
diseases, either as pre-existing conditions or as sequelae of immune-based anti-melanoma therapies,
which complicate patient management and raise the need for more personalized treatments. STAT3
and/or STAT5 cascades are commonly activated during melanoma progression and mediate the
metastatic effects of key oncogenic factors. Deactivation of these cascades enhances antitumor-immune
responses, is efficient against metastatic melanoma in the preclinical setting and emerges as a promising
targeting strategy, especially for patients resistant to immunotherapies. In the light of the recent
realization that cancer and autoimmune diseases share common mechanisms of immune dysregulation,
we suggest that the systemic delivery of STAT3 or STAT5 inhibitors could simultaneously target both,
melanoma and associated autoimmune diseases, thereby decreasing the overall disease burden and
improving quality of life of this patient subpopulation. Herein, we review the recent advances of
STAT3 and STAT5 targeting in melanoma, explore which autoimmune diseases are causatively linked
to STAT3 and/or STAT5 signaling, and propose that these patients may particularly benefit from
treatment with STAT3/STAT5 inhibitors.
Keywords: melanoma; autoimmune disease; inflammation; STAT3; STAT5; immunotherapy; tumor–
immune cell interactions
1. Introduction
Within the last decade, the cancer field has witnessed a rapid paradigm shift from traditional
chemotherapy to immunotherapy. A major advantage of immunotherapeutics is that, instead of directly
targeting and killing the tumor as cytotoxic drugs do, they stimulate a person’s own immune system to
recognize and destroy cancer cells. In this respect, they ally with the immune cells not only to shrink the
primary tumor but also to establish durable responses against circulating cancer cells that might lurk
beyond the primary site. Cancer immunotherapy approaches include (a) checkpoint inhibitors, which
act by releasing the brakes that prevent T-cells from killing cancer cells, (b) monoclonal antibodies,
that are designed to attach to cancer cell-specific antigens, (c) cancer vaccines, boosting the immune
system’s response to tumors, or (d) cell-based therapies, such as chimeric antigen receptor (CAR) T-cell
therapy, where T cells taken from a patient’s tumor are expanded and/or genetically engineered ex vivo
and then administered back to the patient, a process termed adoptive transfer [1]. The field of successful
application of immunotherapy includes, but is not limited to, metastatic melanoma [2], a type of
cancer that arises from melanocytes and represents the deadliest form of skin cancer, with increasing
prevalence. Once it becomes metastatic, the prognosis is very unfavorable and, thus, early diagnosis is
crucial for effective management [3].
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Since 2011, several next-generation immune-based formulations, such as the checkpoint inhibitors
ipilimumab, pembrolizumab, and nivolumab, received approval by the Food and Drug Administration
(FDA) for the indication of metastatic melanoma [2] and led to significant clinical improvements,
either as monotherapies or in combination regimens [4]. However, despite their remarkable success,
only up to 20% to 30% of patients have benefited from these treatments, while the rest are either
non-responders (primary resistance) or partial responders (acquired resistance). Unresponsiveness is
attributed to factors such as CD8+ T cell density in the tumor microenvironment, monocyte frequency,
tumor heterogeneity, and neoantigen load, as well as the composition of patient’s gut microbiota [4].
Other challenges regarding immunotherapy include immune-related toxicities. In particular,
85% of melanoma patients under ipilimumab treatment have experienced immune-related adverse
events of any grade, with over one-third discontinuing therapy or requiring additional systemic
treatment to manage side effects [5]. Immunotherapy faces limitations in patients with both an
overactive (autoimmune disease patients) or a suppressed (organ transplant recipients) immune system.
On the one hand, melanoma patients with pre-existing autoimmune diseases who receive ipilimumab
treatment present frequent disease flares and exacerbations, requiring additional immunosuppression
or therapy discontinuation [6,7]. On the other hand, solid organ transplant recipients are at increased
risk of developing metastatic melanoma, and when they do, they exhibit a higher probability for graft
rejection upon immune checkpoint inhibitor treatment [8,9]. In general, a dysregulated immune system
poses as the Sword of Damocles in the decision of clinicians to prescribe immunotherapy. In this regard,
there is an increasing need to develop drugs for the treatment of melanoma that are not only safer for
such patients but are also able to manage this cancer along with a co-existing immune-related disease.
Herein, we hypothesize that therapeutic management of various clinical disorders simultaneously
can be achieved by targeting their major common pathways. As a representative case, we consider
the Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway, which is
activated in a wide range of autoimmune diseases (AD), as well as in many different cancer types.
It mediates immune responses to several insults from resisting infection to maintaining immune
tolerance, enforcing barrier functions, and guarding against cancer [10]. In this review, we summarize
ADs that are associated with malignant melanoma, we explore how STAT3 and STAT5 signaling
contributes to their pathogenesis, and we evaluate STAT3/STAT5 inhibition as a feasible strategy to
target these diseases in order to achieve their simultaneous management with a single drug.
2. Associations among Melanoma, Inflammation and Autoimmune Diseases
A cancer patient can frequently experience disorders, such as inflammation and autoimmune
diseases, that occur as frequent pre-existing, predisposing, or intercurrent conditions [11–13].
Intriguingly, these diseases seem to be etiologically interrelated with one another. On one side,
cancer has been linked with chronic inflammation. Moreover, there are interconnections between
autoimmune diseases and cancer, since certain autoimmune disorders predispose to neoplasias [14].
Patients suffering from dermatomyositis, inflammatory bowel disease, systemic lupus erythematosus,
rheumatoid arthritis, psoriasis or Sjögren syndrome may have increased risks for malignancies,
whereas the type(s) of cancer they tend to develop depend on the type of the autoimmune disease [15].
For example, rheumatoid arthritis patients are at a greater risk of developing clonal expansions of large
granular lymphocytes [16]. Although an autoimmune disorder does not necessarily lead to cancer, it is,
however, a phenotypic manifestation of a deregulated immune system, which is generally a favorable
background for cancer development [17]. Vice versa, cancer immunotherapy triggers autoimmunity
towards several anatomical sites and can lead to conditions that range from relatively minor, such as
skin depigmentation, to severe colitis, pancreatitis, lung or liver toxicity [18]. Furthermore, a persistent
inflammation can be a fertile ground for the development of an AD [19]. Overall, an inflammation can
potentially progress to a neoplasia or an autoimmune disorder, and this process can be facilitated by
deregulation of the innate immune system [11,14] (Figure 1).
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Figure 1. Associations between inflammation, cancer, and autoimmune disease. An inflammation can
eventually lead to cancer or autoimmune disease. Some autoimmune disorders may predispose to
malignancies. Cancer immunotherapy is associated to autoimmunity.
This interplay among ADs and cancer is evident in the case of melanoma patients. First of
all, there is a long-standing inverse association between melanoma and vitiligo, a condition where
the immune system produces autoantibodies against immunogenic, melanocytic-specific molecules
(melanocytic-differentiation antigens, MDAs) that propel melanin production. These autoantibodies
attack melanocytes, ultimately producing white skin patches. Thus, vitiligo patients show a lower
melanoma risk because the antibodies against melanocytes confer natural cancer protection [20].
Vice versa, some melanoma patients develop a similar antibody-based condition, called melanoma-
associated hypopigmentation or vitiligo-like depigmentation, which is usually considered as a predictor
of better outcomes [21], although there are also reports demonstrating that hypopigmentation can be
associated with disease progression [22–24]. Given that malignant melanoma co-evolves with immune
cell phenotypes [25], this dynamic interaction between autoimmunity-based hypopigmentation and
skin cancer could, in the long run, become a double-edged sword. Specifically, these tumors exhibit a
high intratumoral heterogeneity and plasticity [25]. Therefore, over the course of the disease, tight
immunosurveillance against MDA-expressing cells could serve as a microenvironmental cue that
adds evolutionary pressure for immunoselection of low-MDA expressing cell variants that are poorly
recognized by the autoantibodies. Such MDA-negative cells possess enhanced invasive capabilities.
In this way, anti-MDA responses provoked by the melanoma tumor, can, in turn, promote clonal
expansion of low-MDA-expressing cell variants with activated prometastatic programs that can migrate
to distant sites, giving rise to secondary tumors [24].
Other autoimmune diseases are positively correlated with melanoma progression [2,26].
A retrospective meta-analysis assessed that the prevalence of pre-existing AD in melanoma patients
increased by 1.7-fold within a decade. Prevalence rates were higher in metastatic melanoma patients
compared to primary, non-metastatic skin cancer patients or the general population, suggesting
that a pre-existing AD could possibly favor metastatic progression. The most common ADs
among metastatic melanoma patients were myositis, peripheral neuropathy, type 1 diabetes mellitus,
rheumatoid arthritis, psoriasis, autoimmune pancreatitis, autoimmune aplastic anemia, relapsing
polychondritis, Hashimoto’s encephalopathy, and inflammatory bowel disease. The authors suggested
that disturbances in shared molecular or immune pathways could underlie increased susceptibility of
AD patients to melanoma [2]. Another clinical study showed that only a small percentage of melanoma
patients have a pre-existing AD, but in these patients, progression is faster and prognosis is worse.
This subpopulation has a significantly shorter median overall survival and disease-free survival after
first metastasis versus cases with a primary tumor, while poorer prognosis was independent of the
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side effects of AD treatment. Those patients with an antibody-mediated AD had a worse prognosis in
relation to those with a T cell-related AD. [27]. Together, these data unveil a potential link between
malignant melanoma and immune dysregulation, implying that a pre-existing autoimmune disease
could be a predisposing factor for melanoma development and progression. If that is indeed the case,
further experimental investigations are needed.
The relationship between inflammation and cancer is well established [28] and inflammation
contributes to melanoma initiation and progression [25]. Upregulation of key cancer-related
inflammation genes, such as the transcription factors nuclear factor ‘kappa-light-chain-enhancer’
of activated B-cells (NF-κB) and STAT3, as well as several inflammatory cytokines and angiogenic
factors, facilitate melanoma development. Indeed, inoculation of B16-F10 melanoma cells in chronic
skin inflammation mouse models led to the formation of larger volume tumors in comparison with the
non-inflamed controls, followed by increased periostin expression and M2 macrophage recruitment in
the tumor microenvironment (TME) [29]. Similarly, in a mouse model of melanoma, repetitive UV
exposure promoted metastasis via neutrophilic skin inflammation. In particular, UV irradiation-induced
neutrophil recruitment and activation, which was initiated by the release of high mobility group box 1
(HMGB1) from UV-damaged epidermal keratinocytes. The UV-induced neutrophilic inflammatory
response stimulated angiogenesis and increased the number of lung metastases through modulation of
melanoma–endothelial cell interactions [30]. The association between inflammation and melanoma
is also supported by the fact that anti-inflammatory drugs contribute to melanoma prevention or
treatment. Population-based case-control studies showed that continuous use of low-dose non-steroid
anti-inflammatory drugs (NSAIDs), such as diclofenac, ibuprofen, and naproxen, reduced the incidence
of skin cancer, even though in a sex-dependent manner [31]. Other studies showed that combining
celecoxib, a cyclooxygenase COX-2 selective NSAID, with chemotherapeutics can be an effective
strategy for melanoma treatment [32].
3. A Basis for the Development of Multipotent Drugs against Melanoma, Inflammation, and
Autoimmune Disorders
It is becoming increasingly evident that common molecular mechanisms underlie inflammatory-
driven [12], as well as inflammatory/autoimmune-driven neoplasias [17]. The emerging similarities and
interconnections among these diseases imply that despite their diverse clinical manifestations, outcome,
and response to therapy, a limited number of mutual molecular events might drive their pathogenesis.
In this regard, the mechanistic commonalities between cancer, inflammation, and ADs have created
a basis for drug repurposing. For instance, anti-inflammatory drugs are used in combination with
anticancer regimens [12,33]. Additionally, immunomodulatory drugs used for the treatment of ADs
show efficacy against neoplastic diseases [34,35] and vice-versa, anticancer therapeutics can be applied
to treat non-cancer immune-mediated diseases [36]. Recent network-based studies demonstrate that
disorders with distinct clinical manifestations share a common genetic background [37]. Therefore,
identifying shared signaling networks and cellular pathophenotypes at the core of these diseases is
anticipated to further shape drug development in the future. We use the term ‘multipotent drug’ for
any targeted inhibitor with the potential to act against two or more pathologies, even if these are
different diseases, such as autoimmunity and cancer as an example. Moreover, given that they are
mechanistically interrelated [11,12], we further postulate that the effectiveness of such a multipotent
drug may depend on its interference with ‘root’ pathways that pose as common denominators in the
pathology of these diseases. Hence, identification of these common traits is a prerequisite for the
development of multipotent drugs, which could simultaneously manage cancer in conjunction with
coexisting, pre-existing, or predisposing disorders (Figure 2).
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Figure 2. Proposed rationale for treating melanoma and associated inflammation or autoimmunity
with multipotent drugs. Investigational or Food and Drug Administration (FDA)-approved drugs
could exert anti-inflammatory, immunomodulatory, and anticancer effects. This, to an extent, might be
due to their interference with signaling pathways commonly activated in inflammation, autoimmune
disease, or cancer. These core pathways underlying all-three pathological conditions can be further
characterized to facilitate simultaneous management of associated pathologies due to distinct diseases.
To this end, considering that deregulation of immunity is the main culprit in inflammation,
autoimmune disease, and melanoma, we hypothesized that pathways mediating immune responses
might be suitable therapeutic targets. Given that the JAK/STAT pathway is commonly activated in these
diseases, we postulate that it is an emerging candidate ‘core’ pathway. Herein, we review the current
knowledge of the effects of STAT3 and STAT5 signaling in melanoma, inflammation, and autoimmune
disorders and estimate their value for concurrent management of these interconnected conditions.
4. STAT3 and STAT5 Signaling in Melanoma Initiation and Progression
STAT proteins, particularly STAT3 and, to a lesser extent, STAT5 govern fundamental oncogenic
processes. STAT family members respond to cytokines, growth factors, and hormones, and transduce
signals from the cell membrane to the nucleus to transactivate genes involved in cellular immunity,
proliferation, apoptosis, and differentiation. The STAT family encompasses seven members, STAT1,
STAT2, STAT3, STAT4, STAT5A, STAT5B, and STAT6, which show high homology in their functional
domains. Their main difference lies in the C-terminal transactivation domain that varies among
family members and modulates transcriptional activation of target genes. Under physiologic
conditions, STAT signaling is stimulus-dependent and tightly regulated. The regulation of STAT
activity via phosphorylation of a conserved C-terminal tyrosine residue has been previously described
in detail [38,39]. Constitutive activation of STAT3 and STAT5 is involved in tumor formation and
progression. However, not all STAT members are promoting cancer progression. STAT1, for instance,
exerts proapoptotic and antiproliferative effects, and it seems that both, STAT3 and STAT5 can
antagonize its function [40].
STAT3 is constitutively activated across many types of human cancers, including melanoma,
as a consequence of aberrant autocrine or paracrine stimulation by cytokines and growth factors,
such as interleukins (IL-6, IL-10, IL-12), interferons (IFNs), granulocyte-colony stimulating factor
(G-CSF or CSF3), leptin, prolactin (PRL), growth hormone (HGH), epidermal growth factor (EGF),
hepatocyte growth factor (HGF), basic fibroblast growth factor (FGF2), and virus proteins (e.g., v-Src,
v-Fps, v-Sis). Permanent STAT3 activation can also result from receptors with intrinsic tyrosine kinase
activities (such as erb-b2 receptor tyrosine kinase 2 (ERBB2), epidermal growth factor receptor (EGFR),
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and hepatocyte growth factor receptor HGFR), non-receptor tyrosine kinases (such as c-Src and c-abl),
or G-protein coupled receptors [38,41]. An overactive STAT3 is associated with poor prognosis in
melanoma patients and drives tumor initiation and malignant progression via induction of several
cancer hallmarks, such as apoptosis inhibition, tumor angiogenesis, epithelial–mesenchymal transition
(EMT), and stemness. In particular, upon c-Src activation, STAT3 promotes tumor cell survival and
proliferation by transactivating BCL2L1 (that encodes the Bcl-XL protein) and MCL1, two crucial
anti-apoptotic genes that override cell death regulatory pathways. Additionally, STAT3 regulates the
MYC gene, which mediates escape of melanoma tumor cells from both terminal differentiation and
G0/G1 arrest. Beyond its function as a transcriptional activator, STAT3 can also suppress transcription
of the well-established tumor suppressor TP53 [38]. This suppression can provide an explanation on
why melanomas that lack mutations in either TP53 or its main negative regulator, such as MDM2,
exhibit aggressive characteristics. STAT3 upregulates nodal factors of angiogenesis, mainly vascular
endothelial growth factor (VEGF), hypoxia-inducible factor 1a (HIF-1α) and matrix metalloproteinase-2
(MMP-2) [38] and fosters brain metastasis in melanoma [42]. In addition, drivers of melanoma invasion
and metastasis, such as ΔEx2/3p73 (named DNp73), a transactivation-deficient N-terminally truncated
oncogenic isoform of the TP73 gene, can trigger an IGF1R-AKT/STAT3 signaling cascade, which leads
to the activation of EMT markers and acquisition of mesenchymal cell phenotypes [43,44]. Additionally,
STAT3 is often mentioned in connection with ΔNp63 [45]. ΔNp63α indirectly drives STAT3 (Tyr705)
phosphorylation in an autocrine loop by transactivating interleukin 6 (IL-6) and IL-8. Phosphorylated
STAT3 stabilizes HIF-1α, resulting in an increased production of VEGF in ΔNp63α-overexpressing
cells [44]. In melanoma, ΔEx2/3p73, but not ΔNp63α, mediates STAT3 (Tyr705) phosphorylation
in an EPLIN/IGF-1R-dependent manner [43]. With respect to its ability to promote cancer through
regulating cancer stem cell (CSC) activities [46], STAT3 upregulation mediates reprogramming of
melanoma cells to melanoma stem cells by inducing expression of the Yamanaka factors, providing
hints of STAT3 implication in cancer stemness [47]. Moreover, STAT3 increases chemoresistance of
melanomas to selective inhibitors of BRAF, which are exploited in the treatment of unresectable or
metastatic melanoma with a BRAF-V600 gain-of-function mutation [48].
Similar to STAT3, STAT5 also exerts oncogenic functions. There are two distinct genes,
STAT5A and STAT5B, that have arisen by gene duplication and encode protein products which
share more than 90% peptide sequence similarity and differ primarily in the C-terminus-encoding
region [49]. STAT5A is predominantly expressed in the mammary gland, while STAT5B is prevalent
in muscle and liver. They respond to a number of factors, such as prolactin, Growth Hormone,
erythropoietin, thrombopoietin, EGF, IL-2, IL-3, IL-6, IL-7, IL-9, and IL-15 [40]. STAT5 promotes
malignant transformation in hematological malignancies, breast and prostate cancer, non-small
cell lung carcinoma, and melanoma [50]. The initial correlation between STAT5 activation and
aggressive characteristics of melanoma was first described in a Xiphophorus fish melanoma model [51].
Subsequently, Hassel and colleagues showed that constitutive activation of STAT5 correlated with
the upregulation of its antiapoptotic target gene BCL2L1, an effect which was conserved in both,
human melanoma cells and murine melanocytes [52]. In melanoma patients, STAT5B transcripts
were significantly upregulated, whereas STAT5 was found phosphorylated in 62% of the metastatic
cases versus normal human melanocytes and benign nevi. STAT5 activation is induced by the
EGF/JAK1 axis in melanoma cell lines. Knockdown of STAT5B in these cells causes downregulation
of BCL2, which triggers cell death and G1 arrest, thus underscoring that STAT5B acts as a survival
factor in melanoma [50]. In addition to its antiapoptotic role in melanoma, STAT5 influences the
sensitivity to anti-melanoma treatment, including interferon alpha (IFN-α) immunotherapy and BRAF
inhibitors. For instance, in skin cancer patients under adjuvant IFN-α therapy, STAT5 expression
emerged as an independent predictor of progression-free survival. Recurrence in patients with
STAT5-expressing tumors was observed either during or after IFN-α therapy [53]. In accordance
herewith, STAT5 has been shown to be overexpressed in IFNα-resistant melanoma cells [54]. Moreover,
this transcription factor regulates the nicotinamide phosphoribosyltransferase (NAMPT), a key
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enzyme in the maintenance of cellular nicotinamide adenine dinucleotide (NAD+) levels, in response
to activated B-Raf/extracellular signal-regulated kinases (BRAF/ERK) signaling. NAMPT induces
melanoma cell proliferation accompanied by a phenotypic switch towards an invasive phenotype
and resistance to BRAF inhibitors [55]. Consistently, a combination of the neuroleptic drug pimozide
with indoleamine 2,3-dioxygenase sensitizes melanoma cells to apoptosis and inhibits cell migration
via STAT5 suppression [56]. However, pimozide is not a direct STAT5 inhibitor, but rather targets
upstream pathway activation for degradation.
5. STAT3 and STAT5 in the Crosstalk between Melanoma and Immune Cells
Melanomas display qualitative and quantitative changes in the density, composition, functional
state, and organization of immune infiltrates, the so-called immune contexture, which render immune
cells tolerant to tumors or exhaust their ability to attack tumor cells [57]. STAT3 influences the interplay
between melanoma cells and components of the immune system, thus contributing to immune evasion.
Tumor and immune cells expressing STAT3 develop sophisticated interactions to overall support an
immunosuppressive tumor environment that propels metastatic progression. In detail, melanoma cells
which overexpress STAT3 protein inhibit the expression of proinflammatory cytokines and chemokines,
such as VEGF, IL-10, and IL-6. These, in turn, induce STAT3 activity in hematopoietic progenitor
cells (HPCs) to promote the production of immature myeloid cells (IMCs) and plasmacytoid dendritic
cells (pDCs). Through IL-10, IMCs block the maturation of dendritic cells into antigen-presenting
cells. Thus, these immature dendritic cells are unable to stimulate the antitumor effects of CD8+ T
cells and natural killer (NK) cells. In parallel, pDCs promote the accumulation of regulatory T cells
(Treg) in the tumor microenvironment. IL-10 and TGF-β secreted by Treg cells further enhance the
immunosuppressive microenvironment by restraining both, CD8+ effector T-cell function and DC
maturation [38,58–60]. Direct STAT3 targeting in melanoma cell lines sufficed to modulate these
crosstalks and enhanced antitumor activity through increasing interferon gamma (IFNγ) levels, mature
dendritic cells, and CD8+ T cells. This resulted in reduced tumor growth and prolonged survival
of tumor-bearing mice [61]. There is the first evidence that STAT3 activation in NK cells that trigger
innate immune responses by the destruction of the tumor cells, can suppress their cytotoxicity against
melanoma cells in vivo. The dual effect of STAT3 in melanoma, as well as tumor-attacking immune
cells, is of great therapeutic interest since STAT3 inhibition not only blocks survival of cancer cells
themselves but also boosts the cytotoxic behavior of infiltrating immune cells [62].
The effect of STAT5 on the melanoma–immune cell interplay is just beginning to be unveiled,
mainly via studies in NK cells. The data demonstrate that STAT5 is indispensable for NK cell survival.
Conditional knockdown of STAT5 in NK cells led to an almost entire loss of this cell population in
transgenic mouse models. Subsequent intravenous injections of these mice with B16F10 melanoma cells
increased tumor cell infiltration in the lungs when compared to the control groups [63]. In accordance
with the results described above, Sathe et al. reported that an IL-15/JAK1/STAT5 pathway supports the
generation of NK cells via transactivation of the antiapoptotic protein MCL1, and that MCL1 conditional
knockdown in NK cells in mice led to multiorgan metastases upon transplantation of melanoma
tumors [64]. Other investigations revealed that forced expression of antiapoptotic BCL2 rescues
survival of STAT5-deficient NK cells [65]. Nevertheless, the presence of NK cells expressing high levels
of BCL2, but lacking STAT5 was not sufficient to control tumor growth. As this study shows, lowering
STAT5 levels in NK cells caused exacerbation of tumor growth in vivo, irrespective of the ability of
NK cells to recognize and eradicate tumor cells [65]. They further demonstrated that upregulation of
perforin, granzymes, and IFNγ by STAT5 is the key to the enhancement of NK cell cytotoxicity against
melanoma [65]. In addition to NK cells, a STAT5-induced cytotoxic potential of immune cells towards
skin cancer has also been reported for CD8+ T cells. In particular, genetic modification of CD8+ effector
T cells with a constitutively active form of STAT5 gives them high efficiency for host colonization after
adoptive transfer and transforms them into long-lived antigen-responsive cells. Upon transfer into
melanoma-bearing hosts, these cells accumulate in the tumor site, become activated by tumor antigens,
275
Cancers 2019, 11, 1448
and express the cytolytic factor granzyme B, resulting in tumor regression [66]. It was recently shown
that malignant melanoma cells induce inhibition of STAT5 signaling on cytotoxic NK and CD8+ T cells
to achieve immune evasion and tumor progression. This effect is mediated by the melanoma-secreted
dickkopf WNT signaling pathway inhibitor 2 (DKK2) [67].
In conclusion, STAT3 establishes a reciprocal relationship between melanoma cells and immune
cells in favor of tumor immune evasion. STAT3-expressing cancer cells dysregulate immune cells,
while at the same time, immune cells with high levels of STAT3 are unable to target melanoma
cells. In contrast, STAT5 expression in tumor-attacking immune cells supports antitumor cytotoxicity
(Figure 3). These sophisticated interactions between melanoma and immune cells via STAT proteins
(and perhaps other factors) could provide a precocious basis towards interpreting the associations
between melanoma and co-occurrent autoimmune conditions. Future studies are anticipated to shed
more light on common mechanisms underlying melanoma and AD which could, at least in part,
explain why these distinct pathologies of melanoma and autoimmunity appear, for example, in the
same patients.
Figure 3. STAT3 and STAT5-mediated crosstalks between melanoma and immune cells create an
immunosuppressive network that propels metastatic progression. (A) STAT3-expressing tumors
secrete factors that upregulate STAT3 in hematopoietic progenitor cells (HPCs). This results in the
accumulation of Tregs and immature dendritic cells in the tumor microenvironment, which further
inhibit the maturation of these cells. Due to the lack of mature dendritic cells, the tumor-attacking
CD8+ T cells and NK cells cannot be stimulated. NK cells with inactive STAT3 can repress tumors,
while STAT3 activation in NK cells blocks their tumor-lysing properties. (B) STAT5-activated NK cells
are effective against melanoma cells. This property is suppressed by secretion of DKK2 from melanoma
cells (see main text for details).
276
Cancers 2019, 11, 1448
6. STAT3 and STAT5 Pathways in Inflammation and Melanoma-Associated Autoimmune
Diseases
During inflammation, lymphoid and myeloid cells are recruited to the site of the lesion. By secreting
cytokines, immune cells and macrophages control the development of inflammation. Effective and
timely management of an inflammation is crucial for maintaining the immune system homeostasis.
Any factor that activates inflammation or triggers immune reactions could lead to an autoimmune
disease, whenever immune regulation of the inflammatory response fails to manipulate the situation
appropriately. Thus, the root cause of most autoimmune diseases is the failure of the immune response
to orchestrate the dynamics or magnitude of an inflammatory response, limit it to a relevant body site,
and terminate it at the proper time [19]. The balance between Th17 cells, a subset of proinflammatory
T helper cells which are characterized by IL-17 production, and Tregs that maintain tolerance to
self-antigens is a key determinant in the development of an AD, and the signals that induce Th17
differentiation from CD4+ T cells inhibit Treg differentiation [68]. STATs affect inflammatory disease
since they control the development of hematopoietic cells that regulate inflammation and mediate
the responses of target cells to inflammatory cytokines [69]. For instance, STAT members, such as
STAT1 and STAT3, are highly interlinked with NF-κB [70,71]. Not only does STAT3 respond to
NF-κB-induced IL-6, a critical mediator of the acute phase response in inflammation [72], but it
also physically interacts with this transcription factor to co-regulate inflammatory gene targets [71].
However, as the damage response persists, chronic activation of STAT proteins leads to inflammatory,
idiopathic, and autoimmune conditions [72]. In line with this, STAT3 gain-of-function mutations
can cause early-onset lymphoproliferation and autoimmunity [73] and have been associated with
Th17 hyperactivation [74]. STAT5 signaling is also involved in autoimmunity. Patients with STAT5B
deficiency have decreased numbers of Treg cells and exhibit immunological aberrations, whereas
most of them suffer from severe eczema and AD [49]. Herein, we briefly summarize our current
knowledge of how STAT3 and STAT5 are implicated in inflammatory and autoinflammatory conditions
as well as in autoimmune diseases. The effect of STAT3 and STAT5 on autoimmune diseases with a
demonstrated link to melanoma [2] is described in Section 6.1 to Section 6.8 and depicted in Table 1.
STAT3/STAT5-related inflammatory and autoimmune diseases with a still understudied effect on
melanoma incidence are also mentioned (Sections 6.9–6.12).
Table 1. Effects of STAT3/STAT5 in autoimmune diseases associated with melanoma (conditions are
listed by decreasing prevalence rate in melanoma patients).









signaling pathway n.d. n.d. n.d. [75,76]
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activated in T cells,
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Th17/Treg ratio therapeutic n.d. [80–83]




mutation n.d. n.d. n.d. [86,87]
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Table 1. Cont.














































Peripheral neuropathy is an AD of paraneoplastic etiology, which may appear as melanoma
comorbidity. It has been attributed to an immune response directed against antigens in the tumor that
subsequently cross-react with the same or similar epitopes in the nervous system [75]. First evidence
associates neuropathic pain with an activated JAK/STAT3 signaling pathway [76]. The exact role of
STATs in this condition is yet to be determined.
6.2. Type 1 Diabetes Mellitus
Type 1 diabetes (T1D) is a chronic AD causing immune-mediated loss of pancreatic β cells. The key
mediators of β cell destruction are the CD4+ and CD8+ T cells. Treg cells are also important for the
maintenance of immune tolerance and prevention of autoimmunity. STAT3 is activated in T cells of T1D
patients and favors their resistance to suppression [77]. It also influences diabetes by altering pancreatic
cells development. This was shown in a study where an activating STAT3 mutation caused premature
differentiation of stem cells into cells of the pancreatic endocrine lineage [78]. Similar to STAT3,
STAT5 activation has been correlated with T1D, since persistent STAT5 phosphorylation characterizes
monocytes of individuals with or at-risk for T1D and is suspected of altering the epigenetic regulation
of inflammatory response genes [79].
6.3. Rheumatoid Arthritis
Rheumatoid arthritis (RA) is a chronic disorder manifested with continuous inflammation, swelling,
destruction, and pain in multiple joints. Th17 cells are the pathogenic culprit in RA, while Treg cells
suppress RA. STAT3 and STAT5 knockdown in RA demonstrated that STAT3 increases Th17 but
decreases Treg proportions, whereas STAT5 has the opposite effects on these cell populations [80],
providing insights that STAT5 counteracts STAT3 activity on the reciprocal balance of Th17 and Tregs
in the context of RA. In addition, STAT3 induces factors that lead to inflammation and osteoclast
genesis, while its conditional knockout in mice blocks joint inflammation and destruction and offers
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resistance to collagen-induced arthritis [81]. Consistently, STAT3 phosphorylation and subsequent
upregulation of its downstream gene targets are discriminative for CD4+ T cells of RA patients [82].
It is possible that STAT5 counteracts STAT3 in the context of RA via exerting opposite effects in the
Th17/Treg balance, which is crucial in the pathogenesis of this disease [83].
6.4. Psoriasis
Psoriasis is a chronic autoimmune disease characterized by patches of abnormal skin, which are
typically red, dry, itchy, and scaly. Its most prevalent type is psoriasis vulgaris. It is considered a T
cell-mediated AD modified by genetic susceptibility and environmental stimuli. Th17 lymphocytes,
which differentiate from naïve T cells upon IL-6 induction, play a central role in its pathogenesis,
and recent evidence suggests that inflammatory circuits are established among Th1 and Th17 cells
and keratinocytes, promoting psoriasis. This leads to the hypothesis that STAT3 and STAT5, which
regulate Th17, are possibly associated with psoriasis. Indeed, STAT3 activation has been observed
in the skin of psoriatic patients [84]. Consistently, transgenic mice, in which keratinocytes express
a constitutively active form of STAT3, develop psoriasis-like skin lesions. Topical administration of
STAT3 inhibitor improved psoriatic lesions in both, these mice and in clinical patients [85]. The role of
STAT5 in psoriasis needs to be assessed.
6.5. Autoimmune Pancreatitis
Autoimmune pancreatitis is a unique form of chronic pancreatitis initially reported in 1995.
It exhibits characteristic histological features, frequent elevations of serum IgG4 antibodies, and a
predictable response to steroid therapy. Potential long-term sequelae include pancreatic duct stones
and malignancy [86]. A recent report describes a case of acute pancreatitis that presented in a patient
with a loss-of-function STAT3 mutation [87]. The involvement of STATs in this newly-identified
autoimmune condition remains to be elucidated.
6.6. Autoimmune Aplastic Anemia
Aplastic anemia (AA) is a non-malignant blood disorder, caused by immune destruction of
hematopoietic and progenitor cells, which leads to a failure of bone marrow to sustain blood
production. As a result, the patients develop pancytopenia, evidenced by low levels of all blood cell
types. Clonal hematopoiesis with the formation of a genetically distinct subpopulation of blood cells
has been suggested as a basis of this disease, where clonal cells have acquired the ability of increased
proliferation and immune escape [88]. STAT5B [88] and STAT3 [89] gain-of-function mutations have
been found in T cells of AA patients, while an IL-2/STAT5B pathway characterized patients’ Treg
subpopulations [90]. Overall, these data link STATs with AA, although continued investigation into
the mechanistic connections is necessary.
6.7. Hashimoto’s Encephalopathy
Hashimoto’s encephalopathy is a rare disease of autoimmune origin, characterized by high titers
of antithyroid antibodies. It has been proposed that an abnormal function of the immune system
causes neuronal inflammation, leading to impaired brain function. The condition co-exists with other
ADs, such as T1D mellitus, systemic lupus erythematosus, and Sjögren syndrome [91]. Although the
molecular mechanism of this rare disease remains elusive, a study showing that STAT5 programs a
distinct subset of Granulocyte-macrophage colony-stimulating factor (GM-CSF)-producing T helper
cells, which is essential for autoimmune neuroinflammation [92], could provide a potential link between
STATs and this disorder. Future investigations could shed more light on possible associations of STATs
with the etiopathology of encephalitis.
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6.8. Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) describes a group of chronic, relapsing, autoimmune diseases
of complex etiology that become manifest at the small intestine and colon. It encompasses ulcerative
colitis and Crohn’s disease, which differ in the location of inflammation within the gastrointestinal
tract. Several cytokines that activate STAT3 drive IBD pathogenesis. Data obtained from IBD patients
showed that STAT3 is activated in their inflamed colons. Intriguingly, expression of STAT3 in different
immune cell populations exerts opposing effects on IBD. In particular, phosphorylated protein in
T-cells contributes to colitis, while its activation in myeloid cells (neutrophils and macrophages)
and enterocytes is protective against colitis. In mouse models of IBD, several proinflammatory
cytokines, such as IL-2, IL-6, IL-15, IL-21, IL-23, IL-17, and IL-18, have detrimental effects, whereas
anti-inflammatory cytokines, including IFNα/β, IL-10, IL-11, and IL-22, are beneficial. STAT3 targeting
with small molecule inhibitors ameliorates IBD in vivo and is under consideration as a new approach
to IBD management, particularly in patients that are refractory to current therapies [72]. However,
given the opposing functions of STAT3 on different immune cell types, targeting should be directed
towards the specific cell population which promotes IBD, without jeopardizing those immune cells
that protect from disease [93].
STAT5 has rather anti-inflammatory properties both in the intestinal epithelium and in adaptive
immune cells and has been shown to oppose STAT3 functions in the context of IBD. A GH/STAT5
axis is protective against colitis in animal models. On one side, STAT5 is critical for the proliferation
of intestinal epithelial stem cells and regeneration of the crypt epithelium. STAT5B-deficient mice
are particularly susceptible to chemically induced colitis, a fact that was attributed to apoptosis of
epithelial cells and damage of the mucosal barrier. In agreement, activated STAT5 promotes mucosal
wound healing, increases intestinal epithelial stem cell proliferation, accelerates crypt regeneration,
and confers resistance to intestinal injury [95,96]. Lack of active STAT5 predisposes to Clostridium
difficile infection-induced colitis [97]. Otherwise, STAT5 regulates T cell differentiation, especially Treg
cells. In addition, IL-2 signaling via STAT5 limits Th17 in favor of Treg development. This is opposed
to STAT3 function, which induces Th17 differentiation and negatively controls Treg differentiation.
The balance between Tregs and effector T cells is key in IBD suppression. Moreover, GM-CSF-induced
STAT5 signaling protects dendritic cells from apoptosis, in contrast to the apoptotic effects of an
IL-21/STAT3 axis in these cells [94].
6.9. Asthma
Asthma is a condition characterized by inflammation, which leads to hyperresponsiveness of the
airways and remodeling of the airway wall. Airway inflammation and remodeling is accompanied
by STAT3 activation and by increased levels of Th2- and Th17-type cytokines in the lung. STAT3
regulates immune cell recruitment, specifically Th2 cells, during allergic inflammation. Targeted STAT3
depletion in the airway epithelium prevents house dust mite-mediated allergic inflammation and
airway hyperresponsiveness. Interestingly, other studies suggest that Th2 cells respond to STAT3
activation differentially, depending on their location in the lung [72]. In a similar manner, in animal
models of asthma, the STAT5 pathway-regulates lymphocyte proliferation induced by ovalbumin [98],
while a GM-CSF/STAT5 axis enhances survival of lung granulocytes [99]. Observations on a large cohort
of hospitalized asthma patients revealed an increased cancer incidence, which, however, was highly
cancer type-dependent. These patients presented an increased risk for stomach and colon cancer but
decreased for endometrial cancer and melanoma [100]. Further studies which could also include the
population of outpatient asthma patients are needed to investigate the potential link between asthma
and several cancer types.
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6.10. Cachexia and Polymyositis
Cachexia is an inflammation-driven metabolic syndrome, where impaired regulation of the
balance between anabolism and catabolism results in the loss of adipose tissue and skeletal muscle,
eventually leading to muscle atrophy. Mechanistic studies have shown that STAT3 phosphorylation
in response to overexpression of its upstream cytokine IL-6 is associated with this condition [72].
In a similar manner, levels of phosphorylated STAT3 and cytokine IL-22 have been found elevated
in muscle tissues of patients with polymyositis, an idiopathic inflammatory myopathy that causes
muscle weakness [101]. Several known STAT3 inhibitors that directly target hyperphosphorylated
STAT3 also reduced markers of cachexia in cell culture models and antagonized catabolic signaling
in mice, supporting the concept that STAT3 is a valid target for cachexia treatment [72]. No study
has correlated STAT5 and polymyositis thus far. An association between cachexia and melanoma has
been suggested based on mice studies. In detail, B16F10 melanoma-bearing mice depicted skeletal
muscle and epididymal fat mass reduction, muscle strength loss, and locomotor activity impairment,
associated with elevated IL-6 levels in the plasma [102]. Further studies are needed to investigate if
these effects are mediated by STATs.
6.11. Fibrosis
Tissue fibrosis is an inflammatory condition which is caused upon dysregulation of the
tightly-controlled process of wound healing and is characterized by overproduction of the extracellular
matrix (ECM) and excess matrix contraction. STAT3 drives wound healing following inflammation and
contributes to fibrosis by inducing production of ECM or by transactivating profibrotic metalloproteases,
such as MMP-9. The blockade of STAT3 phosphorylation with small molecule inhibitors could
ameliorate the development of pulmonary fibrosis in mice exposed to bleomycin [72]. In contrast to
the profibrotic function of STAT3, STAT5 seems to protect from fibrosis, perhaps through counteracting
STAT3. In particular, loss of STAT5 causes liver fibrosis through STAT3 activation [103]. It was recently
shown that the dorsal skin of mice contains multiple and diverse lineages of fibroblasts. One of those
lineages is responsible for the fibrotic response to injury and cancer-stroma formation. Ablation of this
specific lineage diminished connective tissue deposition in wounds and reduced melanoma growth
in vivo [104]. This study provides an initial link between melanoma and fibrotic injury, although
further investigation is required to confirm this finding in the cancer patient population and to unveil
the underlying mechanisms.
6.12. Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a chronic, systemic AD that distinguishes itself by
autoreactive lymphocytes and proinflammatory cytokine production. It can often lead to renal injury
and multiple organ damage due to the formation of autoantibodies against nuclear antigens, cell surface,
and serum proteins [105]. Both STAT3 and STAT5 are implicated in SLE etiopathology and have been
found activated in immune cells of SLE patients [106,107]. In T cells of SLE patients, STAT3 and STAT5
synergistically transactivate IL-10 through epigenetic remodeling [108]. In the development of SLE,
dysregulation of the Th17/Treg balance may play an important role and could be responsible for an
increased proinflammatory response, especially in the active form of the disease [109,110]. In this
context, SLE has been recently associated with an active IL-17/STAT3 axis, accompanied by higher Th17
cell numbers [111]. STAT3 inhibitors in combination with immunosuppressive drugs, improve SLE via
restoration of this balance [105], while agents inhibiting STAT3 phosphorylation have shown efficacy
in the treatment of SLE [106]. STAT5 is also implicated in SLE, since activated STAT5 upregulates
the antiapoptotic targets Bcl-2 and Ki-67 in CD4+ T cells, perhaps providing them with a survival
and proliferative advantage over Treg cells [112]. A large patient population-based, retrospective
study recently highlighted a statistically significant association between SLE and melanoma [113].
Dreyer et al. also described that SLE tends to be positively associated with melanoma, although the
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trend was not statistically significant [114]. However, another meta-analysis study reported a decreased
risk of melanoma in SLE patients [115]. Further exploration of the association between malignant
melanoma and SLE is anticipated to shed more light on this issue.
7. Perspectives, Challenges, and Limitations Towards Translating STAT3/STAT5 Targeting to
Therapeutic Solutions for Patients with AD and Melanoma
Recent studies converge to the revolutionary idea of targeting a single nodal molecule to
manage two inter-related pathological conditions simultaneously [116–118]. In line with this notion,
we evaluated whether STAT targeting can be considered for the management of melanoma and its
associated autoimmune comorbidities. An advantage of this approach is that there is an already
established arsenal of STAT3 and STAT5 inhibitors, which are currently under investigation for
the treatment of cancer or autoimmune diseases, as reviewed in detail by Loh and colleagues [40].
This arsenal is being further enriched by indirect epigenetic modifiers of STAT proteins [70,119,120].
STAT3 inhibitors have demonstrated their efficacy in animal tumor models [121] and are currently
under ongoing clinical trials for melanoma treatment (ClinicalTrials.gov Identifiers: NCT01904123,
NCT03195699). In a similar manner, these inhibitory molecules are also efficient in treating several
autoimmune diseases in vivo [85,106] and are now tested in a clinical anti-T1D setting (ClinicalTrials.gov
Identifier: NCT02641522), which has been reported as melanoma-associated comorbidity. Moreover,
it has been reported that cancer patients who exhibit cachexia may benefit from STAT3 inactivation, as it
preserves fat and tissue mass and rescues cachectic phenotypes, in addition to eliminating tumors [122].
Another approach for simultaneous disease management could be achieved through nutritherapeutic
strategies. Several dietary compounds are potent inhibitors of STAT3 regulatory networks [123,124].
These nutriceuticals could have potential applications in patients with chronic ADs, in the sense that
their long-term use as dietary supplements might not only mitigate AD symptoms, but also reduce the
cancer risk. Hence, STAT3 inhibitors may hold therapeutic promise as multipurpose drugs for the
treatment of melanoma in conjunction with associated ADs. Due to its roles in cancer and immunity,
STAT5 is also a proposed therapeutic target [125]. Studies in AD animal models with transplanted
melanoma tumors versus immunocompetent controls will not only provide proof-of-concept about the
feasibility of using agents such as STAT inhibitors against different diseases but might also establish
an experimental approach to facilitate insights into the complex interactions between melanoma and
immune cells.
One challenge regarding the proposed approach remains, namely which melanoma–immune
cell interactions would be suitable for modulation to achieve dual targeting of these diseases without
reducing the beneficial effects of other immune cell populations. Following this direction, it is intriguing
to hypothesize that a possible interplay among melanoma, Th17, and Treg cells could be manipulated
towards this goal. In detail, it has been recognized that an unbalanced Th17/Treg response, on the one
hand, mediates several melanoma-associated Ads, such as psoriasis, IBD, RA, and SLE, and on the other
hand, contributes to carcinogenesis mainly via propelling chronic inflammation [126]. Interestingly,
STAT3 and STAT5 emerge as fine-tuners of the Th17/Treg balance, since STAT3 is responsible for Treg
cells and STAT5 mediates Th17 differentiation [126]. Given that Th17 [127] and Tregs [128] have been
found dysregulated during melanoma progression, it is appealing to postulate that disturbance of the
Th17/Treg homeostasis may favor melanoma cell proliferation in a STAT3/STAT5-dependent manner.
Future studies could shed more light on this issue.
Targeting of the interplay between melanoma cells and NK cells poses as another challenge. While
STAT3 inhibition reactivates NK cells against melanoma, STAT5 inhibition suppresses tumor cytotoxic
activities of NK cells. A hypothetical explanation is that NK cells could be particularly sensitive to a
still understudied equilibrium between STAT3 and STAT5. Such a scenario poses limitations to the
straightforward inhibition of either STAT3 or STAT5 in NK cells and necessitates elucidating how the
STAT3/STAT5 ratio is regulated and what is its contribution to the melanoma–NK cells interplay. In NK
cells, STAT3 inhibition leads to STAT5 activation, and a delicate balance exists between STAT3-mediated
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suppression and STAT5-induced activation of NK-cell cytotoxicity [62]. It has been hypothesized that
this inverse correlation between STAT3 and STAT5 could serve as a regulator of autoimmunity, given
that both factors respond to the same cytokines. In particular, IL-15-induced STAT3 activation could
counteract the IL-15-STAT5-mediated NK-cell cytotoxicity to prevent autoimmunity [62]. A detailed
understanding of the mechanisms governing transactions between melanoma and immune cell
populations could catalyze the development of anticancer strategies aiming at increasing the potential
of killer cells while suppressing self-destruction.
Along with hopes, targeting of STAT factors has also raised skepticism, since its pleiotropic effects
in non-tumor tissues are predicted to potentiate the risk of adverse events [129]. Indeed, STATs are
points of convergence of several signal transduction pathways that affect diverse processes [130], and
as such, their inhibition will have multiple effects, some of which may be manifested as side effects in
nontumor tissues. However, this disadvantage can theoretically turn into an advantage in the event
of multimorbid cancer patients, since in these patients systemic administration of inhibitors against
pleiotropic molecules that are commonly activated in melanoma and associated comorbidities could,
in the long run, simultaneously manage lesions. In this case, the side effect at a site outside the tumor
could be proven beneficial if it actually counteracts a co-existing AD. Such directions could inspire
next-generation therapeutics, especially in melanoma patients whose pre-existing conditions refrain
them from getting benefit from current immunotherapy regimens.
8. Conclusions
Inflammation and autoimmune disorders emerge as comorbidities in melanoma, providing hints
that deregulation in common processes may govern all-three diseases. Crosstalks are established
among melanoma cells and several subpopulations of immune cells, reciprocally modifying their
behavior. Molecular drivers of these crosstalks, such as STAT3 and STAT5 signaling pathways, could be
targeted to manipulate interactions between melanoma cells and immune cells, to develop therapeutics
that coordinately regulate skin cancer and inflammatory and/or autoimmune conditions. In this
review, we (a) state that the high-risk patients with a non-competent immune system (i.e., those
with a pre-existing AD or transplant organ recipients) constitute a special population which requires
personalized management with novel therapeutics that are able to both kill tumor cells and suppress
immune system responses, (b) evaluate if such an approach is feasible, based on the molecular
commonalities between tumors, inflammation, and autoimmune disease, and (c) estimate STAT
targeting as a representative example, although targeting of additional, probably still undiscovered
molecules, may also exert a similar multipotent effect. Immunotherapeutics have taken center stage
and emerge as the blockbusters of pharmacopoieia. Their favorable effects on cancer patients keep
therapeutic hopes high. However, the use of cancer immunotherapy on patients with associated
autoimmune disease could lead to life-threatening side effects. In contrast, drugs with an inherent
ability to cause immune suppression which could theoretically counteract an overactive immune
system might constitute a more suitable option in the context of personalized therapy. To this end,
selected next-generation therapeutics, e.g., STAT inhibitors, may have the potential to shape the first
line of treatment for these patient populations in the future.
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Abstract: All ligands of the epidermal growth factor receptor (EGF-R) are transmembrane proteins,
which need to be proteolytically cleaved in order to be systemically active. The major protease
responsible for this cleavage is the membrane metalloprotease ADAM17, which also has been
implicated in cleavage of TNFα and interleukin-6 (IL-6) receptor. It has been recently shown that in
the absence of ADAM17, the main protease for EGF-R ligand processing, colon cancer formation is
largely abrogated. Intriguingly, colon cancer formation depends on EGF-R activity on myeloid cells
rather than on intestinal epithelial cells. A major activity of EGF-R on myeloid cells is the stimulation
of IL-6 synthesis. Subsequently, IL-6 together with the ADAM17 shed soluble IL-6 receptor acts on
intestinal epithelial cells via IL-6 trans-signaling to induce colon cancer formation, which can be
blocked by the inhibitor of IL-6 trans-signaling, sgp130Fc. Blockade of IL-6 trans-signaling therefore
offers a new therapeutic window downstream of the EGF-R for the treatment of colon cancer and
possibly of other EGF-R related neoplastic diseases.
Keywords: ADAM17; interleukin-6; trans-signaling; epidermal growth factor receptor (EGF-R);
shedding; metalloprotease; tumor necrosis factor alpha (TNFα); inflammation associated cancer;
colon cancer; lung cancer
1. Introduction
IL-6 is a four-helical cytokine with pleiotropic activities, which is synthesized by many cell types
upon appropriate stimulation and which can act on many cell types during several disease states
such as inflammation and cancer [1]. IL-6 exerts its function through binding to the alpha-receptor
Interleukin-6 receptor (IL-6R). The complex of IL-6 and IL-6R binds to the beta-receptor glycoprotein
130 (gp130) and induces dimerization of gp130 [2]. This dimerized gp130 leads to an activation of the
tyrosine kinase Janus kinase 1 (JAK1), which is constitutively associated with the cytoplasmic portion
of gp130. JAK1 phosphorylates tyrosine residues within the cytoplasmic portion of gp130. This leads to
the recruitment of the adapter protein and phosphatase SHP2 that initiates MAP kinase and PI3 kinase
signaling [3]. Furthermore, phosphorylated tyrosine residues recruit the cytoplasmic transcription
factors STAT1 and STAT3, which thereupon become phosphorylated, dimerize, and translocate into
the nucleus, where they bind to DNA and stimulate the transcription of gp130 target genes [3]. One of
the earliest gp130 target genes is the gene coding for SOCS3. The SOCS3 protein is recruited to the
membrane proximal tyrosine residue within the gp130 cytoplasmic tail where it inhibits the activity
of JAK1. Therefore, SOCS3 is a negative feedback inhibitor of gp130 signaling [3]. Recently, it was
shown that gp130 activation leads to the phosphorylation and activation of the YAP pathway (Figure 1).
This pathway was shown to be important in the development of colon cancer [4,5].
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Figure 1. Modes of IL-6 signaling. IL-6 can signal via the membrane-bound IL-6R, which, however,
is only expressed on some cell types. Alternatively, IL-6 can bind to the soluble IL-6R (sIL-6R) and the
complex of IL-6/sIL-6R can stimulate virtually all cells in the body since gp130 is ubiquitously expressed.
In an artificial model of cell-autonomous gp130 stimulation, the extracellular portion of gp130 has been
exchanged for a leucine zipper, leading to constitutive gp130 signaling in the absence of any ligand [6].
The insert shows the main intracellular signaling pathways stimulated by gp130 activation.
While gp130 is expressed on all cells in the body, IL-6R is only expressed on some cells including
hepatocytes, some leukocytes and some epithelial cells. Since IL-6 shows only measurable binding
to the IL-6R but not to gp130, it follows that IL-6 can only act on cells, which express the IL-6R [2,7].
Interestingly, the membrane-bound IL-6R can be cleaved from the cell membrane by A disintegrin
and metalloproteinases (ADAMs), resulting in a soluble form of the receptor [8–10]. The soluble IL-6R
(sIL-6R) can still bind its ligand IL-6 and the complex of IL-6 and sIL-6R can bind to gp130 and induce
dimerization of signaling. This mode of signaling has been called IL-6 trans-signaling [11]. Since gp130
is ubiquitously expressed, IL-6 trans-signaling can lead to the stimulation of virtually every cell in the
body (Figure 1) [12]. However, there are few proteases described that can cleave membrane-bound
IL-6R thus enabling IL-6 trans-signaling. Besides, the closely related ADAM proteases ADAM10 and
ADAM17, meprin metalloproteases were reported to release the soluble form of the IL-6R [13–16].
Moreover, since on most cells gp130 is expressed at higher levels than IL-6R, stimulation by IL-6
leads to the stimulation of only some gp130 molecules whereas stimulation with the IL-6/sIL-6R complex
leads to the activation and stimulation of all gp130 proteins resulting in a higher signal amplitude as a
consequence of IL-6 trans-signaling as compared with IL-6 signaling via the membrane-bound IL-6R.
IL-6 upon binding to the IL-6R is rapidly internalized in contrast to the IL-6/sIL-6R complex, which is
internalized only with low efficacy [17]. This resulted in significantly longer stimulation mediated by
the IL-6/sIL-6R complex as compared to IL-6 alone [17]. This property of IL-6 trans-signaling might be
important for several cellular or tissue responses, which can only be induced by IL-6 trans-signaling
but not by IL-6 classic signaling via the membrane-bound IL-6R [18].
Importantly, IL-6 trans-signaling can be specifically blocked by the extracellular portion of
gp130 fused to the Fc-portion of a human IgG1 antibody (sgp130Fc) [1,19]. This blockade of IL-6
trans-signaling does not affect activities of IL-6 via the membrane-bound IL-6R. In transgenic mice
overexpressing the sgp130Fc, IL-6 trans-signaling is completely blocked. These mice have been widely
used to define the role of IL-6 classic signaling and IL-6 trans-signaling in many mouse models of
human diseases (Figure 1) [1,12,20].
In healthy individuals, IL-6 levels are in the range between 1 and 5 pg/mL, but they can increase
by many orders of magnitude during inflammatory states or upon infection. Plasma IL-6 levels of
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up to several μg/mL have been reported in patients with septic shock [21]. Interestingly, the level
of sIL-6R in the blood of healthy individuals is in the range of 40–80 ng/mL, more than 1000 times
higher than IL-6 [20]. A soluble form of gp130, which is generated by differential splicing [22] is found
in the plasma of healthy individuals at approximately 400 ng/mL [20]. IL-6 binds to the IL-6R with
an affinity of about 1 nM, whereas the complex of IL-6 and sIL-6R binds to gp130 with an affinity of
10 pM. Therefore, IL-6 released into the circulation will bind to sIL-6R and thereafter be trapped by
sgp130. Thus, sIL-6R and sgp130 form a buffer for IL-6 [23]. The important function of the IL-6 buffer
was underlined by studies on the coding single nucleotide polymorphism (SNP; rs2228145) in the
human IL-6R that results in the alteration of Asp358 into Ala358. These amino acid residues are in
close proximity of the proteolytic cleavage site of the IL-6R [16]. Interestingly, the IL-6R with Ala358
is a better protease substrate and is shed more efficiently leading to significantly increased plasma
levels of sIL-6R [24]. Patients with the Ala358 variant of the IL-6R not only show about 2-fold elevated
levels of sIL-6R [25], but they are also protected from inflammatory diseases such as congestive heart
disease, abdominal aneurism, and rheumatoid arthritis [26–28]. Moreover, patients with the rs2228145
SNP showed a significant lower risk of Crohn’s disease and ulcerative colitis as compared to control
individuals [29]. Furthermore, growth rates of abdominal aortic aneurisms in patients were smaller
with the Ala358 variant of the IL-6R [30]. These results can be explained by a higher capacity of the
IL-6 buffer in the blood, which is caused by the higher circulating sIL-6R levels [20,23].
IL-6 is synthesized and secreted by many cell types and the cytokine also acts on many cell types.
IL-6 transgenic animals and IL-6 knock-out animals have been generated to define the major activities
of this cytokine [31–37]. In order to explore cell-specific activities of IL-6, we generated a constitutively
active gp130 construct. To this end, we replaced the entire extracellular portion of gp130 by a leucine
zipper of the c-jun oncogene. Such an arrangement had been used to generate constitutively active
cytokine receptor complexes [38]. Transfection of various cell types with the leucine zipper dimerized
gp130 molecule, which we called L-gp130, was shown to lead to phosphorylation of STAT3 and to
long-term growth of IL-6 dependent cells. Moreover, mouse embryonic stem cells transfected with
the L-gp130 cDNA construct remained undifferentiated even in the absence of exogenously supplied
LIF, indicating that cell autonomous gp130 activation had been achieved [6]. Interestingly, these data
also supported the view that sustained gp130 signaling could not be completely switched off by the
induction of the negative feed-back inhibitor protein SOCS3 (Figure 1) [6]. Recently, we inserted
the L-gp130 cDNA construct into the ROSA26 locus of the mouse. In these mice, by breeding to an
appropriate cre transgenic mouse, the L-gp130 molecule can be switched on constitutively in a cell
autonomous manner. Activating gp130 in B-cells or in the entire hematopoietic system resulted in
B-cell lymphomas and plasma cell disorders with full penetrance [39]. These mice will be useful in the
future to study many more cell-specific activities of IL-6 without confounding activities of other cells
or tissues.
ADAM17 is a membrane-bound metalloprotease, which was originally identified as the protease
responsible for cleavage of the membrane-bound cytokine TNFα [40,41]. Upon gene deletion of
ADAM17, it turned out that this protease is essential for life and it is also responsible for cleavage of
ligands of the EGF-R [42]. In the following years, it was found that ADAM17 is also responsible for
cleavage of the membrane-bound IL-6R [43] and for around 80 additional transmembrane protein
substrates [44,45]. Conditional deletion of ADAM17 [46] and analysis of hypomorphic ADAM17ex/ex
mice [47] revealed important roles of the protease in immune regulation and homeostasis of many
different tissues [44], including the central nervous system [45]. ADAM17 is expressed in most types
of tissues but the cell surface activity of ADAM17 seems to be tightly regulated [44]. It turned out
that intracellular trafficking of ADAM17 through the Golgi to the plasma membrane requires the
presence of iRhoms, which are members of the intramembrane rhomboid proteases and which have
lost protease activity in the course of evolution [48]. In the absence of iRhom1 or iRhom2, ADAM17
mRNA is expressed but the protein does not reach the cell surface [49,50]. Moreover, an additional
protein, FRMD8 or iTAP, which binds to iRhom2 is involved in the activation of the ADAM17 protease
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via phosphorylation [51,52]. An additional mechanism of ADAM17 activation is the cell surface
exposure of phosphatidylserine, which binds to a cationic phosphatidylserine-binding motif within
the membrane-proximal domain of ADAM17 [53]. This mechanism explains the profound activation
of ADAM17 by all inducers of apoptosis analyzed thus far [54].
Since ADAM17 orchestrates at least three major signaling pathways—namely TNFα, IL-6R,
and EGF-R signaling—it is not surprising that the regulation of protease activity is under tight
control. Moreover, the involvement of ADAM17 in fundamental pathophysiologic processes such as
inflammation and cancer can be envisaged. Of note, the importance of ADAM17 has been largely
overlooked by all transcriptomics based studies since the mRNA expression of ADAM17 does not
show major changes between organs as well as in health and disease [44,45]. The role of ADAM17 and
IL-6 trans-signaling in inflammation and cancer will therefore be reviewed in the following paragraphs
(Figure 2).
Figure 2. ADAM17 is a membrane-bound metalloprotease, which cleaves more than 80 substrates [44,45].
Major substrates of ADAM17 are IL-6R, TNFα, and ligands of the EGF-R. Cleavage of the IL-6R is a
prerequisite of the pro-inflammatory IL-6 trans-signaling pathway via the sIL-6R. Cleavage of TNFα
and the formation of soluble TNFα (sTNFα) leads to the stimulation of the pro-inflammatory TNFα
receptor 1 (TNF-RI). Cleavage of ligands of the EGF-R is needed for the systemic activity of the ligands
and therefore for the full stimulation of the EGF-R [47].
2. Results
2.1. IL-6 Trans-Signaling and ADAM17 in Inflammation
IL-6 is essential for the induction, progression and resolution of local and systemic inflammatory
responses that activate acute phase reaction, promote tissue damage and development of autoimmune
reactions, and plays a pivotal role in transition from innate to adaptive immune responses [55].
IL-6 knock-out mice are protected from development of experimental autoimmune
encephalomyelitis (EAE), the mouse model of human multiple sclerosis [56–58] and mouse models
of rheumatoid arthritis [59,60]. These mice also fail to efficiently control bacterial and viral
infections with vaccinia virus, Listeria monocytogenes and Mycobacterium tuberculosis [31,61]. Similar
to IL-6-deficient mice, IL-6R knock-out mice display a deficit in acute phase response, compromised
wound healing, and reduced cellular infiltration during inflammation [62]. While acute phase reactions
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and defense against bacteria is mediated via membrane-bound IL-6R [63] delayed macrophage invasion
in mouse models of inflammation was dependent on the availability of sIL-6R [64–66].
The cellular origin of sIL-6R was longtime unknown. Since it is evident that increased sIL-6R
levels correlate with infiltrated leukocytes in various inflammatory pathologies like arthritic joints [67]
and acute inflammation [64] macrophages were considered as a main source of sIL-6R. Furthermore,
IL-6 stimulates polarization and proliferation of M2 macrophages via induction of IL-4R expression as
shown in mouse models of obesity [68,69].
T cell responses can also be governed by both forms of IL-6 activities. Whereas Treg
development during experimental airway inflammation is controlled via membrane-bound IL-6R [70],
IL-6 trans-signaling orchestrates T cell recruitment in an experimental peritoneal inflammation
model [71]. Recently, it was found that TGFß, together with IL-6, drives the initial differentiation from
naïve T-cells to pathogenic IL-17-producing T-cells (TH17 cells), which are key factors for induction
of tissue damage in a variety of chronic inflammatory and autoimmune diseases [72,73]. Due to
its complex role in immune modulation, it is essential to understand how IL-6 contributes to the
respective pathology.
2.1.1. Rheumatoid Arthritis
The first successful biologics-based therapy of rheumatoid arthritis patients was developed in the
early 1990s by Marc Feldman and Ravinder Maini at the Charing Cross Hospital, London, UK and
made use of antibodies neutralizing TNFα [74]. These TNFα antibodies had originally been prepared
for clinical trials in human sepsis, which, however, entirely failed [75,76]. The first clinical trial with
TNFα antibodies, which only involved few rheumatoid arthritis patients, was highly successful and
led finally to the development of several TNFα-blocking drugs, which by now changed the perception
of rheumatoid arthritis from a vastly debilitating disease to a largely manageable condition [76,77].
A decade ago, blocking IL-6R signaling with anti-IL-6R antibodies was approved for treatment
of rheumatoid arthritis [78]. Beforehand, mouse models of rheumatoid arthritis had shown that
IL-6 signaling drives disease progression by stimulating synovial hyperplasia, preservation of joint
inflammation, and damage of underlying cartilage and bone [79–81]. All these disease symptoms are
largely regulated by STAT3. Interestingly, it turned out that monotherapy with anti-IL-6R antibodies
was superior to treatment of patients with the TNFα antibody adalimumab [82,83].
Mice which carry a Y757F mutation in the cytoplasmic tail of gp130 are unable to initiate the
SHP2–MAP kinase–PI3 kinase axis because Y757 of gp130 is the docking site of SHP2 [84,85]. These
mice can still activate the STAT1/STAT3 pathway [86,87]. Furthermore, these mice do not show
negative regulation by SOCS3 since also this protein requires phosphorylated Y757 for its negative
feedback activity [88,89]. These so-called gp130F/F mice therefore show increased STAT1/STAT3,
but no SHP2–MAP kinase–PI3 kinase signaling [86]. Besides enhanced autoantibody production
against DNA, amplified cell infiltration into the joints and enhanced osteoclast activation, gp130F/F
mice develop arthritis-like symptoms within one year of age, thus resembling human rheumatoid
arthritis [87]. Furthermore, clonal deletion of activated T cells was altered and these chronically
activated T cells showed persistent IL-6-induced STAT3 and JAK1 phosphorylation indicating that IL-6
signaling in T cells plays a critical role in disease progression of rheumatoid arthritis [87]. In contrast,
a dominant-negative STAT3 mutant with reduced STAT3 activity exhibits diminished cell infiltration
into the joints, pannus formation, and cartilage damage in experimental arthritis in mice [90].
IL-6 signaling initiates a range of degenerative and inflammatory processes during rheumatoid
arthritis. In vitro experiments suggested a possible effect of IL-6 and its soluble receptor on synovial
fibroblasts proliferation [91] and survival [92]. Furthermore, IL-6 trans-signaling promotes the
generation of osteoclasts [93–95] and bone resorption by stimulating the expression of receptor activator
of nuclear factor kappa κ B (NFκB) (RANK) ligand (RANKL), which stimulates RANK expressed on
osteoclast precursors leading to differentiation to bone-resorbing osteoclasts [96]. Binding of RANKL to
RANK activates downstream signaling pathways like NFκB, MAPK, JNK, and Akt, which consequently
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stimulate the expression of osteoclastic transcription factors in osteoclast precursors. The study of
Feng et al. [97] showed that IL-6 trans-signaling attenuated RANKL-induced ERK and JNK activation
suggesting that IL-6 trans-signaling differentially regulates RANKL-induced osteoclastogenesis.
Enhanced proliferation and activation of synovial fibroblasts and osteoclasts leads to irreversible
destruction of cartilage and bone of the affected joint. The majority of these processes could be
abrogated by blocking IL-6 trans signaling, which coordinated leukocyte infiltration and severity of
joint damage [79,98,99].
Interestingly, EGF-R inhibition reduced the severity of experimental arthritis, most likely
due to reduction of synovial fibroblasts proliferation, cytokine production, and reduction of
osteoclastogenesis [100]. Furthermore, iRhom2-dependent trafficking of the IL-6R sheddase ADAM17
and its activity on myeloid cells was shown to be involved in development of experimental arthritis in
mice [101]. Since ADAM17 mediates the release of TNFα, sIL-6R, and EGF-R ligands, its activity is
likely to play an important role in the development of rheumatoid arthritis (see below).
2.1.2. Acute Inflammation
Rapid infiltration of neutrophils followed by replacement of mononuclear leukocytes is crucial
for proper resolution of an acute inflammatory situation. IL-6 signaling via its soluble receptor
regulates expression of CXC and CC chemokines that are needed for the switch of initial neutrophil
influx to attraction of monocytes. In this context, IL-6 controls neutrophil infiltration by suppressing
neutrophil-attracting chemokines and directs their apoptosis [64,102]. These effects were shown to be
dependent on STAT3 activity [103]. The switch from neutrophil to monocytic cells could be abrogated
by blocking IL-6 trans-signaling with the sgp130Fc protein in an acute peritonitis model [64,104] and in
an air pouch model of acute inflammation in mice [65]. Furthermore, it was described that depletion of
infiltrating neutrophils reduced the amount of sIL-6R in a model of local and acute inflammation. Thus,
it was reasoned that in local and acute inflammation processes, neutrophils were a major source of
sIL-6R [54]. This led us to investigate if proteolysis by ADAM17 is needed for the local release of sIL-6R
and resolution of an acute inflammation. Contrary to our expectations, local ADAM17 activity was not
critical for proper cell infiltration in acute inflammation in mice since the sIL-6R was infiltrating from
the circulation in an ADAM17-independent process. These studies, however, confirmed the critical
role of IL-6 trans-signaling in local and acute inflammation [105].
Initial recruitment of neutrophils and IL-6 secretion during acute peritonitis was described to
be dependent on IFNγ. Defective IL-6 secretion into the site of inflammation in IFNγ−/− mice could
be restored by treatment with recombinant IFNγ and IL-1ß, but not with IFNγ alone [102]. IL-6
trans-signaling was furthermore shown to be critical for transition between innate and acquired
immune responses. T cell recruitment was impaired in IL-6−/− mice in a mouse model of peritonitis
due to reduced chemokine expression which was mediated by STAT3 activation [71].
Unresolved inflammation leads inevitably to chronic fibrotic tissue damage. IL-6−/− mice were
protected from the development of fibrosis in recurrent inflammatory activation of peritonitis. In this
particular model, IL-6 was needed for survival and expansion of Th1 cells, which were shown to be
crucial for STAT1 activation in stromal cells [106]. Recently, it was shown that IL-6-mediated STAT1
phosphorylation, which reflects the effector characteristics of CD4+ T cells, is critically regulated by
the tyrosine phosphatases PTPN2 and PTPN22. These two phosphatases were described to limit
STAT1-mediated IL-6 signaling in both activated and memory CD4+ T cells thus modulating the
expression of genes associated with particular immune responses [107].
2.1.3. Sepsis
Mice with gp130-dependent STAT3 hyperactivation (gp130F/F) were hypersensitive to LPS-induced
endotoxic shock. Overall survival of these mice was reduced accompanied by increased IL-6 expression
and neutrophil influx into the peritoneal cavity. Both, genetic ablation of IL-6 in gp130F/F or wildtype
mice and specific inhibition of IL-6 trans-signaling led to an increased overall survival of LPS-induced
296
Cancers 2019, 11, 1736
endotoxic shock, suggesting that IL-6 signaling via the sIL-6R triggers the proinflammatory actions of
IL-6 during LPS-induced endotoxic shock [108].
In a large animal study with 120 mice, the effect of total IL-6 blockade or selective inhibition of IL-6
trans-signaling on survival of sepsis induced by cecal ligation puncture was compared. Interestingly,
inhibition of IL-6 trans-signaling via sgp130Fc was far superior to global IL-6 signaling blockade
with an IL-6 neutralizing antibody. In this model, mice treated with sgp130Fc showed an up to 100%
survival rate, an intact acute phase response, and less intestinal epithelial cell apoptosis, whereas no
benefit was seen upon global IL-6 signaling blockade [109]. This enhanced therapeutic efficacy of
inhibiting only the IL-6 trans-signaling pathway might be due to regenerative effects of IL-6 via the
classic signaling pathway that was left intact when only IL-6 trans-signaling was blocked [12,110].
Deficiency of ADAM17 in inflammatory mouse models was shown to greatly diminish
inflammatory responses [46,111,112]. When myeloid cells lacked ADAM17, mice showed slightly better
survival rate after cecal ligation puncture. Blood and peritoneal bacteria levels, as well as inflammatory
cytokine and chemokine plasma concentrations, were reduced in myeloid ADAM17-deficient mice,
while increased neutrophil influx was observed [113]. This was possibly due to reduced proteolysis of
the chemokine receptor CXCR2 or L-selectin [114,115].
2.1.4. Inflammatory Bowel Disease
IL-6 has been described as a T cell activation factor and shown to induce T cell proliferation
and survival [116,117]. This ability has been linked to the pathology of several models of chronic
inflammatory disease [87,118]. In several animal models of intestinal inflammation, the disease could be
alleviated by specific blockade of IL-6 trans-signaling with sgp130Fc. Blockade of IL-6 trans-signaling
led to beneficial T-cell apoptosis in the colon of mice with chronic intestinal inflammation [118],
since an enhanced T-cell resistance against apoptosis may contribute to disease perpetuation in
Crohn’s disease [119]. In a murine model of intestinal inflammation using SAMP1/Yit mice, which is
considered to be similar to inflammatory bowel disease in humans, treatment with sgp130Fc improved
inflammation, as validated by less destruction of the epithelial layer and by less inflammatory infiltrates
in the lamina propria of the small intestine [120]. In patients with inflammatory bowel disease,
treatment with the IL-6R neutralizing antibody Tocilizumab suggested a clinical benefit [121], but this
treatment has not been approved by the FDA. It is possible that, like in the murine cecal ligation
puncture model of sepsis, specific blockade of IL-6 trans-signaling with sgp130Fc might be superior
to global IL-6 blockade due to regenerative effects of IL-6 via the classic signaling pathway [12,110].
Of note, the sgp130Fc protein under the WHO name Olamkicept is currently tested in phase II clinical
trials in patients with inflammatory bowel disease [20].
2.1.5. Lung Pathophysiology: Emphysema, Asthma, and Idiopathic Pulmonary Fibrosis
Proinflammatory actions of IL-6 are implicated in the pathogenesis of lung emphysema and
patients with COPD [122]. Analysis in mice revealed that development of emphysema was reliant on
IL-6. In contrast to wt mice, gp130F/F mice showed spontaneous development of lung emphysema
at 6 months of age due to alveolar cell apoptosis, which was abrogated by genetic deletion of IL-6.
Treatment of wt mice with cigarette smoke increased emphysema-associated lung volume increase,
which was not seen in IL-6-deficient animals [123]. In both models, in the spontaneous development
of lung emphysema seen in gp130F/F mice and in cigarette smoke treated wildtype mice, treatment
with sgp130Fc abrogated alveolar cell apoptosis and disease pathogenesis. This study furthermore
revealed a possible connection of IL-6 trans-signaling and the mTOR pathway. After blockade of the
serine/threonine kinase mTOR with rapamycin, IL-6 mediated lung pathologies were significantly
reduced [124].
IL-6 was claimed to be important for the maintenance of the balance of effector T cells and
regulatory T cells in lung pathogenesis. In a mouse model of asthma, IL-6 trans-signaling rather
supported Th2 cytokine production, whereas classic IL-6 signaling was needed for the development of
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FoxP3+ regulatory T cells in the lung [70]. A recent study revealed an IL-6 trans-signaling specific
gene signature in patients with asthma, which was accompanied by an increase in submucosal T
cell and macrophage infiltration. Stimulation of primary human bronchial epithelial with both IL-6
and sIL-6R induced genes associated with airway remodeling such as matrix metalloproteinases and
reduced expression of genes associated with epithelial barrier function such as ß-catenin. The gene
signature found in this study was hypothesized to be helpful in determining patient subsets with high
submucosal-inflammation and poor asthma control [125].
Idiopathic pulmonary fibrosis (IPF) characterizes a heterogeneous, chronic, and irreversible
disorder in which deposition of collagen results in the loss of lung function. Although it is unsure
if pulmonary fibrosis is the result of an unresolved inflammatory process the role of inflammatory
cytokines is discussed. A study of cytokine levels in serum of patients with IPF revealed that IL-6
and IL-8 were increased in individuals with exacerbated disease state and that these increased levels
correlated with a worse outcome [126]. This deleterious impact of IL-6 on the development of lung
fibrosis was analyzed in different mouse models. In adenosine deaminase-deficient mice, which
develop pulmonary inflammation and remodeling as well as in bleomycin-induced lung injury,
IL-6 was shown to drive cellular infiltration and collagen deposition in the lungs [127,128]. A role
for IL-6 trans-signaling in IPF was suggested as elevated sIL-6R levels were found in the lungs of
patients with IPF and of mice with bleomycin-induced pulmonary fibrosis. Neutralization of IL-6
trans-signaling with sgp130Fc led to reduction of pulmonary inflammation, diminished myofibroblast
accumulation and improved respiratory functions [129]. The development of pulmonary fibrosis in
mice and differentiation of lung fibroblasts to collagen-producing myofibroblasts involves STAT3
activation by TGFß or IL-6 trans-signaling [130]. It was suggested that increased STAT3 activity in
fibroblasts from IPF patients led to reduced apoptosis and thus contributes to the persistence of these
cells [131,132].
2.2. IL-6 Trans-Signaling and ADAM17 in Cancer
It is widely accepted that inflammatory cytokine signaling plays key roles at many stages of
tumorigenesis and supports malignant cell proliferation and metastasis [133]. Intestinal inflammation
in several different animal models was efficiently blocked by a blockade of IL-6 trans-signaling [118,120]
using sgp130Fc. On the other hand, intestinal inflammation was exacerbated by the application of
Hyper-IL-6, a fusion protein of IL-6 and sIL-6R, which is a strong stimulator of IL-6 trans-signaling [134].
Therefore, it was reasonable to assume that inflammation associated cancer might also be driven by
IL-6 trans-signaling [135].
2.2.1. Colorectal Cancer
When mice were treated with a low dose of the mutagen azoxymethane (AOM) followed by
consecutive cycles of orally administered dextran sulfate sodium (DSS), they developed small visible
lesions around day 20, followed by the appearance of large tumors until day 80 [136]. When analyzing
RAG-1 knockout mice, which are defective in B-cell and T-cell receptor recombination and therefore
lack B- and T-lymphocytes and hence are severely immune-deficient, it became clear that these animals
did not develop large tumors indicating that lymphocytes are involved in the regulation of tumor
growth [136]. Colon samples from different time points after AOM/DSS treatment demonstrated
massive IL-6 and sIL-6R accumulation from day 21 onwards. Treatment of the mice with a neutralizing
antibody against IL-6R drastically reduced the tumor score [136]. Interestingly, also selective blockade
of IL-6 trans-signaling by injection of the sgp130Fc protein effectively suppressed colon carcinogenesis,
suggesting that IL-6 trans-signaling by inducing STAT3 phosphorylation and expression of the
anti-apoptotic proteins bcl-xl and bcl-2 was responsible for growth of epithelial tumor cells [136].
In human colon tumor tissues, it was shown that the expression and activity of ADAM17 was
significantly increased as compared with normal tissue, underlining an important role of ADAM17
in mediating the IL-6 trans-signaling response via the sIL-6R [137]. In a different intestinal tumor
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model, mice repeatedly treated only with 9 DSS but not with AOM developed intestinal tumors
after 18 weeks. The incidence and number of tumors was drastically reduced when the mice were
treated with the sgp130Fc protein. Interestingly, it was shown that lamina propria macrophages via
induction of ADAM17 were important for the generation of sIL-6R and therefore for the induction of
IL-6 trans-signaling [138].
When IL-6−/− mice were compared to wt mice in their susceptibility to inflammatory colon cancer
in the AOM/DSS model, it turned out that IL-6−/− mice had less tumors but more inflammation in the
intestine, arguing for a role of IL-6 in the intestinal regeneration response. [110]. Indeed, it was shown
in the same study that deletion of STAT3 in the intestinal epithelium led to more severe DSS colitis with
pronounced colonic ulcerations and body weight loss, indicating that the IL-6 response in the intestinal
epithelial cells was important for regeneration [110]. These data were further corroborated by a parallel
study in which the authors used transgenic mice expressing in intestinal epithelial cells a constitutively
active form of gp130 dimerized by a leucine zipper [6], which led to cell-autonomous STAT3 activation.
These mice were largely resistant to DSS-induced colitis [139]. The above data suggested a role of IL-6
in the regeneration of the intestine. Indeed, treatment of mice with recombinant IL-6 protected the
animals from DSS-induced colitis whereas treatment with a neutralizing IL-6 antibody aggravated
DSS-induced colitis [140,141].
Inflammatory hepatocellular adenomas often harbor mutations in the gp130 gene, which leads to
ligand independent activation of gp130 [142]. Transgenic mice, which express constitutively active
gp130 transgene developed aberrant proliferation of intestinal epithelial cells. Interestingly, it was
observed that the YAP and Notch signaling pathway were activated by the constitutively active gp130
mutant [5]. Furthermore, it was reported by the same authors that loss of APC in mice and in human
patients led to the activation of Src, YAP, Notch, and STAT3. The presence of the activated gp130
transgene in intestinal epithelial cells accelerated the development of colorectal cancer and depended
on the activities of Src family and JAK kinases [4].
Mice with a complete deletion of the ADAM17 gene are not viable [42]. Although, ADAM17 floxed
mice are available [46], it was not completely clear in which cell types we wanted to delete the ADAM17
in order to show a decisive role of the protease, since many cells including macrophages can be the
source of the sIL-6R in vivo [2]. We therefore made use of ADAM17 hypomorphic ADAM17ex/ex mice,
which we had engineered to only express about 5% of ADAM17 protein levels in all cells [47]. ADAM17
hypomorphic ADAM17ex/ex mice were shown to be hypersensitive to DSS-induced colitis due to a
failure to induce EGF-R signaling, which was needed for intestinal regeneration. EGF-R activation could
be compensated by treatment of the mice with recombinant ligands of the EGF-R, which compensated
for the lack of cleavage of these membrane-bound proteins [47]. We therefore applied a colon cancer
model to ADAM17ex/ex mice. In APCmin/+ mice, a heterozygous germ line truncation in the APC gene
results in the formation of intestinal tumors after spontaneous loss of heterozygosity of the remaining
APC wt allele [143,144]. Strikingly, in the absence of ADAM17 activity, almost no intestinal tumors
were detected and the few remaining tumors were only of low-grade dysplasia whereas in the presence
of ADAM17, also high-grade dysplasias and invasive carcinomas were detected [144]. Surprisingly,
we failed to detect significantly elevated levels of phosphorylated EGF-R on intestine sections of wt
and ADAM17ex/ex mice (Figure 3) [144].
Elevated activity of the EGF-R has been associated with an increased risk of colon
carcinogenesis [144,145]. Recently, it was reported that in patients, EGF-R was expressed on myeloid
cells within intestinal tumors and that in mice, EGF-R on myeloid cells but not on intestinal epithelial
cells promoted colitis associated cancer in the AOM/DSS model and tumorigenesis in the APCmin/+
model and protects from colitis in an independent fashion [141]. Moreover, EGF-R activation in
myeloid cells led to strongly increased synthesis and secretion of IL-6 [141].
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Figure 3. Involvement of ADAM17 in the formation of colon cancer. Under inflammatory conditions,
ADAM17 cleaves the membrane-bound EGF-R ligand amphiregulin, leading to the stimulation of the
EGF-R on macrophages. This EGF-R stimulation on macrophages leads to increased IL-6 synthesis via
transcriptional stimulation. Moreover, activation of ADAM17 under inflammatory conditions leads to
cleavage of the membrane-bound IL-6R on macrophages to generate soluble IL-6R (sIL-6R). IL-6 in
complex with sIL-6R leads to stimulation of intestinal epithelial cells (IECs) via IL-6 trans-signaling
resulting in colon cancer formation [144].
ADAM17 on myeloid cells can lead to the shedding of ligands of the EGF-R such as amphiregulin
and to the shedding of the IL-6R [10]. We therefore speculated that IL-6 trans-signaling initiated
by the EGF-R mediated IL-6 secretion and the ADAM17-mediated IL-6R shedding might contribute
to colon cancer formation in the APCmin/+ model. We therefore crossed APCmin/+ mice with either
IL-6−/− mice or mice, which were transgenic for sgp130Fc and in which IL-6 trans-signaling was
blocked [19,65]. Indeed, tumorigenesis was strongly reduced to the same extent in IL-6−/− mice and
sgp130Fc transgenic mice indicating that IL-6 trans-signaling strongly contributed to tumor formation
in the APCmin/+ model [144]. Furthermore, in a chemical colon cancer model, in which mice were
repeatedly treated with AOM but not with DSS, sgp130Fc transgenic mice were protected from colon
cancer [144]. We concluded from these data that in colon cancer, IL-6 trans-signaling apparently acted
downstream of the EGF-R and blockade of IL-6 trans-signaling might represent a novel therapeutic
window for patients resistant to anti-EGF-R antibodies (Figure 3) [146].
2.2.2. Pancreatic Cancer
In the KrasG12D pancreatic cancer model, strong non-cell-autonomous STAT3 activation in tumor
cells was observed [147]. IL-6 mRNA levels were significantly increased in tumor tissue. The cellular
source of IL-6 was infiltrating immune cells, mainly F4/80-positive macrophages. When the pancreatic
KrasG12D mice were crossed with IL-6−/− mice or sgp130Fc transgenic mice. IL-6−/− mice had fewer
and predominantly low grade pancreatic intraepithelial neoplasias. Interestingly, blocking IL-6
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trans-signaling had a similar effect as deletion of the IL-6 gene since sgp130Fc transgenic mice also
showed strongly reduced tumor numbers. This decrease in tumor development was paralleled
by a marked reduction of STAT3 phosphorylation [147]. It was speculated that the concept of
non-cell-autonomous STAT3 activation of tumor cells brought about by IL-6 trans-signaling was a
general phenomenon, which might also be applied to other neoplasias and cancer diseases [147].
2.2.3. Liver Cancer
During liver regeneration, quiescent hepatocytes regain their ability to enter the cell cycle.
Importantly, IL-6 [148] and in particular IL-6 trans-signaling has been found to be required for
liver regeneration [149]. Accordingly, in IL-6/sIL-6R double transgenic mice, permanent hepatocyte
proliferation and formation of adenomas was observed, indicating a possible role of IL-6 trans-signaling
for hepatocellular neoplasia [150,151]. Treatment of mice with diethylnitrosamine is used as one of
the standard models for liver cancer [152]. In this model, it has been recognized that IL-6 deficient
mice develop substantially less tumors as compared to wt mice [153]. When sgp130Fc transgenic
mice were treated with diethylnitrosamine, it turned out that myeloid cell derived sIL-6R increased
upon treatment and liver tumor development the animals was largely blocked [154]. We concluded
from these experiments that IL-6 trans-signaling but not IL-6 classic signaling was involved in the
development of hepatocellular carcinoma, at least in the diethylnitrosamine model [154].
2.2.4. Lung Cancer
As mentioned above, gp130 signal transduction is mediated by the SHP2–MAP kinase–PI3
kinase axis. In addition, STAT1 and STAT3 become recruited to the cytoplasmic tail of gp130,
are phosphorylated by JAK1, and dimerize and travel to the nucleus to act as transcription factors [3].
Mice, which carry a Y757F mutation in the cytoplasmic tail of gp130 are unable to initiate the SHP2–MAP
kinase–PI3 kinase axis because Y757 of gp130 is the docking site of SHP2. These mice can still activate
the STAT1/STAT3 pathway [86]. Furthermore, these mice do not show negative regulation by SOCS3
since also this protein requires phosphorylated Y757 for its negative feedback activity [86]. These
so-called gp130F/F mice therefore show increased STAT1/STAT3 but no SHP2–MAP kinase–PI3 kinase
signaling [86].
The gp130F/F mouse model has been widely used to explore a range of gp130 mediated disease
states. The more pronounced gp130/STAT1/STAT3 response seen in these mice has been used to analyze
novel therapeutic strategies for inflammatory diseases. Gp130F/F mice are more sensitive than wt mice
towards endotoxin. It was found that genetic ablation of IL-6, antibody-mediated inhibition of the
IL-6R or blockade of IL-6 trans-signaling by the sgp130Fc protein completely protected gp130F/F mice
from endotoxin hypersensitivity [108]. Gp130F/F mice spontaneously develop lung emphysema, which
could be prevented by blocking IL-6 trans-signaling [124]. When floxed KrasG12D mice were treated
via intranasal inhalation with adenovirus, which encoded cre recombinase 6 weeks prior to analysis,
massive lung cancer development was observed, which was much more pronounced in gp130F/F mice
as compared to wt mice [155]. Ablation of IL-6 or STAT3 suppressed the extent of lung cancer in this
model [155]. Furthermore, we could demonstrate that specific inhibition of IL-6 trans-signaling by the
sgp130Fc protein significantly ameliorated lung cancer pathogenesis [155].
Since IL-6 trans-signaling depends on the proteolysis of the membrane-bound IL-6R by the
metalloprotease ADAM17, we asked whether in the absence of ADAM17 activity, lung tumor formation
in the KrasG12D mouse model would be blocked. When ADAM17ex/ex mice were crossed with KrasG12D
mice, tumor formation in the lung was largely inhibited [156]. Interestingly, the cytoplasmic portion
of ADAM17 was phosphorylated in KrasG12D mice but not in wt mice [156]. Phosphorylation of the
cytoplasmic portion of ADAM17 has been shown to lead to activation of the enzyme [157]. Interestingly,
in KrasG12D mice, the levels of sIL-6R were significantly elevated, whereas in compound ADAM17ex/ex:
KrasG12D mice, sIL-6R levels were comparable to wt mice. No changes in soluble TNFα levels were
observed [156]. Moreover, in a xenograft model with ADAM17-deleted A549 cells, tumor formation
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was abrogated as compared to unedited A549 cells [156]. Along the same line, pharmacologic inhibition
of ADAM17 activity also led to decreased tumor formation in KrasG12D mice together with decreased
sIL-6R levels [156]. Moreover, in a nicotine-derived nitrosamine ketone model of tobacco-related lung
cancer, genetic or pharmacologic blockade of ADAM17 led to a significant reduction of lung lesions
and concomitant reduced sIL-6R levels [158]. Together, these data indicated that ADAM17 via IL-6
trans-signaling was a prerequisite of lung tumor formation in these animal models.
3. Conclusions and Outlook
ADAM17 activation orchestrates three major signal transduction pathways, namely IL-6
trans-signaling, stimulation of the TNFα signaling pathway via TNF-RI and the EGF-R pathway via
cleavage of EGF-R ligands such as amphiregulin, TGFα, or Hb-EGF. Apparently, in many inflammatory
diseases as well as in colon cancer and lung cancer, the IL-6 trans-signaling pathway plays a dominant
role as compared to the TNFα signaling pathway (Table 1).
Table 1. Efficacy of IL-6 trans-signaling blockade by sgp130Fc in preclinical models of inflammation
and inflammation associated cancer.
Disease Model Outcome of the Study
Intestinal inflammation [118,138] Suppression of colitis activity
Acute inflammation [54,64,65] Blockade of inflammatory processes
Atherosclerosis [159] Regression of advanced atherosclerosis
Rheumatoid arthritis [79,98,99] Improvement of established arthritis
Sepsis [108,109] Up to 100% survival in different sepsis models
Pancreatitis-lung failure [160] 100% survival of severe acute pancreatitis
Lung emphysema [124] Improvement by blockade of alveolar cell apoptosis
Abdominal aortic aneurism [30] Improved survival in two animal models
Colon cancer [110,136–138,144] Blockade of tumor formation
Pancreatic cancer [147] Inhibition of pancreatic neoplasia progression
Liver cancer [154] Protection from tumor formation
Lung cancer [156,158] Amelioration of lung cancer pathogenesis
The dependence of IL-6 trans-signaling via the generation of IL-6 and sIL-6R by the EGF-R on
macrophages demonstrates the existence of a possible novel therapeutic window for the treatment
of colon cancer and lung cancer, which might be important in view of the fact that EGF-R antibodies
including cetuximab or pantuximab are only useful in patients in whom there are no activating KRAS
mutations [161,162]. Even in such patients without KRAS mutations, who show an initial response,
almost invariably resistance against EGF-R blockade is seen [163]. In all of these cases, blockade of the
IL-6 trans-signaling pathway might offer an additional and alternative treatment option. This treatment
option, however, will need to be verified in future human studies.
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Abbreviations
ADAM a disintegrin and metalloprotease
AOM azoxymethane
APC adenomatous polyposis coli protein
COPD chronic obstructive pulmonary disease
DSS dextransulfate sodium
EAE experimental autoimmune encephalomyelitis
EGF epidermal growth factor
FDA US food and drug administration
FoxP3 forkhead box protein 3
FRMD FERM domain containing protein, identical to iTAP
Gp130 glycoprotein 130 kDa




iRhom inactive rhomboid protease
iTAP iRhom Tail-Associated Protein identical to FRMD8
JAK Janus kinase
JNK c-Jun N-terminal kinase
Kras oncogene first identified in Kirsten RAt Sarcoma virus
MAP mitogen-activated protein
mTOR mechanistic target of rapamycin
NFκB nuclear factor kappa-light-chain-enhancer
Notch cell signaling receptor present in most animals
PTPN tyrosine phosphatase
RANK Receptor Activator of NFκB
RANKL ligand of RANK
ROSA26 reverse oriented splice acceptor, Clone 26
SHP2 protein-tyrosine phosphatase shp2
SOCS suppressor of cytokine signaling
Src proto-oncogene tyrosine-protein kinase
STAT signal transducer and activator of transcription
TNF tumor necrosis factor
WHO world health organization
YAP proto-oncogene yes associated protein.
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Abstract: Epithelial ovarian cancer (EOC) is the most lethal of all gynecologic malignancies. Despite
advances in surgical and chemotherapeutic options, most patients with advanced EOC have a relapse
within three years of diagnosis. Unfortunately, recurrent disease is generally not curable. Recent
advances in maintenance therapy with anti-angiogenic agents or Poly ADP-ribose polymerase (PARP)
inhibitors provided a substantial benefit concerning progression-free survival among certain women
with advanced EOC. However, effective treatment options remain limited in most recurrent cases.
Therefore, validated novel molecular therapeutic targets remain urgently needed in the management
of EOC. Signal transducer and activator of transcription-3 (STAT3) and STAT5 are aberrantly activated
through tyrosine phosphorylation in a wide variety of cancer types, including EOC. Extrinsic tumor
microenvironmental factors in EOC, such as inflammatory cytokines, growth factors, hormones, and
oxidative stress, can activate STAT3 and STAT5 through different mechanisms. Persistently activated
STAT3 and, to some extent, STAT5 increase EOC tumor cell proliferation, survival, self-renewal,
angiogenesis, metastasis, and chemoresistance while suppressing anti-tumor immunity. By doing
so, the STAT3 and STAT5 activation in EOC controls properties of both tumor cells and their
microenvironment, driving multiple distinct functions during EOC progression. Clinically, increasing
evidence indicates that the activation of the STAT3/STAT5 pathway has significant correlation with
reduced survival of recurrent EOC, suggesting the importance of STAT3/STAT5 as potential therapeutic
targets for cancer therapy. This review summarizes the distinct role of STAT3 and STAT5 activities in
the progression of EOC and discusses the emerging therapies specifically targeting STAT3 and STAT5
signaling in this disease setting.
Keywords: ovarian cancer; STAT3; STAT5
1. Introduction
Epithelial ovarian cancer (EOC) is a heterogenous entity comprised of different histotypes [1]
with unique molecular features and clinical characteristics that influence chemosensitivity and the
probability of survival [2]. Cytoreductive surgery and platinum/taxane-combination chemotherapy
remain the mainstay of primary treatment for advance-staged diseases, resulting in the initial remission
Cancers 2020, 12, 24; doi:10.3390/cancers12010024 www.mdpi.com/journal/cancers313
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in up to 80% of EOC patients. Nonetheless, approximately 75% of patients with advanced diseases
develop recurrence within three years of diagnosis [3], which is generally not curable, owing to the
development of chemoresistance. In this respect, EOC remains the most lethal of all gynecologic
malignancies, and the relative survival rates at ten years for stage III and IV disease are 23% and 8%,
respectively [4]. Molecular therapeutics targeting the angiogenesis and DNA damage repair pathways
have provided significant steps forward in the management of certain EOC patients. However, there is
still a clear unmet need for most patients with recurrence. Identifying novel molecular therapeutic
targets relevant to the disease progression is thus highly anticipated.
Signal transducers and activators of transcription (STATs) belong to a family of cytoplasmic
transcription factors that communicate signals from the cell membrane to the nucleus. The STAT family
includes seven structurally and functionally related proteins: STAT1, STAT2, STAT3, STAT4, STAT5A,
STAT5B, and STAT6 [5]. STATs have essential roles in fundamental processes, including sustaining
proliferation, evading apoptosis, inducing angiogenesis, promoting invasion, and suppressing
anti-tumor immunity [6,7]. Upon the binding of cytokines or growth factors to cognate receptors
on the cell surface, STATs are tyrosine phosphorylated, particularly by Janus kinase (JAK), Abelson
(Abl) kinase or SRC kinase families. Phosphorylated STAT (pY-STAT) dimer undergoes conformation
change and shuttles into the nucleus, functioning as a transcription factor. Each STAT protein appears
to have distinct physiologic functions in the development, differentiation, and immune response
(For a comprehensive review, please see [7]). In particular, mice carrying homozygous deletion for
STAT5 (STAT5a−/−5b−/−) which later turned out to be hypermorphic STAT5 deletion mice lacking the
N-domains were infertile, with defects in the differentiation of functional corpora lutea, disrupting
ovarian development [8].
STATs activation is rapid and transient under most physiological conditions. Notably, compelling
evidence indicates that constitutive activation of STAT proteins, particularly STAT3 and STAT5, plays a
critical role in oncogenic transformation. Clinically, aberrant activation of STAT3 and, to some extent,
STAT5, is associated with both solid and hematopoietic cancers [9–12]. Accumulating evidence has
indicated that downregulating STAT3/STAT5 mitigates the malignant behavior of cancer cells [13],
highlighting the potential of STAT3/STAT5 as a therapeutic target. Collecting data has shown the
role of STAT3 in the disease progression mechanism of EOC. Compared to normal or benign ovarian
tumors, pY-STAT3/pY-STAT5 protein expression was significantly higher in the malignant EOC tissues,
supporting its role in ovarian carcinogenesis [14,15]. The activation of the STAT3 pathway and the
increase in pY-STAT3 (Tyr705) expression directly correlated with higher clinical stage, lower degree
of differentiation, presence of lymph node metastasis, and more reduced survival in EOC [15–17].
Moreover, elevated pY-STAT3 expression in the omentum was associated with poor survival in patients
with high-grade EOC. The activation and translocation of pY-STAT3 to the nucleus was observed
in 29–58% of all EOC histotypes [13,16]. Specifically, nuclear pY-STAT3 expression was found to
be associated with clear cell and serous carcinoma [17]. The activation of STAT3 pathway was, in
particular, related to overall survival in ovarian clear cell carcinoma patients [16]. In recurrent diseases,
levels of STAT3 activation were doubled, indicating that STAT3 activation could be directly associated
with disease relapse [18]. Moreover, one study suggests STAT5 may be related to RELA (p65 subunit of
NF-kB) and carboplatin resistance in EOC [19].
2. Regulation of STAT3/STAT5 Activation in EOC
Constitutive activation of STAT3/STAT5 has been identified in a wide range of human cancers.
As a primary event during malignant transformation, somatic STAT3 and STAT5 driver mutations
have been identified in hematopoietic neoplasms. For example, somatic mutations in the STAT3 gene
were found in 40% of granular lymphocytic leukemia and T-cell lymphoma patients, with recurrent
mutations located on the gene segment encoding the SH2 domain, which mediates STAT3 dimerization
and activation [20,21]. Also, a small percentage of granular lymphocytic leukemia patients harbored
STAT5B mutations, resulting in increased transcriptional activity and phosphorylation [22]. However,
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genetic mutations that result in hyperactivated STAT3/STAT5 have not been reported in EOC [23]. In
EOC, constitutive upregulation of STATs in the absence of somatic mutations is primarily contributed
through persistent Tyr phosphorylation signals. In general, STAT3/STAT5 are activated in response
to the binding of numerous cytokines, hormones, and growth factors to their receptors and by the
activation of intracellular kinases, mostly in case of tyrosine phosphorylation by the four JAK family
kinases. Typically, STAT3/STAT5 are activated by phosphorylation on critical residues (STAT3 Tyr
residue 705 and Ser727 (ERK, JNK, and other stress kinases); STAT5A Tyr residue 694, Ser725 (CDK8)
and Ser779 (PAK1/2) and STAT5B Tyr residue 699 and Ser730 (CDK8)) [9]. The JAK-STAT signaling in
EOC can be further modulated by various molecular pathways, as summarized in Figure 1.
Figure 1. Signal transducers and activators of transcription (STAT)3 and STAT5 signaling in epithelial
ovarian cancer (EOC) and tumor microenvironment. Distinct families of cytokines such as Interleukins
(IL-6,IL-11) and leukemia inhibitory factor (LIF) bind to their homodimeric cognate receptors IL-6R,
IL-11R and LIFR respectively, and share a signal-transducing receptor gp130. Janus kinase (JAK)
phosphorylate gp130 to enable docking and phosphorylation of STAT3 at Tyrosine (symbol Y or
Tyr) residue 705. Tyrosine phosphorylation of STAT3 can also be mediated by activation of other
oncogenic proteins including growth factor (GF)-mediated receptor Tyrosine kinase (RTK) activation,
granulocyte colony-stimulating factor (G-CSF)-mediated activation, SRC and RAS/MEK/ERK pathway.
Phosphorylated STAT3 dynamically undergo dimerization and nuclear translocation to trigger
STAT3-mediated transcription of target genes. Binding of Prolactin to its receptor facilitate JAK-mediated
phosphorylation of STAT5A and STAT5B at Tyr residue 694 and Tyr residue 699, respectively, leading to
homodimerization or heterodimerization before nuclear translocation for target gene activation. STAT3
and STAT5 signaling in cancer cells release more cytokines into tumor microenvironment that generate
a plethora of immune-compromising functions (highlighted in the main text). Figure created with
Biorender.com.
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2.1. IL-6 Pathway
Upstream to the JAK-STAT signaling, the IL-6 family of cytokines is critical for signal
transduction. The binding of IL-6 family cytokines to the ligand-binding subunit of gp130 initiates
its homodimerization, activates JAK to bind to gp130, and then triggers downstream signaling
cascades [24]. In EOC, The IL-6 family of cytokines is one of the major families of immunoregulatory
cytokines. IL-6, LIF, and IL-11 secreted in the EOC tumor microenvironment function in concert to
induce ovarian cancer cell JAK-STAT signaling [25–27].
2.2. TP53 Mutation
Notably, Tyr phosphorylation of JAK2 can be diminished by wild type but not mutant p53 in EOC
cells [28]. Since there is a high frequency of somatic TP53 mutation in high-grade serous carcinoma
(HGSC), this suggests that STAT3 phosphorylation and its DNA binding activity can be modulated by
the p53 status in HGSC.
2.3. Lipid Metabolism Pathway
STAT3 is also regulated by the cellular redox state controlling the transcription of genes related to
the invasive phenotype. Pathways related to lipid metabolism known to affect the redox state thus
are intriguing mechanisms since obesity is known to be a risk factor for poor EOC survival [29]. For
example, leukotriene B4, a lipoxygenase pathway metabolite, together with their cognate receptor
leukotriene B4 receptor 2 (BLT2) contribute to the generation of reactive oxygen species (ROS) in EOC
cells, which results in the activation of JAK and the STAT3-MMP2 cascade [30]. Leptin is an adipokine
that exerts its activity through the membrane receptor, the obesity receptor (OB-R). The overexpression
of OB-R in EOC significantly correlates with poor progression-free survival [31]. It has been shown
that Leptin/OB-R signaling may phosphorylate STAT3 through the activation of JAK in EOC cells [32].
Recently, CD97, a member of the EGF-TM7 family of G-protein coupled receptors, is known to be
expressed in several malignancies, including EOC. The interaction between overexpressed CD97 and
its ligand CD55 activates JAK2/STAT3 signaling and confers an invasive cell phenotype of EOC [33].
2.4. Receptor Tyrosine Kinases (RTKs)
Several RTKs have been suggested to modulate the JAK-STAT signaling pathway. Vascular
endothelial growth factor (VEGF), a key mediator of angiogenesis in EOC, induces pY-STAT3 through
the binding of VEGF receptor 2 (VEGFR2) in EOC cells [34]. The expressions of VEGF, VEGFR1,
and VEGFR2 are significantly correlated with pY-STAT3/pY-STAT5 in EOC [14]. Epidermal growth
factor (EGF) is known either to directly activate JAK2/STAT3 signaling pathway or to induce the
secondary mediator-like response mediated by the IL-6 axis in an autocrine manner in EOC [35]. EGFR
which is overexpressed in EOC is significantly correlated with pY-STAT3 [17]. Oncogenic RAS and
RAF mutations are prevalent in EOC, and these driver mutations are highly associated with aberrant
ERK signaling, resulting in uncontrolled cellular proliferation [36,37]. Mechanistically, activated
RTKs stimulate RAS activation, which then activates RAF. RAF phosphorylates and activated MEK,
which in turn activates ERK through phosphorylation. Aberrant phosphorylation of ERK mediates
phosphorylation of S727-STAT3 (Figure 1) and contributes to cisplatin resistance in certain EOC cell
lines [38].
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2.5. Alternative Cytokine or Non-Receptor Tyrosine Kinases
Granulocyte-colony stimulation factor (G-CSF), a commonly used cytokine receptor to aid
hematopoietic recovery following chemotherapy, activates the JAK/STAT pathway in EOC through
its cognate receptor, the G-CSFR, which is predominantly expressed in HGSC [39]. Furthermore,
non-receptor tyrosine kinase SRC family members can alternatively tyrosine phosphorylate STAT
proteins, and SRC is overexpressed and activated in late staged EOC. SRC family tyrosine kinases
are essential for STAT activation in EOC, especially during metastasis. It is known that activated
STAT localizes not only to nuclei, but also to focal adhesions. SRC family kinases induce pY-STAT3
and contribute to strong interactions between the pY-STAT3 and the focal adhesion complex [13].
In particular, c-SRC, a member of SRC family kinases, is primarily involved in hypoxia-triggered
intracellular signaling. Under hypoxia, activation of c-SRC induces nuclear pY-STAT3 and enhances
the binding ability of STAT3 to Hypoxia-inducible factor 1-alpha (HIF-1α), which contributes to
chemoresistance in EOC [40]. Moreover, recombinant human erythropoietin (rhEpo) has been shown
to bind to an alternative Epo receptor, EphB4, to activate the SRC-STAT pathway, triggering tumor
growth, and resulting in decreased survival of EOC [41]. This further supports the notion that the use
of rhEpo to treat anemia in cancer patients can compromise their overall survival [42].
2.6. Other Gene Regulatory Mechanisms
A dysregulated transcriptional control of STAT3 by miRNAs was reported in EOC. Increased
expression of miR551b-3p, which is resultant from the frequent q26.2 amplification in HGSC, interacted
with the STAT3 promoter by recruiting RNA-pol-II and TWIST1 to turn on STAT3 transcription [43]. The
upregulation of STAT3 is subsequently required for miR551b-induced growth and metastasis of EOC
cells. Enhancer of zeste homolog 2 (EZH2), a member of the polycomb repressor complex 2, functions
primarily to promote transcriptional silencing via histone 3 on lysine 27 trimethylation (H3K27me3)
and plays an essential role in EOC progression [44,45]. Interestingly, upon Tyr372 phosphorylation of
EZH2 by protein kinase A, pY372-EZH2 efficiently interacted with STAT3 protein. This non-canonical
EZH2 interaction reduced cellular levels of STAT3 and altered STAT3 activation, leading to the
downregulation of downstream target IL-6R in EOC [46]. Furthermore, tyrosine phosphorylation of
EZH2 by JAK3 in lymphoid neoplasia was reported to promote dissociation of the polycomb repressive
complex 2 (PRC2) complex leading to decreased global H3K27me3 levels while it switches EZH2 to a
transcriptional activator [47], but studies in EOC are lacking. Moreover, EZH2 can also interact with the
STAT5 N-terminal oligomerisation domain, which was shown to be essential for B-cell acute leukemic
transformation silencing the kappa light chain expression [48]. Such studies postulate that STAT3/5
interaction with EZH2 could be a valuable target interface for future therapeutic intervention [49], but
future studies with EOC model systems are needed.
3. The Function of STAT3 and STAT5 in EOC
3.1. Apoptosis
Under normal physiological conditions, apoptosis is a process that governs programmed cell
death and is responsible for the elimination of cells in normal tissues, to maintain tissue homeostasis.
This process is commonly observed in several self-renewing tissues, including the gut, bone marrow,
and skin, to accommodate newly generated cells daily. Emphasizing the crucial role of apoptosis
in normal cell turnover, apoptosis remains to be one of the critical cell processes that are highly
dysregulated during cancer progression. Evasion of apoptosis by cancer cells often results in excessive
tumor growth, metastatic spread, and even causing resistance to cancer treatment. Apoptosis primarily
occurs through two pathways. In the extrinsic pathway, binding of external death ligands to death
receptors triggers the cascade, resulting in caspase-mediated cell death. While, in the intrinsic pathway,
internal stimuli such as DNA damage, cellular stress triggers the activation of proapoptotic factors
such as B-cell lymphoma 2 (BCL-2) family members that resemble three functional groups: inhibitors
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of apoptosis (BCL-2, BCL-XL, BCL-W, Mcl-1, BCL-B, and A1), promoters of apoptosis (BAX, BAK, and
BOK); and regulatory proteins (BAD, BIK, BID, HrK, BIM, BMF, NOXA, and PUMA) [50]. Notably,
tumor suppressor p53 is a transcription factor with primary pro-apoptotic function, and it remains one
of the most commonly mutated genes in human cancers, underlining the significance of apoptosis
deregulation in cancer [51].
Activated STAT3/5 proteins target specific inhibitors of apoptosis that mainly act on the intrinsic
pathway to suspend cell death in cancer cells. Inhibition of STAT3 signaling leads to apoptosis of ovarian
clear cell carcinoma and decreased BCL-2 expression [52]. G-CSF and Leptin can both activate STAT3
phosphorylation, and both can promote increased cellular BCL-2 levels, thereby protecting EOC cells
against apoptosis [39,53]. RELA and STAT5 proteins transcriptionally activate the expression of Bcl-xL
through direct promoter binding in ovarian, non-small-cell lung carcinoma and transformed leukemia
cells, as well as render chemoresistance in carboplatin resistant ovarian cancer cell lines [19,54,55].
Also, cell survival signaling diminishes the effectiveness of chemotherapy, which contributes towards
the acquisition and development of chemoresistance in cancer cells. In paclitaxel-resistant ovarian
cancer cells, blocking of STAT3 activity suppresses STAT3 downstream antiapoptotic regulatory genes
BCL2L1, MCL1, and BIRC5, which increases paclitaxel sensitivity in paclitaxel-resistant ovarian cancer
cells in vitro [56]. Similarly, abrogation of constitutive STAT3 activity shows significant reductions in
the expression of the BCL-2, BCL-XL, and Survivin protein, which circumvents cisplatin resistance in
EOC [57].
MicroRNAs contribute to diverse physiological and pathological processes by involving in the
regulation of several essential biological processes. An array of microRNAs induces apoptosis in cancer
cells through JAK/STAT signaling in multiple cancer types. miR-17-5p, miR-133b, miR-134, miR-13,
miR-147, miR-182, miR-204, miR-874 are among a few miRNAs that require either STAT3 or STAT5 to
induce apoptosis. In EOC, miRNA-519a promotes apoptosis of SKOV3 cells by directly targeting the
3’UTR of STAT3, which results in a decrease of the mRNA and protein expression levels of STAT3,
Mcl-1, and BCL-XL [58] (For a detailed list, see Table A1).
3.2. Proliferation
EOC is one of the few cancer types that is partially regulated by hormones. IL-6-induced STAT3
phosphorylation levels were found to be increased in cells treated with follicle-stimulating hormone
(FSH), luteinizing hormone (LH), 17β-estradiol or estrogen and it facilitated cell proliferation in human
ovarian surface epithelial (HOSE) and ovarian cancer (OVCA) cell lines [59]. In the case of ovarian
cancer cell proliferation, Leptin, a hormone secreted by adipose tissue interlinks obesity and EOC
progression [31,60]. At the molecular level, Leptin simultaneous increased pY-STAT3 (Tyr705) and
nuclear localization of Estrogen Receptor (ER)α, and induced STAT3 binding to ERα that resulted in
a significant increase in cell proliferation and migration [32,53,61]. Also, Leptin promoted ovarian
cancer proliferation by induced phosphorylation of STAT5 in SKOV3 and A2780 cells, which mediated
leptin-induced expression of miR-182 and miR-96 and subsequent inhibition of Forkhead box O3 [62].
Prolactin-mediated pY-STAT5 activation complexes with tumor suppressor BRCA1 in the nucleus, and
this complex hinders the transcription of cell-cycle inhibitor p21, leading to increased proliferation [63].
Treatment of metastatic ovarian carcinoma cell line CaOV-3 with Leptin receptor blockers: SHLA and
Lan-2 resulted in a predominantly inhibitory effect on STAT3 phosphorylation and downregulated cell
proliferation through blocking Cyclin D1 and E2F1 [64].
Expression of phosphorylated STAT3 coupled with Ki-67 expression, was found to be increased in
primary human ovarian carcinoma, particularly in patients with high nuclear expression of pY-STAT3
exhibited poor prognosis [15]. EOC cells cultured under hypoxic conditions revealed higher levels of
pY-STAT3 (Tyr705); however, with knockdown of STAT3 expression, the proliferation rate of cancer
cells was significantly reduced [65]. Alternatively, the hyperbaric oxygenation method (a systemic
increase of dissolved oxygen delivery in serum) substantially decreased pY-STAT3 (Tyr705) levels,
along with decreased tumor volume in a murine xenograft model [66]. Recently, it was found that
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activated STAT3 may deploy specific microRNAs to promote ovarian cancer cell proliferation and to
generate associated phenotypes. For instance, high STAT3 levels in SKOV3 cells increased the levels of
oncogenic microRNA-216a, which in turn directly targeted tumor suppressor phosphatase and tensin
homolog (PTEN) expression and rendered cisplatin resistance [67].
Interference of STAT3 activity has been employed as a strategy to hinder ovarian cancer cell
proliferation. In vitro and in vivo studies with ovarian cancer cell lines have shown that siRNA and
shRNA mediated STAT3 depletion, downregulated the expression of Cyclin D1, Survivin as well as
reduced tumor weight [68,69]. Another study has shown that siRNA mediated STAT3 downregulation
suppressed SKOV3 cell growth and arrested the cell cycle in the G1 phase [70]. Several studies have
highlighted that plant-derived phytochemicals, such as Pterostilbene, Cryptotanshinone and Curcumin,
suppressed STAT3 activation, thereby reduced cancer cell proliferation and have been proposed as
possible adjuvants of conventional chemotherapy [71–73].
3.3. Angiogenesis
In general, tumor outgrowth exceeding 2 mm in diameter must gain access to an increased
supply of oxygen and nutrients. These requirements are fulfilled through angiogenesis, a process
that involves the formation of new blood vessels from the existing vasculature. Therefore, tumor
angiogenesis is a hallmark of cancer that promotes tumor progression and metastasis. Tumor cells
cause an angiogenic switch by secreting pro-angiogenic proteins and/or repressing the expression of
anti-angiogenic factors. Most notably, vascular endothelial growth factor (VEGF) and its receptors are
crucial in instigating angiogenesis in tumor cells, exert vascular permeability activity and stimulate
cell migration in macrophage and endothelial cell populations. Activated STAT3 and STAT5 regulate
the expression of VEGF and increased angiogenesis in a variety of cancer, including EOC [14,74,75].
Immunohistochemical staining of patient-derived ovarian epithelial carcinoma tissues identified
significant overlap of expression between VEGF, pY-STAT3, and pY-STAT5 in ovarian carcinoma cells,
compared to the benign and normal group [14]. In ovarian clear cell carcinoma, immunohistochemical
analysis of primary tumors showed high nuclear expression of pY-STAT3 and HIF1α [76]. It is known
that IL-6 signals via STAT3, not only directly induces the transcription of VEGF, but also activates
expression of downstream gene HIF1α, where HIF1α is a paramount transcription factor controlling
VEGF expression [77]. These studies indicate an IL-6/STAT3/HIF1α/VEGF autocrine activation loop in
EOC, especially clear cell carcinoma histotype. (For a detailed list, see Table A2).
Targeting STAT3 activation in EOC directly or indirectly affected angiogenesis. Extract from
cinnamon was a potent inhibitor of VEGF secretion, inhibited the expression and phosphorylation
of STAT3 and AKT, suppressed HIF1α expression as well as significantly reduced tumor growth
and blood vessel formation in mice models [78]. 3,3’-Diindolylmethane (DIM; an active metabolite
found in cruciferous vegetables) treatment blocked IL-6-induced STAT3 phosphorylation, attenuated
angiogenesis by suppressing HIF1α and VEGF expression in SKOV3 cells [79]. In the same study,
oral administration of DIM in combination with intraperitoneal administration of cisplatin treatment
reduced tumor volume by 65% due to downregulation of pY-STAT3, STAT3, and Mcl-1 levels with
simultaneously increased cleavage of Caspase 3 and poly ADP-ribose polymerase (PARP) activity. It
is important to note that clinical trials of EOC patients treated with the VEGF inhibitor aflibercept
revealed more reduced survival rates in patients harboring high levels of circulating IL-6, indicating
that IL-6/STAT3 activation in tumor cells may provide a survival gain during anti-VEGF treatment [80].
The fact that STAT3 is critically involved in the VEGF pathway and tumor angiogenesis indicates that
blockade of STAT3 is a therapeutic target to heighten an effective antiangiogenic treatment in EOC.
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3.4. Tumor Progression and Metastasis
Cancer metastasis is a multi-step process that occurs when a selected group of cells detach from
the primary tumor, utilize blood or lymphatic system to gain access into circulation, and instigate
tumor colonies in secondary organ sites. The metastatic pattern of EOC differs from that of most
other epithelial malignant diseases. After the direct extension, EOC most frequently disseminates via
the transcoelomic route, forming diffuse multifocal intraperitoneal nodes and malignant ascites [81].
Accumulation of pY-STAT3 expression coupled with loss of protein inhibitor of activated STAT3
(PIAS3) in fallopian tube secretory epithelial cells displayed common peritoneal metastatic nodules
that eventually led to the progression of HGSC. AKT2, one of the most frequent amplicon alterations
in HGSC, activates PKM2–STAT3/NF-κB axis, ultimately results in increased migratory and invasive
potential of EOC cells as well as promoting lung metastasis in mouse models [82].
Several hypotheses have been put forward to comprehend the multistep process of metastasis.
Yet, recapitulation of an embryonic cell differentiation program known as epithelial to mesenchymal
transition (EMT) has gained recent advances to support its inevitable role. Briefly stating, EMT is
a process when epithelial cells lose their signature characteristics like cell-cell adhesion to acquire
a mesenchymal phenotype with migratory and invasive behavior [83]. Apart from its role in EOC
metastasis, EMT can promote tumor initiation, stemness, and chemoresistance in EOC [84]. STAT
proteins have been well documented to play a role in fostering EMT in several cancer entities [85–87].
In EOC, inhibition of EGFR or STAT3 activity reduced N-cadherin, Vimentin expression, decreased
colony-forming ability, cell motility, and migration behavior [35,38]. Also, extracellular heat shock
protein (HSP90) promotes the binding of STAT3 to the TWIST1 promoter and thereby increasing
TWIST1 transcription, and these effects were diminished after HSP90 inhibitor treatment [88].
Another critical aspect of EMT that strongly associates with STAT proteins is their role in
self-renewal. STAT3 and STAT5 have essential roles in regulating cancer stem cells (CSCs) of EOC [89].
Over 90% of ascites cells derived from EOC patients showed activated pY-STAT3 signaling (Tyr705),
which increased the migratory potential of EOC cells, and it also increased widespread peritoneal
metastasis [90,91]. Tumor spheroids isolated from the ascites of recurrent EOC patients are enriched with
tumor cells overexpressing STAT3 compared with cells isolated from the ascites of chemotherapy-naïve
patients [92]. EOC spheroids serve as the vehicle for ovarian cancer cell dissemination in the
peritoneal cavity and represent a significant impediment in the efficacy of chemotherapy agents [93].
Mechanistically, STAT3 signaling regulates ovarian CSCs by targeting miR-92a/DKK1 and subsequently
activating Wnt/β-catenin signaling [18]. Therefore, inhibition of STAT3 signaling effectively eliminates
the formation of the metastatic niche, and it suppresses cancer cell persistence after chemotherapy.
Extracellular matrix (ECM) is a complex network of the microenvironment, stabilized through
structural proteins such as Laminins, Collagens, and Fibronectins, that holds epithelial-derived cancer
cells, endothelial and stromal cells in proximity. Degradation of ECM is a characteristic feature of
disseminating cancer cells to determine whether metastatic tumors form or not. Activation of STAT3
in several cancers contributed towards degradation of ECM, primarily mediated through increased
activity of matrix-degrading Matrix Metallo-Proteinases (MMPs). In EOC cells, ligand-mediated and
stress hormone (norepinephrine) mediated activation of STAT3, via nuclear translocation, induced
MMP-2 and MMP-9 expressions and siRNA mediated STAT3 silencing declined MMPs release, denoting
the direct regulation of MMPs by STAT3 [30,94–96]. ECM component hyaluronan (HA) associated
with CD44 to mediate nuclear Nanog-STAT3 interaction, that activated EMT, increased cell migration
and invasion and also triggered the expression of MDR1, which rendered multi-drug resistance to
EOC cells [97,98]. A BET bromodomain and extra-terminal inhibitor, i-BET151, reduced viability
migration and invasion of EOC cells as well as decreased expression of MMP-2 and MMP-9 expression,
highlighting the potential usage of this inhibitor as a treatment strategy [99]. siRNA mediated inhibition
of IL-6R or anti-human IL-6R antibody (tocilizumab) reduced pY-STAT3 and MMP-9 expression levels
suggesting that interference of STAT3 signaling in ovarian clear cell carcinoma could be an effective
therapeutic strategy [100]. (For a detailed list, see Tables A3, A4 and A6).
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Growing evidence emphasizes the role of nano-sized secretory vesicles known as “exosomes”
released from the plasma membrane to facilitate intercellular communication during various
physiological processes such as antigen presentation or exchange of membrane proteins. In
particular, exosomes are highly implicated in mediating cancer metastasis, angiogenesis, and drug
resistance [101,102]. EOC-derived exosomes changed the morphology of human peritoneal mesothelial
cells to a mesenchymal phenotype, through CD44 internalization, and blockage of exosome release,
which suppressed ovarian cancer invasion [103]. Besides, hypoxia is known to drive excessive exosome
release from cancer cells in several tumor types [104]. Under hypoxic conditions, EOC cells showed
activated STAT3 levels, increased the release of exosomes to promote proliferation, which occurs
through altering proteins of the Rab family [105]. A microfluidic ChIP-based exosomes isolation
method confirmed elevated pY-STAT3 levels in exosomes isolated from high-grade serous ovarian
cancer cell lines and patients, implying that vesicles secreted from cancer patients have activated STAT3
signaling that could foster cancer metastasis [101].
4. Tumor Microenvironment
Emerging evidence reveals the presence of vibrant multicellular interactions between malignant
and non-malignant somatic cells, which generate a complex milieu referred to as the “tumor
microenvironment” [106,107]. The tumor microenvironment encompasses a multitude of distinct
cell types, which primarily includes endothelial cells, infiltrating immune cells (tumor-associated
neutrophils, T and B lymphocytes, natural killer cells, tumor-associated macrophages, mast cells)
and cancer-associated fibroblasts. These non-malignant somatic cells are often engaged in delivering
tumor-promoting factors and are involved in every aspect of tumorigenesis as well as in metastasis.
Cellular communications between these cell types are governed by the copious release of cytokines,
growth factors, inflammatory and matrix remodeling components from the tumor bulk (Figure 1).
Although the immune cells of the tumor microenvironment are efficient enough to combat and evade
the cancer cells, these cells are instead confined and manipulated by cancer cells to promote their
growth and distribution, ultimately influencing the patient’s clinical outcome [108]. Henceforth,
understanding the biology of the tumor-host hostile environment becomes inevitable for improving
treatment strategies. Several lines of evidence have highlighted the role of STAT3/5 activation in
non-malignant somatic cells of the EOC tumor microenvironment and the crosstalk between tumor
and host stromal cells.
4.1. Non-Immune Stromal Cells
In the tumor microenvironment, non-immune stromal cells comprise endothelial cells, pericytes,
fibroblasts, and mesenchymal stem cells. STAT3 pathway facilitates crosstalk between tumor cells and
endothelial cells that mediates pro-angiogenic signaling. Conditioned media obtained from EOC cells
stimulated rapid, transient STAT3 phosphorylation and nuclear translocation in cord blood CD34+
progenitor cells, as well as initiated early capillary-like structure formation in human microvascular
endothelial cells [109,110]. CD133+ ovarian cancer stem cells cultured on a cell culture matrix formed
fluid-conducting tube networks activated NF-κB and STAT3 signal pathways, through autocrine
chemokine (C-C motif) ligand 5 (CCL5) upregulation promoting differentiation into endothelial
cells [111]. Implantation of HeyA8 and SKOV3 cells into the peritoneal cavity of female nude mice
secreted significant levels of IL-6 and soluble IL-6 receptor (sIL-6R), activated STAT3 signaling and
facilitated migration of endothelial cells [112].
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Cancer-associated fibroblasts (CAFs) are a heterogeneous cell population that is usually identified
by their high expression of mesenchymal markers including Vimentin, fibroblast-secreted protein-1
(FSP-1), α-smooth muscle actin (αSMA), and fibroblast activation protein (FAP). CAFs favor tumor
growth through increased secretion of cytokines, metabolites, and ECM molecules, thus promoting
angiogenesis and they interfere with antitumor immune response [113]. CAFs mediate EOC cell
proliferation through NF-κB and JNK signaling activation. Moreover, they release VEGF to promote
tumor angiogenesis [114]. CAFs induce EMT in EOC cell lines through IL-6/JAK2/STAT3 pathway, which
subsequently renders resistance to paclitaxel treatment [115]. Also, CAFs release chemokine CCL5 to
increase STAT3 and Akt phosphorylation that mediate cisplatin resistance in EOC cells [116,117].
In the EOC tumor microenvironment, the intra-abdominal fat deposition is regarded as a significant
source of cytokines and has been shown to stimulate growth and promote EOC metastasis [118].
Conditioned media obtained from subcutaneous and visceral fat-derived adipose stromal cells enhanced
growth and migration of EOC cells, through activation of JAK2/STAT3 signaling pathway [119]. Studies
demonstrating the distinct regulation of STAT3 in other non-immune stromal cell populations are quite
preliminary and need further in-depth investigations.
4.2. Immune Function
T lymphocytes play a crucial role in stimulating the adaptive immune response to target
the expanding tumor mass. Depending on the nature of the tissue, T-cells can either be pro- or
anti-tumorigenic. Tumor-infiltrating T-cells exist as distinct populations, and here we highlight a few
main types of T-cell players that are regulated through STAT3/5 signaling.
CD4+ Th17 cell population in EOC is identified to be pro-tumorigenic. EOC cells secrete cytokines,
including IL-1β, IL-6, and IL-23, which are involved in the expansion of CD4+ Th17 cell population
(Figure 1), through activation of STAT3 [120,121]. Phosphorylation and acetylation profiles of STAT3
determine the differentiation and polarization of CD4+ Th17 cells that form the majority of tumor
infiltrated T cells [122,123]. An increase in the Th17 cell population sustains the secretion of more
cytokines (IL-17, IL-23) that eventually stimulates the release of angiogenesis factors VEGF and
TGFβ in fibroblasts and endothelial cells. One study indicated exosomes transfer miRNAs, including
miR-29a-3p and miR-21-5p, to synergistically induce the Treg/Th17 cell imbalance through direct
targeting of STAT3 in CD4+ T cells [124]. Thus, active STAT3 in CD4+ T cells generates an inflammatory
environment around the budding tumor aids its growth by stimulating angiogenesis and abrogates
antitumor response. (For a detailed list, see Table A5).
Another subpopulation of CD4+ cells known as regulatory T (Treg) cells that are involved in
the dampening of antitumor activity in the tumor microenvironment. Accumulation of Treg cells
in tumors and ascites of patients with EOC showed reduced survival rate [125]. STAT3 and STAT5
are known to bind to the promoter and increase the transcription of FOXP3, which is essential for
the conversion of naive CD4+ T cells into CD4+CD25+ FOXP3+ Treg cells [126,127]. In response to
IL-6 and IL-12 stimulation, STAT3 also positively regulates immune check point proteins such as
programmed cell death receptor 1 (PD-1), programmed death-ligand (PD-L1) expression through
direct promoter binding in CD4+ T cells. PD-1/PD-L1 axis promotes the differentiation of CD4+ T
cells into FOXP3+ Treg cells (Figure 1), and EOC patients with high PD-1 expression showed poor
prognosis [128]. Also, STAT3 induces the expression of IL-10 and TGF-β1, through direct promoter
binding, which ultimately restrains the tumor-suppressive role of CD8+ effector T-cell function and
dendritic cells [129,130]. Another important finding revealed that STAT3 sequesters STAT1 through
cytoplasmic heterodimerization and hinders STAT1 mediated transcription of major histocompatibility
complex (MHC) class I genes [131]. Reduced surface expression of MHC class-I genes in cancer
cells pose unfavorable presentation of cancer cells to CD8+ effector cells and thereby diminishing
tumor immunosurveillance.
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CD8+ T lymphocytes in the tumor microenvironment play a crucial role in combating cancer cells
through antigen-specific blockage of immunosuppressive Treg cells. This blockage is regulated by
STAT3 through the secretion of IFN-γ [132]. Using the Mx1-Cre-loxP mice model, Kortylewski et al.
showed that STAT3−/− CD8+ T cells can secrete increased IFN-γ levels, which displayed markedly
enhanced tumor-suppressive functions of dendritic cells, natural killer cells and neutrophils [133].
Moreover, a study reported that when tumor supernatants (from EOC cell lines OVCAR3, CAOV3 and
SKOV3) were co-cultured with CD8+ T cells reduced STAT5 phosphorylation which diminished CD8+
T cell proliferation [134]. EOC patients with increased levels of CD8+ T cells infiltration and a high
CD8+/Treg ratio showed favorable prognosis [135,136].
4.3. Tumor-Associated Macrophages
Tumor-associated macrophages (TAMs) form a prominent component of the inflammatory
tumor microenvironment, which primarily performs a pro-tumorigenic role, including the release
of proangiogenic cytokines, matrix proteases and growth factors, suppression of adaptive immunity,
self-renewal and chemotherapeutic resistance of cancer stem cells [137]. siRNA-mediated STAT3
inhibition in macrophages increased IL-6 and IL-10 secretion, induced Cyclin-D1 mediated cell
proliferation in co-cultured SKOV3 cells [138]. Other studies have shown that the interaction of
TAMs and ovarian cancer stem-like cells (OCSLCs) being involved in the occurrence, recurrence, and
multidrug resistance of ovarian cancers [139]. The OCSLCs co-cultured with macrophages also induces
SKOV3 cell stemness via IL-8/STAT3 signaling [140].
Macrophages exist as a heterogeneous population, that can be broadly classified into two main
phenotypes: classically activated M1 macrophages and alternatively activated M2 macrophages. The
polarization of M1 or M2 macrophages is highly dependent on the cytokines involved in their activation.
M1 macrophages are activated by cytokines such as interferon-γ (IFNγ), IL-12 and they play a crucial
role in recruiting T cells to the tumor microenvironment. M1 macrophages enhanced immune response
in order to restrain tumor development. On the contrary, M2 macrophages are activated by Th2
cytokines (IL-4, IL-10, and IL-13). M2 macrophages interfered with the antitumor activity of T cells or
NK cells. EOC patients with a high number of M2 CD68+ and CD163+ macrophages were associated
with advanced stage and poor progression-free and overall survival [141]. Accordingly, ovarian cancer
patients with high M1 to M2 ratio of TAMs were associated with extended survival rate, indicating
the pro-tumorigenic role of M2 macrophages [142]. Moreover, ascites from EOC patients polarized
macrophages toward the M2 phenotype through STAT3 activation, while non-EOC did not activate
STAT3. Also, the expression of transmembrane protein B4-T7 in TAMs, but not in ovarian carcinoma
cells suppressed the T-cell immune response, inversely correlated with patient survival [143]. These
studies have demonstrated that STAT3 mediated polarization of macrophages is crucial in determining
the pro-tumorigenic nature of tumor microenvironment. (For a detailed list, see Table A5).
5. Targeting of the STAT3/STAT5 Signaling Pathway in EOC
In principle, targeting the constitutive activation of STAT3/5 could be approached in various
ways. These strategies include (1) inhibiting the upstream of STAT3 activation pathway (for example,
ligands antagonist, JAK or SRC inhibitor) (2) blocking the SH2 domain that inhibit STAT dimerization
(3) inhibiting the translocation of phosphorylated dimerized STAT3 into the nucleus (4) inhibit the
binding of activated dimerized STAT to DNA [144,145]. Table 1 lists the names and properties of agents
targeting JAK/STAT that are FDA approved or in clinical development.
The anti-human-IL-6 antibody Siltuximab substantially reduced nuclear pY-STAT3 expression
in IL-6-producing intraperitoneal EOC xenografts [146]. Siltuximab significantly inhibited the
tumor growth of IGROV1 intraperitoneal xenograft, accompanied by reductions in angiogenesis
and macrophage infiltration. In phase 2 clinical trial, single-agent Siltuximab showed modest response
rate (5.6%) with reductions in serum CCL2, CXCL12, and VEGF, in recurrent, platinum-resistant
diseases [146]. In phase 1 dose-finding trial, the anti-IL-6R monoclonal antibody Tocilizumab combined
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with carboplatin/pegylated liposomal doxorubicin and interferon α2b in patients with advanced
EOC was studied. A functional blockade of IL-6 signaling by Tocilizumab decreased pY-STAT3 by
both myeloid cells and the different populations of T cells, leading to increased production of the
tumor-immunity promoting cytokine secretion of IL-12 and IL-1β [147]. The clinical benefit was
observed in 85% (17/20) in a patient with recurrent EOC. The revamping of immunity support for
better tumor control by targeting IL-6/STAT3 signaling in EOC.
JAK inhibitors have been developed in recent years. The utilization of JAK inhibitors has been
attempted to interfere with JAK-mediated STAT3/5 activation and evaluate therapeutic efficacy in
various EOC models. Ruxolitinib, a potent oral JAK1, and JAK2 inhibitor has been approved by FDA
to treat myelofibrosis in 2011. Ruxolitinib significantly inhibited pY-STAT3 in EOC cells. Single-agent
Ruxolitinib suppresses EOC tumor growth in mice. More importantly, Ruxolitinib substantially
enhances the anti-tumor activity of chemotherapy agents, including paclitaxel, cisplatin, carboplatin,
doxorubicin, and topotecan in EOC cells. In an OVCAR-8 murine model, Ruxolitinib synergistically
increased tumor control by paclitaxel [147]. A phase I/II clinical trial of EOC has been conducted
with combination with or without paclitaxel and carboplatin since 2016 and is under recruiting now
(ClinicalTrials.gov Identifier: NCT02713386). The FDA also approved other JAK inhibitors, tofacitinib
(pan JAK with preferentially selectively JAK 3/1) in 2016 and baricitinib (selectively JAK 1/2) in 2018 for
the treatment of rheumatoid arthritis [148]. However, there are, as yet, no studies or trials mentioning
the relationship between these two and gynecologic cancers. Itacitinib, another JAK 1/2 inhibitor, has
been tested in non-small cell lung cancer, lymphoma, and pancreatic cancer. A previous terminated trial
showed an acceptable safety profile in combination with nab-paclitaxel and gemcitabine [149]. It has
been tested in multiple cancers including endometrial cancer and breast cancer in the proceeding phase
Ib/II clinical trial (ClinicalTrials.gov Identifier: NCT02646748). In the preclinical stage, paclitaxel and
Momelotinib (ATP-competitive inhibitor of JAK1/2, previously named CYT387) inhibited JAK2/STAT3
activation, reduced tumor burden, abrogated cancer stem cell expressions and prolonged disease-free
survival in a murine xenograft model [89,150]. MLS-2384 is a synthetic 6-bromoindirubin derivative
with potent dual JAK/SRC inhibitory activity in EOC cells. In vitro, MLS-2384 suppresses the viability
of A2780 cells, which is consistent with the inhibition of phosphorylation of JAK2, SRC, and STAT3 [151].
Although these JAK inhibitors are widely used in medicine, the side effect of JAK inhibitors is significant,
ranging from immunosuppression to organ toxicity. AZD1480, a selective JAK2 inhibitor, reduced
tumor growth, decreased peritoneal dissemination and diminished ascites production in a murine
model for advanced EOC [152]. However, the previous phase I study of the solid tumor was terminated
due to neuropsychiatric side effects [153].
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Pilot studies focusing on analogs from natural compounds have been developed to inhibit
STAT3 activation. The anticancer analogs from curcumin, diarylidenyl piperidone (DAP) derivatives
such as HO-3867, HO-4200, HO-4318, inhibit STAT3 activity and sensitize drug-resistant ovarian
carcinoma and clear cell carcinoma cells to paclitaxel or cisplatin [52,156–158]. Among them, HO-3867
is the most studied and effective in selectively targeting STAT3 and inhibiting EOC tumor growth.
Specifically, HO-3867 effectively blocked ascites-mediated activation of STAT3 in EOC cells, inhibited
invasion, and metastasis in a murine orthotopic EOC model [91]. Additionally, HO-3867 targets
hypoxia-stimulated pY-STAT3 (Tyr705) via the ubiquitin–proteasome degradation pathway, leading
to tumor growth suppression in xenograft mice and the downregulation of proteins involved in cell
survival, proliferation, and angiogenesis [159]. Furthermore, HO-4200 and HO-4318 significantly
inhibited fatty acid synthase and pY-STAT3 and decreased the expression of STAT3 target proteins in
primary platinum-resistant EOC cells, resulting in decreased expression of Ki67 and VEGF in ex-vivo
human tumor specimens [156].
Direct inhibition of STAT3 activity through the interference of SH2 domain dimerization, nucleus
transportation, or DNA binding is another highly investigated therapeutic strategy. However,
most of the molecules proposed are still in preliminary stage of development for EOC treatment.
Small-molecules such as decoy oligo-deoxy-nucleotides (ODN) inhibit STAT3 activation by blocking
the pY-STAT3 nuclear translocation for subsequent transcriptional target gene activation. STAT3-ODN
has been examined in several in vitro EOC cell models and demonstrated significant inhibition of
invasiveness and enhancement sensitivity to chemotherapeutic agents [160–162].
Lastly, proteomic analysis has identified RELA and STAT5 as two vital proteins associated with
carboplatin resistance in HGCS patients. Small-molecule mediated inhibition of NF-kB (by BMS-345541)
and STAT5 (by dasatinib) synergistically sensitized carboplatin-resistant EOC cells towards carboplatin
treatment [19].
6. Conclusions
Research in past decades has facilitated our comprehension of the critical roles of aberrant
STAT3/STAT5 activation in EOC cells as well as in the tumor microenvironment. The STAT3/STAT5
signaling dysregulates a plethora of cellular processes in EOC, which results in uncontrolled cancer
cell proliferation, induction of angiogenesis, promotion of metastasis factors, and suppression of host
immune response. In addition to extracellular signals that activate STAT, phosphorylated STATs
positively regulate the expression of interleukins and growth factors, generating a vicious autocrine
feedback loop that sustains the constitutive STAT3/STAT5 signaling cascade. Accordingly, multiple
studies have provided ample evidence to show that interfering with STAT3/STAT5 signaling, through
knockdown or inhibitor intervention, resulted in antitumor effects in both in vitro and in vivo animal
models carrying human tumors. However, none of the existing candidate compounds showed
anti-tumor efficacy in EOC patients. Given the importance of STAT3/STAT5 as a promising target,
future research should explore inhibitors against upstream regulators for the development of clinically
useful anticancer therapeutics. A histotype-specific approach to target ovarian clear cell carcinoma
with the STAT3 pathway might be an avenue worth pursuing.
Other abbreviations: SHC; SRC homology and collagen family, GRB2; Growth factor
receptor-bound protein 2, SOS; Son of sevenless, NK; Natural killer, PIAS; Protein inhibitor of
activated STAT, PD-1; Programmed cell death protein 1, PD-L1; Programmed death-ligand 1, PTPN11;
Tyrosine-protein phosphatase non-receptor type 11, PTPRT; Protein Tyrosine phosphatase receptor
type T, MHC-I; Major histocompatibility complex class I, VEGF; Vascular endothelial growth factor,
RTK; Receptor Tyrosine kinase.
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Abstract: The canonical prolactin (PRL) Signal Transducer and Activator of Transcription (STAT) 5
pathway has been suggested to contribute to human prostate tumorigenesis via an autocrine/paracrine
mechanism. The probasin (Pb)-PRL transgenic mouse models this mechanism by overexpressing
PRL specifically in the prostate epithelium leading to strong STAT5 activation in luminal cells.
These mice exhibit hypertrophic prostates harboring various pre-neoplastic lesions that aggravate
with age and accumulation of castration-resistant stem/progenitor cells. As STAT5 signaling is
largely predominant over other classical PRL-triggered pathways in Pb-PRL prostates, we reasoned
that Pb-Cre recombinase-driven genetic deletion of a floxed Stat5a/b locus should prevent prostate
tumorigenesis in so-called Pb-PRLΔSTAT5 mice. Anterior and dorsal prostate lobes displayed the
highest Stat5a/b deletion efficiency with no overt compensatory activation of other PRLR signaling
cascade at 6 months of age; hence the development of tumor hallmarks was markedly reduced.
Stat5a/b deletion also reversed the accumulation of stem/progenitor cells, indicating that STAT5
signaling regulates prostate epithelial cell hierarchy. Interestingly, ERK1/2 and AKT, but not STAT3
and androgen signaling, emerged as escape mechanisms leading to delayed tumor development in
aged Pb-PRLΔSTAT5 mice. Unexpectedly, we found that Pb-PRL prostates spontaneously exhibited
age-dependent decline of STAT5 signaling, also to the benefit of AKT and ERK1/2 signaling. As a
consequence, both Pb-PRL and Pb-PRLΔSTAT5 mice ultimately displayed similar pathological prostate
phenotypes at 18 months of age. This preclinical study provides insight on STAT5-dependent
mechanisms of PRL-induced prostate tumorigenesis and alternative pathways bypassing STAT5
signaling down-regulation upon prostate neoplasia progression.
Keywords: STAT5; AKT; ERK1/2; prolactin; androgens; prostate cancer; knockout; escape mechanisms;
stem/progenitor cells; cell hierarchy
1. Introduction
Studies of human prostate cancer specimens support a role for prolactin (PRL) signaling in
disease progression and recurrence [1]. Indeed, PRL is expressed in more than half of prostate
tumors (including local, locally advanced, and hormone refractory) and over 60% metastases [2,3],
Cancers 2019, 11, 929; doi:10.3390/cancers11070929 www.mdpi.com/journal/cancers339
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and its level of expression in primary tumors is positively associated with high Gleason score (i.e.,
high disease severity) [2]. Since circulating PRL levels are not correlated to prostate cancer risk [4,5],
this suggests that the contribution of PRL signaling to prostate tumorigenesis mainly occurs through
an autocrine/paracrine mechanism.
The canonical signaling pathways activated by the PRL receptor (PRLR) involve Janus kinase 2
(JAK2)/Signal Transducer and Activator of Transcription (STAT) pathway, the extracellular regulated
kinase (ERK) 1/2 pathway and the phosphoinositide 3-kinase (PI3K)–AKT pathway [6,7]. In human
and rodent prostate, the PRLR preferentially signals via the STAT5 pathway; in fact, activation of the
other pathways is not detected [2,8,9]. STAT5 involves two highly homologous proteins referred to as
STAT5A (94 kDa) and STAT5B (92 kDa) that are encoded by two distinct genes [10]. In PRL signaling
STAT5A and STAT5B are activated by JAK2-mediated phosphorylation of a conserved C-terminal
tyrosine upon which they form a parallel dimer that allows more efficient translocation into the nucleus
where they activate the transcription of target genes involving many protooncogenes. In various
preclinical models of prostate cancer, STAT5A/B (hereafter referred to as STAT5 unless specifically
discriminated for gene product) has been shown to be critical for cell survival and proliferation through
both androgen-dependent and androgen-independent mechanisms [9,11–14]. Recently, STAT5 was
shown to promote epithelial-to-mesenchymal transition (EMT) and stem-like features in human
prostate cancer cells [15], supporting the earlier finding that this cascade promotes metastatic properties
of prostate cancer cells [16]. Consistent with these observations, inhibition of STAT5 signaling using a
dominant-negative STAT5B mutant inhibited the in vitro growth and invasiveness of cell lines derived
from the TRAMP (transgenic adenocarcinoma of the mouse prostate) mouse model [17]. Additionally,
pharmacological inhibition of the JAK2/STAT5 cascade using the JAK2 inhibitor AZD1480 blocked the
growth of primary androgen-dependent as well as the growth of recurrent castrate-resistant prostate
cancer (CRPC) xenografts [18]. However, so far no transgenic mouse model studies exist for complete
STAT5 deletion to ultimately test its role in prostate cancer initiation and progression, which we
investigated here.
In clinical specimens of human prostate cancer, the STAT5a/b gene locus was shown to undergo
amplification during prostate cancer progression towards metastatic CRPC [19]. Accordingly,
the STAT5a gene locus was found to be amplified in up to 20% of metastatic CRPC with the
neuroendocrine phenotype [20]. Furthermore, STAT5 was shown to be overexpressed in prostate
cancer compared to healthy prostate samples, to be positively correlated with Gleason score and to
predict recurrence after prostatectomy [2,19,21,22]. These findings corroborated the results obtained
in preclinical models and further supported the relevance to develop therapeutic strategies aimed
to inhibit STAT5 signaling in prostate cancer. Small molecule inhibitors were designed to block the
docking of the SH2 domain of STAT5 to the critical tyrosine of the receptor-JAK2 complex and these have
shown potency to inhibit STAT5 tyrosine phosphorylation, nuclear translocation and transcriptional
activity [23]. The lead compound (IST5) induced massive apoptosis of prostate cancer cell lines and
explant culture of patient-derived prostate cancer [23]. More recently this inhibitor was shown to
sensitize prostate cancer to radiation by inhibiting STAT5-mediated DNA repair via the homologous
recombination mechanism [24]. Additional observations supporting the role of PRL/STAT5 signaling
in prostate tumorigenesis and cancer progression can be found in various review articles published
within the last decade [1,14,25–27].
In contrast to the human prostate [28], expression of the Prl gene is not detected in the mouse
prostate. Hence, to decipher the molecular and cellular mechanisms linking the autocrine PRL/STAT5
loop to prostate tumorogenesis, we use here a prostate-specific PRL transgenic mouse model. This model
involves expression of rat PRL under the control of the prostate-specific, androgen-regulated probasin
(Pb) minimal promoter [29]. At six months of age, Pb-PRL mice exhibit dramatically hypertrophied
prostates (all lobes) harboring various pre-neoplastic lesions including prostate-intraepithelial neoplasia
(PINs), increased stroma density, and inflammation [1,30,31]. They also displayed distended ducts
filled with abundant secretions. All these phenotypes aggravate with age. While our seminal report
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indicated occasional occurrence of invasive cancer in 20 month-old mice [30], these findings were not
consistently found in subsequent studies, suggesting possible interference with the genetic background
and/or health/microbiota/immune cell status of transgenics that could drift particularly if animal
facilities were relocated, as was the case.
According to earlier findings mentioned above, STAT5 was the only typical PRLR signaling
pathway that was found to be activated in Pb-PRL prostates [30]. STAT5 was highly activated in
dorsal and lateral lobe, while the ventral lobe displayed much lower level of activation presumably
due to PRLR down-regulation specifically in that lobe [31]. Of interest, we discovered that Pb-PRL
prostates displayed altered cell hierarchy. First, the basal/stem cell compartment was found to be
markedly amplified in the prostate epithelium [30]. Second, these prostates showed amplification of
another primitive cell population that had never been described before as it is very rare in the healthy
prostate. This newly-identified epithelial cell pool, called LSCmed according to its cell sorting profile
(Lin−/Sca-1+/CD49fmed), combines luminal (Cytokeratin [CK] 8 positive) and stem (Stem-cell antigen-1
positive) phenotypic features and exhibits stem/progenitor properties in functional assays [31,32].
Notably, while the basal/stem cell compartment has been long described to be castrate-resistant in
rats [33], we recently reported that the LSCmed cell compartment survived castration even better than
basal/stem cells in mice [32].
The amplification of castrate-resistant, stem/progenitor cells in Pb-PRL prostates further supports
a role for PRL signaling in the progression of prostate tumors including escape to androgen deprivation.
Of interest, careful analysis of immunostaining data suggested that the emergence of these two primitive
cell populations in Pb-PRL tumors may be zonally correlated to elevated STAT5 activation [31]. However,
as neither basal/stem nor LSCmed cell population exhibit detectable levels of PRLR expression [32],
the role of STAT5 signaling in their amplification remains elusive and may involve paracrine mechanisms.
In order to elucidate the actual contribution of STAT5 signaling in the various hallmarks of PRL-induced
prostate tumorigenesis, we took advantage of previously developed floxed Stat5a/b mice [34] to abolish
STAT5 expression in the epithelial cells of Pb-PRL mice. As reported below, in the anterior and dorsal
prostate lobes in which Stat5a/b locus deletion was highly efficient, STAT5 deficiency delayed the
occurrence of PRL-induced pathological phenotypes in young mice, but could not prevent prostate
tumorigenesis in older animals due to the emergence of alternative signaling pathways.
2. Results
2.1. STAT5 Deletion has no Detectable Effect on the Prostate Tissue
The analyses of STAT5 expression in the prostate were performed on 6 month-old animals.
As shown by RT-qPCR (Figure S1A) Stat5a expression was largely prevalent (~5 fold) over Stat5b
expression in control mice (STAT5f/f), but both genes displayed similar lobe-specific expression patterns
with the highest expression in anterior and lateral lobes. While the lobe differences were less marked at
the protein level, the same profile was observed by immunoblot using the G2 antibody that cross-reacts
with both STAT5 isoforms (Figure S1B,C). In ΔSTAT5 mice the fold-reduction in STAT5 expression
was the highest in lateral lobe and the lowest in ventral lobe (Figure S1B,C). The residual expression
of STAT5 detected at the mRNA and protein levels in tissue extracts of the different lobes of ΔSTAT5
mouse prostates accounted for the unaltered STAT5 expression in non-epithelial cells and possibly
to incomplete Stat5 deletion in the epithelium especially in the ventral lobe (mosaicism). To address
this further, we monitored STAT5 expression by immunohistochemistry (IHC) using the G2 antibody
(Figure S1D). In ΔSTAT5 prostates a homogenous reduction of STAT5 immunostaining was observed
in the epithelium of all but the ventral lobes compared to STAT5f/f prostates (Figure S1D). Together
these analyses indicated down-regulation of STAT5A/B expression in the epithelium of the lateral,
dorsal and anterior lobes of ΔSTAT5 mouse prostates.
Prostates harvested from 6, 12, and 18 months old ΔSTAT5 animals failed to display any
macroscopic alterations (e.g., organ atrophy or hypertrophy). Accordingly, the weights of the different
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lobes (normalized to mouse weight) were unaffected by STAT5 deletion (Figure S2A). Histopathological
analyses of prostate sections from these animals were performed blinded by a trained veterinarian
pathologist (E.R.-G.). This analysis failed to identify detectable alterations in ΔSTAT5 compared to
STAT5F/F prostates regarding prostate architecture and histology (Figure S2B). These findings are
consistent with an older study that failed to observe histological defects in dorsal and lateral lobes of
Stat5a-null mice [35]. In fact, systemic STAT5A deficiency induced local disorganization within acinar
epithelium of the ventral lobe only, which could not be confirmed in our study as Pb-Cre4-driven Stat5
gene ablation was inefficient in that lobe.
Taken together, these results indicate that Pb-Cre4 recombinase-driven Stat5 deletion has no major
impact on prostate tissue integrity.
2.2. Lobe-Specific Pattern of STAT5 Deletion in Pb-PRLΔSTAT5 Mice
We next generated Pb-PRL mice harboring Stat5a/b gene deletion in the epithelium (hereafter
called Pb-PRLΔSTAT5). The analyses of Stat5a/b expression were performed on 6 month-old animals.
As observed in STAT5f/f mice, Stat5a mRNA was predominant over Stat5b in Pb-PRLSTAT5f/f prostates,
with highest levels in anterior and lateral lobes (Figure 1A). In Pb-PRLΔSTAT5 the reduction in Stat5a/b
mRNA expression was significant in all but the ventral lobes, and more marked in anterior and
dorsal (>3-fold) than lateral (<2 fold) lobes (Figure 1A). This pattern was globally confirmed at the
protein level using immunoblot and IHC analyses. As shown in Figure 1B (immunoblot) and 1C
(quantification), STAT5 protein was efficiently deleted in anterior and dorsal lobes of Pb-PRLΔSTAT5
mice, and the deletion was homogeneous in the epithelium (Figure 1E). In contrast, no significant
reduction in STAT5 protein levels were observed in ventral prostate, while deletion in the lateral lobe
was intermediate (Figure 1B,C and Figure S3A).
As earlier reported, STAT5 is massively activated by transgenic PRL overexpressed in Pb-PRL
prostates. Therefore tyrosine phosphorylated (p) STAT5 was also monitored by immunoblot
(Figure 1B,D) and IHC (Figure 1F,G and Figure S3B) using a validated anti-pSTAT5 antibody [30,31].
Thanks to the contrasted nuclear staining obtained in IHC using the latter antibody (Figure 1F),
we could quantify the actual level of activated (nuclear) STAT5 in the luminal epithelium of the four
lobes. As expected from above-mentioned studies, the level of STAT5 tyrosine phosphorylation in
Pb-PRLSTAT5f/f mice was the highest in dorsal lobe and the lowest in ventral lobe (Figure 1G). Also,
the pattern of nuclear STAT5 was zonal in the anterior and ventral prostates and more uniformly spread
in dorsal and lateral prostates (Figures 1F and S3B). In Pb-PRLΔSTAT5 mice, the significant reduction
in STAT5 phosphorylation in anterior and dorsal lobes was assessed by immunoblot (Figure 1B,D)
confirming our IHC results of STAT5 down-regulation in epithelial cells (Figure 1F,G). In agreement
with the low efficiency of STAT5 deletion in the ventral lobe (Figure 1A,C), no significant reduction of
pSTAT5 could be detected in that lobe (Figure 1D,G). Finally, in the lateral lobe, despite of the reduction
of STAT5 expression (Figure 1C) there was no significant reduction of STAT5 tyrosine phosphorylation,
as determined by blot (Figure 1B) or by IHC (Figure 1G). This is consistent with the fact that the degree
of STAT5 phosphorylation in that the lobe is intrinsically moderate in Pb-PRLSTAT5f/f mice (Figure 1G),
which limits the impact of mild decreased STAT5 expression.
342
Cancers 2019, 11, 929
Figure 1. Lobe-specific pattern of STAT5 deletion in 6 month-old Pb-PRLΔSTAT5 mice. (A). Lobe-specific
expression of Stat5a and Stat5b mRNA in Pb-PRLSTAT5f/f and Pb-PRLΔSTAT5 mice as determined
by RT-qPCR is shown. (B–D). Lobe-specific expression and phosphorylation of STAT5 protein in
Pb-PRLSTAT5f/f and Pb-PRLΔSTAT5 mice as determined by immunoblot is shown. Quantification of
STAT5/ACTIN (C) and pSTAT5/ACTIN (D) was performed by densitometry and is shown as fold
change versus Pb-PRLSTAT5f/f mice for each lobe. (E,F). Immunohistochemical analysis of STAT5 protein
expression (E) and phosphorylation (F) in anterior (AP) and dorsal (DP) prostates of Pb-PRLSTAT5f/f and
Pb-PRLΔSTAT5 mice, as indicated. In panel F, negatively (neg) next to positively (pos) immunostained
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areas are highlighted. See Figure S3 for the other lobes. (G). The percentage of pSTAT5-positive
epithelial cells as determined using Calopix software is shown for each lobe. Statistics: Stars (* p < 0.05,
** p < 0.01, *** p < 0.001, **** p < 0.0001; idem in all figures below) denote significant differences in a
repeated-measures two-way ANOVA with Sidak’s multiple comparisons. Size bars: 250 μm in large
images and 50 μm in insets.
To confirm that the down-regulation of STAT5 phosphorylation resulted in lower STAT5 signaling,
we monitored the levels of expression of Suppressor of Cytokine Signaling (SOCS)/Cytokine-Inducible
SH2 Containing Protein (CISH) genes as typical negative regulators and direct targets of JAK/STAT
signaling. Based on former reports, SOCS1/2/3 and CISH can be efficiently induced by PRLR/JAK/STAT
signaling [7]. SOCS2 was predominantly expressed in the mouse prostate, while SOCS1 was hardly
detected (see Figure 6D below for relative expression levels). SOCS2, SOCS3 and CISH were all
up-regulated in Pb-PRLSTAT5f/f dorsal prostates and significantly down-regulated in Pb-PRLΔSTAT5
confirming lower STAT5 signaling in the latter (Figure S3C). In addition to SOCS genes, we earlier
reported that PRLR expression (all isoforms) was down-regulated in Pb-PRL prostates compared
to wild-type (WT) littermates [31]; this was confirmed in this study using the dorsal prostate of
Pb-PRLSTAT5f/f mice (Figure S3D). Notably, normal levels of PRLR expression were restored in
Pb-PRLΔSTAT5 prostates suggesting that PRLR expression is negatively regulated by STAT5 signaling
(Figure S3D).
In summary, Pb-Cre4-driven Stat5a/b deletion was highly efficient to down-regulate STAT5
expression and signaling in the anterior and dorsal prostates but not in the ventral prostate; lateral
prostate Stat5a/b deletion was intermediate. As described below, these lobe-specific effects were
used to delineate the actual involvement of epithelial STAT5 pathway in the various tumor-related
phenotypes analyzed.
2.3. STAT5 Deletion Reduces Hallmarks of PRL-Induced Prostate Tumorigenesis at 6 Month of Age
To evaluate the role of STAT5 pathway in PRL-driven prostate phenotypes, we compared the
prostates of Pb-PRLSTAT5f/f and Pb-PRLΔSTAT5 mice regarding the major hallmarks of early tumorigenesis
previously characterized in Pb-PRL prostates [30–32,36].
2.3.1. Prostate Growth
According to former reports involving Pb-PRL mice [30], this study confirmed that prostate
hypertrophy was detectable from 3 months of age in Pb-PRLSTAT5f/f mice compared to control mice.
At 6 months of age prostate weight was more than doubled compared to controls (Figure 2A). All lobes
significantly contributed to prostate hypertrophy (Figures 2A and S4A). This phenotype was primarily
due to cell hyperplasia, as reflected by the higher number of cells obtained in cell sorting (see below
Section 2.4) and was further magnified by the increase in prostatic secretions, especially in the anterior
prostate. Prostate weight of Pb-PRLΔSTAT5 was significantly reduced compared to Pb-PRLSTAT5f/f
mice, but remained higher than in control STAT5f/f mice (Figure 2A, top panel). In fact, anterior and
dorsal lobes of Pb-PRLΔSTAT5 mice exhibited significant weight loss compared to their counterparts
in Pb-PRLSTAT5f/f mice (Figure 2A, bottom panels), but this was not the case for ventral and lateral
prostates (Figure S4A). These results are in agreement with the lobe-specific pattern of STAT5 signaling
down-regulation described above.
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Figure 2. STAT5 deletion reduces hallmarks of early prostate tumorigenesis in 6 month-old
Pb-PRLΔSTAT5 mice. (A). The weight of total prostate and of anterior (AP) and dorsal (DP) prostate lobes
of STAT5f/f, Pb-PRLSTAT5f/f and Pb-PRLΔSTAT5 mice is expressed as the ratio of prostate tissue weight
normalized to the weight of corresponding animal (see Figure S4A for other lobes). (B). Cell proliferation
in anterior and dorsal lobes was assessed by immunostaining using anti-Ki-67 antibody (hematoxylin
counterstaining). Arrows in insets show representative Ki-67 nuclear immunostaining in epithelial cells.
The proliferation index (ratio of Ki-67-positive versus total epithelial cells) was quantified using Calopix
software (see Figure S4 for other lobes). (C). Histological analysis (hematoxylin counterstaining) of
anterior and dorsal lobes of Pb-PRLSTAT5f/f and Pb-PRLΔSTAT5 mice showing similar hyperplasia in both
genotypes (see Figure S4 for other lobes). (D). Inflammation was identified using CD45 immunostaining.
The degree of inflammation was quantified using Calopix software and is represented as the ratio of
CD45+ area versus stroma area. Statistics: Stars denote significant differences in a repeated-measures
one-way ANOVA with Tukey’s multiple comparisons. Size bars: 250 μm in large images and 50 μm
in insets.
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2.3.2. Cell Proliferation
According to their hypertrophic phenotype, all prostate lobes of Pb-PRL mice were previously
shown to exhibit increased cell proliferation index (Ki-67 IHC) compared to control mice [36]. Using a
computer-assisted image analysis methodology for the quantification of Ki-67-positive cells, this was
confirmed in this study involving Pb-PRLSTAT5f/f compared to STAT5f/f mice. In agreement with
lobe weight reduction and STAT5 signaling down-regulation (see above), a significant reduction in
cell proliferation index was observed in the anterior, and to a lesser extent, in the dorsal lobes of
Pb-PRLΔSTAT5 mice (Figure 2B), while no change was observed in ventral prostate (Figure S4B).
2.3.3. Histopathology and Inflammation
At 6 months of age, Pb-PRL displays relatively mild histopathological phenotypes mainly including
low grade PINs (early tumorigenesis step) [37,38]. In this study, we failed to find obvious differences
between the histopathological features of Pb-PRLSTAT5f/f compared to Pb-PRLΔSTAT5 prostates (Figure 2C
and Figure S4C). The main phenotypical hallmark was in fact the reduction of the secretory phenotype
in the latter, in agreement with the role of PRL signaling in prostate secretory function [39].
Inflammatory cell infiltrates are scarce in WT prostates. In contrast, according to previous
reports [38,40], Pb-PRLSTAT5f/f mouse prostates displayed several foci of CD45+ inflammatory cells
especially in the ventral lobe (Figure 2D and Figure S4D). Pb-PRLΔSTAT5 mouse prostates displayed
a less marked inflammatory phenotype in the anterior and dorsal lobes (Figure 2D), suggesting a
role for luminal STAT5 in this phenotype. In contrast, there was a trend for an increased number of
inflammatory cell foci in the two other lobes compared to Pb-PRLSTAT5f/f prostates (Figure S4D).
Taken together, our analyses support a protective role of Stat5 ablation against the early steps
of PRL-triggered prostate tumorigenesis, weakening hyperplasia, lowering cell proliferation, and
reducing chronic inflammation.
2.4. STAT5 Deletion Alters Epithelial Cell Hierarchy
The composition of the prostate epithelium can be determined using cell sorting strategies based
on cell surface expression of Stem cell antigen-1 (Sca-1) and Integrin alpha 6 (CD49f). Using these
validated markers, luminal and basal (also called LSChigh) cells can be discriminated [41]. We recently
discovered in the mouse prostate a third epithelial cell population that we called LSCmed [31]. The basal
and LSCmed cell populations include stem/progenitor cells and exhibit tumor-initiating capacities
when transformed [32,42]. Of interest, in pre-tumoral Pb-PRL prostates both basal and LSCmed cell
populations are amplified at the expense of the luminal compartment [30–32].
Due to the lobe-specific efficacy of Stat5 deletion (see Figure 1), we investigated the distribution
of these three epithelial cell populations individually in each lobe of the three genotypes of interest
using cell sorting. Data in Figure 3A were obtained by pooling 3–6 animals to ensure enough material
for analysis.
In STAT5f/f prostates luminal cells were predominant in all lobes (60% to 90%) and the analysis
revealed very low prevalence of basal/LSCmed cells in ventral prostate compared to other lobes
(Figure 3A,B). In Pb-PRLSTAT5f/f prostate, basal and LSCmed cells were dramatically amplified in all
lobes at the expense of luminal cells that dropped to <20% of the hyperplastic epithelium (Figure 3B).
As shown in Figure 3C, the contents in basal and LSCmed cells in the various lobes were inversely related
(the more basal, the less LSCmed). Plotting these data against the level of STAT5 phosphorylation in the
epithelium of the various lobes of Pb-PRLSTAT5f/f mouse prostates, as determined by IHC (Figure 1G)
revealed that higher levels of STAT5 activation were associated with higher content in basal cells
(Figure 3C).
346
Cancers 2019, 11, 929
Figure 3. STAT5 deletion alters epithelial cell hierarchy in 6 month-old Pb-PRLΔSTAT5 mice.
(A). Representative FACS profiles of anterior (AP) and dorsal (DP) prostate lobes from STAT5f/f,
Pb-PRLSTAT5f/f and Pb-PRLΔSTAT5 mice (3–6 animals per genotype). Graphs depict epithelial cells
only (gated as Lin-/Epithelial cell adhesion molecule (EPCAM)+), with large gates for percentage
analysis. Each FACS profile shows gated epithelial populations: basal/stem (LSChigh), LSCmed and
luminal cells. (B). Quantification of the three cell populations in the four prostate lobes from the three
genotypes is shown. In panels A and B, the arrows indicate the loss of luminal cells in Pb-PRLSTAT5f/f
versus STAT5f/f mice, and their partial rescue in anterior and dorsal prostate of Pb-PRLΔSTAT5 mice
(no similar effect was observed in the two other lobes). (C). For each prostate lobe of Pb-PRLSTAT5f/f
mice, the percentage of the three epithelial cell populations was plotted versus the level of STAT5
phosphorylation, as determined in Figure 1G.
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Analysis of Pb-PRLΔSTAT5 mouse prostates showed that this enrichment in basal/ LSCmed cells
was partly reversed upon STAT5 signaling down-regulation. Compared to Pb-PRLSTAT5f/f mice the
content in luminal cells was partly rescued in the anterior and dorsal lobes of Pb-PRLΔSTAT5 mice at
the expense of basal/LSCmed cells (Figure 3A,B). No similar effect was observed in lateral and ventral
lobes of Pb-PRLΔSTAT5 mice (Figure 3B) in agreement with the unaltered levels of epithelial pSTAT5
compared to Pb-PRLSTAT5f/f mice (Figure 1G).
Taken together, these observations revealed the central role of epithelial STAT5 in the control of
epithelial cell hierarchy by local PRL in the mouse prostate. In particular, up-regulation of STAT5
activation led to the accumulation of stem/progenitor cells previously shown to exhibit tumor-initiating
capacities when transformed.
2.5. STAT5 Deletion does not Promote Alternative PRLR Signaling Cascades
In order to investigate whether Stat5 gene deletion on the Pb-PRL background could promote
compensatory PRLR-triggered signaling pathways that may be responsible for the effects reported
above in Pb-PRLΔSTAT5 animals, we analyzed the phosphorylation status of STAT5, STAT3, ERK1/2,
and AKT in prostates of 6 month old mice of the three genotypes. The immunoblots are shown in
Figure 4A (anterior), B (dorsal) and C (ventral) and quantification for each lobe is shown in Figure 4D.
Virtually no basal phosphorylation could be detected for STAT5 in any lobe of STAT5f/f prostates,
which contrasted with STAT3, ERK1/2, and AKT that all showed some background activation.
Based on densitometric quantification, STAT5 was strongly activated in dorsal and anterior prostates of
Pb-PRLSTAT5f/f mice, reaching >30-fold induction compared to control mice. Mild activation (<2 fold)
of STAT3 (anterior lobe) and AKT (dorsal lobe) was also observed. In ventral prostate, STAT5 was also
activated, but to a much lower degree (~5 fold) than in the other lobes, in agreement with IHC data
(Figure S3B). In contrast to the other lobes, the degree of activation of STAT3 in ventral lobe (~7 fold)
was in the same range as STAT5 activation. Finally, ERK1/2 was not significantly triggered by PRL
in any lobe as shown by unchanged pho/total ERK1/2 ratio (Figure 4D). However, due to slightly
enhanced expression of ERK1/2 protein in the anterior lobe of Pb-PRLSTAT5f/f prostates compared
to STAT5f/f mice (Figure 4A), the tissue content in pERK1/2 in that lobe was significantly increased
(p < 0.01), and the same trend (not significant) was observed in the other lobes (Figure 4B,C).
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Figure 4. STAT5 deletion does not promote alternative signaling in 6 month-old Pb-PRLΔSTAT5
mice. (A–C). Canonical PRLR signaling pathways were analyzed by immunoblot in anterior (A),
dorsal (B) and ventral (C) prostate lobes from STAT5f/f, Pb-PRLSTAT5f/f and Pb-PRLΔSTAT5 mice (each
lane corresponds to a different mouse). (D). The activation of each pathway determined by the ratio of
phosphorylated versus total protein (densitometry) is shown as fold-induction versus STAT5f/f samples.
Statistics: Stars denote significant differences in a repeated-measures one-way ANOVA with Tukey’s
multiple comparisons.
The down-regulation of STAT5 in the anterior (Figure 4A) and dorsal (Figure 4B) lobes of
Pb-PRLΔSTAT5 mice did not result in compensatory activation of alternative PRLR signaling pathways.
In fact, the pathways that were mildly activated in these lobes in Pb-PRLSTAT5f/f prostates, i.e., STAT3
in the anterior lobe and AKT in the dorsal lobe, were back to control levels in Pb-PRLΔSTAT5 prostates
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(Figure 4D). While this effect suggests that activation of these pathways could be STAT5-dependent,
it may also reflect the down-regulation of transgenic PRL protein that was observed in these lobes
(Figure S4E). Since the level of PRL mRNA was unaltered (Figure S4F), this suggests that STAT5
signaling may contribute to PRL protein stability. Finally, in agreement with the poor efficiency of Stat5
deletion in the ventral lobe of Pb-PRLΔSTAT5 mice, PRL expression (Figure S4E) and PRLR signaling
pathways (Figure 4C,D) were unchanged in this lobe compared to Pb-PRLSTAT5f/f mice.
Taken together, these data indicate that at 6 months of age, STAT5 deletion on the Pb-PRL
background does not promote activation of alternative PRLR signaling pathways.
2.6. STAT5 Deletion does not Prevent Prostate Tumor Progression in Aged Pb-PRL Mice
In order to address the long-term effects of STAT5 signaling deletion on PRL-induced tumor
progression, we analyzed Pb-PRLSTAT5f/f and Pb-PRLΔSTAT5 mice at 12 and 18 months of age. In the
latter, the ventral, lateral, and dorsal lobes were often undistinguishable (hereafter called half prostate)
due to massive tissue hypertrophy so that lobe-specific interpretation could not be performed for
all investigations.
The prostate weight of Pb-PRLSTAT5f/f was significantly increased at 12 and even more at 18 months
of age compared to STAT5f/f mouse prostates (Figure 5A for total prostate and Figure S5A for individual
lobes). This weight gain was largely due to the dramatically increased secretory phenotype of
Pb-PRLSTAT5f/f prostates, especially in the anterior lobe that was extremely swollen/hypertrophic
at dissection. This phenotype was confirmed on H&E sections by the presence of abundant and
dense eosinophilic secretions in hypertrophied ducts (“S” on Figure 5B and Figure S5B). Compared to
Pb-PRLSTAT5f/f mice, prostate weight was significantly reduced in Pb-PRLΔSTAT5 mice at 12 months of
age (Figure 5A). This effect was correlated to a less marked secretory phenotype and a reduction in
cell proliferation that was significant in anterior and dorsal lobes only (Figure 5C). In 18 month-old
mice, there was still a trend for reduced prostate weight (Figure 5A) and reduced proliferation index in
Pb-PRLΔSTAT5 mice (Figure 5C).
At the histological level, prostates of 12 month old Pb-PRLSTAT5f/f mice (Figure 5 and Figure S5B)
exhibited various hallmarks of tumorigenesis that further aggravated with age including PINs,
cribriform lesions (“c”), increased stromal density (stars) and inflammation (arrows), especially in
ventral prostate. While these phenotypes tended to be less pronounced in age-matched Pb-PRLΔSTAT5
mice, they ultimately progressed in the latter so that at 18 months of age the mice of both genotypes
became almost undistinguishable irrespective of the lobe (Figure 5B). The inflammatory phenotype
was highly heterogeneous at 12 months of age precluding any clear genotype-related difference in any
lobe (Figure 5D). There was nevertheless a global trend for lower inflammation in Pb-PRLΔSTAT5 mice,
which persisted at 18 months of age (Figure 5D).
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Figure 5. STAT5 deletion does not prevent prostate tumor progression in aged Pb-PRL mice.
(A). The prostate weight in 12 and 18 month-old STAT5f/f, Pb-PRLSTAT5f/f and Pb-PRLΔSTAT5 mice is
expressed as the ratio of total prostate weight normalized to the weight of corresponding animal (see
Figure S5A for data per lobe). (B). Histological analysis (hematoxylin counterstaining) of prostate tumors
of 18 month-old Pb-PRLSTAT5f/f and Pb-PRLΔSTAT5 mice showing similar abnormal histology including
PINs, cribriform lesions (“c”), increased stromal density (stars), inflammation (arrows), and dense
eosinophilic secretions (S). Sections from the anterior lobe (AP) and from fused dorsal/lateral/ventral
lobes are shown. See Figure S5B for 12 month-old animals. (C). The proliferation index in prostates
from 12 (all lobes) and 18 month old (anterior lobe and total prostate) mice is shown (see Figure 2 for
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details). (D). Inflammation was identified using CD45 immunostaining. The degree of inflammation
was quantified using Calopix software and is represented as the ratio of CD45+ area versus stroma area.
(E). Representative FACS profiles of dorsal (DP) and ventral (VP) prostate lobes from 12 month-old
STAT5f/f, Pb-PRLSTAT5f/f and Pb-PRLΔSTAT5 mice (3–4 animals per genotype; see Figure 3A for details).
Arrows show that the loss of luminal cells observed in Pb-PRLSTAT5f/f versus STAT5f/f mice was not
rescued in Pb-PRLΔSTAT5 mice. Statistics: Stars denote significant differences in a repeated-measures
one-way ANOVA with Tukey’s multiple comparisons (A) or two-way ANOVA with Sidak’s multiple
comparisons (C). Size bars: 250 μm in large images and 50 μm in insets.
According to the low efficiency of Stat5 deletion in the ventral lobe, 12 month-old Pb-PRLΔSTAT5
and Pb-PRLSTAT5f/f mice displayed very similar cell sorting profiles for this lobe, with accumulation
of basal and LSCmed cells and low luminal cell content (Figure 5E). Importantly, the dorsal prostates
of these animals also displayed very similar profiles enriched in stem/progenitor cells (Figure 5E),
indicating that the partial rescue of the luminal cells observed in younger animals upon Stat5 deletion
(Figure 3A,B) was no longer maintained in aged mice.
Taken together these data indicate that the deletion of STAT5 delayed, but could not prevent the
appearance of histopathological hallmarks of PRL-driven prostate tumorigenesis.
2.7. Spontaneous STAT5 Signaling Shutdown and Emergence of AKT and ERK1/2 Signaling in Aged
Pb-PRL Mice
To understand further why the protective effect of STAT5 signaling inhibition observed at 6 months
of age was progressively lost in old Pb-PRLΔSTAT5 mice, we compared the canonical PRLR signaling
pathways in the dorsal prostates of the three genotypes at 6, 12, and 18 months of age (Figure 6A).
We discovered that in Pb-PRLSTAT5f/f mice (lanes 1–3, 7–9 and 13–15 on Figure 6A), the degree of
STAT5 activation (pSTAT5/STAT5 ratio) as well as the tissue content in activated STAT5 (pSTAT5/ACTIN)
markedly declined between 6 and 12 months of age (Figure 6A,B). We investigated this phenotype further
by monitoring the mRNA expression of key players of the PRLR/STAT5 pathway in Pb-PRLSTAT5f/f
prostate (Figure 6D). There was neither alteration of transgenic Prl and Prlr expression, nor up-regulation
of short PRLR isoforms that have been shown to act as dominant-negative on STAT5 signaling [43].
The lower level of SOCS2 expression at 12- versus 6-months of age assessed that STAT5 signaling
down-regulation in the latter was not due to unexpected SOCS overexpression; rather, it was associated
with lower STAT5 signaling activity. SOCS7 [44] and nuclear receptor co-repressor 2 (NCOR2,
also known as silencing mediator for retinoid or thyroid-hormone receptors, SMRT) [45] are two
other negative regulators of STAT5 signaling. None of them were affected at the transcriptional level
(Figure 6D and S6A). Otherwise, there was a significant age-related decrease in Stat5a mRNA expression
(Figure 6D) that was also observed at the protein level in prostate lysates (STAT5/ACTIN ratio), although
it did not reach significance, presumably due to unaltered Stat5 expression in non-epithelial cells
(Figure 6B). Comparison of pSTAT5 immunostaining in the epithelium of dorsal prostate of 6- versus
12-month old Pb-PRLSTAT5f/f mice revealed that the reduced tissue content in activated STAT5 in older
mice was associated with both lower number of pSTAT5-positive cells and, in the latter, reduced
intensity of pSTAT5 staining (Figure 6E). Indeed, pSTAT5-positive cells in 12 month old Pb-PRLSTAT5f/f
mice exhibited faint nuclear staining similar to that observed in the few pSTAT5-positive epithelial
cells of healthy prostates (Figure 6E, panels a and c), i.e., markedly lower compared to younger
Pb-PRLSTAT5f/f animals (Figure 6E, panel b). As a consequence, the level of STAT5 signaling in old
Pb-PRLSTAT5f/f mice became undistinguishable from that of age-matched Pb-PRLΔSTAT5 mice (see
quantifications reported in Figure 6E). Accordingly, most of the targets that were regulated by STAT5
signaling in young animals were not significantly affected by Stat5 deletion in older mice (Figure S6A).
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Figure 6. Spontaneous STAT5 signaling shutdown and emergence of AKT and ERK1/2 signaling in aged
Pb-PRL mice. (A). Canonical PRLR signaling pathways activated in dorsal prostates of Pb-PRLSTAT5f/f
(lanes 1–3, 7–9, 13–15) and Pb-PRLΔSTAT5 (lanes 4–6, 10–12, 16–18) mice were compared at 6, 12 and
18 months of age as indicated. (B). Quantifications of the STAT5 pathway regarding STAT5 activation
(pSTAT5/STAT5 ratio), tissue content in activated (pSTAT5/ACTIN) and total (STAT5/ACTIN) STAT5 as
determined in panel A. (C). The activation of STAT3, AKT and ERK1/2 pathways as shown in panel A
was quantified by densitometry as the ratio of phosphorylated versus total protein. (D). Age-dependent
expression of various actors of the PRLR and AR pathways as determined by RT-qPCR in 6 and
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12 month-old Pb-PRLSTAT5f/f mice. The dotted line represents low expressed genes of the PRLR pathway
(upper panels) and target genes of the AR pathway (bottom panel). See Figure S6 for genotype-dependent
expression in 12 month-old mice. (E). Comparison of the number of pSTAT5-positive cells and of
the intensity of pSTAT5 immunostaining (the horizontal dotted line is the background threshold)
in 6 versus 12 month-old STAT5f/f, Pb-PRLSTAT5f/f and Pb-PRLΔSTAT5 mice. Representative images
of low number (arrows)/low intensity (STAT5f/f mice), high number/high intensity (6 month-old
Pb-PRLSTAT5f/f), and high number/low intensity (12 month-old Pb-PRLSTAT5f/f) are shown (positive
cells are red circled). Statistics: Stars denote significant differences in a repeated-measures two-way
ANOVA with Sidak’s multiple comparisons. Size bars: 50 μm.
Concomitant to the age-dependent decline of STAT5 signaling in Pb-PRLSTAT5f/f tumors,
we observed a significant increase in ERK1/2 and AKT phosphorylation at 12 and 18 months of
age, respectively (Figure 6A,C). Of interest, this phenomenon was also observed in Pb-PRLΔSTAT5 mice,
indicating it occurred irrespective of Stat5 status. There was no clear age-related alteration of STAT3
activation as it remained low in Pb-PRLΔSTAT5 mice and was more variable, but did not significantly
increase in PRLSTAT5f/f mice (Figure 6A,C).
Finally, we addressed potential contribution of androgen receptor (AR) signaling to the mechanisms
favoring STAT5-independent tumor progression in aged mice of the Pb-PRL background. To that end
we investigated the mRNA levels of Ar and of several AR target genes [32] in the dorsal prostate of 6
and 12 month old mice. Irrespective of the age, AR signaling was globally lower in Pb-PRLSTAT5f/f
mice compared to STAT5f/f mice based on the down-regulation of several genes of the AR signature
(Mme, Probasin, Nkx3.1; Figure S6B). Additionally, there was also no evidence for age-related increase
of AR signaling in Pb-PRLSTAT5f/f mice (Figure 6D, bottom panel). Finally, Stat5 deletion failed to
rescue normal AR signaling levels in Pb-PRLΔSTAT5 mice, especially at 12 months of age (Figure S6B).
These data clearly indicate that AR signaling up-regulation is not a compensatory mechanism of STAT5
signaling down-regulation in Pb-PRL mice.
Taken together, our analyses show that STAT5 signaling spontaneously decreases in PRL-driven
prostate tumors with aging and our results suggest that alternative compensatory pathways such as
AKT and ERK1/2 signaling, but not STAT3 and AR signaling, promote prostate tumor progression
upon hyper PRL signaling in the absence of STAT5.
3. Discussion
Reports have provided strong evidence regarding the role of PRL/STAT5 pathway in the progression
of human prostate cancer via an autocrine/paracrine mechanism (for reviews, [1,14,25–27]. Indeed,
this pathway was shown to promote survival, proliferation, EMT, stemness, invasiveness, and DNA
repair of/in prostate cancer cells, thereby contributing to prostate cancer progression and resistance to
treatment. Several underlying molecular mechanisms have been described, non-exhaustively including
up-regulation of PRL expression, STAT5 gene amplification and cooperation with androgen signaling
pathway. While some of these biological effects are also observed in Pb-PRL mice (e.g., cell survival,
proliferation, and stemness), the latter mice do not develop prostate cancer despite strong STAT5
action [30,31]. This suggested that hyper-activation of STAT5 signaling per se may not act as an
oncogene in the prostate, but it could tweak prostate cancer progression in a more proto-oncogenic role
driving e.g., enhanced Myc, Bcl2 or D type cyclin family member expressions. However, the promotion
of prostate cancer progression with other oncogenic driver pathways identified in the prostate cancer
genomic landscape could be complex and STAT5 signaling could be more important in other mutational
context [46]. We here present the first genetically-modified mouse model allowing delineation of the
actual role of STAT5 signaling in PRL-driven mouse prostate tumorigenesis.
The lobe-specific pattern of Stat5 gene deficiency—high in dorsal and anterior lobes, low in
ventral lobe of Pb-PRLΔSTAT5 mice—complicated the phenotype/genotype analyses, but at the same
time provided the opportunity to assess the functions that are directly controlled by STAT5 signaling
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by comparing the different lobes within the same prostate sample. These analyses highlighted that
epithelial cell survival/proliferation, immune cell infiltration, Prlr mRNA expression, and PRL protein
stability are tightly dependent on epithelial STAT5 as their regulation (up or down) in Pb-PRLSTAT5f/f
mice (compared to control mice) was partly or totally reversed in the dorsal and anterior lobes, but not
in the ventral lobe of Pb-PRLΔSTAT5 mice. While the STAT5-dependency of prostate epithelial cell
survival/proliferation confirms many earlier reports (for a review, see Reference [26]), the molecular
mechanisms mediating the epithelial STAT5-dependence of immune cell infiltration remains unknown.
While high cell proliferation rate can in some instances be accompanied by increased apoptosis leading
to the release of damage-associated molecular pattern (DAMPs) promoting inflammation. However,
this is unlikely as Dillner and colleagues provided molecular and immunostaining evidence for reduced
apoptosis in Pb-PRL prostates compared to healthy controls [47]. Alternatively, the increased secretory
pattern of Pb-PRL prostates may feed the microenvironment with STAT5-induced cytokines/chemokines
acting as immune cell chemoattractant. The locally high concentration of PRL may also contribute to
inflammation as this hormone has been suggested to mediate inflammation in various pathological
contexts, including association with prostate cancer inflammation [48,49]. Finally, the down-regulation
of Prlr expression by PRL signaling confirmed our previous observation [31] and the reversibility of
this phenotype upon Stat5 ablation (Pb-PRLΔSTAT5 mice) suggested that this negative feedback effect is
mediated by STAT5 signaling.
One of the striking phenotypes harbored by Pb-PRL mice is the amplification of the basal and
LSCmed cell compartments. This was assessed both by cell sorting and by immunochemistry using
cell population-specific phenotypic markers (p63/CK5 for basal and CK4 for LSCmed cells) [30–32].
The stem/progenitor cells contained in these two cell compartments are highly relevant to cancer
progression as they are castrate-resistant and they exhibit tumor-initiating properties when transformed
(e.g., by AKT/ERG overexpression or loss of key tumor suppressors in prostate cancer such as PTEN
or p53) [32,42,50]. In xenograft experiments, the number of tumor-initiating cells present in the
engrafted cell pool is directly correlated to the tumor incidence observed in host mice. In CWR22Rv
xenografts, adenovirus-mediated overexpression of a dominant-negative STAT5A/B variant was
shown to reduce tumor incidence [11], indicating a reduction in stem-like properties following STAT5
inhibition. This is in agreement with the capacity of STAT5 signaling to increase stem-like phenotypic
features and functional properties of human prostate cancer cells in vitro [15]. Thus, the capacity of
PRL/STAT5 signaling to induce the amplification of stem/progenitor cells may directly contribute to
cancer progression by feeding the prostate tissue with cells able to resist treatments and to regrow a
tumor (cancer recurrence).
In this study, the lobe-specific analyses of pSTAT5 by immunohistochemistry on the one hand,
and of the three epithelial cell populations (luminal, basal, LSCmed) by cell sorting on the other hand,
revealed that the prevalence of basal cells was positively correlated to the level of STAT5 activation
in the luminal epithelium. The outcome of these analyses is schematized in Figure 7. This finding
is in agreement with our former quantitative immunostaining investigations showing that basal cell
clusters within the prostates epithelium of Pb-PRL mice are frequently surrounded by luminal cells
displaying elevated levels of pSTAT5 [31]. Furthermore, the enrichment in basal/stem cells was partly
reversed upon Stat5 ablation in anterior and dorsal lobes of Pb-PRLΔSTAT5 mice. Another finding of
these analyses is that the lobe-specific prevalence of basal/stem cells was inversely correlated to that
of LSCmed cells. This supports that the latter emanate from the former in the prostate cell hierarchy,
as proposed in our detailed study reporting the discovery of LSCmed progenitors [31]. Altogether,
these observations demonstrate that the prostate cell hierarchy is tightly controlled by epithelial
STAT5, which appears to limit luminal differentiation and to favor amplification of the basal/stem
compartment (Figure 7). This effect is opposite to what happens in the mammary gland where STAT5A
is mandatory for luminal cell differentiation [51]. The mechanism underlying the regulation of prostate
cell hierarchy by STAT5 signaling is yet to be elucidated. Transcriptomic profiling of basal and LSCmed
cells showed that they express only minimal levels of Prlr (Ref. [32] and our unpublished qPCR data)
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therefore their direct regulation by local PRL is unlikely. Paracrine regulation of basal cells by secreted
factors downstream of PRL/STAT5 signaling in luminal cells is a possibility that is currently under
investigation. As basal and LSCmed cells also express detectable levels of Stat5 (Ref. [32] and our
unpublished qPCR data), a cell-autonomous effect may also contribute to the partial reversion of basal
cell enrichment in Pb-PRLΔSTAT5 mice. Indeed, although the androgen-regulated Pb promoter driving
Cre recombinase expression is preferentially active in luminal cells, some reports suggest that it might
also be active in basal cells [52].
Figure 7. STAT5 signaling prevents luminal differentiation of the prostate epithelium. (A). Schematic
representation of luminal differentiation placing LSCmed cells in-between basal and luminal cells.
(B). The relative content in the three epithelial cell populations (basal/stem, LSCmed, luminal) in the
various prostate lobes of 6-month old Pb-PRL mice or in WT mice (any lobe), as determined in Figure 3
is symbolized by the size of each population name. Below, the level of STAT5 activation in each
lobe as determined in Figure 1 is also schematically represented by the black stair-bar. Based on
these measurements, the highest the level of STAT5 activation, the lowest the level of epithelium
differentiation was observed (see text for discussion).
While we earlier identified STAT5 as the main PRLR signaling pathway activated in Pb-PRL mouse
prostates [30,31], the fact that pre-neoplastic prostate lesions observed in these animals never (or if at
all, only exceptionally) evolve towards malignancy has always seemed in contradiction with the strong
experimental and clinical evidence supporting the promoting role of this pathway in human prostate
cancer (see Introduction). Human prostate specific PRL signaling could be more important than that
of rodent prostates to drive tumorigenesis. Additionally, human prostate cancer is predominant in
elder men and the various genetic and environmental risk factors (e.g., smoking, alcohol abuse, etc.)
could insufficiently be recapitulated in inbred C57Bl/6J transgenics as used here as a study subject.
Irrespective, the present work provides a possible explanation for the absence of prostate cancer
development in Pb-PRL mice as we show that the prostates of these animals progressively lack STAT5
signaling with age. To address whether continuously elevated STAT5 signaling is actually required
for the transformation of pre-neoplastic prostate lesions, it would be interesting to generate mice
with enforced expression of a constitutively-active STAT5 variant in the prostate [53]. In conclusion,
we show, for the first time, that aging can promote alternative compensatory pathway activations to
bypass STAT5 function, but inflammation, cell proliferation and survival as well as prostate epithelium
differentiation are significantly affected by PRL-STAT5 signaling.
The mechanism driving age-related decline of STAT5 signaling in the prostates of ageing
Pb-PRLSTAT5f/f mice remains unclear. No parallel up-regulation of the classical negative regulators
of STAT5 signaling (SOCS proteins, short PRLR isoforms) could explain this observation. Although
we noticed a decrease in STAT5 expression (mRNA and protein) in the dorsal prostates of 12 month
old Pb-PRLSTAT5f/f mice, this alone was insufficient to account for the pronounced loss of STAT5
activation (Figure 6B), suggesting that other mechanisms may be involved. In the breast cancer
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context, it has been shown that increased stiffness/density of the extracellular matrix around the
tumor as a result of altered collagen deposition during cancer progression shifted the balance of PRLR
signaling from JAK2/STAT5 to other pathways including ERK1/2 and AKT pathways through a Focal
adhesion kinase-dependent mechanism [54,55]. Of interest, the pre-neoplastic lesions of Pb-PRL mouse
prostates also exhibit strong remodeling of the extracellular matrix compared to controls, including >10
fold-increased expression of various Collagens [47]. This phenotype aggravated with age, concomitant
to the decline in STAT5 signaling and up-regulation of AKT and ERK1/2 signaling, therefore it is
possible that a similar mechanism as described in breast cancer contributes to the signaling shift
observed in the prostates of ageing Pb-PRLSTAT5f/f mice. No such up-regulation of AKT or ERK1/2
signaling was observed when STAT5 signaling was genetically impaired in younger Pb-PRLΔSTAT5
animals, further supporting that the progressive up-regulation of alternative signaling pathways in
Pb-PRLSTAT5f/f mice involves age-related mechanisms that require time to establish. These alternative
signaling pathways allowed pre-neoplastic lesions to develop further in a STAT5-independent manner,
as reflected by the elevated levels of cell proliferation and inflammation, and by the appearance of
various histopathological phenotypes including cribriform lesions in old mice. In fact, these phenotypes
were observed irrespective of Stat5 status. Thus, although Stat5 deficiency delayed the occurrence of
various pre-neoplastic hallmarks, its protective effect was progressively diluted with age to become
almost undetectable in 18 month-old animals. Of note, neither androgen nor STAT3 signaling could
be identified as a compensatory pathway of age- or genetically-induced down-regulation of STAT5
signaling. There was even a trend for lower STAT3 signaling in Stat5-deficient prostates, suggesting
some level of cooperation between both pathways.
Preventing the progression of established prostate cancers is where the therapeutic challenge
stands. In agreement, there is currently strong research to develop STAT5 inhibitors that could be used
for the treatment of various malignancies, including prostate cancer and myeloid leukemia [23,24,56].
Whatever the mechanisms driving the intrinsic decline of prostatic STAT5 signaling in Pb-PRL mice,
the various genotype- and age-related phenomena observed in our study may shed light on possible
outcomes of long-term pharmacological inhibition of STAT5 in prostate cancer context. On the good
side, as low STAT5 signaling parallels luminal differentiation, pharmacological STAT5 inhibitors are
not expected to result in tumor enrichment in stem/progenitor cells, but they can also act on the stromal
cells such as immune cells. This effect may distinguish anti-STAT5 treatments from current therapeutic
strategies (castration, chemotherapy) which generally kill luminal cells and let stem/progenitor cells
unaffected, which is believed to favor tumor recurrence based on the tumor-initiating capacities of the
latter. In addition, STAT5 inhibition may also decrease autocrine PRL stability as suggested from our
results, which may further contribute to drug efficacy as PRL is presumably the major upstream factor
triggering STAT5 pathway in the prostate. On the negative side, our study identified potential escape
mechanisms to STAT5-targeted therapeutic strategies. In young Pb-PRLΔSTAT5 mice, which model early
stages of STAT5 inhibition, no activation of alternative PRLR signaling pathway could be identified,
and cell proliferation was actually reduced. With time, which is modeled by old Pb-PRLΔSTAT5 mice,
we observed up-regulation of AKT and ERK1/2 signaling. One might speculate that in a context of
pharmacological STAT5 inhibition these pathways may contribute to STAT5-independent prostate
cancer progression. It is currently unknown whether AKT and ERK1/2 are triggered by PRL only or
whether other paracrine growth factors will contribute. With the aim to design appropriate treatment
combination limiting escape mechanisms to STAT5 inhibition, it may be relevant to address this
mechanism in future studies.
4. Materials and Methods
4.1. Transgenic Mouse Strains
The Pb-PRL mouse colony carrying the rat prolactin transgene driven by the short probasin
promoter was established on the C57BL/6J background (>20 backcrosses) in the Paris laboratory as
357
Cancers 2019, 11, 929
previously described [30]. Mice carrying floxed Stat5a/b alleles (STAT5f/f mice) allowing targeted
deletion of the whole Stat5 locus (encompassing both Stat5a and Stat5b genes) were originally developed
by L. Hennighausen [34]. Animals were obtained from the in-house colony of R. Moriggl (Vienna,
Austria) established on a pure C57Bl/6 genetic background. Pb-Cre mice (C57Bl/6 background)
expressing the Cre recombinase under the control of the short probasin promoter [57] were purchased
from the Frederick National Laboratory for Cancer Research (Frederick, MD, USA). Figure S7 displays
the breeding scheme used to generate mice carrying or lacking prostate epithelium-specific deletion of
Stat5a/b genes on the WT (STAT5f/f and ΔSTAT5 mice) and Pb-PRL (Pb-PRLSTAT5f/f and Pb-PRLΔSTAT5
mice) backgrounds. Note that only males were used to transmit the Pb-Cre allele.
Colonies were housed in controlled conditions, on a 12/12-hour light/dark cycle with normal food
and water provided ad libitum. Mice were analyzed at 6, 12 and 18 months of age, and prostate were
harvested immediately after sacrifice by cervical dislocation. To isolate the prostate, dissection of
the urinary tract was performed and left lobes were separately dissected, weighed then rapidly snap
frozen while the right-sided half prostate was fixed in paraformaldehyde (PFA) without being further
dissected, so that tissue organization was preserved for histological analysis [36]. For all genotypes,
we analyzed the four prostate lobes (anterior, dorsal, lateral, ventral) at all ages. Note that at 18 months
of age, dorsal, lateral, and ventral lobes were often fused due to tissue hypertrophy.
Animal experiments were approved by the local ethical committee—Comité d’Ethique en matière
d’Expérimentation Animale Paris Descartes (CEEA 34) for animal experimentation (authorization
CEEA34.VG.095.12) and performed according to the European guidelines for animal experimentation.
4.2. Prostate Subpopulation Sorting by FACS
The procedures for sorting the three epithelial cell populations based on their Lin/Sca-1/CD49f
antigenic profile was previously described [31,32,41]. Cell sorting was performed on a BD FACSAria
III (BD Biosciences, San Jose, CA, USA). Sorted cells were collected in DMEM medium, supplemented
with 50% FBS, glutamine, and penicillin-streptomycin, or in RA1 Lysis Buffer (Macherey-Nagel, Düren,
Germany) to perform RNA extraction as earlier described [32].
4.3. Quantitative PCR
Total RNA was isolated from separate prostate lobes using the NucleoSpin® RNA XS (Macherey
Nagel, Hoerd, France) according to manufacturer’s instructions. RNA integrity was assessed on Agilent
BioAnalyzer (all RNAs scored 7–10). RNA (250 ng) was reverse transcribed using SuperScript™II
Reverse transcriptase with the SuperScript™II First-Strand Synthesis System for RT-PCR kit (Invitrogen,
CA, USA). The cDNAs were then subjected to real-time PCR amplification using gene-specific primers
(0.5 μM final concentration) purchased from IDT DNA (Integrated DNA Technologies, BVBA, Leuven,
Belgium; HPLC purification; referred to as Mm.PT in Table S3) or Eurogentec (Liège, Belgium; Oligold
quality, sequence given in Table S1). PPIA (Peptidyl Prolyl Isomerase A) that encodes Cyclophilin
A that was used as the housekeeping gene in each reaction. Real-time PCR was performed using a
Qtower 2.0 (Analytik Jena, Germany). The qPCR reaction contained 2 μL cDNA sample (12.5 ng) and
8 μL mastermix with 1× GoTaq® qPCR Master Mix (Promega, Charbonnières-les-Bains, France) and
0.5 μM primer. The Qtower 2.0 Instrument was used with the following program: Enzyme activation:
95 ◦C for 2 min; amplification (40 cycles): 95 ◦C for 15 s, 60 ◦C for 60 s. Results were generated with the
Qtower 2.0 software and were analyzed by the comparative cycle threshold method and presented as
fold change in gene expression relative to internal calibrators as mentioned in figures.
4.4. Western Blotting
Freshly dissected prostate lobes were snap frozen in liquid nitrogen and stored at −80 ◦C until
processing as previously described [31]. Protein samples (20–50 μg) were resolved in 4–12% gradient
SDS-PAGE in NuPAGE Bis-Tris Precast Gels (Life Technologies, Saint-Aubin, Fance) or 10% SDS-PAGE
gels. Proteins were then transferred onto nitrocellulose membranes (BioRad, Marnes-la-coquette,
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France). Membranes were cut horizontally according to the size of the proteins of interest and
stained with primary antibodies as described in Table S1. For band detection, Horseradish Peroxidase
(HRP)-coupled secondary anti-rabbit (7074, Cell Signaling, Saint-Quentin-en-Yvelines, France) or
anti-mouse (NA931, GE Healthcare Europe, Freiburg, Germany) antibodies were added before
Enhanced Chemiluminescent (ECL) substrate (Immobilon Western Chemiluminescent HRP Substrate,
Millipore or LumiGLO Reagent, Cell Signaling). Representative parts of blots are shown in the Figures,
whole blot membranes are displayed in Figure S8.
4.5. Prostate Histopathology
Histopathological diagnosis of prostate sections from all mice was performed in blind by an
independent veterinary pathologist (E.R.-G.) trained for mouse prostate analysis [36] following
the recommendations of the Mouse Models of Human Cancer Consortium Prostate Pathology
Committee and the reference classification of prostate intraepithelial neoplasia (PIN) lesions in
genetically-modified animals [58,59]. This qualitative analysis was complemented by quantitative IHC
analyses, as described below.
4.6. Immunohistochemistry (IHC)
All prostate samples were fixed in 4% PFA, paraffin embedded, and underwent heat-induced
antigen retrieval in citrate buffer at pH 6. IHC and IF were performed as previously described [31]
using antibodies listed in Table S2. Vector Elite ABC HRP kit with DAB substrate (Vector Laboratories,
Burlingame, CA, USA) was used for detection of IHC slides, with hematoxylin as counterstain.
4.7. Image Acquisition and Histology Quantifications
Prostate tissue sections (H&E or IHC) were digitally scanned using a NanoZoomer-2.0 RT
scanner (Hamamatsu, Photonics, France) coupled to NDP.view2 software analysis beta version
U12388-01 (Hamamatsu, Photonics, France). For quantification of immunostaining, computer-assisted
analysis of digital (scanned) images was performed using Calopix software (http://www.tribvn.com/).
To quantify nuclear immunostaining (pSTAT5, Ki-67) in the epithelium, first the Random Forest Tree
for tissue recognition was used to delineate and only include the glandular areas in the analysis. Then,
the “morphometry” software was applied to each prostate lobe to discriminate staining-positive (DAB+)
versus staining-negative (DAB−) cells. A value of marking intensity (optical density, <100 considered
as background) was also provided by the algorithm for both classes of cells. The index of proliferation
(Ki-67+) and of STAT5 activation was calculated as the ratio of the number of positive versus total
(positive + negative) cells counted. The whole procedure was validated by comparing the results
obtained by Calopix-assisted versus manual counting of digital images as previously reported [36,38,60].
For the quantification of CD45 staining, results are expressed as the ratio between the surface of CD45+
cell foci versus the total surface of stroma [36,38,60].
4.8. Statistics
The specific statistical tests performed are described in the legends for all results reported.
In summary, Analysis of Variance (ANOVA) tests were used to evaluate differences among three
or more groups. Depending on the number of factors tested, One or Two-way ANOVAs were
used. When prostate lobe samples issued from the same mice were compared in the analysis,
a repeated-measures test was carried out. Post hoc multiple comparisons were performed with Sidak’s
or Tukey’s multiple comparisons. One, two, three or four symbols illustrating significance represent
p values <0.05; <0.01; <0.001 and <0.0001, respectively. A value of p < 0.05 was used as significance
cutoff for all tests. Error bars represent S.E.M. All analyses were performed using GraphPad Prism
version 6.00 for Windows (GraphPad Software, San Diego, CA, USA).
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5. Conclusions
This work confirmed STAT5 signaling as a major driver of autocrine PRL-mediated prostate
tumorigenesis as genetically-induced STAT5 down-regulation delayed the onset of various PRL-induced
tumor hallmarks. The age-related decline in STAT5 signaling observed in Pb-PRL mice harboring intact
Stat5 genes was unexpected, and may explain why malignancies failed to develop despite alternative
signaling pathways were switched on and presumably contributed to the progression of pre-neoplastic
lesions. Stat5 genotype-related differences of prostate phenotypes observed in young animals were
progressively lost in ageing mice. Together, these findings highlight an important role of PRL/STAT5 in
the development of prostate tumors.
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Abstract: Signal transducer and activator of transcription 3 (STAT3) is an oncogene and multifaceted
transcription factor involved in multiple cellular functions. Its role in modifying anti-tumor immunity
has been recently recognized. In this study, the biologic effects of STAT3 on immune checkpoint
expression and anti-tumor responses were investigated in breast cancer (BC). A transcriptional
signature of phosphorylated STAT3 was positively correlated with PD-L1 expression in two
independent cohorts of early BC. Pharmacologic inhibition and gene silencing of STAT3 led to
decreased Programmed Death Ligand 1 (PD-L1) expression levels in vitro, and resulted as well in
reduction of tumor growth and decreased metastatic dissemination in a mammary carcinoma mouse
model. The hampering of tumor progression was correlated to an anti-tumoral macrophage phenotype
and accumulation of natural-killer cells, but also in reduced accrual of cytotoxic lymphocytes. In human
BC, pro-tumoral macrophages correlated to PD-L1 expression, proliferation status and higher grade
of malignancy, indicating a subset of patients with immunosuppressive properties. In conclusion,
this study provides evidence for STAT3-mediated regulation of PD-L1 and modulation of immune
microenvironment in BC.
Keywords: breast cancer; PD-L1; STAT3; M2 macrophages; NK cells; STAT3 inhibitor XIII
1. Introduction
Programmed Death 1 (PD-1, CD279) and its ligand Programmed Death Ligand 1 (PD-L1, CD274)
are transmembrane proteins with role in autoimmunity, infection and anti-tumor immune response.
PD-L1 is mostly expressed in tumor cells but also in dendritic cells and macrophages, while its receptor
PD-1 is predominantly expressed in activated T-cells [1]. Their engagement leads to T-cell inactivation
and to impairment of effective immune response against the tumor [2]. Therefore, the PD-1/PD-L1 axis
represents an important immune checkpoint, and its targeting with monoclonal antibodies has been
Cancers 2019, 11, 1479; doi:10.3390/cancers11101479 www.mdpi.com/journal/cancers365
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proven to be an effective immunotherapeutic strategy, demonstrating durable clinical responses and
improved survival in several tumor types [3].
Breast cancer has been considered as a relatively non-immunogenic tumor due its low mutational
burden. However, the presence of tumor-infiltrating lymphocytes has demonstrated prognostic and
predictive value—at least in the triple negative and HER2 positive subtypes [4,5]. Data indicating the
efficacy of immune checkpoint blockade in breast cancer patients are mostly derived from phase I and
II clinical trial results [6], and recently the first phase III trial results showed that the addition of the
anti-PD-L1 antibody atezolizumab to nab-paclitaxel was associated with improved progression-free
survival in patients with triple-negative metastatic breast cancer [7].
Various genetic, transcriptional and post-translational factors have been involved in the regulation
of PD-L1 and these may be tumor type-specific [8]. Among them, signal transducer and activator
of transcription 3 (STAT3) represents a crucial transcription factor for cell proliferation, survival and
tumor development [9]. A direct link between STAT3 and PD-L1 expression has been previously
described [10], and recent data have provided insight into this regulatory mechanism [11]. STAT3
mediates the expression of important regulators of cell cycle and apoptosis but it can also play an
important role in tumor-immune cells interaction by impairing effective antitumor immunity [12].
STAT3-mediated release of various cytokines and chemokines can interact and influence components
of the tumor microenvironment (TME) and especially immune cell accumulation including T-cells,
Natural Killer (NK) cells as well as tumor-associated macrophages (TAMs) [13]. Of note, TAMs
represent a heterogeneous subpopulation with either pro-tumoral or anti-tumoral properties. Their
accumulation has been correlated with a worse prognosis and therapeutic resistance in most solid
tumors, including breast cancer [14].
In the present study, the role of STAT3 in the regulation of PD-L1 expression and in the potential
modifications of the immune microenvironment in breast cancer was investigated. Our findings
provide evidence for STAT3-mediated regulation of PD-L1 in vitro and impact on accumulation of
pro-tumoral macrophages and other immune cell subpopulations in an in vivo murine mammary tumor
model. The interactions of PD-L1 with STAT3, pro-tumoral macrophages and tumor characteristics
have been explored as well in a well-characterized cohort of breast cancer patients.
2. Results
2.1. Association Between PD-L1 and STAT3 Expression in Breast Cancer Cell Lines and Human Breast Cancer
The association between PD-L1 and STAT3 expression was first assessed in human breast cancer
cell lines. PD-L1 expression pattern was evaluated in three different human breast cancer cell lines
by western blot analysis and immunohistochemistry. MDA-MB-231 and BT549 demonstrated high
levels of PD-L1 compared to MCF7 cells, which showed very low—almost undetectable—PD-L1
protein (Figure 1A,B). STAT3 showed a ubiquitous expression in all three cell lines, as visualized
by western blot (Figure 1C), while MDA-MB-231 and BT549 cells showed a higher degree of STAT3
phosphorylation (at the Y705 residue) compared to MCF7, as visualized by western blot (Figure 1C) and
immunohistochemistry (Figure 1D), notably following the pattern of PD-L1 expression (Figure 1A,B).
Importantly, no amplification of the PDL1 gene locus was detected in any of the breast cancer cell
lines as assessed by Fluorescence In Situ Hybridization (FISH) analysis performed in sections of FFPE
cell blocks (Figure 1E). The association between pSTAT3 and PD-L1 was further assessed in a human
breast cancer cohort for which primary tumor gene expression data were available (n = 619) and PD-L1
protein levels were assessed (n = 539). The scores of a previously published metagene signature of
pSTAT3 in breast cancer (pSTAT3-GS) were positively correlated with PD-L1 transcript expression
levels (Spearman’s rho = 0.34; p < 2.2e−16) (Figure 1F). The positive association between pSTAT3-GS
score and PD-L1 transcript was also confirmed when RNA-sequencing data derived from the Cancer
Genome Atlas (TCGA) Provisional dataset (n = 1081) (Spearman’s rho = 0.38, p < 0.01; Supplementary
Figure S2A) were used. Additionally, in positive cases for PD-L1, total cell protein expression was
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evaluated by immunohistochemistry (Figure 1G), and pSTAT3-GS scores were significantly higher
than those in the PD-L1 negative cases (p = 0.0027) (Figure 1H). Moreover, in a subset of patients
(n = 83) pSTAT3 was assessed by IHC, and high pSTAT3 protein levels were positively associated with
PD-L1—especially in immune cells (Figure S3, Table S4).
Additionally, the expression of PD-L1 transcript and pSTAT3-GS score were higher in
triple-negative (TN) versus non-TN breast tumors in both cohorts (Figure 2A,B and Figure S2) whereas
total STAT3 gene expression did not differ between these two groups (Figure 2C and Figure S2).
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2.2. STAT3 Mediated Regulation of PD-L1 Expression In Vitro
Next, STAT3 regulation of PD-L1 expression was investigated using the STAT3 selective inhibitor
C188-9 (XIII). Suppression of pSTAT3 activity decreased PD-L1 protein levels in MDA-MB-231 cell
line, as detected by western blots (Figure 2D). Additionally, silencing STAT3 gene expression using
specific siRNA constructs led to decreased PD-L1 protein levels in transiently transfected BT549 cells
(Figure 2E). Furthermore, PD-L1 expression in the SKBR3 breast cancer cell line stably transfected with
a constitutively active STAT3 construct was examined. Constitutive activation of STAT3 resulted in
increased protein and mRNA levels of PD-L1 (Figure 2F,G). Treatment of the PD-L1 negative BC cell
line MCF7 with IL-6 resulted in increased protein levels of both PD-L1 and pSTAT3 (Figure 2H).
Figure 2. Expression patterns of STAT3 and PD-L1 in human breast cancer subtypes and regulation of
PD-L1 by STAT3 in breast cancer cell lines. (A) Expression levels of PD-L1 transcript, (B) pSTAT3-GS
score and (C) STAT3 transcript in triple-negative versus non-triple negative breast cancer patients.
(D) Inhibition of STAT3 activity by using STAT3 inhibitor C-188-9 (XIII) resulted in decreased levels
of PD-L1 expression in immunoblot 48 h following treatment in MDA-MB-231 breast cancer cell line.
(E) Knocking down STAT3 using specific siRNA construct led to decreased levels of PD-L1 in the
transiently transfected BT549 cell line. Stable transfection of SKBR3 breast cancer cell line with a STAT3
overexpressing plasmid (STAT3c) resulted in increased levels of PD-L1 (F) protein and (G) transcript
expression. qPCR data are illustrated as the fold change relative to control and normalized to β-actin.
They represent one out of three independent experiments and are depicted as the mean (±standard
error of the mean, SEM; ** p < 0.01). (H) Increased protein levels of PD-L1 were noted in MCF7 cell line
in response to treatment with IL-6.
2.3. Stat3 Silencing Downregulates PD-L1 in Mouse Cells, Restricts Tumor Growth and Metastatic Formation
and Modifies Anti-Tumor Immune Response In Vivo
The impact of Stat3 silencing on PD-L1 levels was explored in a murine model of breast cancer.
More specifically, knocking down Stat3 gene using a specific shRNA plasmid in mouse mammary
carcinoma 4T1 cells (shStat3 cells) resulted in decreased levels of pd-l1 (Figure 3A–C) compared to cells
transduced with corresponding empty vector (shCTR cells). When injected into the mammary fat
pad of BALB/c mice, shStat3 tumors displayed a decreased tumor volume (Day 25: 36.7%) and tumor
weight (Day 25: 31.3%) compared to shCTR tumors (Figure 3E–G). In addition, suppression of Stat3
expression resulted in decreased pulmonary metastatic index compared to control (Figure 3H,I).
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Furthermore, it was investigated whether the reduction in tumor progression by silencing Stat3
expression could affect the tumor immune profile. In fact, flow cytometry analysis (Figures S5 and S6)
showed that silencing Stat3 resulted in a significant increase in F4/80+ TAMs (Figure 4A). However,
these TAMs displayed increased levels of major histocompatibility complex class II (MHC II), indicating
a more “M1”-like anti-tumoral phenotype compared to shCTR tumors (Figure 4B) [15,16]. Consistently
with an anti-tumoral phenotype, NK cell accumulation was increased in shStat3 tumors compared to
controls (Figure 4C). Furthermore, these NK cells displayed higher expression of CD69 (Figure 4D,E)
indicating that they were more activated in shStat3 tumors compared to the controls. Silencing of Stat3
resulted also in an increase of CD4+ T cells (Figure 4F) while cytotoxic CD8+ T cells accumulation was
reduced, as compared to controls (Figure 4G). These CD4+ T cells displayed increased expression of
FoXP3+ in combination with CD25 (Figure 4H,I), indicating an immunosuppressive feature.
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Figure 4. Effect of Stat3 silencing on immunologic profile in mouse model. 4T1-shCTRL and 4T1-shStat3
tumors were dissociated to a single cell level and analysed using flow cytometry for the percentage of
(A). F4/80+ cells out of the gate of CD11b+. Graph (B) shows the mean fluorescence intensity (MFI) of
MHCII out of F480+ cells in 4T1-shCTRL and 4T1-shStat3 tumors. (C) Percentage of CD49b+ NK cells
out of CD45 and percentage (D) and MFI (E) of CD69 out of NK cells in the same tumors. 4T1-shCTRL
and 4T1-shStat3 tumors were also analysed with flow cytometry for the percentages of CD4+ T-cells
(F), CD8+ T-cells (G), FoxP3+ (H) and CD25+ FoxP3+ cells out of CD4+ T-cells (I). Student’s t-test was
performed for all comparisons depicted in the graphs and flow cytometry data are presented as mean
± SEM (n = 8; * p < 0.05; ** p < 0.01; *** p < 0.001); MHC: major histocompatibility complex.
2.4. CD163+ TAM Phenotype Is Associated with Higher PD-L1 Expression, Grade and Proliferation in Breast
Cancer Patients
Apart from the mouse model, it was further explored whether PD-L1 expression correlated to a
pro-tumoral “M2”-like (CD163+) TAM phenotype or an anti-tumoral CD11c+ macrophage/dendritic
cell phenotype in breast cancer patient samples. Hence, 45 patient samples with PD-L1 positive (n = 23)
or PD-L1 negative (n = 22) expression in tumor cells were stained for CD11c and CD163 (Figure 5A) and
three different populations could be detected, i.e., CD163+CD11c−, CD163+CD11c+ and CD163-CD11c+.
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Of note, both the percentage of CD163+ and CD163+CD11c+ cells (Figure 5B,C) as well as their ratio to
CD11c+ antigen-presenting cells (CD163+/CD11c+; Figure 5D and CD163+CD11c+/CD11c+; Figure 5E)
were significantly higher in patients with PD-L1 positive expression in tumor cells. Similar results
were observed when these subpopulations were associated with PD-L1 transcript levels (Figure 5F–I).
Conversely, higher percentage of CD11c+ cells was observed in patients with PD-L1 protein negative
tumors (Figure 5J) and were inversely correlated with PD-L1 mRNA as well (data not shown).
Accumulation of CD163+CD11c-, CD163+CD11c+ cells (Figure S4) and their respective ratio to CD11c+
cells (Figure 6A,B) were observed in patients with grade 3 tumors and with high expression of the
proliferation marker Ki67 (Figure 6C,D and Figure S4). In contrast, CD11c+ were more prominent in
patients with grade 1–2 tumors and with low expression of the proliferation marker Ki67 (Figure 6E,F).
In corroborration, PD-L1 tumor IHC expression was significantly associated with high grade and Ki67
expression (Table S5).
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3. Discussion
Immune checkpoint blockade has revolutionized cancer treatment, improving survival outcomes
in cancer patients, but the underlying mechanisms of PD-L1 regulation are not yet fully understood [8].
Activated (phosphorylated) STAT3, which forms dimers and transports into the nucleus, represents a
key transcription factor that critically controls proliferation, invasiveness, survival and metastasis [17].
It also modifies the immune response through various mechanisms, including regulation of PD-L1
expression [18]. Here, it was shown that STAT3 regulated PD-L1 expression in breast cancer cell lines
and its silencing led to restriction of tumor growth and altered the immune profile in a murine breast
cancer model. Moreover, PD-L1 expression was associated with a pro-tumoral TAM phenotype in
breast cancer patients.
Even though a direct link between PD-L1 and STAT3 has been described in previous reports, in this
study it was shown that STAT3 can influence immune response and PD-L1 expression in mouse models
as well as in patients with early breast cancer. As indicated in a previous breast cancer cell line study,
pSTAT1-pSTAT3 dimers bound on PD-L1 gene promoter inducing its expression and therefore STAT3
inhibition led to partial downregulation of PD-L1 [19]. Similar studies suggesting a STAT3-mediated
transcriptional regulation of PD-L1 have been performed in nucleophosmin—anaplastic lymphoma
kinase (NPM-ALK) positive (+) anaplastic large cell lymphoma (ALCL) [10], in ALK (-) ALCL [11],
in KRAS- and EGFR- mutant non-small cell lung cancer [20,21] and in head and neck squamous cell
carcinoma [22]. By contrast, STAT3 was not directly bound on PD-L1 gene promoter in melanoma
cells [23]. In this study, it was confirmed that STAT3 can regulate PD-L1 expression in vitro.
STAT3 signaling contributes as well to a dynamic crosstalk between tumor cells and immune
cells, including macrophages, CD8+ T-cells, myeloid-derived suppressor cells, T-regs and NK cells [24].
In this study, it was demonstrated that Stat3 gene silencing in 4T1 mouse cell line not only led to
tumor growth restriction but also altered the immunologic profile in vivo. Importantly, a prominent
anti-tumoral macrophage phenotype was denoted in shStat3 tumors compared to shCTR. Decreased
lung metastases were also observed in those tumors, further underscoring the role of skewing
macrophage polarization in metastatic potential [25]. Similarly to our experiments, depletion of Stat3
in epithelial cells of transgenic PyMT-MMTV mice resulted in decreased tumor growth and metastatic
potential, and macrophage accumulation in Stat3-deficient mice [26]. However, in our experimental
setting we could also show that TAMs had acquired an “M1”-like anti-tumoral phenotype that was
correlated to accumulation of activated NK cells. Surprisingly, we also observed an accumulation
of immunosupressive T-regs and less cytotoxic CD8+ T-cells in shStat3 tumors. This effect on T-cell
activation could potentially be explained by the fact that PD-L1 is not only expressed on tumor cells,
but also on immune cells—including macrophages. Indeed, approximately 50 % of TAMs express
PD-L1 (data not shown) independent of Stat3 expression in the 4T1 mammary tumor model system, but
it is still unclear how this can influence the anti-tumor immunity. The expression of other co-inhibitory
markers, transcriptional or post-transcriptional factors may also contribute to this restrained immune
response. Increased PD-1 expression in TAMs was associated with impaired antitumor immune
response in colorectal cancer patients [27], while in another study, PD-L1 expression in macrophages
hindered their proliferation and activation [28]. On the other side, activated NK cells were elevated in
shStat3 tumors, indicating an anti-tumor immune activity, most likely responsible for the moderate
effect on tumor growth. Of importance, the skewing of TAMs towards an anti-tumoral phenotype may
instead dictate the metastatic dissemination, as these macrophages have previously been shown to
hamper tumor cell extravasation into the blood vessels and form secondary tumors [25,29].
At the patient level, correlations between pSTAT3 and PD-L1 both at the mRNA and protein
level were explored and demonstrated in a large breast cancer cohort. Of note, in a subset of
patients PD-L1 expression in tumor cells was significantly associated with “M2”-like macrophage
phenotype (driven by the expression of CD163) while both PD-L1 and “M2”-like macrophages were
associated with higher Ki67 expression and tumor grade. Although it has long been described that
TAM accumulation is correlated with tumor progression and a worse prognosis [30], recent reports
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featured their interaction with immune checkpoints in tumor cells and in TME components [31].
Specifically, the two distinct macrophage phenotypes, the anti-tumoral “M1”-like and the pro-tumoral
“M2”-like can secrete cytokines and other factors, which in turn affect PD-L1 expression and anti-tumor
immune response [32,33] and only few recent studies have shown correlation of PD-L1 levels in tumor
cells with macrophages phenotypes. In a study of gastric adenocarcinoma “M2”-like macrophage
infiltration was correlated with PD-L1 expression [34] while in a mouse model, anti-PD-1 therapy led
to macrophage reprogramming from “M2”-like to “M1”-like phenotype and to a subsequent regression
of osteosarcoma lung metastases [35].
The findings of this study have potential clinical implications. First, therapeutic strategies
involving STAT3 inhibition could enhance the efficacy of anti-PD-L1/PD-1 monoclonal antibodies,
which recently proved efficacy in patients with metastatic triple negative breast cancer [7]. The
STAT3 SH2 domain binder inhibitor C188-9 inhibitor is currently tested in an ongoing phase I trial
(NCT03195699) in patients with advanced-stage cancers, including breast cancer. Previous research
findings indicated that combined targeting of IL-6/JAK/STAT pathway and PD-L1 resulted in restricted
tumor growth in in vivo models [36,37], while in others, STAT3 targeting increased the efficacy
of anti-PD1 mAb [38]. Currently, a phase II trial testing the combination of a pSTAT3 inhibitor
(napabucasin) with the anti-PD-1 antibody nivolumab in microsatellite stable, refractory colorectal
cancer (NCT03647839) is ongoing. Moreover, immune checkpoint blockade could be combined with
agents (e.g., CSF-1 inhibitors) that can inhibit TAMs accumulation and/or re-programme macrophages
towards a more anti-tumoral M1-like phenotype in selected breast cancer patients. Indeed, such
therapeutic combinations are currently under investigation in clinical trials [31,39]. Nevertheless, the
recognition of such immunosuppressive expression patterns may pave the way for the development of
biomarkers and patient stratification. Hence, subgroups of patients who may gain the most benefit of
conventional, targeted and/or immune therapy can be identified towards a more personalized cancer
treatment approach, yet the importance of these findings still need to be prospectively investigated in
breast cancer patients.
4. Materials and Methods
4.1. Cell Lines, Plasmids, and Reagents
The cell lines used in this study, along with their characteristics, are listed in Table S1. The
human breast cancer cell lines BT549 and SKBR3, mouse mammary carcinoma cell line 4T1, as
well as the control anaplastic large cell lymphoma (Mac2A) and Hodgkin lymphoma (HDLM2) cell
lines were grown in complete RPMI-1640 medium (Gibco/Life Technologies, Waltham, MA, USA)
supplemented with 10% fetal bovine serum (FBS) (Gibco/Life Technologies, Waltham, MA, USA), 1%
L-glutamine (Gibco/Life Technologies, Waltham, MA, USA) and 1% penicillin/streptomycin (Gibco/Life
Technologies, Waltham, MA, USA). The breast cancer cell lines MCF7 and MDA-MB-231 were grown
in complete DMEM medium (Gibco/Life Technologies, Waltham, MA, USA) supplemented with 10%
FBS, 1% L-glutamine, and 1% penicillin/streptomycin. Cells were cultured at 37 ◦C in 5% CO2. Vector
control and STAT3C-transfected SKBR3 cells were obtained from Sarah Walker and David Frank,
Department of Medical Oncology, Dana-Farber Cancer Institute, and Department of Medicine, Harvard
Medical School, Boston, MA, USA. Breast cancer cells were treated with STAT3 inhibitor C188-9/XIII
(Calbiochem, St. Louis, MO, USA) and with recombinant human IL-6 (PeproTech, Rocky Hill, NJ, USA)
at the indicated concentrations for 48 and 24 h respectively and whole cell lysates were prepared for
western blot analysis.
4.2. Western Blot Analysis
Tumor cells were collected, washed in cold phosphate-buffered saline (PBS) (GE Healthcare Life
Sciences, Chicago, IL, USA), lysed in lysis buffer and western blot analysis was performed as previously
described [40]. The antibodies used in the present study are listed in Table S2.
377
Cancers 2019, 11, 1479
4.3. RNA Extraction, cDNA Synthesis, and Real Time Quantitative Polymerase Chain Reaction (RT-qPCR)
Total RNA was extracted with the RNeasy® Plus Mini Kit (QIAGEN Inc., Hilden, Germany)
and cDNA was synthesized using the Superscript First Strand Synthesis System (Invitrogen Life
Technologies, Carlsbad, CA, USA) according to the manufacturer’s protocol. The mRNA expression
levels were quantified by RT-qPCR using the Power SYBR® Green PCR Master Mix (Applied Biosystems
by Thermo Fisher Scientific, Waltham, MA, USA) in a one-step reaction and the mRNA expression levels
were determined by the comparative CT (ΔΔCt) method. 18S rRNA and beta-actin were used as the
endogenous control genes as indicated. The primer sequences used are listed in Table S3. The RT-qPCR
program included Amplitaq Gold DNA polymerase activation at 95 ◦C (10 min) followed by 40 cycles
of DNA denaturation (95 ◦C for 15 sec) and annealing/extension (60 ◦C for 30 sec). All reactions were
performed using a Veriti 96-well thermal cycler (Applied Biosystems by Thermo Fisher Scientific,
Waltham, MA, USA).
4.4. Tissue Microarrays, Immunohistochemical Methods and Scoring
Tissue microarrays (TMAs) were constructed using duplicate tumor cores from primary tumors
and an automated tissue microarrayer (VTA-100, Veridiam, San Diego, CA, USA). Tissue sections
from the TMAs were used for PD-L1 immunohistochemistry (IHC) using the Ventana autostainer
system according to manufacturer’s protocols. Positivity was defined by the presence of any single cell
with membranous expression of PD-L1 either in tumor or in immune cells (total cells). In addition,
whole tissue sections (4 μm) were prepared for a subset of patients in this cohort based on the
expression of PD-L1 in tumor cells (positive and randomly selected negative cases) and stained using
an anti-phosphorylated STAT3 (pSTAT3) antibody (Y705). At least 300 tumor cells were counted
in five different high power fields in order to calculate the percentage of pSTAT3 positive cells.
The median percentage of expression was used as a cut-off for dividing patient tumors in pSTAT3-high
and pSTAT3-low expressing ones. Furthermore, cell pellets from cell lines were collected, fixed in
formalin and embedded in paraffin to prepare cell blocks. Subsequently, IHC was performed using
anti-pSTAT3 and anti-PD-L1 antibodies, as previously described [41]. The antibodies used are listed in
Table S2. Moreover, Ki67 immunohistochemical staining and evaluation method have been previously
described [42].
4.5. Fluorescence in Situ Hybridization
The PDL1 gene locus was analyzed on formalin-fixed paraffin-embedded (FFPE) cell pellets by
Fluorescence in situ hybridization using the probe and protocols recommended by the manufacturer
(ZytoVision GmbH, Bremerhaven, Germany).
4.6. Transient Transfections and Gene Silencing
Cells were seeded at a density of 0.2–0.6 × 106 cells/ml 24 h before transfection. Silencing of
breast cancer cell line BT549 with siRNA oligonucleotides specific for the gene sequence of STAT3
was carried out with Lipofectamine 2000 (Thermofisher, Waltham, MA, USA) reagent according to
the company’s protocol. Approximately 3 × 106 cells were transfected with 300 nM specific siRNA or
Control siRNA (All Stars Negative, QIAGEN, Hilden, Germany). Whole-cell lysates were prepared
48 h after transfection. The siRNA oligonucleotides or plasmids with which cells were transfected are
listed in Table S3.
4.7. Proliferation Assay
Mouse 4T1-shCTR and 4T1-shStat3 tumor cells were seeded at a density of 4 × 103 cells per well
containing 100 uL in 96-well plates with complete RPMI-1640 medium for three days. For each cell
line and each time point (0, 24, 48 and 72 h) six replicates were used. A mixture of XTT labeling with
electron-coupling reagents was then made according to manufacturer’s protocol (Cell Proliferation Kit
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II (XTT), Roche, Basel, Switzerland). For each time point, measurement of cell viability was performed
via microplate reader at a wavelength of 490 nm (reference wavelength: 650 nm).
4.8. Lentiviral Vectors
Tumor cells (4T1) were transduced with lentiviral vectors encoding shRNA for murine Stat3 or
corresponding control vector (listed in Table S3) as previously described [43].
4.9. 4T1 Breast Cancer Animal Model and Tumor Growth Assessment
For the in vivo tumor model, 2 × 105 4T1 cells (shCTR and shStat3) in a volume of 50 mL PBS
were injected into the mammary fat pad of anesthetized four to six week-old female BALB/c mice,
purchased from Charles River Laboratory. Mice were sacrificed three weeks after tumor cell injection,
and tumors were weighed after dissection. Tumor size was measured externally using calipers, and
tumor volumes were estimated using the following equation: V = 4/3π × (d/2)2 × D/2, where d is the
minor tumor axis and D is the major tumor axis. All ethical permits were obtained from the Swedish
Board of Agriculture (N95/15).
4.10. Tumor Dissociation
Tumors were cut into smaller pieces using scalpels. Dissected tumors were minced in dissociation
buffer (TrypLe and Stem Cell Pro Accutase (Life Technologies, Waltham, MA, USA); 1:1) and incubated
at 37 ◦C for 30 mins in order single-cell suspensions to be obtained. Thereafter, suspensions were passed
through a 19 G syringe needle, filtered and washed in PBS (10% FBS) to be used for flow cytometry.
4.11. Flow Cytometry
To prevent antibody nonspecific binding, single-cell suspensions of tumors were pre-incubated
with anti-CD16/32 mAb (BioLegend, San Diego, CA, USA) on ice for 15 minutes before a 30-minute
incubation on ice with specific antibodies. Cells were stained using antibodies for extracellular
markers. T-regulatory (FoxP3+) cells were stained as well according to manufacturer’s instruction
(BD Biosciences, San Jose, CA, USA). The viability of cells was verified using 7AAD or the Live/Dead
fixable dead cell stain (Life Technologies, Waltham, MA, USA). Samples were acquired with a LSR
II (BD Biosciences, San Jose, CA, USA) and analyzed using FlowJo software (Tree Star, Ashland, OR,
USA) [15]. All antibodies used are listed in Table S2 and gating strategies are depicted in Supplementary
Figures S5 and S6.
4.12. Lung Metastasis Colony Assay
Lungs from tumor-bearing mice were dissociated to single cells in an enzymatic buffer containing
RPMI (Gibco/Life technologies, Waltham, MA, USA) 5% FBS (Gibco/Life technologies, Waltham,
MA, USA) 0.2 mg/mL collagenase IV (Life technologies, Waltham, MA, USA) 0.2 mg/mL dispase
(Life technologies, Waltham, MA, USA) and 0.1 mg/mL DNAse I (Sigma-Aldrich, St. Louis, MO, USA)
as previously described [44,45]. Cell suspensions were plated in the presence of 60 uM 6-thioguanine
(Sigma-Aldrich, St. Louis, MO, USA). Tumor cells resistant to 6-thioguanine were allowed to form
colonies for approximately 10 days and then fixed with methanol, stained with crystal violet, and
counted under a dissection microscope.
4.13. Immunofluorescence for Macrophage Markers in Human Breast Tumors
Paraffin-embedded breast cancer patient samples were cut in 4 μm thick whole-tissue sections
and treated for antigen retrieval with sodium citrate buffer (Biocare Medical). All tumor sections
were blocked in blocking buffer containing PBS (Sigma, St. Louis, MO, USA), 0.3% Triton X-100
(Sigma), 10 % fetal bovine serum (Gibco, Waltham, MA, USA) and 1% Bovine Serum Albumin (Sigma)
and immunostained with the appropriate antibodies: anti-CD163 (Leica, Wetzlar, Germany) and
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anti-CD11c (Leica) and all secondary antibodies were conjugated with AlexaFluor 488 or AlexaFluor
546 fluorochromes (Life Technologies, Waltham, MA, USA). Cell nuclei were labeled with DAPI
(Invitrogen Corp., Carlsbad, CA, USA). Isotype specific antibodies were used to ensure specificity of
the antibodies. All antibodies used are listed in Table S2. Eight independent fields from each tumor
section were analyzed by using LSM T-PMT Zeiss confocal microscope and quantified by ImageJ
software (NIH, Bethesda, MD, USA).
4.14. Patient Cohorts
The patient cohort used in the study consists of women diagnosed with primary breast cancer
between 1997 and 2005 in Stockholm health care region who were retrospectively selected using the
Stockholm-Gotland Breast Cancer Registry. Data on clinical and pathological tumor characteristics,
survival, loco-regional and systemic treatments, and follow-up have been collected and reported
elsewhere [42]. The Cancer Genome Atlas (TCGA) provisional dataset [46], including 1081 patients
with primary breast cancer, was used as a validation cohort. Available RNA-sequencing data were
retrieved from cBioportal [47,48].
4.15. Gene Expression Profiling Using Microarrays
Gene expression profiling has been performed from all primary tumors in the cohort. Details
regarding experimental methods have been previously described [42] and the gene expression
microarray data can be accessed at the Gene Expression Omnibus database under accession number
GSE48091. All ethical permits were obtained from Karolinska Institutet’s (Stockholm, Sweden) ethics
committee (Dnr 2006/1183-31/2, 2016/1505-32). According to the ethics board, no additional informed
consent from the patients was required for these analyses.
4.16. Preprocessing and Normalization of the Microarray Gene Expression Data
The preprocessing and normalization of the microarray gene expression data were performed
within R computing environment. Specifically, the raw data were background corrected, normalized
and summarized to obtain a log-transformed expression value for each probe set using the RMA
method [49] implemented in the aroma.affymetrix R package [50]. A nonspecific filter was employed
and probe sets with the highest interquartile range were kept in the case of multiple mappings to the
same Entrez Gene ID.
4.17. Phosphorylated STAT3-Associated Gene Signature
The phosphorylated STAT3-associated gene signature (pSTAT3-GS) was applied to the patient
cohort as described in the original publication [51]. Specifically, the provided pSTAT3-GS’s gene
symbols were converted to Entrez Gene IDs using DAVID’s Gene ID Conversion Tool [52] (DAVID
Bioinformatics Resources version 6.8), and mapped to the microarray’s probe sets. The (continuous)
pSTAT3-GS scores, i.e., signed averages, were computed using the “sig.score” function from the genefu
R package [53] (R package version 2.14.0). In total, 114 (out of the 123) pSTAT3-GS’s genes were
mapped and therefore used in the signature scores’ calculation. For the TCGA dataset, in total 122
genes of the pSTAT3-GS were mapped.
4.18. Statistical Analyses
Statistical analyses and graphical representations regarding the in vitro and in vivo models were
performed using GraphPad Prism software version 7.0 (GraphPad Software Inc., San Diego, CA, USA)
while analyses concerning patient material were performed within R computing environment version
3.5.1. Wilcoxon–Mann–Whitney test, Student’s t-test and two-way ANOVA were used as indicated.
Spearman’s rank correlation coefficient was used to evaluate the associations between continuous
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variables and Fisher’s exact test for the associations between categorical variables. A p-value equal to
or less than 0.05 was considered as statistically significant.
5. Conclusions
In this study, STAT3-mediated regulation of PD-L1 and modulation of immune microenvironment
were shown in breast cancer. More research is warranted towards the further characterization of TME
interactions and anti-tumor immunity, thus providing breast cancer patients better therapeutic options
and prognostication factors.
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Abstract: Glioblastoma (GBM), WHO grade IV, is the most aggressive primary brain tumor in
adults. The median survival time using standard therapy is only 12–15 months with a 5-year
survival rate of around 5%. Thus, new and effective treatment modalities are of significant
importance. Signal transducer and activator of transcription 3 (Stat3) is a key signaling protein
driving major hallmarks of cancer and represents a promising target for the development of targeted
glioblastoma therapies. Here we present data showing that the therapeutic application of siRNAs,
formulated in nanoscale lipopolyplexes (LPP) based on polyethylenimine (PEI) and the phospholipid
1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), represents a promising new approach to target
Stat3 in glioma. We demonstrate that the LPP-mediated delivery of siRNA mediates efficient
knockdown of Stat3, suppresses Stat3 activity and limits cell growth in murine (Tu2449) and
human (U87, Mz18) glioma cells in vitro. In a therapeutic setting, intracranial application of the
siRNA-containing LPP leads to knockdown of STAT3 target gene expression, decreased tumor
growth and significantly prolonged survival in Tu2449 glioma-bearing mice compared to negative
control-treated animals. This is a proof-of-concept study introducing PEI-based lipopolyplexes as an
efficient strategy for therapeutically targeting oncoproteins with otherwise limited druggability.
Keywords: STAT3; siRNA/RNAi; polyethylenimine; PEI; lipopolyplex; siRNA delivery; glioma;
glioblastoma
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1. Introduction
Glioblastoma (grade IV glioma, WHO) is the most aggressive primary brain tumor in adults,
with a median survival of ~15 months following standard radiochemotherapy with temozolomide
(TMZ) and a 5-year survival rate below 5% [1]. Due to diffusely infiltrating tumor cells that cannot be
surgically resected, most tumors will quickly recur and afflict the patients with even more aggressive
disease [2]. GBM are further subdivided into distinct subtypes based on their genetic profile. Different
groups reported different subtypes, but it is generally agreed that a proneural subtype with the best
prognosis and a mesenchymal subtype with the worst prognosis exist [3,4]. Another subtype is the
classical one [4], which is sometimes subdivided into a proneural and a neural subtype [3]. One key
molecule that is frequently highly expressed and overactivated in GBM and associated with the
most aggressive and treatment-resistant mesenchymal subtype [5,6] is the oncogenic transcription
factor signal transducer and activator of transcription 3 (Stat3) that acts as a signaling hub promoting
most hallmarks of cancer, including proliferation, cell survival, angiogenesis and immune evasion
(reviewed in [7,8]). STAT3 activation is facilitated by phosphorylation of multiple upstream kinases [9].
Stat3 can be phosphorylated on two different sites (reviewed in [10]), Tyrosine705 (pY705Stat3) and
Serine727 (pS727Stat3), which can exert different functions in different cell types. In glioma it was
shown that S727-phosphorylation is dependent on Y705-phoshorylation, that is necessary for maximal
activation of Stat3 [11]. Activated Stat3 dimerizes and induces gene expression of a variety of genes,
many of which are known to be important for hallmarks of cancers like migration/invasion (Mmp2,
Mmp9; [12,13]) or EMT-like features and immune evasion/suppression (e.g., Snai1; [14,15]). Stat3
is activated in many other human cancers (reviewed in [16]) in addition to gliomas. In particular
Stat3 expression increases with tumor grade in these tumors (Figure S1 and reviewed in [9,17]), and is
negatively correlated with patient survival (reviewed in [9,17]). Additionally, Stat3 is known to be
necessary for activation of microglia [18], the macrophage-like population of immune cells residing in
the brain. In glioma, these cells usually acquire a pro-tumorigenic phenotype that promotes glioma
cell migration and invasion [18].
Consequently, we and others previously demonstrated that targeting Stat3 by upstream signaling
inhibitors of the Stat3 pathway decreases glioma cell proliferation and migration in vitro and prolongs
overall survival of tumor-bearing mice in vivo [19–24].
One strategy to target aberrantly activated and/or overexpressed oncoproteins in tumor therapy
is to ablate their expression by RNA interference (RNAi). This knockdown strategy relies on small
interfering RNA (siRNA) that, due to high sequence specificity, generally exhibits fewer off-target
effects in comparison to the application of pharmacological agents (reviewed in [25,26]). The second
major advantage of RNAi is that it allows to selectively interfere with the activity of otherwise
un-druggable or hard-to-drug targets like Stat3 and other oncogenic transcription factors. Using a
pre-transplantational genetic knockdown approach, we could previously demonstrate that ablation
of Stat3 function with lentiviral shRNA limits tumor growth of Tu2449 gliomas in an orthotopic,
syngeneic mouse model [21], providing support for the concept of therapeutic intervention with
Stat3 activity in vivo. Therapeutic intervention in already established glioma, however, requires the
development of siRNA formulations for their direct application. We have previously established
siRNA complexation with nanoscale polyethlyenimine (PEI)-based complexes for therapeutic siRNA
delivery in vivo. This confers protection, cellular delivery and intracellular release of formulated
small RNA molecules (siRNAs, miRNAs) in vitro and in vivo, and thus allows for their therapeutic
application ([27–30]; see [31] for review). More recently, this was extended towards combinations with
liposomes, leading to lipopolyplexes (LPP) that combine properties of both components [32].
For gene delivery, LPP comprising phospholipids had been previously shown to display strongly
reduced surface charges, enhanced transfection efficiencies, decreased cytotoxicity and high colloidal
stability as compared to their unmodified complex counterparts [33,34]. Likewise, we were able
to demonstrate for siRNA delivery that DPPC-based LPP without co-lipids displayed very good
transfection efficiency and further enhanced biocompatibility in cell culture. Intracellular siRNA
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release was not impaired by the liposomal component. Due to strongly reduced surface charges,
storage stabilities under various conditions were markedly increased by protecting the LPP from
aggregation [35]. Importantly, these favorable properties also translated into therapeutic in vivo
efficacy upon systemic injection into tumor xenograft-bearing mice [32], thus providing the basis for
now switching to another model and another mode of administration.
Here we investigated the therapeutic potential of intracranially applied LPP containing
Stat3-specific siRNA in an orthotopic Tu2449 glioma model. We demonstrate that specific
targeting of Stat3 using LPP significantly reduces tumor growth and improves overall survival.
This proof-of-concept study thus supports the notion that highly therapy-resistant cancers such
as malignant gliomas and hard-to-drug genes like Stat3 can be efficiently targeted using siRNA in vivo.
2. Results
2.1. LPP Nanoparticles Provide a Stable and Efficient siRNA Formulation
As shown previously, the complexation of siRNAs with the ~4–10 kDa low molecular weight
polyethylenimine PEI F25-LMW [36] leads to the formation of positively charged nanoscale complexes
(‘polyplexes’) in a size range of ~100–350 nm, dependent on the buffer conditions used for
complexation [27]. This was confirmed here by NanoSight measurements, yielding PEI/siRNA
complexes of ~130 nm diameter with a zeta potential of 27 mV (Figure 1a,c). The combination of
these polyplexes with DPPC liposomes of about the same size (Figure 1a,b) resulted in the formation
of slightly larger lipopolyplexes (Figure 1a,b,d; [37,38]). The liposomal contribution also affected
the zeta potential of the LPP, which was almost neutral as opposed to the polyplexes (Figure 1a).
Size determinations by NanoSight measurements were confirmed by dynamic light scattering (DLS)
which, however, also indicated the tendency of PEI/siRNA complexes to aggregate, leading to larger
particle sizes (Figure 1a, Supplementary Figure S2). Notably, this was inhibited by lipopolyplex (LPP)
formation (Figure 1a; note PEI/siRNA complex size in DLS measurements). The colloidal stability of
LPP provides an advantage over polyplexes and prompted us to prefer LPP for intracranial siRNA
delivery. In an LDH release assay in Tu2449 cells, the LPP showed excellent biocompatibility in vitro
(Figure 1e). The absence of appreciable cell damage upon transfection suggests the applicability of LPP
also in a sensitive environment in vivo (CNS), and similar results in the case of the parent polyplexes
also indicates that even an LPP decomposition with possible polyplex release would not lead to
toxic effects. Since highly positive surface charges of nanoparticles may lead to enhanced cellular
uptake, we tested next whether the considerably reduced zeta potentials of LPP would negatively
affect biological efficacies. Notably, upon transfection of stable EGFP (Figure 1f) or luciferase (Luc3)
reporter cell lines (Figure 1g) with siRNAs formulated in polyplexes or in LPP, no differences were
observed. More specifically, the comparison of cells transfected with negative control siRNA (siLuc2)
vs specific siRNA (siEGFP or siLuc3, respectively) revealed a profound 50–65% knockdown after 72 h,
indicating biological efficacy of both, polyplexes and LPP. For the reasons stated above, LPP were
selected for further studies.
387
Cancers 2019, 11, 333
Figure 1. (a) Compilation of nanoparticle sizes and zeta potentials, as determined by Zetasizer and
Nanosight. (b–d) Original diagrams of size measurements by Nanosight. (e–g) Biological properties
of nanoparticles. (e) Determination of cytotoxicity by LDH release assay. (f,g) Determination of
knockdown efficacies in EGFP/Luciferase (Luc3) Tu2449 reporter cells. Knockdown of (f) EGFP and
(g) luciferase (Luc3) is shown. For (a–d) two independent samples were measured 10 times; (e) was
performed twice in 4 biological replicates and (f,g) were performed twice in biological duplicate; shown
are the summaries of all experiments.
2.2. Targeting STAT3 Reduces Cancer Cell Proliferation In Vitro
To test the therapeutic potential of LPP-formulated siRNA in vitro and in vivo, we selected
Stat3 as a target because it is frequently overactivated in glioma and also hard-to-drug. Consistent
with a number of previous reports, analysis of the TCGA data-set indicated that high expression of
STAT3 is associated with an especially poor survival of GBM patients (Figure 2a). To validate these
clinical observations in vitro, we knocked down STAT3 in two human GBM cell lines, U87 (Figure 2b)
and Mz18 (Figure 2c). Using two different siRNAs we could significantly reduce STAT3 mRNA
expression in both cell lines, with siSTAT3-2 being more effective than siSTAT3-1. Consistently,
STAT3 suppression was also achieved on the protein level in both cell lines (Figure 2d). Notably,
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we frequently observed a second band below the STAT3 signal in U87, but since both siRNAs target
all three protein coding sequences of STAT3 (NM_213662.1, NM_003150.3 and NM_139276.2) this
is likely an unspecific signal. To assess the antitumor effects of STAT3 depletion, we evaluated the
growth kinetics of U87 (Figure 2e) and Mz18 cells (Figure 2f) after siSTAT3 treatment. Both cell lines
showed significantly reduced proliferation 192 h after siSTAT3-treatment, with siSTAT3-2 again being
more effective than siSTAT3-1. Of note, U87 cells were more sensitive to STAT3 depletion than Mz18
cells, indicating that this line may be particularly addicted to STAT3 activity, in line with findings
described earlier [39]. Mz18 cells also express STAT3 and we could previously show that this line
exhibits moderate levels of tyrosine-phosphorylated STAT3, which could be inhibited by upstream
JAK2-inhibition [22]. We also tested the murine GBM cell line Tu2449, which we previously had
used for in vivo experiments with pre-transplantational depletion of Stat3 with shRNA [21]. First,
we sought out to test if siRNA-mediated Stat3-knockdown also inhibits proliferation and indeed we
observed that siRNA delivery using conventional in vitro reagents like INTERFERinTM also achieved
a reduction in proliferation (Figure 2g). Next, we applied siRNA complexed as polyplexes, in order
to verify that the delivery method does not affect knockdown efficiency. Accordingly, LPP mediated
siStat3 delivery strongly inhibited proliferation (Figure 2h) and was able to efficiently reduce Stat3
and phospho-Stat3 protein levels (Figure 2i), whereas polyplexes without liposomal content were
accompanied by increased nonspecific toxicities although a knockdown could also be achieved (data
not shown). Thus, in these experiments LPP were found to be superior over polyplexes.
Cell cycle analysis of Tu2449 cells showed a significant increase in G1 phase and concomitant
decrease in G2 phase upon siStat3 transfection, suggesting that the observed antiproliferative effect is
at least in part due to a G1 arrest upon Stat3 knockdown (Figure 3a). Decreased cell cycle progression
was also confirmed in the human cell lines U87 and Mz18 (Supplementary Figure S3a,b). To further
verify the dependency of Tu2449 cells on Stat3 in a more complex cell culture system, we generated
Tu2449 tumor spheroids, which resemble an in vivo situation more closely with regard to gradient
access to oxygen, nutrients, as well as therapeutics. siRNA-mediated knockdown of Stat3 lead to
distinctly smaller spheroids than control treatment (Figure 3b,c), also demonstrating that LPP are
efficient in transfecting cells in spheroids.
Figure 2. Cont.
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Figure 2. (a) Kaplan-Meier-Survival Plot from TCGA dataset GBM [40] showing that high STAT3
expression is associated with shorter survival; (b,c) qRT-PCR from (b) U87 and (c) Mz18 human glioma
cell lines after transfection with control siRNA (siCtrl) or two siRNAs against STAT3 (siSTAT3-1 and
siSTAT3-2). STAT3-expression was normalized to Actin as housekeeper and siCtrl-transfected cells
as control sample using the ΔΔCt-method. The data are presented as box-plots (min-to-max) with all
samples displayed as circles; the horizontal line in the box depicts the median value, the plus-symbol
the mean. (d) Western Blot of U87 and Mz18 after transfection as in (b,c) after transfection of
siCtrl, siSTAT3-1 or siSTAT3-2. (e–h) Proliferation (WST-1) assays of the human glioma cell lines
(e) U87 and (f) Mz18, using INTERFERin and the two different siSTAT3 for comparison, and in the
murine glioma cell line Tu2449 after transfection with (g) INTERFERinTM or (h) LPP. The data in
(e–g) are presented as mean +/− SEM; the data in (h) are presented as Box-Plots (min-to-max) with all
samples displayed. (i) Western Blot of Tu2449 cells 96 h after transfection with 150 pmol LPP siCtrl
or LPP siStat3. (b,c) shows the summary of at least three independent experiments performed in
biological duplicates; (d) was performed twice; (e,f,h) were performed three (g) two times in biological
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Figure 3. (a) Cell cycle analysis of Tu2449 cells after transfection of siCtrl or siStat3. A significant
increase in the percentage of cells in the G1 phase suggests antiproliferative properties of Stat3-depletion.
(b,c) Sphere growth assay of Tu2449 after transfection of siCtrl or siStat3. Three representative spheres
for each condition are presented in (b) the quantification after 10 days of sphere growth is shown. Scale
bar: 500 μm. (c) as box-plots (min-to-max) with all samples displayed as circles; the horizontal line
in the box depicts the median value, the plus-symbol the mean. *: p < 0.0.05; **: p < 0.01 and ****:
p < 0.0001 compared to siCtrl treatment. A representative experiment of at least three independent
repetitions is shown.
In conclusion, we could successfully establish siRNA-mediated STAT3/Stat3 depletion and
suppression of tumor cell proliferation by LPP siSTAT3 in vitro and verify Tu2449 as suitable cell line
to explore a Stat3 targeting therapy.
2.3. LPP siStat3 Prolongs Overall Survival and Reduces Tumor Size in Glioma-Bearing Mice
Based on these findings, we pushed our system further towards therapeutic intervention, using a
complex and pathophysiological relevant system. To this end, we employed our syngenic, orthotopic
transplantation model [41] to assess LPP applicability and efficacy in vivo. The treatment scheme is
outlined in Figure 4a. Briefly, after implantation of 10,000 Tu2449 cells into the striatum of 42 mice,
the tumors were allowed to grow for one week. Hereafter, the mice were randomly divided in
two groups of 21 animals each and the intracranial (i.e., intratumoral) treatment with LPPs was
performed every third day. After three weeks of tumor growth, 8 mice were sacrificed for histological
and molecular analyses. 1 tumor in the LPP siCtrl and LPP siStat3 cohort planned for histological
assessment did not grow and were removed from the analysis. The remaining mice were monitored
until they succumbed to the disease. Of those, 2 and 4 tumors of the LPP siCtrl and LPP siStat3 cohort
did not grow well, respectively, and these animals were also removed from the analysis. The survival
analysis (Figure 4b) showed that after LPP siStat3 none of the mice died during the treatment period,
whereas six mice treated with LPP siCtrl had to be euthanized. The median survival was significantly
improved after treatment with LPP siStat3 in comparison to LPP siCtrl from 26 to 33 days, respectively.
Histological analyses (Figure 4c,d) confirmed that the tumors of mice treated with LPP siStat3 were
significantly smaller compared to LPP siCtrl treated mice.
2.4. LPP siStat3 Slightly Reduces Stat3 Activation, But Does Not Affect Gross Tumor Proliferation Rates
In Vivo
Next, we analyzed LPP siStat3 effects on the cellular and molecular level in vivo.
When performing analyses of randomly chosen tumor areas (excluding the tumor border and necrotic
areas), we found phospho-Stat3 (Tyr705) slightly reduced (Figure 5b). This, however, was not
accompanied by alterations in proliferation rates, as determined by Ki67 staining for proliferating
cells (Figure 5a). Decreased phospho-Stat3 levels were also confirmed in western blot analyses of
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whole tumor lysates (Figure 5c, upper panel), while Stat3 protein levels remained stable. Since Stat3
was proposed to modulate the host immune response including activation of microglia [18], we also
analyzed the presence of T-cells and microglia in the tumor. Staining against CD4 and CD8a for T-cells
and Iba1 for microglia showed a slight reduction of CD4-positive cells after LPP siStat3 treatment
(Figure 6a) while no major differences between LPP siCtrl and LPP siStat3 treated animals were seen
with regard to Cd8a and Iba1 (Figure 6b,c).
Figure 4. (a) Schematic presentation of the in vivo experiments. Briefly, 42 mice were injected with
10,000 Tu2449 cells into the right striatum. After 7 days the mice were randomly divided into two groups
of 21 animals each and intracranial treatment was performed every third day. After 21 days 10 mice were
euthanized for histological and molecular analysis. The remaining mice were monitored for long-term
survival. Mice without established tumors were excluded from the analysis (3 (1 for histology; 2 for
survival) for LPP siCtrl; 5 (1 for histology; 4 for survival) for LPP siStat3) (b) Kaplan-Meier-Survival Plot
of B6C3F1 mice after implantation of Tu2449 and treatment with LPP siCtrl or LPP siStat3. The vertical
dotted lines depict the treatment days, the vertical dashed line the day of sample collection. LPP siStat3
treatment significantly increases median survival from 26 days to 33 after LPP siCtrl and LPP siStat3
treatment respectively (c) Three representative brain sections with tumors 21 days after tumor cell
implantation and treatment with LPP siCtrl (left side) or LPP siStat3 (right side); scale bar: 2 mm.
(d) Box-Plots (min-to-max) with all samples displayed as circles; the horizontal line in the box depicts
the median value, the plus-symbol the mean of tumor areas 21 days after tumor cell implantation after
treatment with LPP siCtrl or LPP siStat3. *: p < 0.05; **: p < 0.01 compared to LPP siCtrl.
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Figure 5. (a,b) Immunohistochemical analysis of (a) Ki67 and (b) tyrosine-phosphorylated Stat3
(pStat3) expressing tumor cells 21 days after implantation and treatment with LPP siCtrl and LPP
siStat3. One representative picture is shown for each staining and treatment and the quantification
is presented as box-plots (min-to-max) with all samples displayed as circles; the horizontal line in
the box depicts the median value, the plus-symbol the mean of tumor areas 21 days after tumor cell
implantation after treatment with LPP siCtrl or LPP siStat3. Scale bar: 200 μm. (c) Western Blot of
whole-tumor lysates from two mice each after treatment with LPP siCtrl or LPP siStat3; Gapdh was
used as the loading control.
Figure 6. Cont.
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Figure 6. (a–c) Immunohistochemical analysis of (a) CD4, (b) CD8a and (c) Iba1 expressing tumor
cells 21 days after implantation and treatment with LPP siCtrl and LPP siStat3. One representative
picture is shown for each staining and treatment and the quantification is presented as box-plots
(min-to-max) with all samples displayed as circles; the horizontal line in the box depicts the median
value, the plus-symbol the mean value. scale bar: 200 μm.
2.5. LPP siStat3 Reduces Stat3 Expression in the Core Region of the Tumor
The fact that we observed significantly improved survival and reduced tumor sizes following
treatment with LPP/siStat3, but could not observe a significant Stat3-repression in whole tumor
samples led us to hypothesize that Stat3 depletion might be locally restricted to the area surrounding
the injection site. To further investigate this hypothesis, we performed laser-capture microdissection to
excise the central area of the tumor (Figure 7a) that equals the site of LPP injection. In case a sample
showed necrotic areas in this region, these were first excised and discarded. Next, we isolated RNA
from excised tumor core regions and performed qRT-PCR. We used 6 samples per cohort for the
analyses, and obtained quantifiable data from 4 samples for Stat3 and the housekeeping gene Tbp,
but only 3 for the additional housekeeping Hprt (Figure 7b). These analyses showed that mRNA
expression of Stat3 and the known Stat3 target gene Mmp9 was significantly decreased following LPP
siStat3 treatment. Additionally, Snai1 showed a tendency for reduced expression. The expression of
Mmp2 remained unchanged. Due to the small sample sizes, this can be interpreted as a trend towards
expressional suppression.
These results support our previously proposed hypothesis that LPP siStat3 can specifically target
cancer cells to limit tumor growth in vivo. Despite the robust effects of LPP-formulated siStat3 on
tumor growth, our results also indicate that only a small fraction of tumor cells can be reached using
the current formulations and mode of application. These observations suggest that improvement of
the bioavailability may allow further enhancement of therapeutic efficacies of this approach in vivo.
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Figure 7. (a) Representative histology of tumor centers stained with H&E (left panel) and of unlabeled
sections before (middle panel, pre-LCM) and after (right panel, post-LCM) microdissection of the
central part of the tumor. Scale bar: 400 μm. (b) Taqman-based gene expression analysis normalized
using the housekeepers Hprt and Tbp depicted as box-plots (min-to-max) with all samples displayed
as circles; the horizontal line in the box depicts the median value, the plus-symbol the mean value.
*: p < 0.05 compared to LPP siCtrl.
3. Discussion
Even after decades of research GBM still remains an incurable disease with one of the most dismal
prognosis for cancer patients. The oncogenic transcription factor STAT3 represents a key signaling
hub regulating many tumor-related processes including proliferation, migration, apoptosis-resistance,
angiogenesis and immune evasion (reviewed in [12]). Furthermore, STAT3 expression is correlated
with the highly aggressive mesenchymal subtype of glioma that is particularly resistant to conventional
therapy [5,6] and is known to regulate stemness in glioma cells [6,23]. Previous findings from our
and other groups had demonstrated that upstream pharmacological inhibition [22,42–44] and stable
lentiviral depletion [17,21,23] of Stat3 provokes great antitumoral responses in vitro and improves
survival of tumor-bearing mice in vivo.
To further advance the concept of targeting STAT3 in GBM, we decided to use a gene therapeutic
approach aimed at interfering with STAT3 expression. To this end, we employed a novel approach by
using siRNAs formulated in lipopolyplexes [32,37,45] that was investigated for its effects on cultured
glioma cells and locally administered to syngeneic tumors of orthotopically transplanted mice that
faithfully mimic all the hallmarks of human gliomas including high mitotic activity, focal necrosis
surrounded by pseudopalisading cells and diffuse infiltration into the brain parenchyma [41]. Using
this approach we could show that LPPs loaded with Stat3-siRNA inhibit proliferation of glioma cells
in the absence of unspecific toxicity in vitro, significantly limit tumor growth in vivo and improve
the overall survival of glioma-bearing mice. Our results also show that these antitumor effects
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were not associated with detectable differences in the numbers of infiltrating T-cells and microglia,
suggesting that tumor cell-derived STAT3 represents the primary target of LPP-PEI-siRNA in vivo.
The analyses of microglia were of particular interest because it was proposed that STAT3 is required for
the activation of microglia [18,46] which usually acquire a pro-tumorigenic phenotype in glioma [18].
Since we did neither observe detectable differences in the number of microglia nor in their morphology,
we concluded that Stat3 siRNA had no major influence on these brain-resident immune cells if supplied
as LPP complexes, however.
Various approaches for siRNA delivery were also tested by other groups, e.g., by targeting
Beclin1 using intranasal delivery of PEIs [47], by targeting Survivin upon stereotactic injection [28],
by targeting Eg5 using siRNA delivered via an viral envelope [48], by using multifunctional surfactants
as packaging reagents to target Hif-1α [49] or by dual targeting of EGFR and Akt2 using peptides [50].
This exemplifies that specific targeting of a molecular vulnerability of cancers can be exploited
by various means. Accordingly, all these different approaches suffer, in principle, from the same
drawbacks. These are, limited tissue distribution, securing the release in the target cells and avoidance
of siRNA-degradation and/or capture by unintended cells (e.g., immune cells) or components of
the extracellular matrix. Another recent approach using a compound drug consisting of an aptamer
targeting PDGFbeta and an siRNA targeting Stat3 in glioma showed similar growth retardation in vitro
and in vivo [19], although this study only used subcutaneous xenografts for the in vivo experiments.
Interestingly, this study also indicated that a stable fraction of Stat3 protein remained present in the
tumor cells that cannot be depleted using their approach, whereas reduction of Stat3 phosphorylation
was very well possible. In line with these findings, we could observe depletion of phospho-Stat3
in vitro and in vivo, but did not observe depletion of total Stat3 following administration of LPP-siStat3
in vivo.
The major limitation of this study lies in the comparatively low perfusion range of siRNA achieved,
providing an explanation why reduction of Stat3 expression (and its target genes) in the bulk tumor
can be considered only as minor. Our data suggest that the LPP PEIs only reach a sub-fraction of
the tumor cells, as seen by a clear tendency towards reduced Stat3-mRNA expression in the tumor
core region. Due to the very low sample size (4 samples per group) a definitive answer cannot be
inferred from this data. Based on the fact that (1) most samples after LPP siStat3 treatment have Stat3
expression values below the mean of LPP siCtrl-treated animals and (2) the mRNA of the known
Stat3 target gene Mmp9 was significantly reduced after LPP siStat3 treatment, it can be deduced
that LPP-mediated delivery of siRNA was successfully achieved. Additionally, based on the in vitro
data we deduce that the siRNA can specifically and effectively deplete Stat3 expression, because we
could successfully inhibit proliferation of Tu2449 cells and spheroids after LPP-mediated delivery
of siStat3. Therefore we conclude that delivery to Tu2449 is possible even in more complex settings
(i.e., spheroids). Hence, it is more likely that the limiting factor in our current approach is tissue
dispersion of LPP complexes rather than siRNA specificity. Indeed, when exploring organotypic tissue
slice cultures of intact tumor (xenograft) material with regard to nanoparticle tissue penetration using
fluorophore-labeled siRNAs for microscopic evaluation of tissue penetrance, we did observe LPP to
diffuse into the tissue only to a certain extent. LPP tissue penetration was found to be better than for
polyplexes, reflecting lesser impairment of nanoparticle diffusion with reduced surface charge (zeta
potential; [51]). However, in another in vivo system (non-tumorous mouse brain in an alpha-synuclein
mouse model), even our polyplexes were found to distribute across the CNS down to the lumbar
spinal cord after a single intracerebroventricular infusion, thus emphasizing a distribution sufficient
for exerting biological effects [52].
The changes of Stat3-target genes like Mmp9 and Snai1 also provide mechanistic hints on how
Stat3-depletion increases survival. In particular, the repression of Mmp9 expression might reduce
the migratory capacity of tumor cells due to their inability to modify the ECM. This could be further
potentiated by repression of Snai1, which is a master regulator of EMT [15]. Furthermore, Snai1 has
been shown to enhance an immunosuppressive phenotype in cancers [15]. LPP-siStat3-mediated
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Snai1 depletion might therefore alleviate this phenotype and in turn make the tumors more accessible
or amenable for immunotherapy. Future research should therefore be directed towards increasing
intratumoral dispersion of siRNA in order to increase the knockdown efficiency. This could be achieved
by further improving the existing complexation formulation for LPPs for example by reducing size
and/or surface charges, or by enhancing the LPP concentration for being able to inject larger siRNA
amounts in the maximum possible injection volume and/or development of alternative, increasingly
sophisticated nanoparticle systems for delivery [26].
A different explanation for the limited Stat3-depletion could be changes in Stat3 turnover or
stability. Accordingly, the half-life of Stat3 has been previously determined to be between 30 h in
primary murine neurons to 90 h in hepatocytes [53] and around 50 h in Epstein-Barr-Virus-infected
PBMCs [54] indicating pronounced variations between cell types. Considering that HeLa cells have
a 50% turnover rate of ~60% of their entire proteome within 5 h [55] it might also be possible
that the in vivo microenvironment stimulates the tumor cells to promote faster protein turnover,
because of increased cell divisions. In this case, the treatment frequency every third day might be
too low. However, the fact that we already observe strong increases in survival by 7 days (~25%)
indicates that by continuous delivery of siRNA this issue can likely be resolved. One possibility to
achieve continuous delivery could be to employ convection-enhanced delivery (CED) using implanted
catheters. Accordingly, Chen et al. [56] could show that irinotecan-treatment using CED had the best
survival responses in orthotopic, murine xenografts compared to conventional treatment approaches.
In fact, the use of CED for treating glioma patients has also been tested in several clinical trials for
the delivery of small molecules [57], antisense oligonucleotides [58] or siRNAs [59]. More recent
reports also show the potential for multiplexed targeting using various siRNAs in established murine
tumors [60]. Another study also reported the use of the so-called Cleveland Multiport Catheter
(CMC) [61] which has already been tested in clinical trials (NCT02278510). The main advantage of
the CMC is that it consists of four independent microcatheters and could therefore be employed to
deliver multiple siRNAs and/or chemotherapeutics to more specifically target the vulnerabilities of
a specific tumor. Despite these considerations, even the somewhat limited perfusion of Stat3-siRNA
observed in our in vivo experiments with LPP therapy allowed to achieve impressive effects on tumor
growth and overall survival, further supporting the suitability of STAT3 as an excellent target for
GBM therapy. However, bearing in mind the enhanced colloidal stability of lipopolyplexes over their
polyplex counterparts [35], the above mentioned approach of continuous delivery via direct infusion
of the LPP into the tumor, using convection-enhanced delivery (CED) via an intratumoral catheter
connected to a portable pump, also becomes feasible, especially because it is to be expected that siRNA
stability or release kinetics would not be negatively affected by this approach.
4. Materials and Methods
4.1. Analysis of TCGA Data Sets
The publicly available TCGA datasets GBMLGG [62] and GBM [40] were accessed, analyzed
and the plots were exported via the GlioVis portal (gliovis.bioinfo.cnio.es [63]). Comparison of Stat3
expression in different glioma grades was plotted based on the histology. The survival curves were
derived from the GBM dataset of all GBM subtypes combined with a median cut-off, including
confidence intervals.
4.2. Cells and Compounds
The murine GBM cell line Tu2449 [64] and double reporter cell line Tu2449-EGFP/Luc stably
expressing EGFP and luciferase (Luc3) (kindly provided by Dr Alexander Wurm, Universitätsklinikum
Leipzig, Leipzig, Germany), the human GBM cell line U-87 MG (U87, obtained from ATCC, Manassas,
VA, USA) and Mz18 [65] were cultivated in DMEM Glutamax (high Glucose, Gibco/Thermo
Fisher Scientific, Karlsruhe, Germany) with 10% heat-inactivated fetal calf serum and 1%
397
Cancers 2019, 11, 333
penicillin/streptomycin (all from Gibco). Cultures were maintained in a humidified incubator at
37 ◦C and 5% CO2 and checked for mycoplasma contamination monthly by PCR Mycoplasma Test Kit
II (AppliChem, Darmstadt, Germany) according to the manufacturer’s instructions.
4.3. siRNAs + Sequences
Chemically synthesized siRNAs were purchased from MWG (Ebersberg, Germany),
Dharmacon/GE Healthcare (Lafayette, CO, USA) or Eurogentec (Seraing, Belgium), with sequences
as follows: siLuc2/siCtrl (human cell lines): 5′-CGU ACG CGG AAU ACU UCG AdTdT-3′ (sense),
5′-UCG AAG UAU UCC GCG UAC GdTdT-3′ (antisense); siLuc3: 5′-CUU ACG CUG AGU ACU UCG
AdTdT-3′ (sense), 5′-UCG AAG UAC UCA GCG UAA GdTdT-3′ (antisense); siEGFP: 5′-GCA GCA
CGA CUU CUU CAA G-dTdT-3′ (sense), 5′-CUU GAA GAA GUC GUG CUG CdTdT-3′ (antisense),
human STAT3 (siSTAT3-1: CGU UAU AUA GGA ACC GUA AdTdT (sense) and 5′-UUA CGG UUC
CUA UAU AAC GdTdT (antisense), siSTAT3-2: GCC UCU CUG CAG AAU UCA AdTdT (sense) and
UUG AAU UCU GCA GAG AGG CdTdG (antisense) or murine Stat3 (siStat3: 5′-GGC AUA UCG
AGC CAG CAA AdTdT-3′ (sense) and 5′-UUU GCU GGC UGC AUA UGC CdTdT-3′ (antisense)),
or negative control siRNAs (mouse: 5′-AAU CCG CUG UCG GCU GGA AdTdT-3′ (sense) and 5′-UUC
CAG CCG ACA GCG GAU UdTdT-3′ (antisense)).
4.4. Polyplex and Lipopolyplex Preparation
Liposomes from 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC; Avanti Polar Lipids,
Alabaster, AL, USA) were prepared by the hydration/extrusion method as described previously [32].
For polyplex formation, siRNAs were complexed in HN buffer (150 mM NaCl, 10 mM HEPES, pH 7.4)
with branched 4–12 kDa PEI F25-LMW [36] at PEI/siRNA mass ratio = 7.5:1 (N/P ratio 57) as previously
described [27]. Lipopolyplexes (LPP) for in vitro experiments were prepared by incubating equal
volumes of PEI/siRNA complexes with DPPC liposomes at a PEI/lipid mass ratio of 2.6 [32]. For this,
25 μL polyplex containing 0.8 μg siRNA, 6 μg PEI F25 and 25 μL DPPC liposomes comprising 16
μg lipid were properly mixed by pipetting and vortexing, and incubated for at least 1 h at room
temperature. For in vivo application, lipopolyplexes were prepared by complexing 0.5 μg siRNA
(200 μM), 3.75 μg PEI F25 (4.2 mg/mL) in 3 μL and mixed with 10 μg DPPC (5 mg/mL; 2 μL) to a total
volume of 5 μL per injection.
4.5. qRT-PCR
For preparation of total cellular RNA from cell lines, phenol/chloroform extraction using
250 μL TRI-Reagent (Sigma-Aldrich, Munich, Germany) according to the manufacturer’s protocol
was used. Employing the RevertAidTM H Minus First Strand cDNA Synthesis Kit (Fermentas,
St. Leon-Roth, Germany), cDNA was transcribed from 800 ng RNA according to the manufacturer’s
protocol. Quantitative PCR (qPCR) was performed in a StepOnePlus Real-Time PCR System (Applied
Biosystems, Darmstadt, Germany) using the PerfeCTa SYBR® Green FastMix ROX (Quantabio, Beverly,
MA, USA). All procedures were conducted according to the manufacturers’ protocols with 4 μL cDNA
(diluted 1:10 with nuclease free water), 1 μL primers (5 μM) and 5 μL SYBR Green master mix. After
pre-incubation for 15 s at 95 ◦C, 40 amplification cycles followed: 10 s at 95 ◦C, 10 s at 55 ◦C and 10 s at
72 ◦C. A melting curve for PCR product analysis was recorded by rapid cooling down from 95 ◦C to
65 ◦C followed by incubation at 65 ◦C for 15 s prior to heating to 95 ◦C. Actin-specific primer sets were
always run in parallel for each sample, to normalize for equal mRNA/cDNA amounts. Target levels
were determined by the ΔΔCt method [66]. Following primers were used: human STAT3 fwd: GAG
GAC TGA GCA TCG AGC A and rev: CAT GTG ATC TGA CAC CCT GAA, human Actin fwd: CCA
ACC GCG AGA AGA TGA and rev: CCA GAG GCG TAC AGG GAT AG.
Pooled samples from laser-capture-microdissected formalin-fixed paraffin embedded (FFPE)
tissues were subjected to RNA-Isolation using the Arcturus® Paradise® PLUS FFPE RNA Isolation
Kit (Thermo Fisher) and cDNA-synthesis using SuperScript IV Vilo (life technologies/Thermo
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Fisher) per the manufacturer’s instructions. Briefly, the RNA was eluted in 12 μL DEPC-treated
H2O and used entirely for the cDNA-synthesis without prior RNA quantification. The qPCR
was performed using 20× Taqman Probes (Applied Biosystems, Darmstadt, Germany) and
2× Fast-Start Universal Probe Master Mix (Roche) and 2 μL of cDNA on a StepOne Plus
System (Applied Biosystems) using the standard setting. The gene expression values were
normalized to TATA-Box binding protein (Tbp) or Hypoxanthine-guanine phosphoribosyltransferase
(Hprt) by calculating the mean Ct value of both housekeeping gene and using this value as
reference for further normalization using the ΔΔCt method [66]. The following Probes were
used: Hprt (Mm00446966_m1); Mmp2 (Mm00439506_m1); Mmp9 (Mm00442991_m1); Snai1 (Snail,
Mm01249564_g1); Stat3 (Mm01219775_m1); Tbp (Mm01219775_m1).
4.6. Western Blotting
Preparation of protein lysates from Tu2449 cells [67] and mouse brain tumors [68] were prepared
as described. SDS-PAGE and Western Blotting was performed as described [67]. Membranes were
blocked in 5% BSA/TBS-Tween20 (TBS-T) for 1 h at room temperature. Antibodies were incubated at
4 ◦C overnight in 5% BSA/TBS-T, secondary goat anti-mouse or goat anti-rabbit (dilution 1:10,000,
Li-Cor Biosciences, Bad Homburg, Germany) were incubated at room temperature for 1 h and detection
was achieved using a LI-COR Odyssey reader (LI-COR Biosciences, Bad Homburg, Germany).
For protein analysis of human cell cultures, cells were seeded and transfected in 24-well plates
as described above. After 72 h, medium was removed and cells were washed once with PBS. 80 μL
RIPA lysis buffer (50 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate,
0.1% SDS, 2.5 mM sodium pyrophosphate, 1 mM EDTA, 10 mM NaF, Protease Inhibitor Cocktail Set III
(EDTA-free, Merck, Darmstadt, Germany) was added per well and plates were incubated on ice for
10 min. The suspension was transferred to Eppendorf tubes. After centrifugation (10,000 rpm, 4 ◦C,
10 min), the supernatant was transferred to a new Eppendorf tube.
Using the Bio-Rad DCTM Protein-Assay (Bio-Rad, Munich, Germany), protein concentration was
determined according to manufacturer’s protocol. 4× loading buffer was added (0.25 mM Tris-HCl,
pH 6.8, 20% glycerol, 10% beta-mercaptoethanol, 8% SDS, 0.08% bromophenol blue) to yield a 1×
concentration and 20 μg protein was loaded onto 10% polyacrylamide gels. Proteins were separated
by SDS-PAGE and transferred to a 0.45 μm ImmobilonTM-P Transfer PVDF Membrane (Millipore,
Burlington, MA, USA). Membranes were blocked with blocking buffer (5% (w/v) milk powder in TBST
(10 mM Tris-HCl, pH 7.6, 150 mM NaCl, 0.1% Tween 20) for 30 min. After washing in TBST, membranes
were incubated with primary antibodies diluted in 3% milk powder (w/v) in TBST: anti-human STAT3
(Thermo Fisher Scientific), anti-Actin (Cell signaling Technologies (CST (Frankfurt am Main, Germany)),
or anti-Vinculin (Sigma-Aldrich) overnight at 4 ◦C. Then, blots were washed in TBST and incubated for
1 h with horseradish peroxidase-coupled goat anti-rabbit IgG (CST) or horseradish peroxidase-coupled
goat anti-mouse IgG (Thermo Fisher Scientific) in 3% milk powder (w/v) in TBST before washing
again. Bound antibodies were visualized by enhanced chemiluminescence (ECL kits: SignalFireTM
(CST) or SuperSignal® West Femto (Thermo Fisher Scientific)).
4.7. Antibodies
The following antibodies and dilutions were used: Actin (CST, 13E5, 1:1000 in 3% milk); Cluster
of Differentiation 4 (CD4); Affymetrix eBioscience/Thermo Fisher; clone 4SM95; 14-97664; 1:100 (IHC);
CD8a (Synaptic Systems, Göttingen, Germany) 361003; 1:500 (IHC); Gapdh (Calbiochem, #CB1001,
Darmstadt, Germany) 1:20,000; Iba1 (Wako, 019-19741); 1:1000 (IHC); Ki67 (SP6, Thermo Fisher,
MA5-14520); 1:100 (IHC); Stat3 (Santa Cruz Biotechnology (Heidelberg, Germany)), c-20; sc-482; 1:200
(WB); Stat3 (phospho Tyr705; CST Technologies (CST (Frankfurt am Main, Germany)); D3A7; 9145S;
1:1000 for Western Blot (WB) and 1:500 for Immunohistochemistry (IHC)); STAT3 (Thermo Fisher, 9D8,
1:5000 in 3% milk); Vinculin (Sigma Aldrich, hVIN-1, 1:2000 in 3% milk).
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4.8. Nanoparticle Characterization
Particle sizes and zeta potentials were determined by photon correlation spectroscopy (PCS) and
phase analysis light scattering (PALS), using a Brookhaven ZetaPALS system (Brookhaven Instruments,
Holtsville, NY, USA). The data were analyzed using the manufacturer’s software and applying a
viscosity and refractive index of pure water at 25 ◦C. For size determination, the complexes were
analyzed in five runs with a run duration of 1 min. Results are expressed as intensity weighted
mean diameter from different experiments. Zeta potentials were measured in ten runs, with each run
containing ten cycles, and applying the Smoluchowski model. Additionally, hydrodynamic diameters
of the nanoparticles were determined by nanoparticle tracking analysis (NTA), using a NanoSight LM
10 HS apparatus (Malvern) equipped with a 640 nm sCMOS camera and a temperature controlled
sample chamber, as described previously [45,69].
4.9. Cell Transfection
EGFP and luciferase knockdown experiments were performed in 24-well plates. The day before,
Tu2449-EGFP/Luc cells were seeded at a density of 30,000 cells per well in 0.5 mL fully supplemented
medium. Polyplexes and lipopolyplexes comprising 0.8 μg siRNA per well were prepared as described
above, containing siRNAs against the targets EGFP or luciferase, or the negative control siRNA
(see above Section 4.3).
For transfection using INTERFERinTM (Polyplus, Illkirch, France), 2 × 102 cells were seeded in a
96-well plate (proliferation assay; U87 or Mz18 cells) or 2 × 105 cells in a 24-well plate (cytotoxicity
assay; Tu2449 cells), respectively. Cells were incubated under standard conditions unless stated
otherwise. 10 nM siRNA were transfected according to the manufacturer’s protocol and incubated for
the indicated periods of time.
4.10. Determination of Knockdown Efficacies
Luciferase activities were determined in the double reporter cell line Tu2449-EGFP/Luc 96 h post
transfection using the Beetle-Juice Kit (PJK, Kleinblittersdorf, Germany). The medium was aspirated
and 300 μL lysis buffer (Promega, Mannheim, Germany) was added, prior to incubation for 30 min at
RT. In a test tube, 25 μL luciferin substrate was mixed with 10 μL cell lysate and luminescence was
immediately measured in a luminometer (Berthold, Bad Wildbad, Germany).
The EGFP knockdown was quantitated after 96 h by flow cytometry. Cells were trypsinized
and centrifuged for 3 min at 3000 rpm followed by a washing step with 1% BSA in PBS (1 mL),
and finally resuspended in 0.5 mL of the same buffer. The cells were measured in an Attune® Acoustic
Focusing Cytometer (Life Technologies, Darmstadt, Germany) with appropriate instrument settings.
20,000 events were gated and analyzed using the Attune® software (V2.1.0). The data are presented as
mean fluorescent intensities.
4.11. Cell Proliferation and Viability Assays
For proliferation assays, U87 or Mz18 cells were seeded and transfected in 96-well plates as
described above. The number of viable cells was determined at the time points indicated using
a colorimetric assay. Briefly, 50 μL of a 1:10 dilution of Cell proliferation Reagent WST-1 (Roche
Molecular Biochemicals, Mannheim, Germany) in serum-free medium was added to the cells after
aspirating the media. Cells were incubated for 1 h at 37 ◦C and absorbance at 450 nm was measured in
an ELISA reader.
Acute cell damage upon transfection was analyzed in Tu2449 cells by the lactate dehydrogenase
(LDH) release assay, using the Cytotoxicity Detection Kit (Roche, Mannheim, Germany) according
to the manufacturer’s protocol. Briefly, conditioned medium from knockdown experiments was
collected after 24 h. Conditioned medium from untreated cells served as negative control, and for the
determination of maximum LDH release (100% value), cells were lysed by adding Triton X-100 to final
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concentration of 2% into the medium. In a 96 well plate, 50 μL sample medium was mixed with 50 μL
reagent mix and incubated for 30 min in the dark. The reaction was stopped with 50 μL 1 M acetic
acid and the absorption at 490 nm and 620 nm as reference filter was measured in an ELISA reader.
Fresh fully supplemented medium and reagent mix served as background and was subtracted from all
values. Cytotoxicity values are shown in percent of the maximum value.
4.12. Cell Cycle Analysis
Cell cycle distribution was assessed using flow cytometry. Cells were seeded in 24-well plates and
transfected as described above. 48 h after transfection, cells were trypsinized, transferred to Eppendorf
tubes and centrifuged (1500 rpm, room temperature, 5 min). The supernatant was aspirated and the
cell pellet was resuspended in ice cold 70% ethanol and incubated for at least 1 h at 4 ◦C for fixation.
After centrifugation (1500 rpm, room temperature, 5 min) and discarding the supernatant, cells were
resuspended in an RNase A solution (50 μg/mL RNase A in PBS) and incubated for 30 min at 37 ◦C.
Propidium iodide solution was added to yield a 50 μg/mL concentration. Cell cycle distribution was
analyzed in the BL2 channel using an AttuneTM Flow Cytometer.
4.13. Spheroid Assay
To generate spheroids, 3 × 103 Tu2449 cells were seeded in a 96-well U-shaped ultra-low
attachment plate and incubated under standard conditions. Using SAINT-sRNA transfection reagent
(Synvolux, Leiden, The Netherlands), 90 nM siRNA were transfected according to the manufacturer’s
protocol.After 10 days, spheroid size was documented and measured using a Celigo Imaging Cytometer
(Nexcelom Bioscience, Lawrence, MA, USA) and the corresponding software.
4.14. Animal Experiments
Intracranial implantation of tumor cells into the right striatum of B6C3F1 mice (Envigo,
Huntingdon, UK; average weight 25 g) was performed as described [21]. Briefly, 10,000 viable Tu2449
in 1 μL were injected with a flow rate of 0.5 μL/min at a depth of 3 mm 1.5 mm posterior and 2 mm
lateral to the bregma. 42 mice were implanted with tumor cells and one week after implantation the
animals were randomly divided into two groups; one received LPP siCtrl treatment, the other LPP
siStat3 treatment. Application of LPPs (equivalent to 0.5 μg siRNA in 5 μL which, due to limitations
regarding the total lipopolyplex volume, was the maximum possible amount in this experimental
setting) was performed using the same drill hole in the skull as for tumor cell implantation every
third day one week after tumor cell implantation. 21 days after tumor implantation 10 mice per group
were sacrificed; of those, 8 mice were used for histological analysis and two for molecular analyses.
Those tumors were divided and one half was immediately frozen on dry ice and used for protein
isolation, the other half was stored in RNAlater (Qiagen, Hilden, Germany) and used for RNA isolation.
All intracranial injections were performed on anesthetized animals and treatment was done unblinded.
Histoligical analysis showed that in the LPP siCtrl and LPP siStat3 group three and five tumors could
not be established. Of those, one and two tumors were planned for histological assessment after
21 days. These mice were removed from the survival-analysis. Animals at the collection time point
or those that showed neurological symptoms related to tumor burden were euthanized by cervical
dislocation after they received a lethal injection of anesthetic. Hereafter the brains were immediately
removed, rinsed in PBS and fixed for 2–7 days in 4% PFA (Chemcruz/Santa Cruz). Prior to paraffin
embedding the fixed brains were cut coronally in 2–3 mm thick section and the resulting sections were
aligned horizontally. Embedding in paraffin was performed according to standard paraffin embedding
procedures known from routine pathology. Sildes were first stained with hematoxylin and eosin.
Immunohistochemistry was performed on an automated staining system Bond III (Leica Microsystems,
Wetzlar, Germany) using standard protocols. All animal experiments were approved by the local
administrative council (Regierungspräsidium Darmstadt, FK/1011).
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4.15. Determination of Tumor Size
The area of tumors was determined by measuring the longest distance (a) between tumor borders
and the respective orthogonal line (b) from all tumor sections visible from H&E stained tumor sections.
Using the formulas for ellipses the area (A) was calculated:
A = π × 0.5 × a × b
If a brain contained multiple tumor sections those values were summed to account for the depth
of the tumor. If multiple sections from one mouse were available the area, indicative for the tumor
center, was chosen.
4.16. Laser-Capture Microdissection
Laser capture microdissection (LCM) was performed of 10 μm thick, serial sections mounted
on UV-irradiated MMI membrane slides (MMI, Eching, Germany) and collected on MMI Isolation
caps with diffuser caps (MMI). Prior to microdissection, the sections were dried at 37 ◦C for 1 h and
rehydrated (2 times 10′ xylene, 99%, 96%, 70% EtOH, 30′ ′ each) and the first and last section of the
series were stained with hematoxylin and eosin, dehydrated and mounted using Pertex (Leica, Wetzlar,
Germany). LCM was performed using a laser capture microscope (Oylmpus IX71 equipped with MMI
CellCamera und MMI CellCut) operated by the software MMI CellTools (v. 4.0).
4.17. Statistics
All statistical analysis were performed using GraphPad Prism 7 (GraphPad Software, La Jolla,
CA, USA). Kaplan-Meier-Survival curves were analyzed using log-rank test, all other experiments
using two-tailed T-Test, with assuming equal SD and without corrections for multiple comparisons.
Cell cycle measurement was analyzed by two-way-ANOVA of matched samples with Dunnett’s
multiple comparison test against siCtrl treated cells. Unless stated otherwise, all samples are presented
as Box-Plots (min-to-max), where the horizontal line depicts the median value and the “+” symbol
depticts the calculated mean.
5. Conclusions
In conclusion, we provide first proof-of-concept evidence that intratumoral targeting of oncogenes
like Stat3 using lipopolyplexsosomal siRNA for the treatment of brain tumors is feasible and leads
to improved overall survival in a murine, syngeneic, orthotopic transplantation model. Future
development of nanoparticle systems and the modes of their application will hopefully enhance the
restricted tissue distribution achieved in this study, thereby further improving the tumor targeting
capacity of siRNA. These efforts may lead to the development of new and highly specific treatments
selectively targeting the expression of oncogenes such as STAT3, an avenue recently opened in a clinical
trial focusing on another gene target in brain tumors (NCT03020017).
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Abstract: Hepatitis C virus (HCV) infection compromises the natural defense mechanisms of the liver
leading to a progressive end stage disease such as cirrhosis and hepatocellular carcinoma (HCC). The hepatic
stress response generated due to viral replication in the endoplasmic reticulum (ER) undergoes a stepwise
transition from adaptive to pro-survival signaling to improve host cell survival and liver disease progression.
The minute details of hepatic pro-survival unfolded protein response (UPR) signaling that contribute
to HCC development in cirrhosis are unknown. This study shows that the UPR sensor, the protein
kinase RNA-like ER kinase (PERK), mediates the pro-survival signaling through nuclear factor erythroid
2-related factor 2 (NRF2)-mediated signal transducer and activator of transcription 3 (STAT3) activation in a
persistent HCV infection model of Huh-7.5 liver cells. The NRF2-mediated STAT3 activation in persistently
infected HCV cell culture model resulted in the decreased expression of hepatocyte nuclear factor 4 alpha
(HNF4A), a major liver-specific transcription factor. The stress-induced inhibition of HNF4A expression
resulted in a significant reduction of liver-specific microRNA-122 (miR-122) transcription. It was found
that the reversal of hepatic adaptive pro-survival signaling and restoration of miR-122 level was more
efficient by interferon (IFN)-based antiviral treatment than direct-acting antivirals (DAAs). To test whether
miR-122 levels could be utilized as a biomarker of hepatic adaptive stress response in HCV infection,
serum miR-122 level was measured among healthy controls, and chronic HCV patients with or without
cirrhosis. Our data show that serum miR-122 expression level remained undetectable in most of the
patients with cirrhosis (stage IV fibrosis), suggesting that the pro-survival UPR signaling increases the risk
of HCC through STAT3-mediated suppression of miR-122. In conclusion, our data indicate that hepatic
pro-survival UPR signaling suppresses the liver-specific HNF4A and its downstream target miR-122 in
cirrhosis. These results provide an explanation as to why cirrhosis is a risk factor for the development of
HCC in chronic HCV infection.
Keywords: hepatitis C virus (HCV); cirrhosis; hepatocellular carcinoma (HCC); endoplasmic
reticulum (ER) stress; oxidative stress (OS); unfolded protein response (UPR); microRNA-122 (miR-122);
nuclear factor erythroid 2-related factor 2 (NRF2); signal transducer and activator of transcription 3
(STAT3); hepatocyte nuclear factor 4 alpha (HNF4A)
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1. Introduction
Hepatocellular Carcinoma (HCC) is the most common form of liver cancer. The incidence of HCC
has nearly doubled over the past decade, making it the third-leading cause of cancer-related death
worldwide [1]. In most cases, HCC develops on the background of cirrhosis that is mainly associated
with viral hepatitis, overconsumption of alcohol, and non-alcoholic fatty liver disease. In the USA,
chronic hepatitis C virus (HCV) infection is the leading cause of HCC and liver transplantation [2].
Globally, 30% of all HCC cases are related with persistent HCV infection representing a significant
public health problem [3]. Recently approved direct-acting antivirals (DAAs) enable to cure the majority
of patients with chronic HCV infection, including patients with cirrhosis [4]. HCV treatment reduces
liver inflammation, fibrosis, and HCC thus drops liver-disease related mortality in the future [5,6].
Although the causal relationship between HCV infection and chronic liver disease has been well
documented, the minute mechanisms of the virus-cell interactions involved in disease progression
are not well understood. Since there is no effective treatment option of cirrhosis and late-stage HCC,
it is hoped that understanding the mechanisms of HCV-induced liver cancer will allow developing
better treatment. This knowledge will also result in a better understanding of the pathogenesis of other
agents such as hepatitis B virus (HBV) and non-viral agents leading to cirrhosis and HCC.
The mechanisms of how chronic HCV infections are associated with the development of cirrhosis
and HCC have been a challenge to study due to lack of an appropriate small animal model [7]. In a
previous publication, it was shown that hepatocytes develop an integrated stress response (ISR) due to
the combination of endoplasmic reticulum (ER) and oxidative stress occurring with persistent HCV
replication in the cell culture model [8]. The increased cellular stress response activates nuclear factor
erythroid 2-related factor 2 (NRF2) signaling as a primary cell survival pathway by inducing the
transcription of genes with the antioxidant response [9]. Previously published data have shown that
the stress-induced NRF2 signaling induces expression of LAMP2A and HSC70 leading to induction
of chaperone-mediated autophagy (CMA). The CMA induction in HCV-infected culture improves
cell survival through degradation of major tumor suppressors: p53 and retinoblastoma protein
(pRB) [10–12]. A recent publication from this laboratory has shown that HCV-mediated NRF2 signaling
impairs autophagy process at the level of autophagosome-lysosome fusion leading to activation of
the oncogenic signaling through the tyrosine kinase receptors (EGFR) [13]. These data support that
the activation of NRF2 signaling contributes to cell survival and progression of preneoplastic lesion
to HCC malignancies [14]. Signal transducer and activator of transcription 3 (STAT3) pathway is
also activated as a major cell survival mechanism in HCC but not in the surrounding non-tumor
tissue or normal liver [15,16]. The mechanisms of STAT3 activation could be due to an elevated
expression of cytokines such as interleukin 6 (IL6), interleukin 22 (IL22), oxidative stress or epigenetic
regulation [17,18]. However, studies have shown that STAT3 activation is transient in non-transformed
cells even in the presence of cytokines and STAT3 activating mutations are rarely present in HCC [17,18].
The HCC-specific mechanism of STAT3 activation has not been addressed thoroughly.
Due to these reasons, we investigated the contribution of NRF2-related pro-survival mechanism
through STAT3 activation in HCV culture in response to oxidative stress. We investigated STAT3-mediated
pro-survival mechanism via a circuit that involves downregulation of hepatocyte nuclear factor 4 alpha
(HNF4A) through miR-24 and miR-619 [19,20]. STAT3-inducible miR-24 and miR-629 destabilize the HNF4A
mRNA leading to the permanent suppression of protein expression. HNF4A is a principal transcription
factor required for liver development, hepatocyte differentiation, and hepatic function [21]. Many recent
publications claim that the expression level of HNF4A and its target genes are impaired in cirrhosis and
diminished in HCC [22–27]. HNF4A has been shown to play a role in HCC development related to chronic
inflammation processes of the liver through regulating the transcription of miR-122 [28–30]. The importance
of this circuit in HCC development is further supported by previous reports showing that miR-122 knockout
mice develop HCC [31–33]. Based on these evidences, we hypothesized that the NRF2-mediated activation
of the STAT3-HNF4A inflammatory loop could lead to a long-term suppression of miR-122 that increases
the HCC risk among patients with cirrhosis.
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Using a persistently HCV-infected Huh-7.5 liver cell culture model, it was found that the hepatic
adaptive response through the protein kinase RNA-like ER kinase (PERK)-NRF2 axis activates the
STAT3-HNF4A inflammatory loop as a cell survival mechanism. Data presented in this manuscript
suggest that the NRF2-mediated STAT3 activation silence the expression of HNF4A through miR-24
upregulation. The activation of the STAT3-HNF4A loop leads to suppression of miR-122 in persistently
infected HCV cell culture and chronic HCV patients with cirrhosis. Finally, the data in the study demonstrate
that the serum miR-122 levels are depleted during advanced liver disease such as cirrhosis, which may
explain why HCC develops most of the time on the background of chronic liver disease with cirrhosis.
2. Results
2.1. Persistent HCV Replication Leads to ER Stress and Oxidative Stress
To understand the hepatic adaptive response to ER stress, highly permissive Huh-7.5 cells were
infected with JFH-AM120 at a multiplicity of infection (MOI) of 0.1, and HCV replication was studied
over 21 days with a regular passage of infected cells at three-day intervals. Infected cells collected at
different time points were examined for HCV protein expression by Western blotting. The efficiency
of replication and spread of HCV-green fluorescence protein (GFP) chimera virus were examined by
fluorescence microscopy with nuclear DAPI staining. Quantifications of GFP positive cells by ImageJ
software show that the level of HCV replication increased with time. The percentage of Huh-7.5
cells expressing HCV-GFP fusion was quantified by flow cytometry analysis at 0, 3, 6, 9, and 12 days.
These results indicated that about 5.9% of cells were GFP positive on day 3, and the number increased to
85.4% and 93.5% on day 9 and day 12, respectively. All these results support our previously published
data showing that the high-level replication and spread of JFH-AM120 chimera HCV clone in Huh-7.5
liver cells (Figure S1). When the accumulation of viral protein exceeds the folding capacity of the
ER resident chaperones, it creates a stress response called UPR. The activation of UPR secondary to
ER stress response is the major driver of liver disease progression in HCV infection. Sustained HCV
infection in Huh-7.5 liver cells is expected to accumulate unfolded protein load and expansion of the ER
membranes [34]. We measured misfolded protein stress in the ER membranes by live cell imaging using
a transient transfection-based approach with a commercially available ER-red fluorescence protein
(RFP) construct (ER-RFP, BacMam 2.0, ThermoFisher, Waltham, MA, USA). The staining was intense
in the rough ER around the nucleus of infected cells and the RFP signal overlapped with HCV-GFP.
The ER staining of the uninfected cells was diffuse, whereas it was more intense in HCV-infected cells,
suggesting the evidence of ER membrane expansion and accumulation of ER-RFP protein in the cells
replicating HCV. Interestingly, HCV infection induced an extensive colocalization of ER-Tracker RFP
with NS5A-GFP. The yellow fluorescence signal due to colocalization was markedly increased after
overlaying the images of NS5A-GFP and ER-tracker RFP fluorescence. Quantitative assessment of the
colocalization of HCV-GFP with ER-tracker RFP was significantly higher in HCV-infected cells than
uninfected Huh-7.5 cells. These data confirm that HCV-GFP fusion protein is colocalized with the RFP
protein in the perinuclear region of the infected cells that is consistent with increased GRP78/94 protein
localization in the ER [35–37]. These results are also consistent with previous reports confirming the
activation of the stress sensor of the UPR by Western blot analysis [13]. During HCV replication,
several reactive oxidants such as reactive oxygen species (ROS) or reactive nitrogen species (RNS) are
generated as a by-product of biochemical reactions in mitochondria, peroxisomes, and ER membranes
leading to oxidative stress. A fluorescent-based assay was used to quantify ROS levels between
uninfected and persistently infected cultures with HCV-Renilla luciferase virus (JFH1-V3-Rluc) on
day 9. In this assay, H2DCFDA is converted to the highly fluorescent 2’7’-dichlorofluorescein due to
the presence of ROS. The fluorescence intensity is proportional to the amount of oxidant present in
HCV-infected cells. A flow cytometric analysis based on the quantitative approach displays that the
majority of cells infected with HCV show punctate fluorescence staining due to the presence of high
oxidative stress response. The oxidative stress was significantly higher in HCV-infected culture than
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uninfected Huh-7.5 cells by three repeated analyses. Results shown in Figure S2 confirm previously
published data indicating that HCV infection also induces ER stress and oxidative stress [38–41].
2.2. Oxidative Stress and ER Stress Activate NRF2 Signaling in HCV Infection
A transcription factor, NRF2, plays a critical role in the control of genes involved in cell survival
pathway. It induces varieties of cytoprotective genes harboring a short cis-acting sequence called the
antioxidant response element (ARE) in their promoters [42,43]. First, we demonstrated that robust
expression of the HCV core protein in the infected culture could be detected on day 3 and the number of
positive cells was increased from day 6 and over 90% cells became core positive on day 12. The intensity
of cytoplasmic core staining was quantified by ImageJ software (NIH, Bethesda, MD, USA) and found
to increase over time, indicating active viral replication and spread after HCV infection. The activation
of NRF2 signaling was examined by measuring the nuclear translocation in persistently infected culture
in a kinetic study by immunocytochemical staining. NRF2 nuclear accumulation was found in 100% of
HCV-infected culture starting from day 9 that correlated well with HCV core expression (Figure S3).
These results indicate that HCV infection results in NRF2 activation and nuclear translocation.
2.3. Persistent HCV Infection Activates the NRF2-STAT3-HNF4A Regulatory Axis as a Cytoprotective Response
Increased oxidative stress has been reported in liver disease caused by viral hepatitis and non-viral
etiologies [43]. The NRF2 has a crucial role in enabling adaptation to oxidative stress and ER stress by
transcribing more than 2000 cytoprotective genes involved in cell survival [44,45]. The induction of
NRF2 genes requires a common NRF2-binding motif on the promoter called ARE [46,47]. Five ARE
(TGnnnnGC) and six ARE-like (TGAnnnnGC or TGAnnnnnGC) binding sites were identified in STAT3
promoter region (Figure 1A). Western blot analysis using phosphorylated and unphosphorylated specific
antibodies revealed that HCV infection induced NRF2 and STAT3 activation (Figure 1B). The expression
of STAT3 was found to be increased more in HCV-infected culture as compared to uninfected Huh-7.5
cells. The expression level of β-Actin did not change, suggesting that the differences were not at the
level of protein loading or variation in the protein content of the lysates used. The inflammatory circuit
consisting of HNF4A, miR-122, IL6, STAT3, and miR-24 is implicated in hepatocellular transformation and
liver oncogenesis [19]. The first component of the circuit is the STAT3-mediated suppression of HNF4A
through miR-24. The second component is HNF4A-mediated suppression of miR-122 transcription.
Western blot analysis was performed to verify whether HCV-induced STAT3 also modulates expression
of HNF4A pathway. Results shown in Figure 1B demonstrate that HCV infection increased NRF2,
and STAT3 expression but suppressed HNF4A expression. Western blot data were quantified using
ImageJ software to compare relative expression of NRF2, STAT3 and HNF4A (Figure S4). To determine
the statistical correlation coefficient between the expression levels of STAT3 and HNF4A, the fraction of
variance denoted by R2 values was calculated (Figure 1C,D). Analyses of the R2 values are very close to
1.0, suggesting that the induction of STAT3 correctly predicts the decrease of HNF4A in HCV-infected
cells. Immunolocalization of STAT3 and HNF4A was performed in uninfected and infected cell culture
on day 9 by confocal microscopy. This analysis showed that STAT3 activation in HCV-infected culture
was associated with negative HNF4A expression in the nucleus (Figure 1E,F). These results indicate
an inverse relationship between STAT3 activation and the expression of liver-specific transcription
factor, HNF4A. Real-time RT-PCR data showed that HCV infection induced NRF2 and STAT3 mRNA
levels, whereas HNF4A mRNA levels were decreased (Figure 1G–I), suggesting that activation of NRF2
signaling decreases the HNF4A protein level by altering the stability or reduced transcription of HNF4A.
These results are consistent with the previous report suggesting that HCV infection inhibits HNF4A
expression by reducing its mRNA levels [48]. To test the consistency of this observation, results were
verified using an HCV infection model of primary human hepatocytes (PHHs). It was found that the
expression of total NRF2 and phosphorylated NRF2 (pNRF2) were induced in HCV-infected PHHs
by Western blot analysis measured for 12 days (Figure 2A). It was observed that the expression of
total STAT3 and phosphorylated STAT3 (pSTAT3) were increased in a time-dependent manner in the
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infected PHHs culture as compared to uninfected PHHs, indicating that HCV replication induces STAT3
pathway. The expression level of HNF4A was decreased after HCV infection and inversely correlated
with expression of HCV NS3 by Western blot analysis. All the Western blot bands were quantified using
ImageJ software to compare the relative expression of NRF2, STAT3 and HNF4A (Figure S5). Total RNA
isolated from infected PHHs was used to quantify the mRNA levels of STAT3, NRF2, HNF4A and
internal control β-Actin by real-time RT-PCR. First, Ct values of individual gene were normalized with
β-ActinmRNA and then, the fold change was determined as compared to uninfected PHHs. The mRNA
levels of NRF2 and STAT3 were found to be increased in a time-dependent manner in HCV-infected
PHHs (Figure 2B,C), whereas HNF4A mRNA levels were decreased over time post infection (Figure 2D).
Figure 1. Persistent hepatitis C virus (HCV) replication induces nuclear factor erythroid 2-related factor 2
(NRF2)-mediated regulation of the signal transducer and activator of transcription 3 (STAT3)-hepatocyte
nuclear factor 4 alpha (HNF4A) inflammatory loop. (A) STAT3-promoter region was examined for the
presence of antioxidant response element (ARE) consensus sequences indicated by arrowheads, and
ARE-like sequences shown by arrows. (B) Western blot analysis shows expression levels of total and
phosphorylated NRF2, and STAT3 in infected Huh-7.5 liver cells over 21 days. The expression of HNF4A
was inversely correlated with HCV NS3 protein expression. (C) Band intensities of phosphorylated
STAT3 (pSTAT3) and phosphorylated NRF2 (pNRF2) were quantified using ImageJ software and R2
values were determined by excel software. (D) Western blot results of HNF4A and pSTAT3 were
quantified using ImageJ software and R2 values were determined by excel software. (E) Colocalization
of HCV-green fluorescence protein (GFP) with STAT3 by confocal microscopy. (F) Colocalization
studies by confocal microscopy between HCV-GFP and nuclear expression of HNF4A in infected
Huh-7.5 cells on day 9. Messenger RNA (mRNA) levels of individual genes in HCV-infected Huh-7.5
culture were measured by real-time RT-PCR analysis. (G) NRF2 mRNA levels (H) STAT3 mRNA levels.
(I) HNF4A mRNA levels. The results are expressed as the mean ± standard deviation (SD) of three
experiments. Error bars represent SD. p-values were calculated by ANOVA as compared to uninfected
control. * p-value < 0.05, *** p-value < 0.001. Original magnification ×60. Scale bars = 10 μm.
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Figure 2. Hepatic stress response due to hepatitis C virus (HCV) replication in non-proliferative primary
human hepatocytes (PHHs) activates nuclear factor erythroid 2-related factor 2 (NRF2)-mediated
signal transducer and activator of transcription 3 (STAT3)-hepatocyte nuclear factor 4 alpha (HNF4A)
expression. (A) Cell lysate was examined for the presence of HCV NS3 protein and for the activation
of NRF2, STAT3 and HNF4A protein expression in infected PHH by Western blot. Messenger RNA
(mRNA) levels of individual genes in HCV-infected PHHs were measured by real-time RT-PCR analysis.
(B) Shown are NRF2 mRNA levels (C) Shown are STAT3 mRNA levels. (D) Shown are HNF4A
mRNA levels. The results are expressed as the mean ± standard deviation (SD) of three experiments.
Error bars represent SD. p-values were calculated by ANOVA as compared to day 0. * p-value < 0.05,
** p-value < 0.01, *** p-value < 0.001.
2.4. Silencing PERK and NRF2 Pathway Restore Expression of STAT3-HNF4A Inflammatory Loop
Persistent HCV replication induces sustained nuclear translocation of NRF2 as a cytoprotective
mechanism in response to ER stress and oxidative stress. The impact of silencing NRF2 by a small
interfering RNA (siRNA) treatment on the expression of STAT3 and HNF4A was examined in a
persistently infected HCV cell culture model. The siRNA treatment was performed using day 9
infected HCV-GFP culture. As shown in Figure 3A, knockdown of NRF2 by siRNA decreased STAT3
expression and restored HNF4A expression indicating that the increased NRF2-mediated STAT3
expression is inversely associated with HNF4A downregulation. Uninfected Huh-7.5 cells treated with
the NRF2 activator (sulforaphane) shows increased expression of phosphorylated NRF2 and STAT3 but
suppressed HNF4A expression (Figure 3B). These data suggest that NRF2 mediated the regulation of
the STAT3-HNF4A inflammatory loop in HCV infection. The relationship of NRF2 activation and ER
stress was determined in infected Huh-7.5 cells after treatment with the ER stress inhibitor. As shown
in Figure 3C, tauroursodeoxycholic acid (TUDCA) treatment decreased NRF2 expression, and STAT3
activation but restored HNF4A expression. To test the role of the PERK pathway on regulating the
STAT3-HNF4A axis, the expression levels of STAT3 and HNF4A were measured after treatment with the
PERK inhibitor by Western blotting. As shown in Figure 3D, inhibiting PERK blocked STAT3 induction
and restored HNF4A expression. It is well known that STAT3 is phosphorylated by Janus kinases
(JAK) leading to homo- or heterodimers, and nuclear translocation for transcriptional regulation of
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microRNAs and numerous genes involved in cell survival pathway. We examined whether treatment
with the JAK inhibitor could also prevent STAT3 phosphorylation and restore HNF4A expression in
HCV-infected culture. Day 9 infected Huh-7.5 cell culture was treated with increasing concentrations
of the JAK inhibitor (pyridone 6, Calbiochem, San Diego, CA, USA) and after 72 hours, the expression
of STAT3, pSTAT3 and HNF4A levels was examined by Western blotting (Figure 3E). Treatment with
the JAK inhibitor did not block HCV replication but prevented STAT3 phosphorylation and restored
expression of HNF4A. Furthermore, we found that infected Huh-7.5 cells treated with a highly specific
STAT3 inhibitor (S3I-201, Selleck Chemicals, Houston, TX, USA) restored the expression level of HNF4A
without altering level of HCV core expression (Figure 3F). Over expression of STAT3 by transient
transfection downregulated the expression of HNF4A (Figure 3G). Huh-7.5 cells transfected with a
control plasmid did not alter expression of HNF4A, suggesting specific regulation by STAT3 expression.
The relative expression of NRF2, STAT3 and HNF4A under different siRNA or chemical treatments
was compared by quantifying the Western blot results by ImageJ software (Figure S6).
Figure 3. Shown is the nuclear factor erythroid 2-related factor 2 (NRF2)-dependent regulation of
signal transducer and activator of transcription 3 (STAT3)-hepatocyte nuclear factor 4 alpha (HNF4A)
expression in hepatitis C infection (HCV) infection. (A) The effect of NRF2 silencing on the expression
of STAT3-HNF4A in HCV culture. Infected Huh-7.5 cells on day 9 were treated with combination
of two small interfering RNAs (siRNAs) targeted to NRF2 and scrambled siRNA and the expression
of STAT3 and HNF4A was measured by Western blot analysis after 72 hours. The effect of siRNA
transfection did not alter HCV core expression or expression of β-Actin levels. (B) Shown is the effect of
treatment with the NRF2 activator, sulforaphane, on the expression of STAT3 and HNF4A in uninfected
Huh-7.5 liver cells. (C) Western blot analysis shows the effect of the endoplasmic reticulum (ER) stress
inhibitor (TUDCA) on the expression levels of STAT3 and HNF4A in HCV-infected culture. (D) Shown
are the expression levels of STAT3-HNF4A in HCV culture treated with the protein kinase RNA-like
ER kinase (PERK) inhibitor by Western blot analysis. (E) Shown is the effect of the Janus kinase (JAK)
inhibitor on the phosphorylation of STAT3 and HNF4A regulation. (F) Shown is the effect of the STAT3
inhibitor on the expression levels of HNF4A in infected cells by Western blot analysis. (G) The effect of
STAT3 over expression by plasmid transfection on the levels of HNF4A in uninfected Huh-7.5 cells.
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2.5. Persistent HCV Replication in Huh-7.5 Cells Leads to STAT3-HNF4A-Mediated Silencing of miR-122
STAT3-inducible miR-24 controls the stability of HNF4A mRNA through binding to the
3’untranslated region (3’UTR). This regulation is linked to HNF4A-mediated induction of liver-specific
miR-122 transcription [49]. We tested the hypothesis whether NRF2-mediated cellular adaptive
response to HCV infection regulates the STAT3-HNF4A inflammatory loop through modulating the
expression of miR-122 and miR-24 (Figure 4A). We used a RT-PCR assay to measure their expression in
persistently infected culture over 21 days. As expected, the miR-24 expression progressively increased
whereas the copy number of miR-122 decreased in HCV culture over time (Figure 4B). We found
that HCV-induced stress response decreased the expression of miR-122 in a time-dependent manner.
The appearance of control unrelated miR-16 did not change under similar assay conditions. The impact
of HCV replication on the regulation of microRNA loop was also verified in infected PHHs model.
It was observed that miR-122 level decreased in HCV-infected PHHs whereas miR-24 level increased
(Figure 4C). The level of miR-16 did not change due to HCV infection in PHHs. We conducted as a
next step a series of antiviral treatment using HCV-infected Huh-7.5 cells on day 9 to see whether
HCV clearance could reverse the expression of miR-122. As shown in Figure 4D, IFN alpha (IFNα),
sofosbuvir, ledipasvir and a combination of sofosbuvir and ledipasvir effectively cleared HCV-GFP
expression without affecting viability of infected Huh-7.5 cells. Furthermore, it was found that inducing
HCV clearance by treatment with either IFNα or DAAs (sofosbuvir, and ledipasvir) inhibited STAT3
protein levels and restored HNF4A expression (Figure 4E). The relative expression of STAT3, HNF4A
and HCV core was determined quantifying the Western blot results by ImageJ software (Figure S7).
The cross-regulatory effect of STAT3 and HNF4A expression on miR-24 and miR-122 levels was also
verified after HCV clearance with different antivirals. It was found that restoration of miR-122 level
was more efficient by IFN-based antiviral treatment than by DAAs (Figure 4F,G). These results suggest
that cellular adaptive response to HCV-induced stress activated the STAT3-HNF4A inflammatory loop
that leads to decreased expression of miR-122.
It was also of interest to determine if the treatment of HCV-infected cells with small molecule
inhibitors of PERK and ER stress could show a differential effect on the expression of microRNA
that controls the expression of STAT3 and HNF4A. Infected Huh-7.5 cells on day 9 was treated with
a PERK inhibitor or TUDCA for 72 hours and then the expression levels of miR-24 and miR-122
were examined by real-time RT-PCR. Data shown in Figure 5A indicate that this treatment did not
inhibit HCV replication since no difference of HCV-GFP expression between untreated and treated
groups was seen. The expression level of miR-24 was higher in HCV-infected untreated culture due to
STAT3 activation (Figure 5B). As expected, persistently infected HCV culture treated with the PERK
inhibitor and TUDCA inhibited miR-24 expression but restored expression of miR-122 in HCV culture
(Figure 5B,C). Taken together, these results suggested that HCV-induced PERK activation promoted
the activation of the STAT3-HNF4A inflammatory loop to overcome the stress response associated
with persistent HCV replication.
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Figure 4. Relationship between signal transducer and activator of transcription 3 (STAT3)-hepatocyte
nuclear factor 4 alpha (HNF4A) and the expression miR-122 and miR-24 in hepatitis C virus
(HCV)-infected Huh-7.5 cells and primary human hepatocytes (PHHs). (A) Shown is the proposed
hypothesis relating stress and STAT3-miR-24-HNF4A-miR-122 feedback circuit in HCV infection.
(B) Quantification of miR-16, miR-24 and miR-122 levels in persistently HCV-infected Huh-7.5 cells by
real-time RT-PCR analysis over 21 days. (C) Quantification of miR-122, miR-24 and miR-122 levels in
HCV-infected PHHs over 12 days. (D) Shown is the HCV-green fluorescence protein (GFP) expression
in the infected culture with or without antiviral treatment. (E) Western blot shows the expression levels
of STAT3 and HNF4A in the infected culture on day 9 with or without antiviral treatment. (F) The
expression levels of miR-24 in HCV-infected culture before and after treatment with interferon alpha
(IFNα) or direct-acting antivirals (DAAs). (G) The expression levels of miR-122 in HCV-infected culture
treated with IFNα or DAA. The results are expressed as the mean ± standard deviation (SD) of three
experiments. Error bars represent SD. p-values were calculated by ANOVA between different groups
as compared to untreated HCV-infected group. * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001.
Original magnification ×40, scale bars = 25 μm.
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Figure 5. The expression of miR-24 and miR-122 in hepatitis C virus (HCV)-infected Huh-7.5 cells in the
presence of the protein kinase RNA-like ER kinase (PERK) or endoplasmic reticulum (ER) stress inhibitors.
Infected Huh-7.5 cells were treated with the PERK inhibitor or ER stress inhibitors for 72 hours. Cells were
collected and the expression levels of miR-24 and miR-122 were measured by real-time RT-PCR. (A) Shown
are expression levels of HCV-green fluorescence protein (GFP) chimera in day 9 HCV culture by fluorescence
microscopy before and after treatment. (B) Shown are amounts of miR-24 before and after treatment with the
PERK inhibitor or tauroursodeoxycholic (TUDCA) in HCV-infected culture. (C) The levels of miR-122 in
uninfected and infected Huh-7.5 cells treated with either with the PERK inhibitor or TUDCA. The results are
expressed as the mean± standard deviation (SD) of three experiments. Error bars represent SD. p-values were
calculated by ANOVA between different groups as compared to untreated HCV-infected group. *** p-value
< 0.001. Original magnification ×40. Scale bars = 25 μm.
2.6. Persistent HCV Replication in Huh-7.5 Cells Leads to Decreased miR-122 Promoter Activity
An in vitro assessment was done to study the impact of the HCV-induced stress response
on miR-122 promoter activity in the presence and absence of a stress inducer and inhibitors.
A firefly luciferase reporter construct p-(5.7/3.8k) that contained the 3726 to 5645 bp region
(chr18: 54263641-54265560) in the pGL3-basic vector (Figure 6A) was used to measure the impact of HCV
replication on miR-122 promoter activity [50]. First, we measured the impact of HCV replication on the
promoter activity in a transient transfection assay. The infected culture on day 9 was transfected with
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microRNA-promoter plasmid for 24 hours, and then firefly luciferase activity was measured. The firefly
activity was normalized with protein concentration. It was found that HCV infection significantly
suppressed miR-122 promoter activity in Huh-7.5 cells. The promoter activity in the HCV culture was
enhanced in the presence of the STAT3 inhibitor and JAK inhibitor. The PERK inhibitor as well as the
ER stress inhibitor, TUDCA, also increased miR-122 promoter activity (Figure 6B). Second, we tested
whether uninfected Huh-7.5 cells treated with the ER stress or the NRF2 activator could modulate
miR-122 promoter activity. As shown in Figure 6C, inducing ER stress in uninfected Huh-7.5 cells by
thapsigargin (TG) treatment suppressed the miR-122 promoter activity significantly. The treatment
with sulforaphane also suppressed the miR-122 promoter activity in a concentration-dependent manner
(Figure 6D). All these results support the conclusion that the ER stress and the NRF2 activators
actively suppressed the miR-122 promoter activity, but ER stress inhibitors restored the HCV-induced
suppression of the promoter activity.
Figure 6. The impact of endoplasmic reticulum (ER) stress on the miR-122 promoter activity. (A) There
are three hepatocyte nuclear factor 4 alpha (HNF4A) binding sites present in miR-122 promoter,
which explain why HNF4A downregulation decreases miR-122 under stress. (B) The effect of small
molecule inhibitors targeted to signal transducer and activator of transcription 3 (STAT3), Janus kinase
1 (JAK1), protein kinase RNA-like ER kinase (PERK) and ER stress on the miR-122 promoter regulation.
Uninfected and hepatitis C virus (HCV)-infected Huh-7.5 cells were transfected with one microgram of
miR-122 promoter-construct with firefly luciferase. Following the transfection step, cells were treated
with or without thapsigargin (TG), sulforaphane, and STAT3 inhibitors. After 24 hours, the luciferase
activity was measured. Luciferase assays were performed three times. (C) ER stress activator regulation
of miR-122 promoter. (D) The impact of a nuclear factor erythroid 2-related factor 2 (NRF2) activator,
sulforaphane, on miR-122 promoter activity. The results are expressed as the mean ± standard deviation
(SD) of three experiments. Error bars represent SD. p-values were calculated by ANOVA between
different groups as compared to untreated HCV-infected group. ** p-value < 0.01, *** p-value < 0.001.
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2.7. Decreased Expression of miR-122 Correlates with Patients with Cirrhosis
MiR-122 is the most abundant liver-specific microRNA that accounts for about 70% of the total
microRNA population in the adult liver [49]. Based on the fact that the cellular stress adaptation
to HCV infection leads to decreased expression of miR-122 through STAT3-HNF4A, suggesting this
liver-specific microRNA may be used as a biomarker for assessing the stress response among patients
with chronic HCV infection. We next sought to test this hypothesis to see whether the expression
levels of miR-122 would be different among chronically infected patient with or without cirrhosis.
A retrospective analysis of serum miR-122 levels of patients with chronic hepatitis C patients with or
without cirrhosis was performed. The analysis measured the levels of miR-122 in sera from 18 healthy,
18 chronic HCV without cirrhosis and 18 chronic HCV patients with cirrhosis samples. Total RNA
was isolated from 200 μL of serum samples, and miR-122 levels were quantified by real-time reverse
transcription. Tables 1 and 2 summarize the characteristics of the subjects included in this study.
The viral titer was available in all patients with chronic hepatitis C. All cirrhotic patients were positive
for HCV but viral titer was available for only 6 individuals (Table 2). It was found that the copy
number of miR-122 was higher in chronic HCV infection as compared to healthy control (p < 0.01).
Interestingly, the miR-122 levels were almost undetectable among most of the patients with stage IV
fibrosis (Figure 7A). To rule out the possibility that decreased miR-122 expression relates to the poor
hepatic biosynthetic capability of cirrhotic liver, we measured expression of two additional microRNAs.
A liver-specific miR-221 level was measured in the same serum samples by real-time RT-PCR. These data
showed that miR-221 levels were detectable adequately (Figure 7B). The levels of STAT3-induced miR-24
level were found to be increased in serum samples of patients with cirrhosis as compared to healthy
individuals (Figure 7C). There was no difference in the serum miR-16 level between the healthy control
and chronic HCV infection without cirrhosis. The copy number of miR-16 was comparable between
normal, chronic HCV infection with or without cirrhosis (Figure 7D). There was no correlation between
the age and serum miR-122, and miR-16 levels, suggesting that the differences in the expression level are
not related to the mean differences in the age of these patients. Serum miR-122 levels were consistently
found to be decreased since we found a significant difference between chronic HCV infection with
or without cirrhosis (p < 0.001). Since the microRNA is required for HCV replication, we found that
serum miR-122 level was increased during chronic HCV infection. Difference in the miR-122 level
between normal healthy control and chronic HCV infection was also significant (p < 0.05) (Figure 8A).
These data from serum testing suggest that miR-122 expression is decreased in the advanced stage of
liver disease. It was of interest to know if serum miR-122 could be a potential diagnostic marker for
cirrhosis through Receiver Operating Characteristic (ROC) plot analysis. The data showed that levels
of serum miR-122 are a potential marker for discriminating cirrhosis patients from chronic HCV and
healthy control (Figure 8B). The ROC curve analysis revealed a strong separation between chronic
HCV patients with cirrhosis versus without cirrhosis with an area under the curve (AUC) value 1.0,
suggesting that miR-122 is a handy marker for discriminating patients with chronic HCV from the
cirrhosis group. The analysis revealed that serum levels of other miR-16, miR-221 and miR-24 were
not reliable to accurately differentiate chronic HCV patients with or without cirrhosis. In summary,
these results suggested that hepatic adaptive response to cellular stress associated with chronic HCV
infection was stronger among the cirrhotic group that leads to depletion of serum miR-122 level.
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Table 1. Characteristics of the patients with Chronic Hepatitis C.
Patient Number Age Sex HCV RNA IU/mL HCV Genotype Metavir Score
1 48 F 2,000,000 1a 3
2 46 F 29,000 1b 0
3 27 F 1,000,000 1a 1.2
4 59 F 553,000 1a 3
5 64 M 2,000,000 1a 1.2
6 34 F 7,000,000 1a 1,2
7 59 F 1,000,000 2 0
8 44 M 170,000 1a 1
9 50 M 3,000,000 1b 0
10 33 F 3,000,000 1b 1.2
11 53 M 904,000 1a 1
12 62 M 7062 1a 0
13 69 F 10,000,000 1b 2
14 47 F 2,000,000 2 0
15 50 F 10,000,000 1a 0
16 48 M 2,000,000 1b 0
17 40 F 200,000 1a 1
18 53 M 815,000 1a 1
HCV: hepatitis C virus; M: male; F: female.
Table 2. Characteristics of the patients with cirrhosis.
Patient Number Age Sex HCV RNA IU/mL HCV Genotype Metavir Score
1 57 M + 1a 4
2 52 M + 1a 4
3 60 F + 1a 4
4 64 F + N/A 4
5 62 M 2,700,000 1b 4
6 66 M + 1a 4
7 54 M + 1a 4
8 54 M + 1b 4
9 62 F + N/A 4
10 58 F + N/A 4
11 64 M + 2 4
12 66 F + N/A 4
13 57 F + N/A 4
14 56 M 5,940,000 N/A 4
15 60 M 7,200,000 1a 4
16 60 M 2,860,000 1b 4
17 56 M 4,310,000 1a 4
18 60 M 6,480,000 1a 4
HCV: hepatitis C virus; M: male; F: female; N/A: Not Available.
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Figure 7. Serum levels of miR-122, miR-221, miR-24 and miR-16 were measured by real-time RT-PCR.
(A) Shown are the serum miR-122 levels among healthy individuals, chronic hepatitis C virus (HCV)
infection and chronic HCV infection with cirrhosis. (B) Serum levels of another control liver-specific
miR-221 using the same set of serum samples. (C) Serum levels of signal transducer and activator of
transcription 3 (STAT3)-regulated miR-24 among healthy, chronic HCV infection and chronic HCV with
cirrhosis. (D) Shown are the serum levels of miR-16 in the same sets of serum samples. The results
are expressed as the box plot with the median bar in triplicates. Whiskers represent minimum and
maximum observed values. p-values were calculated by ANOVA between different groups. ns: not
significant, * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001.
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Figure 8. Serum miR-122 levels discriminating patients with hepatitis C virus (HCV) infection and
cirrhosis from healthy controls. (A) Copy number variation of serum miR-122 levels between healthy,
chronic HCV and chronic HCV with cirrhosis. (B) Receiver Operating Characteristic (ROC) plot. Data
shown in panel A was used to generate ROC plot for determining diagnostic value of serum miR-122 of
cirrhosis and chronic HCV patients from healthy controls. The results are expressed as the mean ±
standard error of mean (SEM). Error bars represent SEM. p-values were calculated by ANOVA between
different groups. * p- value < 0.05, *** p-value < 0.001.
3. Discussion
Chronic liver disease associated with hepatitis virus infection (HBV and HCV) contributes to
more than 70% of the HCC worldwide, whereas the remaining cases relate to non-viral etiologies [51].
Since most of HCC cases related to viral and non-viral etiology develop on the background of cirrhosis,
suggesting that there may be a common pathway involved in the development of cirrhosis and HCC.
However, approximately 20–35% of HCC develop without cirrhosis in the liver, suggesting that
inflammation is not an absolute requirement for HCC development [52,53]. The molecular mechanism
that drives the progression of cirrhosis and HCC during the chronic stage of liver disease is not
understood. Whole genome sequencing found that many driver genes show altered expression in HCC
related to chronic HCV infection [51]. Our hypothesis was that the ISR triggered in the infected cells as
a compensatory mechanism to deal with varieties of stress responses such as oxidative stress, and ER
stress during HCV replication in hepatocytes. The presence of long-lasting unresolved stress response
also compromises liver function that leads to cirrhosis and HCC development. In support of this
hypothesis, we showed that HCV infection induced ISR in response to ER stress and oxidative stress in
cirrhosis that lead to decreased expression of type I IFN receptors [54]. Due to this reason, patients
with cirrhosis frequently remain as non-responders to IFN/ribavirin-based antiviral therapy. Some of
the pro-survival outcomes of the stress response are the inhibition of host protein synthesis due to
increased eukaryotic translation initiation factor 2 subunit alpha (EIF2A) phosphorylation, degradation
of misfolded proteins by ER-assisted protein degradation (ERAD) and autophagy. We showed that
prolonged stress response activated PERK-induced NRF2 signaling as a cell survival mechanism [13].
The NRF2 signaling activates tumor-promoting autophagy (CMA) that degrades tumor suppressors
and induces oncogenic signaling implicated in cell survival.
In this study, we found that NRF2 signaling activated transcription of STAT3, a member of STAT
protein family, that is known to be induced by IL6 and participates in inflammation, tumorigenesis and
autophagy [55]. STAT3 protein gets phosphorylated at tyrosine 705 by JAK2/tyrosine kinase 2 (TYK2),
resulting from dissociation from the cytoplasmic tail of the cytokine receptors, homodimerizes and
enters to the nucleus to activate gene transcriptions. Increased STAT3 activity is associated with HCC
development and poor prognosis [56]. Activated STAT3 can inhibit cellular autophagy for promoting
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cell survival, supporting our hypothesis that prolonged stress response inhibits autophagy [57].
Other investigators and we have demonstrated that chronic inflammatory responses can activate
STAT3 through IFN and IL6 production [22,58]. Although STAT3 activation occurs due to a variety of
mechanisms, HCC-specific STAT3 activation mechanisms have not been well established. Our data show
that cellular adaptive response to HCV-induced stress activates STAT3-mediated programing through
HNF4A that leads to silencing of liver-specific miR-122. To support this hypothesis, we demonstrated
that the excessive cellular stress associated with HCV infection activated STAT3 transcription through
NRF2 signaling. Our data showed that persistent HCV infection promotes STAT3-inducible expression
of miR-24. The increased miR-24 transcription correlated with the decreased expression of HNF4A
mRNA through binding to the 3’UTR in HCV infection. Our data support the data published earlier
showing that an oncogenic circuit consisting of HNF4A, miR-122, IL6, STAT3, and miR-24 is involved
in the cell survival mechanisms under stress during HCV infection [19]. Cellular adaptive stress
response associated with chronic HCV infection activated STAT3 and utilized this oncogenic circuit,
which resulted in a decrease in the expression of HNF4A through miR-24. Nuclear HNF4A is a
crucial transcription factor during embryonic liver development and hepatocyte differentiation [59].
Available literature shows that HNF4A is the major liver-specific transcription factor that modulates
the expression of nearly 42% of the genes expressed in hepatocytes, involved in glucose, fatty acid
metabolism, synthesis of blood coagulation factor VII, enzymes involved in hepatic detoxification,
and hepatic differentiation [60–65]. Our data is supported by studies showing that mRNA and protein
expression levels of HNF4A decreased severely patients with cirrhosis. Hemorrhage is a common
cause of death in cirrhosis, especially variceal bleeding. Hepatocytes synthesize both clotting factors
and endogenous anticoagulants. The levels of these proteins are reduced in cirrhosis. HNF4A induces
the production of blood coagulation factor VII. Our study also provides an explanation why HNF4A
targeted protein expression is decreased in cirrhosis due to severe hepatic stress response. Studies have
shown that decreased expression of HNF4A is also correlate with bleeding disorder due to decreased
expression of the blood coagulation factor VII [64,65].
The activation of this STAT3- HNF4A inflammatory loop led to decreased expression of miR-124
and miR-122. These two microRNAs were regulated by HNF4A. This study was extended to see
whether this hypothesis could be validated using prospectively collected serum samples of patients
chronically infected with HCV. The measurement of serum miR-122 levels was performed using
serum samples from patients with chronic HCV infection with or without cirrhosis. It was observed
that miR-122 levels increased during the chronic stage of HCV infection, the levels significantly
decreased in advanced liver disease, particularly with stage IV fibrosis called cirrhosis. Interestingly,
we report here that the levels of miR-122 have remained below the detection limit among all cirrhotic
patients tested in our hand. Our study results are in agreement with a prior report showing that the
serum miR-122 level was found to decreased in liver injury in humans with advanced liver disease,
including cirrhosis [66–69]. Decreased expression of miR-122 has also been found in cirrhosis related
to non-alcoholic steatohepatitis (NASH) [33]. The decreased production of miR-122 in the cirrhotic
patients was not related to the impaired biosynthetic capability of hepatocytes present in the cirrhotic
liver because the expressions of a liver-specific miR-221 and STAT3-specific miR-24 were detectable.
Our data show that unresolved stress response depletes the expression of miR-122, suggesting that
the activation of the STAT3-HNF4A inflammatory loop also occurs in the chronic HCV infection in
humans. Our findings provide two pieces of new information that may increase our understanding
why STAT3 is transcriptionally activated in liver cancer. First, we show that cellular adaptive response
to ER stress in HCV infection causes STAT3 activation at the level of mRNA transcription as well as
phosphorylation. Second, we found that STAT3 activation is involved in silencing of miR-122 in the
cirrhosis. Recent studies have observed that epigenetic programing is involved in HCC development
in cirrhosis after the viral cure [70–72]. We claimed that our results show a novel adaptive cell
survival mechanism related to excessive ER stress that involved STAT3-mediated silencing of miR-122
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expression, the major liver-specific microRNA. The early silencing of miR-122 and HNF4A increases
the risk for HCC development in cirrhosis.
The miR-122 plays a central role in liver development, differentiation, hepatic metabolic function
and innate immunity in the liver [66]. However, the studies investigating the regulation of miR-122
expression during chronic liver diseases related to viral and non-viral etiologies have produced
conflicting results. A handful of publications showed that the levels of miR-122 decreased during
advanced liver disease related to hepatitis C, hepatitis B, and non-viral etiologies [73–75]. MiR-122
expression in the liver is critical for maintaining innate immunity and IFN production. A report by
Xu et al. [73] shows that miR-122 supports innate immunity by removing the negative regulation
of STAT3 signaling on IFN expression. They showed that miR-122 targets three receptor tyrosine
kinases that directly modulate STAT3 phosphorylation. Another recent study by Van Renne et al. [74]
showed that the tumor suppressor protein, tyrosine phosphatase receptor delta (PTPRD) controls
the STAT3 activation in HCV-induced HCC. They found that high expression of PTPRD suppressed
STAT3 phosphorylation in healthy liver tissue but low expression of this protein in HCC resulted in
the tumor-specific STAT3 activation. These reports are consistent with our results that HCV infection
activates STAT3. On the other hand, the liver-specific miR-122 expression is also decreased during
chronic HBV infection. Chen et al. [75] demonstrated that miR-122 binds to the highly conserved region
of HBV pre genomic RNA, causing RNA degradation and reduce viral replication. Data presented in
this study show that HCV replication decreased the expression of miR-122 in a time-dependent manner.
Data from recent publications confirm the downregulated expression of miR-122 during HCV-induced
advanced liver disease [69,76,77]. A report by Luna et al. [76] showed that HCV RNA replication
occurs independent of the miR-122 interaction. The team showed that the Argonaute (AGO) protein
directly binds to the miR-122 binding sites in HCV RNA, specifically sequesters miR-122, to repress
the liver target genes during chronic HCV infection. Their investigation showed that the miR-122
expression decreased in the liver tissues of humans and chimpanzees infected with HCV. Another
report by Hyrina et al. [77] showed that the plasma level of miR-122 decreased during chronic HCV
infection and were not restored after HCV cure. Their study also showed that serum miR-122 level
was correlated with liver transaminases. These results suggest that miR-122 could be a liver-specific
biomarker after HCV cure. A study by Sarasin-Filipowicz et al. [69] reported decreased expression
of miR-122 in the liver of HCV-infected patients who were resistant to IFN-based therapy. Our data
showed that severe ER stress response during high-level HCV replication in cell culture models of
Huh-7.5 liver cells and PHHs decreased the expression of miR-122. The expression levels of miR-122
were depleted among patients with cirrhosis, but not with chronic HCV infections. The reason why the
miR-122 level decreased only in cirrhosis, but not during chronic liver disease is unclear. The host factor
requirement for HCV replication has not been fully established. It is possible that HCV replication in
the cirrhotic liver may depend on factors other than miR-122. The potential liver regeneration and
increased inflammation may contribute to increased miR-122 level in the blood during chronic HCV
infection. However, data presented in this report do not support the earlier finding showing that
miR-122 is an essential host factor for HCV replication. The miR-122 binding does not cause HCV
RNA degradation instead it stabilizes the viral genome and promotes translation [78]. In summary, the
results presented in this article are consistent with many earlier publications suggesting that decreased
expression of miR-122 in cirrhosis may be associated with loss of hepatic function and innate immunity,
impaired liver regeneration, as well as increased risk of HCC development.
4. Materials and Methods
4.1. Cell Culture, Antibodies and Chemicals
The highly permissive transformed liver Huh-7.5 cell line was obtained from the laboratory of
Charles M. Rice (Rockefeller University, New York). The Huh-7.5 cells were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM) supplemented with two mM L-glutamine, sodium pyruvate,
423
Cancers 2019, 11, 1407
nonessential amino acids, 100 U/mL penicillin, 100 μg/mL streptomycin, and 10% fetal bovine serum.
Huh-7.5 cell culture was infected with either JFH1-GFP chimera HCV or JFH-dV3-Rluc HCV using a
protocol developed in our laboratory as previously described [79]. PHHs were obtained from XenoTech
LLC (Kansas City, MO, USA) and cultured with hepatocyte culture media supplemented with 10%
human serum (Invitrogen, Brown Deer, WI, USA). After 24 hours they were infected with cell culture
grown HCV-GFP chimera virus with a MOI of 0.1. After 18 hours of infection, hepatocytes were replaced
with fresh hepatocyte culture media (XenoTech, LLC, Kansas City, MO, USA) supplemented with
10% human serum (Invitrogen, Brown Deer, WI, USA). Uninfected or infected PHH were harvested
every 3 days and cell pellets were used for RNA isolation and Western blot analysis. The success of
HCV replication in the infected PHHs was assessed by Western blot analysis of HCV NS3 protein.
Sofosbuvir was purchased from Acme Biosciences, Inc. (Palo Alto, CA, USA), and IFNα was purchased
from EMD Merck (Billerica, MA, USA). Ledipasvir and S3I-201 were obtained from Selleck Chemicals
(Houston, TX, USA). TG, TUDCA, the PERK inhibitor (GSK 2606414), and sulforaphane were obtained
from Sigma-Aldrich (St. Louis, CA, USA). Pyridone 6 was obtained from Calbiochem (San Diego,
CA, USA). The antibody to phospho-NRF2 was purchased from Abcam (Cambridge, MA, USA).
Antibodies to GRP78 (BIP), EIF2A, STAT3, phospho-STAT3, HNF4A, and β-Actin were obtained from
Cell Signaling (Beverly, MA, USA). Antibody to NS3 was purchased from Virogen Inc. (Boston, MA,
USA). The Antibody to HCV core was purchased from Thermo Scientific (Waltham, MA, USA).
The antibody to total NRF2 was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
4.2. Quantitative Assessment of Misfolded Protein Burden in the ER
The accumulation of misfolded proteins in the infected culture was quantified using an ER-tracker
reagent called CellLight ER-RFP BacMam 2.0 (Thermo Fisher Scientific). This construct expresses Red
Fluorescence Protein (RFP) fused to the ER signal sequence of calreticulin and KDEL (ER-retention
signal) to quantitate the extent of red fluorescence by fluorescence microscopy and flow cytometry.
This reagent allows live multiplexing imaging of ER in the cells expressing HCV-GFP fusion protein.
Briefly, HCV-infected Huh-7.5 cells, and uninfected Huh-7.5 cells were incubated with ER-tracker dye
overnight at 37 ◦C, and the next day, cells were observed using a fluorescence microscope. For nuclear
staining and imaging, the cells were directly incubated with Hoechst 33342 (Thermo Fisher Scientific)
at 1 μg/mL for 5 minutes in 6-well plate. Then, the cells were washed with PBS and fixed for 10 minutes
with 2% paraformaldehyde. The colocalization of GFP and RFP between infected and uninfected cells
quantified by flow analysis.
4.3. Detection of Reactive Oxygen Species (ROS)
ROS in HCV culture measured using the cell-permeant H2DCFDA reagent (Thermo Fisher
Scientific) according to the manufacturer’s instructions. The 2′,7′-dichlorodihydrofluorescein diacetate
(H2DCFDA) fluorescent probe reacts with ROS including hydrogen peroxide and hydroxyl radicals.
The cell-permeant H2DCFDA diffuses into cells and is retained in the cytoplasm after cleavage by
intracellular esterase. The ROS converts the non-fluorescent H2DCFDA to the highly fluorescent
2′,7′-dichlorofluorescein (DCF), which could be detected by fluorescent microscopy or quantified by
flow cytometry.
4.4. Immunohistochemical Staining
Tissue culture cells were immobilized onto a glass slide by cytospin. Immunostaining of
the cytospin slides of infected cells was performed using a standard protocol established in our
laboratory [11]. We used a monoclonal antibody to HCV core protein (Thermo Scientific) and
monoclonal antibody that detects phosphorylated NRF2 (Abcam).
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4.5. SDS-PAGE and Western Blotting
Infected Huh-7.5 cells were harvested by the treatment of trypsin-ethylenediaminetetraacetic acid
(EDTA). Cells were lysed in ice-cold lysis buffer (50 mM Tris HCl pH 8.0, 140 mM NaCl, 1.5 mM MgCl2,
0.5% NP-40 with complete protease inhibitor from Invitrogen) for 10 minutes in ice (about 1 × 106
cells/200 μL). Infected Huh-7.5 cells pelleted by low-speed centrifugation. The detergent compatible
(DC) protein assay determined protein concentration. Samples were boiled for 10 minutes at 80 ◦C in
the presence of 1× sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)-loading
buffer (250 mM Tris-HCl pH 6.8, 40% glycerol, 8% SDS, 0.57M β-mercaptoethanol, 0.12% bromophenol
blue). Approximately 20 μg of protein was loaded onto 12% SDS-PAGE and transferred into a
nitrocellulose membrane (Thermo Scientific). The membrane was blocked using a solution containing
5% of blotting-grade milk power (Bio-Rad, Hercules, CA, USA) for 2 hours then incubated with a
primary antibody. After overnight incubation, the antigen-antibody complex was visualized with
horseradish peroxidase (HRP)-conjugated goat anti-rabbit or anti-mouse Immunoglobulin G (IgG) and
the ECL detection system (Amersham ECL, GE Healthcare Bio-Sciences, Pittsburgh, PA, USA).
4.6. siRNA Transfection
Persistently HCV-infected Huh-7.5 cells were cultured in 6-well plates (up to 60% confluence in
DMEM supplemented with 10% FBS media) without antibiotics. The next day, culture media was
replaced with fresh DMEM with 2% FBS and cells were then transfected with siRNA to either NRF2
(siRNA1: 5′-GAAUGGUCCUAAAACACCA-3′, siRNA2: 5′-UGACAGAAGUUGACAAUUA-3′)
synthesized by Invitrogen [80,81] or scramble siRNA (Invitrogen) using Lipofectamine (Life Technology,
Grand Island, NY, USA). The knockdown efficiency was analyzed by Western blot.
4.7. Quantification of mRNA Levels by RT-qPCR
Infected Huh-7.5 cells and PHHs were harvested at different time points post HCV infection,
and total RNA was isolated using the RNeasy Mini kit (Qiagen, Germantown, MD, USA). The first
strand of complementary DNA (cDNA) was synthesized from 1 μg of total RNA using an iScript
Reverse Transcription Supermix (Bio-Rad). 100 ng cDNA was amplified using iTaq Universal SYBR
Green Supermix (Bio-Rad) with gene-specific forward and reverse primers following instructions in
the kit. The mRNA levels of NRF2, STAT3, HNF4A, and β-Actin (as internal control) were quantified
using quantitative RT-PCR (RT-qPCR). Amplification, data acquisition, and analysis were carried out
on the CFX96 real-time instrument using CFX manager software version 3.0 (Bio-Rad). The expression
levels of mRNAs were normalized with the β-ActinmRNA level using the comparative threshold
cycle method. The nucleotide sequences of oligonucleotide primers for NRF2 mRNA (sense primer
5’-TACTCCCAGGTTGCCCACA-3’ and antisense primer 5’-CATCTACAAACGGGAATGTCTGC-3’) [82],
for STAT3 mRNA (sense primer 5’-TGGAAGAGGCGGCAGCAGATAGC-3’ and antisense
primer 5’-CACGGCCCCCATTCCCACAT-3’) [83], for HNF4A mRNA (sense primer
5’-TGTCCCGACAGATCACCTC-3‘ and antisense primer 5’-CACTCAACGAGAACCAGCAG-3’) [20],
and for β-ActinmRNA (sense primer 5’-GAGCTACGAGCTGCCTGAC-3’ and antisense primer
5’-AGCACTGTGTTGGCGTACAG-3’) [84] were derived from previous published reports.
4.8. Quantification of Serum microRNA Levels by RT-qPCR
Total microRNA was isolated from 20 μL serum samples using miRNeasy kit (Qiagen) used for
reverse transcription using miScript II RT kit (Qiagen) as described previously [85]. Individual
microRNA was amplified using cDNA templates, a universal primer and a PCR kit using a
recommended protocol. A standard curve was generated for determining microRNA copy number
and Ct values using serially diluted synthetic microRNA. The copy number of each microRNA in the
serum was calculated from the Ct values.
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4.9. Statistical Analysis
Western blot, immunostaining, and immunofluorescence images were quantified using a computer
image analysis software package (ImageJ version 1.52c, NIH, Bethesda, MD, USA). All measurements
were made at least in triplicate (n = 3). To compare means within groups, we performed a one-factor
analysis of variance (ANOVA) using the GraphPad Prism software (GraphPad Company, San Diego,
CA, USA). Data were tested and found to be normally distributed. To determine the statistical
correlation coefficient between protein expressions, fraction of variance denoted by R2 values was
determined using excel software. Sensitivity of the assays was plotted against the false positivity
(1-specificity) using ROC curves using the GraphPad Prism software. Comparison of AUC was
performed, which compares the AUC to the diagonal line of no information (AUC 0.5). We applied
Dunnet’s post hoc test to compare control samples with experimental samples when the overall p-value
for the ANOVA analysis was significant (p < 0.05). When performing comparisons between multiple
groups, each analyzed with ANOVA; we used the Bonferroni correction to determine a revised cutoff
for statistical significance that gives a combined 5% type I error probability. * p-value < 0.05, ** p-value
< 0.01, *** p-value < 0.001.
5. Conclusions
Hepatic adaptive response to HCV-induced stress reduces liver-specific miR-122 through activation
of STAT3-HNF4A inflammatory feedback loop. Serum miR-122 could be used as a biomarker to
monitor the activation of this inflammatory loop in liver cirrhosis.
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Abstract: STAT3 is an oncoprotein which has been shown to contribute to drug resistance in multiple
myeloma (MM). Nonetheless, the clinical utility of STAT3 inhibitors in treating MM has been limited,
partly related to some of their pharmacologic properties. To overcome these challenges, our group
had previously packaged STAT3 inhibitors using a novel formulation of nanoparticles (NP) and
found encouraging results. In this study, we aimed to further improve the pharmacologic properties
of these NP by decorating them with monoclonal anti-CD38 antibodies. NP loaded with S3I-1757
(a STAT3 inhibitor), labeled as S3I-NP, were generated. S3I-NP decorated with anti-CD38 (labeled as
CD38-S3I-NP) were found to have a similar nanoparticular size, drug encapsulation, and loading as
S3I-NP. The release of S3I-1757 at 24 h was also similar between the two formulations. Using Cy5.5
labeling of the NP, we found that the decoration of anti-CD38 on these NP significantly increased the
cellular uptake by two MM cell lines (p < 0.001). Accordingly, CD38-S3I-NP showed a significantly
lower inhibitory concentration at 50% (IC50) compared to S3I-NP in two IL6-stimulated MM cell lines
(p < 0.001). In a xenograft mouse model, CD38-S3I-NP significantly reduced the tumor size by 4-fold
compared to S3I-NP on day 12 after drug administration (p = 0.006). The efficacy of CD38-S3I-NP in
suppressing STAT3 phosphorylation in the xenografts was confirmed by using immunocytochemistry
and Western blot analysis. In conclusion, our study suggests that the decoration of anti-CD38 on NP
loaded with STAT3 inhibitors can further improve their therapeutic effects against MM.
Keywords: multiple myeloma; STAT3; S3I-1757; nanoparticle; CD38
1. Introduction
Recent studies have shown that nanoparticles (NP) can be an effective drug delivery system
to treat cancers [1]. In addition to its usefulness in delivering hydrophobic drugs, NP can promote
drug accumulation at tumor sites due to the fact that NP are too large to pass through the normal
capillaries but small enough to leak through the poorly-formed vasculatures frequently present in
malignant tumors [2]. To further increase the targeting ability and reduce drug toxicity, researchers
Cancers 2019, 11, 248; doi:10.3390/cancers11020248 www.mdpi.com/journal/cancers433
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have conjugated NP with various tumor-specific antibodies [3]. For example, different forms of NP
conjugated with anti-human epidermal receptor-2 (HER2) antibodies have been generated to treat
HER2-positive breast cancer [4–7]. Based on the results of a few studies, it appears that the decoration
of NP with tumor-specific antibodies can indeed result in superior cellular uptake/cytotoxicity
in vitro, as well as significantly improved tumor suppression in vivo, compared to their unconjugated
counterparts [7–12]. Some studies also suggest that the conjugation of antibodies on the surface
of NP is useful in overcoming drug resistance in cancers which overexpress drug efflux pumps
(e.g., p-glycoprotein) [8,13]. The conjugation of antibodies on NP is versatile, and a variety of
antibodies have been used to achieve specific experimental objectives, such as the use of antibodies
targeting the vascular endothelial growth factor receptor (i.e., to block tumor angiogenesis) [12],
matrix metalloproteinases (i.e., to block tumor invasion) [14], and transferrin receptor (i.e., to facilitate
the crossing of NP through the blood-brain barrier) [15].
Multiple myeloma (MM) is a hematological disease which is characterized by a high frequency
of relapses and resistance to chemotherapy. A signal transducer and activator of transcription 3
(STAT3), which is found to be active in more than 50% of MM, has been shown to contribute to the
resistance to bortezomib, thalidomide, and dexamethasone in MM [16–19]. In view of its significance
in cancer biology, STAT3 has been postulated to be an attractive anti-cancer target, and many STAT3
inhibitors (such as Stattic, S3I-201, and S3I-1757) have been developed [20–22]. However, the clinical
utility of these compounds has been limited, which is likely related to some of their pharmacologic
properties, such as their small size and hydrophobicity. Consequently, STAT3 inhibitors have been
found to have relatively low therapeutic efficacy and high toxicity. In this regard, a clinical trial of
OPB-31121 (an orally administered STAT3 inhibitor) in a cohort of patients with various types of solid
cancer has reported that >80% of patients experienced significant nausea/diarrhea without therapeutic
benefits [23]. To overcome these challenges, our group has recently generated NP to package STAT3
inhibitors. Specifically, we synthesized NP based on the poly(ethylene oxide)-block-poly(α-benzyl
carboxylate-ε-caprolactone) (PEO-b-PBCL) backbone, and we used these NP to package S3I-1757
(denoted as S3I-NP); we found that S3I-NP exhibited significantly better anti-tumor effects in mice
xenografted with a human melanoma cell line compared to free drugs [24].
In this study, we aimed to further improve the pharmacologic properties of S3I-NP by conjugating
monoclonal antibodies against human CD38, a cell-surface marker highly expressed on MM cells,
on the surface of S3I-NP (denoted as CD38-S3I-NP). We hypothesized that, due to the active targeting
properties of anti-CD38 for MM cells, CD38-S3I-NP will demonstrate improved cellular uptake in vitro
cytotoxicity and in vivo therapeutic efficacy compared to S3I-NP. Our results have provided the
proof-of-principle that anti-CD38-conjugated NP loaded with STAT3 inhibitors are useful therapeutic
agents for MM patients.
2. Results
2.1. Synthesis and Characterization of CD38-S3I-NP
To generate CD38-S3I-NP, we conjugated anti-CD38 monoclonal antibodies to the hydrophilic
portion of PEO-b-PBCL. As illustrated in Figure 1A, anti-CD38 was first thiolated at the lysine residue
located in the constant region of the heavy chain of the antibody. Thiolated anti-CD38 antibodies were
then combined with maleimide-functionalized PEO-b-PBCL, such that antibodies were attached to
the surface of the polymers. Lastly, anti-CD38-conjugated polymers were mixed with NP loaded with
S3I-1757 (i.e., S3I-NP) to generate CD38-S3I-NP.
We then determined if the conjugation of anti-CD38 on the surface of S3I-NP significantly altered
their physical properties. As summarized in Table 1, the average size of CD38-S3I-NP was 91.4 ±
9.4 nm, which is not significantly different from that of S3I-NP (97.4 ± 5.2 nm) (p = 0.39). Similarly,
there is no significant difference in drug encapsulation efficiency between CD38-S3I-NP and S3I-NP
(81.6 ± 7.2% versus 87.0 ± 9.2%, p = 0.47) as well as drug loading (14.7 ± 1.3% versus 15.7 ± 1.7%,
434
Cancers 2019, 11, 248
p = 0.47). The polydispersity index was significantly higher in CD38-S3I-NP compared to that of
S3I-NP (0.367 ± 0.016 versus 0.273 ± 0.003, p < 0.001), suggesting that CD38-S3I-NP is less uniform in
size compared to S3I-NP, possibly due to antibody aggregation. As shown in Figure 1B, significantly
more S3I-1757 was found to be released from CD38-S3I-NP than that from S3I-NP after 1, 2, and 4
hours of incubation (p < 0.001, p < 0.001, and p = 0.002, respectively). Nevertheless, both formulations
reached a comparable amount of S3I-1757 release (~68%, p = 0.59) at 24 h. Taken together, the physical
properties between these two formulations are not substantially different.
Figure 1. The synthesis of CD38-S3I-NP. (A) Chemical reactions of the anti-CD38 conjugation to
PEO-b-PBCL, the building block of our nanoparticles (NP). The final product was mixed with S3I-NP to
generate CD38-S3I-NP. (B) The release of S3I-1757 from S3I-NP or CD38-S3I-NP in vitro. The percentage
of S3I-1757 released was calculated by the lost amount of S3I-1757 compared to the initial total amount
of S3I-1757. The error bar represents the standard deviation from a triplicate experiment; * p < 0.05,
via Student’s t-test.











S3I-NP 97.4 ± 5.2 0.273 ± 0.003 87.0 ± 9.2% 15.7 ± 1.7%
CD38-S3I-NP 91.4 ± 9.4 0.367 ± 0.016* 81.6 ± 7.2% 14.7 ± 1.3%
* p < 0.05, compared to S3I-NP.
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2.2. Anti-CD38 Conjugation on NP Results in More Cellular Uptake by MM Cells
We then determined if the conjugation of anti-CD38 to NP can significantly improve the uptake
of NP by MM cells. To facilitate the detection and quantification of NP in vitro, we synthesized Cy5.5
(a fluorophore)-conjugated NP with or without the coating of anti-CD38 (denoted as Cy5.5-CD38-NP
and Cy5.5-NP, respectively). The NP used in these experiments was not loaded with the STAT3
inhibitor to avoid drug-induced cytotoxicity, which can potentially interfere with our assays. Two MM
cell lines (U266 and RPMI8226) were used. SupM2, an ALK-positive anaplastic large cell lymphoma
cell line, was used as a negative control. The CD38 expression in the two MM cell lines and the absence
of CD38 expression in SupM2 are illustrated in Figure S1A,B. As shown in Figure 2, both MM cell
lines incubated with Cy5.5-CD38-NP for 4 h exhibited a significantly higher level of intracellular Cy5.5
compared to cells incubated with Cy5.5-NP. Specifically, in U266 cells, Cy5.5-CD38-NP treatment
yielded 43.2 ± 0.1% Cy5.5-positive cells, whereas Cy5.5-NP treatment resulted in only 0.4 ± 0.1%
Cy5.5-positive cells (p < 0.001). Similarly, in RMMI8226 cells, Cy5.5-CD38-NP yielded significantly more
Cy5.5-positive cells than Cy5.5-NP treatment (76.7 ± 1.1% versus 1.2 ± 0.1%) (p < 0.001). Compared
to the background (i.e., no treatment), Cy5.5-CD38-NP only minimally increased the proportion of
Cy5.5-positive cells in SupM2 cells (9.2 ± 0.3%).
Figure 2. Flow cytometry analysis of the Cy5.5-positive cell population 4 h after treatment of Cy5.5-NP
or Cy5.5-CD38-NP. Anti-CD38-conjugated NP exhibits improved cellular uptake of NP by multiple
myeloma (MM) cells. Cy5.5 was chemically conjugated to the core of NP. The gated area was defined
using the cells without NP treatment. The representative dot plot from a triplicate experiment is shown.
The error values represent the standard deviation from the triplicate experiment. A non-MM cell line,
SupM2, was included for comparison. The fold change in cell uptake was calculated by dividing the
percentage of Cy5.5-positive cells with Cy5.5-CD38-NP treatment by that with Cy5.5-NP treatment.
The error bar represents standard deviation from a triplicate experiment; * p < 0.05, via Student’s t-test.
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2.3. CD38-S3I-NP is More Cytotoxic to MM Cells than S3I-NP
We next assessed the cytotoxicity of CD38-S3I-NP compared to S3I-NP in two MM cell lines
(U266 and RPMI8226) using MTS assay. In these experiments, we added exogenous IL6 (2 ng/mL)
to the cell culture to enhance STAT3 activity in the cells. As shown in Figure 3A, in RPMI8226 cells,
the addition of CD38-S3I-NP led to significantly lower cell viability compared to S3I-NP at 48 h (50
μM, p = 0.001). In U266 cells, significantly lower cell viability of CD38-S3I-NP was seen at 100 μM
compared to S3I-NP (p = 0.007). In contrast, there was no significant difference in reducing cell viability
of SupM2 between the two formulations, although these cells are known to be highly STAT3-active
due to an endogenous tyrosine kinase, NPM-ALK [25]. As a comparison, we repeated the experiments
using the combination of S3I-NP and free CD38 antibodies. As shown in Figure 3A, the results were
similar to those of S3I-NP and significantly inferior to those CD38-S3I-NP in the two MM cell lines. The
inhibitory concentration at 50% (IC50) values generated from all of these experiments is summarized
in Table 2. In the same experiments, we also confirmed that CD38-S3I-NP and S3I-NP were effective in
suppressing STAT3 phosphorylation at residue Y705 (i.e., pSTAT3). Using Western blot analysis, we
found that pSTAT3 induced by IL6 (2 ng/mL) in the two MM cell lines was substantially decreased by
both formulations at 24 h (Figure 3B).
Table 2. IC50 values of U266, RPMI8226, and SupM2 cells treated with different NP.
Cell Line Treatment
IC50 (μM)
24 h 48 h
U266
S3I-NP 136.7–163.6 115.4–148.6 **
CD38-S3I-NP 127.7–151.3 106.3–114.0
S3I-NP + Free Anti-CD38 143.5–172.4 128.6–139.4 **
RPMI8226
S3I-NP 110.9–124.5 88.2–98.1 **
CD38-S3I-NP 100.4–109.8 64.0–73.6




S3I-NP + Free Anti-CD38 90.1–110.0 106.9–134.9
** p < 0.0001, compared to the corresponding CD38-S3I-NP treatment.
2.4. CD38-S3I-NP is More Effective in Suppressing MM Tumor Growth In Vivo Compared to S3I-NP
We then elucidated if CD38-S3I-NP has therapeutic advantages over S3I-NP in a SCID mouse
xenograft model. As detailed in Materials and Methods, we xenografted U266 cells stably expressing
a luciferase expression construct (U266-luc) in SCID mice, such that the growth of tumors can be
easily tracked ex vivo using bioluminescence imaging. When the tumors became detectable, S3I-NP
or CD38-S3I-NP was injected intravenously. On day 15 after the injection of NP, 4/4 animals in
the S3I-NP group reached the endpoints as defined in Materials and Methods, while 1/4 animals
in the CD38-S3I-NP group did not. Statistical analysis reveals a trend for a longer survival for
the CD38-S3I-NP group, although the difference between the two groups does not reach statistical
significance (p = 0.079, Mantel-Cox test), most likely due to the small sample size. As a control,
both mice treated with phosphate buffered saline (PBS) reached the endpoints on day 12.
Other than the time needed to reach the endpoints, we also directly assessed tumor growth in
the two study groups. Specifically, we summed up the levels of detectable bioluminescence (radiance
ranged between 4.00 × 105 and 1.00 × 107 p/sec/cm2/scr) by using the IVIS Spectrum In Vivo Imaging
System, as described in Materials and Methods. Images of a representative animal from each of the
CD38-S3I-NP, S3I-NP, and PBS groups are shown in Figure 4A. Animals in the CD38-S3I-NP group
had significantly lower tumor volume compared to the S3I-NP group at 240 and 288 h (p = 0.018 and
p = 0.006, respectively). Since we had only two animals in the PBS group, the statistical significance
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cannot be determined for this group. Nonetheless, it is evident that the tumors grew substantially
faster than those in the CD38-S3I-NP group (tumor volume at 288 h was 16.8 times higher).
Figure 3. CD38-S3I-NP induces cytotoxicity and inhibits STAT3 activity in MM cells. (A) U266 and
RPMI8226 cells were then treated with S3I-NP, CD38-S3I-NP, or S3I-NP with free CD38 antibody
at a concentration which is equivalent to CD38-S3I-NP (1.4 mg/mL) with the presence of IL6
(2 ng/mL) for 24 and 48 h. Cell viability was measured using a 3-(4,5-dimethylthiazol-2-yl)-
5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) cell viability assay in triplicate;
* p < 0.05, via Student’s t-test. (B) Western blot analysis of STAT3 and pSTAT3 levels in U266 and
RPMI8226 cells treated with S3I-NP or CD38-S3I-NP with the presence of IL6 (2 ng/mL) for 24 h.
β-actin was blotted as a loading control.
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Figure 4. CD38-S3I-NP is more tumor suppressive than S3I-NP in MM xenograft. (A) SCID mice
intravenously injected with PBS (black line, n = 2), 3 mg/kg S3I-NP (green line, n = 4) or CD38-S3I-NP
(blue line, n = 4) every day for two days as indicated by arrows on the x-axis. Animal numbers other
than the initial numbers at different time points are indicated. The tumor size was quantified by the
bioluminescence intensity and normalized to the initial bioluminescence signal (i.e., 2 h post-injection).
The representative bioluminescence images of animals treated with PBS, S3I-NP, or CD38-S3I-NP
were shown. * p < 0.05, via Student’s t-test; EU—euthanized. (B) The pSTAT3 levels in bone marrow
mononuclear cells extracted from the SCID mice in (A) at the endpoint. Non-tumorous brain tissue
from a SCID mouse was used as a negative control. SupM2 cells were used as a positive control for
pSTAT3. β-actin was blotted as a loading control. (C) Immunocytochemical staining of pSTAT3 and in
bone marrow mononuclear cells from (B). Each image represents bone marrow cells from one animal.
The images were taken at a magnification of 400×.
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We then assessed if the differences in tumor growth and survival between the CD38-S3I-NP
and S3I-NP groups correlates with a difference in STAT3 down-regulation. To achieve this goal,
we extracted bone marrow cells from specific bone fragments in which the involvement by MM was
confirmed by the expression of bioluminescence. The expression of pSTAT3 was then detected using
Western blot analysis and immunocytochemistry. The vast majority of cells extracted from the lesions
(detailed in Materials and Methods) were confirmed to MM cells morphologically by using CD38
immunocytochemistry. pSTAT3 immunocytochemistry was then performed, and we found that MM
cells from the CD38-S3I-NP group had no or barely detectable pSTAT3 signals, whereas MM cells
from the S3I-NP group had relatively strong pSTAT3 signals in most of the cells examined (Figure 4B).
This difference in pSTAT3 expression between the two groups was further confirmed by Western blot
analysis (Figure 4C).
3. Discussion
It has been demonstrated that a number of novel NP drug delivery systems can significantly
improve drug bioavailability in experimental models [26]. The mechanism for this improvement
is believed to be attributed to the large size of the NP, which can pass through the leaky tumorous
vasculature but not the normal blood vessels, resulting in the preferential accumulation of these NP in
the tumors [26]. Many NP also allow the encapsulation of hydrophobic drugs which otherwise cannot
be delivered to the cellular targets in their free form [27]. In this regard, our group had previously
developed an NP which can effectively encapsulate and deliver cucurbitacin, a naturally occurring
STAT3 inhibitor, making it more compatible for clinical use [28]. More recently, we used the same NP to
encapsulate S3I-1757, a newly developed STAT3 inhibitor with higher potency and specificity, and we
found that this NP (i.e., S3I-NP) demonstrated significant therapeutic efficacy against melanoma in a
SCID mouse xenograft model [24].
To further improve the therapeutic potential of NP in treating cancer, various researchers have
attempted to decorate NP with various targeting moieties such as monoclonal antibodies. For example,
in a subcutaneous breast cancer xenograft mouse model, it was found that trastuzumab (an anti-HER2
antibody)-conjugated NP carrying doxorubicin was accumulated in the xenografts better than NP
without antibodies, and this finding correlated with a >50% improvement in the reduction of tumor
volume [7]. Similarly, in two other studies, cetuximab (an anti-EGFR antibody)-conjugated NP
loaded with paclitaxel or gemcitabine was also found to show superior efficacy and tumor-targeting
effects compared to NP without antibody conjugation [29,30]. Our group has previously found that
anti-CD30 conjugated to a commercially available liposomal doxorubicin (Doxil®) was significantly
more effective in treating ALK-positive anaplastic large cell lymphoma in a SCID mouse xenograft
model [31]. In addition to the targeting function, antibodies conjugated on the surface of NP are also
believed to prevent the uptake/removal of the drugs by the reticuloendothelial system [32].
The testing of STAT3 inhibitors in treating MM has been previously attempted. Previous studies
have reported that novel STAT3 inhibitors such as atovaquone, SC99, and LLL12 can kill STAT3-active
MM cells and significantly suppress subcutaneous tumors in SCID-mouse xenograft models [33–35].
However, these new anti-STAT3 agents appear to be structurally hydrophobic; without a carrier,
their clinical uses will be limited as they are water-insoluble. Regarding CD38, we believed that this
is a good target for MM because it is highly expressed in most cases of MM and its expression
is relatively restricted in normal cells [36]. CD38 has been regarded as a therapeutic target for
MM, and daratumumab is the first human anti-CD38 antibody approved by the Food and Drug
Administration for treating MM [37,38]. To the best of our knowledge, our study is the second to
report the development of an antibody-conjugated NP to treat MM. The first study was reported in
early 2018, in which anti-CD38 conjugated NP carrying bortezomib exhibited a 2 to 3-fold increase in
cell uptake by MM cells and a ~50% greater reduction of MM tumor growth compared to non-targeted
NP [39]. These results are in line with our findings. Taken together, we believe that NP carrying a
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potent STAT3 inhibitor (such as S3I-1757) decorated by anti-CD38 is a reasonable approach to treat
MM. Our data is in support of this concept.
The method we employed to conjugate anti-CD38 onto NP involved thiolation of the lysine
residues of the constant region of immunoglobulins. The thiolated antibody then formed a highly
stable thioester bond with the maleimide polymers. We believe that our conjugation method can
provide two main advantages compared to that used in the other study of using anti-CD38 conjugated
NP to treat MM, in which anti-CD38 was attached to NP via biotinylation [39]. First, the covalent
thioester bond between the antibody and NP is substantially more stable than the non-covalent
biotinylation bond, which likely results in a longer half-life of NP in vivo. Second, compared to
biotinylation, the thiolation process of anti-CD38 is limited to its constant region, thus minimizing
the risk of re-directing the antibodies in the wrong orientation (i.e., the hypervariable region of the
immunoglobulin pointing inward). Thus, we believe that thiolation of the immunoglobulin can confer
better stability and therapeutic efficacy to the NP.
Due to the NP barrier and the superior MM cell-targeting ability, we speculated that CD38-S3I-NP
would possess a higher maximal tolerable dose and lower incidences of adverse effects compared
to S3I-NP and free S3I-1757. Unlike OPB-31121, CD38-S3I-NP is not orally available since it can
dissemble under conditions of adverse pH within the gastrointestinal tract. Thus, intravenous injection
will be the best method to administer CD38-S3I-NP. Because STAT3 activity is linked to resistance
to chemotherapy in MM, combined therapy of bortezomib, thalidomide, or dexamethasone with
CD38-S3I-NP may improve response rates. One possible caveat of using CD38-S3I-NP in clinical
settings is the fast clearance through the liver and kidneys. Therefore, approaches which prevent rapid
NP clearance have to be developed to avoid toxicity to these organs.
4. Materials and Methods
4.1. Materials and Cell Culture
S3I-1757 (white powder with a molecular weight of 521.6 g/mol, soluble in DMSO) was
obtained from Glixx Laboratories (Hopkinton, MA, USA). Methoxy-PEO (average molecular weight
of 5000 g/mol), diisopropylamine (99%), benzyl chloroformate (tech 95%), sodium (in kerosin),
butyllithium in hexane (2.5 M solution), palladium-coated charcoal, pyrene, and Cremophor® EL
were purchased from Sigma Aldrich (St. Louis, MO, USA). α-benzyl carboxylate ε-caprolactone
was prepared by Alberta Research Chemicals Incorporation (Edmonton, AB, Canada). Stannous
octoate was purchased from MP Biomedicals Incorporation (Solon, OH, USA). All other chemicals
were reagent grade. U266 and SupM2 cells were purchased from American Type Culture Collection
(Manassas, VA, USA). RPMI8226 cells are a gift from Dr. Linda Pilarski (Department of Oncology,
University of Alberta, Edmonton, AB, Canada). The cells were cultured in RPMI 1460 medium
with L-glutamine (Life Technology, Carlsbad, CA, USA), 10% FBS (Life technology) and, 100U/mL
penicillin/streptomycin (Sigma Aldrich). All cells were incubated at 37 ◦C supplied with 5%
atmospheric CO2.
4.2. Purification of Anti-CD38
The hybridoma cells (TBH-7) producing humanized anti-CD38 were cultured in RPMI1460
medium supplied with 10% fetal bovine serum. When the cells were confluent, they were transferred
to RPMI1460 medium with 10% ultra-low IgG fetal bovine serum (ThermoFisher, Waltham, MA,
USA). The cell supernatant was collected after 48 h. 150 mL of supernatant was concentrated to 5 mL
using Amicon Ultra-15 Centrifugal Filter Unit (Millipore, Burlington, MA, USA). The concentrated
supernatant was incubated in NAb™ Protein A/G Spin Column (ThermoFisher) for 10 min. The bound
antibody was eluted out using the elution buffer (ThermoFisher). The concentration of purified
anti-CD38 was measured by NanoDrop™ 1000 Spectrophotometer (ThermoFisher). The purified
anti-CD38 was dialyzed in sterile PBS overnight prior to NP conjugation.
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4.3. Preparation of NP
Poly-(ethylene oxide)-block-poly-(α-benzyl carboxylate ε-caprolactone) (PEO-b-PBCL) was
synthesized using the method previously described [40]. In brief, α-benzyl carboxylate ε-caprolactone
was mixed with methoxy-poly-(ethylene oxide) at 1:1.12 weight ratio with a trace amount of stannous
octoate. The reaction mixture was incubated for 4 h at 140 ◦C in the vacuum oven and stopped
by cooling the reaction at room temperature overnight. S3I-NP was prepared from PEO-b-PBCL
block copolymers as previously described [24]. In brief, 20 mg of block copolymer was dissolved in
tetrahydrofuran and was mixed with 2 mg S3I-1757 dissolved in DMSO. The mixture was incubated at
room temperature with stirring overnight. The excess S3I-1757 was removed by centrifugation. For
anti-CD38 conjugation, anti-CD38 was mixed with 2-imidothiolane at room temperature at pH 8.0 to
synthesize thiolated anti-CD38. The maleimide PEO-b-PBCL was prepared by following a previously
established protocol [41]. Micellized maleimide PEO-b-PBCL was mixed with thiolated anti-CD38.
The anti-CD38 conjugated NP were mixed with S3I-NP in water to form CD38-S3I-NP through
post-insertion method. The size and polydispersity index of S3I-NP and CD38-S3I-NP were measured
by Zetasizer Nano®. The S3I-1757 concentrations in CD38-S3I-NP and S3I-NP were measured by
high-performance liquid chromatography (HPLC) using a previously established protocol [24]. For the
synthesis of Cy5.5-conjugated NP, a previously described protocol was followed [42].
4.4. In Vitro Release Assay
In vitro release assay was carried out as previously described [24]. In brief, 1 mL of CD38-S3I-NP
or S3I-NP was put in a semi-permeable dialysis bag (molecular weight cutoff: 12,000–14,000 kDa).
The bag was placed in sterile PBS and incubated in a shaking water bath at 37 ◦C. A 50 μL aliquot
from the dialysis bag was collected at various time points for S3I-1757 concentration measurement by
HPLC analysis. To maintain the total volume, 50 μL of PBS was added back to the dialysis bag after
aliquot collection.
4.5. Cellular Uptake Assay
NP chemically conjugated with Cy5.5 (an amount equivalent to 0.2 ng Cy5.5) was added to 1.0 ×
106 U266, RPMI8226 and SupM2 cells and cultured at 37 ◦C in dark for 4 h. Cells were washed with
sterile PBS twice and subjected to flow cytometry (BD FACSCantoII, Franklin Lakes, NJ, USA) analysis
using the Per-Cy5.5-APC fluorescence channel.
4.6. Cell Viability Assay
Cell proliferation was assessed by the CellTiter 96® AQueous one solution cell proliferation
MTS assay (Promega, Madison, WI, USA). Approximately 2.5 × 104 U266 or RPMI8226 cells were
seeded in each well of a 96-well plate and treated for 24 or 48 h, and 20 μL 3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) was added to each well.
The absorbance of light at 490 nm was measured by a FLUOstar OPTIMA microplate reader (BMG
Labtech, Cary, NC, USA). The IC50 values were calculated by Graph Prism 7 from the cell viability
versus the logarithm of the concentration curve.
4.7. Western Blot Analysis
Total cell lysates were prepared and lysed with 1× RIPA buffer (10× stock solution from Cell
Signaling Technology, Danvers, MA, USA) with 0.05% protease inhibitor cocktail (Millipore) and 0.05%
phosphatase inhibitor cocktail (Millipore). Protein concentrations were measured using a Pierce™
BCA Protein Assay Kit (ThermoFisher). Cell lysates treated with SDS were subject to SDS-PAGE and
transferred onto a nitrocellulose membrane. The membrane was probed with anti-STAT3 (1:1000, CST,
#9139), anti-pSTAT3 (Y705) (1:2000, CST, #9145), and anti-β-actin (1:1000, CST, #58169) diluted in 5%
BSA in TBS-Tween20 (0.05%, v/v). These antibodies were probed with anti-mouse IgG conjugated
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with horseradish peroxidase (1:1000, Cell Signaling). The membrane was washed three times with
TBS-T after secondary antibody treatment. The bands on the membrane were visualized with Pierce™
ECL Western blotting substrate (Thermo Scientific) and exposed to X-ray films (Fuji, Tokyo, Japan).
4.8. Preparation of U266-luc Cells by Lentiviral Transduction
Lentiviral particles carrying pLenti-Puro-luc were a kind gift from Dr. Kyle Potts and Dr. Mary
Hitt (Department of Oncology, University of Alberta, Edmonton, AB, Canada). Also, 2 × 106 U266
cells were transduced with 2 mL of lentiviral particles and 6 μg/mL polybrene on a 6-well plate after
30 min of spin inoculation at 1000× g. After 24 h, cells were washed and replenished with fresh
lentiviral particles for another 24 h. Transduced cells were washed with PBS and resuspended in fresh
growth medium for 2 days. The transduced cells were selected with 2 μg puromycin (ThermoFisher)
in the medium. The luciferase activity of U266-luc cells was measured by bioluminescence imaging
(Figure S2A). The growth rate and responsiveness to S3I-1757 of U266-luc were confirmed to be
insignificantly different from parental U266 cells (Figure S2B,C).
4.9. In Vivo Studies Using MM Xenograft
The experimental protocols for all in vivo studies in this manuscript were approved by Animal
Care and Use Committees, University of Alberta (#AUP00000282). Half of a million U266-luc was
injected into SCID mice (Jackson, strain NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) intravenously. Twelve
days after injection, 100 μL of S3I-NP or CD38-S3I-NP colloidal dispersions in dextrose 5 % was
injected into the mice intravenously via the tail vein for two consecutive days at a dose of 3 mg/kg per
day. The tumor size was measured by quantifying the total flux of bioluminescence signals detectable
(radiance ranged between 4.00 × 105 and 1.00 × 107 p/sec/cm2/scr) on the ventral side of each
animal at various time points using Living Image Software (PerkinElmer, Waltham, MA, USA). At
the endpoint defined by the approved protocol, the animals were euthanized and the bone marrow
cells with MM bone lesion (visualized by bioluminescence) were removed from the femoral bone and
split into two portions. One portion was stored at −80 ◦C as cell pellets for Western blot analysis, and
another was stored in 4% paraformaldehyde at 4 ◦C for immunocytochemistry.
4.10. Immunocytochemistry
Mouse bone marrow cells in 4% paraformaldehyde (Sigma Aldrich) were pelleted and
resuspended in liquid histogel (Thermo Scientific) and transferred to a 15 × 15 mm2 plastic mold
(Leica, Wetzlar, Germany). Upon solidification, the cell-histogel was subjected to processing and
embedding. The cell blocks were sectioned into 5-μm slides. Slides were rehydrated in xylene and
decreasing concentrations of ethanol. The antigens were retrieved using 1× citrate buffer (Sigma) by
microwaving in a pressure cooker for 20 min. pSTAT3 (1:50, Santa Cruz, #sc-8059) and CD38 antibodies
(1:100, Abcam, #ab108403) were diluted at 1:100 in antibody diluent (DAKO, Glostrup, Denmark).
MACH2 mouse HRP polymer (Biocare Medical, Pacheco, CA, USA) was used as a secondary antibody.
The chromogen and substrate were mixed and applied to each slide for 2 min for color development
(DAKO).
4.11. Statistical Analysis
All numerical data in this study was presented as the mean from experiment replicates or
independent experiments as described in the figure legends. For the comparison of IC50 values in
Table 2, two-way ANOVA and Tukey’s multiple comparison test were employed. For survival analysis
in the animal study, Statistical significance between groups was analyzed using the Mantel-Cox test
(α = 0.05). For the remaining comparisons, a Student’s t-test with α = 0.05 was used for the statistical
analysis. The analysis was done using Microsoft Excel 365, except for Table 2, Figure 4A, and the
overall survival analysis in the animal study, for which GraphPad Prism 7 was used for analysis.
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5. Conclusions
In summary, this study has provided the proof-of-principle that the decoration of anti-CD38 on
NP loaded with STAT3 inhibitors can further improve their therapeutic effects against MM. We also
predict that the use of these NP can significantly lower the unwanted side effects of STAT3 inhibitors,
as they are targeted to cancer cells, and preferentially released inside of these cells. These encouraging
results provide sufficient basis for a Phase I clinical trial.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/2/248/s1,
Figure S1: MM cell lines express high levels of CD38, Figure S2: Characterization of U266-luc cells.
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Abstract: The use of transgenic mouse models has revolutionized the study of many human diseases.
However, murine models are limited in their representation of spontaneously arising tumors and
often lack key clinical signs and pathological changes. Thus, a closer representation of complex
human diseases is of high therapeutic relevance. Given the high failure rate of drugs at the clinical
trial phase (i.e., around 90%), there is a critical need for additional clinically relevant animal models.
Companion animals like cats and dogs display chronic inflammatory or neoplastic diseases that
closely resemble the human counterpart. Cat and dog patients can also be treated with clinically
approved inhibitors or, if ethics and drug safety studies allow, pilot studies can be conducted using,
e.g., inhibitors of the evolutionary conserved JAK-STAT pathway. The incidence by which different
types of cancers occur in companion animals as well as mechanisms of disease are unique between
humans and companion animals, where one can learn from each other. Taking advantage of this
situation, existing inhibitors of known oncogenic STAT3/5 or JAK kinase signaling pathways can be
studied in the context of rare human diseases, benefitting both, the development of drugs for human
use and their application in veterinary medicine.
Keywords: cancer models; companion animals; STAT3; STAT5; comparative oncology
1. Introduction
Almost half of all households in the United States have at least one companion animal. This means
that approximately 77 million dogs and 58 million cats share a common environment with their human
owners and are largely exposed to the same health risk factors [1]. In the absence of significant
cardiovascular disease, cancer is the number one cause of death for dogs, killing between 40% and 50%
of individuals older than 10 years, and between 20% and 25% regardless of age [2–4]. Numbers are less
detailed for cats, but the overall tumor incidence ranges between 30% and 35% [5]. The prevalence of
cancer in companion animals has increased in the last decades, which may be the result of a real increase
in cancer incidence, an increase in the population of companion animals at risk or the awareness
and willingness of the animal owners to pursue diagnostic and treatment options [6]. While the full
spectrum of tumor types seen in humans also occurs in cats and dogs, the rates for individual tumor
types are often different. Canine osteosarcoma, soft tissue sarcoma and feline non-Hodgkin’s lymphoma
for example are significantly higher than in humans (Table 1), whereas other tumor entities like lung,
prostate and colon tumors are rare in companion animals. Cancer in companion animals, particularly
in dogs, resembles cancer in humans in many ways, including spontaneous disease occurring without
an isogenic background or genetic engineering and shared environmental and societal status with
owners. Further similarities in chronology of the disease adapted to lifespan, organization into various
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well-characterized breeds that show different incidences of tumor types, and shared environmental
and societal status with owners makes them attractive objects for comparison.
Table 1. Incidence rates of various tumor types from human, dog and cat.
Tissue Human Dog Cat
Mammary 127.5 [7] 250 [8] 13–25 [9]
Melanoma 22.2 [7] 19.8 [10] ND
Testes 5.9 [7] 16.7 [11] ND
Connective Tissue 3.5 [7] 40.1 [10] 17.0 [1]
Skin 98.85 [12] 103.3 [10] 34.7 [1]
Oral 11.3 [7] 20.4 [1] 11.6 [1]
NHL/Leukemia 33.7 [7] 76.3 [13] 41 [14]
Bone 1.0 [7] 27.2 [15] 3.1–4.9 [16]
Numbers represent cases per 100,000. ND = not determined.
The mouse has been an extremely useful tool to gain cellular and mechanistic understanding into
the development of cancer [17]. The concept of oncogenes and tumor suppressors balancing cellular
proliferation of multicellular organisms has been proven in vivo in genetically modified mice [18,19].
The use of mice deleted for a single gene has allowed us to determine the involvement of signaling
pathways, genetic regulators like transcription factors, epigenetic factors, etc. in the development
and sustained growth of cancer. Overall, experiments in mouse models have been invaluable in
understanding the mechanistic basis of cancer biology. However, while offering critical insights into
basic concepts, murine models underrepresent the heterogeneity and complex interplay between
human immune and cancer cells [20,21].
The Janus kinase (JAK)—signal transducer and activator of transcription (STAT) signaling
pathway—provides a fast and efficient way for relaying signals from the extracellular space to the
nucleus and modifying gene expression [22]. Main targets of this pathway represent regulators of
cell division and apoptosis as broadly discussed in several publications in this special issue [23–25].
As these are central aspects in the development of cancer, it is not surprising that members of this
pathway are over-activated in many cancers [26,27]. The kinases of this pathway, JAK 1-3 and TYK2
are constantly activated in several different tumor types and are subject to pharmacological inhibition.
Recently, also STAT proteins have come into focus of cancer researchers. Particularly STAT3 and STAT5
are activated in over 70% of all human cancer types and constitute a critical node in the signaling
networks of tumor cells [28].
This review will highlight, why companion animals and particularly the dog represent an attractive
link between murine models, addressing basic mechanistic aspects and human diseases specifically in
the context of JAK-STAT signaling.
2. Preclinical Models
The vast majority of cancer models currently are represented by mice, and their fundamental
importance for preclinical research is clearly established [20,29]. These animals come as various strains
that have been inbred over many generations and thereby are genetically highly homogenous [30].
When used for experiments, they are matched for age, sex and size, receive the same sterile diets and
are housed under specific pathogen-free (SPF) conditions. All of these factors are controlled for in
order to generate standardized conditions that allow us to draw scientifically sound conclusions based
on the variation of one single parameter [31]. Furthermore, this reduction of variables and thereby
“noise” allows us to reduce the number of animals necessary to reach statistically significant results.
While this concept has proven its scientific merits and is logical within itself, it is questionable, whether
young, sex-matched and inbred mice on sterile nutrition are a good representation of the typically
older, obese and genetically diverse human cancer patients [32].
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The controlled environment also affects the outcome of cancer-related experiments. For example,
it has become clear recently, that the microbiome influences the response to cancer treatment [33,34].
Accordingly, mice raised under SPF conditions in various research institutions show differences in the
composition of their gut microbiome, affecting tumor growth rates [35]. Again, while differences in the
gut microbiome are likely to exist in human cancer patients, the single standardized composition under
which these experiments are carried out in laboratory mice are very likely no close representation
of the much broader spectrum in humans. Additionally, rodents have adopted to most ecosystems
metabolically, but in regard to drug metabolism, due to growth-hormone regulated p450 cytochrome
components, pharmacodynamic and pharmacokinetic properties, canines are by far superior and
therefore used as key models for FDA-drug approved testing [36].
Another important aspect is the genetic background and its modification particularly with
respect to the immune system. Mice used for tumor experiments usually are highly inbred, reducing
genetic variability [37]. Experiments regarding the consequences of a narrow genetic background have
demonstrated potential phenotypic tilting, which may result in unrepresentative biased phenotypes [38].
Furthermore, the buffering of genetic variation, including disease-causing mutations, is impaired under
these circumstances [39]. One effort to overcome limitations due to a narrow genetic background is
to establish new reference populations derived from the crossing of several different mouse strains,
as exemplified by the Collaborative Cross project [40]. By broadening and defining the genetic basis,
it offers the perspective of enhancing genetic stability and reproducibility, thereby also representing a
new and potentially better resource of murine models for human diseases.
Additionally, and probably of higher practical relevance is the fact that development and
proliferation of tumor cells happens in a complex interplay with cells of the immune system [41].
However, cancer-studies in mice are often performed in the absence of a fully functional immune system,
using immunocompromised mice as hosts for transplantations of human cell lines, patient-derived
xenografts or human tumor-derived immune cell xenografts [42]. The immune system constitutes the
major player in the counter-selection against tumor cells, thereby necessitating evasion or adaption
strategies on the side of the tumor cells. Since this aspect is missing in such mouse models, the results
from experiments thereof likely reflect only partial aspects of tumor biology and challenge their
biological relevance.
One way to overcome these problems are humanized mice, which express human instead of
murine components of the immune system like major histocompatibility complex, allowing the
transplantation of tumor cells in an immunologically at least partially competent environment [43].
These models clearly represent a step forward, however, they are costly, technically complicated and
still do not represent all components of a functional and homogenous immune system [44]. Moreover,
human patients that have developed cancer are not living under special pathogen-free conditions
and are very likely to have chronic viral infections, like the Epstein–Barr virus, cytomegalovirus
or herpes simplex, which are present in up to 90% of the total population [45–47]. Such chronic
infections exert a constant pressure and shape the immune system, which is not the case in mice
under SPF conditions. Co-housing of “dirty” outbred immunocompetent mice could be a way for
improvement, still mammalian viral species barriers exist, that make companion animals superior in
these infectious aspects.
Finally, genetically engineered mice harboring the deletion of a tumor suppressor gene or the
ectopic expression of an oncogene or combinations thereof can be used [48]. In this case, the tumors
develop in the presence of a competent immune system and problems related to cross-species
compatibility do not arise. This setting also enables the introduction of defined mutations that occur
in human tumors. However, this comes at the price of costly and time-consuming development,
often requiring years of work before availability. Furthermore, whereas the targeted insertion of defined
mutations reflecting the human situation is a clear advantage, cancer development is a multi-step
process, and the heterogeneity of these further steps is often different between engineered mice and
human patients [49,50].
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Overall, the mouse has been highly instructive in determining genes involved and their mechanistic
contribution to the origin and development of cancer [51]. However, the limitations of this model,
in particular the differences in environment and microbiome, life span, tumor etiology and genetic
status may be the reason why certain aspects are not reflected closely in this model, resulting in
only 11% of oncology drugs that work in mice being approved for human use [52]. Therefore, it is
desirable from a translational perspective to add another layer that closer reflects human biology and
cancer development.
3. Advantages and Disadvantages of Canine Tumor Models
Roughly 4,000,000 dogs and a similar number of cats are diagnosed with cancer each year in the
U.S. [53]. Although exact epidemiological data are not available for companion animals, this translates
into approximately 5300 cases per 100,000 dogs, which is around ten times higher than in humans
with 500 cases per 100,000 persons. This large number of pets provides the opportunity to study
spontaneous cancers that are highly similar to those occurring in humans, especially since most pet
owners are highly motivated to seek out novel treatments for their companion animals.
There are several advantages of using companion animals as models for human cancer.
Among them is the fact that tumors arise spontaneously, just as in humans, and that tumor initiation
and progression are influenced by similar factors like age, nutrition, sex, reproductive status and
environmental exposure [54]. The risk for developing cancer of the nasal cavity for example is increased
up to 60% in animals that are kept by smokers in comparison to pets of non-smoking owners [55,56].
Although there are differences in the diet of humans and companion animals, many components
such as meat, vegetables and carbohydrates are derived from the same sources and are consumed
non-sterile as opposed to mice under SPF conditions [57]. Furthermore, studies have shown that the
contact between owner and pet leads to a large overlap in the microbiome, the importance of which for
human tumor development has come into focus recently [58].
Pets, and in particular dogs are large and relatively outbred in comparison to laboratory mice.
In fact, the genetic variation across dog breeds or in mixed breeds is similar to the variation in
humans on the basis of single nucleotide polymorphisms [59]. In individual pure breeds however,
the level of genetic diversity is more restricted [60]. The canine genome has been sequenced with
a coverage of 99%, revealing that the approximately 19,000 genes identified in the dog match to
homologous or orthologous genes in humans [59]. Actually, for many gene families, particularly for
those associated with cancer, the homologies are significantly closer than the relationship between
human and mouse [61]. Accordingly, most oncogenes and tumor suppressors that are known from
human cancers have been shown to contribute to canine cancers [62].
Dogs and cats of all breeds develop cancer, and the spectrum of cancers seen in companion
animals is as diverse as that seen in human patients [63]. The dog is the species in which comparative
oncology has shown the most growth, and where it is best characterized [64]. Interestingly, there are
breed-specific differences as to the cancer subtypes, reflecting the underlying genetics of the various
breeds (Table 2). Mast cell tumors and gliomas for example are over-represented in Boxers, Staffordshire,
Weimaraner and Golden Retriever, osteosarcoma in Rottweilers, Greyhounds and Golden Retrievers,
bladder cancer in Scottish Terriers, histiocytic sarcomas in Flat-Coated Retrievers and Bernese Mountain
Dogs and melanoma and gastric carcinoma in Chow-Chows [65–67].
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Table 2. Oncological disposition of various dog breeds.
Breeds Most Frequent Tumor Types
Bernese Mountain Dog Histiocytic sarcoma [68], Lymphoma [68,69], Osteosarcoma [68]
Boxer Glioma [67,69], Mast cell tumor [10,67]
Flat-Coated Retriever Soft tissue sarcoma, Histiocytic sarcoma, Hemangiosarcoma [70]
Golden Retriever Mast cell tumor, Lymphoma, Oral Melanoma, Fibrosarcoma [67]
Magyar Viszla Mast cell tumor, Hemangiosarcoma, Lymphoma [10,71]
Giant Schnauzer Epidermal tumor, Hair follicle tumor, Melanocytic tumor [10]
Airedale Terrier Melanoma [72], Lymphoma [67], Prostatic carcinoma [67]
Bullmastiff Mast cell tumor, Lymphoma [67]
St. Bernard Lymphoma [67], Osteosarcoma [73]
Irish Wolfhound Osteosarcoma [67,74], Lymphoma [75]
The most frequent tumor types of dog breeds with high tumor incidence.
The global expression pattern of canine and human osteosarcoma for example shows a strong
similarity, and cluster analysis of orthologous gene signatures does not segregate human and canine
tumors [73]. Finally, many chemotherapy protocols used for the treatment of canine cancers have been
adopted from human medicine. The same chemotherapeutics used in human lymphoma for example
are also active in canine lymphoma (e.g., vincristine, cyclophosphamide, doxorubicin, mitoxantrone,
cytarabine and methotrexate), and drugs that are ineffective in human lymphomas are also inactive in
canines (i.e., gemcitabine, cisplatin and carboplatin) [5].
One of the biggest advantages of companion animals as models for human cancer is the spontaneous
development of tumors in the presence of an intact immune system. Immune cells pose a significant
barrier to the development of cancer, and undergo changes themselves, as cancer cells co-opt the
immune response [76,77]. As a result, the tumor influences innate as well as adaptive immune cells
to become regulatory, rather than tumoricidal [78,79]. This interplay results in the selection of tumor
cells that are invisible to anti-tumor T-cell-mediated destruction, and is central for tumor editing and
immune evasion. Additionally, similar to humans, dogs with advanced cancer exhibit intrinsic T-cell
defects as well as T-cell exhaustion [80]. Immune cell interplay with cancer cells is a JAK-STAT3/5
affair, as detailed in the special issue in several articles [24,25,81].
Like all other model systems, companion animals have strengths as well as weaknesses,
both practically and conceptually. The biggest hurdle, when working with cats and dogs in research
is the paucity of investigational tools. Many antibodies and recombinant products that are available
for humans and mice do not show cross-species reactivity. However, the sequencing of the canine
genome and the development of genome editing via the CRISPR/Cas9 technology has relieved many
of the restrictions [82]. It is now possible to introduced genetic alterations with high efficiency into
any desired locus, facilitating for example the visualization of specific cell types via the expression of
marker proteins, or targeted deletion of single genes [83,84]. Conceptually, the lack of standardized
housing conditions, making it difficult to control for variables, has been held against non-rodent models.
However, as pointed out here, this represents an advantage when it comes to closely mimicking the
translational aspects in tumor biology.
The potential of companion animals as biological models between the basic mechanistic work that
is possible in the mouse and translation to humans is demonstrated by 1. The high conservation at the
genomic level, 2. The involvement of similar genetic and environmental risk factors, 3. The successful
use of canine cancer as biological models for the early development of bone marrow transplantation
protocols and 4. canine trials for the development of drug level and exposure durations. This sets
an ideal stage to combine new perspectives of targeted therapies and specific molecular inhibitors in
the field of comparative oncology for the benefit of human as well as veterinary medicine (Figure 1).
Furthermore, this approach is not limited to cancer but applicable to any comparative condition
including infectious or inflammatory diseases like inflammatory bowel disease or pre-malignant
conditions like adenoma formation or clonal hematopoiesis.
451
Cancers 2019, 11, 2035
Figure 1. Advantages and disadvantages of different models during drug discovery. (A) Companion
animals can be used as an intermediate step between the mechanistic work in murine models and clinical
studies in humans, particularly with regard to comparative aspects of tumor biology. (B) Advantages
and disadvantages of the individual models for translation into human clinical studies.
4. Relevance and Conservation of the JAK-STAT Signaling Pathway
JAK-STAT proteins constitute an evolutionary conserved signaling pathway [85]. Ligand binding
of receptors leads to the activation of JAK kinases and STAT proteins, inducing transcription. The family
of JAK kinases consists of four members, JAK1-3 and TYK2, and there are seven highly homologous
STAT proteins, STAT1–4, STAT5a and STAT5b and STAT6 [22,86]. For details on the mechanism see
also other reviews in this issue [87,88]. As such, this pathway provides a remarkably elegant and
straightforward mechanism to transduce signals from receptors to the nucleus.
All family members show the same structural organization, i.e., an N-terminal domain required
for oligomerization of dimers into tetramers, a coiled-coil domain, a DNA-binding domain, a linker
domain, a Src homology 2 (Sh2) domain for dimerization and a C-terminal transactivation domain
(Figure 2). Functionally, STAT2, STAT4 and STAT6 regulate specific immune cell responses, whereas
STAT1, STAT3 and STAT5 have diverse physiological roles. STAT1 is mostly involved in immunity,
host defense against pathogens and cell death, stimulating the transcription of pro-inflammatory
and anti-proliferative genes like caspases, NOS2, MDM2, CDKN1A and CDKN1B. On the contrary,
STAT3 and STAT5 are mostly involved in cell proliferation and prevention of apoptosis, activating
the transcription of genes like CCND1, BIRC5, c-MYC, VEGF, MCL1, BCL2L1 and BCL2. Additionally,
STAT3 can also be found in mitochondria, where it supports RAS-dependent malignant transformation
via sustained altered glycolytic and oxidative phosphorylation [89,90]. Given their roles in the
stimulation of cellular proliferation, the prevention of apoptosis and the stimulation of metabolism,
STAT5, and even more so STAT3, are activated in nearly 70% of solid and hematological human
tumors [91–93].
Silencing or inhibition of STAT3 or STAT5 signaling impairs tumor growth and survival in murine
and human studies, while only slightly affecting normal differentiated cells [94–97]. These findings
lead to the concept of STAT3 and STAT5 constituting a “signaling bottleneck” situation for tumor cells,
making them attractive targets for inhibition [98]. However, caution has to be exerted with regard to
tissue-specificity, as tumor-suppressive functions have been ascribed to STAT3 in neuronal, hepatic
and colorectal tumors and to STAT5 in breast cancer [99,100].
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Figure 2. Cross-species conservation of STAT protein domains. (A) STAT1, STAT3, STAT5a and
STAT5b from dog, cat and mouse are analyzed for their overall homology compared to the respective
human protein (grey boxes, left). In the schematic representation of STAT protein domains, the amino
acid positions are indicated above. All proteins share the same domain positions, except for murine
STAT1, which has a five amino acid insertion in the DNA binding domain (numbers below the
scheme indicate the aa position in this case). Percentages in the domain boxes of dog, cat and
mouse STAT proteins show the homology of each domain to the human counterpart. Analyses
were carried out using ClustalX. (B) Comparison of key phosphorylation sites in the transactivation
domain of STAT1, STAT3, STAT5a and STAT5b from dog, cat and mouse to the human sequence.
Amino acid sequence is shown, with phosphorylation sites in green and position indicated; positive
amino acid exchanges (conserving protein function) are indicated in yellow, other exchanges in
red. (STAT1: human NP_009330.1, dog XP_848353.1, cat XP_006935505.1, mouse NP_001192242.1;
STAT3: human NP_644805.1, dog XP_005624514.1, cat XP_003996930.1, mouse NP_998824.1; STAT5a:
human NP_001275647.1, dog XP_548091.2, cat XP_023099834.1, mouse NP_001157534.1; STAT5b:
human NP_036580.2, dog XP_548092.1, cat XP_023100377.1, mouse NP_035619.3).
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Several different ways of inhibiting STAT signaling are possible. Upstream of STAT proteins,
JAK kinases are mutated in a broad range of diseases from severe combined immunodeficiency to
various forms of cancer, including JAK1 in acute myeloid leukemia, JAK2 in myeloproliferative diseases
and JAK3 in different leukemias and lymphomas, and inhibitors against JAK kinases are already
approved by the US Food and Drug Administration (FDA) for clinical use [27]. Interestingly, different
layers of negative regulators of JAK-STAT signaling are present such as suppressor of cytokine signaling
(SOCS), protein inhibitor of activated STAT (PIAS) and protein tyrosine phosphatases, arguing for the
necessity of a tightly controlled down-regulation of this signaling pathway [101].
Due to the broad activation, minor side-effects and the overall importance, major efforts by many
laboratories and pharmaceutical companies are ongoing to develop inhibitors against STAT3 and
STAT5. In both cases, all current inhibitors target one of three STAT motifs: the SH2 domain necessary
for the interaction of phosphorylated monomers to form dimers, the N-terminal domain mediating the
formation of tetramers from activated STAT dimers and the DNA-binding domain [102]. STAT3 and
STAT5 from companion animals show more than 96% homology at the overall protein level to their
human counterparts, with a particular high level of conservation of 98% to complete alignment in
these three domains (Figure 2). This high level of conservation opens up the possibility to use pet
animals as models for diseases in which the JAK-STAT signaling pathway is over-activated.
A good example for such a successful application is already established. Cytokine dysregulation
has been implicated in allergic skin disease, particularly in atopic dermatitis in humans. T-helper cells
type 2 (Th2) produce increased levels of IL4, IL5, IL10, IL13 and IL31, in addition to elevated
production of IFNγ by T-helper cells type 1 (Th1), signals that all converge on the JAK-STAT signaling
pathway [27,103–105]. Dermatological problems are the second most common reason for dogs to present
to veterinary practices, frequently including allergic skin diseases like atopic dermatitis [106,107].
In the skin of atopic dogs, a cytokine profile can be found that resembles the human condition,
and in an experimental model of canine allergic dermatitis, elevated transcripts of IL6, IL13 and
IL18 and IFNγ were detected, supporting the idea that cytokine dysregulation plays a role in allergic
skin disease [108–110]. The novel JAK inhibitor oclacitinib is most potent against JAK1, but also
affects JAK2 and JAK3 at reduced efficiency, inhibiting the function of JAK1-dependent inflammatory
cytokines [111]. Treatment of dogs suffering from atopic dermatitis results in a reduction of associated
skin lesions and oclacitinib recently has been approved in the US and Europe for the treatment of
allergic/atopic dermatitis [112–114]. Overall, inhibition of JAK1-dependent cytokines is an effective
and novel way to treat canine allergic skin disease, proving the high similarity and cross-species
conservation of JAK-STAT signaling.
5. Inhibition of STAT3 and STAT5 in Companion Animals: Current Status/Future Perspectives
Currently, STAT3 and STAT5 are studied in several cancer types of companion animals.
Canine mammary cancer cells and diffuse large B cell lymphoma as well as feline oral squamous cell
carcinoma and mammary tumors show activation of STAT3 or STAT5. First results indicate reduced
proliferation and increased apoptosis upon inhibition of JAK1/2 or STAT3 respectively [115–121].
Two areas exemplify the potential of research and development concerning STAT proteins and
human—canine comparative oncology best [122,123]. Osteosarcoma is the most frequent form of
malignant bone disease in dogs, however, it is relatively rare in humans. The estimated incidence rate
is at least 13.9/100,000 in canines and 1.02/100,000 in humans, affecting primarily children [124,125].
Such a high incidence rate provides a good opportunity to study a rare human disease using dogs as a
preclinical model. Moreover, canine and human osteosarcoma share many key features like tumor
location, early metastasis, development of chemotherapy-resistant metastases and altered expression
or activation of several proteins [126].
Consistent activation of STAT3 occurs in a large subset of human and canine osteosarcoma and
osteosarcoma cell lines, but not in normal osteoblasts. Down-regulation of STAT3 expression or activity
reduces proliferation and induces apoptosis in human and canine cell lines [127–130]. Additionally,
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human and canine osteosarcoma possess overlapping transcriptional profiles, further supporting the
concept that these diseases are similar at the molecular level [131]. Spontaneous canine osteosarcoma
has been used for the development of novel therapeutics such as muramyl tripeptide, IGF-1R inhibitors
and rapamycin [132]. However, despite aggressive treatment, 30–40% of children and >90% of dogs are
still dying from disease, demonstrating the need for new therapeutic options. The similarities between
human and canine osteosarcoma, together with the dependency on JAK-STAT signaling, particularly
STAT3, make osteosarcoma one of the prime areas for comparative oncology studies, especially since a
large number of STAT3 inhibitors are currently being developed.
Mast cell tumors arise from the uncontrolled proliferation of transformed mast cells mostly in
skin, spreading primarily to spleen, liver and bone marrow [133]. While mast cell tumors are relatively
rare in humans, they are frequent in dogs, accounting for 7–21% of cutaneous tumors [134,135].
Metastasized tumors in humans as well as in canines have a poor prognosis and short survival
times [133,134,136]. Stem cell factor and its receptor c-KIT are essential for mast cell survival and
inhibition of apoptosis, and gain-of-function mutations are present in human and canine mast cell
tumors [137–142]. Accordingly, two inhibitors of c-KIT, masitinib and toceranib have been approved
for use in c-KIT driven mast cell tumors in dogs. Both drugs are able to suppress tumor growth
temporarily, however, relapses are high, indicating the need for the identification of further targets and
therapeutic options [143,144].
STAT1, STAT3 and STAT5 are activated down-stream of mutant c-KIT, but only STAT5 is
transcriptionally active in neoplastic mast cells [145,146]. Inhibition of JAK2 and STAT5 was recently
discovered to inhibit proliferation and survival of canine mastocytoma cell lines, identifying JAK2/STAT5
signaling as a new potential target in mast cell tumors [147]. Therefore, an attractive option is to
use the frequent occurrence of canine mast cell tumors to determine if inhibitors of STAT5 can be
used alone or in combination with inhibitors of c-kit or other kinases as a new therapeutic option.
Indeed, the potential of STAT5 inhibitors to overcome resistance to a multi-kinase inhibitor in neoplastic
mast cells has been demonstrated [148]. Consequently, the next step is to determine the potential of
new STAT5 inhibitors in vivo [149]. Both of these examples, osteosarcoma as well as mast cell tumors
offer thereby the possibility of using new pharmaceutical in companion animals as a closer biological
mimic of the human situation.
6. Conclusions
Taken together, cancer in dogs resembles cancer in humans in many ways, like its latency, clinical
manifestation and metastatic behavior, its pathobiological characteristics like tumor heterogeneity,
its genomic instability and pharmacogenomic signatures including chemoresistance and last but not
least its multifactorial nature, including genetic and environmental risk factors [150]. The inability of
murine cancer models to recapitulate certain aspects of human tumors is increasingly recognized and
illuminates the huge potential of spontaneous canine and, to a lesser extent, feline cancer [151–153].
The JAK-STAT pathway is activated in the vast majority of solid and hematological tumors, and is
necessary for tumor growth and prevention of apoptosis. The major efforts that are ongoing to develop
inhibitors specifically for STAT3 and STAT5 can be extended to studies in companion animals, an option
that is particularly attractive for rare human diseases occurring more frequently in dogs and/or cats.
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Abstract: While cells from multicellular organisms are dependent upon exogenous signals for their
survival, growth, and proliferation, commitment to a specific cell fate requires the correct folding
and maturation of proteins, as well as the degradation of misfolded or aggregated proteins within
the cell. This general control of protein quality involves the expression and the activity of molecular
chaperones such as heat shock proteins (HSPs). HSPs, through their interaction with the STAT3/STAT5
transcription factor pathway, can be crucial both for the tumorigenic properties of cancer cells (cell
proliferation, survival) and for the microenvironmental immune cell compartment (differentiation,
activation, cytokine secretion) that contributes to immunosuppression, which, in turn, potentially
promotes tumor progression. Understanding the contribution of chaperones such as HSP27, HSP70,
HSP90, and HSP110 to the STAT3/5 signaling pathway has raised the possibility of targeting such
HSPs to specifically restrain STAT3/5 oncogenic functions. In this review, we present how HSPs
control STAT3 and STAT5 activation, and vice versa, how the STAT signaling pathways modulate
HSP expression. We also discuss whether targeting HSPs is a valid therapeutic option and which
HSP would be the best candidate for such a strategy.
Keywords: heat shock proteins; chaperones; stabilization; targeted therapy
1. Introduction to Heat Shock Proteins/Chaperones
Heat shock proteins (HSPs), also called stress proteins, are highly conserved molecular chaperones
induced by a broad variety of exogenous or intracellular stresses, including chemotherapy. Based
on their molecular weight, HSPs have been classified into five conserved families: HSP110 (also
called HSPH), HSP90 (HSPC), HSP70 (HSPA), HSP60 (HSPD/E), and the small HSPs (HSPB). The
expression of HSPs is mostly regulated by heat shock factor 1 (HSF1), which is able to translocate
from the cytoplasm to the nucleus following stress to bind to a short, highly conserved DNA sequence
known as a heat shock element (HSE) [1]. As cytoprotective proteins, HSPs participate in the correct
folding, activity, transport, and stability of proteins [2], which are essential processes for cell survival.
In physiological conditions, these proteins support neosynthesized proteins, favoring post-translational
modification processes and protein folding. Otherwise, the functions attributed to them include
the subcellular transport of their “client” proteins, or participation in certain signaling pathways.
In response to stress, many partially denatured proteins accumulate and cluster together forming
protein aggregates via the exposure of their hydrophobic residues. Some HSP proteins are then able
to bind to these partially denatured proteins, thus preventing protein aggregation and favoring their
Cancers 2020, 12, 21; doi:10.3390/cancers12010021 www.mdpi.com/journal/cancers463
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correct folding. However, HSPs can also promote the elimination of these proteins by orienting them
towards different degradation pathways, notably the ubiquitin–proteasome system, when correct
folding is no longer possible. It has also been reported that HSP proteins are able to inhibit the intrinsic
apoptotic (inhibition of apoptosome formation) and extrinsic (inhibition of signal transduction of
death receptors) processes [3,4]. Interestingly, HSPs can also be secreted and act extracellularly via
membrane receptors or within extracellular vesicles as a damage-associated molecular pattern and
exhibit immune-cell dysregulation properties.
2. HSP Chaperones and Cancer
As cancer cells accumulate mutations and generate physiologically stressful conditions, they
require a constitutively high level of HSPs for their survival and maintenance. In 2011, in order to
simplify the complexity of this disease, researchers suggested that tumor development was organized
around six essential alterations [5]. These major modifications include (i) self-sufficiency in growth
signals; (ii) insensitivity to growth inhibition; (iii) tissue invasion and capacity to develop metastases;
(iv) unlimited replication potential; (v) de novo angiogenesis; and (vi) inhibition of programmed cell
death. Although the appearance of these changes is mainly linked to instability genomics, many
studies have demonstrated the involvement of HSPs in these processes, indicating that these molecular
chaperones have an oncogenic role. Comprehensive discussion about the oncogene-like functions of
these different molecular chaperones and their participation in the progression of resistance to cancer
treatment can be found in excellent recent reviews elsewhere [6,7]. Given the role of HSPs in cancer
biology, these chaperones have also been suggested as potential therapeutic targets [3,8]. A number of
these proteins have been correlated to cancer aggressiveness and/or cancer resistance to radiotherapy
and adjuvant chemotherapy [9].
Targeting HSPs has emerged as a promising sensitization strategy in cancer therapy since HSPs
have oncogene-like functions and mediate “non-oncogene addiction” of stressed tumor cells that must
adapt to a hostile microenvironment. Except for one inhibitor of HSP27 (an antisense oligonucleotide
in phase I/II) [10], all the HSP inhibitors used in clinical trials target HSP90 [11,12]. In this review,
we mainly focused on the chaperones HSP90, HSP70, HSP110, and HSP27 and their regulation of
protein misfolding and signaling in TYK2-STAT3/5 core cancer pathways, as well as the possibility
of targeting such HSPs to specifically restrain STAT3/5 oncogenic functions. We also discuss the
machinery behind the chaperones, which is becoming a major therapeutic target in cancer, and the
emergence of promising HSP inhibitor-based drugs, which are currently being clinically tested or
developed for cancer treatment (Table 1).
Table 1. Summary of the main strategies for HSP inhibition.
Inhibitor








in vitro/preclinical Prostate, Ovary [13,14]





in vitro/preclinical Pancreatic, NSCLC [15,16]






ribonucleoside ASOs in vitro Pancreatic [18]




nucleoside analog in vitro/preclinical/clinical Pancreatic [20]
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Table 1. Cont.
Inhibitor









VER-155008 ATP-derivative inhibitor in vitro Breast, Colon,Prostatic, Myeloma [23–25]
A17/A8 Peptide aptamer in vitro/preclinical Cervix (HeLa cells),Melanoma [26]










A specific amino acid











natural product isolated from
the fungus Monosporium
bonorden
in vitro CML [30]
17-AAG; 17-DMAG Derivative of the antibiotic
geldanamycin
in vitro/preclinical Breast, Brain,Medulloblastoma [31–33]
17-DMAG in vitro CLL [34]



















produced by the actinomycete
Streptomyces nivens
in vitro/preclinical Leukemia, Prostate [42–44]
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Inhibitor
















































in vitro/preclinical Melanoma [62]
in vitro/preclinical NSCLC [63]
in vitro/preclinical NSCLC [64]
XL888
Orally available inhibitor with
high selectivity for HSP90α
and HSP90β




small molecule inhibitors that
competitively bind to HSP90α,















inhibitors, based on pyridyl
scaffolds mimicking α-helix
in vitro/preclinical Colorectal [72]
ALL: acute lymphoblastic leukemia; AML: acute myeloid leukemia; ASOs: antisense oligonucleotides; CLL: chronic
lymphocytic leukemia; CML: chronic myelogenous leukemia; CRPC: castration-resistant prostate cancer; EGFR:
epidermal growth factor receptor; ET: essential thrombocytosis; MPN: myeloproliferative neoplasm; NK: natural
killer cells; NSCLC: non-small cell lung cancer; PES: 2-phenylethynesulfonamide; PV: polycythemia vera.
3. HSP90
3.1. HSP90 Structure and Functions
HSP90 (also known as HSPC) is one of the most abundant chaperones in eukaryotic cells in
the absence of stress. HSP90 is critical for the operation of cellular machinery under physiological
conditions through interactions with so-called “client” proteins. This is only achieved through the
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formation of a multimeric protein complex of cochaperones that binds to all three domains of HSP90.
Hundreds of client proteins for HSP90 have been identified so far [73]. Many of these proteins are
involved in essential cellular functions that promote cell growth, proliferation, cell survival, and
immune responses. Most of these processes are also involved in cancer development. Three main
groups of “client proteins” can be described for HSP90: first, the group of kinases represents the main
group because HSP90 interacts with 60% of them [74]; second, the group of multiprotein complexes
for which HSP90 promotes assembly [75]; and third, the group of ligands that HSP90 stabilizes with
their receptors. It is difficult to identify new client proteins because HSP90 does not bind particular
sequences. In contrast, the interaction seems to be based on the overall structural instability of the
client proteins [74,76]. Among the client proteins, here we focus on the kinases and receptor tyrosine
kinases involved in the STAT3/5 signaling pathway.
3.2. HSP90 and Nonfusion Protein Kinases
3.2.1. Jak Kinases
The mammalian family of Janus kinases (JAKs) is composed of 4 members: JAK1, JAK2, JAK3, and
Tyrosine kinase 2 (Tyk2). This family is the main activator of STAT proteins. JAK regulation by HSP90
was discovered by studying the effect of HSP90 inhibitors on the type I and II Interferon (IFN) signaling.
In several cell lines, this treatment suppressed the expression of multiple IFN-γ-induced genes and
decreased IFN-γ-induced STAT1 phosphorylation on Tyr-701, required for dimerization, and on Ser-727,
required for transcription factor activation. As JAK1/2 were known to be the protein kinases responsible
for STAT1 phosphorylation, Shang et al. investigated the effect of HSP90 inhibitors on JAK1/2. They
showed that HSP90 inhibition led to the proteasome-mediated degradation of JAK1/2. Further they
showed that JAK1 interacted with HSP90 (and the CDC37 cochaperone [77]), and that both interactions
were destabilized by HSP90 inhibitors [78]. As overactivation or constitutive JAK1/2 signaling promotes
cell proliferation and survival in a variety of solid tumors and leukemia [79,80], this discovery paved
the way for the identification of the critical role of HSP90 in the aberrant JAK/STAT signaling pathway.
In particular, an activating point mutation in JAK2 (JAK2V617F) was described as being highly frequent
in chronic myeloproliferative neoplasms (MPN) that promote disease progression [81–84].
Despite this activating mutation, HSP90 inhibition in cell lines homozygous for JAK2V617F reduced
total and phospho-JAK2, and subsequently cell viability [85]. In vivo experiments in a mouse model of
MPN confirmed the efficacy of HSP90 targeting because treatment with the HSP90 inhibitor PU-H71
resulted in significant reductions in disease parameters and better chances of survival [49]. Furthermore,
combined treatment that included HSP90 inhibitors and JAK2 inhibitors induced a greater depletion of
the signaling proteins than a single inhibitor alone, and synergistically induced apoptosis in human
primary CD34(+) MPN cells harboring JAK2V617F [50]. Therefore, HSP90 interaction with JAK2 is
not altered by activated mutations, but instead could be used as a therapeutic target. This point is of
great value, as mutations within the JAK2 kinase domain that confer resistance across a panel of JAK
inhibitors have been described (G935R, Y931C, and E864K). Fortunately, genetic resistance to JAK2
enzymatic inhibitors can be overcome by HSP90 inhibitors, which still promote the degradation of
both wild-type and mutant JAK2 [60]. Recently, results from a phase II clinical trial with the HSP90
inhibitor AUY922 (Novartis, transferred to Vernalis) have been published and have demonstrated a
clinical response in five out of seven patients with MPN [58]. This response correlated with a reduction
in overall levels of JAK2, pYSTAT3, and pYSTAT5. Unfortunately, most patients experienced severe
adverse effects due to the toxicity of the inhibitor, a phenomenon that has already been observed with
other HSP90 inhibitors.
3.2.2. Src Kinases
The members of the Src family of nonreceptor tyrosine kinases (Src, Fyn, Yes, Blk, Yrk, Rak, Fgr,
Hck, Lck, Srm, and Lyn) are implicated in numerous important functions in eukaryotic cells. They
control proliferation, survival, and differentiation, therefore playing a critical role in many cancer
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types [86]. Src members can activate STAT3 directly and synergize with JAK family tyrosine kinase
action [87]. Among the family members, c-Src has been linked to cancer development [88]. The viral
homolog of c-Src kinase, v-Src (from the Rous sarcoma virus), has a constitutive kinase activity and was
the first discovered oncogene [89,90]. Both homologs bind to the HSP90/CDC37 complex but with
striking differences. HSP90, which binds weakly and transiently to c-Src, binds strongly to v-Src, which
appears to be its strongest client protein [91–93]. Accordingly, v-Src kinase activity depends strongly
on HSP90 [74,94]. Recently, Boczek et al. provided more insight by determining the influence of HSP90
isoforms α and β on purified c-Src and v-Src activity. They have shown that HSP90 does not affect
c-Src activity in vitro, whereas v-Src activity was increased two-fold when human HSP90β (but not
HSP90α) was added to the experimental setting. HSP90β also stabilized v-Src at high temperatures
when it would be inactive otherwise. Until recently, the mechanism behind this striking difference was
unknown [76,95]. To solve this issue, Bolcek et al. generated an Src mutant that mimics the oncogenic
v-Src kinase activity (c-src3MΔC). This mutant exhibited a more extended activation loop (A-loop)
(usually present in an open form during wild-type Src active state to allow substrate binding). The
A-loop from c-Src3MΔC is also less stable in comparison with the wild-type Src. Consequently, the
c-Src3MΔC is conformationally uncontrolled, which enhances its interaction with HSP90 and suggests
this could be a more general mechanism for the interaction between HSP90 and oncogenic kinases
than the presence of a general client sequence motif. Indeed, HSP90 potentially interacts more strongly
with structurally extended kinases, a frequent state observed upon activating mutations. Interestingly,
a very similar mechanism needed to aid the initial folding of immature kinases such as c-Src, which is
furtive is this case, governs the binding of HSP90 to conformationally unstable but mature kinases like
v-Src. In this context, CDC37 appears to bind to parts of the unfolded kinase first (which might be
considered as an independent kinase binding unit), partly unfolding it further before HSP90 clamps
around the CDC37/kinase complex [96]. Other Src family members, like LckY505F and HCK499F, are
probably stabilized by the same mechanism [97,98].
3.2.3. ACK1
Another nonreceptor tyrosine kinase, activated CDC42-associated kinase-1 (ACK1), catalyzes the
phosphorylation of STAT1, STAT3, and STAT5. HSP90 interacts with ACK1 [99] and is necessary for
the phosphorylation of STAT1 in transformed kidney cells and STAT3 in primary lung adenocarcinoma
by ACK1 [61].
3.2.4. BRAF
The activated serine/threonine kinase BRAF mutant is a main driver of melanoma growth and
progression [100] and is a HSP90 client protein [74,101]. Inhibition of HSP90 by AT13387 delays the
emergence of resistance to BRAF inhibitors [62]. A recent phase I dose escalation clinical trial in
melanoma has shown that another HSP90 inhibitor (XL888) in combination with a specific anti BRAF
inhibitor (vemurafenib) has clinical activity in patients with advanced BRAFV600-mutant melanoma,
with a tolerable side effect profile [65].
3.3. HSP90 and Fusion Protein Kinases
3.3.1. BCR-ABL
Chronic myeloid leukemia (CML) is driven by the BCR-ABL fusion oncoprotein [102], which
is involved, among other pathways, in the transcriptional regulation of STAT3 [103,104] and
STAT5 [105,106]. In this context, the BCR-ABL/STAT3/STAT5 signaling pathway is mainly involved in
tumor-initiating stem cell maintenance [107]. BCR-ABL is a HSP90 client protein that is destabilized
by HSP90 inhibition, which leads to cell death [56]. In CML cells, BCR-ABL forms a high molecular
weight network with JAK2, STAT3, and AKT. This network pushes disease progression, but could also
be its Achilles’ heel. Indeed, HSP90 directly binds to this signaling network, and its inhibition breaks
the whole network apart [56]. As for other targeted therapies, resistance to BCR-ABL tyrosine kinase
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inhibitors can develop during the course of the treatment because of acquired BCR-ABL mutations.
Hopefully, combination therapies involving HSP90 inhibitors and anti-JAK2 may overcome this
resistance [57].
We are still unsure of how this mechanism of action can be extended to the interaction with other
oncogenic mature kinases, but an important process for protein stabilization by HSP90 and CDC37 has
been uncovered.
3.3.2. EML4-ALK
The echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK)
fusion gene is an oncogenic driver in about 5% of patients with non-small cell lung cancer (NSCLC).
It is also an HSP90 client protein (one of the most sensitive), which is very rapidly degraded upon
exposure to HSP90 inhibitors [40]. These results prompted the initiation of numerous clinical trials
reviewed elsewhere [41,108]. Yet despite encouraging results, clinical response was weak, and so the
development of HSP90 inhibitors was halted for NSCLC.
3.4. HSP90 and ErbB Family of Receptor Tyrosine Kinase (RTK)
STAT3 and STAT5 are also known to be phosphorylated by several receptor tyrosine kinases
(RTK), such as the ErbB family, IGF-1R, or FGFR [109], most of which are HSP90 client proteins.
Interestingly, they are also activated or captured for signal transduction by those RTK without
phosphorylation [110]. Given their membrane localization, these RTK must go through a complex
process of folding, maturation, and membrane insertion that requires significant chaperone cooperation.
This is particularly true for mutated RTK, which is frequently observed in cancers. For instance, ErbB2
stability and maturation is regulated by its binding to HSP90 through its cytoplasmic tail [111] and is
ATP dependent [112].
Accordingly, HSP90 inhibition leads to RTK destabilization and absence of STAT3 activation in
different models of cancer [47,66,67]. Many drugs have been developed to inhibit mutated or rearranged
RTK, but despite early success, most patients develop resistance and eventually relapse [113]. The
strong HSP90/EGFR interaction has then been used to propose an alternative therapeutic strategy
combining an HSP90 inhibitor with an EGFR inhibitor. Interestingly, this combination (with the
EGFR inhibitor erlotinib) resulted in prolonged animal survival in nonmutated and erlotinib-resistant
models [67,68,70,71,114,115].
3.5. STAT3/5 and HSP90
The STAT3/5 signaling pathway is also regulated downstream from the tyrosine kinases and
RTK. Indeed, HSP90 is found within the cytosol, directly bound to dimers of STAT3 or STAT5 via its
N-terminal regions [116]. However, in contrast to its role in TK or RTK folding and stabilization, HSP90
is not required for STAT3/5 maturation or total protein levels. They are therefore nonclassical HSP90
client proteins. The chaperone would rather change STAT conformation to ease the phosphorylation
process and/or, once phosphorylated, maintain this active state for a prolonged period of time.
Moulick et al. have suggested this pattern in chronic myeloid leukemia [69]. They showed that HSP90
directly binds to active pYSTAT5 (Tyr694), but not to inactive STAT5, and that pYSTAT5 acquires a
conformation that is more susceptible to trypsine cleavage in the presence of HSP90. HSP90/STAT3
also protects pYSTAT3 from dephosphorylation by the phosphatase SHP-1 in gastric cancer cells.
Luteolin (3,4,5,7-tetrahydroxyflavone), a natural flavonoid present in fruits and vegetables, inhibits
STAT3 activation by disrupting the association of HSP90 to STAT3, which allows it to interact with
SHP-1 [117].
In order to function as a transcription factor, STAT3/5 needs to translocate into the nucleus and
form a stable interaction with DNA. In this context, as suggested by Longshaw et al., HSP90 appears to
play a specific role in association with the cochaperone HOP [118]. They have shown that the depletion
of HOP decreased the nuclear localization of STAT3. Although it is not yet clear how HSP90 promotes
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STAT3/5 nuclear shuttling, it may involve the capacity of HSP90 to form molecular complexes with
specific carriers, like importins alpha [119], that can transport STAT3 to the nucleus. This scheme
would mimic what has been described for other molecular complexes implicating HSP90, such as the
glucocorticoid receptor [120] or PKCZeta [121]. After entering the nucleus, HSP90 seems to promote
STAT3/5 transcriptional activity as STAT3/5 interaction with promoters of target genes is enhanced by
the presence of HSP90. Indeed, the STAT3/5 complexes and HSP90 have been shown to colocalize
in MYC and in CCND2 promoters [69]. Furthermore, nuclear hormone receptors form multiprotein
complexes with STAT3 and STAT5 [122,123], which together with HSPs could contribute to chromatin
landscaping [124].
In conclusion, HSP90 appears to be a key chaperone for the STAT3/5 pathway. It operates at
all levels of message transmission, from interaction with RTK in the cytoplasmic membrane, to the
interaction with multiple kinases in the cytosol, and to favoring active STAT3/5 localization and binding
of target genes the nucleus (Figure 1). This role is also central in the pathological overactivation of
STAT signaling where HSP90 favors oncogenic proteins (Figure 1), promoting the development of
several inhibitors for cancer treatment (Table 1, Figure 2). However so far, most clinical trials have
yielded mixed results and frequent side effects that precluded the broad utilization of these treatments.
 
Figure 1. Localization and described functions of HSP90 within the STAT3 and STAT5 signaling
pathways. HSP90 promotes those pathways through direct interaction with STAT3 or STAT5 dimers
and favors their phosphorylation, nuclear localization, and promoter binding, but HSP90 also limits
dephosphorylation and proteasomal degradation. Upstream of STAT3/STAT5 activation, HSP90
stabilizes several kinases, like JAK2, JAK2V617F, c-Src, v-Src, ACK1, BCR-ABL, EML4-ALK, LckY505F,
and HCK499F, and several receptor tyrosine kinases, such as the ErbB family.
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Figure 2. Structure of the main HSP90 inhibitors. The inhibitors targeting the ATP binding site at the
N-terminus and the C-terminus of HSP90 are depicted in green and orange, respectively.
4. HSP27
4.1. HSP27 Structure
HSP27 (27 kDa), also known as HSPB1, belongs to the small HSP family. In contrast to other HSPs,
it is an ATP-independent chaperone [125]. HSP27 shows a highly dynamic process of oligomerization
that transforms proteins from dimers to large oligomers, which can culminate at 1000 kDa. This state
of oligomerization dictates the affinity of HSP27 towards the proteins to be chaperoned, given that the
multimer form is the most binding-competent state [126].
Four phosphorylation sites (S15, S78, S82 and T143) in the N-terminal domain regulate the
assembly of oligomers [127]. Phosphorylation promotes the formation of small oligomers, while
dephosphorylation promotes the formation of large oligomers [128]. Stressors such as anticancer agents,
hydrogen peroxide, mitogens, inflammatory cytokines (TNF-α, IL-1b, etc.), and kinases (p38 MAPK,
p70RSK, PKB, PKC, PKD and PKG) can promote HSP27 phosphorylation [129]. However, we have
also shown that oligomerization can occur independently of phosphorylation through cell–cell contact,
as observed in confluent cultures in vitro or solid tumors in vivo [130].
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4.2. HSP27 Functions
HSP27 chaperone functions have been less described than higher molecular weight HSPs like
HSP70 and HSP90. However, HSP27’s main function as a chaperone is to stabilize denatured or
aggregated proteins to bring them to a soluble and stable form [131,132].
HSP27 plays an important role and has been associated with poor prognosis in many cancers (for
a recent review, see [127]). For instance, Rocchi et al. described the promotion of the STAT3 signaling
pathway in prostate tumors [133]. They showed that HSP27 directly interacts with STAT3 and that total
STAT3 levels correlated directly with HSP27 levels. Furthermore, the cytoprotective effect of HSP27
was attenuated by STAT3-reduced expression, underlying the importance of this pathway in prostate
cancer [133]. HSP27 is also involved in the process of prostate cancer metastasis through the promotion
of IL-6-mediated epithelial-to-mesenchymal transition (EMT), because reduced HSP27 expression
decreases cell migration and invasion [134]. In the absence of HSP27, IL-6-induced phosphorylation
of STAT3 is reduced, but not total STAT3 content. This inhibition leads naturally to reduced STAT3
nuclear localization and binding to the TWIST gene, which codes for a key EMT transcription factor.
Beside cancer development, HSP27 regulation of STAT3 has recently been implicated in placental
implantation. HSP27 is indeed expressed during placenta formation and in the first two trimesters
of pregnancy [135,136]. In particular, HSP27 is highly expressed during the differentiation of
cytotrophoblast cells and extravillous trophoblast cells, and its silencing was found to significantly
reduce total STAT3. Interestingly, the phosphorylation state of STAT3 was not altered in the absence of
HSP27 in placental explants, suggesting a role in protein protection from proteasomal degradation [137].
This could be explained by the fact that STAT3 and STAT5 have a relatively low thermodynamic
stability as isolated proteins and are thus more prone to aggregation, which would be limited by
HSP27 [124]. Given the importance of STAT3 in embryonic development (STAT3 knock-out mice have
a lethal embryonic phenotype) [138], this finding revealed the critical role of HSP27 in this process.
There has been little study of the state of HSP27 phosphorylation, and consequently the state of
oligomerization, required for STAT3/5 binding, despite the fact that therapeutic targeting of specific
kinases would logically impact HSP27 functions. We only know, from one study of prostate cancer,
that IL-6 stimulation leads to HSP27 phosphorylation and correlates with the EMT, suggesting the
phosphorylated form is required for STAT3 activation [134]. Other STAT family members are HSP27
client proteins, like STAT2 (a STAT family member involved in viral or interferon responses), which
was also shown to be degraded upon HSP27 knockdown in Hela cells [139]. However, this process
was reversed by proteasome inhibition. However, STAT3 and 5 were not or were only weakly reduced
in this particular tumor cell line. Again, the discrepancy between tumoral contexts or cell lines could
come from differences in HSP27 phosphorylation or oligomerization status.
As stated previously, HSP27/STAT3 interaction occurs also in nontumoral contexts. In normal liver
cells under a high fat diet, the phosphorylated form of HSP27 stimulates autophagy and lipid droplet
clearance through interaction with STAT3. In this particular situation, no STAT3 activation by HSP27 is
described, but rather the disruption of STAT3/PKR complexes, facilitating PKR and eIF2α mediated
autophagy [140]. These data suggest that dimers and multiprotein complexes can be displaced by the
action of phospho-HSP27 on different binding partners, including STAT3, and this can also mediate
critical cellular physiological processes.
Upstream from STAT3/5 activation, JAK2 plays a major role that can be modulated by HSP27 [141].
In the specific context of thrombopoietin- and JAK2V617F-induced myelofibrosis (a chronic degenerative
disorder of the hematopoietic system associated with the aberrant activation of the JAK/STAT
pathway) [142], our team has recently shown that HSP27 interacts directly with JAK2/STAT5, stabilizing
the complex. Neither total JAK2 nor STAT5 protein levels were affected, but we found that the state of
phosphorylation of STAT5 (Tyr694) by JAK2 was HSP27 dependent. We demonstrated that HSP27,
through interaction with STAT5, physically prevented its dephosphorylation by the phosphatase SHP2
in those cells.
472
Cancers 2020, 12, 21
In conclusion, HSP27 plays a very important role in STAT3/5 signaling, both in contexts of
tumor development and others such as placenta development. In contrast with HSP90, whose
functions depend on the client proteins, HSP27′s different functions (protein stability, phosphorylation,
disruption of complex of proteins, etc.) may rely on the phosphorylation and oligomerization status
of the chaperone (Figure 3). The general vision is mainly dichotomous: on one side there are large
phosphorylated oligomers, and on the other nonphosphorylated dimers. This simplistic description
does not reflect the reality of cellular dynamics. Future studies will be needed to specify the proportion
of each HSP27 oligomer within the cells and the associated function.
 
Figure 3. Localization and described functions of HSP27 within the STAT3 and STAT5 signaling
pathways. HSP27 state of oligomerization varies dynamically to modulate its binding capacity to
target proteins in a context-dependent way. HSP27 directly interacts with pYSTAT3 and total STAT3 to
promote stabilization and phosphorylation. HSP27 directly binds to JAK2V617F/STAT5 complexes to
prevent STAT5 dephosphorylation by SHP-2 in MPN. HSP27 also displaces multiprotein complexes
like the STAT3/PKR complex.
5. HSP110
5.1. HSP110 Structure
The 110 kDa heat shock protein (HSP110), also known as HSP105 or HSPH1, belongs to the
members of the HSPH family. Although it appears to be distinct from other HSPs (HSP27, HSP40,
HSP70, and HSP90) because of its molecular weight and the specificity of certain sequences, HSP110
is a member of the family of HSP70 proteins [143,144]. Until quite recently, HSP110 was considered
as a mere nucleotide exchange factor of HSP70. However, it is now well established that HSP110
is able to act as an unfolding chaperone on its own using ATP hydrolysis to lead to conversion of
stable misfolded polypeptide substrates into natively refolded products, even when HSP70 is not
present [145]. In an ATP-independent manner, HSP110 also has the antiaggregating properties of
unfolded or misfolded proteins.
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5.2. HSP110 Functions
In contrast to other chaperones, like HSP90 or HSP70, little is known about the cellular and
extracellular functions of HSP110. It is a ubiquitous and conserved chaperone with antiaggregation
capabilities that act in synergy with the refolding activity of HSP70, which contributes to efficient
protein homeostasis [145,146]. HSP110 expression is induced by a wide array of stress including
hyperthermia, ethanol, oxidative stress, recovery from anoxia (i.e., reperfusion injury), some anticancer
drugs, and inflammation. HSP110 is approximately four-fold more efficient at binding and stabilizing
denatured protein substrates than HSP70 [147]. Due to its strong chaperone (or holder) function,
HSP110 is a very good antigen carrier. It is therefore used in vaccine formulations [148] as a recombinant
chaperone vaccine for antigen-targeted cancer immunotherapy. These vaccines have generated robust
antigen-specific T lymphocyte responses in different preclinical cancer models [149]. Two forms of
HSP110 exist: HSP110α and an alternatively spliced form called HSP110β, which contains 43 fewer
amino acids [150]. While HSP110α is constitutively expressed in the cytoplasm of cells and can be
induced in stressful conditions such as heat shock, HSP110β is strictly heat-inducible and specifically
localized in the nucleus (Figure 4) [151]. Beyond the different localization of these two forms of HSP110,
their differential roles remain unclear. Like other HSP proteins, the expression of HSP110 can be
induced by a number of physical or chemical sources of stress and depends on the heat shock factor 1
(HSF1) transcription factor. Moreover, the presence STAT3 on the HSP110 promoter has been recently
reported in humans, suggesting its regulation by STAT3 [152]. Conversely, HSP110β can induce HSP70
expression through STAT3 in mammalian cells (Figure 4) [153]. It is now clearly established that
HSP110 favors several signaling pathways, including the Wnt/β-Catenin, MyD88/TLR, and STAT3
pathways [154,155].
Concerning the STAT signaling pathway, we have demonstrated that HSP110 directly binds
to STAT3 and favors its phosphorylation (Tyr705) by JAK2 in the cytosol, thereby promoting cell
proliferation (Figure 4) [156]. Colon cancer cells in which HSP110 has been shRNA-mediated and
knocked down hardly proliferate, but proliferation is reactivated by the re-expression of HSP110 in
these cells. Tumors from patients with high levels of HSP110 show high STAT3 phosphorylation levels
and strong expression of proliferation markers [154,156]. Therefore, both the protein homeostasis
function and the role of HSP110 on proliferative pathways may explain why this protein is linked to
aggressive tumors. We suggest that HSP110 expression could be a surrogate prognostic marker and a
potential therapeutic target, particularly for treatment of carcinomas, particularly colorectal cancer, for
which there is strong evidence.
Given the emerging role of HSP110 in cancer and its role on STAT3 in particular, we selected two
foldamers upon screening of a chemical library based on their ability to inhibit and block recombinant
HSP110-mediated antiaggregation activity and to disrupt HSP110–STAT3 interaction [72]. These
compounds, named 33 and 52 (Table 1, Figure 5), inhibit HSP110 chaperone function and colorectal
cancer growth in vitro and in vivo [72]. Altogether these results confirm the interest of targeting
HSP110, at least in colorectal cancers, and probably in other types of cancer, such as B-cell lymphoma.
Although HSPs are generally considered intracellular proteins, we now know that HSP110 can
also be released to act extracellularly like HSP27, 70, and 90 [157–159]. The release of HSP110 from
human intestinal epithelial cells has also been described, suggesting a role in the physiological process
of epithelial renewal [160]. More recently, we have demonstrated that HSP110, like other HSPs,
can be secreted by cancer cells and is abundantly observed in the cancer microenvironment [161].
Interestingly, extracellular HSP110 affects macrophage differentiation/polarization by favoring a
protumor, anti-inflammatory profile and the formation of tumor-associated macrophages (TAMs),
which are associated with immune suppression. Furthermore, we found a correlation between the
level of extracellular HSP110 and the number of TAMs in patient biopsies [161], suggesting that the
effect of extracellular HSP110 function on macrophages may also contribute to the poor outcomes that
are associated with HSP110 expression.
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Figure 4. Localization and described functions of HSP110 and HSP70 within the STAT3 and STAT5
signaling pathways. HSP110 directly binds to STAT3 in the cytosol and favors its phosphorylation
through JAK2, and, through this mechanism, participates in the promotion of cell proliferation.
HSP110α and HSP110β localize to the cytoplasm and nucleus of cells, respectively. HSP110β induces the
expression of HSP70 in mammalian cells. Overexpression of HSP110β stimulated the phosphorylation
of STAT3 (Tyr705) and its translocation to the nucleus. STAT3 binds to the sequence of the HSP70
promoter at the level of a sequence (−206 to −187 base pair) whose mutation abrogated the activation
of the HSP110β-mediated HSP70 promoter. HSP70 directly interacts with STAT3 and STAT5. It favors
STAT3 phosphorylation and activity, and STAT5 levels, phosphorylation, and activity.
Figure 5. Structure of the main small-molecule inhibitors of HSP27 (blue), HSP70 (Green), and HSP110
(Orange). RP101 can inhibit HSP27 function via direct binding to Phe29 and Phe33. VER-155008 binds
to the ATP-binding site at the N-terminus of HSP70. Pifithrin-μ inhibits specifically function of HSP70
via direct binding to its substrate binding domain. Compounds 52 and 33 bind to the ATP binding site
at the N-terminus of HSP110.
475
Cancers 2020, 12, 21
6. HSP70
6.1. HSP70 Structure
Stress-inducible HSP70 (also called HSP72 or HSP1A, HSPA1B) is another member of the HSP
superfamily that has emerged as a viable and very promising target for development of antitumor
drugs to combat various forms of cancer [162–164]. As the most ubiquitous stress-inducible chaperone,
HSP70 exhibits numerous chaperone functions that are critical for both the folding and proteasomal
degradation of misfolded proteins. It thus participates in cellular protein quality control systems,
leading to cell homeostasis and survival during stress conditions. The human HSP70 protein family
consists of at least 13 members, including stress-induced HSP70 and the heat shock cognate protein
70 (HSC70) [165]. The chaperone mechanism of HSP70 has been extensively studied [166]. HSP70
associates with misfolded proteins in a manner controlled by its ATPase cycle and cochaperones such
as HSP40, BAG family proteins, HIP, HOP, and HSPBP1 [165].
6.2. HSP70 Functions
Based on immunoprecipitation analysis from normal rat kidney interstitial fibroblast (NRK-49F)
cells, HSP70 has been shown to directly interact with multiple STAT proteins, including STAT3/5
(Figure 4). This interaction increased when cells were stressed by exposure to advanced glycation end
product [167]. Although the data are still limited, studies show that manipulating HSP70 expression
or activity affects STAT protein activity within cells. HSP70 (HSP701A/B) knock down using siRNA
further decreased constitutive STAT3 activity in an acute myeloid leukemia cell line (HEL) treated with
arsenic trioxide and the HSP90 inhibitor 17-DMAG [168]. In addition, increasing HSP70 activity with
administration of geranylgeranylacetone before and three days after intracerebral hemorrhage resulted
in increased STAT3 and AKT phosphorylation and also cerebral levels of eNOS, which are collectively
associated with preserved cerebral blood flow, decreased neuronal cell death, and improved functional
recovery in rats [169]. Uchida et al. suggested that the mechanism for HSP70 induction through
geranylgeranylacetone may be the result of geranylgeranylacetone-induced induction of protein kinase
C [170].
It is worth noting that upregulation of HSP70 could stimulate cell proliferation through the
control of tyrosine kinase functions. In cancer cells derived from chronic myeloid leukemia cells,
BCR-ABL tyrosine kinase activity results in the phosphorylation and activation of AKT, and in the
phosphorylation and DNA-binding activity of STAT5, which leads in turn to an increase in the
expression of antiapoptotic protein Bcl-xL [171]. Interestingly, while increased expression of HSP70
results in the upregulation of STAT5 level and activity, inhibition of the BCR-ABL tyrosine kinase
activity with imatinib or inhibition of PI-3K activity with wortmannin both result in a decrease in HSP70
expression and STAT5 activity. Thus, uncontrolled cell signaling may result in the transcription of
HSP70, which in turn regulates the level and activity of STAT5 (Figure 4) [171]. Besides the intracellular
role of HSP70 as a survival factor that promotes tumorigenesis [172], it is now known that HSP70 also
regulates diverse immunoregulatory activities such as antigen cross presentation [173,174], dendritic
cell maturation [175,176], and natural killer cell [177,178] and myeloid-derived suppressor cell [179]
activities, by acting extracellularly as a cytokine [180,181]. We demonstrated that membrane-associated
HSP70 is found extracellularly in tumor-derived exosomes and that it restrained tumor immune
surveillance by promoting myeloid-derived suppressor cell functions in both mice and humans.
Interestingly, tumor-derived exosomes harboring HSP70 were found to mediate the suppressive
activity of the myeloid-derived suppressor cells via activation of STAT3 and ERK [179].
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7. Regulation Mechanisms of HSF/HSPs by JAK/STAT Signaling: A Feedback Loop?
7.1. HSF and SOCS Regulation
The activation of the JAK family and the subsequent STAT signaling is regulated by the family
of suppressors of cytokine signaling (SOCS) proteins. This system aims to protect organisms from
permanent and/or overstimulation that could lead, for instance, to severe systemic inflammations
mediated by IFN-γ signaling [182]. Conversely, a deficit in SOCS expression could play a pivotal role
in the development and progression of cancers [183]. Expression of SOCS3, which has been shown to
inhibit JAK1, JAK2, and TYK2 [184], is frequently reduced in cancer cells, thereby leading to a growth
advantage. The effect of HSF1 and HSP on SOCS3 expression changes depending on the tissue and
whether the context is normal or tumoral. In nontumoral microglia cells, the activation of HSF1 by
paeoniflorin induced an indirect increase of SOCS3 expression mediated by HSP70 production and
autocrine action [185]. Conversely, it was recently shown that HSF1 could directly bind to the SOCS3
promoter region and inhibit the transcriptional activity of its promoter [186]. This reinforces the role of
HSF1 as a transcription factor for many genes not related to heat shock response [3]. SOCS3 repression
of expression can also be mediated by HSPs, as seen in chronic lymphocytic leukemia. In this context,
HSP90 inhibition by 17-DMAG induces the expression of SOCS3 through the activation of the p38
MAPK signaling [34]. This regulation is probably a specific to tumors, as normal B cells were not found
to upregulate SOCS3 expression upon HSP90 inhibition, and their migration was not affected [34].
7.2. HSF/HSPs and JAK/STAT
The regulation of the STAT signaling pathway by HSPs has been largely described, but in a
positive feedback loop STAT3/5 has been shown to regulate HSPs. Little is known about HSP regulation
apart from the fundamental role of HSF. The STAT3/5 pathway modulates expression of HSP27, HSP70,
HSP90, and HSP110 when faced with different stressful stimuli [187]. Among those, mild heat shock
is a type of stress (that was used to first describe the function of HSPs) during which the induction
of HSPs prevents cell death from intense heat shock that otherwise would have been lethal. This
thermotolerance is also accompanied by STAT3 phosphorylation. Inhibition of STAT3 activation by
STAT3 inhibitors AG490 or static partially suppresses thermotolerance and HSP110 expression, but not
HSP70 and HSP27 [188]. This result underlines a particular role for HSP110 in the process, which is in
line with its capacity to interact with α-tubulin. This mechanism could therefore protect microtubules
from severe heat shock [189]. Besides STAT3, STAT1 is also involved in HSP70 and HSP90 regulation,
particularly after IFN-γ activation [190,191] or under heat shock [192]. Together with HSF1, STAT1 is
recruited to the first intron of the HSP90β gene to favor the recruitment of a chromatin-remodeling
complex, leading to enhanced HSP90β expression.
Other types of stress, such as hypoxic stress (a common phenomenon in a majority of tumors), are
strong inducers of HSP90α expression. In these conditions, STAT5 is one of the transcription factors that
regulate HSP90α, and hypoxia increases the binding of STAT5 to the HSP90α promoter [193]. When
the STAT signaling pathway is constitutively active in tumors, like in breast and colon cancer, STAT3
has also been shown to transcriptionally induce HSP27 expression [194]. Though less documented, this
mechanism also exists in hematological malignancies like Burkitt’s lymphoma, where pharmacological
inhibition of STAT3 by AG490 downregulates HSP70 expression [195].
8. Conclusions
We have reviewed here the multiple roles of HSPs in the STAT3/5 activation network. From receptor
tyrosine kinases to promoter binding of STAT3/5 target genes, HSPs appear to use several mechanisms
to control this pathway. Among the various HSPs, HSP90 has a central role in the cellular machinery
and is one of the most abundant cytosolic proteins. This role is clearly exposed when we describe both
kinases and STAT proteins as HSP90 client proteins. The current literature points to the important role
of HSP90/STAT3/STAT5 in cancer growth and the ability to thwart chemotherapy [3,196–198].
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This discovery has prompted the development of drugs specifically targeting HSP90 and the
subsequent initiation of clinical trials for cancer patients (Table 1, Figure 2). Almost all of the trials have
reported clinical responses, confirming the relevance of this strategy. However, adverse side-effects
were also frequent due to the inherent toxicity of HSP90 inhibitors. This could be explained by the
number of client proteins that are simultaneously chaperoned by HSP90, which obviously endangers
critical physiological processes in normal cells. A strategic question emerges from this observation:
should we continue searching for more specific, less toxic drugs? Or should we limit studies to
fundamental science to uncover new biological mechanisms? Other HSPs are gaining interest in
the scientific community. In particular, HSP110 is a newly discovered player in the field of cancer
aggressiveness that controls the STAT3 pathway in colon cancers and in B-cell lymphomas. Our team
recently identified the first HSP110 inhibitors (Table 1, Figure 5) that block interaction with STAT3
and that effectively limit colon cancer progression in mouse models; we plan to bring these to the
clinic within the next few years. No toxicity has been demonstrated so far, and we believe this new
type of inhibitor is promising for cancers whose poor prognosis is associated with HSP110/pYSTAT3
expression. Both intra- and extracellular HSP70, which belong to a related HSP family, favor STAT3/5
phosphorylation by JAK2. This dual action is of particular therapeutic interest since targeting HSP70
would simultaneously blunt the macrophage-mediated immunosuppression and block the intratumoral
growth signal. To reach the goal of bringing HSP70 inhibitors to the clinic, we have identified peptide
aptamers that bind to the peptide-binding domain of HSP70. This has not been an easy task since HSP70,
contrary to HSP90, is not a “druggable” protein. Despite this limitation, our HSP70 inhibitors are
specific and have proven effective in xenograft models of colon cancer. Of course, further studies will be
needed before clinical trials can be initiated. Finally, HSP27 has recently been found to play new roles in
myeloproliferative neoplasms. In this disease, which is driven by the JAK2V617F/STAT5 pathway, HSP27
inhibition destabilizes the protein complex and limits disease related myelofibrosis. Furthermore, in
contrast to HSP90 inhibitors, the HSP27 inhibitor does not induce the compensatory expression of
other HSPs that usually account for resistance to treatment. Targeting HSP27 would therefore be an
alternative to the failed HSP90 therapy, which also targeted JAK2V617F. An oligonucleotide antisense
of second generation (OGX427) is currently under clinical evaluation (Table 1).
Furthermore, small molecules targeting STAT3/5 have been identified as enhancing protein
degradation. The inhibition of STAT pathways is therefore likely highly amenable to HSP inhibition
and presents a potential synergistic therapeutic strategy (Table 1).
In conclusion, we show in this review that the STAT3/5 pathways rely on multiple HSPs
under physiological and pathological conditions. Targeting various members of the HSP family,
alone or in combination, will probably improve the inhibition of this central pathway and should
foster the development of new, more specific and less toxic HSP inhibitors to complete the existing
therapeutic arsenal.
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Abstract: Signal transducer and activator of transcription 3 (STAT3) plays a critical role in promoting
the proliferation and survival of tumor cells. As a ubiquitously-expressed transcription factor, STAT3
has commonly been considered an “undruggable” target for therapy; thus, much research has focused
on targeting upstream pathways to reduce the expression or phosphorylation/activation of STAT3
in tumor cells. Recently, however, novel approaches have been developed to directly inhibit STAT3
in human cancers, in the hope of reducing the survival and proliferation of tumor cells. Several of
these agents are nucleic acid-based, including the antisense molecule AZD9150, CpG-coupled STAT3
siRNA, G-quartet oligodeoxynucleotides (GQ-ODNs), and STAT3 decoys. While the AZD9150 and
CpG-STAT3 siRNA interfere with STAT3 expression, STAT3 decoys and GQ-ODNs target constitutively
activated STAT3 and modulate its ability to bind to target genes. Both STAT3 decoy and AZD9150
have advanced to clinical testing in humans. Here we will review the current understanding of the
structures, mechanisms, and potential clinical utilities of the nucleic acid-based STAT3 inhibitors.
Keywords: hedging; transaction costs; dynamic programming; risk management; post-decision
state variable
1. Introduction
Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that is
overexpressed and/or hyperactivated in multiple human cancers, where it enhances tumor cell
survival and invasion through transcription of anti-apoptotic and pro-proliferative genes [1]. STAT3
has also been shown to directly interact with mitochondrial DNA to contribute to Ras-dependent
malignant transformation and cancer progression by amplifying electron transport chain function [2–6].
STAT3 overexpression has been significantly associated with poor overall survival rates in patients with
solid tumors [7]. Aberrant phosphorylation of STAT3 on Tyrosine 705 or Serine 727 by upstream kinases
results in hyperactivation of the STAT3 protein [8,9]. In addition, genome silencing of phosphatases
that play a role in dephosphorylation/inactivation of STAT3, such as those encoded by PTPR genes [10],
can also result in constitutive activation of STAT3 in cancer [11].
In addition to contributing to the proliferation and survival of tumor cells, STAT3 hyperactivation
plays an important role in the resistance of tumors to conventional chemotherapy drugs, as
well as molecular targeting agents [12]. Moreover, STAT3 promotes immunosuppression in the
tumor microenvironment [13]. STAT3 activation in tumor cells leads to increased production of
immunosuppressive cytokines, including interleukin-6 (IL-6), IL-10, vascular endothelial growth
factor (VEGF), and transforming growth factor-b1 (TGF-β1) [14–17]. Cytokines and growth factors
produced by tumor cells also commonly lead to STAT3 activation in tumor-infiltrating immune
cells. The activation of STAT3 in infiltrating immune cells, in general, inhibits anti-tumor immunity.
Specifically, STAT3 exhibits cell-autonomous inhibitory activities against cytotoxic T cells (CTLs),
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natural killer (NK) cells, and dendritic cells (DCs), while increasing the levels of immunosuppressive T
regulatory (Treg) and myeloid-derived suppressor cells (MDSCs) [18].
Activation of STAT3 is known to occur via several general pathways (Figure 1). Ligand binding
initiates engagement of receptor tyrosine kinases, such as the receptors for epidermal growth factor
(EGF) or vascular endothelial growth factor (VEGF), or receptors that lack intrinsic tyrosine kinase
activity, such as the IL-6 receptor/gp130 complex, and/or nonreceptor tyrosine kinases such as c-Src [19].
Figure 1. Pathways of signal transducer and activator of transcription 3 (STAT3) activation. Activation
of STAT3 occurs via the initial phosphorylation of tyrosine 705 on the STAT3 molecule. This can
occur in several ways: (1) Ligand binding activates Janus kinases (JAKs) that are associated with a
receptor that lacks intrinsic tyrosine kinase activity, such as the interleukin-6 (IL-6) receptor/gp130
complex; (2) Activated JAKs phosphorylate the cytoplasmic region of the receptor molecule which
then serves as a recruitment site for STAT3; (3) STAT3 is then phosphorylated by JAK. (4) Receptor
tyrosine kinases (RTK) such as epidermal growth factor receptor (EGFR) or vascular endothelial
growth factor receptor (VEGFR) have intrinsic kinase capabilities which directly phosphorylate STAT3
following ligand binding. (5) Receptor independent tyrosine kinases such as c–SRC can phosphorylate
JAK without receptor activation. Once Y705 of STAT3 is phosphorylated the SH2 domain of each
STAT3 molecule binds the phospho-tyrosine of another, resulting in dimerization of the two proteins.
These homodimers are then able to translocate to the nucleus and bind the promoter regions of target
genes and induce their transcription. Many of these target genes encode proteins that drive cellular
proliferation and survival.
In the case of receptors lacking kinase activity, the binding of ligand leads to activation of
receptor-associated Janus kinases (JAK). Activated JAKs phosphorylate the cytoplasmic region of the
receptor molecule, which then serves as a docking site for STAT3. Recruitment of STAT3 then results in
the direct phosphorylation of Tyrosine 705 by JAK. Phosphorylation of Serine 727 has also been shown
to occur secondarily as a mechanism for maximal activation [20]. Receptor tyrosine kinases, including
EGFR and VEGFR, harbor intrinsic kinase activity. Following ligand binding, the cytoplasmic regions
of receptor tyrosine kinases are subjected to autophosphorylation, and these sites of phosphorylation
then serve to recruit STAT3 which is subsequently phosphorylated/activated by the activated receptor.
Phosphorylation of Tyrosine 705 leads to homodimerization of STAT3 proteins, but STAT3 can
also participate in alternative heterodimerization with STAT1α [21,22]. Canonical homodimerization
occurs via SH2 recognition of the phospho-tyrosine residue in another STAT3 molecule and subsequent
binding. STAT3 homodimers translocate to the nucleus where they bind to the promoter regions of
STAT3 target genes, inducing the transcription of a broad number of genes whose products drive
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cellular proliferation and survival. STAT3 has also been demonstrated in an important role as a
transcription modulator for mitochondrial respiration and oxidative metabolism [23–25].
1.1. Peptide and Small Molecule Inhibitors of STAT3
The critical role that overexpression and/or hyperactivation of STAT3 plays in the development
of multiple cancers has spawned considerable effort to develop inhibitory molecules with potential
for clinical application. Early efforts were focused on the development of peptide-based inhibitors.
Additional pursuits have led to the identification of several small molecule inhibitors of STAT3.
Furthermore, natural derivatives and natural models as lead scaffolds for molecular design have
recently gained ground and demonstrated efficacy in STAT3 inhibition. In general, both peptidic
inhibitors and small molecule inhibitors of STAT3 suffer from issues of low potency, poor cell penetrance,
or undesirable nonspecific activities. However, a few recently discovered small molecule inhibitors
are showing considerable promise and have reached the stage of advancing to clinical testing [26].
Hence, before describing nucleic acid-based inhibitors of STAT3 we will briefly review progress made
in developing peptide and small molecule inhibitors.
1.2. Peptide Inhibitors
Critical to the function of STAT3 is the recognition of phosphotyrosine residues on activated cell
surface receptors (for the purpose of binding to the receptor), or phosphotyrosine 705 on another STAT3
molecule (for the purpose of homodimerization). Recognition of these phosphotyrosine residues occurs
via the STAT3 SH2 domain, which recognizes the consensus sequence PY*LKTK (where Y* represents
phosphotyrosine). Early studies by Turkson et al. demonstrated that phosphorylated PY*LKTK
peptide inhibited the DNA binding activity of STAT3 in nuclear extracts, but had no activity against
STAT5 [27]. However, exceptionally high concentrations of the phosphorylated peptide were required
to inhibit STAT3 activity in cells. In an effort to generate a more stable version of the PY*LKTK peptide,
a peptidomimetic version named ISS-610 was developed and shown to have improved capacity for
inhibiting STAT3 DNA binding activity in NIH3T3 cells (IC50 = 42 μM) [28]. ISS-610 also demonstrated
growth inhibitory activity against several different cancer cell lines characterized by hyperactivation of
STAT3. Mandal et al. made additional modifications in an effort to prevent dephophorylation of the
peptide, generating the agent PM-73G [29]. This novel drug disrupted STAT3 DNA binding activity in
the nanomolar range and also slowed the growth of MDA-MB-468 tumor xenografts.
Despite advances made in generating peptide and peptidomimetic inhibitors of STAT3, further
development is hindered by multiple factors. The potencies, stabilities, and cellular uptake of peptides
and peptidomimetic compounds will need to be improved and specificities will need to be closely
evaluated. Moreover, there is concern that peptides and peptidomimetics may stimulate an immune
response, which could limit their effectiveness.
1.3. Small Molecule Inhibitors
Given the obstacles associated with developing clinically relevant peptide inhibitors, greater
emphasis has been placed on identifying small molecule inhibitors of STAT3 [30,31]. A number of
small-molecule STAT3 inhibitors have been discovered using either experimental screening strategies
or virtual screening approaches. Among the best characterized small molecule inhibitors are STATTIC,
OPB-31121, OPB-51602, OPB-111077, and C188-9. In addition, an alternative pathway in mitochondrial
STAT3 inhibition has been described in the small molecule MDC-1112.
STATTIC was identified in a screen of 17,000 compounds that used a fluorescence polarization assay
to detect compounds capable of dissociating phosphopeptide from the SH2 domain of STAT3 [29,32].
STATTIC inhibits STAT3 DNA binding activity and slows the growth of xenograft tumors representing
breast cancer and head and neck squamous cell carcinoma [31]. Treatment with STATTIC has been
shown to enhance the activities of chemotherapy and radiation against cancer cells in vitro [33].
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OPB-31121, OPB-51602, and OPB-111077 are orally bioavailable inhibitors developed by Otsuka
Pharmaceutical Company. Molecular and computational modeling studies indicate high affinity
binding (Kd = 10 nM) of these compounds to the SH2 domain of STAT3 [34]. Preclinical studies with
OPB-31121 have shown that the compound inhibits STAT3 DNA binding and enhances the activities
of chemotherapy drugs in leukemia and gastric cancer models [34–36]. OPB-31121 also slows the
growth of primary leukemia and SNU484 gastric cancer xenograft tumors in mice [35,36]. A Phase
I trial of OPB-31121 revealed considerable dose-limiting toxicities at doses below those needed for
STAT3 inhibition. Furthermore, limited anti-tumor activity was observed [37]. Similar to OPB-31121,
OPB-51602 demonstrates growth inhibition against xenograft tumors in preclinical models [38].
Phase I testing of OPB-51602 demonstrated reduction of phosphorylated STAT3 in monocytic cells and
regression of tumors in two patients with non-small cell lung cancer [39]. One of these patients exhibited
complete regression of target lesions and a progression-free survival interval of 6.9 months, while the
other responder showed a 41 percent decline in tumor burden. However, treatment with OPB-51602
for multiple cycles resulted in substantial toxicities in multiple patients, including diarrhea, nausea,
lactic acidosis, and peripheral neuropathy, leading to necessary discontinuation of treatment [38,39].
Phase I evaluation of OPB-111077 has demonstrated greater tolerability, with only mild or moderate
side effects. To date, only modest anti-tumor responses have been observed with the OPB-111077, and
further clinical investigation is necessary.
The small molecule C188 was discovered via virtual screening of a large compound library (920,000
compounds) to identify small molecules that may bind to the STAT3 SH2 domain [40]. Evaluation of
C188 in cell-free assays demonstrated its ability to abrogate binding of phosphopeptide to the SH2
domain. Chemical optimization of C188 yielded the compound C188-9, also called TTI-101, with the
capacity to inhibit phosphopeptide/SH2 interactions in the low nanomolar range [41]. C188-9 is an
orally bioavailable STAT3 inhibitor that exhibits in vitro and in vivo activity against preclinical models
of non-small cell lung cancer [42], head and neck squamous cell carcinoma [41], liver cancer [43], and
breast cancer [44]. Phase I evaluation of C188-9 in patients with solid tumors is currently underway.
MDC-1112, or V-P, is a valporic acid derivative synthesized by Medicon Pharmaceuticals Inc.
which blocks the translocation of STAT3 into the mitochondria and promotes the production of reactive
oxygen species, inducing cellular apoptosis [45]. In combination with cimetidine, MDC-1112 inhibited
the growth of pancreatic cancer xenografts in mice by 60–70% [45] and glioblastoma multiforme
xenografts by 78.2% [46].
Napabucasin (2-acetylfuro-1,4-naphthoquinone or BBI-608) is a small molecule in clinical
development that has been reported to abrogate STAT3 signaling. A small Phase I trial in
combination with paclitaxel for advanced/recurrent gastric cancer reported that the combination
was well tolerated [47]. A Phase III trial investigating napabucassin in combination with nab-paclitaxel
and gemcitabine for metastatic pancreatic cancer is ongoing [48].
1.4. Future Directions for Small Molecule STAT3 Inhibitors
Although current small molecule inhibitors of STAT3, particularly C188-9, hold potential promise,
the success rate for generating clinically viable small molecule inhibitors is low. A number of factors
contribute to this low rate of success, including poor pharmacokinetic properties, insufficient potency,
and unacceptable levels of nonspecific activity leading to toxic side effects. In addition, acquired
resistance to small molecule inhibitors frequently occurs via mutation of the binding site on the target
protein. A new approach towards drug development using molecules called proteolysis-targeting
chimeras (PROTACs) may help to overcome some of the issues related to nonspecific activity and
acquired resistance [49,50]. In the PROTACs approach, a fusion molecule is generated in which a linker
sequence is used to covalently connect a small molecule inhibitor to a molecule (eg., thalidomide) that
can attract an intracellular E3 ubiquitin ligase. By bringing the E3 ligase in close proximity to the target
protein (eg., STAT3), the inhibitor fusion molecule serves to facilitate ubiquitination and subsequent
proteasomal degradation of the target protein [49,50]. This process is both rapid and catalytic, meaning
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the fusion inhibitor molecule is released after destruction of the target protein and can subsequently
interact and facilitate destruction of additional target molecules. Because of this catalytic nature, low
doses of the inhibitor fusion molecule can be used to achieve efficient removal of the target protein,
minimizing the impact of nonspecific activities that would be seen when higher doses are required for
target inhibition by a conventional small molecule inhibitor. Moreover, because elimination of the
target protein occurs rapidly, the risk of developing acquired resistance via target protein mutation is
minimized. The application of PROTACs to inhibition of STAT3 signaling is an exciting opportunity,
although, to date, no STAT3 PROTACs inhibitors have been reported.
1.5. Natural Inhibitors
Of the currently available anti-cancer agents used in current practice, it was found that over
40% were based in or derived from natural products [51]. Because of the increasing development
of resistance to chemotherapeutic drugs, novel strategies to generate treatments can be sought in
bioprospecting and combinatorial biosynthesis from nature-based derivatives. Recent advances in
plant-based derivatives that have shown efficacy in STAT3 inhibition include Erasin, bruceanitol,
and Curcumin.
Erasin is a chromone-based STAT5 inhibitor that has hydrophobic substituents at the 6-position,
resulting in STAT3 specific inhibition. Derived from the natural product classes of flavones and
isoflavones, it was determined to decrease STAT3 Y705 phosphorylation and increase apoptosis in
MDA-MB-231 breast cancer cells, as well as Erlotinib resistant non-small cell lung cancer (NSCLC)
cells [52].
From Brucinea javanica, a chinese plant used to treat cancer, bruceanitol (BOL) was isolated and
discovered to have potent anti-leukemic activity. BOL demonstrated the ability to suppress cell growth
in a wide range of genetically varied colorectal cancer cell lines, all of which were equally sensitive to
the compound [53]. Reductions in phosphorylated STAT3 and downstream target expression of Mcl-1,
c-Myc, and Survivin was observed at BOL concentrations of 30 nM. In vivo experiments on mice with
CRC xenografts reflected similar results with doses of 2 mg/kg and 4 mg/kg reducing p-STAT3 32%
and 80%, and tumor volume 35% and 58% respectively [53].
Diferuloylmethane is a polyphenol derived from the plant Curcuma longa, known as Curcumin,
and has been shown to downregulate the expression of downstream STAT3 expression targets such
as BCL-2 and Bcl-xL. Curcumin was shown to downregulate the production of Survivin mRNA
concordant with the reduction of p-STAT3 in pancreatic cancer cell lines [54].
Collectively these naturally-derived small molecules offer considerable potential in the inhibition
of STAT3 hyperactivation in pre-clinical studies. Natural products serve as promising starting points
for development of inhibitors, but represent a platform that is currently difficult to exploit because of
the lack of knowledge surrounding lead structures for rational design.
1.6. Nucleic Acid-Based Agents to Inhibit Expression of STAT3
1.6.1. AZD9150
Inhibition of STAT3-mediated gene expression can be achieved by directly inhibiting STAT3
expression using antisense oligonucleotides that promote the destruction or inhibit the translation
of STAT3 mRNA. These oligonucleotides are short, 12–25 nucleotide strands with sequences
such as 5′-GCTCCAGCATCTGCTGCTTC-3′, designed to pair with complementary STAT3 mRNA
sequence(s) [55,56]. Binding results in cleavage of the target via RNAse H, alteration of
post-transcriptional RNA splicing, or arrest of translation, leading to downmodulation of STAT3
expression [55]. Several generations of antisense oligonucleotides have been developed and chemically
modified to optimize stability and allow systemic administration [57].
Early versions of the STAT3 antisense molecule contained 2′-O-methyl or 2′-O-methoxyethyl
moieties to prevent free-end degradation and were synthesized with phosphorothioate chemistry
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to provide further stability [58]. Expression of STAT3 and STAT3 response genes was reduced
when prostate (DU145) [59,60], breast (SCK), and melanoma (B16) [61] cell lines were treated
with STAT3 antisense oligonucleotides. Furthermore, in vivo experiments showed inhibition of
STAT3-mediated tumorigenesis, angiogenesis, and tumor growth in xenograft mouse models of
prostate and hepatocellular carcinoma [59,62]. Sensitivity to STAT3 antisense treatment was also
demonstrated in androgen-resistant models of prostate cancer and in lung metastases arising from
hepatocellular primary tumors [59,62].
The second-generation antisense oligonucleotide AZD9150 (ISIS 481464) is the only STAT3
antisense molecule to enter clinical trials. The ASO structure of AZD9150 was optimized by replacing
the 2′-O-methoxyethyl groups with constrained ethyl modifications to increase stability and potency [63].
Preclinical studies with AZD9150 in lymphoma (KARPAS299 and SUP-M2) [63] and neuroblastoma
(IMR 32) [64] cell lines with aberrantly activated STAT3 showed a decrease in the expression of
STAT3 protein and downstream signaling targets. AZD9150 also demonstrated selective uptake
and promoted impaired growth in hematopoietic myelodysplastic and leukemic stem cells [65].
Systemic administration of AZD9150 to immunodeficient mice harboring lymphoma, neuroblastoma,
or non-small-cell lung cancer xenografts resulted in decreased STAT3 expression in tumor cells
and reduction of tumor initiating potential following serial implantation of the AZD9150-treated
tumors [63,64]. While established tumor growth in neuroblastoma xenografts was not inhibited,
systemic administration of AZD9150 led to reversal of STAT3-mediated resistance to cisplatin, as
indicated by a twofold decrease in the IC50 for cisplatin [64].
As a class, antisense oligonucleotides have demonstrated nonspecific immune system activation
due to the presence of unmethylated CpG motifs that are recognized as pathogenic [66]. Toxicological
effects of AZD9150 have been studied in cynomolgus monkeys and in mice, with key findings being
transient prolongation of intrinsic pathway clotting times, elevation of serum transaminase levels, and
accumulation in renal and liver tissue [67]. However, these effects occur in doses far greater than those
used in clinical trials, with no signs of end organ damage in kidneys or liver until doses of 40 mg/kg or
70 mg/kg, respectively, are reached.
A sufficient therapeutic margin provided the foundation to carry out a phase I clinical trial
(NCT01563302) in 30 patients with hematologic and solid malignancies refractory to at least one prior
systemic therapy [68]. All responses following administration of AZD9150 at dose levels of 2 mg/kg
and 3 mg/kg occurred in diffuse large B cell lymphoma (DLBCL) patients. Two DLBCL patients
achieved complete response, two achieved a partial response, and one maintained stable disease for a
response rate of 13% [69]. There was no significant difference in progression-free and overall survival
between the dose levels. Notable adverse events included transaminitis, fatigue, thrombocytopenia,
nausea, and anemia with thrombocytopenia being more closely related to high-grade events. Based on
the observed toxicities, the recommended phase 2 trial dose was 3 mg/kg. Peripheral blood analyses in
this trial suggested an impact of AZD9150 in selected immune cell populations [69].
The heterogeneity in the response of lymphoma patients, five of whom had DLBCL, to AZD9150
highlights the importance of exploring what factors predict the efficacy of treatment. STAT3 inhibition
may increase the immunogenicity of malignant cells through cell-autonomous processes and prevent
tumor microenvironment immunosuppression [70]. Immunogenic biomarkers could thus offer clues
to treatment progress and success. This could also lay the foundation for examining how combination
with immunotherapeutic agents may further increase therapeutic benefits.
1.6.2. CpG-coupled STAT3 siRNA
While STAT3 is known to be overexpressed in tumor cells, it is also dysregulated in tumor-associated
myeloid cells, such as dendritic cells and macrophages [71]. This results in a loss of MHCII expression
and the accumulation of inactive antigen presenting cells. In effect, there is reduced Th-1-mediated
CD8+ cytotoxicity towards tumor cells [13], and an increased presence of myeloid-derived
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suppressor cells (MDSCs) and regulatory T-cells (Tregs) generating an immunosuppressive tumor
microenvironment [72].
Selective targeting of STAT3 in tumor-associated myeloid-derived cells is possible with siRNA
conjugation to a CpG TLR-9 ligand [73]. TLR9 is a cell-surface transmembrane receptor that is
upregulated under conditions of cellular or environmental stress and is known to be expressed on
myeloid-derived cells in the tumor microenvironment [74]. It is also upregulated in acute myeloid
leukemia, multiple myeloma, and B-cell lymphoma, and activation has been shown to increase
antigenicity of primary malignant B-cells and induce apoptosis [75]. When activated by CpG
binding, TLR9 facilitates immunostimulatory signaling and the release of proinflammatory cytokines
as well as the presentation of tumor-specific antigens [74]. However, STAT3 signaling abrogates
CpG-activated immunostimulation.
Therefore, to generate a sufficient immune response, it is necessary to both stimulate TLR9 and
deactivate STAT3 [76,77]. RNA interference or RNAi, is another mechanism by which STAT3 mRNA
can be degraded, thereby silencing its expression. A segment of double-stranded RNA targeted to
the STAT3 sequence is introduced to cells where it is metabolized to 20-21 base-pair fragments and
incorporated into an RNA-induced silencing complex, RISC. The two strands of RNA are unwound, and
this allows the antisense strand to bind STAT3 mRNA. RISC endonuclease activity can then cleave the
target [78]. CpG-conjugated STAT3 siRNA is internalized into cells by endocytosis, where TLR9 binding
facilitates the release of Dicer-uncoupled siRNA from the early endosome before acidification [79].
In vitro studies of CpG-conjugated STAT3 siRNA showed that more than 80% of mouse
dendritic cells, macrophages, and B-cells were positive for uptake without transfection reagent
within 60 minutes [73]. STAT3 gene silencing was achieved with maximal reduction in expression
at high siRNA concentrations of 1 μM [73]. In mice bearing B16 melanoma, C4 melanoma, or
CT26 colon xenograft tumors, peritumoral injection with CpG-Stat3 siRNA led to tumor regression
and systemic administration reduced the number of B16 lung cancer metastases [73]. This was
associated with enhanced CD8+ T-Cell recruitment and cytolytic activity in association with increased
immunostimulatory cytokine and chemokine production [73,80].
Studies with murine models of AML have shown that intravenous delivery of CpG-STAT3 siRNA
results in a 70-80%, CD8+ T-cell-mediated, reduction of leukemic cells in bone marrow, spleen, lymph
nodes, and peripheral blood while simultaneously reducing Treg levels [81]. Combination intratumoral
administration of CpG-STAT3 siRNA with radiotherapy has demonstrated complete rejection of A20
lymphoma tumors in mice and generates long-term protective immunity against the primary tumor [75].
Similarly, CpG-STAT3 siRNA inhibits tumor growth of androgen-independent prostate cancer, with a
concomitant reduction of immunosuppressive MDSC levels in peritumoral lymph nodes [82].
1.7. Nucleic Acid-Based Agents that Act as Competitive Inhibitors of STAT3
1.7.1. G-Quartet Oligodeoxynucleotides (GQ-ODNs)
G-quartet oligodeoxynucleotides are macrocycles composed of four guanosine bases that, upon
hydrogen-bonding, form a polyguanylate, tetrad-helical structure in the presence of a monovalent
cation, usually potassium (Figure 2) [83,84]. In vivo, G-quartets are found in telomeric regions of
chromosomes and in the transcriptional regulatory regions of some oncogenes [85]. Their therapeutic
potential has been demonstrated as direct competitive inhibitors of HIV-1 integrase, blocking HIV-1
DNA integration into the host genome [86–88].
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Figure 2. Structure of G-quartet inhibitor. (A) The G-quartet oligodeoxynucleotide is comprised of
four guanosine macrocycles stacked on top of one another. To date, they have been used as competitive
inhibitors of HIV-1 integrase but have demonstrated potential STAT3 dimerization inhibitors. With
i.p. and i.v. injection in vivo mouse xenografts, G-quartets have been shown to reduce tumor growth
in breast, prostate, and non-small cell lung cancers [85–87]. (B) An overhead view of a G-macrocycle
demonstrates how hydrogen bonding generates a tetrad-helical structure with a monovalent cation at
its core.
GQ-ODNs have been proposed as a class of unique, anti-cancer STAT3 inhibitors which directly
destabilize the homodimerization of STAT3, and thus interfere with its DNA binding activity [89,90].
Computational analyses revealed a GQ-ODN interacts with residues Q643, Q644, N646, and N647
of the SH2 domain [91]. The folds that comprise the G-quartet intramolecular structure significantly
occlude single-stranded endonuclease access to its phosphodiester linkages, resulting in an inability to
cleave the oligonucleotide and in a long serum half-life [92]. However, because of their large size and
charge, G-quartets cannot penetrate cell membranes and must be delivered via a polyethyleneimine
(PEI) complex [93], or another delivery vehicle.
Preliminary in vitro assays demonstrated inhibition of IL-6-induced STAT3 activation in Hep2G
cells incubated with the PEI-GQ-ODN T40214 (90% inhibition at 50 ng/mL). Preincubation at the same
concentration inhibited the expression of anti-apoptotic mediators, with complete blockage of Bcl-XL
mRNA upregulation and 50% blockage of Mcl-1 mRNA upregulation [89].
Treatment with GQ-ODN has demonstrated inhibition of STAT3 and tumor growth in in vivo
models of head and neck squamous cell carcinoma (HNSCC) [94], breast cancer, prostate cancer [93],
and non-small cell lung cancer (NSCLC) [95]. Inhibition of tumor growth was accompanied by a
reduction in anti-apoptotic Bcl-2, Bcl-XL, Mcl-1, survivin, and VEGF in tumor tissue, and decreased
expression of proliferation mediators cyclin D and c-Myc.
GQ-ODN selectivity for STAT3 is a potential consideration, given that a negative regulator of cell
growth, STAT1 shares 50% sequence similarity with STAT3. Computational docking models indicate a
two- to four-fold greater IC50 for STAT1 over STAT3 [89], and 3D analysis showed different residues
involved in STAT1 and STAT3 surface interaction [96]. However, optimization of specificity for the
therapeutic target is necessary for further development of clinical potential.
1.7.2. STAT3 Decoys
Once activated, STAT3 acts as a transcription factor, binding to a response element in the promoter
regions of target genes to induce gene expression. Early investigation determined that STAT3 bound to
a 15-base pair (bp) response element termed human serum-inducible element (hSIE) in the promoter
region of the c-fos gene. We derived the decoy by systematically shortening the double stranded
oligonucleotide to determine the smallest formulation that retained binding activity to STAT3 on
gel shift assays. Figure 3A depicts the sequence of the SIE from the murine, feline, canine, and
human c-fos genes, demonstrating nearly perfect conservation across these species. Subsequent
studies identified optimal binding of STAT3 to a variant sequence of hSIE, specifically the sequence
5′-CATTTCCCGTAAATC-3′ (Figure 3A; [97]).
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Figure 3. STAT3 response elements and STAT3 decoys. (A) The human serum-inducible element (hSIE)
sequence is located upstream in the promoter region of the human c-fos gene and is almost perfectly
conserved across human, feline, canine, and murine species. Sequence differences are shown in red.
Below these is an optimized STAT3 binding sequence, with sequence modifications, shown in red,
at positions 3 and 11 [52]. This allows the decoy to act as a direct competitive inhibitor of the DNA
binding domain in the STAT3 molecule and thus inhibit expression of downstream anti-apoptotic and
pro-proliferative signals. (B) Structure of the first-generation linear STAT3 decoy and mutant STAT3
decoy which is administered intratumorally in in vivo models. The location of the mutation in the
mutant decoy is shown in blue. (C) Structure of the cyclic STAT3 decoy and mutant cyclic STAT3 decoy,
with hexaethylene glycol linkages which is administered intravenously in in vivo models. The location
of the mutation in the mutant decoy is shown in blue.499
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We synthesized the double-stranded STAT3 binding sequence (Figure 3B), the STAT3 decoy,
and determined its effects when added to cells in culture [98]. As a negative control for binding
specificity, a point mutant version of the decoy (termed mutant STAT3 decoy, or MT STAT3 decoy)
was also synthesized and evaluated. In cell-free assays the STAT3 decoy, but not the MT STAT3
decoy, was confirmed to competitively inhibit binding of STAT3 protein to a radiolabeled decoy
sequence. Fluorescently-tagged versions of both the STAT3 decoy and the MT STAT3 decoy were
readily incorporated into the cytosol and nucleus of HNSCC cells and normal oral keratinocytes
(NOKs) within 6 hours after treatment. Remarkably, the STAT3 decoy potently inhibited the growth
of STAT3-dependent cancer cell lines, but not NOKs. The control molecule, MT STAT3, was largely
ineffective against either the cancer cell lines or the NOKs.
The inhibition of cell growth resulting from treatment with STAT3 decoy was associated with
induction of apoptosis and downregulation of the STAT3 target gene encoding Bcl-XL. Further
investigation [99] revealed that the STAT3 decoy also inhibits the STAT1 protein, which is known to
form heterodimers with STAT3. This finding was initially troubling, as STAT1 is known to have tumor
suppressor activity. However, the expression or activation of STAT1 did not alter the apoptosis-inducing
activity of the STAT3 decoy, indicating that the therapeutic activity of the decoy is independent of
STAT1 signaling. Subsequent studies have determined that the STAT3 decoy can inhibit the growth of
a broad variety of cancer cell lines, including cells representing melanoma and cancers of the bladder,
brain, breast, colon, liver, lung, and ovary [98,100–103]. In addition, intratumoral injection of STAT3
decoy has been shown to inhibit the in vivo growth of breast, glioma, head and neck, lung, and
ovarian xenograft tumors [98,100–103]. The anti-tumor effects of STAT3 decoy are associated with
reduced tumor cell proliferation, induction of apoptosis, and reduced expression of STAT3 target genes,
including the genes encoding Bcl-XL and cyclin D1 [101,104]. Based on these promising preclinical
results, we conducted a Phase 0 clinical trial to assess the pharmacodynamic impact of the STAT3
decoy [105]. Intratumoral delivery of the decoy was found to downmodulate expression of Bcl-XL and
cyclin D1 in the tumors of patients undergoing surgical resection of their head and neck cancer.
Fusion of the STAT3 decoy with CpG has enabled targeting of the decoy to TLR9-expressing
leukemia and lymphoma cells [106,107]. Treatment of preclinical mouse models harboring leukemia or
lymphoma with the CpG-STAT3 decoy resulted in potent in vivo growth inhibition of the malignant
cells. Hence, the CpG-STAT3 decoy fusion molecule may provide an effective means for treating
TLR9-expressing hematologic malignancies.
A major limitation of the first generation STAT3 decoy was the necessity for intratumoral injection.
In preclinical studies, systemic delivery of STAT3 decoy failed to inhibit xenograft tumor growth [105],
presumably due to rapid degradation of the molecule by nucleases in the blood. In an effort to produce
a more stable molecule, we [105] generated a cyclic version of the decoy, using hexaethylene glycol
linkages to cyclize the free ends (Figure 3C). The cyclic STAT3 decoy exhibited markedly enhanced
thermal stability and a longer half-life in human serum (8 hours; [105,108]). Intravenous delivery of
the cyclic STAT3 decoy has been shown to potently inhibit the growth of both non-small cell lung
cancer and head and neck cancer xenograft tumors [105,109,110]. The cyclic STAT3 decoy was well
tolerated in wild-type mice, with no apparent toxicity, even when delivered at a dose 20-fold higher
than the maximal effective dose for growth inhibition of HNSCC xenograft tumors [110].
The therapeutic value of treatment with the STAT3 decoy, as with other STAT3 inhibitors, may
be best realized in combination with other anticancer agents. In this regard, STAT3 decoy treatment
has been shown to enhance the sensitivity of head and neck xenograft tumors to cisplatin [101,104].
Similarly, the STAT3 decoy heightens the response of head and neck cancer cells to bortezomib [111],
ovarian cancer cells to paclitaxel [112], and leukemia cells to Adriamycin [113]. FDA IND-directed
pharmacologic and toxicity studies are planned to enable a Phase I trial of the cyclic STAT3 decoy in
cancer patients.
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2. Conclusion
Hyperactivation of STAT3 in malignant cells and tumor-associated immune cells promotes cancer
survival and growth through expression of anti-apoptotic and proliferative genes, as well as cytokines
that generate an immunosuppressive tumor microenvironment. Understanding the role of STAT3 in
cancer has led to promising strides in the development of specific nucleotide inhibitors (Figure 4).
These anti-STAT3 agents can silence STAT3 expression or directly inhibit STAT3 DNA-binding ability
and have shown promising in vivo results beyond proof-of-principle studies. However, optimization
of specificity, potency, stability, and delivery of these nucleotide therapeutics will be important for
enhancing their therapeutic benefits in the clinic.
Figure 4. Mechanisms of STAT3 inhibition with nucleic acid-based agents. STAT3 inhibition with
nucleic acid-based agents occurs via two main mechanisms: (1 and 2) STAT3 decoys or G-quartet
deoxyoligonucleotides prevent STAT3 binding to promoter regions of target genes, and (3 and 4)
antisense or siRNAs promote degradation of STAT3 mRNA.
3. Discussion
Currently, there are four classes of drugs that directly inhibit STAT3: SH2 domain inhibitors;
DNA-binding domain inhibitors (eg., STAT3 decoys); N-terminal domain inhibitors; and STAT3
antisense and siRNA [114]. As a whole, translation to the clinical setting has been challenged by
intracellular drug delivery, selectivity for the target, and minimization of systemic toxicity. More
clinical success has been achieved with inhibition of upstream Janus kinases (JAKs) using Tofacitinib,
developed for the treatment of rheumatoid arthritis [115], and Ruxolitinib, developed for the treatment
of myelofibrosis [116]. Still, small molecule drugs often exhibit off-target effects and a lack of targeted
potency; thus, the limitations of monotherapy should be considered.
The future of STAT3 inhibition is likely to be in combination therapy with currently existing or
newly developed drugs. Blocking STAT3 could result in synergistic anti-tumor effects in combination
with inhibition of EGFR or other tumorigenic dysregulated transcription factors [117,118]. STAT3
inhibition resulting in resensitization to immunotherapies could pave the way for more efficacious
responses to checkpoint inhibitors or other immunotherapies [119–123]. Looking to the future, while
the role of STAT3 has been established in cancer biology, identifying tumor biomarkers that can indicate
patient sensitivity to STAT3 inhibition and expansion of target inhibition to other aberrant transcription
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factors will be important. Research efforts should continue to search for novel applications of STAT3
inhibition and continue to pursue clinical validation of efficacy.
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Abstract: Signal transducer and activator of transcription (STAT) proteins are transcription factors
that in the latent state are located predominantly in the cytoplasm. Activation of STATs through
phosphorylation of a single tyrosine residue results in nuclear translocation. The requirement of tyrosine
phosphorylation for nuclear accumulation is shared by all STAT family members but mechanisms of
nuclear translocation vary between different STATs. These differences offer opportunities for specific
intervention. To achieve this, the molecular mechanisms of nucleocytoplasmic shuttling of STATs need
to be understood in more detail. In this review we will give an overview on the various aspects of
nucleocytoplasmic shuttling of latent and activated STATs with a special focus on STAT3 and STAT5.
Potential targets for cancer treatment will be identified and discussed.
Keywords: STAT3; STAT5; nuclear pore complex; nuclear transport receptors; nucleocytoplasmic
shuttling; cancer; targeting
1. Aim and Scope
STAT (Signal transducer and activator of transcription) proteins can be seen as intracellular
messengers that relay signals sensed at the plasma membrane to chromatin and genes in the nucleus.
To achieve this, STATs must pass the nuclear envelope through nuclear pore complexes (NPCs). Thus,
passage through the NPC is an essential step in the sequence of events from activation of STATs at
cytokine receptors to DNA-binding and target gene induction. As detailed in the reviews and articles
of this Special Issue of Cancers, deregulated activation of STAT3 and STAT5 contributes to various
cancers in many ways. Thus, STAT3 and STAT5 proteins have emerged as promising therapeutic
targets. Protein–protein interactions involved in nucleocytoplasmic transfer of STATs have not been
exploited yet as molecular targets for intervention. Detailed knowledge of the involved molecules and
mechanisms is an essential prerequisite for successful and specific targeting. In this review, we will
first describe the general mechanisms involved in import and export of proteins in and out of the
nucleus, concentrating on those which are most relevant for transcription factors. We will then focus
on the mechanisms involved in nucleocytoplasmic shuttling of STAT3 and STAT5 and finally assess
possible molecular targets for specific intervention.
2. General Mechanisms of Nucleocytoplasmic Transport of Proteins
2.1. The Nuclear Pore Complex
To enter or exit the nucleus, proteins must pass through the nuclear pore complex (NPC) [1].
NPCs are huge macromolecular assemblies (about 120 MDa in humans) made up of multiple copies of
Nucleoporins (NUPs). More than 30 different NUPs have been identified that are built into the NPC as
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multiples of eight (8–64) resulting in the eight-fold rotational symmetry of the NPC [2]. The NPC can
be seen as a channel that allows selective transfer of cargo and at the same time forms a soft barrier for
free diffusion of macromolecules larger than about 30 kDa [3,4], preventing their access to the nucleus
without permission. The barrier is formed by phenylalanine-glycine (FG)-repeats that protrude from
certain NUPs into the lumen of the channel [5,6].
How exactly the FG-repeats form a selective permeability barrier is not completely understood
and several models are currently being discussed [7,8]. One of the most prevalent is the selective
phase model that relies on interactions between the FG-repeats creating a sieve-like meshwork with
hydrogel-like properties, which would explain the observed mass exclusion limit [9]. Selectivity for
cargo allowed to pass might result from phase separation that prevents passage of macromolecules
that are unable to mix or interact with the selective phase made up by the FG-repeats [8].
The import/export pathways through the NPC involve soluble nuclear transport receptors (NTRs)
that bind cargo in conjunction with the Ran-GTP/GDP cycle. NTRs can interact with FG-repeats [10] and
facilitate passage of bound cargo through the NPC. According to the selective phase model, interaction
of NTRs with the FG-repeats leads to local disturbance of the meshwork allowing the NTR/cargo
complex to travel almost freely between cytoplasm and nucleoplasm [11]. The energy-consuming
Ran-GTP/GDP cycle provides directionality of the transport through control of cargo to NTR binding
which is differently regulated in nucleoplasm vs. cytoplasm [12,13].
NTRs, also known as Karyopherins, can be subdivided in Importins and Exportins, facilitating
nuclear import and export, respectively. Biportins have also been described that support transport of
cargo in both directions with imported and exported cargo being distinct [14].
2.2. Importins
The best characterized Karyopherin is Importin-β1 which either binds cargo directly or indirectly
through interaction with adapters such as α-Importins or Snurportin-1 [15]. The transcription factors
Snail1 [16,17] and SREBP2 [18] are among the cargoes directly bound by Importin-β1. Snurportin-1 is
best known for its involvement in the nuclear import of spliceosomal snRNPs [19]. The interaction site of
Importin-β1 with FG-repeats has been mapped [20,21] and is different from the well-defined interaction
sites with cargoes and adapters [22]. This means that cargo-loaded Importin-β1 can interact with
FG-Nucleoporins of the NPC and thereby facilitate passage of the Importin-β1/adapter/cargo complex.
The import pathway using α-Importins as adapters to connect cargo with Importin-β1 has been
intensively studied and is now known as the classical import pathway [23]. Accordingly, the term
classical nuclear localization signal (cNLS) refers to linear sequence motifs of cargoes that bind
to α-Importins. The cNLS can be further subdivided into monopartite cNLS and bipartite cNLS.
Monopartite cNLS consist of a short stretch of basic amino acid residues, the sequence PKKKRRV
of the SV40 large T-antigen being the first identified [24]. The first bipartite cNLS has been found in
the Nucleoplasmin protein of Xenopus laevis, consisting of two short stretches of basic amino acids,
both essential for its function, separated by a few less relevant amino acids [25].
In humans, seven Importin-α isoforms have been identified: Importin-α1, -α3, -α4, -α5, -α6,
-α7 [23] and the most recently discovered Importin-α8 [26]. All α-Importins are mainly built up of
ten Armadillo (ARM)-repeats resulting in a structurally conserved solenoid protein domain [27]. The
cNLS of cargo binds along a groove on the inner concave surface of α-Importins. Although the cNLS
binding region is quite conserved, the α-Importins are specific for a set of cargo proteins with some
considerable overlap. This specificity results in part from preferential binding of certain NLS but also
from the three-dimensional context in which the NLS is presented by the cargo [28]. Apart from cNLS,
so called non-classical or atypical NLS have been identified, which do not fit in the cNLS consensus
motifs [29]. A short sequence termed Importin- β binding (IBB) domain precedes the solenoid domain
of α-Importins. In the absence of cargo, the IBB folds back to the NLS binding site. Upon binding of
cargo, the IBB is replaced by the cNLS of the cargo protein. The now exposed IBB binds to Importin-β1,
facilitating the nuclear import of the ternary Importin-β1/Importin-α/cargo complex [30].
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Transportin-1, also known as Importin-β2, also imports a broad spectrum of cargoes, including
transcription factors and mRNA-binding proteins. Transportin-1 binds cargo directly through a broad
range of loosely related NLS that are different from cNLS [31]. Symportin-1 has been identified as an
adapter for nuclear import of some ribosomal proteins by Transportin-1 [32]. Transportin-3 recognizes
arginine-serine (RS)-rich NLS found in proteins typically involved in mRNA metabolism such as
the Splicing Factor 2 (SF2) [33]. Importin-13 is closely related to Transportin-3 but mediates both
protein import and export. Therefore, by definition Importin-13 can be regarded as a Biportin. Some
transcription factors are among the many cargoes identified so far. Cargo binding by Importin-13 relies
on the recognition of folded domains rather than linear NLS [34,35].
Some import pathways have been identified that do not rely on β-Importins. Among those,
Calmodulin-mediated nuclear import seems to be most relevant for transcription factors [36]. Finally,
some proteins including transcription factors enter the nucleus independent of NTR or other carrier
proteins, e.g., through direct interaction with NUPs [37].
2.3. Exportins
Crm1 (Chromosome region maintenance 1; in the systematic nomenclature of Karyopherins
designated as Exportin-1 or Xpo1) is the most promiscuous Exportin, which mediates the export of
about 1000 substrates, including various RNAs, ribonucleoproteins, and transcription factors [38]. Most
protein cargo of Crm1 contains a leucine-rich nuclear export signal (NES) of 8–15 amino acids [39–41].
Like all β-Karyopherins, Crm1 is built up of HEAT-repeats (Huntingtin, Elongation factor 3, protein
phosphatase 2A and TOR kinase). Each HEAT-repeat consists of two α-helices connected by loops of
varying length. Similar to the ARM repeats of α-Importins, the HEAT-repeats of β-Karyopherins form
a solenoid protein domain [42] with a slightly curved superhelical structure of high conformational
flexibility. In all of the available structures of cargo bound to Crm1, the NES of the cargo fits into
a hydrophobic groove between HEAT repeats 11 and 12 (out of 20) at the outer convex surface of
Crm1 [43]. Binding at the outer convex surface of Crm1 allows accommodation of cargo of various sizes.
Other Exportins, such as Exportin-5, Exportin-t, and Exportin-2 (better known as CAS for Cellular
Apoptosis Susceptibility), bind their cargo on the inner concave surface. Accordingly, these Exportins
are more selective. Exportin-5 mediates export of several types of RNA but not protein; Exportin-t
is even more restricted to the export of tRNAs [44]. CAS is specialized for the nuclear export of
α-Importins, which is needed to maintain the classical import pathway [45]. Exportin-4, a distant
member of the β-Karyopherin family, originally described to mediate nuclear export of the translation
initiation factor 5A [46] and the transcription factor Smad3 [47], has more recently been described
to be involved in the nuclear import of Sox transcription factors [48], thus acting as a Biportin.
Another Biportin, Exportin-7 (also known as RanBP16) [49], has recently been described to act as a
broad-spectrum Karyopherin with about 200 export and 30 import substrates [50].
2.4. Ran-GTP/GDP Cycle
In principle, through interaction with the FG-repeats, β-Karyopherins can pass the NPC in both
directions [51]. Directionality of nucleocytoplasmic transport is achieved through coupling of cargo
binding to β-Karyopherins with the energy-consuming Ran-GTP/GDP cycle [12,52]. Ran is a small
G-protein of the Ras superfamily of GTPases that exists in a GTP- or GDP-bound state. The GTP-bound
state results from replacement of bound GDP with GTP that requires the activity of a Ran-specific,
chromatin-bound guanine-nucleotide exchange factor (RanGEF, also known as RCC1), which is
predominantly located in the nucleus. Therefore, the Ran-GTP concentration in the nucleus is high.
The GDP-bound state is generated through release of the β-phosphate of bound GTP by hydrolysis,
which requires the activity of a ran-specific GTPase-activating protein (RanGAP). Through interaction
with the Nucleoporin Ran-binding protein 2 (RanBP2, Nup358), RanGAP is located predominantly
at the cytoplasmic surface of the NPC. Therefore, in the cytoplasm close to the nuclear envelope,
the Ran-GTP concentration is low and the Ran-GDP concentration is high [53,54].
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Cargo binding to Importins in the cytoplasm is Ran-independent. After passage of the
Importin/cargo complex through the NPC, release of cargo in the nucleus is induced upon Ran-GTP
binding. In contrast, Ran-GTP-binding to Exportins is required for cargo loading in the nucleus. After
passage of the Exportin/cargo/Ran-GTP complex through the NPC, RanGAP-mediated GTP-hydrolysis
results in release of RanGDP and cargo into the cytoplasm [55].
As mentioned above, NTRs facilitate nucleocytoplasmic transport through transient interactions
with the hydrophobic FG-repeats within the channel of the NPC. In principle, other proteins with
hydrophobic surface patches should to some extent also be able to disturb the FG-repeat meshwork,
allowing them to shuttle between the cytoplasm and the nucleus in an NTR- and Ran-independent,
passive manner. Indeed, in a recent study [56] it has been found that a continuum exists with gradual
differences in the ability of proteins to pass the NPC in an active (i.e., NTR- and Ran-dependent) or
passive manner. Depending on their surface properties, even large proteins can leak into the nucleus
without involvement of NTRs.
3. STAT1—Using a Side Track for Nuclear Import
STAT1 is deeply involved in the antiviral response triggered by endogenously produced Interferons
but also in the therapeutic responses to exogenously administered Interferons in cancer treatments
and anti-viral therapies [57]. STAT1 is best known for its tumor suppressive activity in cancer but
some tumor-promoting effects have also been documented [58]. IFNγ (type II Interferon) induces
the activation of STAT1 through phosphorylation of Y701 by IFNγ receptor-associated Janus kinase 1
(JAK1) and JAK2, leading to dimerization and nuclear accumulation of the transcription factor [59].
Among all STAT family members, the mechanism of nuclear accumulation of the activated STAT1
dimer is best understood. Activated STAT1 interacts with Importin-α5 [60], but in an unconventional
manner. Instead of employing the binding site for cNLS, which would involve ARM repeats 2–4 and
6–8 as the major and minor binding sites, respectively [22], STAT1 binds to the more C-terminally
located ARM repeats of Importin-α5 [61] involving a critical tyrosine residue (Y476) located in ARM
repeat 10 [62]. Accordingly, the activated STAT1 dimer does not expose a cNLS but a dimer-specific
surface area to interact with Importin-α5. This surface has been termed dimer-specific NLS (dsNLS)
and includes regions within the N-terminal domain (NTD) [63] and the DNA-binding domain (DBD;
see Figure 1a for a scheme of the domain structure of STAT proteins; see Table 1 for an overview on
putative NLS and NES sequences of STAT proteins; and see Figure 1b showing the corresponding
putative NLS and NES motifs in the STAT1 dimer structure) [64]. Hence, Importin-α5 can be displaced
from STAT1 by DNA-binding [65,66]. Most interestingly, this unique mode of interaction is exploited
by the Ebola virus VP24 protein, that interacts with ARM repeats 8–10 of Importin-α5, preventing
binding and nuclear translocation of activated STAT1 [67]. Interaction of Importin-α5 with cNLS cargo
remains unaffected by VP24 binding. This example shows that, in principle, nuclear accumulation of a
STAT transcription factor can be selectively blocked.
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Figure 1. Structures of STAT proteins with putative nuclear localization signals (NLS) and nuclear export
signals (NES) highlighted as listed in Table 1. In this context, “putative” means that the corresponding
sequences do not fulfill classical NLS or NES functions but are required for nuclear transport or interaction
with nuclear transport receptors. (a) General scheme of structural domains of STAT proteins (NTD,
N-terminal domain; CCD coiled-coil domain; DBD, DNA-binding domain; LD, linker domain; SD, SH2
domain; TAD, transactivation domain). Numbers refer to amino acid positions. (b–d) Structures of
individual STAT proteins as ribbon representations (left) or space-filling representations (middle and
right). Domains are stained according to the coloring of the scheme in (a), DNA is shown in pink.
Putative NLS and NES are marked in red and cyan, respectively. The corresponding references are listed
in Table 1. PDB IDs: STAT1, 1BF5; STAT3, 1BG1; STAT5A, 1Y1U. Images of structures were generated
with PyMOL.
Table 1. NTRs, NLS and NES involved in transport of STAT proteins.
STAT1 STAT3 STAT5A STAT5B
Importin α5 [60,68], α7 [69] α1 [70], α3 [70–72],























1 n.d., not determined; 2 in this context, “putative” means that the corresponding sequences do not fulfill classical
NLS or NES functions but are required for nuclear transport or interaction with NTRs.
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4. STAT3—Acting on Many Stages
4.1. Role of STAT3 in Cancer
STAT3 is involved in cancer in multiple ways, as detailed in several reviews and articles of
this Special Issue of Cancers. Besides acting as an oncogene in a cell autonomous manner [80,81],
activation of STAT3 in the tumor microenvironment contributes to metastasis, angiogenesis, cancer
stem cell maintenance, and immune evasion [82]. Therefore, blocking STAT3 activity in cancer is
of particular interest. However, it should also be noted that in some cancers STAT3 has tumor
suppressive activities [83,84]. Several steps in the STAT3 activation pathway are potentially targetable
and thus might be used to interfere with STAT3 activation. These include phosphorylation on Y705 by
(oncogenic) tyrosine kinases, dimerization through phosphotyrosine/SH2 domain interactions, nuclear
translocation, DNA-binding to GAS (γ-interferon activated sequence) elements, and interaction with
cofactors. However, passage of the activated STAT3 dimer through the NPC has only rarely been
considered as a potential molecular target for intervention [85,86]. This might be due to the fact that
import mechanism for activated STAT3 and the interactions of STAT3 with NTRs have been analyzed
in some detail but are not completely understood as outlined below.
4.2. Nuclear Import
Compared to STAT1, the mechanism of nuclear import of the activated STAT3 dimer is less well
defined. Reports on interactions with α-Importins are contradictory in part. In one of the first studies,
interactions of STAT3 with Importin-α1, -α3, and -α5 were detected [70]. Additionally, interactions of
STAT3 with Importin-α5 and -α7, but not with Importin-α1, -α3, and -α4, were found [69]. In both
reports, interactions were only seen upon activation of STAT3. Other groups found interactions
with Importin-α3 and -α6 [71] and Importin-α3, -α5, and -α7 [72] being independent of activation
of STAT3. In this context it is worth noting that expression of Importin-α6 is restricted to testis [87].
Therefore, Importin-α6 is less relevant for nuclear import of ubiquitously expressed transcription
factors such as STAT3 and STAT5. Based on import assays with permeabilized cells, the MgcRacGAP
protein bound to Rac has been suggested as an NLS-containing adapter for Importin-α-mediated
nuclear import of STAT3 and STAT5 [88]. In another study using an MgcRacGAP inhibitor and siRNA
mediated knockdown, the functional role of MgcRacGAP for nuclear import of STAT3 could not be
substantiated [89]. These discrepancies might be the result of different experimental conditions and
cellular systems used. For instance, subcellular distribution of STAT3 analyzed by immunofluorescence
heavily depends on the applied fixation method [90]. Alternatively, the different findings indicate
that STAT3 employs a different import system depending on the cytokines used for its activation,
e.g., Interleukin-6 (IL-6) vs. Epidermal Growth Factor (EGF). Clearly, more work is required for
better understanding.
Functional relevance of Importin-α5 in nuclear import of activated STAT3 has been demonstrated,
as well as the involvement of Importin-β and Ran [70]. Moreover, it has been shown that the epitope on
Importin-α5 employed in the interaction with STAT3 is different from the one used for the interaction
with STAT1. A mutation in ARM repeat 10 of Importin-α5 blocks interaction with STAT1 [62] but
does not affect the interaction with STAT3 [72]. Correspondingly, the epitopes used by STAT3 and
STAT1 for interaction with Importin-α5 are also different. Amino acids in the DBD of STAT1 are
involved in the recognition of Importin-α5 [65,66], connecting Importin-binding and nuclear presence
with DNA-binding activity of STAT1 [91]. In STAT3, mutation of R214 and R215 located in the
coiled-coil domain (CCD) abolishes binding of Importin-α5 and nuclear accumulation in response to
stimulation [69]. Liu et al. [71] defined the sequence D150-K163 as being indispensable for nuclear
import of STAT3, which is also located in the CCD. Nuclear accumulation of activated STAT3 does not
require DNA-binding activity [72]. Common to STAT3 and STAT1 is the involvement of the N-terminal
domain in stimulation-dependent nuclear import [63,74,75]. The essential role of the NTD for active
nuclear import of STAT3 is further supported by the observation that the tumor suppressor ARHI
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(A Ras Homologue member I/DIRAS3) blocks nuclear translocation of phosphorylated STAT3 via
direct interaction with the NTD [92].
It seems that Importin-α5 is a major determinant for nuclear import of STAT3 and STAT1 but the
molecular interfaces of the interactions are considerably different. This opens an avenue for specific
interventions. However, to achieve a selective block of nuclear import of STAT3, the structural details
of the interactions with NTRs must be characterized in more detail. It should be noted that no classical
NLS or NES sequences have been identified in STAT3 in the sense of transferable functional motifs.
The above-mentioned amino acids in the putative NLS and NES are most probably important for the
integrity of domain structures or the part of epitopes that interact with NTRs in a non-conventional
manner [75], as exemplified for STAT1 [62] (Figure 1c showing putative NLS and NES motifs in the
activated STAT3 dimer structure).
4.3. Nuclear Export and Nucleocytoplasmic Shuttling
In the course of defining nuclear export signals of STAT3, it was found that pharmacological
inhibition of Crm1-mediated nuclear export results in partial nuclear accumulation of STAT3
independent of cytokine stimulation [79]. From these and other studies it became evident that
the subcellular distribution of latent STAT3 with high cytoplasmic and low nuclear concentration is the
result of a steady-state of constitutive nuclear import and rapid export independent of phosphorylation
at Y705 [93,94]. Determinants of stimulation-dependent nuclear import, such as the NTD and the
R214/R215-motif, are not involved in basal nuclear import of latent STAT3 [75]. Unphosphorylated
STAT1 has also been detected in the nucleus [95], and the mechanisms of nuclear import of latent and
activated STAT1 were also found to be different [64]. Nuclear import of unphosphorylated STAT3
might be independent of NTRs and could involve direct interactions with FG-repeat NUPs of the
NPC as observed for STAT1 [96]. From the three sequence motifs identified as putative NES in STAT3,
at least the one containing L525/L528 is involved in constitutive nucleocytoplasmic shuttling [75,79].
It has been firmly established that STAT3 and STAT1 form homodimers in the absence of the
activating tyrosine phosphorylation resulting in so called preformed dimers [97,98]. The phosphotyrosine-
independent dimerization involves homotypic interactions of the NTDs [99]. However, basal
nucleocytoplasmic shuttling of STAT3 does not require the NTD [75] and is not sensitive to a single
point mutation (L78R) that prevents preformed dimer formation [100]. Not only is dimer formation not
required for basal shuttling, but monomeric STAT3 shuttles even faster [75]. The increased shuttling
rate of monomeric STAT3 could be attributed to the smaller size compared to the preformed dimer.
However, a recent study suggests that hydrophobic surface patches that interact with FG-repeats
of FG-Nups might be a stronger predictor for NTR-independent passage of the NPC than size [56].
Thus, accessible hydrophobic surfaces that are masked in the dimer may facilitate faster shuttling of
monomeric STAT3 in an NTR-independent manner.
Since basal and stimulation-dependent nuclear import of STATs occur through different
mechanisms, they could, in principle, be targeted independently of each other. However, the functional
relevance of nuclear presence of unphosphorylated STAT3 and STAT1 (U-STATs) is not entirely clear.
Nuclear U-STATs might be involved as cofactors in gene regulation independent of their DNA-binding
activity [101].
5. STAT5—Leukemia and More
Important functional roles in hematopoiesis downstream of hematopoietic cytokines such as
Erythropoietin and Thrombopoietin have been attributed to STAT5. Consequently, deregulated
STAT5 signaling is prominently implicated in myeloproliferative diseases and leukemias [102].
The involvement of STAT5 in solid tumors is also well documented, both as an oncogene and a
tumor suppressor [103], as detailed in several reviews and articles of this Special Issue of Cancers.
In particular, in myeloproliferative neoplasms and leukemias, STAT5 has been identified as a promising
therapeutic target.
515
Cancers 2019, 11, 1815
Compared with the many reports on STAT3 and STAT1, only a handful of studies dedicated to the
molecular mechanisms governing nucleocytoplasmic distribution of STAT5 exist. In one of the first
studies [104], a sequence motif in the DNA-binding domain of STAT5B (V466-I469) was identified whose
mutation prevented Growth Hormone-induced nuclear accumulation and DNA-binding. However,
from this finding it cannot be concluded that DNA-binding per se is required for nuclear accumulation
of activated STAT5B because the mutation could also interfere with binding of NTRs, which was not
investigated in this study. We found that another mutation that affects DNA-binding of STAT5A does not
impair nuclear accumulation upon Epo stimulation, in agreement with the DNA-binding independent
nuclear accumulation of activated STAT3 [72]. In general, nuclear accumulation of STATs through
retention by binding to nuclear structures seems to be of minor importance. If nuclear accumulation
was dependent on retention of STATs on subnuclear structures, nuclear accumulation would be
saturable, meaning that as soon as all binding sites are occupied, the remaining STAT molecules would
not accumulate in the nucleus. This is not what is observed in the above-mentioned experiments with
transfected cells: Even upon forced overexpression, STATs almost completely accumulate in the nucleus
upon stimulation. This view is supported by the results of fluorescence recovery after photobleaching
(FRAP) experiments that have been exemplarily performed on STAT1-GFP. Upon nuclear accumulation
induced by Interferon treatment, STAT1-GFP freely diffuses through the nucleoplasm with the exclusion
of nucleoli [105]. In this and another study [93], the involvement of the cytoskeleton in directed nuclear
import of STAT1 and STAT3 was also excluded.
In one of the reports on binding of α-Importins to STAT3, binding to STAT5A and STAT5B was
analyzed in parallel but no interaction could be detected [69]. This is in agreement with our own
observations made with co-precipitation experiments from cellular lysates using Importins fused to
GST (glutathione-S-transferase). Accordingly, no cNLS has been detected in STAT5. In another study,
interaction of STAT5A with Importin-α3 has been shown [73], again supporting the notion that the
outcomes of in vitro assays (mostly co-precipitations) for studying the interaction of STATs with NTRs
are very sensitive to the experimental conditions used.
Similar to STAT3 and STAT1, constitutive nucleocytoplasmic shuttling of STAT5 independent
of tyrosine phosphorylation has been detected [77]. A functional role of nuclear U-STAT5 has been
established in megakaryocyte differentiation [106]. Basal and cytokine-induced import of STAT5A
requires an intact CCD [73] and was abolished upon deletion of eight amino acids in the CCD
(L142–E149, see Table 1 and Figure 1d showing putative NLS and NES motifs in the STAT5A monomer
structure; a structure of the activated STAT5 dimer is not available) [76]. Interaction of STAT5A with
Importin-α3 occurs in an unconventional manner involving the CCD [73]. As for STAT3 and STAT1,
stimulation-dependent but not basal nuclear translocation requires the NTD of STAT5 [77]. In a study
that tested all sequence motifs that might function as a cNES, a region between aa578 and aa675 in
STAT5B comprising the SH2 domain was identified to be required for nuclear export [77]. Another
region important for Crm1-mediated export was identified involving L119 and L133 in the NTD of
STAT5A [73].
A discrepancy between nuclear localization of STAT5A and STAT5B was found in response to
phosphorylation of the critical tyrosine residue (Y694 in STAT5A and Y699 in STAT5B) by Src family
kinases (SFK). While phosphorylation of Y699 in STAT5B, as well as Y705 in STAT3, by Src leads to
nuclear accumulation of the transcription factors, phosphorylation of Y694 in STAT5A by Src does
not [107]. Later it was found that this observation is of some relevance in Bcr-Abl-positive chronic
myeloid leukemia (CML), where STAT5 is predominantly localized in the cytoplasm despite being
phosphorylated at the critical tyrosine residue [108]. Cytoplasmic retention of STAT5A in response to
activation by Bcr-Abl was found to be mediated by SFK such as Src and Hck. Specific inhibition of SFKs
resulted in nuclear accumulation of STAT5A, enhanced STAT5 target gene expression, and increased
colony formation of CML cells [109]. SFK interfere specifically with dimerization of activated STAT5A
and thereby prevent nuclear accumulation [110]. In another report, phosphorylation of S779 has been
suggested as an additional requirement for the nuclear translocation of STAT5A in Bcr-Abl positive
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cells [111]. These intriguing examples show that even the highly homologous transcription factors
STAT5A and STAT5B differ in some aspects of nucleocytoplasmic shuttling and these differences might
be relevant for disease.
6. Perspectives for Therapeutic Interventions
Nucleocytoplasmic transport has been recognized as a target for cancer therapy [112,113] in
part based on the observation that components of the nuclear transport machinery are differentially
expressed in transformed cells [114]. These changes in expression can be relevant for disease.
It has been shown that Crm1-mediated nuclear export contributes to drug resistance in multiple
ways [115]. For example, Topoisomerase II inhibitors such as doxorubicin require nuclear Topoisomerase
activity. As a drug resistance mechanism, Topoisomerase II can be exported from the nucleus in
a Crm1-dependent manner [116]. Treatment with Crm1 inhibitors therefore sensitizes cancer cells
to doxorubicin treatment [117]. Only recently, in two independent studies, was Crm1 convincingly
identified as a synthetic lethality gene in different types of cancer [118,119]. Earlier clinical studies
already showed that the highly efficient Crm1 inhibitor leptomycin B is not well tolerated by
patients [120]. Less toxic small molecule inhibitors of Crm1 termed Selective Inhibitors of Nuclear
Export (SINE), such as selinexor, are currently used in clinical trials in patients with hematological
malignancies and solid tumors [112]. Most recently, selinexor in combination with dexamethasone has
been approved for the treatment of refractory multiple myeloma. In this context, it has already been
recognized that a more selective export inhibition could be more effective and reduce the serious side
effects of treatment [115]. There are only a few inhibitors for some other NTRs available (Importin-β1,
Importin-α/β1 heterodimers, and Transportin-1) which have not been explored in such detail yet [121].
For transcription factors that respond to extracellular cues, control of nucleocytoplasmic
distribution contributes to efficient signal transduction. High cytoplasmic concentration of the latent
transcription factor increases the sensitivity to stimulation, which usually occurs at the cytoplasmic
face of membrane-bound receptors. After stimulation and activation of the transcription factor, high
nuclear concentration increases the efficiency of DNA-binding and thus gene induction. However,
the molecular mechanisms involved in the control of subcellular distribution vary considerably between
different transcription factors. For instance, the NLS of NF-κB is masked by IκB [122]. Upon sensing
of inflammatory mediators by membrane-bound receptors, IκB is phosphorylated and ubiquitinated
resulting in its proteasomal degradation. The now exposed NLS facilitates α-Importin-mediated
nuclear accumulation of NF-κB [123]. Likewise, the NLS of some nuclear receptors, such as the
Glucocorticoid Receptor and Estrogen Receptor, are masked. Ligand binding to the receptors results
in release of Hsp90 and exposition of the NLS [124]. Similar cytoplasmic interaction partners that
would prevent nuclear translocation of latent STAT proteins have not been identified yet. Various other
mechanisms involving SUMOylation, ubiquitination, mono-ADP-ribosylation, and acetylation have
been described to control the nucleocytoplasmic distribution of transcription factors [22,125]. Beside the
well-established Karyopherin-mediated transport, other non-conventional transport mechanisms
exist [126]. Nucleocytoplasmic transport of β-Catenin is regulated independently of Ran and classical
transport factors [127,128]. At the same time, β-Catenin acts as a transport receptor for its transcription
factor partner LEF-1 [129]. The regulatory 14-3-3 proteins have also been suggested to be involved
in such a piggy-back mechanism of nuclear transport [130,131], which has so far not been described
for STAT proteins. Because of these various transport modes, specific interference should be feasible
in principle.
In the case of STAT transcription factors, a non-classical NLS is generated through phosphorylation-
induced dimerization (dsNLS) that is recognized by α-Importins or other yet uncharacterized factors.
Because this mechanism is quite unique, a specific intervention through targeting the dsNLS/α-Importin
interface should in general be feasible, as exemplified for STAT1 [67]. Extended surface areas are
involved in the STAT/NTR interaction, including the NTD, DBD and CCD. The NTD seems to be a
common denominator of nuclear import of activated STATs. Because the NTDs of different STATs vary
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in their sequence, a specific targeting should be possible, as exemplified by the specific interaction
of ARHI with the NTD of STAT3, but not with the NTDs of STAT5 and STAT1 [92]. The impact of
the ARHI/STAT3-NTD interaction on Importin-binding was further analyzed in a study applying
homology modelling and molecular dynamics simulation [132]. Indeed, targeting of the NTD of
STAT3 has been reported, however, with a focus on the role of the NTD as a tetramerization domain at
enhancers and its function in gene induction [133]. The more recently solved structure of the NTD of
STAT3 [134] should pave the way for a closer inspection of the surface areas involved in nuclear import
by mutation of surface-exposed residues. For nuclear import of STAT5 and STAT3, data concerning
use of the classical α-Importin/β1-Importin pathway are conflicting. Here, a fresh approach is needed
to identify the NTRs involved, including α-Importins/Importin-β1-independent pathways mentioned
in Section 2 of this review.
Reduced export of the imported STAT dimers also contributes to nuclear accumulation because
export and redistribution requires dephosphorylation [135]. Blocking nuclear export of STATs as
a therapeutic approach seems at first sight counterintuitive because it might trap the activated
transcription factor in the nucleus where it could drive persistent oncogenic gene induction. However,
STAT1, STAT3, and STAT5 are dephosphorylated in the nucleus by TC45, the 45 kDa isoform of
T Cell Protein Tyrosine Phosphatase (TC-PTP) [136–138]. For STAT1 it has been shown that only
the dephosphorylated form leaves the nucleus for reactivation at the receptor [91]. Exit out of the
nucleus is required for reactivation of STATs [139]. Thus, STAT-mediated gene induction could be
inhibited by trapping the dephosphorylated, transcriptionally inactive STATs (in the sense of canonical
STAT signaling) in the nucleus through blockade of nuclear export. This has already been shown for
STAT3 using the Crm1 inhibitor ratjadone A [140]. The more clinically advanced SINE have also been
tested. These compounds inhibited STAT3-mediated Survivin expression in breast cancer models [141].
To interfere more specifically with export of STATs, the Exportins or Biportins involved must be
characterized and the molecular interfaces of the STAT/NTR interaction mapped in detail.
Mechanistically, the export of dephosphorylated STATs most probably corresponds to the exit
mechanisms involved in constitutive shuttling of latent STATs. Treatment of cells with specific inhibitors
for the Exportin Crm1 often leads to only a partial nuclear accumulation of latent STATs. This means
that either passive NTR-independent export occurs through direct hydrophobic interactions with
FG-Nups or that other Exportins are involved. Specifically for STAT5A, a Crm1-independent export
signal in the DBD has been mapped [73]. Redundancy in cargo recognition by NTRs in the sense that
one cargo is transported by several NTRs is not unusual. As outlined in Section 2, broad-specificity
Exportins or Biportins have been identified in recent years, worthy of analysis with respect to their
involvement in the nuclear export of STAT proteins.
7. Conclusions
Taken together, effective inhibition of oncogenic STAT activity can in principle be achieved
through specific blockade of both nuclear import of phosphorylated STAT dimers and export of
dephosphorylated STATs out of the nucleus. However, this requires a deeper understanding of the
protein–protein interactions involved in these processes. First, all NTRs facilitating nucleocytoplasmic
shuttling need to be unambiguously identified for the individual STAT proteins. These studies should
also include those NTRs that have been characterized in more detail in recent years. Then, the interactions
between STATs and NTRs must be mapped in more detail using all structural data available. The ultimate
goal would be to solve the structure of STAT/NTR complexes by X-ray crystallography or cryo-electron
microscopy. Furthermore, the contribution of NTR-independent nuclear transport of STATs should be
evaluated through assessment and mutation of surface patches as delineated by Frey et al. [56]. Based
on solid structural and functional data, specific blockade of nucleocytoplasmic transport of individual
STATs by tailor-made inhibitory molecules might be feasible.
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Katharina Wöss, Natalija Simonović, Birgit Strobl, Sabine Macho-Maschler and Mathias Müller *
Institute of Animal Breeding and Genetics, University of Veterinary Medicine Vienna, A-1210 Vienna, Austria;
Katharina.Woess@vetmeduni.ac.at (K.W.); natalijabozovic@gmail.com (N.S.);
birgit.strobl@vetmeduni.ac.at (B.S.); sabine.macho-maschler@vetmeduni.ac.at (S.M.-M.)
* Correspondence: mathias.mueller@vetmeduni.ac.at
Received: 30 September 2019; Accepted: 2 November 2019; Published: 5 November 2019
Abstract: In this review we concentrate on the recent findings describing the oncogenic potential of
the protein tyrosine kinase 2 (TYK2). The overview on the current understanding of TYK2 functions
in cytokine responses and carcinogenesis focusses on the activation of the signal transducers and
activators of transcription (STAT) 3 and 5. Insight gained from loss-of-function (LOF) gene-modified
mice and human patients homozygous for Tyk2/TYK2-mutated alleles established the central
role in immunological and inflammatory responses. For the description of physiological TYK2
structure/function relationships in cytokine signaling and of overarching molecular and pathologic
properties in carcinogenesis, we mainly refer to the most recent reviews. Dysregulated TYK2
activation, aberrant TYK2 protein levels, and gain-of-function (GOF) TYK2 mutations are found in
various cancers. We discuss the molecular consequences thereof and briefly describe the molecular
means to counteract TYK2 activity under (patho-)physiological conditions by cellular effectors and by
pharmacological intervention. For the role of TYK2 in tumor immune-surveillance we refer to the
recent Special Issue of Cancers “JAK-STAT Signaling Pathway in Cancer”.
Keywords: tyrosine kinase 2; JAK family of protein tyrosine kinases; signal transducer and activator
of transcription; cytokine receptor signaling; gain-of-function mutation; tumorigenesis
1. TYK2-Mediated Cytokine Signaling and Activation of STAT3 and STAT5
TYK2 was the first identified member of a family of non-receptor kinases later termed Janus kinases
(JAK), which additionally comprises JAK1-3 [1,2]. JAKs are associated with cytokine and growth factor
receptors and activate STAT (STAT1-4, STAT5A, STAT5B, STAT6) family members [2,3]. JAKs share
four functional domains (from N- to C-terminal): (i) a four-point-one, ezrin, radixin, moesin (FERM)
homology domain; (ii) an atypical Src-homology 2 (SH2) domain, both facilitating protein-protein
interactions (PPIs); (iii) a kinase-like or pseudokinase (JAK homology (JH) 2) domain negatively
regulating the kinase activity; and (iv) a tyrosine kinase (JH1) domain which, upon conformational
changes at ligand bound receptors, increases its catalytic activity by trans-/autophosphorylation of its
activation loop [2,4].
To date, the requirement for TYK2 in signaling has been shown for numerous cytokines, including
distinct interleukin (ILs) and interferons (IFNs), which comprise several subtypes (i.e., type I and III
IFNs). The heterodimeric cytokine receptor complexes are composed of four distinct TYK2-associated
receptor chains (IFNAR1, IL-12Rβ1, IL-10R2, and IL-13Rα1) and a respective second receptor chain
associated either with JAK1 or JAK2, which serves as the signal transducing chain harboring STAT
docking sites. Usually, these sites contain critical tyrosine residues that are phosphorylated by JAKs
upon receptor complex activation (Figure 1). TYK2 also associates with the gp130 receptor chain,
yet there is no evidence that gp130-utilizing cytokines rely on TYK2 for signal transduction [5,6].
Note that comprehensive reviews [2,7] provide lists of various other receptors utilizing TYK2-STAT
signaling; however, TYK2-STAT activation/utilization is frequently only biochemically assessed by
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phosphorylation of critical tyrosine residues and cannot be put on a level with dissected downstream
cellular activities. Here we review the cytokines which clearly transduce the TYK2 phosphorylation





























































Figure 1. Cytokine receptor families signaling with the participation of TYK2 and JAK1 or JAK2.
Cytokines are depicted only upon appearance in humans and mice and proof of TYK2 dependency.
The color codes indicate the major STAT(s) activated by the respective cytokines. STAT1-STAT2
heterodimers combine with IFN regulatory factor (IRF) 9 and form the interferon-stimulated gene factor
3 (ISGF3) complex; * STAT activation is dependent on cell type or of less clear biological relevance.
The biological relevance for TYK2-dependent cytokines activating STAT3 is best established
for the IL-10R2 utilizing IL-22 [8,9] and the IL-12Rβ1-utilizing IL-12 and IL-23 [10–12]. IL-22 is a
central cytokine in tissue-barrier function, wound healing, and epithelial homeostasis and repair.
Cancer promoting, as well as restraining, functions were described [13,14]. IL-23 is a key mediator of
inflammation, bridges innate and adaptive immune responses, and is known to support tumorigenesis
and metastasis [15,16]. IL-12 is central in promoting cell-mediated immunity to infection and cancer [12].
However, this anti-carcinogenic function can be counteracted by IL-12-STAT3-promoted production
of pro-carcinogenic IL-23 [17]. While STAT3 is activated by type I and III IFN stimulation in various
cell types, its biological functions in the IFN responses are less clear. Growing evidence suggests that
STAT3 is a negative regulator of type I IFN activities, thereby providing a pro-viral and pro-survival
cellular program [18]; there is, however, also a report on an opposite, i.e., anti-viral activity of
STAT3 [19]. The role of TYK2 in IL-10 signaling through STAT3 is not entirely clear and may be cell
type- or context-dependent [6]. The double-edged role of IL-10 in immunity and cancer is reviewed
elsewhere [9,20]. IL-19, IL-20, IL-24, and IL-26 (absent in mice) constitute a subfamily within the
IL-10 cytokine family and signal primarily through activation of STAT3 [9]. Activation of TYK2 at
the respective receptors has not been formally shown but can be inferred from the receptor-chain
composition. As this subfamily constitutes relatively recently discovered cytokines, cellular responses
are still poorly defined, and we refer to recent publications and reviews for a potential cancer
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connection [21–23]. Lastly, without specification of the cytokines involved, TYK2 via STAT3 was
reported to be crucial for the mediation of cell death in an auto-inflammatory context [24].
STAT5, in contrast, is not among the primarily activated STATs downstream of TYK2 (Figure 1)
and occurs dependently on cell type and differentiation stage, in response to type I and III IFNs [25,26],
IL-10R2-, and IL-12Rβ1-receptor family cytokines [9,12]. Neither a cytokine-TYK2-STAT5 axis nor its
significance have been established under physiological conditions.
2. Aberrant Expression and/or Activity of TYK2 in Cancers
The JAK-STAT pathway is recognized as a core cancer pathway [27] and directly contributes
to all hallmarks of cancer [28]. Oncogenic JAK activity can originate from aberrant JAK expression,
deregulated upstream signals, GOF mutations, or generation of fusion proteins, as well as loss of
negative feedback regulation [2,29–31]. Initially, cancer research focused on JAK1-3, while the TYK2
impact on disease was predominantly studied in inflammatory and (auto-)immune diseases [32,33].
Table 1 summarizes the literature on constitutive or hyperactivated TYK2, as well as GOF-mutated
TYK2 and the resulting activation of STATs in cancers.
2.1. Aberrant TYK2 Levels
In vitro studies with overexpressed JAKs revealed that aberrant TYK2 levels lead to cellular
transformation with constitutive phosphorylation of STAT3 [34]. An unusually high expression
of TYK2 associated with or causative for carcinogenesis (reviewed [35]) was described for various
cancer cell lines and samples from patients suffering from prostate [36,37], ovarian [38], cervical [39],
and breast cancer [40,41], as well as malignant peripheral nerve sheath tumors (MPNST) [42,43].
Conflictingly, lowered TYK2 levels in tumor samples and sections (tumor cells and stroma) are
generally considered to be an unfavorable prognostic marker (e.g., [44], www.proteinatlas.org). This is
supported by a recently published meta-analysis of JAKs and STATs in hepatocellular carcinoma
(HCC) patients, where normal or higher TYK2 levels correlated with longer survival and were
found in healthy tissue [45]. The underlying reason for these conflicting reports may be attributed
to the anti-proliferative/pro-apoptotic and/or tumor surveillance properties of TYK2 [5], as well as
the undetermined tumor cell intrinsic and extrinsic state of TYK2. The important role of TYK2 in
immune-surveillance is also in line with findings in patients who carry mutated TYK2 alleles which
lead to loss of TYK2, lowered TYK2 levels [46], or expression of kinase-inactive TYK2 [47–49], and that
show primarily immunodeficiencies. Nonetheless, proteomics suggested that low TYK2 facilitates
local metastasis in breast cancer [50], and a comprehensive screen for protein tyrosine kinase variants
in numerous cancer cell lines identified splice variants that render TYK2 inactive [51]. On a molecular
mechanistic level, the cell intrinsic tumor-promoting consequences of low TYK2 or LOF of TYK2
currently remain elusive.
2.2. Aberrant Activation of TYK2
A comprehensive list of receptors (over-)expressed in various cancer types which allows us to
deduce putative upstream signals involved in hyperactivation of TYK2 was compiled recently [7].
Primary hematological neoplasm (ALCL, anaplastic large cell lymphoma; T-ALL, T cell acute
lymphoblastic leukemia) patient samples and cell lines were shown to be dependent on TYK2
activated by upstream IL-10 and/or IL-22 signals and established an upregulation of anti-apoptotic
BCL2 family members via STAT1 and/or STAT3 [52,53]. A similar high TYK2-STAT1/3-BCL2 axis
was found in MPNST [43]. Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4, CD152) is mainly
expressed on T cells and is a well-established immune checkpoint. CTLA4 signaling is initiated
through binding to CD80 (B7-1) or CD86 (B7-2) on the surface of antigen-presenting cells (APCs).
Ectopic expression of CTLA4 was found on diverse B-cell lymphoma. Mechanistically, it was established
that CD86-CTLA4 engagement resulted in recruitment/activation of TYK2, which, in turn, led to a
STAT3-driven tumor-promoting transcriptional program [54]. A STAT-independent involvement of
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activated TYK2 in fibroblast growth factor 2 (FGF-2) mediated escape from drug-induced death was
reported for a sarcoma cell line [55].
2.3. TYK2 Mutations
Oncogenic JAK2 with the prominent JAK2V617F mutation found in over 50% of myeloproliferative
neoplasia (MPN) patients [56] is the paradigm for the understanding of structure/function relations
of JAK activity [57–59] and for the general alertness of the cancer field for mutated JAK family
members as potential oncogenes. TYK2 joined the club of GOF-mutated JAKs causative for patient
hematopoietic malignancies only recently: In 2013, the first TYK2 GOF point mutations were found
in T-ALL cell lines and characterized to have transforming capacity via STAT1 and a BCL2 family
member [53]. With respect to biochemical studies, the first GOF mutation of TYK2 was V678F, which is
the homologous mutation to JAK2V617F [60,61]. Until now, this mutation was not found in patients.
The only mutation reported in a public cancer genome database (www.stjude.cloud) for this residue is
the V678L mutation, albeit with unknown structure/function consequences. Point mutations at the
TYK2 locus are distributed throughout the whole gene body, with GOF mutations—similar to the
other JAKs—primarily accumulating in the JH1 and JH2 domains ([2,5] and see public databases, e.g.,
Genomic Data Commons of the National Cancer Institute [62,63], Catalogue of Somatic Mutations in
Cancer (COSMIC [64], and cBioPortal for Cancer Genomics [65,66]).
In addition to the somatic cancer cell mutations, two GOF TYK2 germline mutations (P760L and
G761V) were found in pediatric patients developing several de novo leukemias. These mutations are
located in the JH2 pseudokinase domain of TYK2 and are predicted to attenuate the negative regulation
on the JH1 kinase domain, leading to constitutively activated TYK2 [67].
A prominent germline TYK2 mutation is P1104A/V, which was first found to be associated with
solid and hematopoietic cancers [68,69] and later with immunological and inflammatory disorders
(reviewed in [5]). While analyzing MPNST tumor samples, it was proposed that TYK2P1104A is an
unfavorable prognostic marker for the disease [42]. Notably, this study solely genotyped the somatic
cancer cells and overlooked that this mutation impairs TYK2 catalytic activity; cellular signaling,
however, is not completely abrogated, and the detected induction of BCL2 expression might favor
an anti-apoptotic program [69,70]. Recent studies show that TYK2P1104A is a LOF mutation, because
patients homozygous for this allele are either susceptible to microbial infection or protected from
autoimmune disease [47,49,71]. These mechanistic and phenotypic features of TYK2P1104A were
confirmed in independent mouse models [48,71].
2.4. TYK2 Fusion Proteins
Chromosomal rearrangements account for a number of driver kinase fusion genes in cancer [72–74].
The first fusion kinase involving a JAK was TEL-JAK2, consisting of a 3′ portion of JAK2 and a 5′
region of TEL, a member of the ETS transcription factor family [75]. This chromosomal translocation is
found in T-ALL in patients [75] and transgenic mice expressing TEL-JAK2 develop T-cell leukemia [76].
In vitro studies with a TEL-TYK2 fusion showed constitutive activation of STAT1/3/5 and transforming
capacities [77], albeit respective translocations have not yet been identified in patients. As observed for
GOF-mutated JAKs, JAK2 kinase fusions occur most frequently compared to the other JAKs, which
suggests that the JAK2 locus is a mutation and rearrangement hotspot [56,78,79]. The first leukemia
patients carrying TYK2 fusion genes described were combinations of the TYK2 kinase domain and a
part of the pseudokinase domain with 5′ portions of nucleophosmin (NPM) 1, polyadenylate binding
protein (PABPC) 4, or the transcription factors MYB or NFκB2 [80–82]. Structurally and mechanistically,
the TYK2 fusion proteins lack the negatively regulating function of the pseudokinase (JH2) domain
leading to a GOF kinase activity and hyperactivity of STAT3 and depending on the cellularity also
STAT1 and 5 (reviewed in [5,58,59]).
Subsequent analysis of patient samples and cell lines [83–87] and screening of cancer data sets
revealed more than 50 chromosomal TYK2 rearrangements found mostly in hematological, but also in
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solid cancers [88]. For the fusions, it is currently not known if they contribute as driver oncogenes to
early tumorigenesis or are rather the result of genomic instability at later tumor stages [89]. Recently,
chromothripsis was identified as a new type of chromosomal rearrangement during carcinogenesis.
Based on a single chromosome-shattering event and DNA repair complex, intra- and interchromosomal
rearrangements, such as fusion genes, are produced within a few cell cycles. If the fusion event(s) allow
for growth or survival advantages, a cancer driver gene might be generated [90,91]. Chromothripsis
was assigned to genomic alterations in childhood cancer [92], and mechanistically it is caused by
defects in the nuclear envelope composition or formation and failures during mitosis [93]. It is
tempting to speculate that the remarkably high number of described TYK2 fusions were—at least in
part—generated through chromothripsis and thus might act as driver mutations.
3. Tumor-Promoting Activities of (Hyper-)Active TYK2
The molecular contribution of TYK2 signaling and known protein–protein interactions to the
hallmarks of cancer were reviewed previously [5,28]. Here, we highlight the latest findings on the
consequences of TYK2 hyperactivity in cancer cells.
3.1. TYK2 Activation of (Oncogenic) STAT Signaling
As shown in Figure 1, the heterodimeric cytokine receptors with engagement of TYK2 are capable
of activating all STATs. Hyperactive, GOF-mutated TYK2 or TYK2 fusions in oncogenic settings
preferentially lead to aberrant activation of STAT1, STAT3, and STAT5. The oncogenic potential of STAT3
and STAT5 was recognized early on and is well documented [94,95]. STAT1 was initially considered to
exert tumor suppressor functions, and its oncogenic potential emerged more recently [96–98].
STAT1/3/5 were found hyperactivated in patient-tailored cell lines with activated TYK2 [53],
as well as carrying somatic or germline TYK2 GOF mutations [53,67] or TYK2-NPM1 and -NFkB2
fusions [80,82]. In other tumor samples or experimental tissue culture settings, STAT3 only, or other
dual combinations of activated STAT1/3/5, are described (see Table 1).
Interestingly, TYK2 does not only phosphorylate the major phosphorylation site Y705 in STAT3,
but also Y640, which represses STAT3 activation [99]. This phosphorylation site in STAT3 is often
mutated in cancers [100,101]. Neither the general (patho-)physiological impact nor the contribution to
malignancies of this phosphorylation event are currently known.
Table 1. (Hyper-)active TYK2, GOF-, or LOF-mutated TYK2 and STAT activation in various cancers
and cancer cell lines.
TYK2 Status Disease Activated STAT Ref.
Activating somatic mutations (GOF)
TYK2-G36D; -S47N T-ALL STAT1, STAT3 [53] (3) (2) (2 *)
TYK2-731I T-ALL STAT1, STAT3, STAT4 [53] (3) (2) (2 *)
TYK2-E957D T-ALL STAT1, STAT3, STAT5 [53] (3) (2) (2 *)
TYK2-R1027H T-ALL STAT1, STAT3 [53] (3) (2) (2 *)
TYK2-V678F — STAT3, STAT5 [61] (2 *)
Inactivating germline mutations (LOF)
TYK2-P1104A MPNST n.d. [42] (4 *) (1)
TYK2-P1104A Breast-, colon-, stomach-cancer n.d. [68] (1)
TYK2-P1104V AML n.d. [69] (5) (1) (2 *)
Activating germline mutations (GOF)
TYK2-P760L B-ALL STAT1, STAT3, STAT5 [67] (3) (1) (2 *)
TYK2-G761V T-ALL STAT1, STAT3, STAT5 [67] (3) (1) (2 *)
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Table 1. Cont.
TYK2 Status Disease Activated STAT Ref.
Oncogenic fusion proteins (GOF)
NPM1-TYK2 CD30-positive LPDs STAT1, STAT3, STAT5 [82] (3) (1) (2) (2 *)
NFkB2-TYK2 ALCL STAT1, STAT3, STAT5 [80] (3) (1) (2 *)
ELAVL1-TYK2 AML STAT3, STAT5 [84] (2)
PABPC4-TYK2 ALCL n.d. [80] (1)
TEL-TYK2 — STAT1, STAT3, STAT5 [77] (2 *)
MYB-TYK2 Ph-like ALL n.d. [81] (1)
High wildtype TYK2 levels
TYK2 WT T-ALL STAT1, STAT3, STAT4, STAT5 [53] (1) (2) (2 *)
TYK2 WT ALCL STAT1, STAT3 [52] (4) (1) (2)
TYK2 WT Hepatocarcinoma STAT1, STAT3 [102] (3 *) (2 **)
TYK2 WT MPNST STAT1, STAT3 [43] (4) (?) (1) (2)
TYK2 WT B-cell lymphoma STAT3 [54] (3 *) (2)
TYK2 WT Lung cancer STAT3 [103] (3 *) (1) (2) (2 *)
TYK2 WT Hepatocarcinoma STAT3 [104] (3 *) (2 **)
TYK2 WT Ovarian cancer STAT3 [38] (3 *) (2)
TYK2 WT Prostate cancer n.d. [36] (4) (1) (2)
TYK2 WT Prostate cancer n.d. [37] (4) (1) (2)
TYK2 WT Osteosarcoma no [55] (3 *) (2)
TYK2 WT Breast cancer n.d. [40,41] (4) (1) (2)
TYK2 WT Squamous cervical carcinoma n.d. [39] (4) (1)
TYK2 WT MPNST n.d. [42] (4) (?) (1)
TYK2 WT Lung cancer STAT1 [105] (2 **)
Low wildtype TYK2 levels
TYK2 WT Breast cancer (metastatic) n.d. [50] (6) (1) (2)
— Unrelated to disease, in vitro findings in stable cell lines, (1) found in patient samples and primary material,
(2) in vitro findings endogenous TYK2 expression, (2 *) in vitro findings exogenous TYK2 expression, (2 **) in vitro
findings exogenous claudin expression, (3) phosphorylated mutated TYK2 protein, (3 *) phosphorylated wildtype
TYK2 protein, (4) high levels of wildtype TYK2, (4 *) high levels of mutated TYK2, (5) reduced levels of phosphorylated
mutated TYK2, (6) reduced levels of wildtype TYK2, and (?) not specified if wildtype or mutated TYK2. Please note
that some references did not study the activation of all STATs and that not all described STATs in the table are active
in all cell systems used. Ph = Philadelphia, and n.d. not determined.
3.2. TYK2 Stimulation of Tumor Cell Invasion
The families of tight junction proteins claudins (CLDNs) and of matrix metalloproteinases
(MMPs) are central for the invasion of tumor cells and, in consequence, metastasis formation [106,107].
Recent studies show that, in liver and lung carcinoma, high levels of CLDN9/12/17 caused activation of
TYK2 and STAT1/3 and promoted metastasis [102,104,105]. The promoters of various MMP genes harbor
STAT binding sites, and many MMPs are transcriptionally activated through TYK2-associated cytokine
receptors [108,109]. Gene-targeted mice revealed that TYK2 and STAT1 are required for expression
of MMP2/9/14 under inflammatory conditions [110]. Biochemical studies showed that, dependent
on context and inflammatory conditions, MMP1/3 induction involves STAT1 alone [108] or also
STAT3 [111]. In a hematopoietic tumor TYK2-STAT3 induced MMP9 and tumor cell invasiveness [54]
and in a solid tumor TYK2-STAT3 signaling induced MMP1 expression [103].
The urokinase-type plasminogen activator (uPA)/receptor (uPAR) system is central for a cascade
of proteolytic events, including activation of MMPs, which allow for tumor cell migration and
metastasis [112]. Signaling via uPAR involves TYK2 and PI3K [113], and, at the post-transcriptional
level, TYK2 inhibits the accumulation of plasminogen activator inhibitor (PAI) 2 [114]. In prostate
cancer, high levels of TYK2 correlate with invasion and metastasis [36,37]. In an ovarian cancer
cell line pY-STAT3 co-localizes with TYK2 and JAK2 at focal adhesions, and hyperactive STAT3 was
shown to promote cancer cell motility [38]. Without providing molecular details, a mouse model for
aggressive lymphoma showed reduced tumor cell invasiveness upon loss of TYK2 [115]. In addition,
without providing molecular insights, a siRNA screen assessing the role of the tyrosine kinome in
metastasis formation identified TYK2 as a promoter of invadopodia, which are cellular structures
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characteristic for tumor cell migration [116,117]. Connexin43 (Cx43) is the most widely expressed
member of a large family of transmembrane proteins involved in gap junction formation. Cx43 can
be both pro- and anti-tumorigenic, e.g., by promoting invasion and metastasis and by acting as a
tumor suppressor [118,119]. TYK2 was found to play a dual role in regulation of Cx43: On the
one hand, TYK2 is capable of directly phosphorylating Cx43, thereby decreasing its stability; on the
other hand, angiotensin II-activated TYK2 increased Cx43 levels in a STAT3-dependent manner [120].
This regulatory loop has not yet been studied in the context of carcinogenesis. Furthermore, knockdown
of TYK2 reduced migration of breast cancer cell lines [50].
3.3. TYK2 Prevention of Apoptosis
IFNs in general are capable of promoting apoptosis of cancer cells [121]; hence, provided that
IFN stimulus and responsiveness in the tumor is given, TYK2 acts tumor suppressive. Tumor cells are
able to resist cell death by upregulation of anti-apoptotic BCL-2 family members [122,123]. TYK2 was
shown to drive either in a STAT1- and/or a STAT3-dependent manner or in a STAT-independent but
ERK1/2-dependent manner high expression of BCL-2 [43,53,55] or its family members BCL-2L1 [54]
and MCL1 [52,55]. In contrast, an in vitro study demonstrated that TYK2 physically interacts with
SIVA-1 and promotes SIVA-1 mediated apoptosis, as well as inhibits BCL-2 [124].
3.4. TYK2 Crosstalk to Oncogenes and Proto-Oncogenic Pathways
In a mouse model of ALCL, as well as in patient cells, TYK2 showed co-operativity with the
oncogenic fusion kinase NPM-ALK [52]. In contrast, no co-operation of TYK2 with mutated FLT3-ITD
or JAK2V617F in MPN mouse models was found [125,126]. The latter is consistent with the observation
that, in JAK2V617F MPN patients (see below) resistant to pharmacological JAK2 inhibition, only JAK1,
and not TYK2, leads to heterodimeric STAT activation, despite both kinases show equal tyrosine
phosphorylation at the activating loop [127]. This is to be expected, since, in contrast to the other JAKs,
loss of TYK2 at heterodimeric JAK-associated cytokine receptors leads only to a partial impairment in
signaling [5,6], and, as experimentally described for the IFNAR receptor, TYK2 is the subordinated
JAK at cytokine receptors [128,129].
Early biochemical studies suggest that, upon type I IFN treatment, TYK2 interacts with various
proto-oncogenes, including the guanine nucleotide exchange factor 1 VAV, the E3 ubiquitin-protein
ligase C-CBL, and the SRC family tyrosine kinases FYN and LYN [130–134]. The importance of
these PPIs for tumorigenesis is currently unknown. In cancer samples or cell lines, TYK2 was
found to cooperate with other oncogenic effectors and pathways, such as the RAF/ERK [53,55,61],
MAPKs [135], PIM1/2 [84], and PI3K/AKT/mTOR pathway [36,53,61]. Reported solely in the context of
skin inflammation is the TYK2-STAT3 requirement for expression of IκBζ (encoded by NFKBIZ) [136];
however, emerging reports suggest cell-intrinsic oncogenic, as well as tumor-suppressive, functions of
IκBζ [137].
The mapped and predicted PPIs of TYK2 based on proteomics [138,139] and next generation
sequencing (NGS) are accessible at various open-source databases (for a review, see [140]). The TYK2
kinase domain and a STAT3-based reporter system were used to establish the first mammalian two
hybrid kinase substrate sensor (KISS) screening platform [141,142]. These databases and the screening
approaches should be systematically exploited to further define and fine tune the TYK2 interactome in
health and disease.
4. Deactivation and Stabilization of TYK2 under (Patho-)Physiological Conditions
JAK activity is counter regulated by molecule-intrinsic events, such as post-translational
modifications (PTMs) and the inhibitory function of the pseudokinase domain [143] as well as
by extrinsic inhibitory regulators, such as suppressor of cytokine signaling (SOCS) proteins and protein
tyrosine phosphatases (PTPs) [144].
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Databases [145,146] provide curated PTMs, but with the exception of the well described activating
phosphotyrosines, there is still a lack of information on the properties of JAKs that are defined by
PTMs. For TYK2, ubiquitination and phosphorylation are detected at multiple residues and discussed
in the context of stability/decay (PhosphoSitePlus®, [146]), albeit the (patho-) physiological relevance
is unknown.
SOCS proteins are encoded by STAT target genes and are negative feedback inhibitors of JAK
signaling. SOCS1 and 3 are the most potent JAK inhibitors because, in addition to recruitment of JAKs
to E3 ubiquitination/degradation mediated by all SOCS family members, they also harbor a kinase
inhibitory region (KIR), which efficiently shuts down JAK activity by binding to the JH1 domain [147].
Activated JAKs and cytokine receptor chains are dephosphorylated by multiple PTPs [148]. The current
literature regarding deactivation of TYK2 by SOCS1/3, the PTPs PTB1B and SHP1, as well as the global
impact of SOCS and PTP family members in cancer are reviewed elsewhere [5,149–151].
In vitro studies showed that in hematopoietic tumor cells the PTP SHP1 suppresses growth
via accelerating the TYK2 protein degradation [152]. In lung cancer cells, overexpression of the E3
ubiquitin ligase seven-in-absentia-2 (SIAH2) accelerates the proteasomal degradation of TYK2, thereby
attenuating STAT3 signaling [103].
HSP90 is a chaperone supporting folding, stability, and function of many client proteins, including
JAKs and STATs [153–155]. Cancer cells frequently use HSP90 to stabilize and/or increase the function
of numerous oncogenes, and HSP90 inhibitors have been studied as anticancer drugs for more than
two decades [156,157]. Physical interaction of HSP90 with TYK2 was demonstrated in cancer cell lines
and confirmed in a proteome-wide assessment of the HSP90 interactome [158,159]. HSP90 inhibitor
treatments in various tumor settings showed beneficial effects by reducing the activity of TYK2 or its
fusion proteins [158,160,161].
An emerging field is the involvement of noncoding RNAs in the regulation of the JAK-STAT
pathway in carcinogenesis [162–164]. Recently, the long noncoding RNA (lncRNA) MEG3 in concert
with a microRNA (miR-147) was reported to modulate JAK-STAT signaling in chronic myeloid leukemia
(CML). Interestingly, the lncRNA was found to physically interact with TYK2, JAK2, and STAT3,
thereby diminishing the activity level of STAT3 (and STAT5) [165].
5. Pharmaceutical TYK2 Inhibition
The first selective JAK inhibitor (JAKinib) to be tested in humans was tofacitinib, which potently
inhibits JAK3 and JAK1, and, to a lesser extent JAK2, and has little effect on TYK2 [166]. Historically,
JAKinibs were developed as immunosuppressive drugs for the clinical use in organ transplants and
autoimmune diseases [167]. The success story of ruxolitinib, a JAK2 and JAK1 inhibitor which was
the first JAKinib approved for treatment of a hematopoietic malignancy, pushed the perception of
JAKinibs as anticancer drugs [168,169]. For insight in development and clinical use, as well as side
effects of JAKinibs, we refer to the most recent reviews [170–173].
TYK2inibs are mainly envisaged as therapeutics for treatment of autoimmune and inflammatory
diseases [33,174], in which JAKinib selectivity is currently considered not to be of utmost
importance [175]. As for the other JAKinibs, the first generation TYK2inibs are directed to the
JH1 domain and compete with ATP in binding to the enzymatic pocket. These inhibitors are potent in
inhibiting wildtype (overexpressed) TYK2, mutated (hyperactive) TYK2, and TYK2 fusion proteins
harboring the JH1 domain. Since the JAKs show high homology in the JH1 domain, it is hard to
develop ATP-competing inhibitors with high selectivity for one particular JAK family member [170,172].
A next-generation inhibitor of TYK2 is directed against the JH2 domain and recently passed the phase
II clinical trial for psoriasis treatment [176]. A comprehensive report on the high selectivity and the
biological effects of this TYK2inib in mouse models, as well as its efficacy in human cells collected
from autoimmune patients, was recently published [177]. JH2-specific TYK2inibs are currently further
improved, and additional compounds are being developed [178–181]. The only TYK2inib reported
and successfully tested to block TYK2 activity in an oncogenic setting is a JH1-specific TYK2inib [135].
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Notably, JH2 domain inhibitors might not be working for treatment of diseases driven by TYK2 fusion
genes missing parts of the JH2 domain.
6. Conclusions and Future Perspectives
Since the discovery of TYK2 and the JAK-STAT signaling paradigm in the early 1990s, enormous
progress has been made in the structural and functional understanding of the linear JAK-STAT axis and
the crosstalk of JAKs or STATs to other signaling hubs, as well as the cell type-specific contributions of
JAKs and STATs in health and disease. The striking phenotypical similarities between mouse models
deficient for TYK2 or engineered to express kinase-inactive TYK2 and human patients carrying the
respective germline mutations established TYK2 as a fundamental component in both innate and
adaptive immunity. The (patho-)physiological and molecular pathway similarities of TYK2 in human
and mice allow for highly informative comparative biomedical studies and efficient translation of basic
molecular insights into clinical applications. The use of TYK2inibs in the treatment of immunological
and inflammatory diseases is within reach [182] and is also attractive for malignancies with the
involvement of hyperactivated TYK2. The role of TYK2 and GOF-mutated TYK2 upstream of oncogenic
STAT3—and, less frequently, STAT1—is established, while, up to now, no mechanistic evidence for
an oncogenic TYK2-STAT5 axis is given. Mouse models as genetic mimics of kinase-inhibited TYK2
exist [48,71,183,184] and are currently exploited to further dissect the kinase-dependent from the
scaffolding functions of TYK2.
In a short-term perspective, work should concentrate on the use of refined TYK2 mouse models
that allow studying the kinase-independent and cell type-specific functions, in order to fully in vivo
assess TYK2inibs with respect to their benefits and unwanted side effects. Mouse models to study the
consequences of aberrant high TYK2 and GOF-mutated TYK2 are underway (K. Wöss, T. Rülicke et al.,
unpublished). For pharmacological intervention with oncogenic TYK2, TYK2inibs with the highest
possible selectivity are required, and efforts should focus on the further development and in vivo
testing of these next-generation TYK2inibs.
In a long-term perspective, the further understanding of the TYK2 function requires the in-depth
elucidation of the PTMs and the interactome of TYK2 under spatiotemporal conditions. Additionally,
computational modelling and structure predictions (e.g., [185]) should complement the attempts
to determine the holo-crystal structure of TYK2 and to use high-resolution imaging (e.g., [186]) to
gain insight into the structural features of full-length wildtype and mutated TYK2, as well as its
conformation bound to various cytokine receptors.
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Abstract: Shwachman–Diamond syndrome (SDS) is a rare inherited bone marrow failure syndrome,
resulting in neutropenia and a risk of myeloid neoplasia. A mutation in a ribosome maturation factor
accounts for almost all of the cases. Lymphoid involvement in SDS has not been well characterized.
We recently reported that lymphocyte subpopulations are reduced in SDS patients. We have also
shown that the mTOR-STAT3 pathway is hyper-activated in SDS myeloid cell populations. Here
we show that mTOR-STAT3 signaling is markedly upregulated in the lymphoid compartment of
SDS patients. Furthermore, our data reveal elevated IL-6 levels in cellular supernatants obtained
from lymphoblasts, bone marrow mononuclear and mesenchymal stromal cells, and plasma samples
obtained from a cohort of 10 patients. Of note, everolimus-mediated inhibition of mTOR signaling is
associated with basal state of phosphorylated STAT3. Finally, inhibition of mTOR-STAT3 pathway
activation leads to normalization of IL-6 expression in SDS cells. Altogether, our data strengthen the
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hypothesis that SDS affects both lymphoid and myeloid blood compartment and suggest everolimus
as a potential therapeutic agent to reduce excessive mTOR-STAT3 activation in SDS.
Keywords: STAT3; mTOR; Bone Marrow Failure Syndromes; lymphocytes
1. Introduction
Shwachman–Diamond syndrome (SDS) is one of the most common inherited bone marrow failure
syndromes (IBMFS), occurring in almost 1 out of 75,000 live births [1]. SDS results from biallelic
mutations in the Shwachman–Bodian–Diamond syndrome gene (SBDS), which encode the SBDS
protein. SBDS protein cooperates with its partner elongation factor-like GTPase 1 (EFL1) to catalyze
the release of the ribosomal anti-association factor eIF6, facilitating the assembly of the functional 80S
ribosome [2–4]. The IBMFS are also cancer predisposition syndromes, in particular myelodysplastic
syndrome (MDS) and acute myeloid leukemia (AML). In the general population, MDS has an incidence
ranging from 2–12 cases per 100,000 people, which increases as individuals age [5]. Patients with
SDS demonstrate a risk of evolution to MDS of 8.1% and 36% at 10 and 30 years, respectively [6].
A recent genomic analysis of 1514 patients with MDS who underwent a stem cell transplant showed
that 4% of the young adult patients had undiagnosed compound heterozygous mutations in SBDS,
suggesting that SDS prevalence among MDS/AML patients may be underestimated [7]. AML derives
from dysregulated proliferation and accumulation of immature myeloid progenitor cells into the bone
marrow and peripheral blood, which finally leads to a severe impairment of the hematopoietic system.
Acute leukemias rapidly disseminate after initial inception, escaping the anti-leukemic immunity
process. Regulatory T cells play a key role in the maintenance of immune tolerance, which acts as a
regulator of the tumor immunity [8]. CD4/CD8 double negative (DN) T cells have gained prominence
among T regulatory cell subsets engaged in immunosurveillance. DN T cells are mature T cells
representing almost 3–5% of the total peripheral T cell population [9]. Most human and murine T cells
express and rearrange the α and β chains of the T cell receptor (TCR) and are recognized as TCRαβ T
cells, whereas a small part of T cells do express the γ and δ chains, which are mostly DN T cells [9].
Interestingly, DN T cells showed anti-leukemic activity and synergy with conventional chemotherapies
both in vitro and in patient-derived xenograft models of AML [10,11]. In a mouse model of AML, the
leukemic cells promoted T cell tolerance with suppression of anti-tumor CD8+ T cells [12]. Failure of T
cell-mediated anti-cancer immune response is associated with disease progression and poor outcome
in MDS and AML.
IL-6/JAK/STAT3 signaling axis plays a key role in leukemogenesis [13]. The genes encoding
the kinase protein JAK2 have indeed often been mutated in myeloproliferative disorders, leading to
constitutive hyper-activation of its downstream effector, the transcription factor STAT3 [14]. Of note,
STAT3 hyper-activation has been found in tumor-infiltrating leukocytes, in which STAT3 orchestrates
the crosstalk between cancer and immune cells [15]. Furthermore, it has been reported that STAT3
inhibition in the myeloid compartment remarkably induces the anti-tumor capabilities of T cells and
promotes their expansion in vivo [16,17]. STAT3 activation in immune cells is indeed associated with
suppression of anti-tumor immunity. STAT3 excessive activation may be triggered by elevated levels
of IL-6 present in the serum or released within the tumor microenvironment [14]. IL-6 may act in
an autocrine or paracrine manner. IL-6 binds to its IL-6 receptor (IL-6R), localized onto the plasma
membrane (membrane bound (mb)IL-6R), which is physically associated with the gp130 protein. This
process is recognized as classical IL-6 signaling and leads to gp130 homodimerization, resulting in
the activation of the IL-6 receptor complex [18]. In addition, IL-6 binds to the small extracellular
secretory soluble IL-6 receptor (sIL-6R), which is generated by alternative splicing of IL-6R gene or by
metalloproteinase-dependent cleavage of mbIL-6R. The sIL-6R mediates JAK-STAT3 activation in gp130
positive cells, which do not express mbIL-6R through a process termed IL-6 trans-signaling [19]. The
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IL-6 trans-signaling pathway has been reported in murine hematopoietic stem cells [20,21]. Elevated
levels of IL-6 have been found in adult bone marrow niche of patients with AML [22]. Serum IL-6 levels
were found to be significantly increased in pediatric patients with AML [23]. Moreover, increased
IL-6 serum levels are associated with poor prognosis in several types of cancer, including AML [23].
Interestingly, IL-6 gene expression can be regulated by STAT3 itself, resulting in a feedforward autocrine
feedback loop [14].
STAT3 has been reported as a direct substrate for the mammalian target of rapamycin (mTOR),
which induces STAT3 S727 phosphorylation [24,25]. In addition, the mTOR-inhibitor rapamycin
inhibits STAT3 S727 phosphorylation [24]. Moreover, we have previously shown that mTOR can
promote STAT3 phosphorylation both at residue tyrosine 705 and serine 727 in SDS leukocytes [26].
Previous studies have reported that relapse of AML is associated with the gain of additional mutations
in the mTOR gene, often due to the cytotoxic chemotherapy received by patients [27,28]. Inhibition of
the mTOR pathway using rapamycin or other analogue molecules, including everolimus (RAD001) as
anti-leukemic agent, has shown potent anti-cancer capabilities both in vitro and in vivo [29,30].
To date, no pharmacological therapy has been developed for IBMFS-related MDS or AML,
and allogeneic hematopoietic stem cell transplantation remains the unique option in these
cases. Unfortunately, its efficacy is limited by the morbidity and mortality associated with
graft-versus-host disease.
Here we show further analysis of the mTOR-STAT3 axis in an extended panel of lymphocytic
populations including CD4+, CD8+, T cells, DN T cells, γδT cells, and Natural Killer cells (NK).
Moreover, we have checked the expression of IL-6 in different cellular and clinical SDS models,
including lymphoblastoid cell lines (LCL), bone marrow mononuclear hematopoietic progenitors
(BM-MNC) and mesenchymal stromal cells (BM-MSC), and plasma obtained from an enlarged cohort
of 31 patients with SDS (Table 1). Our data indicate that everolimus can restore a normal level of
mTOR and STAT3 activation in primary SDS lymphocytes. Importantly, mTOR-STAT3 inhibition was
paralleled by a downregulation of IL-6 expression in hematopoietic SDS cells. Our results suggest the
existence of a mTOR-STAT3-IL-6 loop of activation in hematopoietic SDS cells, which may affect both
myeloid and lymphoid compartment, thus contributing to malignant transformation over the time.
Taken together, these data strengthen the hypothesis of the involvement of lymphoid lineage in SDS
and suggest everolimus or new rapalogs as potential therapeutic agents in SDS patients.
Table 1. Clinical data and genetics of patients with SDS recruited in this study.




1 M 27 258+2T>C/183–184TA>CT 1460




6 M 27 258+2T>C/101A>T 3515















26 M 16 258+2T>C/183–184TA>CT 58
PI, FTT, bone malformation,
thrombocytopenia 46, XY
33 F 8 258+2T>C/183–184TA>CT 1100
PI, FTT, bone malformation,
thrombocytopenia 46, XX
35 F 15 258+2T>C/183–184TA>CT 970 PI, FTT, thrombocytopenia, anemia 46, XX
37 F 10 258+2T>C/183–184TA>CT 1280 PI, FTT, recurrent infections
46, XX,
i(7)(q10)
43 M 22 258+2T>C/258+2T>C+533–549+403del 970




47 M 12 258+2T>C/183–184TA>CT 550
PI, FTT, recurrent infections, bone
malformation, thrombocytopenia 46, XY
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Table 1. Cont.




52 M 10 258+2T>C/183–184TA>CT+258+2T>C 1070 PI, FTT, bone malformation 46, XY
56 F 15 258+2T>C/183–184TA>CT 1840
PI, FTT, recurrent infections, HbF > 2%,
bone malformation, thrombocytopenia 46, XX
57 F 40 258+2T>C/G63C 500




58 M 12 258+2T>C/183–184TA>CT 390
PI, FTT, HbF > 2%, bone malformation,
thrombocytopenia, anemia 46, XY
63 M 15 258+2T>C/183–184TA>CT+258+2T>C 536
PI, FTT, recurrent infections, HbF > 2%,
bone malformation, thrombocytopenia 46, XY
65 M 19 258+2T>C/258+2T>C 1390










67 M 8 258+2T>C/183–184TA>CT 500 PI, FTT, HbF > 2%, bone malformation 46, XY
68 M 22 258+2T>C/183–184TA>CT+258+2T>C 600




69 F 8 258+2T>C/183–184TA>CT 770
PI, FTT, HbF > 2%, anemia, cognitive
impairment 46, XX
72 M 28 258+2T>C/183–184TA>CT 380




73 F 7 258+2T>C/183–184TA>CT 520 PI, FTT, HbF > 2%, thrombocytopenia 46, XX
74 M 9 258+2T>C/183–184TA>CT 1430
PI, FTT, HbF > 2%, cognitive
impairment 46, XY
75 F 7 258+2T>C/183–184TA>CT 1000




80 M 7 258+2T>C/183–184TA>CT 680




82 M 16 258+2T>C/183–184TA>CT 300




87 M 18 258+2T>C/183–184TA>CT 880
PI, FTT, recurrent infections, bone
malformation, cognitive impairment 46, XY
91 M 4 258+2T>C/183–184TA>CT+258+2T>C 1050 PI, FTT, bone malformation 46, XY
94 F 19 258+2T>C/352A>G 2420 PI, HbF > 2%, thrombocytopenia 46, XX
104 M 10 258+2T>C/183–184TA>CT 500
PI, FTT, recurrent infections, HbF > 2%,
bone malformation, thrombocytopenia 46, XY
106 M 36 258+2T>C/183–184TA>CT 1210 PI, FTT, bone malformation, anemia 46, XY
108 M 17 258+2T>C/183–184TA>CT 970 PS, FTT, bone malformation, anemia 46, XY
UPN, unique patient number; PI, pancreas insufficiency; PS, pancreas sufficiency; FTT, failure to thrive; HbF,
fetal hemoglobin.
2. Results
2.1. mTOR-STAT3 Pathway is Hyper-Activated Also in SDS Lymphocyte Subsets and Everolimus Can Reduce
This Process In Vitro
The JAK/STAT3 pathway regulates T cell cytotoxic gene expression, proliferation, and survival.
STAT3 inhibition in the myeloid compartment displays a remarkable induction of the T cell anti-tumor
capabilities and promotes their expansion in vivo [16,17]. Thus, STAT3 activation in immune cells is
associated with suppression of anti-tumor immunity. The protein kinase mTOR acts as an activator
of the STAT3 pathway [24,25,31]. Accordingly, we recently reported that mTOR can activate STAT3
pathway in B cells, neutrophils and monocytes from SDS patients [26]. To assess the activation of
mTOR-STAT3 pathway in SDS lymphoid compartment, we determined the phosphorylation of mTOR
(S2448) and STAT3 (Y705 and S727) in CD4+ and CD8+ T cells, DN T cells, γδT cells, and NK cells
isolated from peripheral blood from seven patients with SDS. In SDS patients, all cell subsets except NK
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displayed significantly elevated levels of phospho-mTOR (Figure 1) and -STAT3 (Figure 2) compared
to age-matched healthy donors. Then, we tested the effect of the clinically-approved rapamycin analog,
everolimus (RAD001) on mTOR, and STAT3 phosphorylation in SDS patient-derived T cell subsets.
Results show that everolimus restores normal levels of phosphorylation of mTOR (Figure 1) and STAT3
(Figure 2), confirming the existence of an mTOR-STAT3 axis activation in the lymphoid compartment
of SDS patients. To determine whether upregulation STAT3 gene expression eventually exists in SDS
cells along with hyper-phosphorylation, we measured and correlated STAT3 transcript expression
with protein levels in LCL and primary PBMC isolated from several SDS patients with different
genotypes, compared to age-matched healthy controls. Our studies showed that STAT3 expression is
elevated in lymphocytes obtained from SDS patients compared to control subjects (Figures 3 and 4,
Figures S1 and S2).
Figure 1. Phospho-flow analysis of mTOR S2448 in a panel of primary lymphocyte subsets.
(a) Representative experiments conducted on peripheral blood samples obtained from patients with
549
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SDS. Red histograms represent age-matched healthy control cells; green histograms represent SDS
lymphocytes; blue histograms represent SDS lymphocytes upon everolimus (350 nM) treatment. (b) Data
are mean ± SEM of seven experiments conducted on SDS lymphocytes obtained from seven SDS
patients (UPN37, UPN58, UPN69, UPN73, UPN87, UPN106, UPN108). Statistics: normal distribution
was tested by the Shapiro–Wilk test. Subsequently, the Mann–Whitney Rank Sum Test was calculated.
* p < 0.05; ** p < 0.01.
Figure 2. Phospho-flow analysis of STAT3 in a panel of primary lymphocyte subsets. (a) Representative
analysis of phospho-STAT3 Y705 in lymphocyte subsets. (b) Representative analysis of phospho-STAT3
S727 in lymphocyte subsets. Red histograms represent age-matched healthy control cells; green
histograms represent SDS patient-derived lymphocytes; blue histograms represent SDS lymphocytes
upon everolimus (350nM) treatment. Data are mean ± SEM of seven experiments conducted on SDS
patient-derived lymphocytes obtained from seven SDS patients (UPN37, UPN58, UPN69, UPN73,
UPN87, UPN106, UPN108). Statistical Student’s t test for paired data has been calculated. * p < 0.05;
** p < 0.01. (c) STAT3 (Y705) Median Fluorescence Intensity as measured by phospho-flow assays.
(d) STAT3 (S727) Median Fluorescence Intensity as measured by phospho-flow assays. Data are mean ±
SEM of seven experiments conducted on SDS lymphocytes obtained from seven SDS patients (UPN37,
UPN58, UPN69, UPN73, UPN87, UPN106, UPN108). Statistics: Normal distribution was tested by
the Shapiro–Wilk test. Subsequently, the Mann–Whitney Rank Sum Test was calculated. * p < 0.05;
** p < 0.01.
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Figure 3. STAT3 transcript and protein expression is upregulated in SDS patient-derived LCL.
(a) STAT3 mRNA expression in LCL isolated from UPN6, UPN43, UPN58, UPN82 (black bar), and from
age-matched controls (white bar), measured by qRT-PCR. Data are mean ± SEM of four experiments
performed in duplicate. (b) STAT3 protein level was measured in LCL (UPN6, UPN43, UPN58, UPN82)
by Western blot analysis. (c,d) Densitometric analysis of Western blots showed in panel (b). Statistics:
Normal distribution was tested by the Shapiro–Wilk test. Subsequently, the Mann–Whitney Rank Sum
Test was calculated and reported within histograms.
Figure 4. STAT3 transcript and protein expression is upregulated in SDS patient-derived primary
PBMC. (a) STAT3 mRNA expression in primary PBMC isolated from UPN26, UPN69, UPN73, UPN87,
UPN94, UPN106, and UPN108 (black bar), and from age-matched controls (white bar), measured by
qRT-PCR. Data are mean ± SEM of seven experiments. (b) STAT3 protein level was measured in PBMC
(UPN52 and UPN74) by Western blot analysis. (c) Densitometric analysis of Western blots showed
in panel b. Statistics: Normal distribution was tested by the Shapiro–Wilk test. Subsequently, the
Mann-Whitney Rank Sum Test was calculated and reported within histograms.
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2.2. IL-6 Expression Is Upregulated in SDS
Plasma levels of IL-6 are generally close to the detection limit (1 pg/mL) in healthy individuals
but significantly increase during the inflammatory process and cancers [32]. IL-6 is a major activator of
JAK-STAT3 signaling, and IL-6 transcript expression is upregulated by STAT3 activation, generating
an autocrine/paracrine loop of activation [14]. Since mTOR-STAT3 axis is upregulated in SDS
patient-derived myeloid cells [26], we sought to find out whether hyper-activation of this pathway
is associated with IL-6 over-expression in non-myeloid SDS cell models. Both LCL and BM-MSC
obtained from patients with SDS displayed significantly upregulated IL-6 release into cell culture
supernatants compared with age-matched healthy controls (Figure 5a,b). In particular, IL-6 levels
were significantly elevated in primary SDS BM-MSC, which released ~8 ng/mL in 2 × 105 cells in our
experimental conditions (Figure 5b). Plasma samples obtained from the peripheral blood collected
from an expanded cohort of 21 patients with SDS showed significantly increased levels of IL-6 (mean
3.66 ± 4.58) compared to aged-matched controls (mean 1.19 ± 1.89), consistent with in vitro results
(Figure 5c). Since SDS BM-MSC showed an impressive upregulation of IL-6 expression, we sought to
find out whether IL-6 were further concentrated in plasma derived from the bone marrow of patients.
IL-6 levels in bone marrow plasma were even more elevated (mean 4.75 ± 3.82) than those found in
peripheral blood (mean 3.04 ± 2.05) obtained in parallel, from the same patients (Figure 5d).
Figure 5. IL-6 release is elevated in SDS specimens compared to age-matched donor controls.
(a) Measurement of IL-6 released in supernatants collected from 1 × 106 LCL after 48h. Data are mean ±
SEM of 10 experiments conducted on LCL obtained from UPN24, UPN26, UPN58, UPN68, UPN75, and
UPN106. (b) IL-6 released in supernatants collected from 2 × 105 primary BM-MSC after 48 h. (c) IL-6
concentration in peripheral blood (PB) plasma samples obtained from 21 patients with SDS (UPN1,
13, 26, 37, 47, 52, 56, 57, 58, 63, 65, 66, 69, 72, 73, 74, 87, 94, 104, 106, 108) compared with age-matched
plasma controls. (d) IL-6 concentration in bone marrow (BM) plasma samples obtained from eight
patients with SDS (UPN 47, 56, 65, 74, 87, 94, 106, 108) compared to PB plasma samples obtained from
the same patients. Normal distribution was tested by the Shapiro–Wilk test. The Mann–Whitney Rank
Sum Test was calculated and reported within histograms.
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2.3. Patients with SDS ShowReduced Levels of Soluble IL-6 Receptor
IL-6 signaling cascade occurs by classical activation through mbIL-6R or trans-signaling via the
soluble sIL-6R [19]. The latter mechanism allows cells that do not express mbIL-6R, but do express
gp130, to be responsive to IL-6. Undifferentiated MSC lack the expression of IL-6 receptor although
they normally express gp130 [33]. Thus, trans-signaling should be required to activate these cells
upon IL-6 stimulation. Nevertheless, BM-MSC can constitutively release large quantities of IL-6 [34].
In this work, we quantified sIL-6R in plasma samples obtained from 21 patients with SDS. In healthy
individuals, plasma levels of sIL-6R range between 50–70 ng/mL [35]. Of note, we found that the
soluble receptor release is reduced in SDS patients (44.3 ± 15.4 pg/μL) compared to age-matched
healthy donors (71.6 ± 14.7 pg/μL) (Figure 6a). To verify whether the bone marrow compartment,
which showed increased levels of IL-6, exhibits also higher levels of sIL-6R, we compared sIL-6R
expression in peripheral blood plasma with the expression found in bone marrow plasma obtained
in parallel from the same patients. However, peripheral blood and bone marrow plasma showed
comparable levels of sIL-6R expression (Figure 6b).
Figure 6. sIL6-R release is reduced in patients with SDS. (a) sIL-6R protein release was quantified by
ELISA in PB plasma samples obtained from 21 patients with SDS (UPN 1, 13, 26, 37, 47, 52, 56, 57, 58,
63, 65, 66, 69, 72, 73, 74, 87, 94, 104, 106, 108) compared with age-matched plasma controls. (b) sIL-6R
concentration in BM plasma samples obtained from eight patients with SDS (UPN 47, 56, 65, 74, 87, 94,
106, 108) compared with PB plasma samples obtained from the same patients. Normal distribution
was tested by the Shapiro–Wilk test. The Mann–Whitney Rank Sum Test was calculated and reported
within histograms.
2.4. Elevated IL-6 Gene Expressionin Hematopoietic CellsIs Primarily Driven by mTOR-STAT3 Pathway
in SDS
Fifty to eighty percent of patients with AML present a constitutive activation of the mTOR
pathway, showing significantly shorter disease-free and overall survival rates compared with patients
without constitutive activation [36,37]. In the last decade, the development of new rapamycin
(sirolimus) analogs showing improved pharmacokinetic profile, such as the clinically approved rapalog
everolimus, have given rise to great interest for anti-cancer therapy [29]. We previously reported that
rapamycin-dependent mTOR inhibition leads to normal levels of phosphorylation of STAT3 in SDS
cells [26]. Here we show that everolimus (350 nM) and STAT3 inhibitor stattic (7.5 μM) significantly
reduce IL-6 mRNA expression in LCL and in primary BM-MNC obtained from patients with SDS
(Figure 7a,c). Decreased IL-6 mRNA expression is paralleled by a reduction of IL-6 release in culture
supernatants upon everolimus and stattic treatments both in LCL (-46.6% and -68%, respectively)
and BM-MNC (-34.6% and -66%, respectively) (Figure 7b,d). In order to validate these data, we also
knocked-down the expression of mTOR and STAT3 in SDS cells using a short interference (si)RNA
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strategy. To this aim, we transfected two different siRNA sequences for each target gene and a negative
control sequence (scrambled), which was previously validated [29], using siRNA-specific liposomes as
a vector. We significantly knocked-down mTOR and STAT3 gene expression in SDS LCL (Figure 8a,b).
Consistently with pharmacological inhibition, both mTOR and STAT3 gene silencing lead to a strong
inhibition of IL-6 expression in SDS cells (Figure 8c,d). In particular, knock-down of the STAT3 gene
resulted in a statistically significant reduction of IL-6 expression in terms of mRNA (-85%) and protein
release (-51%). However, no effect of everolimus nor stattic on IL-6 release was reported in BM-MSC
obtained from four SDS patients (Figure 7f), and IL-6 mRNA transcription was surprisingly increased
(two-fold increase) upon stattic treatment in these cells (Figure 7e).
Figure 7. Everolimus and stattic inhibit IL-6 expression in SDS patient-derived hematopoietic cells.
(a) IL-6 transcript expression in LCL incubated in the absence (DMSO) or in the presence of 350
nM everolimus or 7.5 μM stattic for 24 h was quantified by qRT-PCR. Data are mean ± SEM of six
experiments performed in duplicate from three affected individuals (UPN58, UPN75, and UPN106).
(b) IL-6 release in supernatants collected from LCL incubated in the absence (DMSO) or in the presence
of 350 nM everolimus or 7.5 μM stattic for 24 h, as measured by Bio-plex assay. Data are mean ± SEM
of six experiments conducted as reported in panel a. (c) IL-6 mRNA expression in primary BM-MNC
incubated in the absence (DMSO) or in the presence of 350 nM everolimus or 7.5 μM stattic for 24 h was
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quantified by qRT-PCR. Data are mean ± SEM of four experiments performed in duplicate from four
affected individuals (UPN74, UPN80, UPN94, and UPN106). (d) IL-6 release in supernatants collected
from BM-MNC as measured by Bio-plex assay. Data are mean ± SEM of four experiments conducted as
reported in panel c. (e) IL-6 transcript expression in BM-MSC incubated in the absence (DMSO) or in
the presence of 350 nM everolimus or 7.5 μM stattic for 24 h was quantified by qRT-PCR. Data are mean
± SEM of four experiments performed in duplicate from four affected individuals (UPN33, UPN35,
UPN67 and UPN91). (f) IL-6 release in supernatants collected from BM-MSC (UPN33, UPN35, UPN67
and UPN91) as measured by Bio-plex assay. Data are mean ± SEM of four experiments conducted
as reported in panel e. Statistics: Normal distribution was tested by the Shapiro–Wilk test, and the
Student’s t test for paired data has been calculated and reported within histograms, accordingly.
Figure 8. STAT3 and mTOR gene silencing inhibit IL-6 expression in LCL from SDS patients. (a) Reduced
expression of mTOR mRNA after siRNA-mediated gene silencing. LCL obtained from UPN58, UPN75
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and UPN106 were cultured with two different siRNA sequences against target genes, or scrambled
sequence (negative control for 48 h). Data are mean ± SEM of four experiments performed in duplicate.
(b) Reduced expression of STAT3 mRNA after siRNA-mediated gene silencing in LCL, as performed in
panel a. Data are mean ± SEM of four experiments performed in duplicate. (c) IL-6 mRNA expression
in LCL treated as indicated in panels (a) and (b). (d) IL-6 release was measured by Bio-plex assay in
supenatants obtained from LCL treated as indicated in a. Statistics: Normal distribution was tested by
the Shapiro–Wilk test. Subsequently, the Mann–Whitney Rank Sum Test was calculated and reported
within histograms.
3. Discussion
Although it has been widely reported that SDS mainly involves the neutrophil lineage, a number
of patients suffer from anemia, thrombocytopenia or pancytopenia (Table 1). Because the bone marrow
is often hypocellular, lymphoid and stromal cells may contribute to reduced blood cell formation and
myelodysplasia. We recently described a severe deficit of T cells, in particular of DN T subpopulation
in SDS patients [38]. Here we show that T cell subpopulations isolated from SDS patients display also
hyper-activation of mTOR-STAT3 pathway. In addition, STAT3 transcript and protein expression are
markedly increased in PBMC and LCL obtained from SDS patients, confirming the involvement of
the STAT3 pathway in lymphoid lineages. Given the key role of STAT3 in reducing T regulatory cell
accumulation [39], our results could partially explain the reduced number of DN T cells observed in
SDS patients [38]. Furthermore, STAT3 activation in lymphocytes is associated with T cell impaired
functions [17] and reduced anti-tumor activity [16,40]. Accordingly, impaired functions of T cells
have been previously described in SDS [41]. Thus, STAT3 pathway upregulation could lead to
harmful consequences both on myeloid differentiation in the bone marrow and on innate and adaptive
immunosurveillance mechanisms in SDS.
IL-6 is a major activator of STAT3, and IL-6 transcript expression is itself a target of STAT3 [14].
Thus, we measured IL-6 expression both at mRNA and protein levels in several SDS cell types. We found
that IL-6 expression is elevated in LCL, primary BM-MNC and BM-MSC, compared to age-matched
healthy controls. BM-MSC produce large amounts of IL-6 even in unstimulated and undifferentiated
conditions [34]. Accordingly, BM-MSC obtained from SDS patients released huge amounts of IL-6
protein into the supernatants (~8 ng/mL, from 2 × 105 cells), that is an amount comparable with the dose
of IL-6 commonly used to stimulate in vitro these cells (10 ng/mL). Interestingly, that concentration of
IL-6 has been also reported as the driving force leading to a further increase of mTOR-STAT3 activation
in SDS leukocytes [26], suggesting the existence of a feedforward autocrine/paracrine feedback loop
between STAT3 and IL-6 in SDS bone marrow. In order to verify this hypothesis in clinical samples, we
measured peripheral blood plasma levels of IL-6 in a cohort of 21 patients with SDS. We found that IL-6
levels in peripheral blood plasma are elevated in SDS patients. Then, we measured IL-6 released into
bone marrow plasma and we found even more elevated cytokine levels. Since BM-MNC do release very
low amounts of IL-6 compared to BM-MSC, we speculate that IL-6 accumulation into the bone marrow
environment is mainly due to the contribution from the stromal compartment. The MSC compartment
is involved in AML development, contributing to disease initiation both in animal models and in
patients [42–44]. For instance, studies on BM-MSC obtained from patients with MDS or AML reported
altered expression of several cytokines and other soluble pro-inflammatory mediators [45]. Thus,
increased interleukin-6 levels in bone marrow of patients with SDS, together with mTOR-STAT3 axis
hyper-activation in hematopoietic cells, may clarify the reason why these subjects are prone to develop
AML. We previously reported that rapamycin (sirolimus) treatment reduced the phosphorylation
of both mTOR (S2448) and STAT3 (Y705 and S727) in cell lines as well as in primary neutrophils,
monocytes and B cells isolated from patients with SDS. Here, we show that the clinically approved
rapalog, everolimus, can restore normal level of activation of both mTOR and STAT3 in SDS lymphocyte
populations. Importantly, in this study we show that everolimus and a commercially available STAT3
556
Cancers 2020, 12, 597
chemical inhibitor, namely stattic, can significantly inhibit IL-6 release in SDS LCL and BM-MNC. In
the light of these findings, novel clinically approved inhibitors of mTOR and STAT3 might be helpful
in reducing pro-leukemic pathways in SDS hematopoietic cells. STAT3 inhibitors are being evaluated
as chemotherapeutic agents in leukemias, due to their strong pro-apoptotic activity [13]. Although we
used 7.5 μM stattic, which was a previously reported dose that can inhibit STAT3 without affecting
lymphoid cell viability in vitro [46], we observed a stattic-dependent induction of late apoptosis in
LCL (Figure S3). We cannot exclude the fact that the effect observed in this case may partially be due to
pro-apoptotic activity. However, since everolimus reduced both STAT3 activation and IL-6 expression
in SDS LCL and BM-MNC without inducing pro-apoptotic processes (Figure S3), we can assume that
mTOR-STAT3 pathway inhibition might be useful in reducing the excessive cytokine release. Both
everolimus and stattic did not reduce the huge release of IL-6 from undifferentiated SDS BM-MSC,
which remains one of the main sources of IL-6 within the bone marrow compartment. This finding
suggests other regulatory pathways of IL-6 gene expression exist in BM-MSC.
IL-6 can trigger JAK-STAT3 signaling activation through the direct binding to mbIL-6R or via the
soluble sIL-6R (IL-6 trans-signaling), as result of alternative splicing or protease cleavage of mbIL-6R [19].
In order to evaluate whether the mTOR-STAT3-IL6 loop is generated by increased IL-6 trans-signaling
in SDS, we measured sIL-6R levels in plasma samples obtained from 21 patients. However, results
indicate that sIL-6R expression is reduced in SDS patients compared to age-matched healthy donors,
thus suggesting that this loop is mainly generated via the classical IL-6 signaling in hematopoietic cells.
Interestingly, ex vivo undifferentiated BM-MSC lack the expression of mbIL-6R, even if they normally
do express the gp130 protein [33]. Besides, only a few cell types do express mbIL-6R and therefore
are able to respond to IL-6 generating the IL-6-STAT3-IL6 loop of activation. Among these cells,
major players are represented by macrophages, neutrophils, T-cells, and hepatocytes. On the contrary,
gp130 is generally ubiquitously expressed [47,48]. It has been suggested that the lack of mbIL-6R
is a regulatory mechanism of BM-MSC that inhibits the IL-6-dependent chondrogenic/osteogenic
differentiation, thus maintaining the stemness [33]. During osteogenic differentiation, the expression
of IL-6R indeed increases in BM-MSC, allowing the autocrine/paracrine activation of the IL-6-STAT3
signaling pathway [49]. Thus, reduced sIL-6R levels in plasma suggest that the impaired ossification
reported in SDS [50] might be partially due to decreased IL-6 trans-signaling in BM-MSC. The lack of
IL-6 trans-signaling might therefore also partially explain why everolimus and stattic cannot reduce IL-6
expression in BM-MSC. Our results indicate that BM-MSC are unable to activate the autocrine/paracrine
feedforward loop of mTOR-STAT3-IL6.
4. Materials and Methods
4.1. Human Subjects
Human samples were obtained and analyzed in accordance with the declaration of Helsinki,
after written consent. All protocols were approved by the Ethics Committee of San Gerardo Hospital
(Monza, Italy), approval No. 504 4/9/2012, Azienda Ospedaliera Universitaria Integrata (Verona, Italy),
approval No. 658 CESC, and Azienda Ospedaliero Universitaria Ospedali Riuniti (Ancona, Italy),
approval No. CERM 2018-82.
4.2. Plasma Isolation
Bone marrow and peripheral blood specimens were collected into EDTA-containing tubes from
patients. Specimens were collected during a bone marrow harvest from healthy donors serving as
donors for a related HLA-matched transplant, as permitted by the local hospital ethics committee
and after informed consent was obtained. Peripheral blood and bone marrow plasma samples were
prepared by centrifugation for 10 min at 600× g at 4 ◦C. To obtain platelet-poor plasma fractions,
another centrifugation was performed for 15 min at 1800× g. Plasma specimens were then stored at
−80 ◦C until analysis.
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4.3. Cell Cultures
LCL, PBMC, BM-MNC, and BM-MSC were obtained from peripheral blood or bone marrow
samples from31 patients with Shwachman–Diamond Syndrome. All patients enrolled in this study
were diagnosed as affected by SDS on the basis of clinical and genetics criteria, and they were excluded
if MDS/AML were present (Table 1). None of the patients underwent granulocyte colony-stimulating
factor (G-CSF, filgrastim) nor steroids therapies. PBMC and BM-MNC were separated by stratification
on Ficoll-Paque PLUS (density 1.077 g/mL, GE Healthcare, Waukesha, WI, USA) gradient and washed
twice with PBS (Euroclone, Milan, Italy). Cells were seeded in 6-wells cell culture plates at 1 × 106
BM-MNC/well in 1 mL RPMI-1640 Medium (Gibco, Waltham, MA, USA) supplemented with 10%
FBS (Sigma-Aldrich, St. Louis, MO) and incubated in the presence or absence of 350 nM everolimus
(Sigma-Aldrich) or 7.5 μM stattic (Selleckchem, Houston, TX, USA) at 37 ◦C in humidified atmosphere,
with 5% CO2 for 24 h. Treated cell pellets were collected by centrifugation and the supernatant isolated
and stored at −80 ◦C. BM-MSC were isolated after seeding 1.6 × 105 BM-MNC cells/cm2 from fresh
bone marrow, in Dulbecco’s Modified Eagle Medium low glucose (Gibco) supplemented with 10% of
FBS, 1% L-glutamine and 1% penicillin/streptomycin. BM-MNC were incubated at 37 ◦C in humidified
atmosphere, with 5% CO2 for 24 h. Subsequently, non-adherent cells were removed by washing with
PBS and culture medium was finally replaced.BM-MSC were seeded at 4 × 103 cell/cm2 and incubated
at 37 ◦C in humidified atmosphere, with 5% CO2 since they reached 70–80% confluence. 1 × 105 MSC
were seeded in a 6-well plate and incubated for 48 h at 37 ◦C in humidified atmosphere, with 5% CO2.
Eventually, treated cells were collected and the supernatant isolated and stored at −80 ◦C. To obtain
LCL, B cells were seeded at a density of 3 × 106 cells in 12-well cell culture plates, incubated with 3 mL
RPMI-1640 supplemented with 10% FBS, and infected for 18 h with Epstein–Barr virus (EBV) released
from marmoset blood leukocytes B95.8 virus-producer cell lines as previously described [26]. 1 × 106
LCL were seeded in 6 well-cell culture plate in RPMI-1640 supplemented with 10% FBS and incubated
for 48 h at 37 ◦C in humidified atmosphere, with 5% CO2. Eventually,1 × 106 LCL were seeded in 6
well-cell culture plate in RPMI-1640 supplemented with 10% FBS, in the presence or absence of 350
nM everolimus or 7.5 μM stattic at 37 ◦C in humidified atmosphere, with 5% CO2 for 24 h. Treated
cell pellets were collected by centrifugation and the supernatant isolated and stored at −80 ◦C. LCL,
BM-MNC and MSC cultured in medium containing DMSO (Sigma, dilution 1:10,000) were used as
negative control.
4.4. Flow Cytometry
Plasma was separated from peripheral blood samples derived from SDS patients or healthy
subjects by centrifugation at 1500× g for 10 min. Red blood cells were lysed in 40 mL of solution
containing 0.89% (w/v) NH4Cl, 0.10% (w/v) KHCO3 and 200 μM EDTA. Leukocytes were cultured in
6-well plates containing RPMI-1640 supplemented with 10% freshly prepared, heat-inactivated human
plasma, in the presence or absence (DMSO) of 350 nM everolimus for 1h. Fifty to one-hundred-100
microliter aliquots of blood cells were incubated for 15 min at room temperature with combinations of
the following fluorochrome-conjugated monoclonal antibodies: CD3-APC750, CD4-PC7, CD8-ECD,
CD16-Pacific Blue, CD19-Chrome-Orange, CD45-APC700, and CD56-PC5 (Beckman-Coulter). Cells
were gently centrifuged (600× g) for 10 min, washed with ice-cold PBS, fixed, and permeabilized with
Intracellular Fixation and Permeabilization Buffer Set (eBioscience, San Diego, CA, USA), following the
manufacturer’s recommendations. Subsequently, cells were washed with flow buffer and stained with
anti-pS727-STAT3-PE, anti-Y705-STAT3-PE, anti-p-S2448-mTOR-PE or isotype control-PE conjugated
antibodies for 30 min. Data acquisition was performed by a 10 color, three laser Navios flow cytometer
(Beckman Coulter, Indianapolis, IN, USA). Analysis of the acquired data was performed by the
“Navios” or Kaluza software, version 1.3 (Beckman Coulter, Indianapolis, IN, USA). In order to define
different subsets of lymphocytes, gating strategy and data filtering were established as follows. Cell
debris were excluded using a dot plot for morphological parameters (FS, SS). Lymphocytes were gated
into the side scatter (SS low) and CD45 positive area. Within the lymphocyte compartment, CD3+
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events were further gated into CD4+ and CD8+ T cells. NK cells were instead identified as CD3/CD19
double-negative events (CD56+ and/or CD16+). Double-negative T cells were gated by plotting T cells
(CD3+) in CD4 versus CD8 dot plots. Since it has been reported that TCR γδ+T cells are recognizable
by the bright expression on their membrane of the CD3 molecule [51], CD3 bright DN T cells (DN
γδ) were gated by plotting CD3 bright positive area into CD4 versus CD8 dot plots. Flow cytometry
was performed on at least 25,000 events. The total white blood cell count (WBC) was determined by
Hematology Analyzer XN- 9000 (Sysmex Europe GmbH, Norderstedt, Germany).
4.5. qRT-PCR
Total RNA from LCL and MNC was isolated using High Pure RNA Isolation Kit (Roche, Mannheim,
Germany) following the manufacturer’s instructions. RNA was eluted in 50 μL of RNAse free water.
Final RNA concentration was determined using NanoDrop 2000 spectrophotometer (Thermo Fisher
Scientific, Foster City, CA, USA) and then stored at −80 ◦C until use. A total amount of 500 ng of RNA
was reverse transcribed to cDNA using a High Capacity cDNA Reverse Transcription Kit with random
primers (Applied Biosystems by Thermo Fisher Scientific) for 120 min at 37 ◦C and 5 min at 85 ◦C in a
final reaction volume of 20 μL. For real-time qPCR analysis, 5 Ml of cDNA were used for each reaction to
quantify the relative gene expression. The cDNA was then amplified for 45 PCR cycles using Platinum
SYBR Green qPCR Super Mix-UDG (Invitrogen by Thermo Fisher Scientific) in a 20μL reaction using the
Rotor-Gene 6000 cycler (Qiagen, Hilden, Germany). In order to perform the PCR reaction, QuantiTect
Primer Assays (Qiagen) for IL-6 (Hs_IL6_1_SG, NM_000600), STAT3 (Hs_STAT3_1_SG, NM_003150),
mTOR (Hs_MTOR_1_SG, NM_004958), and GAPDH (HS_GAPDH_1_SG, NM_001256799) were
purchased. Each target gene expression was normalized with GAPDH gene expression and relative
quantification was calculated by the ΔCt method.
4.6. IL-6 and sIL-6R Detection
Bio-Plex Pro Human IL-6 Assay (Bio-Rad Laboratories, Philadelphia, PA, USA) was used to
measure IL-6 protein released into cell supernatants and plasma samples (sample volume 50 μL). The
assays were performed using the Bio-Plex Suspension Array System, with the Bio-Rad 96-well plate
reader. Data were analyzed by the Bio-Plex Manager software (Bio-Rad Laboratories). The in-vitro
quantitative determination of soluble IL-6 Receptor (sIL-6R) in plasma was performed by using the
Human IL-6R/CD126 ELISA Kit (Origene, Rockville, MD, USA), according to the manufacturer’s
instructions. Plasma samples were assayed after 1:200 dilution.
4.7. Western Blot
A total of 30 μg of cell extract was denatured for 5 min at 95 ◦C in 4× Laemmli Sample Buffer,
(277.8 mM Tris-HCl, pH 6.8, 44.4% glycerol, 4.4% LDS, 0.02% bromophenol blue) (Bio-Rad Laboratoires)
supplemented with 355 mM 2-mercaptoethanol. The samples were loaded on 7.5% polyacrylamide
SDS-PAGE gel in Tris-glycine Buffer (25 mM Tris, 192 mM glycine, and 0.1% SDS) using tag protein
ladder (Spectra Multicolor Broad Range Protein Ladder, Thermo Scientific, Waltham, MA, USA)
to determine molecular weight. The electrotransfer was performed into nitrocellulose membrane
(iBlot Gel Transfer Stacks Nitrocellulose, Thermo Fisher) at 20V using iBlot Dry Blotting System
(Invitrogen, Waltham, MA, USA) for 10 min. The membranes were blocked in BSA 5% for 90 min
at room temperature and washed with TBS (5 mM Tris-HCl pH 7.6, 150 mM NaCl) supplemented
with 0.05% tween-20 (TBS/T) for 15 min. Subsequently, membranes were probed with primary
anti-human STAT3 rabbit polyclonal antibody (SAB2104912 Sigma-Aldrich, Missouri, USA, dilution
1:500) in primary antibody dilution buffer (TBS/T with 5% BSA) and incubated overnight at 4 ◦C. After
washes, membranes were incubated with mouse anti-rabbit IgG- Horseradish Peroxidase-Coupled
secondary antibody (Sigma-Aldrich, dilution 1:2000) diluted TBS/T for 90 min at room temperature.
Immunocomplexes were visualized using chemiluminescence (ECL Plus Western Blotting Substrate,
Pierce, Thermo Scientific), incubating ECL for 5 min at room temperature. Band intensity was calculated
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by scanning video densitometry using the Chemi Doc imaging system (UVP, LCC, Upland, CA, USA).
Blots were re-probed with monoclonal β-Actin-Peroxidase clone AC-15 antibody (Sigma-Aldrich,
dilution1:5000) in TBS/T for 90 min.
4.8. Gene Silencing
Both mTOR and STAT3 genes were knocked-down by siRNA. The lipid-based agent for reverse
transfection, siPORT NeoFX (Thermo Fisher), was used according to the manufacturer’s instructions.
LCL derived from healthy donors and SDS patients were transiently transfected with two different
specific siRNA sequences designed against mTOR and STAT3 genes or with a scrambled sequence
as control. The siRNA molecules were complexed with cationic liposomes, siPORT Neo-FX (Thermo
Fisher). Briefly, siPORT Neo-FX (1 μL/well) was complexed with siRNA or Scrambled oligos (40 nM
each) in 250 μL RPMI-1640 medium supplemented with 0.5% FBS. 1 × 105 LCL were incubated in
24-wells plates for 48 h at 37 ◦C. Knock-down of mTOR and STAT3 gene expression was determined by
Real Time qRT-PCR.
4.9. Statistical Analysis
Normal distribution was tested in each experiment using the Shapiro–Wilk test. Based on that
evaluation, independent group determination was tested using Mann–Whitney test, while Student’s
t-test was used in case of paired data. A p-value < 0.05 was considered statistically significant.
The statistical software SigmaPlot (Systat Software Inc., San Jose, CA, USA) was used.
5. Conclusions
STAT3 acts as a double-edged sword in SDS cells, as this pathways controls myeloid progenitor
growth and proliferation [52] and promotes leukemogenesis. Extending our findings on mTOR-STAT3
signaling dysregulation in myeloid lineage [26], we now show that constitutive activation of
mTOR-STAT3 axis occurs in the lymphoid compartment of SDS patients. An autocrine or paracrine
feedforward loop of STAT3-IL6 exists in hematopoietic SDS cells. Since the loss of SBDS expression in
healthy donor-derived cells is sufficient to reproduce the hyper-activation of mTOR-STAT3 signaling [26],
we assume that alteration of the mTOR-STAT3-IL6 axis could be used by SDS cells as a survival
mechanism that induces cell proliferation and myeloid growth in bone marrow, thus trying to escape
from incoming neutropenia/aplasia processes.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/3/597/s1,
Figure S1: Whole blots showing all the bands with all molecular weight markers on the Western blot reported in
Figure 3b, Figure S2: Whole blots showing all the bands with all molecular weight markers on the Western blot
reported in Figure 4b, Figure S3: Apoptosis assay in LCL.
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